Clustering O 0 6.963285272831854e-07
of O 0 8.821285035764959e-08
missense O 0 1.3142375792085659e-06
mutations O 0 9.979574855378814e-08
in O 0 3.106528811969156e-09
the O 0 9.03445425137761e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 3.5147038488503313e-06
in O 0 1.805123872600234e-08
a O 0 1.0265060801373238e-08
sporadic B-Disease 0 1.6459830476378556e-06
T I-Disease 0 1.2186422281956766e-05
- I-Disease 0 2.3146856165112695e-06
cell I-Disease 0 0.0011837745551019907
leukaemia I-Disease 1 0.998721182346344
. O 0 2.6810997155735095e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.424554694322126e-10
is O 0 3.665432887767217e-11
a O 0 1.444967062669278e-10
recessive B-Disease 0 8.464404288588412e-08
multi I-Disease 0 4.06249728257535e-06
- I-Disease 0 9.731026011650101e-07
system I-Disease 0 1.501950741555902e-08
disorder I-Disease 0 6.466906052082777e-05
caused O 0 1.4889327992761991e-08
by O 0 3.55843063348793e-11
mutations O 0 5.328549823602202e-10
in O 0 4.7225966193220614e-11
the O 0 5.303171235482296e-10
ATM O 0 1.2207121358187578e-07
gene O 0 1.125516391198289e-08
at O 0 5.235228428546179e-08
11q22 O 0 6.669382059953932e-07
- O 0 1.0907989178576827e-07
q23 O 0 5.068228574600653e-07
( O 0 4.2970258462560196e-09
ref O 0 2.5996467911681975e-07
. O 0 1.8428696790806498e-08
3 O 0 1.590797467088123e-07
) O 0 1.0945916173454862e-08
. O 0 1.3213831095981732e-07

The O 0 2.993784846694325e-07
risk O 0 3.2113250654219883e-06
of O 0 2.5504303380330384e-07
cancer B-Disease 0 8.260551112471148e-06
, O 0 4.907254602670719e-09
especially O 0 4.208582282672069e-08
lymphoid B-Disease 0 5.592533489107154e-05
neoplasias I-Disease 1 0.9894959330558777
, O 0 2.568387946766393e-09
is O 0 3.443364204880339e-10
substantially O 0 1.1901094332245066e-08
elevated O 0 9.850675297684575e-08
in O 0 6.953535081066775e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.304361560045436e-08
and O 0 1.7314000233525917e-09
has O 0 1.5046186518929971e-10
long O 0 2.1713865080985606e-11
been O 0 2.2865794327420197e-11
associated O 0 9.619705032548609e-10
with O 0 2.571171942022943e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 1.398676886310568e-06

By O 0 3.1676442802108795e-08
analysing O 0 6.680089086330554e-07
tumour B-Disease 1 0.9999755620956421
DNA O 0 6.149246445374956e-08
from O 0 2.073859306506165e-09
patients O 0 2.1036178354805202e-10
with O 0 6.279569225720039e-11
sporadic B-Disease 0 2.930931373157364e-07
T I-Disease 0 1.3783208032691618e-06
- I-Disease 0 3.241711965529248e-07
cell I-Disease 0 9.711366146802902e-06
prolymphocytic I-Disease 0 0.00030632864218205214
leukaemia I-Disease 1 0.6840730905532837
( O 0 7.800418977410573e-09
T B-Disease 0 5.565849505728693e-07
- I-Disease 0 1.2561270068545127e-07
PLL I-Disease 0 6.820396265538875e-07
) O 0 1.420601830615098e-10
, O 0 1.6379172323999214e-11
a O 0 1.9457798219879585e-11
rare O 0 1.310826336364812e-09
clonal B-Disease 0 5.526192481397629e-08
malignancy I-Disease 0 5.003585670237953e-07
with O 0 1.3804550558216278e-10
similarities O 0 6.446369216206449e-09
to O 0 9.54522572094163e-10
a O 0 1.3163188761211586e-08
mature B-Disease 0 1.2407328142671759e-07
T I-Disease 0 1.848296278694761e-06
- I-Disease 0 2.6296513055967807e-07
cell I-Disease 0 5.559064675253467e-07
leukaemia I-Disease 0 4.387175067677163e-06
seen O 0 4.7974837436015605e-09
in O 0 5.104535683031486e-10
A B-Disease 1 1.0
- I-Disease 0 3.6359517253004014e-05
T I-Disease 1 1.0
, O 0 1.1331215965526553e-09
we O 0 8.21776743875624e-11
demonstrate O 0 1.0109761638954495e-10
a O 0 1.1399799854094894e-10
high O 0 2.923750130889857e-10
frequency O 0 9.280022306157321e-10
of O 0 9.040686532735265e-10
ATM O 0 1.1345698567311047e-06
mutations O 0 3.1715350701233547e-07
in O 0 1.8874438012517203e-07
T B-Disease 0 0.0005117261898703873
- I-Disease 0 7.10776075720787e-05
PLL I-Disease 0 0.00033222936326637864
. O 0 1.3956707789475331e-06

In O 0 2.0757914498403807e-08
marked O 0 3.787639357710759e-08
contrast O 0 3.4917451152693957e-09
to O 0 3.687263550045117e-10
the O 0 2.848167701685611e-09
ATM O 0 4.1655539462226443e-07
mutation O 0 1.1585164827465633e-08
pattern O 0 1.7495226600772185e-08
in O 0 4.3802059757069856e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 3.1530431598980613e-09
the O 0 3.044263452434137e-10
most O 0 5.940570257934041e-11
frequent O 0 2.0123618049705527e-10
nucleotide O 0 8.895161274224961e-10
changes O 0 3.722404329220552e-10
in O 0 1.469682847643483e-10
this O 0 2.9350155639207287e-09
leukaemia B-Disease 0 3.165265661664307e-05
were O 0 2.860805814464129e-08
missense O 0 5.085958036943339e-06
mutations O 0 1.309769459112431e-06
. O 0 9.223278425452008e-07

These O 0 4.413333343222803e-08
clustered O 0 1.8457372163993568e-07
in O 0 6.322380396994731e-10
the O 0 1.3875434135002251e-09
region O 0 2.3692892092697093e-09
corresponding O 0 1.2688375905511862e-09
to O 0 7.708846339049558e-10
the O 0 8.482194502335005e-09
kinase O 0 3.429973389756924e-07
domain O 0 4.181537605063568e-08
, O 0 1.2500240842427957e-09
which O 0 2.61187987904421e-10
is O 0 1.8000817503249777e-10
highly O 0 1.0449922038802129e-09
conserved O 0 5.487285736904823e-09
in O 0 8.96333729460963e-10
ATM O 0 6.047316674084868e-07
- O 0 3.957942951160476e-08
related O 0 1.601375743121025e-08
proteins O 0 2.5507689294101965e-09
in O 0 9.0595020374451e-10
mouse O 0 5.967991878463863e-09
, O 0 6.834689481038936e-10
yeast O 0 1.6522591295142774e-08
and O 0 4.550178456241838e-09
Drosophila O 0 6.041441480419962e-08
. O 0 1.0517275939037063e-07

The O 0 1.0175662055189605e-06
resulting O 0 9.617252771931817e-07
amino O 0 1.1327762194923707e-06
- O 0 6.107482164452449e-08
acid O 0 2.2404366362138717e-08
substitutions O 0 3.76718300998391e-09
are O 0 1.6519643986079302e-10
predicted O 0 4.159913746804023e-09
to O 0 8.082778335527507e-10
interfere O 0 2.78952931864751e-08
with O 0 5.2717794574164145e-09
ATP O 0 6.058421149646165e-06
binding O 0 1.8163663639825245e-07
or O 0 1.7413928077303353e-08
substrate O 0 2.505990437384753e-07
recognition O 0 2.2733156868071092e-07
. O 0 8.160321272043802e-07

Two O 0 1.241760259063085e-07
of O 0 1.898922903365019e-07
seventeen O 0 4.3437140107016603e-07
mutated O 0 9.164244261228305e-07
T B-Disease 0 1.4549598290614085e-06
- I-Disease 0 2.857011338619486e-07
PLL I-Disease 0 1.183604467769328e-06
samples O 0 6.435803445725696e-09
had O 0 3.0286453345240716e-09
a O 0 4.562046573841627e-10
previously O 0 1.2204526278480898e-09
reported O 0 3.058560693602885e-08
A B-Disease 1 1.0
- I-Disease 1 0.8243677616119385
T I-Disease 1 1.0
allele O 0 2.7117307581647765e-06
. O 0 4.810227096641029e-07

In O 0 7.437225946205217e-08
contrast O 0 1.5318434520850133e-07
, O 0 2.3107393776200524e-09
no O 0 1.8304955329284667e-09
mutations O 0 9.706703885115076e-09
were O 0 7.589215922365611e-10
detected O 0 1.9064883005626143e-09
in O 0 9.583220328401865e-11
the O 0 3.3726712533876935e-09
p53 O 0 3.95714288004001e-08
gene O 0 9.69819158314067e-09
, O 0 2.7974456084933763e-09
suggesting O 0 2.237228624579757e-09
that O 0 1.5745577064407712e-10
this O 0 8.116255445500542e-10
tumour B-Disease 1 1.0
suppressor O 0 1.7541929992148653e-05
is O 0 1.008290340109852e-09
not O 0 3.0236796400018306e-10
frequently O 0 1.0986362930509586e-09
altered O 0 5.3002517930167414e-09
in O 0 5.898662114312003e-10
this O 0 7.095104948007247e-09
leukaemia B-Disease 0 0.00011761419591493905
. O 0 4.7466519959016296e-07

Occasional O 0 1.111504479922587e-05
missense O 0 4.414025625010254e-06
mutations O 0 1.454497748909489e-07
in O 0 9.189842664625303e-09
ATM O 0 2.2640822407993255e-06
were O 0 1.3976801938042627e-08
also O 0 1.9823837016375023e-10
found O 0 1.403820948375767e-10
in O 0 3.095148026766026e-10
tumour B-Disease 1 0.9999983310699463
DNA O 0 4.106843221052259e-08
from O 0 2.2994661730280086e-09
patients O 0 2.2227110429984265e-10
with O 0 2.2523329035184503e-10
B B-Disease 0 2.4970157141979143e-07
- I-Disease 0 2.7257989643203473e-08
cell I-Disease 0 7.875746632635128e-06
non I-Disease 1 0.9998947381973267
- I-Disease 0 0.28471747040748596
Hodgkins I-Disease 1 0.8906356692314148
lymphomas I-Disease 0 1.2734151368931634e-06
( O 0 2.1585546683411394e-09
B B-Disease 0 7.742982433001089e-08
- I-Disease 0 2.9349036534398465e-09
NHL I-Disease 0 4.248949153407011e-06
) O 0 1.2705661522893763e-10
and O 0 1.2027549789461744e-10
a O 0 1.460517706775022e-09
B B-Disease 0 1.3308377333487442e-07
- I-Disease 0 2.0620904095380865e-08
NHL I-Disease 0 0.000238190550589934
cell O 0 4.3434287363197654e-05
line O 0 1.532745227450505e-05
. O 0 4.4537122789733985e-07

The O 0 1.460724607937891e-08
evidence O 0 2.610508076372753e-08
of O 0 3.2004612293690116e-09
a O 0 2.880607419264436e-10
significant O 0 2.5224800026535377e-09
proportion O 0 7.79885667157032e-09
of O 0 1.3343086635586587e-09
loss O 0 6.496135629419086e-09
- O 0 5.714914763643719e-09
of O 0 5.603547492682992e-08
- O 0 9.941081735576063e-09
function O 0 1.3869533299626369e-09
mutations O 0 2.2727071335992832e-09
and O 0 1.0015563378651393e-10
a O 0 4.540273365605252e-11
complete O 0 3.3877753380373576e-10
absence O 0 1.5985010648478237e-08
of O 0 6.706756483509935e-09
the O 0 1.562537654820062e-09
normal O 0 9.173568571441137e-10
copy O 0 2.8687985320630105e-09
of O 0 9.25520438066485e-10
ATM O 0 5.376845635396421e-08
in O 0 3.3694547152407495e-10
the O 0 7.13131276253165e-10
majority O 0 2.849828983908509e-10
of O 0 1.6830796756295285e-09
mutated O 0 2.4451442186546046e-06
tumours B-Disease 1 0.9999997615814209
establishes O 0 7.844376881394055e-08
somatic O 0 1.7672249441602617e-07
inactivation O 0 1.4400605152786738e-07
of O 0 1.1637824037791233e-09
this O 0 9.976820758428318e-11
gene O 0 2.484342453978883e-10
in O 0 4.009906295898702e-10
the O 0 1.7073229496844533e-09
pathogenesis O 0 1.2734576557704713e-06
of O 0 2.4018916633394838e-08
sporadic B-Disease 0 8.729038199817296e-06
T I-Disease 0 2.302892244188115e-05
- I-Disease 0 6.819811915192986e-06
PLL I-Disease 0 4.935962351737544e-05
and O 0 4.88639839701932e-09
suggests O 0 6.210205238943445e-09
that O 0 1.573086799711021e-10
ATM O 0 1.553961510580848e-07
acts O 0 1.3691649591862642e-08
as O 0 2.4803632925340935e-08
a O 0 1.0075741130322058e-07
tumour B-Disease 1 1.0
suppressor O 0 0.0007792591350153089
. O 0 1.3771750673186034e-06

As O 0 5.749071974037179e-08
constitutional O 0 5.551526527369788e-08
DNA O 0 7.402708490644727e-08
was O 0 1.3209718652262836e-08
not O 0 3.983118002093278e-11
available O 0 7.857591799442787e-10
, O 0 1.477209049527417e-10
a O 0 9.436323944456149e-10
putative O 0 3.4754398257064167e-06
hereditary O 1 0.9960286617279053
predisposition O 1 0.9999997615814209
to O 0 1.3616754586109892e-05
T B-Disease 1 0.9999804496765137
- I-Disease 0 3.6217563319951296e-05
PLL I-Disease 0 4.255425210430985e-06
will O 0 6.533322216561999e-10
require O 0 7.301136917270412e-10
further O 0 6.650402006869172e-09
investigation O 0 6.63580568271982e-09
. O 0 1.7157034903902968e-08
. O 0 1.7058792423085833e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00015070171502884477
kinase O 0 3.900347110175062e-06
is O 0 7.013899461227879e-10
involved O 0 2.6210511192004127e-11
in O 0 5.8011061232488e-12
the O 0 1.9288525637817244e-11
modulation O 0 2.0856635862820383e-10
of O 0 1.8472563756422034e-10
the O 0 8.992687705600133e-10
Ca2 O 0 4.808011411228108e-08
+ O 0 2.9481864771696564e-07
homeostasis O 0 2.0316939242093213e-07
in O 0 2.4566618961330278e-08
skeletal O 0 9.053928806679323e-06
muscle O 0 2.1484429453266785e-06
cells O 0 1.5677678675274365e-06
. O 0 1.8449489402883046e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9765768051147461
DM B-Disease 1 1.0
) O 0 6.089116055818522e-08
, O 0 5.902713873240373e-10
the O 0 4.0904377107686685e-10
most O 0 6.601414415108309e-10
prevalent O 0 1.0641855396897881e-06
muscular B-Disease 0 0.015766184777021408
disorder I-Disease 1 0.9999740123748779
in O 0 3.537604653658377e-09
adults O 0 3.563888739677168e-09
, O 0 5.0402737539201325e-11
is O 0 1.2327197422556946e-11
caused O 0 7.198686091669515e-10
by O 0 1.0524491278474102e-09
( O 0 4.217081350788021e-09
CTG O 0 6.725487082803738e-07
) O 0 3.079566601726924e-10
n O 0 1.5717619428201601e-09
- O 0 7.80301934177885e-10
repeat O 0 8.949209706621275e-10
expansion O 0 2.401354448622328e-09
in O 0 1.0129951738546694e-10
a O 0 2.622762840243098e-10
gene O 0 3.90167897990068e-10
encoding O 0 7.231869769697141e-09
a O 0 6.098379401464626e-08
protein O 0 1.9787571545748506e-06
kinase O 0 9.543562555336393e-06
( O 0 4.87622514810937e-07
DM B-Disease 1 0.9999998807907104
protein O 0 8.955737484939164e-07
kinase O 0 3.365864813531516e-07
; O 0 1.5353647242477564e-08
DMPK O 0 1.3370347005547956e-05
) O 0 1.8870598139653083e-10
and O 0 4.502621192559175e-11
involves O 0 6.918311756809459e-11
changes O 0 3.9202233126367503e-10
in O 0 2.3875668109241133e-09
cytoarchitecture O 0 1.525328684692795e-06
and O 0 3.961976702271386e-08
ion O 0 8.103398613457102e-06
homeostasis O 0 2.1468686099979095e-05
. O 0 4.591395736497361e-06

To O 0 4.497458405694488e-09
obtain O 0 4.619218074708442e-08
clues O 0 6.622240675824287e-07
to O 0 6.253659257104971e-10
the O 0 1.1971664770626944e-09
normal O 0 7.226713005792362e-09
biological O 0 3.435416573438488e-08
role O 0 1.6495567134455769e-09
of O 0 2.5328374064770287e-08
DMPK O 0 0.0010129783768206835
in O 0 7.4389396864660284e-09
cellular O 0 5.8129803193196494e-08
ion O 0 7.96763174548687e-07
homeostasis O 0 1.438619250393458e-07
, O 0 5.4065840693340306e-09
we O 0 7.472126251073519e-10
have O 0 2.843714985711898e-10
compared O 0 1.6284864567950308e-09
the O 0 3.2528832960565524e-09
resting O 0 8.00010084844871e-08
[ O 0 8.268606244143939e-09
Ca2 O 0 8.389643646466993e-09
+ O 0 1.3462474690584258e-08
] O 0 8.217493352447036e-09
i O 0 1.7240480154612214e-09
, O 0 1.2963648210462253e-10
the O 0 1.878788652431851e-10
amplitude O 0 1.017212647447252e-09
and O 0 3.5495389960615853e-10
shape O 0 8.14207545829504e-09
of O 0 2.8704693733061504e-08
depolarization O 0 4.511878515245371e-08
- O 0 9.748807627829592e-08
induced O 0 1.2510126623510587e-07
Ca2 O 0 2.8111346139780835e-08
+ O 0 1.820305683963852e-08
transients O 0 1.3179870528290394e-08
, O 0 7.371193933014553e-11
and O 0 2.3661708009603544e-11
the O 0 8.446957716623515e-11
content O 0 1.5825976085181992e-09
of O 0 4.150419119497428e-09
ATP O 0 3.708278484282346e-07
- O 0 7.284132408358346e-08
driven O 0 1.9210722257412272e-07
ion O 0 6.295083920804245e-08
pumps O 0 1.4395876490880255e-08
in O 0 9.060452388354179e-10
cultured O 0 7.02600928548236e-08
skeletal O 0 2.3098684209799103e-07
muscle O 0 1.821594253215153e-08
cells O 0 1.4167553352706364e-08
of O 0 1.6102118749472538e-08
wild O 0 2.553192768317558e-09
- O 0 6.133392682627914e-10
type O 0 1.6585607331975893e-09
and O 0 3.811945870069167e-09
DMPK O 0 1.728871666273335e-06
[ O 0 1.9314436272566127e-08
- O 0 6.059421764348372e-08
/ O 0 1.0777514347637407e-07
- O 0 2.1616999390516867e-07
] O 0 4.688981292133576e-08
knockout O 0 8.533832556167908e-07
mice O 0 2.2039236569071363e-07
. O 0 1.2033993357363215e-07

In O 0 7.690861707487784e-07
vitro O 0 2.916481889769784e-06
- O 0 2.616176288938732e-06
differentiated O 0 2.1132109395693988e-06
DMPK O 0 6.644966924795881e-05
[ O 0 2.1799721139359463e-07
- O 0 1.0593883814635774e-07
/ O 0 4.983470347497132e-08
- O 0 5.9468373336812874e-08
] O 0 1.2318332132110754e-08
myotubes O 0 5.323740381868447e-08
exhibit O 0 3.185090635682286e-09
a O 0 1.2947319882883335e-09
higher O 0 1.4303475737165172e-08
resting O 0 4.0727854866418056e-08
[ O 0 6.667217888889354e-09
Ca2 O 0 1.4378369606049546e-08
+ O 0 2.6475644787637975e-08
] O 0 2.043586100342054e-08
i O 0 3.364922118720415e-09
than O 0 3.380578317280225e-10
do O 0 3.611478893716935e-10
wild O 0 3.0477100843029348e-09
- O 0 7.887623332258897e-10
type O 0 1.3527770015286933e-09
myotubes O 0 3.139458470968748e-08
because O 0 9.127039124479097e-10
of O 0 6.427727794466875e-10
an O 0 1.8829574011114403e-10
altered O 0 1.132507976286945e-09
open O 0 3.778925783404219e-10
probability O 0 1.408689942472563e-09
of O 0 2.404260124322377e-09
voltage O 0 5.07455979459337e-07
- O 0 7.31331155634507e-08
dependent O 0 1.2964260065473354e-07
l O 0 7.61347607181051e-09
- O 0 2.8914530769696967e-09
type O 0 1.0140472905817433e-09
Ca2 O 0 2.1436981079148154e-09
+ O 0 4.085153104682604e-09
and O 0 2.3947817062719423e-09
Na O 0 4.598320835214054e-09
+ O 0 1.2770446922161227e-08
channels O 0 5.5262454168314434e-08
. O 0 7.151492553703065e-08

The O 0 1.1448661325630383e-06
mutant O 0 2.1878479401493678e-06
myotubes O 0 3.939103862649063e-06
exhibit O 0 8.902468096039229e-08
smaller O 0 7.544535662873386e-09
and O 0 6.799206198060403e-10
slower O 0 1.0831399777089246e-08
Ca2 O 0 1.0769804603683042e-08
+ O 0 8.938483730958069e-09
responses O 0 1.6210643938308067e-09
upon O 0 2.4028847800394715e-09
triggering O 0 4.300420020086904e-09
by O 0 2.901129891874632e-10
acetylcholine O 0 1.4229630096451729e-07
or O 0 1.515776126836954e-08
high O 0 5.479465414737206e-08
external O 0 1.2946431127147662e-07
K O 0 3.3867749493765587e-07
+ O 0 1.9906180170892185e-07
. O 0 1.4955836036278924e-07

In O 0 4.501649186750001e-08
addition O 0 2.6781396655906065e-08
, O 0 5.395128788165948e-09
we O 0 8.673606277653789e-10
observed O 0 7.306528160277992e-10
that O 0 1.207664523938945e-11
these O 0 2.2972689028843973e-10
Ca2 O 0 7.599927442925036e-08
+ O 0 3.1437554071089835e-07
transients O 0 2.046910339004171e-07
partially O 0 1.1436005920018033e-08
result O 0 6.540940566956976e-10
from O 0 3.2839642116755385e-10
an O 0 1.5867709923789164e-10
influx O 0 2.837875490158126e-09
of O 0 1.3832547329784006e-09
extracellular O 0 1.0555456064764712e-08
Ca2 O 0 1.9605687739954192e-08
+ O 0 9.006372536646268e-09
through O 0 3.020107941509309e-09
the O 0 8.931172246207097e-09
l O 0 1.857152542861229e-09
- O 0 1.0957358353991253e-09
type O 0 9.483417384714699e-10
Ca2 O 0 7.118827305419018e-09
+ O 0 4.431544908811702e-08
channel O 0 7.622153930242348e-08
. O 0 4.821704280288941e-08

Neither O 0 1.9502529085002607e-06
the O 0 4.2094892904742665e-08
content O 0 3.0220107305467536e-08
nor O 0 6.914337546959359e-08
the O 0 2.3776052238133616e-09
activity O 0 7.614477937067932e-09
of O 0 6.8853820422987155e-09
Na O 0 1.7115199923978253e-08
+ O 0 4.40843699323068e-08
/ O 0 3.32165122074457e-08
K O 0 5.016725523887544e-08
+ O 0 1.627940626747204e-08
ATPase O 0 2.281820954408431e-08
and O 0 2.020990486073515e-09
sarcoplasmic O 0 8.991254674128868e-08
reticulum O 0 6.629040427696964e-08
Ca2 O 0 2.835452939109473e-08
+ O 0 3.229110134839175e-08
- O 0 2.5489464761108138e-08
ATPase O 0 1.3396951104027721e-08
are O 0 3.016644573028415e-11
affected O 0 7.280402947174025e-10
by O 0 1.3994693182084461e-09
DMPK O 0 0.00025328624178655446
absence O 0 3.5447737900540233e-06
. O 0 5.215504756961309e-07

In O 0 9.666541700426023e-08
conclusion O 0 8.237212796302629e-07
, O 0 6.464123014637835e-09
our O 0 3.4762352996153822e-09
data O 0 3.031436657252584e-09
suggest O 0 5.253049994990988e-09
that O 0 1.2871212984322256e-09
DMPK O 0 1.9647764929686673e-05
is O 0 3.5352554217382703e-10
involved O 0 1.4676714010786185e-10
in O 0 8.447908345088351e-11
modulating O 0 9.046866367157236e-09
the O 0 7.614008867840028e-10
initial O 0 5.428611449254106e-10
events O 0 1.562521917408688e-10
of O 0 1.5506320671931917e-09
excitation O 0 1.3091175787849352e-06
- O 0 4.2680474621192843e-07
contraction O 0 3.7963548749075926e-08
coupling O 0 1.1302125457746115e-08
in O 0 6.056080525951302e-09
skeletal O 0 1.0367408549427637e-06
muscle O 0 1.4285568283867178e-07
. O 0 7.549002134510374e-08
. O 0 1.219848542177715e-07

Constitutional O 0 6.013297752360813e-05
RB1 O 0 0.011506374925374985
- O 0 2.433352847219794e-06
gene O 0 6.461598900386889e-08
mutations O 0 6.331461577246955e-08
in O 0 6.064966306951192e-10
patients O 0 2.380721730865787e-10
with O 0 2.2348253456150324e-11
isolated O 0 2.2315191472443985e-08
unilateral B-Disease 0 1.3168935311114183e-06
retinoblastoma I-Disease 1 0.9999865293502808
. O 0 3.281217686890159e-06

In O 0 1.1934099930499542e-08
most O 0 2.7254127843434617e-09
patients O 0 2.2273156929930593e-10
with O 0 4.8800227747669567e-11
isolated O 0 1.889669221100121e-08
unilateral B-Disease 0 1.8721840433499892e-07
retinoblastoma I-Disease 1 0.9998918771743774
, O 0 6.384964112982061e-09
tumor B-Disease 0 3.1902123964755447e-07
development O 0 1.1115532494443414e-08
is O 0 3.029664713549707e-11
initiated O 0 4.022727984054342e-11
by O 0 8.96248960463586e-12
somatic O 0 2.1504890312940006e-08
inactivation O 0 4.629520233834228e-08
of O 0 6.289653242674831e-10
both O 0 4.99823016308909e-10
alleles O 0 5.42980549411709e-09
of O 0 1.1315563597236178e-08
the O 0 1.1846405101323398e-07
RB1 O 0 6.177142495289445e-05
gene O 0 5.702438556909328e-07
. O 0 1.7977525885726209e-06

However O 0 3.8602675545007514e-07
, O 0 4.193844382882617e-09
some O 0 8.32457380806062e-10
of O 0 2.0143480217171827e-09
these O 0 4.4367587381799467e-10
patients O 0 4.2261139032717665e-10
can O 0 3.258917857795751e-10
transmit O 0 7.93301495605192e-08
retinoblastoma B-Disease 0 0.0694323182106018
predisposition O 0 5.943158976151608e-05
to O 0 8.86354634133113e-09
their O 0 4.393721653173088e-08
offspring O 0 3.12061638396699e-06
. O 0 5.523009463104245e-07

To O 0 2.2727242310338625e-09
determine O 0 4.5067327647529964e-09
the O 0 1.1607629302190503e-09
frequency O 0 7.275672952999912e-09
and O 0 9.850323334781308e-11
nature O 0 1.8251059552554239e-09
of O 0 2.856632930203773e-09
constitutional O 0 5.31803664216568e-07
RB1 O 0 0.0013983346289023757
- O 0 1.5153229071529495e-07
gene O 0 5.662918134419215e-09
mutations O 0 1.2272928451295684e-08
in O 0 1.890914924640441e-10
patients O 0 1.3572448720466923e-10
with O 0 4.9819138397966256e-11
isolated O 0 1.052646414478886e-08
unilateral B-Disease 0 4.415631948972987e-08
retinoblastoma I-Disease 0 3.0094255635049194e-05
, O 0 2.7683264569589028e-09
we O 0 1.1283725065425187e-09
analyzed O 0 3.922513869270006e-09
DNA O 0 1.4960381378159582e-08
from O 0 7.3122619070886685e-09
peripheral O 0 8.323150382238964e-07
blood O 0 2.44244446889752e-08
and O 0 3.929493175292009e-09
from O 0 1.0848788534190135e-08
tumor B-Disease 0 4.74510414960605e-07
tissue O 0 3.4312068919462035e-07
. O 0 3.0734881306671014e-07

The O 0 8.458981426429091e-08
analysis O 0 1.0160849939211403e-07
of O 0 2.0257311916793697e-07
tumors B-Disease 1 1.0
from O 0 7.45165280591209e-08
54 O 0 6.304227895270742e-08
( O 0 2.776240903834548e-10
71 O 0 1.1281040102062434e-08
% O 0 1.7269202734482292e-10
) O 0 3.3407567077287093e-12
of O 0 2.331270176902933e-10
76 O 0 7.776057131536618e-09
informative O 0 5.297583705043962e-09
patients O 0 5.364138577768074e-10
showed O 0 1.9745922674729854e-09
loss O 0 3.7487617454701194e-09
of O 0 9.923937227540591e-09
constitutional O 0 8.010335363906051e-07
heterozygosity O 1 0.9999997615814209
( O 0 0.01769980974495411
LOH O 1 1.0
) O 0 3.2535364624664e-08
at O 0 7.74494637312273e-08
intragenic O 0 3.3734304452082142e-06
loci O 0 8.944317073655839e-07
. O 0 8.390318271267461e-07

Three O 0 3.546663833731145e-07
of O 0 2.589331700164621e-07
13 O 0 2.879276337353076e-07
uninformative O 0 3.024746365554165e-05
patients O 0 4.4526672127176425e-08
had O 0 1.087267342825271e-08
constitutional O 0 1.1380089404156024e-07
deletions O 0 6.22221659796196e-06
. O 0 1.691504735390481e-06

For O 0 1.505634230625219e-07
39 O 0 2.590806388980127e-06
randomly O 0 6.90627146582301e-08
selected O 0 3.4081884336956136e-07
tumors B-Disease 1 1.0
, O 0 6.995428236677981e-08
SSCP O 0 0.004760303068906069
, O 0 1.900397172960311e-08
hetero O 0 1.2340429123014474e-07
- O 0 1.5192378910455773e-08
duplex O 0 1.67271156925608e-08
analysis O 0 1.2762282342038134e-09
, O 0 3.153785912979323e-11
sequencing O 0 7.733834406220552e-11
, O 0 6.306456051818898e-11
and O 0 9.306942716502675e-11
Southern O 0 2.0300499059544563e-09
blot O 0 6.065342006422725e-08
analysis O 0 3.4432605655609905e-09
were O 0 4.5296452699794543e-10
used O 0 2.683019639793116e-10
to O 0 1.4952384885802417e-09
identify O 0 1.8678504432045884e-07
mutations O 0 7.585844741697656e-06
. O 0 2.4152686819434166e-06

Mutations O 0 3.613164381022216e-07
were O 0 7.738210072716356e-09
detected O 0 5.532380331629838e-09
in O 0 2.5199062281267004e-10
21 O 0 6.570265220773308e-09
( O 0 2.1013682460768734e-10
91 O 0 1.1657779630525056e-08
% O 0 4.501722050687107e-10
) O 0 1.684671152579753e-11
of O 0 1.365044410839289e-09
23 O 0 5.938285312367952e-07
tumors B-Disease 1 1.0
with O 0 0.0008747776155360043
LOH O 1 1.0
. O 0 7.762627319607418e-06

In O 0 6.216465209263333e-08
6 O 0 2.55243065794275e-07
( O 0 2.191945069895951e-09
38 O 0 5.0533916606809726e-08
% O 0 8.963422226671014e-10
) O 0 3.4348350552715345e-11
of O 0 1.985930975223482e-09
16 O 0 1.1624080542560478e-07
tumors B-Disease 1 1.0
without O 0 0.0011738651664927602
LOH O 1 1.0
, O 0 1.5157580746105737e-09
one O 0 4.09224792941032e-10
mutation O 0 5.763932664493154e-10
was O 0 5.688246540458408e-10
detected O 0 3.2874111766112435e-10
, O 0 4.575830686581739e-11
and O 0 9.69333641132053e-11
in O 0 3.194799702566087e-10
9 O 0 9.27992083177287e-09
( O 0 1.6503740041251547e-10
56 O 0 1.0482446022308523e-08
% O 0 4.5603762433010786e-10
) O 0 1.6721284079590504e-11
of O 0 4.896453242864141e-10
the O 0 1.7164596854968295e-08
tumors B-Disease 1 1.0
without O 0 1.4564756384061184e-05
LOH O 1 1.0
, O 0 7.498185183862915e-09
both O 0 3.4321270270254445e-09
mutations O 0 2.9907937459938694e-08
were O 0 9.351829532988631e-09
found O 0 1.8345510000017384e-08
. O 0 1.889089702444835e-07

Thus O 0 1.1591335180582973e-07
, O 0 9.571515802164754e-10
a O 0 3.5693017985671815e-10
total O 0 6.49786613404757e-10
of O 0 1.0078153866999173e-09
45 O 0 2.794155351537597e-09
mutations O 0 2.3053992048716054e-09
were O 0 7.29718285796821e-10
identified O 0 4.894084248974195e-09
in O 0 3.531847037052671e-09
tumors B-Disease 1 1.0
of O 0 9.422723792340548e-07
36 O 0 4.946650733472779e-07
patients O 0 1.494044887806467e-08
. O 0 1.4029156147898902e-07

Thirty O 0 1.1549794862730778e-06
- O 0 4.0109430443635574e-08
nine O 0 2.104827956372901e-08
of O 0 7.241863553275607e-09
the O 0 1.4003130877071612e-09
mutations O 0 1.4077095045195165e-09
- O 0 1.5599618263806292e-09
including O 0 1.360689616536348e-10
34 O 0 2.7847661954183422e-08
small O 0 2.7325595119975787e-09
mutations O 0 1.0009137518807165e-08
, O 0 1.1584031511802095e-09
2 O 0 6.350810544120122e-09
large O 0 4.217564075759128e-09
structural O 0 1.4617118893056613e-07
alterations O 0 3.863523261316004e-07
, O 0 6.018093134940727e-09
and O 0 4.251640373098553e-09
hypermethylation O 0 4.363915650174022e-06
in O 0 3.712325735705235e-08
3 O 0 5.40247754088341e-07
tumors O 1 1.0
- O 0 5.757606391654235e-09
were O 0 1.908750379975288e-10
not O 0 2.916379984729822e-11
detected O 0 1.987707082262702e-10
in O 0 1.2187439425714874e-11
the O 0 1.8306693660985474e-10
corresponding O 0 9.119701438464745e-09
peripheral O 0 9.508572134109272e-07
blood O 0 1.2964557072336902e-07
DNA O 0 1.987443738471484e-06
. O 0 8.116059007079457e-07

In O 0 1.4075094156851264e-07
6 O 0 4.961325430485886e-07
( O 0 2.1063009114641318e-09
17 O 0 2.9242997356959677e-08
% O 0 7.83137776849685e-10
) O 0 6.5856248405993245e-12
of O 0 2.5377669410353576e-10
the O 0 1.585564457506905e-09
36 O 0 1.3613738580886547e-08
patients O 0 1.044119457560555e-09
, O 0 1.6130781432810437e-10
a O 0 3.5580796642342705e-10
mutation O 0 1.3232936968421427e-09
was O 0 2.0123551713879806e-09
detected O 0 3.779040969043024e-10
in O 0 4.353158111758404e-11
constitutional O 0 1.700718677000168e-09
DNA O 0 1.4175771667623849e-08
, O 0 9.322529415101144e-10
and O 0 3.6176078799243783e-10
1 O 0 6.257695250866391e-09
of O 0 1.4144433402307754e-09
these O 0 1.2305222396591375e-09
mutations O 0 1.0675115902358812e-08
is O 0 3.607953658057994e-10
known O 0 1.6221120280324186e-10
to O 0 2.9876548457430374e-10
be O 0 1.1684309075832289e-09
associated O 0 1.8650448296853028e-08
with O 0 1.4609301546286702e-09
reduced O 0 2.249197734727204e-07
expressivity O 0 2.7743288228521124e-05
. O 0 5.674835961144709e-07

The O 0 8.584083133200693e-08
presence O 0 1.9434608589108393e-08
of O 0 2.9619094732424855e-08
a O 0 2.1784409831582252e-09
constitutional O 0 8.999624157013386e-09
mutation O 0 6.427682386345168e-09
was O 0 2.2228945351088214e-09
not O 0 3.9886906277875056e-11
associated O 0 1.4023391337047997e-09
with O 0 2.202159288255956e-11
an O 0 2.5256127744732737e-10
early O 0 3.1286608859204534e-09
age O 0 1.316323849920309e-08
at O 0 5.684724246890482e-09
treatment O 0 2.7398046498205986e-08
. O 0 1.907777402720967e-07

In O 0 3.156540984150524e-08
1 O 0 1.6920422751809383e-07
patient O 0 3.888265709406369e-08
, O 0 2.014613365020068e-09
somatic O 0 1.7598730437384802e-06
mosaicism O 0 8.55061716720229e-06
was O 0 1.1721212445081619e-08
demonstrated O 0 4.6454901037051854e-10
by O 0 2.3154974465589007e-11
molecular O 0 5.365202726537177e-10
analysis O 0 3.506011314602375e-10
of O 0 2.803886289814983e-10
DNA O 0 3.8657392842367244e-09
and O 0 1.971077745466232e-09
RNA O 0 5.576082884317657e-08
from O 0 2.458316394893245e-08
peripheral O 0 1.0532465239521116e-05
blood O 0 1.1348696489221766e-06
. O 0 4.1234994796468527e-07

In O 0 3.946123783293842e-08
2 O 0 3.7739017244575734e-08
patients O 0 5.012473769383519e-10
without O 0 7.893688480642425e-10
a O 0 6.897089566137993e-10
detectable O 0 1.3768938345037895e-07
mutation O 0 2.0270050082871194e-09
in O 0 1.4720225038900026e-10
peripheral O 0 1.7929362172708352e-07
blood O 0 2.416057398590965e-08
, O 0 7.704598625757342e-10
mosaicism O 0 3.9233319171216863e-07
was O 0 3.0508855441979676e-09
suggested O 0 6.241527850114892e-10
because O 0 1.657408793542814e-10
1 O 0 2.730772497017142e-09
of O 0 1.2093807066904105e-09
the O 0 3.827529404532015e-09
patients O 0 1.0804782846207672e-08
showed O 0 2.0370681852455164e-07
multifocal O 0 0.07528680562973022
tumors B-Disease 1 1.0
and O 0 4.347934901005601e-09
the O 0 2.271848931201248e-09
other O 0 5.48025458346757e-10
later O 0 2.3671029580896175e-09
developed O 0 4.353486460217937e-09
bilateral B-Disease 0 3.7426164567477826e-07
retinoblastoma I-Disease 0 0.0002791119331959635
. O 0 1.5507002899539657e-06

In O 0 2.2000298471880342e-08
conclusion O 0 3.595376085741009e-07
, O 0 4.041667001075666e-09
our O 0 2.6410216236172346e-09
results O 0 2.865582882094486e-09
emphasize O 0 4.529155273047536e-09
that O 0 6.320689804883983e-11
the O 0 6.29852503486461e-10
manifestation O 0 7.244629784963763e-08
and O 0 6.666222573947778e-10
transmissibility O 0 4.6915218376852863e-07
of O 0 3.902707934599903e-09
retinoblastoma B-Disease 0 6.203246698532894e-07
depend O 0 1.4146276150484027e-08
on O 0 2.4068480541927784e-09
the O 0 4.538474873694298e-10
nature O 0 1.4890910726705897e-09
of O 0 1.4704547579569294e-09
the O 0 2.5296300609767286e-09
first O 0 9.43913280870845e-10
mutation O 0 8.905584603091654e-10
, O 0 1.027443338741385e-10
its O 0 1.0568338565386526e-10
time O 0 4.394513641869935e-10
in O 0 3.513180579783892e-10
development O 0 7.985537564536571e-09
, O 0 2.757474526493553e-10
and O 0 1.3282999700159337e-10
the O 0 9.600110706387e-10
number O 0 7.491033904294397e-10
and O 0 4.5315548535818095e-10
types O 0 5.136416181272807e-09
of O 0 5.738387098830344e-09
cells O 0 2.592158487857432e-09
that O 0 1.0574614517366854e-09
are O 0 2.4573340584588266e-10
affected O 0 7.4158905682963905e-09
. O 0 6.899698590245862e-09
. O 0 1.4997183939158276e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 1.3291284631122835e-05
fifth I-Disease 0 3.840647764263849e-07
component I-Disease 0 6.228440696531834e-08
of I-Disease 0 1.3414639399300654e-09
complement I-Disease 0 1.587313391837597e-09
in O 0 3.427940153954978e-09
man O 0 8.248036920122104e-07
. O 0 5.613763391920656e-07

I O 0 0.010792083106935024
. O 0 2.0815319658140652e-05

Clinical O 0 3.842647856799886e-06
, O 0 6.877850466935342e-08
immunochemical O 0 1.926466211443767e-05
, O 0 1.8777337018605067e-08
and O 0 4.988555790674809e-09
family O 0 4.609360715335242e-08
studies O 0 7.051745853914326e-08
. O 0 1.1719942705212816e-07

The O 0 4.391216634758166e-08
first O 0 3.2405227390341906e-09
recognized O 0 3.722171904030347e-09
human O 0 5.438376859956406e-09
kindred O 0 0.14426054060459137
with O 0 5.798810875923266e-10
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999966621398926
the I-Disease 0 1.8236912069369282e-07
fifth I-Disease 0 4.5445169405411434e-08
component I-Disease 0 8.168616005832519e-08
of I-Disease 0 4.034290412846531e-08
complement I-Disease 0 1.2013605044103315e-07
( O 0 6.289514686841358e-08
C5 O 1 0.9904438853263855
) O 0 2.0436630165932e-09
is O 0 1.9141142004741596e-09
described O 0 2.657526465554838e-08
. O 0 3.075517156503338e-07

The O 0 1.3552099744629231e-06
proband O 0 1.482166499044979e-05
, O 0 9.264286227050889e-09
a O 0 4.996783431465701e-09
20 O 0 1.1638406682834557e-08
- O 0 1.0349000545417653e-09
year O 0 1.8622178243887788e-09
- O 0 4.438741818546532e-09
old O 0 4.9497842269374814e-08
black O 0 1.7028674026420276e-09
female O 0 1.5539868281067015e-09
with O 0 1.0258479621327865e-09
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.0005004580016247928
age O 0 2.732532720983727e-06
11 O 0 3.2343002942525345e-08
, O 0 9.050313831693302e-10
lacked O 0 7.628305809248559e-08
serum O 0 7.474585572708747e-08
hemolytic O 0 1.0120760407517082e-06
complement O 0 5.613913955926364e-08
activity O 0 1.9976106102603808e-07
, O 0 1.1586549497621945e-09
even O 0 1.3701101364560486e-09
during O 0 7.01423763516118e-09
remission O 0 1.9579385934775928e-07
. O 0 4.5754976696343874e-08

C5 O 0 0.007492361590266228
was O 0 2.1709072370867943e-06
undetectable O 0 3.115880247150926e-07
in O 0 1.1835463720188955e-09
her O 0 6.227603432940043e-10
serum O 0 1.1839460523077605e-09
by O 0 1.7541756935912645e-10
both O 0 4.457865632190305e-09
immunodiffusion O 0 5.446348495752318e-06
and O 0 2.8680611663389755e-08
hemolytic O 0 6.007089905324392e-05
assays O 0 3.4327390494581778e-06
. O 0 2.706506620597793e-06

Other O 0 9.461488481576907e-09
complement O 0 4.548564636053243e-09
components O 0 2.8171891486294953e-08
were O 0 6.827132748021825e-10
normal O 0 4.436422340603485e-09
during O 0 5.83906645257315e-10
remission O 0 2.618232208817517e-08
of O 0 5.349122478293111e-09
lupus O 0 1.6301071070756734e-07
, O 0 9.519940391555792e-09
but O 0 5.630825228308822e-08
C1 O 0 1.8655375697562704e-06
, O 0 3.930446723643399e-08
C4 O 0 1.1880933016072959e-05
, O 0 3.9942467111586666e-08
C2 O 0 2.7840314942295663e-07
, O 0 1.2991161923991967e-08
and O 0 5.178057449484186e-08
C3 O 0 0.00016202710685320199
levels O 0 1.305698674514133e-06
fell O 0 1.723452987789642e-05
during O 0 5.220102750058686e-08
exacerbations O 0 7.544011896243319e-05
. O 0 1.5427937114509405e-06

A O 0 2.2652555344393477e-05
younger O 0 2.282952209498035e-06
half O 0 7.939975148474332e-07
- O 0 5.28192742876854e-08
sister O 0 1.0819015727747683e-07
, O 0 2.3985256003555833e-09
who O 0 3.0185758337353263e-09
had O 0 1.6761279031385357e-09
no O 0 2.099278084699563e-09
underlying O 0 1.4100702117048058e-07
disease O 0 2.4864700662874384e-06
, O 0 5.398543834189695e-10
was O 0 1.694179374567284e-08
also O 0 9.444008769454726e-11
found O 0 1.720620868006506e-10
to O 0 1.7651683448249855e-09
lack O 0 2.0535188014036976e-05
immunochemically O 0 0.012436825782060623
detectable O 0 0.14551834762096405
C5 O 0 0.013231983408331871
. O 0 1.4690167517983355e-06

By O 0 1.6214987397233926e-07
hemolytic O 0 9.407751349499449e-05
assay O 0 1.4514813528876402e-06
, O 0 2.6910432993076938e-08
she O 0 1.590252929339897e-09
exhibited O 0 3.876556409210252e-09
1 O 0 1.4480356913537662e-09
- O 0 2.8351040959329055e-10
2 O 0 6.464218049728743e-10
% O 0 3.5248578361679606e-11
of O 0 3.930988173861394e-11
the O 0 1.4091326716592079e-10
normal O 0 4.772704453870347e-09
serum O 0 1.536630200860145e-08
C5 O 0 6.800910909987579e-07
level O 0 1.3886533700713244e-08
and O 0 4.693718747006415e-10
normal O 0 2.667264853428719e-09
concentrations O 0 5.627633026250578e-09
of O 0 6.22579765519049e-10
other O 0 5.17932585708536e-10
complement O 0 1.3268604881488955e-08
components O 0 4.663116897063446e-07
. O 0 3.7673970609830576e-07

C5 O 0 0.0002986108011100441
levels O 0 1.196713270701366e-07
of O 0 6.460339374569912e-09
other O 0 5.790885548861979e-10
family O 0 1.0424976437661826e-09
members O 0 3.9864545692269715e-11
were O 0 1.1049106768412642e-10
either O 0 2.8308352884032217e-10
normal O 0 1.8414493263563259e-09
or O 0 1.126556903319198e-10
approximately O 0 3.370155265969288e-10
half O 0 3.6539540282376493e-09
- O 0 1.955261286212817e-09
normal O 0 1.0073124556697621e-08
, O 0 1.650037328992937e-10
consistent O 0 3.778811930033044e-09
with O 0 1.3258523445802695e-10
autosomal O 0 1.3908223195358005e-07
codominant O 0 8.923256018533721e-07
inheritance O 0 5.362855048929305e-08
of O 0 4.586530710781744e-09
the O 0 5.2625268587291885e-09
gene O 0 4.982454129276448e-07
determining O 0 0.011642190627753735
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.610131772002205e-06

Normal O 0 6.779759132768959e-05
hemolytic O 0 0.0028495625592768192
titers O 0 2.9842076401109807e-05
were O 0 1.0926913596165377e-08
restored O 0 1.9133851836272697e-08
to O 0 2.5487686960978806e-10
both O 0 1.843452501759657e-09
homozygous O 0 2.5358833681821125e-06
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.9444289591774577e-06
C5D B-Disease 1 1.0
) O 0 4.766727457194975e-09
sera O 0 3.776695578494582e-08
by O 0 3.2752925371859476e-11
addition O 0 9.83009562638415e-10
of O 0 8.06331978964181e-09
highly O 0 5.570916172814577e-08
purified O 0 5.867148615834594e-07
human O 0 1.1992032113994355e-06
C5 O 1 0.9996627569198608
. O 0 1.6041598200899898e-06

In O 0 6.770483196305577e-08
specific O 0 7.409686304526986e-07
C5 O 0 0.00022270259796641767
titrations O 0 3.740457941603381e-06
, O 0 5.613492781719742e-09
however O 0 4.25564827821745e-09
, O 0 1.7664540663542283e-10
it O 0 1.443738323336774e-10
was O 0 2.282620759075371e-09
noted O 0 1.6369695599038891e-09
that O 0 3.906532042297073e-11
when O 0 1.4266353376424235e-10
limited O 0 1.1514349890218156e-10
amounts O 0 2.297436463294389e-09
of O 0 2.1632132529703085e-08
C5 O 0 8.691789844306186e-06
were O 0 5.699457350516468e-09
assayed O 0 1.654611736512379e-08
in O 0 1.5975301637105588e-10
the O 0 7.024194559335228e-10
presence O 0 2.3170900753655133e-09
of O 0 6.829402376951066e-09
low O 0 5.140838865713704e-08
dilutions O 0 3.024709940291359e-07
of O 0 3.3019368572695385e-08
either O 0 7.452397881024808e-07
C5D B-Disease 1 1.0
serum O 0 8.55969460644701e-07
, O 0 6.808748231890149e-09
curving O 0 1.4545699400514422e-07
rather O 0 1.925145820536045e-09
than O 0 6.114295181269824e-10
linear O 0 9.836252701234116e-09
dose O 0 9.175235682334915e-09
- O 0 2.5803641445776293e-09
response O 0 2.1582171605416534e-09
plots O 0 2.577699298456082e-08
were O 0 3.568588979874221e-09
consistently O 0 2.452082092929686e-09
obtained O 0 8.143565821683296e-09
, O 0 4.76517048042524e-10
suggesting O 0 3.275752114006991e-09
some O 0 1.2621995670869524e-09
inhibitory O 0 6.244367227736802e-07
effect O 0 8.254009458141809e-07
. O 0 7.155038588280149e-07

Further O 0 4.307470362618915e-07
studies O 0 3.845173424110726e-08
suggested O 0 1.0075987155744315e-08
that O 0 4.437317180361333e-10
low O 0 2.969206569503058e-08
dilutions O 0 5.067970505479025e-06
of O 0 1.9504541626247374e-07
C5D B-Disease 1 1.0
serum O 0 9.15604374540635e-08
contain O 0 3.6379734780211948e-09
a O 0 2.2350621353695033e-09
factor O 0 1.179744835155816e-08
( O 0 3.252906277673162e-10
or O 0 8.000383133754951e-10
factors O 0 1.2531018001027405e-08
) O 0 1.5782980478107334e-10
interfering O 0 1.27031474228545e-09
at O 0 1.462661547435573e-09
some O 0 8.170661369710785e-11
step O 0 6.797701845862036e-10
in O 0 2.9505844989508034e-10
the O 0 5.8831370886025525e-09
hemolytic O 0 3.020394160557771e-06
assay O 0 1.2244470326550072e-06
of O 0 8.664732717988954e-07
C5 O 0 0.0010572083992883563
, O 0 2.504521479096411e-09
rather O 0 1.1473535455053252e-09
than O 0 5.32442534506572e-10
a O 0 5.240720746257921e-09
true O 0 1.2374830760109035e-07
C5 O 0 5.5926520872162655e-06
inhibitor O 0 9.154105384823197e-08
or O 0 3.985928387351123e-08
inactivator O 0 6.264012426981935e-06
. O 0 6.553678417731135e-07

Of O 0 3.6721920082527504e-07
clinical O 0 1.7328202375210822e-06
interest O 0 1.9949654870288214e-06
are O 0 2.9795299560930744e-09
( O 0 7.284250425065864e-10
a O 0 2.0570141145981324e-09
) O 0 1.7198324361866746e-11
the O 0 8.429672238019492e-11
documentation O 0 3.889749322638636e-08
of O 0 3.7682269748984254e-08
membranous O 1 0.9999897480010986
glomerulonephritis B-Disease 1 1.0
, O 0 4.6252793595158437e-07
vasculitis B-Disease 1 1.0
, O 0 2.4357127870189288e-08
and O 0 3.754731636718134e-08
arthritis B-Disease 1 1.0
in O 0 2.003764265623431e-09
an O 0 1.0249677773188637e-09
individual O 0 1.8611739927010262e-09
lacking O 0 0.0030165393836796284
C5 O 1 0.9999293088912964
( O 0 2.5082311783108935e-09
and O 0 4.355651950227468e-10
its O 0 5.296105776153581e-10
biologic O 0 8.282989938379615e-08
functions O 0 8.828598407895072e-10
) O 0 4.824236149447714e-11
, O 0 1.427884754878761e-10
and O 0 2.080887406830101e-10
( O 0 1.2338259580690902e-10
b O 0 1.3109413554701632e-09
) O 0 2.995904566094332e-11
a O 0 1.7805563967687732e-10
remarkable O 0 5.021787430337099e-09
propensity O 0 1.0368746927724715e-07
to O 0 1.9066299650205565e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.7947164587805986e-10
the O 0 1.1768406249501595e-09
proband O 0 1.2061842369348597e-07
, O 0 1.637412150312656e-10
even O 0 3.4556146832898094e-10
during O 0 5.248100287680302e-10
periods O 0 3.0807328244009113e-08
of O 0 1.0683669948718943e-08
low O 0 8.937192319535825e-08
- O 0 4.312906032311048e-09
dose O 0 7.706586480082933e-09
or O 0 1.7227266280173126e-09
alternate O 0 4.1759104618677156e-08
- O 0 2.971812662622142e-08
day O 0 8.857664823835876e-09
corticosteroid O 0 1.2113757748011267e-06
therapy O 0 1.4142963777885598e-07
. O 0 2.1504403946437378e-07

Other O 0 4.4955573486049616e-08
observations O 0 6.727655232907637e-08
indicate O 0 9.872113793107928e-09
that O 0 2.984841263042881e-10
the O 0 9.191174932254853e-09
C5D B-Disease 1 1.0
state O 0 2.0423769342414744e-09
is O 0 1.61845592483445e-10
compatible O 0 1.0768484992595972e-09
with O 0 6.914697286974913e-11
normal O 0 2.7683899617159113e-09
coagulation O 0 7.287895620322615e-09
function O 0 1.094975332627257e-09
and O 0 3.401242343326061e-10
the O 0 9.875781303847475e-10
capacity O 0 2.1023274232589984e-09
to O 0 1.4319136987239744e-09
mount O 0 3.7172009115238325e-07
a O 0 1.6170852745744924e-07
neutrophilic O 0 0.0026335371658205986
leukocytosis O 0 0.00018448913760948926
during O 0 5.089777914690785e-07
pyogenic B-Disease 0 8.254279964603484e-05
infection I-Disease 0 3.640794261627889e-07
. O 0 1.2100182189556108e-08
. O 0 1.1475558636675487e-07

Susceptibility O 0 6.629306881222874e-06
to O 0 3.0993578548077494e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 1.209577931149397e-07
twins O 0 9.894569075186155e-08
: O 0 9.542837353659905e-11
the O 0 3.069503817787478e-10
role O 0 9.522641564174705e-10
of O 0 4.755103866216359e-09
genes O 0 8.812502727550964e-09
, O 0 3.4123948111641766e-09
HLA O 0 3.8056350604165345e-07
, O 0 3.1939668687641642e-09
and O 0 1.3194477732625387e-09
the O 0 1.7863206025481304e-08
environment O 0 2.3347753597136034e-07
. O 0 4.901139618596062e-07

OBJECTIVE O 0 2.7293683615425834e-06
To O 0 5.11781339529449e-10
determine O 0 2.987981195801126e-09
the O 0 7.79217690372036e-10
relative O 0 6.942975261381434e-08
effects O 0 6.175456945811675e-08
of O 0 2.053094361187391e-09
genetic O 0 1.4001589221379618e-08
and O 0 4.913114914906203e-10
environmental O 0 5.998404883911235e-09
factors O 0 9.32159149868994e-09
in O 0 1.1097811558613557e-10
susceptibility O 0 7.01682154158334e-07
to O 0 1.0555882568041852e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 2.298030722158728e-06
AS B-Disease 1 1.0
) O 0 1.0942179606843183e-08
. O 0 6.122411377873505e-08

METHODS O 0 1.1599884601309896e-05
Twins O 0 3.2570420671618194e-07
with O 0 1.2131534665726917e-09
AS B-Disease 1 1.0
were O 0 8.46639425233775e-11
identified O 0 6.297549287603843e-11
from O 0 3.4479231969530844e-11
the O 0 1.915033548405276e-10
Royal O 0 5.615559572902384e-09
National O 0 8.330073519857706e-09
Hospital O 0 4.187850208836608e-06
for O 0 3.2576332742451086e-09
Rheumatic B-Disease 1 0.9999998807907104
Diseases I-Disease 0 0.0007739183492958546
database O 0 3.996964039743034e-07
. O 0 2.0871306105618714e-07

Clinical O 0 3.577873712856672e-07
and O 0 4.868406566771455e-09
radiographic O 0 6.006621902088227e-07
examinations O 0 3.7532281282892654e-08
were O 0 3.709160312226345e-09
performed O 0 2.036645990743935e-10
to O 0 2.2870734472935084e-10
establish O 0 1.4763712030685383e-08
diagnoses O 0 1.0022119568020571e-05
, O 0 3.0600586509166305e-09
and O 0 1.1640909347576667e-09
disease O 0 6.640682386205299e-07
severity O 0 8.071306183410343e-06
was O 0 4.507128448238973e-09
assessed O 0 2.800947918046859e-09
using O 0 1.2079923172869655e-10
a O 0 4.793063723695923e-10
combination O 0 3.313853635944497e-09
of O 0 5.575771400145868e-09
validated O 0 9.817138391099434e-08
scoring O 0 2.1530198068830941e-07
systems O 0 3.817000902017753e-07
. O 0 7.597766966682684e-07

HLA O 0 3.3774442272260785e-05
typing O 0 2.456835943576152e-07
for O 0 1.3407892573980007e-08
HLA O 0 6.723909677930351e-07
- O 0 2.4506999807272223e-07
B27 O 0 4.76949480798794e-07
, O 0 1.3902905493523576e-09
HLA O 0 1.4180017160470015e-08
- O 0 5.285603510429837e-09
B60 O 0 2.7241252809062644e-08
, O 0 1.1569981084313952e-10
and O 0 9.692467661803761e-11
HLA O 0 1.607477706500049e-08
- O 0 6.574455113650401e-08
DR1 O 0 1.7340391423203982e-05
was O 0 7.146853331363445e-09
performed O 0 2.6685596440922943e-11
by O 0 4.2139899208981646e-11
polymerase O 0 1.8081348640563988e-09
chain O 0 2.7066855423640845e-09
reaction O 0 3.6348524190543685e-09
with O 0 6.135238150850597e-11
sequence O 0 2.988566616402011e-10
- O 0 2.651195096792236e-10
specific O 0 2.7414692738148005e-10
primers O 0 5.65650593031819e-09
, O 0 6.376490446768912e-10
and O 0 5.124846658155491e-10
zygosity O 0 3.071785386055126e-07
was O 0 9.002937062518868e-09
assessed O 0 1.086417356077618e-08
using O 0 6.563927179570328e-09
microsatellite O 0 2.0029378902108874e-06
markers O 0 2.2667743451165734e-06
. O 0 2.455749381624628e-06

Genetic O 0 2.6028223487628566e-07
and O 0 4.12035161545532e-09
environmental O 0 4.567064060267967e-09
variance O 0 4.785995155742739e-09
components O 0 3.799757397615622e-09
were O 0 1.6421536352950739e-10
assessed O 0 6.425353138439505e-09
with O 0 5.901405059072218e-11
the O 0 1.2300529483866285e-09
program O 0 3.872172305019461e-10
Mx O 0 1.92422811018389e-09
, O 0 1.1967201535290073e-11
using O 0 1.3103169807862636e-12
data O 0 5.102508346399581e-11
from O 0 4.369370837364883e-11
this O 0 3.1190171972950154e-11
and O 0 8.382661925709911e-11
previous O 0 6.416385200935792e-10
studies O 0 9.471233797242462e-10
of O 0 2.1410297978974313e-09
twins O 0 2.8473218449676096e-08
with O 0 2.184536551652627e-09
AS B-Disease 1 1.0
. O 0 3.729280706465943e-07

RESULTS O 0 2.816509777403553e-06
Six O 0 9.484113405733297e-08
of O 0 8.496042624983602e-08
8 O 0 2.6606386427374673e-07
monozygotic O 0 1.7211859812960029e-06
( O 0 3.937132575515534e-08
MZ O 0 9.685746772447601e-05
) O 0 7.3391315247306466e-09
twin O 0 3.9245811933597e-08
pairs O 0 4.789712182429184e-09
were O 0 1.5412026099781428e-09
disease O 0 5.044715223334606e-08
concordant O 0 2.4511115270797745e-07
, O 0 2.801742726710188e-10
compared O 0 3.8170874794296594e-10
with O 0 1.9515482979626242e-11
4 O 0 1.7135639573950812e-09
of O 0 2.220627459692537e-09
15 O 0 1.121648196544811e-08
B27 O 0 1.325383891526144e-07
- O 0 2.0201589734369918e-08
positive O 0 4.388066354721332e-09
dizygotic O 0 3.219065547455102e-07
( O 0 6.5871170740194884e-09
DZ O 0 1.4787716509090387e-06
) O 0 1.9013459695571555e-09
twin O 0 3.8094761123375065e-08
pairs O 0 5.916648948556258e-09
( O 0 1.1758063411804187e-09
27 O 0 7.223574272074984e-08
% O 0 7.751086994467471e-10
) O 0 5.7320558889684126e-12
and O 0 4.065227668381688e-11
4 O 0 1.7415614506077759e-09
of O 0 1.2823387685045873e-08
32 O 0 6.75119792958867e-07
DZ O 0 4.6920737077016383e-05
twin O 0 8.103236268652836e-07
pairs O 0 7.339455976307363e-08
overall O 0 5.12980534495e-07
( O 0 4.601716341312567e-09
12 O 0 2.95596116473007e-08
. O 0 2.5564821370949176e-09
5 O 0 2.398979859208339e-08
% O 0 3.1289295598924127e-09
) O 0 3.8308434202605213e-10
. O 0 2.121372943975075e-08

Nonsignificant O 0 6.356390713335713e-06
increases O 0 2.7365821608782426e-08
in O 0 3.8980338401550796e-10
similarity O 0 9.336003969906415e-09
with O 0 3.791240238415483e-11
regard O 0 1.1823528822674234e-09
to O 0 1.555993806023892e-10
age O 0 1.012744998973858e-08
at O 0 1.2854677322593488e-09
disease O 0 9.781006227171929e-09
onset O 0 3.214264054918203e-08
and O 0 4.142704235210459e-11
all O 0 1.2820603953467291e-11
of O 0 1.0700708374944412e-10
the O 0 1.9160237285653636e-10
disease O 0 5.007010805968548e-09
severity O 0 2.3819005434688734e-08
scores O 0 3.811444049262036e-09
assessed O 0 2.0794413302382964e-08
were O 0 1.6149939163767613e-09
noted O 0 5.0671138396296556e-09
in O 0 6.739439561975757e-10
disease O 0 8.555445418778618e-08
- O 0 4.4839791257800243e-07
concordant O 0 0.00017528283933643252
MZ O 0 0.0016822072211652994
twins O 0 2.2357586715315847e-07
compared O 0 1.0368426117679519e-08
with O 0 2.6599895619483505e-09
concordant O 0 8.103003347059712e-05
DZ O 0 0.0012135907309129834
twins O 0 1.7389756976626813e-05
. O 0 1.8127510656995582e-06

HLA O 0 1.5341373000410385e-05
- O 0 1.4927991287549958e-06
B27 O 0 1.2938991176270065e-06
and O 0 1.3544009247468125e-09
B60 O 0 5.970350969164429e-08
were O 0 1.658211901123252e-10
associated O 0 5.517108991881514e-10
with O 0 3.700577691501117e-11
the O 0 4.1997735844567785e-10
disease O 0 1.2030889173786363e-08
in O 0 1.7656287543132976e-10
probands O 0 1.8724300616668188e-06
, O 0 1.9634409376134698e-10
and O 0 3.021550717963173e-11
the O 0 1.656334375210733e-10
rate O 0 1.895624768266657e-09
of O 0 3.684310911911126e-10
disease O 0 1.2728473386403039e-08
concordance O 0 6.157999887790311e-09
was O 0 2.1717108666940987e-10
significantly O 0 2.567789036955759e-10
increased O 0 7.962810411044074e-10
among O 0 6.537327124078729e-09
DZ O 0 5.732838872063439e-06
twin O 0 7.755649278351484e-08
pairs O 0 1.6720694828720184e-09
in O 0 3.7869346547481086e-10
which O 0 3.0939559247933346e-10
the O 0 5.0030202203288354e-09
co O 0 9.714352877665533e-09
- O 0 2.4952440114134333e-08
twin O 0 7.86802232255468e-08
was O 0 5.093188537586002e-09
positive O 0 1.7663495666120355e-10
for O 0 1.4133935688498411e-10
both O 0 5.977173866966723e-09
B27 O 0 3.912118700100109e-06
and O 0 2.0228394248533732e-07
DR1 O 0 0.01585528999567032
. O 0 2.336557827220531e-06

Additive O 0 1.0336285072298779e-07
genetic O 0 4.3352756051717733e-08
effects O 0 6.000558983032533e-08
were O 0 4.3030518037667775e-10
estimated O 0 7.842002047731e-11
to O 0 4.63132136807598e-12
contribute O 0 1.135626592763117e-10
97 O 0 2.960450995459496e-09
% O 0 3.0863745587028646e-11
of O 0 8.229228930234367e-12
the O 0 2.520688519025427e-11
population O 0 1.156203952024093e-10
variance O 0 1.886111711257854e-08
. O 0 9.366006992195253e-08

CONCLUSION O 0 2.9174389055697247e-06
Susceptibility O 0 1.7189636025705113e-07
to O 0 1.3861130021552981e-08
AS B-Disease 1 1.0
is O 0 1.4885571664180475e-09
largely O 0 1.870893884259317e-09
genetically O 0 4.2643810704845464e-10
determined O 0 2.355132755482714e-09
, O 0 1.3721491998186508e-10
and O 0 8.390468181351807e-11
the O 0 2.087032491271401e-10
environmental O 0 5.013595316682995e-09
trigger O 0 3.812682081161256e-08
for O 0 6.890528148062458e-10
the O 0 2.205592508630616e-08
disease O 0 3.1758330010234204e-07
is O 0 7.834650150861933e-10
probably O 0 1.5838969247283785e-08
ubiquitous O 0 5.285656925479998e-07
. O 0 2.2511461850172054e-07

HLA O 0 3.073697007494047e-05
- O 0 1.213650307363423e-06
B27 O 0 5.232283797340642e-07
accounts O 0 7.687614433926626e-10
for O 0 1.868203335086971e-11
a O 0 8.729100775539678e-11
minority O 0 2.5717235632716218e-11
of O 0 1.3750810212709297e-10
the O 0 3.994905517501479e-10
overall O 0 3.2499622992787636e-09
genetic O 0 3.1855542204084486e-08
susceptibility O 0 6.293871592788491e-07
to O 0 8.377958948813102e-08
AS B-Disease 1 1.0
. O 0 1.5377494264612324e-06

Cell O 0 7.765055670461152e-06
cycle O 0 9.188590297526389e-07
- O 0 1.0807589490013925e-07
dependent O 0 1.0954567386534109e-07
colocalization O 0 3.134917392344505e-07
of O 0 1.3296625134273654e-08
BARD1 O 0 1.3667791790794581e-05
and O 0 7.139958846380523e-09
BRCA1 O 0 4.139911968792376e-09
proteins O 0 3.292393302434249e-10
in O 0 1.3491610606486404e-10
discrete O 0 1.5258153851505085e-08
nuclear O 0 2.6919164497485326e-07
domains O 0 1.2642477713598055e-06
. O 0 8.865441145644581e-07

Germ O 0 5.4778254707343876e-05
- O 0 3.3302142128377454e-06
line O 0 4.361555170362408e-07
mutations O 0 6.611917058307881e-08
of O 0 2.068136595312353e-08
the O 0 2.101374363405739e-08
BRCA1 O 0 4.954658194833428e-08
gene O 0 2.1384678916547273e-08
predispose O 0 6.2272265495266765e-06
women O 0 4.325436453456177e-09
to O 0 8.786147920325504e-10
early O 0 5.616761882265564e-07
- O 0 7.337146712416143e-07
onset O 1 0.9999992847442627
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.348883227336728e-10
compromising O 0 2.4554893673922606e-09
the O 0 2.588521064161853e-10
genes O 0 2.259317177788489e-09
presumptive O 0 2.8814127972509596e-08
function O 0 1.0993154164751218e-09
as O 0 1.8714936267372195e-09
a O 0 6.1072351620339305e-09
tumor B-Disease 0 1.438061190128792e-06
suppressor O 0 4.291861841920763e-05
. O 0 1.3038521728958585e-06

Although O 0 2.540297572295458e-08
the O 0 8.101581627784071e-09
biochemical O 0 6.945318773432518e-07
properties O 0 8.286899628728861e-07
of O 0 4.873556349593855e-07
BRCA1 O 0 1.6946731307143637e-07
polypeptides O 0 7.094282494790605e-08
are O 0 1.8259337097870088e-10
not O 0 2.4843474499824936e-10
understood O 0 9.071091433554557e-09
, O 0 9.891611835177727e-11
their O 0 5.4715201119881485e-11
expression O 0 3.336979137458229e-09
pattern O 0 7.022818326873903e-09
and O 0 4.6130765873897417e-10
subcellular O 0 6.240974244065001e-07
localization O 0 1.52849295886881e-07
suggest O 0 1.709435260011105e-08
a O 0 8.335588219665624e-09
role O 0 7.394689305328939e-09
in O 0 8.803144879721003e-09
cell O 0 1.1395438832551008e-06
- O 0 4.0238549559035164e-07
cycle O 0 7.34640295263489e-08
regulation O 0 3.2565915830673475e-07
. O 0 4.2038331571347953e-07

When O 0 8.86916211584321e-07
resting O 0 3.8434613998106215e-06
cells O 0 9.455538929614704e-08
are O 0 5.675382386272076e-10
induced O 0 8.809897700245983e-09
to O 0 6.647821182426128e-11
proliferate O 0 3.221541700071384e-09
, O 0 6.059933110869054e-11
the O 0 2.1447398024232456e-10
steady O 0 9.098851450062284e-09
- O 0 9.950385654322602e-11
state O 0 7.560432141451301e-11
levels O 0 7.794094258883888e-10
of O 0 7.946985292051068e-10
BRCA1 O 0 1.198617427533577e-09
increase O 0 3.0160535180456804e-10
in O 0 3.800400549813787e-10
late O 0 2.5380171564393095e-07
G1 O 0 8.048755972822619e-08
and O 0 1.9911715332110447e-10
reach O 0 2.0838393233191255e-09
a O 0 4.1551853624532953e-10
maximum O 0 8.737587542384517e-09
during O 0 1.9309942089762444e-08
S O 0 1.2565791394081316e-06
phase O 0 3.1402225886267843e-07
. O 0 7.048477641546924e-07

Moreover O 0 1.524579715805885e-06
, O 0 2.86510335456569e-08
in O 0 1.2940661875404658e-08
S O 0 7.890675419730542e-07
phase O 0 9.683832757900745e-08
cells O 0 1.0613683798510465e-07
, O 0 2.242274987906967e-08
BRCA1 O 0 6.773415606176059e-08
polypeptides O 0 2.9574781734709177e-08
are O 0 9.638089215613377e-10
hyperphosphorylated O 0 1.6587488005370687e-07
and O 0 2.0192836291954563e-09
accumulate O 0 7.49073780781373e-09
into O 0 2.6764430671732953e-09
discrete O 0 7.088912923336466e-08
subnuclear O 0 7.428711796819698e-07
foci O 0 7.890231472629239e-07
termed O 0 2.9889494612689305e-07
" O 0 7.882111674462067e-08
BRCA1 O 0 3.2962552154458535e-07
nuclear O 0 7.335061695812328e-07
dots O 0 3.336712097734562e-06
. O 0 1.1395026149330079e-06

" O 0 2.4135117655532667e-06
BRCA1 O 0 2.2626275040238397e-06
associates O 0 4.968370603819494e-07
in O 0 1.0730171418060763e-08
vivo O 0 3.020788952312614e-08
with O 0 1.069574914747129e-10
a O 0 1.6978826122837631e-09
structurally O 0 4.123860364302345e-08
related O 0 3.227226130775307e-08
protein O 0 6.531075086968485e-06
termed O 0 2.530807705625193e-06
BARD1 O 1 0.9995777010917664
. O 0 7.714015168858168e-07

Here O 0 1.685339583445966e-07
we O 0 6.027604637637296e-09
show O 0 1.260530013702521e-09
that O 0 1.1221649304227199e-10
the O 0 1.0049476806273105e-09
steady O 0 5.2985363652169326e-08
- O 0 7.658154665968198e-10
state O 0 5.165395888795388e-10
levels O 0 6.324507140220703e-09
of O 0 7.60417329104257e-09
BARD1 O 0 2.4627295715617947e-05
, O 0 2.0836317393690962e-10
unlike O 0 1.7480633607291907e-10
those O 0 2.4032364986936727e-10
of O 0 4.0750518515153544e-09
BRCA1 O 0 1.4485944888065205e-08
, O 0 2.115370656419202e-10
remain O 0 3.9241732086026104e-10
relatively O 0 5.88277537794113e-10
constant O 0 4.567534350741198e-09
during O 0 2.2396879906239064e-09
cell O 0 4.164092501923733e-07
cycle O 0 5.466563024469906e-08
progression O 0 6.944683264009655e-07
. O 0 3.144672859889397e-07

However O 0 1.70391342635412e-06
, O 0 1.0907572800533671e-07
immunostaining O 0 1.1515168807818554e-05
revealed O 0 2.1365826796682086e-07
that O 0 5.501139543895306e-09
BARD1 O 0 0.0006058502476662397
resides O 0 4.3709448505069304e-07
within O 0 2.196147619315525e-08
BRCA1 O 0 5.012431358863978e-08
nuclear O 0 5.621060239491271e-08
dots O 0 1.6115423662199646e-08
during O 0 2.204805005234789e-09
S O 0 1.2650033021088802e-08
phase O 0 1.910466895793661e-09
of O 0 1.5090971805520326e-09
the O 0 3.291239725200512e-09
cell O 0 1.7809114183364727e-08
cycle O 0 5.715307338505227e-09
, O 0 8.157673841990842e-11
but O 0 1.369892532743222e-10
not O 0 1.2017530026664502e-10
during O 0 2.6068993630445902e-09
the O 0 2.4939019738212664e-08
G1 O 0 1.5880766568443505e-06
phase O 0 4.4313338776191813e-07
. O 0 1.0157464203075506e-06

Nevertheless O 0 1.7492362530902028e-05
, O 0 1.47890830248798e-07
BARD1 O 0 6.911814125487581e-05
polypeptides O 0 1.251337238272754e-07
are O 0 2.5798951863720276e-10
found O 0 1.9566331888043464e-10
exclusively O 0 2.1140880712700039e-10
in O 0 3.723929498100631e-11
the O 0 2.855046477012735e-10
nuclear O 0 4.6945629605943395e-09
fractions O 0 1.1341513506124556e-08
of O 0 1.0620159862639866e-08
both O 0 5.57831336678305e-09
G1 O 0 1.8712130156472995e-07
- O 0 2.7465906882184754e-08
and O 0 2.17578435268706e-08
S O 0 7.973363267410605e-07
- O 0 4.781144014032179e-08
phase O 0 5.171740014020543e-08
cells O 0 2.669526395493449e-07
. O 0 4.4635686435867683e-07

Therefore O 0 4.6637526907034044e-07
, O 0 7.165894544414186e-09
progression O 0 4.335664272048234e-08
to O 0 3.825427530301795e-09
S O 0 1.3882092275707691e-07
phase O 0 1.1598054072692321e-08
is O 0 2.739232451975937e-10
accompanied O 0 1.5795035279708713e-09
by O 0 1.329937687755134e-10
the O 0 1.748737932238953e-09
aggregation O 0 3.459060593513641e-08
of O 0 8.421356056942386e-09
nuclear O 0 6.000599341859925e-07
BARD1 O 0 0.0005563581944443285
polypeptides O 0 1.4525835467793513e-06
into O 0 1.212643212511466e-07
BRCA1 O 0 1.2327766398811946e-06
nuclear O 0 2.12054737858125e-06
dots O 0 5.326657174009597e-06
. O 0 1.1230866903133574e-06

This O 0 5.270706182614049e-08
cell O 0 1.0912790457950905e-06
cycle O 0 1.0997400323731199e-07
- O 0 1.758136569662838e-08
dependent O 0 2.7076991315766463e-08
colocalization O 0 2.45382921093551e-07
of O 0 9.236515552402125e-09
BARD1 O 0 0.00010675584780983627
and O 0 9.786735866157414e-09
BRCA1 O 0 2.3653395686551448e-08
indicates O 0 3.544263771360079e-09
a O 0 2.7531862900609383e-10
role O 0 5.568105976294646e-10
for O 0 6.38208763614756e-10
BARD1 O 0 0.000662018486764282
in O 0 3.5385042451707704e-08
BRCA1 O 0 6.276240583247272e-06
- O 0 7.89452315075323e-06
mediated O 0 1.7732239939505234e-05
tumor B-Disease 0 1.97049007510941e-06
suppression O 0 1.6213022036026814e-06
. O 0 2.077226071151017e-07

Ethnic O 0 1.7324157397524687e-07
differences O 0 3.7483889059330977e-07
in O 0 1.1330184790381281e-08
the O 0 1.5418626730934193e-07
HFE O 0 0.0006132724811322987
codon O 0 1.0506071703275666e-05
282 O 0 5.481349035107996e-06
( O 0 9.23253594464768e-07
Cys O 0 0.00012800830882042646
/ O 0 4.38845108874375e-06
Tyr O 0 5.752511242462788e-06
) O 0 7.728651496563543e-09
polymorphism O 0 1.6632918686809717e-07
. O 0 5.779625666946231e-07

Recent O 0 6.591078260953509e-08
studies O 0 9.207931306320916e-09
have O 0 9.45891698300727e-11
shown O 0 3.6254896307319484e-10
that O 0 3.0555036278911984e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9992309808731079
HH B-Disease 1 1.0
) O 0 5.936993674460211e-10
is O 0 5.249599019374607e-11
likely O 0 1.1764629548327576e-10
to O 0 5.628303725857542e-11
be O 0 3.2818292527991844e-10
caused O 0 1.4096286804488045e-08
by O 0 7.485878028568038e-10
homozygosity O 0 8.015921935111692e-07
for O 0 7.676888569285722e-10
a O 0 5.343860465245598e-09
Cys282Tyr O 0 3.482960835299309e-07
mutation O 0 4.115152218986395e-09
in O 0 8.530083306368397e-10
the O 0 3.781453017381864e-08
HFE O 0 2.74167578027118e-05
gene O 0 2.422111435862462e-07
located O 0 9.65271965469583e-07
4 O 0 1.0670828487491235e-06
. O 0 4.44201759819407e-07

5 O 0 1.1348836778779514e-05
Mb O 0 2.438451929265284e-06
telomeric O 0 2.920731958511169e-06
to O 0 3.979957341471163e-08
HLA O 0 3.6674950933957007e-06
- O 0 6.486832830887579e-07
A O 0 1.6650805036988459e-06
. O 0 2.0880663953448675e-07

Population O 0 3.787593794157829e-09
studies O 0 1.654311243548534e-09
of O 0 4.632368655332897e-10
this O 0 4.2649887094237116e-11
polymorphism O 0 1.3072758431320608e-09
are O 0 5.904354782870769e-11
facilitated O 0 1.960175355364413e-09
by O 0 1.8404933133098211e-10
the O 0 1.2551750749878465e-09
fact O 0 1.4603868114804186e-09
that O 0 2.5307678175323645e-10
the O 0 5.829676297253172e-09
Cys282Tyr O 0 2.6932311811833642e-06
mutation O 0 1.1116809162103891e-07
creates O 0 9.430251424191738e-08
a O 0 2.4244174667842344e-08
Rsal O 0 2.3704308205196867e-06
restriction O 0 5.42347265763965e-07
site O 0 1.667511924097198e-06
. O 0 6.05289017130417e-07

We O 0 8.515738159076136e-08
have O 0 2.8856570466473386e-09
studied O 0 2.994458370153552e-08
the O 0 4.837721334638445e-09
codon O 0 4.533089565939008e-07
282 O 0 7.017370649009536e-07
( O 0 9.56313073174897e-08
Cys O 0 1.4113664292381145e-05
/ O 0 6.211369054653915e-07
Tyr O 0 2.3271682891845558e-07
) O 0 5.2454554588798885e-11
polymorphism O 0 8.921390709515364e-11
in O 0 5.513297457460098e-11
different O 0 2.2305807201306038e-10
ethnic O 0 8.157604369785076e-09
groups O 0 4.027246092164205e-09
. O 0 4.995699498522299e-08

In O 0 5.002390501829268e-09
agreement O 0 3.343893340002069e-08
with O 0 3.8642630761920316e-10
previous O 0 1.037772534573378e-08
observations O 0 4.035729261886445e-08
the O 0 5.715372619619075e-09
Tyr O 0 6.130994734121487e-07
allele O 0 1.3599204429226575e-08
appeared O 0 1.2372206370514505e-08
to O 0 3.4055203101956977e-10
be O 0 2.799606102499297e-10
rare O 0 3.599762044004251e-09
or O 0 2.656445508009142e-09
absent O 0 4.824832089411757e-08
in O 0 1.0840881525808754e-09
Asiatic O 0 1.0394112592848614e-07
( O 0 1.3487905237141717e-10
Indian O 0 5.334539476820055e-10
, O 0 2.1832692598255932e-10
Chinese O 0 1.5378961437662042e-09
) O 0 2.9549998559197377e-10
populations O 0 5.7222444560522945e-09
. O 0 1.064427550545588e-07

The O 0 3.945288540307956e-08
highest O 0 5.231275679307146e-08
allele O 0 1.4277800275408481e-08
frequency O 0 7.990687223013992e-09
( O 0 2.0727668192943582e-10
7 O 0 1.2435794616294515e-09
. O 0 1.2767632784349559e-10
5 O 0 7.771575050163904e-10
% O 0 1.0899862262769844e-10
) O 0 4.417164550796215e-12
was O 0 3.6975175699005547e-10
found O 0 7.994566814106818e-11
in O 0 5.450077056323721e-10
Swedes O 0 1.787650631968063e-07
. O 0 8.340226145264751e-07

Saamis O 0 7.391479448415339e-05
( O 0 4.797449548732402e-08
2 O 0 1.2762416190525983e-07
% O 0 2.2879385053187207e-09
) O 0 3.8748226849349976e-11
and O 0 1.2690039297158506e-10
Mordvinians O 0 2.191971049114727e-08
( O 0 7.959830017334468e-11
1 O 0 1.6617525133710842e-09
. O 0 3.4926625480657947e-10
8 O 0 1.9217196722820518e-09
% O 0 1.503382279777199e-10
) O 0 2.2996864829094577e-12
had O 0 1.4763265263062486e-11
significantly O 0 1.3350283378787964e-10
lower O 0 4.934969655145949e-10
frequencies O 0 2.2625861184621954e-09
of O 0 2.861060943715188e-09
the O 0 2.0844407089271044e-08
Tyr O 0 3.2487139378645224e-06
allele O 0 3.59023005103154e-07
. O 0 5.072996600574697e-07

Comparisons O 0 3.5338777593096893e-07
with O 0 1.984000075339054e-09
allele O 0 1.3112771313217308e-08
frequencies O 0 1.6722322415674284e-09
based O 0 4.940139963771628e-10
on O 0 2.691163680790254e-10
prevalence O 0 4.234556261195621e-09
estimates O 0 4.692978006204385e-09
of O 0 3.6660732227744575e-09
HH B-Disease 1 0.9978004097938538
showed O 0 1.7576813604591734e-07
some O 0 4.358745364640981e-09
disagreements O 0 3.7661939700228686e-07
with O 0 9.480234375303098e-10
the O 0 8.561628739300886e-09
RFLP O 0 7.435694016066918e-08
data O 0 1.6075206943355624e-08
, O 0 1.0584179088724e-09
particularly O 0 3.401536163849528e-09
in O 0 4.551159449306397e-09
Finns O 0 1.4880051821819507e-06
. O 0 1.1895044735865667e-06

The O 0 2.4307112198584946e-06
newly O 0 6.126253538241144e-06
described O 0 6.213252845554962e-07
HFE O 0 0.037730466574430466
marker O 0 9.101594855565054e-07
provides O 0 1.2072012722796899e-08
a O 0 1.191812537548742e-09
new O 0 4.974111678102133e-10
approach O 0 3.370521639567414e-10
to O 0 5.793203070036945e-11
the O 0 1.6610735009692235e-10
screening O 0 2.0963519808958608e-10
of O 0 5.138415026806342e-09
HH B-Disease 0 6.479967851191759e-05
as O 0 8.1936102347413e-09
well O 0 5.782950229793471e-10
as O 0 1.3114083430298962e-10
studies O 0 1.339877792050359e-10
of O 0 2.885468530777757e-10
the O 0 1.263182225486048e-09
relationship O 0 4.4677399557713215e-09
between O 0 1.3614256388905233e-08
the O 0 1.7847888500455156e-07
HFE O 0 0.0010903457878157496
Tyr O 0 5.303194939187961e-06
allele O 0 5.750782605673521e-08
and O 0 3.581203333880012e-09
different O 0 2.1776527248107413e-08
disorders O 0 0.0004722843586932868
including O 0 9.734255854709772e-07
cancer B-Disease 1 0.9999995231628418

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9598118662834167
associated O 0 1.086106582448565e-08
with O 0 8.063141820890962e-11
a O 0 7.471128715685893e-10
missense O 0 1.5658738306001396e-08
mutation O 0 5.167248295911975e-10
encoding O 0 5.113756529340208e-09
Gly23 O 0 8.979324093161267e-07
- O 0 1.1324765836207007e-07
- O 0 1.568493104286972e-07
> O 0 8.114173510875844e-08
Val O 0 2.4580959490094756e-08
in O 0 5.15219333863115e-09
neurophysin O 0 2.8711731374642113e-06
II O 0 4.118155993637629e-05
. O 0 1.3738483630731935e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 3.8482994568767026e-07
ADNDI B-Disease 1 1.0
) O 0 8.651432903405976e-10
is O 0 6.921215683908244e-11
an O 0 4.848249579580965e-10
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 1.2479507631724118e-06
by O 0 1.2485128209061003e-10
progressive O 0 0.007471265271306038
degeneration O 1 1.0
of O 0 4.859296520720591e-09
the O 0 1.4529214498182341e-09
magnocellular O 0 2.520063162592123e-07
neurons O 0 4.670655684435587e-08
of O 0 2.4644886131852672e-09
the O 0 1.9835761921882522e-09
hypothalamus O 0 1.1056433102396568e-08
leading O 0 6.644316208337386e-09
to O 0 2.1082974255293152e-10
decreased O 0 9.406930345789988e-09
ability O 0 1.9533294426388181e-10
to O 0 3.4754446542883954e-10
produce O 0 1.8803429924219017e-08
the O 0 2.327664638812621e-08
hormone O 0 9.331909609500144e-07
arginine O 0 2.5658439426479163e-06
vasopressin O 0 7.363050372077851e-06
( O 0 4.7059421603989904e-07
AVP O 0 1.2775248251273297e-05
) O 0 3.14496659825636e-08
. O 0 2.9307386739674257e-07

Affected O 0 2.1492799362476944e-07
individuals O 0 3.4023277528660856e-09
are O 0 3.9267039619872435e-10
not O 0 3.6719777218863214e-10
symptomatic O 0 9.376012712891679e-07
at O 0 3.2261782134668238e-09
birth O 0 7.595431839035882e-09
, O 0 4.827956923136867e-10
but O 0 9.202326123336491e-10
usually O 0 2.71345168556536e-09
develop O 0 7.662208645342616e-08
diabetes B-Disease 1 0.9999827146530151
insipidus I-Disease 0 0.0029975606594234705
at O 0 7.599840756711274e-08
1 O 0 2.2276498157225433e-07
- O 0 7.37819547680374e-08
6 O 0 2.534664531594899e-07
yr O 0 7.74665238623129e-07
of O 0 3.3573911650819355e-08
age O 0 4.3870645072274783e-07
. O 0 7.313136052289337e-07

The O 0 1.6654180257091866e-08
genetic O 0 4.1579497178645397e-07
locus O 0 3.0029806907805323e-07
of O 0 3.0212557788900085e-08
the O 0 6.90856083451763e-09
disease O 0 8.53762571750849e-07
is O 0 1.0189681320937893e-09
the O 0 2.0019507829260874e-08
AVP O 0 1.6093257727334276e-05
- O 0 8.186769377971359e-07
neurophysin O 0 3.570824264897965e-05
II O 1 0.998145580291748
( O 0 1.262070838947693e-07
NPII O 0 0.0014604296302422881
) O 0 1.874469468532425e-09
gene O 0 4.773988315776023e-09
, O 0 3.4820817340630583e-09
and O 0 8.285668262608681e-10
mutations O 0 8.80709194461815e-09
that O 0 5.582898587874752e-10
cause O 0 2.884894456656184e-07
ADNDI B-Disease 1 0.9934178590774536
have O 0 4.886153703864693e-10
been O 0 2.0844705128642005e-10
found O 0 7.978510907502567e-11
in O 0 2.31758726793041e-11
both O 0 8.860578937230912e-11
the O 0 6.798363538784713e-10
signal O 0 1.4020296035255342e-08
peptide O 0 4.5342893884026125e-09
of O 0 1.0649003456819628e-08
the O 0 8.360765946235915e-08
prepro O 0 2.922846942965407e-05
- O 0 1.4341811947815586e-05
AVP O 0 4.5638298615813255e-05
- O 0 2.8608549200725975e-06
NPII O 0 6.92238099873066e-05
precursor O 0 4.628703607068019e-07
and O 0 1.3138280685609516e-08
within O 0 7.088723208426018e-08
NPII O 0 0.0016710709314793348
itself O 0 2.346120737684032e-07
. O 0 3.7261841612235003e-07

An O 0 1.939720561949798e-08
affected O 0 6.129959473355484e-08
girl O 0 5.380467626991958e-08
who O 0 3.1790152732469323e-09
presented O 0 1.2215640943225026e-08
at O 0 2.0052208782317393e-09
9 O 0 1.901578228213907e-09
months O 0 2.7629026844167015e-10
of O 0 1.098904522933708e-09
age O 0 9.342095985687138e-09
and O 0 1.981432351527701e-09
her O 0 1.3695273803904229e-09
similarly O 0 9.729258509949545e-10
affected O 0 3.8239829081021526e-09
younger O 0 3.540401039003882e-08
brother O 0 8.968919473772985e-08
and O 0 1.1397070842633639e-08
father O 0 1.2770328794431407e-07
were O 0 2.8017335118590836e-09
all O 0 1.8009815860864364e-10
found O 0 1.4931345049262745e-10
to O 0 9.753443885873736e-11
have O 0 1.4204121212557652e-10
a O 0 1.1451147807761686e-09
novel O 0 9.852062277104778e-09
missense O 0 1.7657188777775445e-07
mutation O 0 1.4628827926799204e-08
( O 0 2.556433509326439e-09
G1758 O 0 1.455302509612011e-07
- O 0 2.094947149089421e-08
- O 0 3.128614878278313e-08
> O 0 9.101594145022318e-09
T O 0 4.540572362543571e-09
) O 0 1.0355505515591279e-11
encoding O 0 1.896462709094493e-10
the O 0 1.6906986921583211e-09
amino O 0 1.5955211596363483e-09
acid O 0 4.6543327525405687e-10
substitution O 0 2.1063972788226693e-09
Gly23 O 0 7.254364220443676e-08
- O 0 1.6122186252687243e-08
- O 0 3.9541173890711434e-08
> O 0 3.0093907810169185e-08
Val O 0 2.6445817979947606e-08
within O 0 6.58799947927946e-08
NPII O 0 0.0002982574515044689
. O 0 8.482811040266824e-07

The O 0 1.9343308110819635e-07
mutation O 0 8.325390865593363e-08
was O 0 1.2283981831728852e-08
confirmed O 0 5.722121665385771e-10
by O 0 7.194070339444636e-11
restriction O 0 1.5062825653444634e-08
endonuclease O 0 4.4612195893023454e-07
analysis O 0 1.0153584639738256e-07
. O 0 3.7527345853050065e-07

A O 0 1.8742272004601546e-05
T1 O 0 2.5891768018482253e-05
- O 0 1.5325886693062785e-07
weighted O 0 5.7166076317116676e-08
magnetic O 0 4.543362130959849e-09
resonance O 0 2.6276962827864736e-09
imaging O 0 1.1883111739052765e-07
of O 0 3.4073426746772384e-08
the O 0 3.029236381735245e-07
fathers O 0 1.3751154256169684e-05
pituitary O 0 0.0007871568668633699
gland O 0 2.49619461101247e-05
demonstrates O 0 4.132675996970647e-07
an O 0 1.3047506186580904e-08
attenuated O 0 2.267075251438655e-05
posterior O 0 9.324502025265247e-05
pituitary O 0 0.2864474952220917
bright O 1 0.9911122918128967
spot O 0 0.00014494347851723433
. O 0 1.8370900534137036e-06

This O 0 4.6588045421458446e-08
mutation O 0 1.1686726963944238e-07
may O 0 8.217995173254167e-09
be O 0 1.519503745051054e-09
valuable O 0 3.0572891773772426e-08
for O 0 5.268801506197462e-10
developing O 0 1.5035988454314975e-08
models O 0 7.779591015832921e-08
of O 0 4.920181240208876e-08
dominantly B-Disease 0 2.9176640964578837e-05
inherited I-Disease 1 0.9732270836830139
neurodegeneration I-Disease 1 1.0
, O 0 5.09722175578986e-09
as O 0 2.500892271051214e-10
the O 0 4.2933431115832477e-11
early O 0 2.925953646037982e-10
age O 0 6.972908361824182e-10
of O 0 4.2884182316349495e-10
onset O 0 1.6098545074783033e-06
of O 0 6.442877786838608e-09
symptoms O 0 1.9673882434290135e-06
suggests O 0 1.7802923579779417e-09
that O 0 2.722100843344233e-11
this O 0 8.437425064178328e-11
mutation O 0 1.3520340402806141e-09
may O 0 4.751067317343427e-10
be O 0 7.209321473133912e-10
particularly O 0 3.6538287950804715e-09
deleterious O 0 6.14992188729957e-07
to O 0 1.5427561450565008e-08
the O 0 3.449639507380198e-07
magnocellular O 0 5.045796206104569e-05
neuron O 0 2.2823513063485734e-05
. O 0 1.8085933106704033e-07
. O 0 6.682612365693785e-07

Frequent O 0 2.421250883344328e-06
inactivation O 0 2.039618448179681e-05
of O 0 2.2014924070390407e-06
PTEN O 1 0.9999997615814209
/ O 1 0.9966788291931152
MMAC1 O 1 1.0
in O 0 2.3522682113252813e-07
primary O 1 0.9999123811721802
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.940036539366702e-07

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 4.002994558049977e-08
the O 0 1.35429756298322e-09
most O 0 2.557422051907565e-10
common O 0 3.96318200479584e-10
male B-Disease 0 3.1538113787199507e-10
cancer I-Disease 0 7.455612238693732e-10
in O 0 2.4098865264443603e-11
the O 0 3.6549419046849607e-10
Western O 0 3.4670974979889024e-09
world O 0 1.3301203194426847e-10
, O 0 3.147091962030224e-11
yet O 0 8.780900312421736e-11
many O 0 1.5895538357790784e-11
of O 0 9.120943583740271e-11
the O 0 1.5523507479464627e-10
major O 0 1.1376801722917662e-09
genetic O 0 2.1956187978844355e-09
events O 0 7.691501324735839e-10
involved O 0 6.01151628476515e-10
in O 0 2.741720184218366e-10
the O 0 2.0456558669224023e-09
progression O 0 3.3942662014396774e-08
of O 0 1.6602951236066588e-09
this O 0 8.805408069356702e-10
often O 0 2.5021353877718866e-08
fatal O 0 1.7472137869845028e-06
cancer B-Disease 0 1.2495250985011808e-06
remain O 0 1.3160101453024708e-08
to O 0 1.3197346548921018e-09
be O 0 1.3819868804887392e-08
elucidated O 0 6.9615257416444365e-06
. O 0 5.61231217943714e-07

Numerous O 0 1.198729705720325e-06
cytogenetic O 0 4.409207758726552e-05
and O 0 9.18404552407992e-08
allelotype O 0 6.275851774262264e-06
studies O 0 7.535820856219289e-09
have O 0 4.9107794219960255e-11
reported O 0 4.850432833158891e-10
frequent O 0 4.157056365805545e-10
loss O 0 2.6811231013113e-09
of O 0 7.2570180975617404e-09
heterozygosity O 0 0.03862642124295235
on O 0 6.296777428360656e-07
chromosomal O 0 1.717665873002261e-05
arm O 0 1.932554823724786e-06
10q O 0 1.853542357821425e-06
in O 0 1.1997456361712011e-08
sporadic B-Disease 1 0.9999982118606567
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.271597380371531e-07

Deletion O 0 3.4789573533089424e-07
mapping O 0 3.0813507123639283e-07
studies O 0 2.684778266370813e-08
have O 0 4.334642644820974e-10
unambiguously O 0 2.5528922975581736e-08
identified O 0 3.858461106176492e-09
a O 0 7.689095471441476e-10
region O 0 6.239983640909941e-09
of O 0 3.115096625094793e-09
chromosome O 0 2.6201904645972718e-08
10q23 O 0 6.876906155639517e-08
to O 0 2.832071799296898e-10
be O 0 1.6041681871747926e-10
the O 0 5.220027743391142e-10
minimal O 0 7.121885658989413e-08
area O 0 7.817148173216992e-08
of O 0 2.090412998256852e-08
loss O 0 1.6540744809390162e-06
. O 0 1.1922653584406362e-06

A O 0 1.1759169865399599e-05
new O 0 2.807874466270732e-07
tumor B-Disease 0 1.1120547469545272e-06
suppressor O 0 2.6078364498971496e-06
gene O 0 9.895758523725817e-08
, O 0 3.541900284176336e-08
PTEN O 0 4.340351733844727e-05
/ O 0 4.726884128558595e-07
MMAC1 O 0 0.00039797130739316344
, O 0 1.5627581451127526e-09
was O 0 8.177934773812012e-09
isolated O 0 1.0273150330419867e-08
recently O 0 5.327676078081822e-10
at O 0 1.540596400451122e-10
this O 0 2.341237100023097e-11
region O 0 6.122393703122953e-10
of O 0 1.2828347273341478e-09
chromosome O 0 7.676541180501317e-09
10q23 O 0 6.53315410659161e-08
and O 0 7.37734429101522e-10
found O 0 3.047371244235819e-10
to O 0 1.4396576986097642e-10
be O 0 1.1032175867287108e-10
inactivated O 0 1.606349053773215e-09
by O 0 2.4924669966841506e-11
mutation O 0 2.0073025464029115e-09
in O 0 2.429925149982637e-09
three O 0 2.1510352610221162e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 5.7304669098812155e-06
lines O 0 2.0845209292019717e-07
. O 0 6.958101295140295e-08

We O 0 5.622302978736116e-07
screened O 0 3.505973154460662e-06
80 O 0 9.51100275869976e-07
prostate B-Disease 0 4.178558810963295e-06
tumors I-Disease 1 0.9999998807907104
by O 0 5.202454023134351e-10
microsatellite O 0 6.074173164449803e-09
analysis O 0 1.3231170603589248e-09
and O 0 1.7888383829767207e-10
found O 0 4.597362490699197e-10
chromosome O 0 5.412712944519171e-09
10q23 O 0 3.9751018476863464e-08
to O 0 1.4454253349782675e-09
be O 0 2.883280281196221e-09
deleted O 0 1.5959754406935645e-08
in O 0 9.089931030104026e-10
23 O 0 2.4391530573097953e-08
cases O 0 1.0282109386139382e-08
. O 0 2.3648124169994844e-07

We O 0 6.773118599312511e-08
then O 0 7.856757022750571e-09
proceeded O 0 6.2989604643348684e-09
with O 0 6.209721972738613e-12
sequence O 0 7.284788744454929e-11
analysis O 0 3.910492485381667e-10
of O 0 6.446328471021445e-10
the O 0 5.199768171593178e-09
entire O 0 3.266526391598745e-07
PTEN O 0 0.00025173628819175065
/ O 0 5.307422270561801e-07
MMAC1 O 0 4.435614300746238e-06
coding O 0 1.8352825037482035e-08
region O 0 2.421436562372037e-08
and O 0 4.958066179838738e-10
tested O 0 2.1796865701251278e-10
for O 0 1.2354178791085246e-10
homozygous O 0 2.4294199985064324e-09
deletion O 0 4.3087786671947015e-09
with O 0 3.7826614063263264e-10
new O 0 1.1383341380621914e-08
intragenic O 0 6.687853328912752e-07
markers O 0 3.699044981431143e-08
in O 0 4.953784049632759e-10
these O 0 5.174092820858789e-10
23 O 0 5.703002070589491e-09
cases O 0 2.1296979457741116e-10
with O 0 1.6408979730542228e-10
10q23 O 0 2.9221206432339386e-07
loss O 0 2.5362355771108014e-08
of O 0 6.211831049540706e-08
heterozygosity O 0 0.0003173253790009767
. O 0 6.057543032511603e-06

The O 0 1.6972576677432016e-09
identification O 0 4.433487355015586e-09
of O 0 5.838400429780677e-09
the O 0 4.53506743269827e-09
second O 0 1.583489250833736e-08
mutational O 0 8.410009399995033e-07
event O 0 1.5757219529177746e-08
in O 0 3.4834501949632113e-09
10 O 0 3.001468584784561e-08
( O 0 5.691114246531015e-09
43 O 0 5.818625936626631e-07
% O 0 4.8964771792725514e-08
) O 0 8.14832112894237e-09
tumors B-Disease 1 1.0
establishes O 0 1.367538629892806e-06
PTEN O 0 0.0023582512512803078
/ O 0 2.222481498392881e-06
MMAC1 O 0 0.00011282867490081117
as O 0 1.2540838367769425e-09
a O 0 4.914473827888344e-10
main O 0 3.951665217272193e-09
inactivation O 0 2.6759952476140825e-08
target O 0 5.803516334168535e-09
of O 0 7.078263308812893e-09
10q O 0 1.7268649799007108e-06
loss O 0 2.81477298358368e-07
in O 0 4.7253156054694045e-08
sporadic B-Disease 1 0.9999998807907104
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.032689572217805e-08
. O 0 2.5368402489789332e-08

Risk O 0 2.1765620203950675e-06
reversals O 0 2.369273715885356e-06
in O 0 2.859991576897869e-09
predictive O 0 7.864076678743004e-08
testing O 0 3.823851901785247e-09
for O 0 1.8221433251142116e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 7.347285304604156e-07

The O 0 3.440124629605634e-08
first O 0 1.5410263065618324e-09
predictive O 0 4.45850334429565e-09
testing O 0 7.435417836987313e-10
for O 0 4.745300596908919e-09
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.221188372646509e-09
HD B-Disease 0 3.3635313201330064e-08
) O 0 1.584178448144069e-11
was O 0 7.217655639824017e-11
based O 0 2.4154409375420904e-11
on O 0 7.091404546910596e-11
analysis O 0 5.124924373767215e-10
of O 0 1.1405634214867177e-09
linked O 0 2.7088560727861477e-08
polymorphic O 0 6.428258370050344e-09
DNA O 0 1.7162763654710034e-08
markers O 0 8.209942059522746e-09
to O 0 1.9949046581313468e-10
estimate O 0 1.1406640965105908e-08
the O 0 1.9765694636575404e-10
likelihood O 0 2.2282312883703526e-08
of O 0 7.126801815360295e-09
inheriting O 0 1.9417979046920664e-07
the O 0 8.946022589384484e-09
mutation O 0 1.4189052599533625e-08
for O 0 1.037165109352145e-08
HD B-Disease 0 2.9725226340815425e-05
. O 0 2.1824880604981445e-06

Limits O 0 4.5554255478919004e-08
to O 0 1.730785847975369e-09
accuracy O 0 2.8220616954399702e-08
included O 0 7.311324323744373e-10
recombination O 0 9.098429787357531e-10
between O 0 3.4911260549108647e-09
the O 0 2.4635111728343873e-09
DNA O 0 2.5641359258088414e-08
markers O 0 6.878414637867536e-08
and O 0 4.481856663574035e-09
the O 0 8.630802739162391e-09
mutation O 0 1.667830851204144e-08
, O 0 1.4950730653495725e-09
pedigree O 0 3.653516955637315e-08
structure O 0 2.9111491883782037e-08
, O 0 2.2431210222606524e-09
and O 0 5.068039321542983e-10
whether O 0 5.95773042011416e-10
DNA O 0 4.506380602009585e-09
samples O 0 8.759860614659942e-10
were O 0 3.1812399936548275e-10
available O 0 1.6141070702246907e-09
from O 0 3.1309892456476973e-09
family O 0 1.1183200143705108e-08
members O 0 2.8498956528011377e-09
. O 0 1.620608287566938e-07

With O 0 3.749805799202477e-09
direct O 0 2.1797054827743523e-08
tests O 0 4.4467388105040584e-10
for O 0 7.070352636695532e-10
the O 0 1.2002949745237856e-08
HD B-Disease 0 4.7336331476799387e-07
mutation O 0 1.3244357610631141e-08
, O 0 8.505811055492529e-10
we O 0 2.857007408429979e-10
have O 0 1.0762955110488193e-10
assessed O 0 6.757308046445587e-09
the O 0 7.507468535727924e-10
accuracy O 0 2.334097715106509e-08
of O 0 2.1178061526683223e-09
results O 0 1.0792089444322528e-09
obtained O 0 4.589295610202271e-09
by O 0 3.8961459059017045e-10
linkage O 0 5.218201337697792e-08
approaches O 0 8.988336297477417e-09
when O 0 3.186413910505337e-10
requested O 0 1.0490300850207745e-09
to O 0 4.020666577453369e-10
do O 0 4.515421092587957e-10
so O 0 3.694859973535358e-10
by O 0 1.988241793426937e-10
the O 0 5.202315245256273e-10
test O 0 2.129787318727594e-10
individuals O 0 2.514266350672756e-09
. O 0 5.152280095899187e-07

For O 0 2.1041579145730793e-08
six O 0 3.4389813219348753e-09
such O 0 1.907934921163701e-10
individuals O 0 2.643525121026613e-10
, O 0 2.432404833108137e-10
there O 0 9.200461920100267e-11
was O 0 1.2509011881878251e-10
significant O 0 2.1379396863974165e-10
disparity O 0 3.3720937153702835e-08
between O 0 7.200255502937125e-09
the O 0 1.747281785924315e-08
tests O 0 6.837796107106442e-09
. O 0 1.9069952372774424e-07

Three O 0 1.660217492371885e-07
went O 0 6.340114566683042e-08
from O 0 1.3330926362797868e-09
a O 0 1.3839144274996329e-09
decreased O 0 2.57478536269673e-08
risk O 0 3.8694258908122947e-10
to O 0 4.453000121418249e-11
an O 0 1.1932768662070714e-10
increased O 0 6.50561715609399e-10
risk O 0 1.3628018713518486e-09
, O 0 6.69339583758699e-11
while O 0 7.135268764724145e-11
in O 0 6.95724242105733e-11
another O 0 1.2461628395854518e-09
three O 0 3.5868888415002687e-10
the O 0 1.5599945779598556e-09
risk O 0 1.6848149542170177e-08
was O 0 2.6457170676508213e-08
decreased O 0 2.8285074904488283e-07
. O 0 2.4254077857222e-07

Knowledge O 0 3.666995098683401e-07
of O 0 7.44555777032474e-08
the O 0 5.6674562820546726e-09
potential O 0 1.3425113465359573e-08
reasons O 0 6.639312655210006e-09
for O 0 7.07422037615757e-11
these O 0 8.47246786617184e-11
changes O 0 3.907785761647631e-10
in O 0 1.0921568510680046e-10
results O 0 2.080467575993339e-09
and O 0 3.2309552255860297e-10
impact O 0 1.1081535689072552e-08
of O 0 1.0764705793420148e-09
these O 0 3.9477909830054614e-10
risk O 0 5.646265677228257e-09
reversals O 0 4.111192808409214e-08
on O 0 5.1028634651117954e-09
both O 0 2.8890370651346586e-10
patients O 0 1.394001997168104e-10
and O 0 2.499256634980185e-10
the O 0 6.982543987454903e-10
counseling O 0 3.3601488258483414e-10
team O 0 1.519482595302435e-10
can O 0 5.680653863970875e-11
assist O 0 6.654095052738285e-09
in O 0 4.866259617486435e-10
the O 0 7.462672257929626e-09
development O 0 3.847205576335e-08
of O 0 5.27203081190919e-09
strategies O 0 1.9793662264788736e-09
for O 0 1.4513475143917987e-10
the O 0 8.892649949743259e-10
prevention O 0 2.2082982109594695e-09
and O 0 4.283015053729855e-10
, O 0 1.4937610870457974e-10
where O 0 1.3148646060834324e-10
necessary O 0 1.1844000225025297e-09
, O 0 2.3703231044613915e-10
management O 0 4.4647982533341235e-10
of O 0 1.3727466940949284e-09
a O 0 1.6032757343964477e-09
risk O 0 1.3447922775355892e-08
reversal O 0 2.3131789816943638e-08
in O 0 3.0521296601193626e-10
any O 0 3.0366158476624605e-09
predictive O 0 1.0936629379898477e-08
testing O 0 6.277404707155654e-10
program O 0 4.808678788492671e-09
. O 0 1.012102046615837e-08
. O 0 1.5444645384832256e-07

A O 0 8.631117225377238e-07
novel O 0 6.317782208498102e-08
common O 0 1.3445126789690676e-08
missense O 0 3.73785780993785e-07
mutation O 0 9.371793119328231e-09
G301C O 0 4.5293909067822824e-08
in O 0 9.495925157310126e-10
the O 0 9.788564625523577e-09
N O 0 1.1352881301718298e-07
- O 0 3.832864337027786e-08
acetylgalactosamine O 0 4.046922583711421e-07
- O 0 1.2086577783065877e-07
6 O 0 1.83340077342109e-07
- O 0 4.640942918854307e-08
sulfate O 0 5.084435983349067e-08
sulfatase O 0 1.7097327997817047e-07
gene O 0 4.694634458957125e-09
in O 0 8.272597717962071e-09
mucopolysaccharidosis B-Disease 0 1.4404535249923356e-05
IVA I-Disease 1 0.9999744892120361
. O 0 4.26707265432924e-06

Mucopolysaccharidosis B-Disease 0 0.004517591558396816
IVA I-Disease 1 1.0
( O 0 0.00045064708683639765
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 4.225328353868463e-08
is O 0 6.756157855392075e-10
an O 0 5.661859425742932e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999113082885742
by O 0 2.7396190871442627e-10
a O 0 3.800873837889185e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 6.027397692065506e-09
N O 0 5.9107861716256593e-08
- O 0 6.704058197470886e-09
acetylgalactosamine O 0 1.223801007199654e-07
- O 0 2.5862437524892812e-08
6 O 0 1.3159541367713246e-07
- O 0 6.876473435113439e-08
sulfate O 0 2.4462821102133603e-07
sulfatase O 0 2.3702002636127872e-06
( O 0 8.056666445099836e-08
GALNS O 0 0.00011785647075157613
) O 0 5.9143047792531434e-08
. O 0 2.7496739107846224e-07

In O 0 5.456188034713705e-08
previous O 0 1.2764168388912367e-07
studies O 0 3.374834989244846e-08
, O 0 4.0069397799769035e-10
we O 0 2.0730910044175488e-10
have O 0 5.124843605042173e-11
found O 0 3.114097035794572e-10
two O 0 7.506147786662254e-11
common O 0 1.3518658414923834e-10
mutations O 0 2.963240208764262e-10
in O 0 1.5725289126411468e-10
Caucasians O 0 3.093048706048762e-09
and O 0 3.0471677958665566e-10
Japanese O 0 2.474239479965945e-08
, O 0 2.709722890514854e-09
respectively O 0 4.603369063715945e-08
. O 0 3.7015934140072204e-07

To O 0 1.8810101920507805e-08
characterize O 0 3.621281337018445e-07
the O 0 3.011951932307966e-08
mutational O 0 3.5414318517723586e-06
spectrum O 0 4.317583091051347e-08
in O 0 1.8388827960347243e-10
various O 0 6.391321361043367e-10
ethnic O 0 8.397965101103466e-10
groups O 0 8.9561719152087e-11
, O 0 4.023088806537345e-11
mutations O 0 3.1834615499271024e-10
in O 0 1.1382460946007811e-10
the O 0 2.3736224097348213e-09
GALNS O 0 5.05406717365986e-07
gene O 0 9.447309601284815e-10
in O 0 1.268266491827319e-09
Colombian O 0 9.80157892627176e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 6.74826683422225e-09
were O 0 8.158238529176742e-10
investigated O 0 1.887874301331749e-09
, O 0 9.618067453587287e-11
and O 0 7.776360805289428e-11
genetic O 0 5.9936016150174964e-09
backgrounds O 0 2.7547175207587316e-08
were O 0 2.3076560662360635e-09
extensively O 0 4.538682762955659e-10
analyzed O 0 8.35125912868051e-10
to O 0 4.9418809322521184e-11
identify O 0 2.1222135160314792e-09
racial O 0 2.1327477561783326e-09
origin O 0 1.9999268907611167e-09
, O 0 1.2889705969243437e-10
based O 0 5.400376812403351e-10
on O 0 9.764542507895158e-10
mitochondrial O 0 6.608031455357377e-09
DNA O 0 1.1039768565979102e-07
( O 0 2.395573339697421e-08
mtDNA O 0 1.700944096683088e-07
) O 0 1.2387460834872854e-08
lineages O 0 2.0916758103339816e-07
. O 0 2.5605638143133547e-07

Three O 0 1.6471467745304835e-07
novel O 0 3.649060147381533e-07
missense O 0 3.840925728582079e-06
mutations O 0 5.483856284627109e-07
never O 0 1.2460998277674662e-07
identified O 0 2.281359634537239e-08
previously O 0 2.6107458417357066e-09
in O 0 2.9182274652317375e-11
other O 0 5.135607564210609e-11
populations O 0 2.7729279983290667e-10
and O 0 6.728955587176344e-11
found O 0 1.561255846826981e-10
in O 0 7.065078383439172e-11
16 O 0 1.8538400814449574e-09
out O 0 1.9683116248003785e-10
of O 0 5.055720286861742e-10
19 O 0 7.466345763873505e-09
Colombian O 0 2.2715518355198583e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
unrelated O 0 9.796301014830533e-08
alleles O 0 2.4377191376601104e-09
account O 0 1.909260971544313e-09
for O 0 1.9730110878413143e-09
84 O 0 5.403219915933732e-07
. O 0 3.077673795814917e-07

2 O 0 3.817965534835821e-07
% O 0 5.269678471364614e-09
of O 0 1.3635402806855268e-09
the O 0 1.2532637150286519e-09
alleles O 0 5.818409642976974e-10
in O 0 3.5907563034065504e-10
this O 0 4.4668685417192933e-10
study O 0 1.9371093618048008e-09
. O 0 3.1829301860852866e-08

The O 0 1.2838214615840116e-06
G301C O 0 4.2121669139305595e-06
and O 0 2.4766096728967568e-08
S162F O 0 4.828169153370254e-07
mutations O 0 1.4634464307050621e-08
account O 0 2.783846042575533e-09
for O 0 2.654799269308228e-09
68 O 0 4.5224714995129034e-07
. O 0 1.8989084082932095e-07

4 O 0 4.703860668087145e-06
% O 0 6.236428617967249e-08
and O 0 3.524955660694218e-09
10 O 0 4.0145859969697995e-08
. O 0 1.120098716000939e-07

5 O 0 8.853975259626168e-07
% O 0 1.6267364344457746e-08
of O 0 4.30362856462807e-09
mutations O 0 4.476004455966631e-09
, O 0 1.039257679913419e-09
respectively O 0 1.4804422132641548e-09
, O 0 9.364922032295553e-11
whereas O 0 1.664772653064972e-09
the O 0 9.097185227346927e-09
remaining O 0 5.734162186854519e-06
F69V O 1 0.8442025184631348
is O 0 5.447780004885772e-10
limited O 0 1.7432222332303127e-10
to O 0 1.6491720489231199e-10
a O 0 3.4409628479892262e-09
single O 0 1.854272291268444e-08
allele O 0 3.9107246152525477e-07
. O 0 4.983979238204483e-07

The O 0 2.6106056338903727e-07
skewed O 0 7.087708695507899e-07
prevalence O 0 2.0033340319969284e-07
of O 0 5.867079266863584e-09
G301C O 0 5.7151570587166134e-08
in O 0 1.5568547839794888e-10
only O 0 2.938262688712001e-10
Colombian O 0 7.856726824684301e-09
patients O 0 1.3365163142875502e-10
and O 0 5.1302521258955736e-11
haplotype O 0 1.2169426577557374e-09
analysis O 0 1.0444456410851899e-10
by O 0 1.170057800647939e-11
restriction O 0 2.3513400115859895e-09
fragment O 0 1.6471052077804416e-08
length O 0 4.431103484137111e-09
polymorphisms O 0 2.8618263314683645e-08
in O 0 5.172595685110082e-09
the O 0 9.755205354622376e-08
GALNS O 0 0.0001898522168630734
gene O 0 2.2757360440550656e-08
suggest O 0 2.1057275034763734e-08
that O 0 5.533939972934832e-10
G301C O 0 6.614919811909203e-08
originated O 0 7.270165802708561e-09
from O 0 3.5863895186949435e-10
a O 0 9.773616360675419e-10
common O 0 3.186281904987709e-09
ancestor O 0 3.4992649489140604e-07
. O 0 3.654047304735286e-07

Investigation O 0 1.1795022913929643e-07
of O 0 4.492188665494723e-08
the O 0 5.457454932411565e-09
genetic O 0 1.0569155328710167e-08
background O 0 2.403205856538193e-09
by O 0 4.984346962944031e-11
means O 0 1.2515269931512307e-09
of O 0 1.0087424229254793e-09
mtDNA O 0 7.557152237325226e-09
lineages O 0 4.453887925137678e-09
indicate O 0 6.161548160577013e-09
that O 0 3.403922699263262e-10
all O 0 5.66570235172037e-10
our O 0 3.2321525456069367e-09
patients O 0 2.6848831491399494e-10
are O 0 1.5544742576478754e-11
probably O 0 8.771330328727345e-10
of O 0 1.1551355427741328e-09
native O 0 1.2326158760345152e-08
American O 0 1.7918799244398542e-07
descent O 0 1.347001852991525e-05

Low O 0 4.7282279069804645e-07
frequency O 0 9.025532676787407e-08
of O 0 3.03039726645693e-08
BRCA1 O 0 2.2577121683298174e-07
germline O 0 2.650050987540453e-07
mutations O 0 1.0059300059594989e-08
in O 0 1.1193779236862156e-09
45 O 0 9.175747095468978e-08
German O 1 0.9994489550590515
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5669824549036093e-08
. O 0 1.606150590305333e-08

In O 0 2.2520087128441446e-08
this O 0 2.172275248568667e-09
study O 0 1.175171737699543e-09
we O 0 2.1197206490075615e-10
investigated O 0 3.4774754187338885e-09
45 O 0 1.552752060263174e-08
German O 0 0.00013239083637017757
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2804579618830303e-10
for O 0 1.879795104298143e-11
germline O 0 1.781964797942237e-08
mutations O 0 3.7430747390487795e-09
in O 0 5.308991024577381e-10
the O 0 1.2115978442750475e-08
BRCA1 O 0 1.6014038806133613e-07
gene O 0 2.703318671137822e-07
. O 0 1.1202605492144357e-06

We O 0 5.349706810875432e-08
identified O 0 1.6060135976658785e-07
four O 0 1.3712975643898062e-08
germline O 0 1.0540004495851463e-06
mutations O 0 2.1879408507174958e-07
in O 0 2.118518160898475e-08
three O 0 3.356340982918482e-08
breast B-Disease 0 9.948160339945389e-08
cancer I-Disease 0 8.687440100629829e-08
families O 0 3.0072317969143114e-09
and O 0 6.617715264667368e-10
in O 0 2.4790045571876362e-09
one O 1 0.9863144159317017
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 7.822275271962553e-09
. O 0 2.97061229781459e-11
among O 0 7.878353351642442e-12
these O 0 1.075066077826925e-11
were O 0 4.863445757230522e-11
one O 0 1.560151313695357e-10
frameshift O 0 3.31799121511267e-08
mutation O 0 2.055688286262125e-09
, O 0 6.349753500778377e-10
one O 0 2.446336244688041e-09
nonsense O 0 3.615397048406521e-08
mutation O 0 2.1660083504571048e-08
, O 0 3.0110198778743325e-09
one O 0 3.6744525200305134e-09
novel O 0 1.848467157117284e-08
splice O 0 3.359531319802045e-07
site O 0 5.5592931147430136e-08
mutation O 0 5.5089097728000525e-09
, O 0 9.329537142832578e-10
and O 0 7.625213793716057e-10
one O 0 5.841386041538499e-09
missense O 0 1.7133446590378298e-06
mutation O 0 4.804070385944215e-07
. O 0 5.240493692326709e-07

The O 0 5.121656840856303e-07
missense O 0 3.5469479371386115e-06
mutation O 0 1.9750683577512973e-07
was O 0 6.338614610967852e-08
also O 0 8.364538506278052e-10
found O 0 3.201051645973507e-10
in O 0 8.798340389581938e-10
2 O 0 2.366120810393113e-07
. O 0 2.61747373997423e-07

8 O 0 7.21826381777646e-07
% O 0 9.76521796758334e-09
of O 0 1.8462815720710068e-09
the O 0 2.695017542464484e-09
general O 0 7.573039084718403e-09
population O 0 9.948188939290503e-10
, O 0 6.871808677644253e-11
suggesting O 0 1.4419694327472143e-09
that O 0 9.59992363380735e-11
it O 0 1.7583025313516742e-10
is O 0 9.82244424685419e-11
not O 0 9.701349723556518e-10
disease O 0 5.812404069160948e-08
associated O 0 4.2724047943920596e-07
. O 0 7.759494451420323e-07

The O 0 3.969798001435265e-08
average O 0 4.0678784785086464e-08
age O 0 7.862663409241577e-09
of O 0 1.6928768387103332e-09
disease O 0 5.896462766941113e-07
onset O 0 2.2624872144660912e-06
in O 0 6.350101694474475e-11
those O 0 1.1941921063129968e-10
families O 0 4.2416672951794965e-10
harbouring O 0 2.5279192072957812e-08
causative O 0 3.583706131848885e-08
mutations O 0 1.2149858008569936e-08
was O 0 7.509134647420979e-09
between O 0 6.537165031517134e-09
32 O 0 4.6227083316807693e-07
. O 0 3.0264294537118985e-07

3 O 0 8.467191037198063e-06
and O 0 1.8798738210534793e-07
37 O 0 5.304090336721856e-06
. O 0 6.213898586793221e-07

4 O 0 1.5663421208955697e-06
years O 0 2.8838977428335966e-08
, O 0 7.607621754779359e-10
whereas O 0 2.172407809197807e-09
the O 0 1.3791344732894117e-09
family O 0 2.6935478292244852e-09
harbouring O 0 3.598493591994156e-08
the O 0 2.2383170872330993e-09
missense O 0 4.612562420902577e-08
mutation O 0 1.1515388642635571e-09
had O 0 1.2540855853782062e-10
an O 0 2.373819196765936e-11
average O 0 2.063654247486113e-10
age O 0 2.874361582083651e-10
of O 0 1.1171789049413405e-09
onset O 0 9.613909242034424e-06
of O 0 6.838137664999522e-07
51 O 0 2.623632099130191e-06
. O 0 5.617056331175263e-07

2 O 0 1.8039601854979992e-05
years O 0 5.533902367460541e-07
. O 0 1.4651008086730144e-06

These O 0 4.3474479127780796e-08
findings O 0 5.0759581426973455e-08
show O 0 3.730558972847575e-09
that O 0 9.209753515371233e-10
BRCA1 O 0 8.283511476747663e-08
is O 0 1.9235384396409927e-09
implicated O 0 3.845325391438337e-09
in O 0 1.4635231915249847e-10
a O 0 3.9994724199132747e-10
small O 0 5.014596515806602e-10
fraction O 0 3.3615879857507025e-08
of O 0 5.651143055729335e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.622243808347307e-11
suggesting O 0 5.159751098604559e-11
the O 0 3.818831102037068e-12
involvement O 0 5.087154655858406e-11
of O 0 4.0666314066184484e-11
another O 0 1.613755240548187e-10
susceptibility O 0 1.305602026491215e-08
gene O 0 6.642583372240551e-08
( O 0 4.063699350354e-07
s O 0 6.831137852714164e-06
) O 0 3.7483636106117046e-07

Paternal O 0 0.0021631380077451468
transmission O 0 0.09836694598197937
of O 0 3.466296402621083e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.10216203331947327

We O 0 1.079353992849974e-07
report O 0 1.6655166135137733e-08
a O 0 4.543775911081127e-10
rare O 0 1.946609762271123e-09
case O 0 4.324075320027987e-09
of O 0 1.3248577346303136e-08
paternally O 1 0.9919378161430359
transmitted O 1 0.9875468611717224
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00030120418523438275
DM B-Disease 1 1.0
) O 0 1.6658216139830984e-08
. O 0 4.499717931594205e-08

The O 0 5.873228019481758e-07
proband O 0 2.048245551122818e-05
is O 0 5.3282378509322825e-09
a O 0 4.4328021253647876e-09
23 O 0 4.868761749321493e-08
year O 0 9.131362332936988e-09
old O 0 6.090427632443607e-06
, O 0 2.1114149717504915e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.4394019544124603
who O 0 1.751924543214045e-07
suffers O 0 0.016034021973609924
severe O 1 0.9710350632667542
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 8.344089110323694e-06

He O 0 5.217624021724987e-08
presented O 0 3.137494886118475e-08
with O 0 1.0208121015153893e-09
respiratory O 1 0.999538779258728
and O 0 1.1493143325935762e-08
feeding O 0 5.638228799398348e-07
difficulties O 0 1.8292055301571963e-06
at O 0 7.902101373247206e-08
birth O 0 2.8801464395655785e-06
. O 0 1.2245976677149883e-06

His O 0 2.1676364667655434e-06
two O 0 4.975791512151773e-07
sibs O 1 0.5653908252716064
suffer O 0 1.2258245988050476e-05
from O 0 2.3528313874976448e-07
childhood O 1 0.9998903274536133
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 6.666306489933049e-06

Their O 0 2.7072807995409676e-08
late O 0 4.041525244247168e-06
father O 0 3.0655871796625433e-07
had O 0 2.977711854867948e-09
the O 0 9.649157861613133e-11
adult O 0 7.142403335436143e-11
type O 0 4.3184025799725134e-10
of O 0 3.514932123138692e-09
DM B-Disease 1 1.0
, O 0 2.7256674695053107e-09
with O 0 2.2473765903807674e-10
onset O 0 1.472768508392619e-05
around O 0 2.2560704415752753e-09
30 O 0 1.7383232631118517e-08
years O 0 7.509764365920546e-09
. O 0 6.630254034689642e-08

Only O 0 2.3717861452610123e-08
six O 0 1.0477984035972554e-09
other O 0 3.831776909657414e-11
cases O 0 8.5824326812034e-11
of O 0 2.3854943020928943e-10
paternal O 0 7.845355867175385e-06
transmission O 0 0.019632818177342415
of O 0 1.4348296645039227e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.2875251798050158e-07
been O 0 1.738448385246727e-09
reported O 0 4.6142321075137716e-09
recently O 0 4.04381816920818e-09
. O 0 1.583673459037982e-08

We O 0 3.27127693822149e-08
review O 0 6.554994325114194e-09
the O 0 8.367586068480648e-10
sex O 0 1.1693533641388143e-10
related O 0 9.090034280845316e-10
effects O 0 7.1557053615833865e-09
on O 0 2.2093558094127275e-09
transmission O 0 6.454054073401494e-07
of O 0 1.1186746462499286e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 5.8820067351916805e-05

Decreased O 0 1.0483065580046969e-06
fertility O 0 2.5624979471672304e-08
of O 0 1.0857974519495883e-09
males O 0 4.532797401313182e-11
with O 0 2.533692006201349e-12
adult O 0 2.93479018864673e-10
onset O 0 1.562211195960117e-07
DM B-Disease 1 1.0
and O 0 1.386198933417404e-10
contraction O 0 1.2728564868780268e-09
of O 0 5.081144949237171e-10
the O 0 3.499697753817088e-10
repeat O 0 5.732969099447871e-10
upon O 0 2.946648924861961e-09
male O 0 5.42203060227564e-10
transmission O 0 2.0564089320274093e-10
contribute O 0 6.20588927469079e-11
to O 0 4.3379074637917014e-11
the O 0 7.443491933933899e-10
almost O 0 9.346475815519284e-10
absent O 0 7.872176688294985e-09
occurrence O 0 7.263069701224367e-09
of O 0 1.0155357665908582e-09
paternal O 0 4.9551294978300575e-06
transmission O 0 1.1235859346925281e-05
of O 0 2.431110033285222e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 2.279245381942019e-05

Also O 0 3.1288536206375284e-08
the O 0 1.2167784113614744e-08
fathers O 0 7.327357565145576e-08
of O 0 2.3485936750944347e-08
the O 0 2.2623542150768117e-08
reported O 0 7.05531135736237e-08
congenitally O 0 1.883819777503959e-06
affected O 0 1.2838928142855366e-08
children O 0 3.2499560820298257e-09
showed O 0 7.65405516744977e-09
, O 0 2.235534257710725e-10
on O 0 2.6317641399487e-09
average O 0 9.872189288273603e-09
, O 0 8.611575896821932e-10
shorter O 0 1.1394967458500105e-07
CTG O 0 2.36241453421826e-06
repeat O 0 4.8717343048565454e-08
lengths O 0 3.741492093922716e-07
and O 0 2.5082453891656087e-09
hence O 0 1.0982744491627727e-08
less O 0 2.80775713790149e-09
severe O 0 1.3207657900693448e-07
clinical O 0 2.212393113154576e-08
symptoms O 0 2.2658650067342023e-08
than O 0 7.250715305939792e-11
the O 0 4.86034157365367e-10
mothers O 0 4.375678153145657e-10
of O 0 6.390589724070139e-10
children O 0 1.2085881628820516e-08
with O 0 5.2372858050375726e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.076161515811691e-05

We O 0 4.61420768260723e-08
conclude O 0 5.3921482390251185e-08
that O 0 4.727519486991127e-10
paternal O 0 1.1593693898248603e-06
transmission O 0 3.0268561204138678e-06
of O 0 7.252585874084616e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 5.023923943525688e-09
rare O 0 3.6119060520256596e-10
and O 0 4.152363175524698e-11
preferentially O 0 8.422407909991492e-11
occurs O 0 5.138253017511474e-11
with O 0 4.234485158349788e-12
onset O 0 1.2150233885677153e-07
of O 0 4.202237491313099e-08
DM B-Disease 1 1.0
past O 0 2.9158005787621732e-08
30 O 0 3.6644092205051493e-09
years O 0 1.1681496048243645e-10
in O 0 8.261741291093472e-11
the O 0 2.676973975823671e-09
father O 0 8.244122540190801e-08
. O 0 2.0012519641454674e-08
. O 0 1.723076508142185e-07

The O 0 3.4501799746067263e-06
RB1 O 0 0.00041773065458983183
gene O 0 8.096471759699853e-08
mutation O 0 5.596358931825307e-08
in O 0 2.2791926124199335e-09
a O 0 5.423284488159652e-09
child O 0 7.574573857027644e-08
with O 0 8.308655452538005e-08
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 2.216264692833647e-05

The O 0 2.120375484082615e-06
RB1 O 0 8.257861918536946e-05
gene O 0 1.0257119242851331e-07
mutation O 0 4.165187306170992e-08
was O 0 1.1733447102812988e-08
investigated O 0 1.41638445416703e-09
in O 0 8.143402618898676e-11
a O 0 1.6447812001274542e-09
child O 0 3.625444477961537e-08
with O 0 3.58368517083818e-08
ectopic B-Disease 1 1.0
intracranial I-Disease 1 0.9999996423721313
retinoblastoma I-Disease 0 5.133405466040131e-06
using O 0 2.346334793124072e-10
DNA O 0 9.186350569123647e-10
obtained O 0 2.204355142865211e-09
from O 0 7.433206272722259e-10
both O 0 6.509936478771294e-10
the O 0 1.0357180002529276e-08
pineal B-Disease 0 9.715201485960279e-06
and I-Disease 0 1.1971968305601877e-08
retinal I-Disease 1 0.9981483221054077
tumours I-Disease 1 1.0
of O 0 1.913254408236753e-07
the O 0 4.998606328854294e-08
patient O 0 1.493569641297654e-07
. O 0 1.9912141624445212e-07

A O 0 3.1416743695444893e-06
nonsense O 0 6.623668014071882e-07
mutation O 0 1.5242243023294577e-08
in O 0 2.7434061689035616e-09
exon O 0 6.794157059175632e-08
17 O 0 2.3217238265260676e-07
( O 0 3.607611542832956e-09
codon O 0 8.277683605228958e-08
556 O 0 3.17171320318721e-08
) O 0 1.960940715362014e-10
of O 0 4.714393320170984e-09
the O 0 4.671778697229456e-08
RB1 O 0 1.1073654604842886e-05
gene O 0 2.0577136439214883e-08
was O 0 7.236246801767265e-08
found O 0 1.6470282082625687e-10
to O 0 5.6751957300260614e-11
be O 0 2.0028652347736653e-10
present O 0 1.5661359986651746e-09
homozygously O 0 5.271490977065696e-07
in O 0 1.5545410514405944e-09
both O 0 3.962806083279702e-09
the O 0 1.162332186055437e-08
retinal B-Disease 0 1.996263199544046e-05
and I-Disease 0 6.182835221579808e-08
the I-Disease 0 7.909329724498093e-07
pineal I-Disease 1 0.9999939203262329
tumours I-Disease 1 1.0
. O 0 4.12407143812743e-06

The O 0 3.092094758017083e-08
same O 0 4.289148591851699e-09
mutation O 0 7.469906471158083e-09
was O 0 2.48074050190894e-09
present O 0 3.0427599329030386e-10
heterozygously O 0 2.945964894252029e-08
in O 0 9.281345136891161e-11
the O 0 1.4518236612914848e-10
DNA O 0 1.3167450463313912e-09
from O 0 5.907692668394304e-10
the O 0 1.014498041129741e-09
constitutional O 0 4.77506301166386e-09
cells O 0 3.200204989894928e-09
of O 0 4.9886699216017405e-09
the O 0 1.885714917548853e-09
patient O 0 3.4172340512839128e-09
, O 0 1.1234885244348902e-10
proving O 0 2.4240138785103227e-09
it O 0 2.7540565314398968e-11
to O 0 1.0183438814426182e-10
be O 0 6.41346087348893e-10
of O 0 1.0848911990990473e-08
germline O 0 3.373598019607016e-06
origin O 0 1.1351380635460373e-06
. O 0 1.2990067261853255e-06

The O 0 4.489738714141822e-08
initial O 0 1.0847195142105193e-08
mutation O 0 2.6149817866638614e-09
was O 0 1.3151763011975959e-09
shown O 0 2.0686031013128492e-11
to O 0 3.184977975800862e-11
have O 0 3.911243898202521e-11
occurred O 0 5.0165316345385236e-09
in O 0 1.5634789296559148e-10
the O 0 7.632013243608071e-09
paternally O 0 4.370187980384799e-06
derived O 0 8.335415486726561e-07
RB1 O 0 0.0001895463647088036
allele O 0 7.249508371387492e-07
. O 0 4.521096172993566e-07

The O 0 1.5099250560979272e-07
mutation O 0 2.1374157554987505e-08
is O 0 3.2310720765593715e-10
in O 0 3.8162993598600536e-11
an O 0 1.013708422759052e-10
area O 0 2.166469892372902e-09
of O 0 6.663184448640891e-10
the O 0 2.8613882374628474e-09
gene O 0 8.033947396235419e-10
that O 0 1.2088779977048603e-09
encodes O 0 5.398093083641697e-09
the O 0 4.420450228082018e-09
protein O 0 6.915337191770732e-09
- O 0 1.3586700653434036e-09
binding O 0 4.296271782777694e-09
region O 0 2.3741309362890206e-08
known O 0 1.162943630284019e-09
as O 0 7.298170956460126e-10
the O 0 1.635580670900083e-09
pocket O 0 5.010940071770165e-07
region O 0 5.8068962971447036e-08
and O 0 6.265004071082103e-09
has O 0 1.0128758942684613e-09
been O 0 4.521539809232422e-10
detected O 0 1.1876779559827355e-09
in O 0 2.513913729962347e-11
other O 0 9.28842835978827e-11
cases O 0 1.5919827678345655e-09
of O 0 1.3146754795911875e-08
retinoblastoma B-Disease 0 6.557856522704242e-06
. O 0 4.732450165079172e-08
. O 0 3.315442427265225e-07

Low O 0 1.141747816291172e-06
levels O 0 3.413131821616844e-08
of O 0 3.833155126642396e-09
beta O 0 8.55829807022701e-09
hexosaminidase O 0 1.1848417358351071e-07
A O 0 1.1744867300933493e-08
in O 0 1.250393122376181e-10
healthy O 0 1.2924621373144873e-09
individuals O 0 1.0170297937150963e-10
with O 0 2.5005297832336737e-10
apparent O 0 2.404831548119546e-06
deficiency O 0 0.0005123528535477817
of O 0 8.28477553227458e-08
this O 0 3.4059832731969664e-09
enzyme O 0 1.6691823248038418e-06
. O 0 2.9369053322625405e-07

Appreciable O 0 2.2120582798379473e-05
beta O 0 2.277621888424619e-06
hexosaminidase O 0 1.7106742234318517e-05
A O 0 1.761878252182214e-06
( O 0 1.580972153192306e-08
hex O 0 9.788584520720178e-07
A O 0 2.2576926994588575e-07
) O 0 3.676406401531551e-10
activity O 0 5.467582386842196e-09
has O 0 1.4190472408248667e-10
been O 0 8.931675538059736e-11
detected O 0 4.539323361640868e-10
in O 0 2.437132162746991e-10
cultured O 0 2.4819729560476844e-07
skin O 0 1.200063479700475e-06
fibroblasts O 0 5.554067570301413e-07
and O 0 1.9850761034945208e-08
melanoma B-Disease 0 1.5850308443532413e-07
tissue O 0 2.8204887314586813e-09
from O 0 1.4151423366470794e-09
healthy O 0 5.207358433345632e-10
individuals O 0 2.2183900549865854e-11
previously O 0 3.094947353954325e-10
reported O 0 2.6887317372548125e-10
as O 0 1.5931787833434186e-10
having O 0 4.782598206354294e-10
deficiency B-Disease 0 7.917367383925011e-07
of I-Disease 0 3.4743891319521936e-06
hex I-Disease 0 3.42559433192946e-05
A I-Disease 0 1.0642916237202371e-07
activity O 0 1.2414993477705139e-08
indistinguishable O 0 1.4278235482834134e-08
from O 0 1.4769724332452938e-10
that O 0 1.993747181239236e-11
of O 0 1.0523001220397177e-10
patients O 0 2.4836083190038494e-10
with O 0 1.921713099761746e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.26761693258959e-07
TSD B-Disease 0 0.33741381764411926
) O 0 3.3077423466920663e-08
. O 0 1.876298796332776e-07

Identification O 0 7.278660518750257e-08
and O 0 1.805692129153158e-08
quantitation O 0 3.730918251676485e-05
of O 0 1.2266688827367034e-05
hex O 0 5.835477713844739e-05
A O 0 1.1565534805413336e-06
, O 0 2.9329898509899976e-09
amounting O 0 6.14073503157897e-09
to O 0 2.9726614503289284e-09
3 O 0 2.335269613240598e-07
. O 0 2.9353958552746917e-07

5 O 0 6.511149422294693e-06
% O 0 2.4801511244731955e-07
- O 0 1.368094046938495e-07
6 O 0 5.088365355732094e-07
. O 0 1.7071846514227218e-07

9 O 0 6.480742626990832e-07
% O 0 6.86804213501091e-09
of O 0 2.364088924622365e-09
total O 0 7.613515373705582e-10
beta O 0 6.422608667122631e-09
hexosaminidase O 0 3.40881207705479e-08
activity O 0 1.7663614571006292e-08
, O 0 3.410271787185337e-10
has O 0 1.425830009615936e-10
been O 0 1.0189753207878738e-10
obtained O 0 5.151230553224195e-09
by O 0 3.4382072744421066e-09
cellulose O 0 1.4611129017794156e-06
acetate O 0 9.619205911803874e-07
gel O 0 6.336571232168353e-07
electrophoresis O 0 4.777570339342674e-08
, O 0 2.9028930370600392e-08
DEAE O 0 4.940794951835414e-06
- O 0 8.755659308690156e-08
cellulose O 0 8.353447924491775e-07
ion O 0 6.84237761561235e-07
- O 0 2.2552761436145374e-07
exchange O 0 3.5795150665762776e-07
chromatography O 0 1.679838987911353e-07
, O 0 1.2448473363235735e-08
radial O 0 7.140117759263376e-07
immunodiffusion O 0 3.4943068385473453e-06
, O 0 3.236787549099063e-08
and O 0 4.358141225679901e-08
radioimmunoassay O 0 7.45153593015857e-05
. O 0 3.505080485410872e-06

Previous O 0 9.829719601839315e-06
family O 0 1.7317087497303874e-07
studies O 0 1.4804598436057859e-08
suggested O 0 1.7342390856711631e-09
that O 0 2.238605308069186e-11
these O 0 2.193967230113003e-11
individuals O 0 5.370769801116282e-11
may O 0 4.701191658185166e-10
be O 0 2.411800481549875e-10
compound O 0 1.0703535835432376e-08
heterozygotes O 0 3.5629454941954464e-08
for O 0 1.2975769070333598e-10
the O 0 1.061104204502783e-09
common O 0 2.2718706915725306e-09
mutant O 0 1.0329623734151028e-07
TSD B-Disease 0 9.502470561528753e-07
gene O 0 3.0376585691271885e-09
and O 0 1.5592924729190827e-09
a O 0 4.838348832691963e-09
rare O 0 2.9325438077876242e-08
( O 0 4.234846695538863e-09
allelic O 0 1.4886238375311223e-07
) O 0 1.8312429350686443e-09
mutant O 0 2.2074654992820797e-08
gene O 0 2.1858093646187626e-07
. O 0 8.053837063926039e-07

Thus O 0 2.694983720630262e-07
, O 0 2.5650150892175816e-09
the O 0 1.569691820968444e-09
postulated O 0 4.3757452772297256e-07
rate O 0 4.506027995176964e-09
mutant O 0 3.84975784584185e-09
gene O 0 2.145731148317509e-09
appears O 0 2.013606836825943e-09
to O 0 1.3782259188077628e-11
code O 0 7.531987186726319e-12
for O 0 2.4078464916366116e-11
the O 0 2.56125898268067e-10
expression O 0 2.302586787905625e-09
of O 0 3.1320643856247443e-09
low O 0 6.607098868016692e-09
amounts O 0 2.3136719207172973e-09
of O 0 2.225300832492394e-08
hex O 0 2.254715809613117e-06
A O 0 2.659628762557986e-06
. O 0 1.1713165122273494e-06

Heterozygotes O 0 1.4010879567649681e-06
for O 0 9.067458783817983e-09
the O 0 1.0744075851221169e-08
rare O 0 1.1041365155506355e-08
mutant O 0 5.300487160297962e-08
may O 0 2.6297870547864477e-09
be O 0 3.0197547240540246e-10
indistinguishable O 0 2.2068382676820875e-08
from O 0 2.7108951194954045e-10
heterozygotes O 0 7.437904070428658e-09
for O 0 1.6029111371551608e-10
the O 0 4.837167999482972e-09
common O 0 9.435289172188277e-08
TSD B-Disease 0 5.619225703412667e-05
mutant O 0 1.6530100310774287e-06
. O 0 1.0197130677624955e-06

However O 0 1.478053803793955e-07
, O 0 1.5531333996676722e-09
direct O 0 2.750379701765837e-09
visualization O 0 9.119304422711139e-08
and O 0 1.2977162677785259e-09
quantitation O 0 1.0639404536050279e-05
of O 0 1.8694094023885555e-06
hex O 0 2.946088443422923e-06
A O 0 3.694603023518539e-08
by O 0 2.430067813641301e-10
the O 0 8.928885963932487e-10
methods O 0 2.4306343604507674e-09
described O 0 3.765767697672118e-09
may O 0 1.2575666064051916e-09
prevent O 0 6.248952466592073e-09
false O 0 1.4464801267877192e-07
- O 0 2.449979774610256e-08
positive O 0 3.4716103325393988e-09
prenatal O 0 2.451190361796307e-08
diagnosis O 0 4.0271942225444946e-08
of O 0 1.4208688448036355e-08
TSD B-Disease 0 2.8672477128566243e-05
in O 0 1.2089270917670092e-08
fetuses O 0 1.1288836532230562e-07
having O 0 2.8926832040809813e-09
the O 0 4.357324279169461e-09
incomplete O 0 5.389412081058254e-07
hex B-Disease 0 2.981040552185732e-06
A I-Disease 0 1.9279366370028583e-07
deficiency I-Disease 0 1.213895757246064e-06
of O 0 1.5908597106317757e-07
the O 0 8.43624281543498e-09
type O 0 1.6578120209942426e-08
described O 0 1.6328345342486728e-09
in O 0 3.000979187373076e-10
the O 0 1.7542911123769045e-08
four O 0 1.652331604873325e-08
healthy O 0 1.0896323487941117e-07
individuals O 0 1.083454463923772e-07

The O 0 9.748218872118741e-07
tumor B-Disease 0 1.5079410331964027e-05
suppressor O 0 2.179555485781748e-05
gene O 0 5.676167234014429e-07
Smad4 O 0 1.5177024579315912e-05
/ O 0 2.13558664086122e-07
Dpc4 O 0 1.285118287341902e-07
is O 0 2.1282675274902907e-11
required O 0 1.3921200997524252e-11
for O 0 8.043112009747944e-11
gastrulation O 0 3.968647277474702e-08
and O 0 3.480260524213463e-10
later O 0 1.4583075857999006e-09
for O 0 3.262499992384704e-10
anterior O 0 2.6301427169528324e-07
development O 0 1.0797221783320765e-08
of O 0 8.904789794428325e-09
the O 0 1.1895421536678441e-08
mouse O 0 3.909862655859797e-08
embryo O 0 8.5040488784216e-07
. O 0 8.468560963592608e-07

Mutations O 0 1.942625431183842e-06
in O 0 5.326248952997048e-08
the O 0 6.640200922447548e-07
SMAD4 O 1 0.9999997615814209
/ O 0 8.023499685805291e-05
DPC4 O 0 0.00021991309768054634
tumor B-Disease 0 9.644373903938686e-07
suppressor O 0 5.301457690620737e-07
gene O 0 3.520292723990792e-09
, O 0 4.1872319500591004e-10
a O 0 2.2685611722472743e-10
key O 0 5.8487441556565045e-09
signal O 0 2.9934646761375916e-08
transducer O 0 3.442750085014268e-08
in O 0 5.234796152109311e-09
most O 0 1.8478255370268926e-08
TGFbeta O 0 1.7367179907523678e-06
- O 0 3.9870382551043804e-08
related O 0 6.184910716910963e-08
pathways O 0 6.687636755486892e-08
, O 0 2.7770089006118326e-10
are O 0 1.0476853759544547e-11
involved O 0 2.5189968166916543e-11
in O 0 5.269924427397932e-11
50 O 0 5.990310469883298e-09
% O 0 1.338081112578493e-08
of O 0 2.490479644734478e-08
pancreatic B-Disease 0 0.013607488945126534
cancers I-Disease 1 0.6071527004241943
. O 0 1.0463627404533327e-06

Homozygous O 0 5.861377758265007e-06
Smad4 O 0 0.00017890903109218925
mutant O 0 1.991767931031063e-06
mice O 0 1.9311274002120626e-07
die O 0 2.2105966479557537e-07
before O 0 2.021411482644453e-08
day O 0 2.2836974977735736e-08
7 O 0 1.544741508041625e-07
. O 0 1.7333015023268672e-07

5 O 0 4.271791567589389e-06
of O 0 5.774226110588643e-07
embryogenesis O 0 8.711715054232627e-06
. O 0 2.630577000672929e-06

Mutant O 0 4.7459687380069226e-07
embryos O 0 1.792331119077062e-07
have O 0 1.750146028101085e-09
reduced O 0 1.2499627999318363e-08
size O 0 7.270748447751885e-09
, O 0 5.064609287508404e-10
fail O 0 5.000530212129206e-09
to O 0 1.5580349232990898e-09
gastrulate O 0 1.1315130450384459e-06
or O 0 3.7093301763491127e-09
express O 0 1.9609380785823305e-09
a O 0 6.457908652279798e-10
mesodermal O 0 3.2130449767464597e-07
marker O 0 2.445804057060741e-07
, O 0 4.133481557033747e-09
and O 0 5.134613623170026e-09
show O 0 5.444461947945456e-08
abnormal O 0 1.1668790875773993e-06
visceral O 0 3.516472133924253e-05
endoderm O 0 0.00026365151279605925
development O 0 2.5189870029862504e-06
. O 0 7.032833764242241e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 6.91073137204512e-06
the O 0 1.1537768074276755e-07
Smad4 O 0 9.296571988670621e-06
- O 0 2.834056260780926e-07
deficient O 0 3.068657861149404e-08
embryos O 0 7.620216457837614e-09
results O 0 3.766694067763865e-09
from O 0 2.5721531571321066e-09
reduced O 0 1.49609231669956e-08
cell O 0 2.3825863948445658e-08
proliferation O 0 3.322874420064181e-08
rather O 0 3.653422564475761e-10
than O 0 7.577438676520387e-11
increased O 0 2.659132247728735e-09
apoptosis O 0 3.235503811538365e-07
. O 0 2.3826054018627474e-07

Aggregation O 0 7.751817179268983e-07
of O 0 1.8220396214019274e-07
mutant O 0 7.946558753246791e-07
Smad4 O 0 2.7501520889927633e-05
ES O 0 4.37009612141992e-06
cells O 0 3.983729790490997e-09
with O 0 4.217578231102692e-10
wild O 0 5.4445106201228555e-09
- O 0 4.1792871385837316e-09
type O 0 5.121428614529577e-09
tetraploid O 0 8.552603958378313e-07
morulae O 0 1.5987883443813189e-06
rescues O 0 3.3977389080064313e-07
the O 0 1.5512600981537616e-08
gastrulation B-Disease 0 5.814748874399811e-06
defect I-Disease 0 7.206981990748318e-06
. O 0 1.3664513289768365e-06

These O 0 7.947174651690148e-08
results O 0 8.53922443866395e-08
indicate O 0 4.9144222913355406e-08
that O 0 1.2185684683529985e-09
Smad4 O 0 5.679085575138743e-07
is O 0 1.7441867394829558e-10
initially O 0 6.903878163599941e-11
required O 0 1.4721959762376002e-11
for O 0 3.975111212417559e-11
the O 0 7.255810396955553e-10
differentiation O 0 2.045200275802017e-08
of O 0 1.0570203379245413e-08
the O 0 6.823178466675017e-09
visceral O 0 6.070330869079044e-07
endoderm O 0 8.05229319666978e-07
and O 0 3.8700312399164716e-10
that O 0 1.1105010661038861e-10
the O 0 7.559239345589219e-10
gastrulation B-Disease 0 5.651386203453512e-08
defect I-Disease 0 1.3814230648279135e-08
in O 0 1.1753039652617758e-09
the O 0 1.6410623970841698e-08
epiblast O 0 2.087923803628655e-06
is O 0 2.4929354136560278e-09
secondary O 0 2.5863915453783193e-08
and O 0 2.58701193800448e-09
non O 0 3.552753753410798e-07
- O 0 1.5427099242515396e-07
cell O 0 1.0992951501975767e-05
autonomous O 0 3.4487554785300745e-06
. O 0 6.1818451513318e-07

Rescued O 0 6.999297511356417e-06
embryos O 0 1.0331048088119132e-06
show O 0 5.600917916126491e-07
severe O 0 3.790974005823955e-05
anterior O 0 0.004907543305307627
truncations O 0 8.890915341908112e-05
, O 0 5.98574212418157e-09
indicating O 0 2.824301681414454e-08
a O 0 1.2400172000326393e-09
second O 0 1.2325235276833268e-09
important O 0 2.782879704454899e-09
role O 0 1.7042548483559017e-09
for O 0 2.990016456649869e-09
Smad4 O 0 1.547622559883166e-05
in O 0 4.4024879741755285e-08
anterior O 0 2.9572571293101646e-05
patterning O 0 5.205439720157301e-06
during O 0 1.7094360771352513e-07
embryogenesis O 0 5.6576263887109235e-06
. O 0 6.023389573783788e-07

Prevalence O 0 6.470123025792418e-06
of O 0 1.0921937843022533e-07
p16 O 0 1.1765470162572456e-06
and O 0 6.339594449400465e-08
CDK4 O 0 0.007411669939756393
germline O 0 7.2177658694272395e-06
mutations O 0 3.47227512520476e-07
in O 0 2.195691095607799e-08
48 O 0 4.2685684320531436e-07
melanoma B-Disease 0 6.67178028379567e-07
- O 0 2.597128734294074e-08
prone O 0 1.8640381682644147e-08
families O 0 2.110974284263989e-09
in O 0 1.3728567171966688e-09
France O 0 9.465824746257567e-08
. O 0 2.5115315338553046e-07

The O 0 1.4455150676440098e-06
French O 0 4.3062194890808314e-05
Familial B-Disease 0 3.231456867069937e-05
Melanoma I-Disease 0 2.5793679014896043e-05
Study O 0 9.157314906360625e-09
Group O 0 3.6024820904145827e-09
. O 0 1.9608457080266817e-08

Germline O 0 1.8639566405909136e-05
mutations O 0 8.043090815590404e-07
in O 0 9.852476168248359e-09
the O 0 1.6964850857448255e-08
p16 O 0 1.3957331645997328e-07
and O 0 4.225027883109078e-09
CDK4 O 0 7.187687515397556e-06
genes O 0 6.92499924070944e-09
have O 0 2.931450082677145e-10
been O 0 1.5588098867258537e-10
reported O 0 2.687701172732204e-10
in O 0 1.123892992560549e-11
a O 0 2.240135438258406e-10
subset O 0 2.639426632811137e-08
of O 0 2.1943723282902283e-08
melanoma B-Disease 0 6.229735163287842e-07
pedigrees O 0 1.3248720165393024e-07
, O 0 2.6294759702949477e-09
but O 0 9.410443535529112e-10
their O 0 1.4171330775525348e-09
prevalence O 0 1.0184171372884521e-07
is O 0 1.14990308941465e-10
not O 0 3.831603090365121e-10
well O 0 4.524561614260847e-09
known O 0 7.512402788734107e-08
. O 0 5.010849122299987e-07

We O 0 3.593370223597958e-08
searched O 0 2.817962929668738e-08
for O 0 3.080612431816121e-10
such O 0 1.7763374104973195e-09
germline O 0 1.4043707778910175e-06
mutations O 0 1.0322041532617732e-07
in O 0 6.557770326764967e-09
48 O 0 2.2785097542055155e-07
French O 0 7.551146268269804e-07
melanoma B-Disease 0 1.2848723827119102e-06
- O 0 9.830325886639457e-09
prone O 0 3.6447662665750613e-09
families O 0 1.8103528398594193e-10
selected O 0 1.039235364430624e-10
according O 0 4.810526976761764e-11
to O 0 2.3069804747088973e-11
two O 0 3.3810280963830763e-11
major O 0 3.704788975600337e-10
criteria O 0 7.198054374768503e-10
families O 0 1.2738150811930637e-10
with O 0 3.374012527701531e-11
at O 0 4.2337058858699095e-10
least O 0 2.0642999809528106e-10
three O 0 1.8523121925184682e-10
affected O 0 1.3618014493843589e-09
members O 0 1.470950444781849e-10
( O 0 2.9398097844968163e-10
n O 0 2.2943098532124395e-09
= O 0 3.2123503856951174e-09
20 O 0 1.6606181985068247e-09
) O 0 5.511697001581162e-12
or O 0 1.042793022071331e-11
families O 0 2.4777020712907216e-11
with O 0 3.3452839023201397e-12
two O 0 6.062010702440057e-12
affected O 0 1.0269750327918103e-10
members O 0 1.1028067348206605e-11
, O 0 1.7645976693736465e-11
one O 0 2.7718053546843535e-11
of O 0 1.1807566036026174e-10
them O 0 1.0022557089817141e-10
affected O 0 8.836162912473355e-10
before O 0 1.9469614809253244e-10
the O 0 2.632108975220149e-10
age O 0 1.5501264716277774e-09
of O 0 3.2925708826070377e-09
50 O 0 3.94877242015923e-09
( O 0 3.515533419928829e-10
n O 0 2.2110504538375153e-09
= O 0 1.1691604129282496e-08
28 O 0 4.548566678863608e-08
) O 0 1.827752532657101e-10
, O 0 8.576787891012572e-11
and O 0 1.0365965030789681e-10
one O 0 6.994990697783976e-11
additional O 0 4.868163094862155e-10
minor O 0 1.8866550988150266e-08
criterion O 0 1.3135923836671282e-05
. O 0 1.0108780088557978e-06

Sixteen O 0 4.6397226469707675e-06
different O 0 9.234369713340129e-08
p16 O 0 9.896868959913263e-07
germline O 0 5.081499239167897e-07
mutations O 0 2.432472001601127e-08
were O 0 1.0575118558620034e-09
found O 0 4.745160167574092e-11
in O 0 2.3327947212825606e-11
21 O 0 9.357196129045064e-10
families O 0 1.5586464063854777e-10
, O 0 1.2081237399375055e-10
while O 0 1.8017236314005203e-10
one O 0 6.477214320455005e-10
germline O 0 6.038319355639032e-08
mutation O 0 1.2633107004944577e-08
, O 0 1.3432048806549801e-09
Arg24His O 0 9.585664884070866e-08
, O 0 6.788269946156333e-10
was O 0 1.7804316909675322e-09
detected O 0 1.1469268867969618e-09
in O 0 2.2526294718439033e-10
the O 0 1.4627543620804317e-08
CDK4 O 0 9.055957343662158e-05
gene O 0 5.342599820323812e-07
. O 0 1.4399303154277732e-06

The O 0 3.7300342370372164e-08
frequency O 0 4.0923847421936443e-08
of O 0 7.793816259038522e-09
p16 O 0 1.5616326010103876e-08
gene O 0 2.0448522874971786e-09
mutation O 0 2.0676229617322406e-09
in O 0 3.09336556369999e-10
our O 0 9.261738043164769e-10
sample O 0 3.1658287102942495e-10
( O 0 1.3293544043335714e-10
44 O 0 5.739646091740269e-09
% O 0 2.3941504334601404e-10
) O 0 2.090747713845431e-12
is O 0 3.804023068765261e-12
among O 0 1.257311095514968e-11
the O 0 1.5392981334017009e-10
highest O 0 2.4110200502747148e-09
rates O 0 6.547256070632557e-10
yet O 0 2.3949905947340255e-10
reported O 0 1.5954846332988382e-09
and O 0 1.5341160286563849e-10
the O 0 2.31595920219263e-09
CDK4 O 0 7.322520559682744e-06
mutation O 0 1.4329574193894246e-09
is O 0 1.2273992933131694e-10
the O 0 3.6523079005590375e-10
second O 0 1.5791721263980207e-09
mutation O 0 6.6525971398334605e-09
detected O 0 1.9535539852455486e-09
in O 0 1.2489961842554465e-10
this O 0 3.8628703014076393e-10
gene O 0 1.2390886539037638e-08
worldwide O 0 3.5080621074712326e-08
. O 0 2.788809183584817e-07

In O 0 7.463597739842953e-09
summary O 0 6.57479347410117e-07
, O 0 3.736412512722609e-09
our O 0 2.3107216140516584e-09
results O 0 3.763247491406219e-09
show O 0 1.7174707211964346e-09
frequent O 0 2.501065132776148e-09
involvement O 0 2.7688864534525237e-09
of O 0 1.7626249348978718e-09
the O 0 4.189998570325315e-09
p16 O 0 2.80889960180275e-08
gene O 0 2.379701324883854e-09
in O 0 1.8243994093225524e-09
familial B-Disease 0 3.283329306214e-07
melanoma I-Disease 0 1.0948635065233248e-07
and O 0 5.252043244752258e-11
confirm O 0 6.418527376261807e-10
the O 0 6.968667309870114e-10
role O 0 9.922852539645532e-10
of O 0 2.2533535926072545e-08
the O 0 8.894389225133637e-08
CDK4 O 1 0.9399132132530212
gene O 0 1.5327547231436256e-08
as O 0 2.5372711931481717e-08
a O 0 4.053920932278743e-08
melanoma B-Disease 0 5.918367378399125e-07
- O 0 2.045193241428933e-07
predisposing O 0 2.612080152175622e-06
gene O 0 9.218215524242623e-08
. O 0 1.42613117759538e-07
. O 0 4.6465140712825814e-07

Progression O 0 2.2393339804693824e-06
of O 0 4.219232039304188e-07
somatic O 0 0.00013154807675164193
CTG O 0 5.5347554734908044e-05
repeat O 0 5.031914795949888e-08
length O 0 4.220541693911173e-09
heterogeneity O 0 1.7203788615915983e-07
in O 0 1.1699518021046629e-09
the O 0 3.574720075505411e-09
blood O 0 8.182802879730389e-09
cells O 0 2.6217753301693847e-08
of O 0 4.570970446593492e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.39918868678069e-07
. O 0 9.523031252456349e-08

The O 0 3.854724539564813e-09
genetic O 0 2.0956946400474408e-08
basis O 0 2.9250470490183034e-08
of O 0 1.5926577390246166e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.3748898709309287e-05
DM B-Disease 1 1.0
) O 0 2.1876001010667778e-10
is O 0 1.5310605214202688e-11
the O 0 2.2963434972989027e-11
expansion O 0 2.249084474215124e-09
of O 0 2.978467472658508e-09
an O 0 1.3027016798616842e-08
unstable O 0 4.667595203500241e-05
CTG O 0 4.086179251316935e-05
repeat O 0 2.1699657182239207e-08
in O 0 1.866000909345189e-09
the O 0 1.2663528003997726e-08
34 O 0 5.5855885250366555e-08
UTR O 0 5.1164377509849146e-05
of O 0 7.492298692568511e-08
the O 0 5.406121772466577e-07
DM B-Disease 1 1.0
protein O 0 1.7209415545949014e-06
kinase O 0 4.2358672658338037e-07
gene O 0 2.029598000774513e-08
on O 0 5.853635087760267e-08
chromosome O 0 1.7066456337033742e-07
19 O 0 6.141253265923297e-07
. O 0 2.435225781027839e-07

One O 0 4.3110986780448e-08
of O 0 2.5014958993097025e-08
the O 0 1.3849925650788464e-08
principal O 0 2.057824133316899e-07
features O 0 2.050926095620298e-09
of O 0 6.87304790858434e-09
the O 0 8.259641504082538e-08
DM B-Disease 1 1.0
mutation O 0 4.588974533703549e-08
is O 0 1.8800397350027254e-10
an O 0 1.6633752708550276e-10
extraordinarily O 0 2.5842994411107156e-09
high O 0 6.419424547488006e-09
level O 0 1.2635444690545228e-08
of O 0 1.2250571224114992e-08
somatic O 0 9.251256415154785e-05
mosaicism O 0 1.766552304616198e-05
, O 0 4.3960560192068954e-10
due O 0 8.716327659641365e-10
to O 0 6.736917274041687e-11
an O 0 9.942474621382758e-11
extremely O 0 1.284572448412291e-10
high O 0 2.561527934208385e-10
degree O 0 1.9225552261303847e-09
of O 0 6.703082533476845e-10
somatic O 0 9.028991030390898e-07
instability O 0 9.17728684157737e-08
both O 0 7.854474848301152e-10
within O 0 1.0786698201314948e-09
and O 0 5.35092581355201e-10
between O 0 7.638242260910033e-10
different O 0 4.837545919400554e-09
tissues O 0 3.669510419967992e-07
. O 0 2.6803482455761696e-07

This O 0 3.853682883914189e-08
instability O 0 5.697356186828983e-07
appears O 0 1.6823873849602933e-08
to O 0 2.9217489538879704e-10
be O 0 5.666578317686799e-10
biased O 0 2.3071995869372586e-08
towards O 0 3.0765503478136225e-09
further O 0 3.528976555422503e-10
expansion O 0 2.7087048160012728e-09
and O 0 2.312082747479849e-10
continuous O 0 3.021444427986353e-09
throughout O 0 9.443922310836683e-10
the O 0 1.1948032563324773e-09
life O 0 1.308990027482082e-09
of O 0 1.939560512198568e-09
an O 0 2.7005114811018416e-10
individual O 0 3.3550895395251246e-10
, O 0 2.7584898254495727e-10
features O 0 1.1031298097208264e-09
that O 0 8.594883138535181e-11
could O 0 3.4285727035232583e-10
be O 0 1.793949988559973e-10
associated O 0 4.283981169805884e-09
with O 0 1.5974022105069707e-10
the O 0 5.876789277436956e-09
progressive O 0 4.700980866800819e-07
nature O 0 2.0517605392456062e-08
of O 0 5.160415650351524e-09
the O 0 2.6852033485624816e-08
disease O 0 3.243428068344656e-07
. O 0 1.5549191800801054e-07

Although O 0 2.0429391511811446e-08
increasing O 0 5.666915825486285e-09
measured O 0 2.1482864376309863e-09
allele O 0 7.8841339012925e-10
size O 0 2.2993204562560265e-10
between O 0 5.486194831760827e-10
patients O 0 8.739733936558025e-10
clearly O 0 1.37854017090433e-09
correlates O 0 1.68551161916497e-09
with O 0 6.414307561659893e-13
an O 0 2.8462625051989265e-12
increased O 0 2.4075158533420904e-11
severity O 0 6.84698386876903e-09
of O 0 1.4725961561268264e-09
symptoms O 0 1.4950916238376522e-07
and O 0 1.2377671110286315e-10
an O 0 5.890036375300056e-11
earlier O 0 1.1405497379879392e-10
age O 0 1.0959281260269904e-09
of O 0 1.5255381402567991e-09
onset O 0 2.8472891600017647e-08
, O 0 9.817162360814535e-11
this O 0 4.901552774772e-11
correlation O 0 1.3292891232197235e-09
is O 0 1.679627270601003e-11
not O 0 2.0921290741493515e-11
precise O 0 1.0045208220788027e-08
and O 0 1.3502893247974157e-09
measured O 0 5.2468616118517275e-09
allele O 0 2.271008270327002e-09
length O 0 1.2985803543585916e-09
cannot O 0 2.805701226904489e-09
be O 0 1.0955226725783973e-09
used O 0 8.757822800298243e-10
as O 0 5.047087192622257e-10
an O 0 1.0878884598719551e-10
accurate O 0 3.627236111469756e-08
predictor O 0 5.828011921948928e-07
of O 0 2.6601787439517466e-08
age O 0 1.0756151596069685e-06
of O 0 1.3171761565899942e-06
onset O 0 0.022122466936707497
. O 0 1.920648855957552e-06

In O 0 5.823519888537021e-09
order O 0 1.5634290528865336e-09
to O 0 1.8295034931448129e-10
further O 0 2.431997714325007e-09
characterize O 0 1.8152299219309498e-08
the O 0 4.0165910597522725e-09
dynamics O 0 3.0021161023796594e-07
of O 0 3.363429357250425e-07
DM B-Disease 1 1.0
CTG O 0 4.485513272811659e-05
repeat O 0 5.489371801559173e-08
somatic O 0 4.902425416730694e-07
instability O 0 1.361532611099392e-07
, O 0 1.031380536531401e-09
we O 0 2.22412754879997e-10
have O 0 5.312138229296437e-11
studied O 0 1.4793301028603878e-09
repeat O 0 6.647469241727322e-10
length O 0 4.529031871758349e-10
changes O 0 3.7625780269223696e-10
over O 0 5.03700858800471e-10
time O 0 4.6125400721130916e-10
in O 0 7.464149298641587e-10
111 O 0 6.774060921088676e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999972581863403
patients O 0 3.8584152539655747e-10
with O 0 4.048959518360151e-12
varying O 0 4.2000378175366393e-10
clinical O 0 7.632212639663294e-10
severity O 0 6.753960946070947e-08
and O 0 4.050209501116342e-09
CTG O 0 1.182495338980516e-06
repeat O 0 5.536634706260202e-09
size O 0 3.785318725135767e-09
over O 0 7.161654602683143e-10
time O 0 2.076305349874019e-09
intervals O 0 7.375954957922204e-09
of O 0 4.1402827832826006e-09
1 O 0 5.1773358933360214e-08
- O 0 2.873991711282997e-08
7 O 0 9.588755034428686e-08
years O 0 3.1757867446913224e-08
. O 0 2.41528397282309e-07

We O 0 5.223678201105031e-08
have O 0 7.624007536399802e-10
found O 0 2.391731257489482e-10
a O 0 8.549674856972445e-11
direct O 0 9.301801551231392e-10
progression O 0 1.0913915993171486e-08
of O 0 1.7154148101994338e-09
the O 0 1.6995836960020938e-09
size O 0 6.547122399780392e-09
heterogeneity O 0 3.013590230693808e-07
over O 0 2.92220159181511e-09
time O 0 7.290741899090847e-10
related O 0 4.619638893643696e-09
to O 0 1.5531836927706877e-09
initial O 0 9.500099196202427e-08
CTG O 0 7.737946816632757e-07
repeat O 0 2.669504173269388e-09
size O 0 1.8473876872704409e-09
and O 0 9.45037381683278e-10
the O 0 2.7186477513652108e-09
time O 0 2.6399740171711983e-09
interval O 0 1.3810883991993705e-08
and O 0 1.7186667644608633e-09
always O 0 6.671504682032037e-09
biased O 0 1.8561803472039173e-07
towards O 0 1.8683808278296965e-08
further O 0 2.5409468307202587e-08
expansion O 0 1.267637912860664e-06
. O 0 1.3738772395299748e-06

Attempts O 0 8.039427257244824e-08
to O 0 1.5762652294526447e-09
mathematically O 0 9.49363325730701e-08
model O 0 3.448277041684378e-08
the O 0 1.8954954938976698e-08
dynamics O 0 2.698059233807726e-07
have O 0 3.3511513564121742e-09
proved O 0 1.2610216515440698e-07
only O 0 9.91638682279472e-09
partially O 0 8.332571610480954e-08
successful O 0 2.089933337501293e-09
suggesting O 0 4.924422647434312e-09
that O 0 9.626234531712186e-11
individual O 0 1.8908535848183305e-10
specific O 0 1.3775807161664488e-09
genetic O 0 4.032236589068816e-08
and O 0 1.9179624555221153e-09
/ O 0 8.167708287487585e-09
or O 0 2.0332188710447952e-10
environmental O 0 3.723095165497625e-09
factors O 0 3.3498350759941786e-09
also O 0 1.5358961324984932e-10
play O 0 2.539015941938061e-10
a O 0 1.5648311535443327e-09
role O 0 1.4896875955017208e-09
in O 0 2.5957207494542445e-09
somatic O 0 2.054288415820338e-05
mosaicism O 0 2.9817609174642712e-05
. O 0 9.402377543210605e-08
. O 0 4.4493393147604365e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 4.2427723201399203e-07
Palestinian O 0 0.000209709643968381
Arabs O 0 3.478331109363353e-06
. O 0 8.153576800395967e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9995380640029907
AGU B-Disease 1 1.0
) O 0 1.1612662831339549e-08
is O 0 3.949207072473371e-10
a O 0 2.36610397941206e-10
rare O 0 1.2211611277734846e-08
disorder B-Disease 1 1.0
of I-Disease 1 0.9997010827064514
glycoprotein I-Disease 0 0.0008294587023556232
metabolism I-Disease 1 0.9995437264442444
caused O 0 7.454793831129791e-07
by O 0 3.1412464296387554e-10
the O 0 1.0923391080552847e-08
deficiency B-Disease 1 0.9999849796295166
of I-Disease 0 1.8576744196252548e-06
the I-Disease 0 9.35358102083228e-08
lysosomal I-Disease 0 6.553605089720804e-06
enzyme I-Disease 0 4.890064701612573e-06
aspartylglucosaminidase I-Disease 0 1.22596948131104e-05
( O 0 2.9536053602896573e-08
AGA O 0 2.79523701465223e-05
) O 0 2.8280588537654694e-08
. O 0 1.7830500098625635e-07

AGU B-Disease 1 1.0
is O 0 5.40030896445387e-07
inherited O 0 1.8020293282461353e-05
as O 0 4.34133262672276e-08
an O 0 6.535731067458528e-09
autosomal O 0 3.1144622880674433e-06
recessive O 0 1.7929891100720852e-06
trait O 0 4.402097886213596e-07
and O 0 1.664994114802809e-10
occurs O 0 9.567550918188061e-11
with O 0 1.6076093364500443e-12
a O 0 3.4932338272009034e-11
high O 0 2.9387001165837034e-10
frequency O 0 2.1623200452403069e-10
in O 0 7.263242091104516e-11
Finland O 0 1.3972609735901642e-09
because O 0 2.4813082699637334e-09
of O 0 2.102136065218474e-08
a O 0 2.4244403817874627e-08
founder O 0 2.574840323177341e-07
effect O 0 5.747788236476481e-07
. O 0 7.742479510852718e-07

While O 0 2.830768721651111e-07
very O 0 2.2211875005950787e-08
few O 0 1.0545917028537133e-08
patients O 0 1.4469894171753594e-09
with O 0 8.719669430945487e-10
AGU B-Disease 1 1.0
have O 0 1.5500762895470643e-09
been O 0 1.6774064082181184e-10
reported O 0 2.6380950202131714e-10
from O 0 8.422536279528714e-11
non O 0 1.3365756279526408e-09
- O 0 1.6886642084656955e-10
Finnish O 0 6.3137073347263595e-09
origin O 0 5.918364465173909e-09
, O 0 1.7179162536962167e-09
we O 0 2.7554885040359522e-09
diagnosed O 0 2.6170221190113807e-07
the O 0 7.015909631036266e-09
disorder O 0 6.380948747164439e-08
in O 0 2.349769823162262e-10
8 O 0 1.9456261046713053e-09
patients O 0 3.252309185852731e-11
originating O 0 5.310297201965852e-10
from O 0 1.629697488070292e-10
3 O 0 8.769958093068908e-10
unrelated O 0 7.202751728385692e-10
families O 0 5.672728606298527e-11
, O 0 1.5905424546880376e-11
all O 0 1.960068565787232e-11
Palestinian O 0 1.1936467814166463e-08
Arabs O 0 2.9771896059571645e-09
from O 0 3.4620206701418965e-10
the O 0 4.2545181266895327e-10
region O 0 3.3038314306566008e-09
of O 0 1.2916052227751607e-08
Jerusalem O 0 9.733478691487107e-06
. O 0 9.811941481530084e-07

The O 0 8.52231849535201e-08
clinical O 0 1.5386633833713859e-07
diagnosis O 0 0.00037636098568327725
of O 1 0.6625503301620483
AGU B-Disease 1 1.0
is O 0 3.884388988240062e-08
often O 0 4.524645658143811e-10
difficult O 0 4.989942348210263e-10
, O 0 2.551832183061986e-11
in O 0 1.3328217869645886e-11
particular O 0 1.3020966249666088e-10
early O 0 1.3216970851104293e-09
in O 0 4.319009733189105e-11
the O 0 4.832895750261912e-10
course O 0 1.2176113450834691e-09
of O 0 1.2486182088267128e-09
the O 0 3.887003163782765e-09
disease O 0 7.209132402152818e-09
, O 0 1.2658250836405927e-10
and O 0 5.036161071503287e-11
most O 0 8.863081102372661e-11
of O 0 4.725346780531936e-10
the O 0 6.866218149603753e-10
patients O 0 5.259523927492182e-10
are O 0 1.57983709447862e-10
diagnosed O 0 1.5666439256989406e-09
after O 0 2.1174416386937622e-10
the O 0 3.209653653968303e-10
age O 0 5.586331397466893e-09
of O 0 8.676159346521217e-09
5 O 0 2.5308379392185998e-08
years O 0 2.6710130995866166e-08
. O 0 2.844508060206863e-07

However O 0 8.240929219027748e-07
, O 0 9.507583165202504e-09
since O 0 2.5082311783108935e-09
these O 0 1.5531066432927787e-09
patients O 0 1.955984929580268e-09
excrete O 0 1.370779845188963e-08
early O 0 1.93610483201212e-09
large O 0 2.478280081152917e-10
amounts O 0 8.550379848593082e-10
of O 0 4.3622634393614135e-09
aspartylglucosamine O 0 2.2884290729052736e-07
in O 0 1.4639817136341549e-09
urine O 0 3.722654851046059e-09
, O 0 5.626653587498254e-10
biochemical O 0 1.3174214608113743e-08
screening O 0 1.1009646527782024e-09
is O 0 6.301985600032367e-10
easy O 0 9.321022176322913e-09
by O 0 5.290535565194432e-09
urine O 0 2.714799229863729e-08
chromatography O 0 2.244783416927021e-07
. O 0 6.105024397129455e-08
. O 0 3.6083639542994206e-07

Detection O 0 8.546280128030048e-08
of O 0 1.0287523721785874e-08
heterozygous O 0 1.1138469035998355e-09
carriers O 0 1.033262919669653e-09
of O 0 2.329986648064164e-09
the O 0 5.93579976282399e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.6200225445572869e-06
ATM O 0 1.2027230695821345e-05
) O 0 7.081851771673087e-10
gene O 0 6.824685261364039e-10
by O 0 4.316936530468496e-10
G2 O 0 1.552737813881322e-07
phase O 0 1.2477665123356019e-08
chromosomal O 0 3.3880834848787345e-07
radiosensitivity O 0 1.472983967687469e-06
of O 0 8.595518607990016e-08
peripheral O 0 2.0857667550444603e-05
blood O 0 3.260978246544255e-06
lymphocytes O 0 2.5983680984609236e-07
. O 0 1.1283434275810578e-07

In O 0 8.092687835414836e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.034192590043119e-10
patients O 0 5.352028265015463e-10
, O 0 3.202534071267138e-11
mutations O 0 1.3920703478831342e-10
in O 0 4.448755600017229e-11
a O 0 2.0222193364283214e-10
single O 0 5.924547658020529e-11
gene O 0 1.6615424314192495e-10
, O 0 1.7377645156191335e-10
ATM O 0 1.6984598616431867e-08
, O 0 5.880920750378493e-11
result O 0 1.7984344569121902e-10
in O 0 5.7486137378104374e-11
an O 0 5.4219324141513425e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.0889689977821035e-09
embraces O 0 4.615912985173054e-09
a O 0 1.1936591992611767e-10
variety O 0 3.810700366368991e-10
of O 0 1.1643374042691335e-09
clinical O 0 5.40027667028653e-09
features O 0 5.453584250858512e-09
and O 0 1.0999740007733294e-09
manifests O 0 3.339731335927354e-08
extreme O 0 8.082631808292717e-08
radiosensitivity O 0 1.1713030971804983e-06
and O 0 2.558574907496336e-09
a O 0 9.164653924642607e-09
strong O 0 5.568929495325392e-08
pre O 0 3.5148605093127117e-07
- O 0 1.530517579340085e-07
disposition O 0 4.555479335976997e-06
to O 0 9.387826338524974e-08
malignancy B-Disease 0 3.6549641663441435e-05
. O 0 5.032289323025907e-07

Heterozygotes O 0 9.550412869430147e-07
for O 0 9.190210370491059e-09
the O 0 3.9254349104567154e-08
ATM O 0 1.068883648258634e-06
gene O 0 1.7171473132293613e-08
have O 0 9.502284514795178e-10
no O 0 3.7064568081390803e-10
clinical O 0 4.973674805341943e-10
expression O 0 2.7805242552858545e-09
of O 0 1.5138149933591194e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.0746109069259546e-07
may O 0 8.784293292762868e-09
be O 0 3.943668946959633e-09
cancer B-Disease 0 2.429421286365141e-08
prone O 0 2.479340288630283e-09
with O 0 2.2679068692466053e-11
a O 0 5.98757710079667e-10
moderate O 0 1.1143404421432024e-08
increase O 0 4.856514634887787e-10
in O 0 1.61987340208114e-10
in O 0 2.6661917118531164e-09
vitro O 0 6.921673048054799e-07
radiosensitivity O 0 1.0917560757661704e-05
. O 0 5.803480007671169e-07

We O 0 1.708370263031611e-07
performed O 0 1.5044939516428713e-08
a O 0 1.8061296458427023e-08
blind O 0 2.1170605180031998e-07
chromosomal O 0 2.887016421482258e-07
analysis O 0 7.01783946510659e-08
on O 0 4.902728889533137e-08
G2 O 0 4.075416200066684e-07
- O 0 8.766617654032416e-09
phase O 0 5.2234958580754665e-09
lymphocytes O 0 8.828935360583046e-10
from O 0 3.377935708925861e-10
7 O 0 3.688770844334499e-09
unrelated O 0 1.5442465439718944e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
patients O 0 3.4393619063877168e-09
, O 0 1.6488732601516176e-10
13 O 0 1.150816331119131e-09
obligate O 0 6.078521153085603e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
heterozygotes O 0 2.2829011925296072e-07
( O 0 2.0694644609076107e-10
parents O 0 1.8234277976425517e-10
of O 0 3.54552665005059e-10
the O 0 2.4834234668702493e-10
patients O 0 2.516130012675255e-11
) O 0 4.004636032506337e-12
, O 0 1.6941316405283402e-11
and O 0 1.5669240904792048e-10
14 O 0 6.349066605793041e-09
normal O 0 1.330238408314699e-08
controls O 0 6.160914001185347e-09
following O 0 5.702150973618814e-10
X O 0 2.4355825800626008e-08
- O 0 2.1395192284501263e-09
irradiation O 0 1.0258680127606112e-08
with O 0 7.174229266215804e-11
1 O 0 5.035877492787222e-09
Gy O 0 1.1461975191195961e-07
in O 0 5.178454193233151e-11
order O 0 1.7026619003601695e-10
to O 0 1.9048732036175409e-10
evaluate O 0 2.3579149743824246e-09
this O 0 5.693185367583453e-10
cytogenetic O 0 3.8186212236723804e-07
method O 0 2.6544563880293026e-08
as O 0 1.410087713260566e-09
a O 0 6.07359051940648e-10
tool O 0 5.560043092600608e-09
for O 0 6.046932399250693e-11
detection O 0 1.2665557491686741e-08
of O 0 1.670087890204286e-08
ATM O 0 1.667347714828793e-05
carriers O 0 4.719560138255474e-07
. O 0 5.77394530409947e-07

Both O 0 2.5637014005042147e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 1.0457123380547273e-06
and O 0 2.166279822191086e-09
heterozygotes O 0 3.180120700108091e-08
showed O 0 1.1506320340970433e-09
significantly O 0 5.157028137858788e-10
increased O 0 2.7796795420975684e-10
levels O 0 3.029562156697807e-10
of O 0 4.658080587915947e-10
radiation O 0 9.15492307740351e-07
- O 0 4.674541642657459e-08
induced O 0 3.731101969606243e-07
chromatid O 0 2.6106482664545183e-07
damage O 0 2.184894469792198e-07
relative O 0 1.3254972230924977e-08
to O 0 1.453353132285784e-10
that O 0 1.0819289214536454e-10
of O 0 2.3999902065696688e-09
normal O 0 5.040175210524467e-08
controls O 0 3.0970826969678455e-07
. O 0 6.718768759128579e-07

These O 0 1.0848312470557175e-08
results O 0 2.7248944434177247e-08
show O 0 5.383266721281643e-09
that O 0 7.776067567633049e-10
the O 0 1.1772587349412333e-08
G2 O 0 1.5047771739773452e-06
- O 0 6.981658629001686e-08
phase O 0 1.3857460601229832e-07
chromosomal O 0 1.1476537338239723e-06
radiosensitivity O 0 1.7476470475230599e-06
assay O 0 5.663785174192526e-08
can O 0 9.136095768802477e-10
be O 0 2.0388576937868663e-10
used O 0 6.589209039509214e-11
for O 0 1.9703088119382706e-11
the O 0 7.953092351353774e-11
detection O 0 9.967054737103354e-09
of O 0 1.2425527984305518e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 7.73918436607346e-05
. O 0 1.5499196024393314e-06

In O 0 1.6619180698285163e-08
combination O 0 4.00562178981545e-08
with O 0 4.334427816665709e-10
molecular O 0 1.951126904486955e-08
genetic O 0 2.80974088440189e-08
analyses O 0 9.067718131916536e-09
, O 0 9.940237521988138e-11
this O 0 1.900140461641442e-11
test O 0 2.2924396755885645e-11
may O 0 1.9789649086110472e-10
be O 0 7.996076023530918e-11
of O 0 2.2899543372645326e-10
value O 0 1.0972374120399309e-09
in O 0 3.80020320767116e-11
studies O 0 7.394206913424739e-10
of O 0 6.24369500545896e-10
familial B-Disease 0 1.929532622568786e-08
and I-Disease 0 3.7160148291803807e-09
sporadic I-Disease 0 8.485910143463116e-07
cancers I-Disease 0 2.5661424274403544e-07
aimed O 0 1.2068282373434158e-08
at O 0 3.017331107191268e-10
determination O 0 1.9567786280205723e-10
of O 0 3.2768002200533886e-10
the O 0 1.555210543680019e-10
potential O 0 2.4623696415204677e-09
involvement O 0 8.313042698659956e-09
of O 0 1.9259035255458912e-08
ATM O 0 4.390377944218926e-05
mutations O 0 3.1616718842997216e-07
in O 0 9.938124101438461e-09
tumor B-Disease 0 2.976651330754976e-06
risk O 0 3.436773354792422e-08
or O 0 2.3280808392200925e-09
development O 0 1.0007916273480078e-08
. O 0 3.2104636726870694e-09
. O 0 7.364459264636025e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.4092899291995309e-08
identification O 0 3.893243505359578e-09
and O 0 6.93378132687883e-11
detection O 0 6.881705427730367e-09
of O 0 8.485980806938187e-09
founder O 0 9.40603683829977e-08
- O 0 1.2533097226707923e-08
effect O 0 2.4984251112414313e-08
mutations O 0 8.890670422090352e-09
in O 0 3.795235792303231e-10
the O 0 9.995949623586853e-10
ATM O 0 3.457642350213064e-08
gene O 0 1.3173480084560651e-09
in O 0 7.223374676179617e-10
ethnic O 0 1.601986632238095e-08
populations O 0 1.8410288404879793e-08
. O 0 8.75098464803159e-08

To O 0 3.0489308855408126e-09
facilitate O 0 1.1612818262562996e-08
the O 0 1.970434926334974e-09
evaluation O 0 6.283433329201671e-09
of O 0 1.5745532877531332e-08
ATM O 0 0.00010048213880509138
heterozygotes O 0 1.4756609516552999e-06
for O 0 2.7309130512520596e-09
susceptibility O 0 2.3861025510996114e-07
to O 0 3.4037883622772824e-09
other O 0 8.572266452233634e-09
diseases O 0 4.4115215132478625e-05
, O 0 6.833998367206107e-10
such O 0 1.2133108961975836e-09
as O 0 2.488856409854634e-07
breast B-Disease 0 4.174517300725711e-07
cancer I-Disease 0 1.3281287465360947e-06
, O 0 6.993420287315644e-10
we O 0 2.625380468579408e-10
have O 0 6.197348884073861e-11
attempted O 0 8.95812368728599e-10
to O 0 8.878782431498422e-11
define O 0 3.670985071480004e-09
the O 0 2.067713777975655e-09
most O 0 4.5349096700064706e-10
common O 0 2.5450960783324206e-10
mutations O 0 8.676865892454089e-10
and O 0 9.952227236764699e-11
their O 0 4.9604941682046544e-11
frequencies O 0 7.725365236410653e-09
in O 0 2.978547186671676e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.8099493980407715
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 9.592313610085057e-10
homozygotes O 0 1.2274778526943919e-08
from O 0 6.534456309381653e-10
10 O 0 5.869661423574257e-10
ethnic O 0 5.236781008832736e-10
populations O 0 2.3249435709971067e-09
. O 0 2.3788993885887066e-08

Both O 0 6.677108643771135e-08
genomic O 0 9.672222489598425e-08
mutations O 0 5.030820560136817e-08
and O 0 1.1616866357755384e-09
their O 0 1.89991314347715e-10
effects O 0 7.988127492808417e-09
on O 0 4.636101280652838e-09
cDNA O 0 3.0628282132738605e-08
were O 0 9.617802554373611e-09
characterized O 0 5.802434799306866e-08
. O 0 2.0422656632490543e-07

Protein O 0 1.2190268989797914e-06
- O 0 7.739217267044296e-08
truncation O 0 3.987646834957559e-08
testing O 0 4.662435992841552e-10
of O 0 1.7752230796475033e-09
the O 0 2.1135930783344747e-09
entire O 0 9.883041052205499e-09
ATM O 0 1.4484182031537784e-07
cDNA O 0 5.337669861660288e-08
detected O 0 1.91315887576593e-08
92 O 0 1.6723541662599928e-08
( O 0 2.6912766459830095e-10
66 O 0 6.7029453099110015e-09
% O 0 3.771408463304482e-10
) O 0 1.4383421537145225e-11
truncating O 0 1.7761376813751895e-09
mutations O 0 6.766798232860083e-10
in O 0 2.707928603573606e-10
140 O 0 1.5184954405000894e-09
mutant O 0 8.507226922915834e-09
alleles O 0 1.5673380815428573e-08
screened O 0 1.0886144252708618e-07
. O 0 1.503800177715675e-07

The O 0 3.028823130080127e-07
haplotyping O 0 4.014683872810565e-05
of O 0 7.211747998780993e-08
patients O 0 3.066836784526572e-09
with O 0 2.1589489918039106e-10
identical O 0 6.909430805279726e-09
mutations O 0 2.5103764400569162e-08
indicates O 0 2.3565268847391962e-08
that O 0 4.314110874092947e-11
almost O 0 3.2118341319886667e-10
all O 0 4.0174832210970735e-11
of O 0 9.871144179829372e-11
these O 0 5.291185892208894e-11
represent O 0 3.9623429537449795e-10
common O 0 2.0615624762854168e-09
ancestry O 0 8.306084708920025e-09
and O 0 9.588618787859104e-10
that O 0 4.354754890023571e-10
very O 0 2.589475078806913e-09
few O 0 2.321258385507008e-08
spontaneously O 0 9.139154855120069e-08
recurring O 0 2.8715243161059334e-07
ATM O 0 5.882146524527343e-06
mutations O 0 9.216191187988443e-07
exist O 0 6.520101578644244e-07
. O 0 1.3298853218657314e-06

Assays O 0 1.5584703305648873e-07
requiring O 0 3.966747641470647e-08
minimal O 0 3.71616266647834e-07
amounts O 0 4.504578043906804e-08
of O 0 1.203708777097745e-08
genomic O 0 2.398257059610387e-08
DNA O 0 4.166411216033339e-08
were O 0 1.861883980325274e-09
designed O 0 7.13106795835472e-10
to O 0 5.424199631121063e-11
allow O 0 1.6779055922455655e-10
rapid O 0 1.1759363482966023e-09
screening O 0 1.163693030825641e-10
for O 0 3.6619530324744076e-11
common O 0 2.5239768053353373e-09
ethnic O 0 1.7235393556802592e-08
mutations O 0 7.454167985088134e-07
. O 0 3.3850051295303274e-07

These O 0 2.690375922043131e-08
rapid O 0 3.610635701534193e-07
assays O 0 7.269628099493275e-08
detected O 0 7.050922956608474e-09
mutations O 0 7.640456600732648e-10
in O 0 9.379759469130278e-11
76 O 0 2.0383490451081343e-09
% O 0 4.0461127503998995e-11
of O 0 9.431281450256179e-11
Costa O 0 1.804159377449821e-09
Rican O 0 8.47252490387973e-09
patients O 0 2.9354732533626304e-10
( O 0 4.924492411073622e-11
3 O 0 8.816079533069399e-10
) O 0 4.43315089498908e-12
, O 0 7.75062132529758e-12
50 O 0 5.856183593611064e-11
% O 0 4.9275177688157257e-11
of O 0 2.6055407831293564e-10
Norwegian O 0 3.218104183133619e-08
patients O 0 5.294499838548461e-10
( O 0 1.2146463002071783e-10
1 O 0 3.983402940832548e-09
) O 0 3.2637309521632574e-11
, O 0 4.533472208745337e-11
25 O 0 7.660623246863452e-10
% O 0 1.3534963427819235e-10
of O 0 2.771912699373047e-10
Polish O 0 3.275809845604272e-08
patients O 0 1.8167807258606672e-09
( O 0 2.504271789938173e-10
4 O 0 4.841367751140524e-09
) O 0 2.5695319136320727e-11
, O 0 4.051394983384249e-11
and O 0 5.577223058383929e-11
14 O 0 1.7966182985773571e-09
% O 0 4.3291401019551756e-10
of O 0 4.2798953270306583e-10
Italian O 0 6.764039994777704e-09
patients O 0 4.798076380652105e-10
( O 0 1.795079362931773e-10
1 O 0 9.774348441737857e-09
) O 0 1.6666018565203444e-10
, O 0 2.1429405472339624e-10
as O 0 6.83005041413054e-10
well O 0 4.1498313119170405e-10
as O 0 5.419094617487019e-10
in O 0 1.2860433551420414e-10
patients O 0 5.089524912627041e-10
of O 0 7.2709975817986106e-09
Amish O 0 1.9584913957260142e-07
/ O 0 9.019854019243212e-08
Mennonite O 0 4.515774207902723e-07
and O 0 4.384117957556555e-09
Irish O 0 1.0125461358256871e-08
English O 0 2.7414197134589813e-08
backgrounds O 0 4.1457542465650477e-07
. O 0 6.146772761894681e-07

Additional O 0 6.964846477330866e-08
mutations O 0 1.288520081743627e-07
were O 0 6.462582469168865e-09
observed O 0 2.2579644820552858e-09
in O 0 1.509479208294806e-10
Japanese O 0 5.7495075367342e-09
, O 0 2.724662717668025e-10
Utah O 0 5.364611865843472e-09
Mormon O 0 9.727740390985673e-09
, O 0 1.2608827870685957e-10
and O 0 1.5751314141887462e-10
African O 0 5.09350672750486e-10
American O 0 5.106953082645305e-09
patients O 0 5.1028634651117954e-09
. O 0 6.328382795572907e-08

These O 0 4.089599059398097e-08
assays O 0 1.9305595344576432e-08
should O 0 4.850432833158891e-10
facilitate O 0 1.09496689493227e-09
screening O 0 8.518279970282094e-10
for O 0 4.632733308085335e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999747276306152
T I-Disease 1 1.0
heterozygotes O 0 1.4284995586422156e-07
in O 0 8.1768386506198e-10
the O 0 1.3474721338724294e-09
populations O 0 1.8349770591896686e-09
studied O 0 8.126127326590904e-09
. O 0 3.7634197980196404e-09
. O 0 5.3149232570604e-08

The O 0 1.5677223927923478e-05
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999984502792358
Lindau I-Disease 1 0.9860300421714783
tumor I-Disease 0 5.185010741115548e-05
suppressor O 0 4.807218829228077e-06
gene O 0 7.462473305963613e-09
is O 0 7.952213193496149e-11
required O 0 3.443756391163788e-11
for O 0 1.0022595947623003e-10
cell O 0 2.4823510358373824e-08
cycle O 0 8.712175869618477e-09
exit O 0 1.4050947960697613e-08
upon O 0 8.461253031555316e-09
serum O 0 1.6815732806207961e-07
withdrawal O 0 4.886139777227072e-07
. O 0 8.572397973694024e-07

The O 0 4.646487639092811e-07
inactivation O 0 1.906879333546385e-05
of O 0 2.7689571879818686e-07
the O 0 5.71006239624694e-07
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 0.0034505182411521673
VHL I-Disease 1 1.0
) I-Disease 0 1.0155521579235938e-07
tumor I-Disease 0 4.029102456115652e-06
suppressor O 0 3.0506073471769923e-06
gene O 0 1.6885854492443286e-08
predisposes O 0 1.8445406624323368e-07
affected O 0 3.1833842228934373e-09
individuals O 0 2.0310626444586255e-11
to O 0 1.314686554065858e-10
the O 0 7.726511097594368e-10
human O 0 1.0018153488999815e-06
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9655252695083618
and O 0 4.6429721178853356e-11
is O 0 6.5132218195207425e-12
associated O 0 1.8865199680195843e-10
with O 0 1.3861381487068059e-10
sporadic B-Disease 1 0.9780160784721375
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 1.4455425798587385e-06
RCC B-Disease 1 0.9999998807907104
) O 0 1.0473752531936498e-08
and O 0 1.712512620599682e-08
brain B-Disease 0 0.03860621154308319
hemangioblastomas I-Disease 0 0.00015924317995086312
. O 0 5.664109039571485e-07

VHL O 1 0.9906704425811768
- O 0 0.00012226105900481343
negative O 0 2.4507028228981653e-06
786 O 0 3.3575113320694072e-06
- O 0 4.378621270006988e-07
0 O 0 3.6587823615263915e-07
RCC B-Disease 0 7.014305992925074e-06
cells O 0 1.8425394543442053e-08
are O 0 2.71046074473702e-10
tumorigenic O 0 2.2864875859340827e-07
in O 0 3.1529889810144596e-09
nude O 0 1.4763435274289805e-07
mice O 0 1.391089021751668e-09
which O 0 8.421219277465752e-11
is O 0 1.30683823137967e-11
suppressed O 0 2.2000697097457333e-10
by O 0 3.97282207131866e-11
the O 0 1.4453757080090668e-09
reintroduction O 0 7.342403023358202e-07
of O 0 1.5398612163153302e-07
VHL B-Disease 0 0.004119358956813812
. O 0 4.3334798647265416e-06

Remarkably O 0 2.186579877161421e-05
, O 0 4.705015044237371e-09
this O 0 9.883370510888057e-11
occurs O 0 1.8376661303776132e-10
without O 0 1.642867925033542e-10
affecting O 0 2.9377262844576535e-09
the O 0 7.226130804838249e-10
growth O 0 5.184190854379267e-09
rate O 0 1.0147863660492362e-09
and O 0 1.4747035537165942e-10
cell O 0 5.954858828260967e-09
cycle O 0 3.6710130491002246e-09
profile O 0 2.9941085166740322e-09
of O 0 1.643912450610685e-09
these O 0 7.921787670284175e-10
cells O 0 2.8549609343286875e-09
in O 0 8.159172226740452e-10
culture O 0 3.6130533231926165e-08
. O 0 5.717610562783193e-08

The O 0 9.952693744708085e-07
786 O 0 2.3462530407414306e-06
- O 0 1.095511024118423e-07
0 O 0 3.432521467061633e-08
cell O 0 3.1598961669487835e-08
line O 0 1.5934637076497893e-07
, O 0 3.1635233321836154e-10
like O 0 1.6285880977129352e-10
many O 0 6.013443076824387e-10
cancer B-Disease 0 9.155865399179675e-09
cells O 0 3.338443299583105e-09
, O 0 1.2104139912594292e-10
fails O 0 5.458846707995235e-10
to O 0 5.678963896360578e-11
exit O 0 4.369858253028269e-09
the O 0 8.289240960301925e-10
cell O 0 1.3388623543164613e-08
cycle O 0 3.769511813800364e-09
upon O 0 7.556230308125578e-09
serum O 0 5.71164839868743e-08
withdrawal O 0 3.587419996620156e-07
. O 0 7.466440479220182e-07

Here O 0 4.78272227155685e-07
, O 0 6.948258413075337e-09
it O 0 5.290270443936151e-10
is O 0 4.821936253063264e-11
shown O 0 5.231108254899475e-11
that O 0 1.2439506022476898e-11
reintroduction O 0 3.1329321359407913e-08
of O 0 6.008779251942542e-09
the O 0 2.9596282757893277e-08
wild O 0 2.399278002940264e-07
- O 0 1.983710262720706e-07
type O 0 1.6844782635416777e-07
VHL B-Disease 0 0.0001157777223852463
gene O 0 6.758921955452024e-08
restores O 0 7.191199529188452e-07
the O 0 2.79795253632642e-09
ability O 0 8.855857380751786e-09
of O 0 2.3601396037520317e-07
VHL O 1 1.0
- O 1 0.9995208978652954
negative O 0 5.857411815668456e-05
RCC B-Disease 0 0.029378129169344902
cancer I-Disease 0 2.2284827139174013e-07
cells O 0 1.022763096436563e-09
to O 0 1.239059133073539e-10
exit O 0 3.126173764300688e-09
the O 0 2.675635268900578e-10
cell O 0 5.360949906219048e-09
cycle O 0 1.9600669975972096e-09
and O 0 7.379553634834224e-10
enter O 0 4.81444466515768e-08
G0 O 0 1.633708416193258e-05
/ O 0 5.392692514760711e-07
quiescence O 0 9.523645871922781e-07
in O 0 1.9902623549228338e-08
low O 0 7.782282978041621e-07
serum O 0 1.9519315230809298e-07
. O 0 1.6770377442298923e-07

Both O 0 6.662670784862712e-06
VHL O 1 0.9990373849868774
- O 0 2.0942014089087024e-05
positive O 0 1.5249781881720992e-07
and O 0 1.9613132451468118e-08
VHL O 1 0.9972633123397827
- O 0 7.295655450434424e-06
negative O 0 4.272486364698125e-07
RCC B-Disease 0 5.406227955973009e-06
cells O 0 1.9815768581565862e-08
exit O 0 2.4619435379236165e-08
the O 0 2.469677795602365e-10
cell O 0 9.180639581884975e-10
cycle O 0 1.8115928202000475e-10
by O 0 3.261627426476288e-11
contact O 0 1.5202523684365588e-08
inhibition O 0 4.5171572082836065e-07
. O 0 1.6836078486903716e-07

The O 0 7.2516149884904735e-06
cyclin O 0 1.759591032168828e-05
- O 0 5.04986473970348e-06
dependent O 0 1.039642711475608e-06
kinase O 0 1.5861784277149127e-06
inhibitor O 0 1.61006823873322e-07
, O 0 5.5942961374455535e-09
p27 O 0 1.3117328023781738e-07
, O 0 2.428232892537352e-10
accumulates O 0 8.948394025765083e-09
upon O 0 9.64441526640769e-10
serum O 0 2.142639399238533e-09
withdrawal O 0 4.081391669075174e-09
, O 0 1.3214870864253214e-10
only O 0 9.97980864614334e-11
in O 0 4.7524425367262424e-11
the O 0 6.733991697593922e-10
presence O 0 6.161383847569368e-09
of O 0 7.0928756201738e-08
VHL B-Disease 1 0.999870777130127
, O 0 2.9264741741030775e-09
as O 0 3.02833147447501e-10
a O 0 5.020144716594288e-11
result O 0 2.827047484998957e-10
of O 0 3.6598463148962423e-10
the O 0 2.389519970780185e-10
stabilization O 0 1.6866218643940556e-08
of O 0 7.279490343847783e-09
the O 0 1.7481184499956726e-08
protein O 0 1.52097084082925e-06
. O 0 3.123612941635656e-07

We O 0 2.996612380457009e-08
propose O 0 7.982385419325055e-09
that O 0 4.2117981324807374e-10
the O 0 1.1964520485463481e-09
loss O 0 1.4195739694855547e-08
of O 0 1.7922179296192553e-08
wild O 0 5.631651944781879e-08
- O 0 7.011016123215086e-08
type O 0 1.701662881714583e-07
VHL B-Disease 0 9.020138531923294e-05
gene O 0 8.318862931844251e-09
results O 0 4.473469594756807e-09
in O 0 8.148608177105388e-11
a O 0 9.842097969947616e-11
specific O 0 6.70730360141647e-10
cellular O 0 2.1144085593505224e-08
defect O 0 4.7829590954506784e-08
in O 0 1.4164628359125686e-09
serum O 0 2.576082103189492e-08
- O 0 6.469478819326469e-08
dependent O 0 4.910899633614463e-07
growth O 0 9.485773944106768e-09
control O 0 4.389539842719614e-09
, O 0 5.583953299748146e-10
which O 0 2.3316348851665225e-10
may O 0 2.8865818624268513e-09
initiate O 0 4.6298911371422946e-08
tumor B-Disease 0 2.594539864730905e-06
formation O 0 4.983427857041534e-07
. O 0 1.0153695484405034e-06

This O 0 3.045555985181636e-08
is O 0 4.457151092651657e-09
corrected O 0 2.8639176363753904e-08
by O 0 2.3532906179291047e-10
the O 0 2.0030077596544515e-09
reintroduction O 0 2.5676456516521284e-07
of O 0 2.1841920272436255e-08
wild O 0 2.697516379157605e-07
- O 0 5.183650273465901e-07
type O 0 3.976436346420087e-06
VHL B-Disease 1 0.9999977350234985
, O 0 8.84716655491502e-08
implicating O 0 4.0889703086577356e-05
VHL B-Disease 1 1.0
as O 0 5.0185249733658566e-08
the O 0 7.196822693344984e-09
first O 0 1.1849400349817074e-09
tumor B-Disease 0 1.0849118936562263e-08
suppressor O 0 8.137126883411838e-08
involved O 0 2.2052286385854103e-10
in O 0 6.684643116816602e-11
the O 0 7.366531273866883e-10
regulation O 0 2.0251780696867172e-08
of O 0 4.171221590354435e-08
cell O 0 1.1174653735679385e-07
cycle O 0 1.2431770279874854e-08
exit O 0 1.92312850089138e-08
, O 0 1.3708489898789367e-10
which O 0 5.903791344685771e-11
is O 0 7.773305610303538e-11
consistent O 0 2.4404407383826765e-09
with O 0 7.067355728418434e-11
its O 0 1.4393947145308061e-09
gatekeeper O 0 4.1088643598641283e-08
function O 0 1.6154590998240792e-09
in O 0 8.9025614657956e-10
the O 0 2.6452831036749558e-08
kidney O 0 1.3039068562648026e-06
. O 0 5.4217878187046153e-08
. O 0 2.6694428356677236e-07

Piebaldism B-Disease 1 1.0
with O 0 0.0003893834655173123
deafness B-Disease 1 1.0
: O 0 7.530852741410854e-08
molecular O 0 9.714431570273518e-08
evidence O 0 7.3084973628567695e-09
for O 0 2.422658462730709e-10
an O 0 6.5855937370074e-10
expanded O 0 3.2713266762129933e-08
syndrome O 0 0.007804397959262133
. O 0 7.671201274206396e-07

In O 0 5.6020268424106234e-09
a O 0 4.232698636030818e-09
South O 0 3.587520502890129e-09
African O 0 1.3186652880747829e-09
girl O 0 9.736335293553111e-09
of O 0 3.433849204981243e-09
Xhosa O 0 3.449191154913933e-08
stock O 0 9.519759203158173e-09
with O 0 2.5736815456589568e-11
severe O 0 7.848133520838019e-08
piebaldism B-Disease 0 2.4283294806082267e-06
and O 0 7.98885846364783e-09
profound O 1 0.9999774694442749
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.2679436167672975e-07
identified O 0 1.3910067542255433e-09
a O 0 5.524465954143132e-11
novel O 0 5.870635644278366e-10
missense O 0 7.1000734180870495e-09
substitution O 0 2.430570589240233e-08
at O 0 6.203587421538259e-09
a O 0 9.256016508807363e-10
highly O 0 3.5370579798410517e-09
conserved O 0 1.0730907717970695e-08
residue O 0 3.4918933522476436e-08
in O 0 7.596602236148442e-10
the O 0 6.442030020537004e-09
intracellular O 0 8.688748209806363e-08
kinase O 0 1.510151150796446e-07
domain O 0 3.58296787794643e-08
of O 0 7.496415577179505e-08
the O 0 1.6706971450730634e-07
KIT O 0 1.4320341506390832e-05
proto O 0 5.505988610821078e-06
- O 0 1.3284073929753504e-06
oncogene O 0 6.785985078749945e-06
, O 0 3.4758855349537043e-08
R796G O 0 3.3867308957269415e-06
. O 0 5.556419750973873e-07

Though O 0 3.008117346325889e-07
auditory B-Disease 0 0.0001845090155256912
anomalies I-Disease 0 1.409315245837206e-05
have O 0 1.7008321417932848e-09
been O 0 1.128426352359213e-09
observed O 0 1.405895622141884e-09
in O 0 2.417078204253187e-10
mice O 0 9.684452129121723e-10
with O 0 3.5291516931046374e-10
dominant O 0 3.5302733181197254e-07
white O 0 7.988127492808417e-09
spotting O 0 2.4777825728961034e-06
( O 0 6.862215240488467e-09
W O 0 2.4563591068726964e-05
) O 0 6.437850252893895e-10
due O 0 1.799403825941681e-08
to O 0 3.5185743207932774e-09
KIT O 0 0.00024163196212612092
mutations O 0 7.130467110982863e-06
, O 0 2.674761105936341e-07
deafness B-Disease 1 1.0
is O 0 5.372353228949578e-09
not O 0 1.8833129500350765e-10
typical O 0 6.093679338903257e-09
in O 0 5.100428412951885e-10
human O 0 2.8678588392949678e-08
piebaldism B-Disease 0 1.6548474377486855e-05
. O 0 5.330573458195431e-07

Thus O 0 1.442278829699717e-07
, O 0 7.5262363008477e-10
the O 0 2.2588507453402684e-10
occurrence O 0 3.2471135114064964e-08
of O 0 3.77955657882012e-08
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 3.1564360369884525e-07
this O 0 4.3193743026748166e-10
patient O 0 1.162823837219662e-09
extends O 0 4.780491558165068e-10
considerably O 0 4.3999651144766005e-10
the O 0 9.368567033263275e-11
phenotypic O 0 8.236669124528362e-09
range O 0 4.9086143150134376e-08
of O 0 1.1679145650589362e-08
piebaldism B-Disease 0 1.025025881062902e-06
due O 0 2.3507269020228705e-08
to O 0 5.049438644988413e-09
KIT O 0 2.0761862629115058e-07
gene O 0 6.347697922848283e-09
mutation O 0 3.3332960835963377e-09
in O 0 1.2473369559451442e-10
humans O 0 8.836938403256056e-10
and O 0 3.0787328242354306e-10
tightens O 0 7.595490458811582e-09
the O 0 6.025716592361618e-10
clinical O 0 2.638443685754055e-09
similarity O 0 2.2316042347370058e-08
between O 0 9.109721865740994e-09
piebaldism B-Disease 0 2.581537728474359e-06
and O 0 4.2378103803919487e-10
the O 0 2.603831872338702e-10
various O 0 2.8588609257695907e-10
forms O 0 8.702212284106281e-09
of O 0 7.711809502097822e-08
Waardenburg B-Disease 1 0.9989784955978394
syndrome I-Disease 0 0.002833247184753418
. O 0 5.348400833327105e-08
. O 0 2.9897049103055906e-07

Cycloheximide O 0 1.0157978067582007e-05
facilitates O 0 1.0084584545211328e-07
the O 0 1.5209795645176882e-09
identification O 0 1.4459168085068086e-08
of O 0 4.068344239271937e-08
aberrant O 0 3.164057886806404e-07
transcripts O 0 5.522041135463951e-08
resulting O 0 6.488955506256389e-08
from O 0 6.574038202700194e-09
a O 0 4.613325277347258e-09
novel O 0 2.099355178586393e-08
splice O 0 1.9337849721523526e-07
- O 0 1.2491714329598835e-08
site O 0 1.865219090291248e-08
mutation O 0 2.491148176630986e-09
in O 0 1.1891672091479677e-09
COL17A1 O 0 0.00014946397277526557
in O 0 9.70035163305738e-10
a O 0 2.905517382245648e-09
patient O 0 1.2900861712239475e-08
with O 0 1.7315716638321987e-09
generalized O 1 0.9999833106994629
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9990803003311157
. O 0 3.824667146545835e-06

Patients O 0 1.5598457991927717e-07
with O 0 1.3275769816800675e-08
generalized O 1 0.9999988079071045
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 0 0.02183942124247551
often O 0 1.4864498965039274e-08
show O 0 3.0676032825027733e-09
decreased O 0 2.2070402394547273e-08
expression O 0 6.199021740371791e-09
of O 0 5.197200003692615e-09
type O 0 1.422680924179076e-07
XVII O 0 4.393044946482405e-05
collagen O 0 7.025057584542083e-07
, O 0 2.0720692717191014e-08
a O 0 3.2299727337203876e-08
transmembrane O 0 2.8592708645192033e-07
hemidesmosomal O 0 3.351748318891623e-07
protein O 0 3.2757100143498974e-08
encoded O 0 7.969180870759374e-09
by O 0 2.3215152467059852e-08
COL17A1 O 0 0.0009371641208417714
. O 0 1.5399125459225615e-06

This O 0 6.208905034554846e-08
report O 0 4.5637833068212785e-08
documents O 0 1.4082800703363318e-07
a O 0 3.348955246451624e-08
novel O 0 1.0299994102069832e-07
splice O 0 1.2901964510092512e-06
- O 0 3.4867021270201803e-08
site O 0 1.605146238148336e-08
mutation O 0 2.660745845872725e-09
in O 0 3.61751822941514e-10
COL17A1 O 0 0.00046303082490339875
in O 0 5.749131726240364e-10
a O 0 1.453802855877484e-09
patient O 0 7.231248932981771e-09
with O 0 8.294824271892765e-10
generalized O 1 0.999982476234436
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999972581863403
bullosa I-Disease 0 0.0003166502865497023
, O 0 2.4079132021626037e-09
and O 0 5.068375233396871e-11
applies O 0 6.843262845279696e-09
a O 0 3.5985245339098526e-10
new O 0 3.6179045870277093e-10
methodology O 0 1.8028315507123693e-09
to O 0 1.8247220401335085e-10
define O 0 1.1357100149211874e-08
and O 0 2.9900621978384834e-09
characterize O 0 1.1169731095606039e-07
the O 0 2.7544391656419975e-08
resulting O 0 5.648972489780135e-08
mRNA O 0 3.868559872444166e-07
splice O 0 1.6936792235355824e-06
variants O 0 7.778646704537096e-07
. O 0 1.4212747601050069e-06

Mutational O 0 1.968873039004393e-05
analysis O 0 1.9329847589233395e-07
of O 0 3.5605347648015595e-07
COL17A1 O 1 0.9891869425773621
identified O 0 2.3645823432616453e-07
a O 0 5.601613395356253e-08
maternally O 0 6.628343953707372e-07
inherited O 0 4.904389356852334e-07
G O 0 3.6370948919284274e-07
- O 0 2.8324800283030527e-08
to O 0 7.541601121374697e-09
- O 0 7.71366330809542e-08
T O 0 8.923820615791556e-08
transversion O 0 1.4393616254437802e-07
at O 0 3.642625534538979e-09
the O 0 8.01137656214479e-10
- O 0 1.8826522285575464e-10
1 O 0 1.1065626193129674e-09
position O 0 3.925987090980243e-09
of O 0 4.428492239583193e-09
exon O 0 3.222502087396606e-08
32 O 0 8.783841849435703e-07
. O 0 4.1244510384785826e-07

This O 0 5.3549538137076524e-08
acceptor O 0 8.736108725315717e-08
splice O 0 6.064618446544046e-06
- O 0 1.6213967057865375e-07
site O 0 3.397951786610065e-08
mutation O 0 4.195916503135777e-09
led O 0 1.0792933213821243e-09
to O 0 9.864707661844108e-11
the O 0 7.02302827004786e-10
formation O 0 4.299616662706285e-09
of O 0 1.702952623361398e-08
aberrant O 0 4.33433271496142e-08
transcripts O 0 2.647675678701944e-08
present O 0 1.5288305732497065e-08
at O 0 2.642418550635739e-08
extremely O 0 2.620885375392845e-08
low O 0 1.5772410222325561e-07
levels O 0 2.9057570571922042e-08
. O 0 6.940367569541195e-08

Based O 0 3.837436679532402e-07
on O 0 5.58735742117733e-08
our O 0 1.1019337442519372e-08
recent O 0 1.3123998554576133e-09
finding O 0 4.29184066064181e-09
that O 0 3.0468369494052183e-10
cycloheximide O 0 5.673558689522906e-07
stabilized O 0 6.565670105374011e-07
mutant O 0 4.383986507150439e-08
COL17A1 O 0 4.6931695578678045e-06
transcripts O 0 2.3704386009626432e-08
in O 0 1.0429611618789636e-09
keratinocytes O 0 2.3666804338517977e-07
homozygous O 0 2.348619299041843e-09
for O 0 2.1800442007169352e-10
a O 0 1.865751775298463e-09
frameshift O 0 2.570473043306265e-07
mutation O 0 1.5199470571047868e-09
, O 0 1.275536481992745e-10
the O 0 2.58957771892554e-10
effects O 0 5.637132716174165e-08
of O 0 6.815324837816661e-08
the O 0 6.509657168862759e-08
splice O 0 3.328253797008074e-07
- O 0 2.9471001639080896e-08
site O 0 2.8062325796440746e-08
mutation O 0 8.391784489525378e-10
on O 0 1.0507743564147631e-09
splicing O 0 9.298577019478671e-09
of O 0 2.150624567320847e-08
COL17A1 O 0 1.508603963884525e-05
transcripts O 0 1.1327519899850813e-07
were O 0 5.862906604647833e-09
determined O 0 4.643614381905081e-09
using O 0 8.066022849639864e-10
reverse O 0 1.1161251478597478e-08
transcriptase O 0 4.386409457879381e-09
polymerase O 0 1.0393091942617616e-09
chain O 0 1.7576428090748664e-09
reaction O 0 5.140218473087543e-09
of O 0 6.639945926423252e-09
total O 0 1.810305350069541e-09
RNA O 0 7.1307995064273655e-09
from O 0 5.302102312754187e-09
keratinocytes O 0 3.6053782537237566e-07
incubated O 0 6.60543832964322e-08
for O 0 1.3730346859475162e-09
2 O 0 1.1577657232919591e-07
. O 0 1.8442030125243036e-07

5 O 0 8.642599027552933e-07
h O 0 6.115280370977416e-08
in O 0 1.3182100966346866e-09
the O 0 3.349784005735046e-09
presence O 0 7.907028809484018e-09
or O 0 5.013336856762862e-09
absence O 0 6.00300268160936e-07
of O 0 6.51892619885075e-08
10 O 0 6.428187049323242e-08
microg O 0 3.1367765132017666e-06
cycloheximide O 0 2.5822689622145845e-06
per O 0 1.5923532714623434e-07
ml O 0 2.54409968647451e-07
. O 0 1.3352173766634223e-07

Using O 0 5.377868816935916e-09
this O 0 1.4975503059844186e-09
approach O 0 1.552065143073378e-08
, O 0 1.3084208161373567e-09
an O 0 3.5396834352496853e-09
abnormally O 0 5.70975302593979e-08
spliced O 0 1.3857857084076386e-07
transcript O 0 4.2094254126823216e-07
was O 0 2.5372274947699225e-08
identified O 0 1.5139521858387184e-09
that O 0 2.432821132047902e-11
contains O 0 7.129921653081794e-11
an O 0 1.0012469325859641e-10
extra O 0 7.434028392871994e-10
264 O 0 3.39030470364321e-09
bases O 0 5.9807088170771294e-09
upstream O 0 1.14115088933886e-07
from O 0 4.894448402126272e-09
exon O 0 9.328741334968527e-09
32 O 0 1.871933541508497e-08
, O 0 1.7162189724917454e-10
resulting O 0 1.2813453631466132e-09
in O 0 2.104709601047361e-10
a O 0 4.054885760496063e-09
premature O 0 1.024516677716747e-06
termination O 0 1.4761056945644668e-06
codon O 0 3.165330326737603e-06
27 O 0 3.8636003409919795e-06
bp O 0 1.418551619281061e-06
downstream O 0 3.9946303331817035e-06
from O 0 9.129676215025029e-08
the O 0 2.1297697117006464e-07
cryptic O 0 3.560837512850412e-06
splice O 0 4.275324954505777e-06
site O 0 1.400753944835742e-06
. O 0 1.5142755955821485e-06

Three O 0 8.556278174864929e-08
other O 0 5.298291139155253e-09
splice O 0 9.236818954150294e-08
variants O 0 3.092824440997788e-09
, O 0 9.400177164442525e-11
including O 0 6.268748107413069e-12
one O 0 2.4778155222060505e-11
derived O 0 1.904168628330538e-10
from O 0 1.8321573425073012e-10
the O 0 1.1720311388074833e-09
skipping O 0 7.984288785678473e-09
of O 0 4.8122572593456425e-09
exon O 0 3.1685187806829163e-09
32 O 0 4.519621299436949e-08
, O 0 4.316206059229444e-09
were O 0 3.987218999412789e-09
also O 0 6.235105765028948e-09
identified O 0 8.730645362220457e-08
. O 0 5.645008513965877e-07

These O 0 1.3453130165430593e-08
results O 0 2.556522460395172e-08
indicate O 0 4.686817334231819e-08
the O 0 1.9643295878779554e-09
usefulness O 0 7.704870341740389e-08
of O 0 2.023300638143155e-09
cycloheximide O 0 2.472098081796048e-08
treatment O 0 5.613361997447441e-10
in O 0 6.322981027651053e-11
evaluating O 0 1.6224656063101861e-09
the O 0 1.5000317654667583e-09
abnormal O 0 8.499393189254079e-09
processing O 0 2.7359611465271882e-08
of O 0 2.347523242463012e-08
mRNA O 0 2.777557881472603e-07
due O 0 1.6481320130878885e-07
to O 0 1.562395368637226e-08
splice O 0 1.466497224100749e-06
- O 0 6.273855746030677e-08
site O 0 2.869806969840738e-08
mutations O 0 7.307479510387793e-09
, O 0 1.3553829170120935e-09
because O 0 1.7844579147663353e-08
( O 0 1.0694108709685679e-08
i O 0 6.687483278255968e-08
) O 0 1.942733529602947e-09
aberrant O 0 1.9736443590545605e-08
splicing O 0 1.0773235636918344e-08
often O 0 1.82114867630645e-09
generates O 0 5.608655762046055e-09
a O 0 7.069408392013088e-10
premature O 0 5.6917141222356804e-08
termination O 0 1.426325724196431e-07
codon O 0 2.4313712287948874e-07
, O 0 9.317485449855667e-09
( O 0 7.945878954807029e-10
ii O 0 6.883743708385737e-08
) O 0 1.0002930705965696e-09
transcripts O 0 1.0013548212839396e-08
with O 0 4.015348054053902e-10
premature O 0 4.4054615955246845e-08
termination O 0 2.5052775853851017e-08
codons O 0 1.5206264691869364e-08
can O 0 8.87893925050065e-10
occur O 0 1.0070683842400285e-08
at O 0 1.7074084368573494e-08
low O 0 1.3272065757519158e-07
or O 0 3.987949082073783e-09
undetectable O 0 3.4641114865507916e-08
levels O 0 1.0043478271271056e-09
due O 0 1.3092921191670825e-09
to O 0 5.387187917982317e-10
nonsense O 0 2.2836147195448575e-08
- O 0 1.01961017406893e-08
mediated O 0 3.6782338952434657e-08
mRNA O 0 1.1437249369805613e-08
decay O 0 4.643191786612988e-08
, O 0 3.4988301145233436e-10
and O 0 2.948733479612997e-10
( O 0 9.639996439991805e-11
iii O 0 1.201046107013326e-08
) O 0 3.5058642100516124e-10
the O 0 2.2774282459891992e-09
levels O 0 4.922488194836205e-09
of O 0 1.963516682579325e-09
these O 0 4.416748078384103e-10
transcripts O 0 3.438036966230129e-09
can O 0 3.031533080122273e-10
be O 0 2.960884315506007e-10
increased O 0 2.602825066588821e-09
by O 0 3.487345523467411e-09
cycloheximide O 0 4.927863756165607e-06
. O 0 4.253338090620673e-07

A O 0 1.1567078672669595e-06
deletion O 0 1.6694707483111415e-07
mutation O 0 3.386222147128137e-08
in O 0 7.479060037951513e-09
COL17A1 O 0 0.00018681836081668735
in O 0 1.0310422515757978e-09
five O 0 1.4688317229172299e-09
Austrian O 0 4.1116631877002874e-08
families O 0 3.923180003084781e-09
with O 0 9.040048709607618e-10
generalized O 1 0.9718183875083923
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 0 0.10704001039266586
represents O 0 2.6595799340611848e-08
propagation O 0 1.2776420987847814e-07
of O 0 8.225678804762993e-09
an O 0 3.0708227072295813e-09
ancestral O 0 3.679280098367599e-07
allele O 0 7.244228186209511e-07
. O 0 3.143605624700285e-07

Patients O 0 2.7755510245697224e-07
with O 0 1.4529110359262631e-08
generalized O 1 0.9999995231628418
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999982118606567
, O 0 1.8684877645114284e-08
a O 0 2.503327545255729e-09
usually O 0 9.974180370520003e-10
nonlethal O 0 2.9978590987411735e-07
form O 0 2.372003393702471e-08
of O 0 4.671021258673136e-07
junctional B-Disease 1 0.9999953508377075
epidermolysis I-Disease 1 0.9999990463256836
bullosa I-Disease 1 0.9981613755226135
, O 0 8.023282305202883e-08
have O 0 4.808440312586981e-09
generalized O 0 1.1303859537292738e-06
blistering B-Disease 0 5.58296915187384e-06
, O 0 7.144470970388284e-08
nail B-Disease 0 0.0006474059191532433
dystrophy I-Disease 1 0.9999483823776245
, O 0 3.847796506306622e-06
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 4.817792955691402e-07
and O 0 3.322613110867678e-06
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.021419627591967583

Skin B-Disease 1 0.9983935952186584
fragility I-Disease 0 6.898236460983753e-05
in O 0 2.4588309166517774e-09
most O 0 3.061569331386238e-10
cases O 0 2.672284338256503e-10
is O 0 2.1347968531815198e-11
due O 0 1.8832733983398242e-10
to O 0 7.65753710441075e-11
mutations O 0 2.577953628346563e-09
in O 0 2.3778673474694756e-10
the O 0 1.1513785480588012e-09
gene O 0 3.9719623146083904e-09
encoding O 0 8.947271368242582e-08
type O 0 1.7209333691425854e-06
XVII O 0 0.00018922654271591455
collagen O 0 8.15385556052206e-06
( O 0 5.460934744405677e-07
COL17A1 O 0 0.01705012656748295
) O 0 3.0041661602808745e-08
. O 0 2.0795768307380058e-07

Recently O 0 7.499045864278742e-07
, O 0 6.4802332389035655e-09
we O 0 6.360456605847276e-10
reported O 0 1.7567010068830768e-09
five O 0 9.491808727890572e-11
Austrian O 0 9.658742250451269e-09
families O 0 7.762168130476255e-10
with O 0 6.03958161260465e-10
generalized O 1 0.9996601343154907
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999880313873291
who O 0 3.0548818585884874e-08
share O 0 3.939939929864522e-09
the O 0 1.6379502199015405e-09
same O 0 9.196329919802793e-09
COL17A1 O 0 5.290730405249633e-05
mutation O 0 5.642150426865555e-07
. O 0 3.5105659890177776e-07

Affected O 0 7.188676676150862e-08
individuals O 0 4.3880221678449516e-10
in O 0 6.56482534999725e-10
three O 0 4.95201768480058e-10
families O 0 2.5025290173452674e-10
are O 0 1.7106491570495486e-11
homozygous O 0 1.5798341801431803e-10
for O 0 4.253268570675317e-10
4003delTC O 0 3.808582604847288e-08
, O 0 3.0763261382737994e-10
whereas O 0 9.270645917602849e-10
those O 0 4.755038029990999e-10
in O 0 7.314783223577592e-10
two O 0 1.4370464818114215e-09
others O 0 3.477548471408909e-09
are O 0 3.0098701309100306e-10
compound O 0 7.294031689752956e-08
heterozygotes O 0 1.2775935829267837e-06
. O 0 6.235191563064291e-07

To O 0 2.8435755972111565e-09
determine O 0 8.275343965635784e-09
if O 0 3.1269669076294804e-09
the O 0 1.1359867491123055e-09
occurrence O 0 9.612282525495175e-09
of O 0 1.97096494680693e-09
4003delTC O 0 2.4717301982946083e-08
in O 0 6.472407332314134e-11
these O 0 7.108670596611688e-11
unrelated O 0 1.852238917798843e-09
families O 0 8.42631173170183e-11
signifies O 0 9.34804456065308e-10
propagation O 0 4.225132688162603e-09
of O 0 1.1336102057057929e-09
an O 0 9.218330543347975e-10
ancestral O 0 1.295338449835981e-07
allele O 0 3.108486268388333e-08
or O 0 2.786395780773887e-09
a O 0 5.116507661995229e-09
mutational O 0 1.3362139270611806e-06
hot O 0 4.450591291060846e-07
spot O 0 1.1543392020030296e-07
, O 0 8.326511147238591e-10
haplotypes O 0 1.8577273053210774e-08
were O 0 3.2880381750644005e-10
determined O 0 9.226879260637588e-10
for O 0 3.711954077445512e-10
polymorphisms O 0 5.430750604773493e-08
both O 0 1.4457789632160711e-08
within O 0 8.306563614723927e-08
and O 0 1.5247439932863927e-07
flanking O 0 4.108897701371461e-05
COL17A1 O 1 0.9998993873596191
. O 0 1.7082672911783447e-06

Five O 0 3.9110901184358227e-07
intragenic O 0 5.3954222494212445e-06
polymorphisms O 0 2.8750889669026947e-07
were O 0 7.22523818552645e-09
chosen O 0 3.17958548379238e-09
based O 0 2.611657112794319e-09
on O 0 8.988662258957447e-09
their O 0 8.789437622169771e-09
informativeness O 0 2.9299520974745974e-05
. O 0 1.0627230722093373e-06

One O 0 4.927196428639036e-08
of O 0 2.3085332756522803e-08
these O 0 5.020255322563116e-09
, O 0 7.068856056058337e-10
not O 0 3.54764384535855e-10
previously O 0 2.233928375616756e-09
reported O 0 4.818227150593657e-09
, O 0 1.266472204886071e-10
was O 0 4.904699757446451e-09
2988 O 0 1.9178762045157782e-07
A O 0 9.127222000415713e-08
or O 0 9.66323820961179e-09
C O 0 8.159784101735568e-07
that O 0 2.1531464111657073e-10
introduces O 0 7.257876522004381e-09
a O 0 6.586673984010361e-10
new O 0 4.684935772658605e-10
restriction O 0 9.421564861611387e-09
site O 0 1.0636783009942974e-08
for O 0 4.367466832633227e-09
Eco0109 O 0 1.701189648883883e-05
I O 0 3.061144525418058e-05
. O 0 2.860783979485859e-06

All O 0 9.979990167607866e-09
the O 0 9.393392730316918e-09
4003delTC O 0 1.4014607074841479e-07
alleles O 0 7.580784888716607e-09
showed O 0 3.2662252902326827e-09
the O 0 2.2098939345127633e-10
same O 0 1.650355130333736e-10
haplotype O 0 6.38769304117659e-09
for O 0 1.604309046721042e-10
these O 0 7.070581342638604e-10
five O 0 2.861404668763612e-09
polymorphic O 0 1.0717308640550982e-07
markers O 0 1.5664377315260936e-06
. O 0 1.2731068181892624e-06

Fourteen O 0 4.928141152049648e-06
microsatellite O 0 9.074396984942723e-07
polymorphisms O 0 1.3723814618060715e-07
were O 0 3.732281150803374e-09
selected O 0 3.1255298349464056e-09
based O 0 1.6420729220811836e-09
on O 0 1.7638522864515949e-09
their O 0 4.529204788994434e-10
high O 0 8.133293505352412e-08
heterozygosity O 0 4.630585408449406e-06
and O 0 5.4172262231588775e-09
their O 0 2.749073635399668e-09
location O 0 2.5707032591526513e-07
within O 0 3.58590739324427e-08
10q23 O 0 2.027150912908837e-06
- O 0 2.2833106072539522e-07
q25 O 0 6.804227268730756e-06
near O 0 2.4672731342434417e-06
COL17A1 O 0 0.0004917363985441625
. O 0 1.3302684465088532e-06

Three O 0 3.047374619313814e-08
families O 0 8.345754309857512e-09
shared O 0 1.2104891311537358e-08
microsatellite O 0 3.673817161597981e-07
polymorphisms O 0 4.323491964441928e-07
covering O 0 3.127279057935084e-07
at O 0 2.1772914138296073e-08
most O 0 3.833886097481809e-09
19 O 0 1.5248524221078696e-08
cM O 0 1.1797628651777359e-08
, O 0 1.5914962403495991e-10
whereas O 0 7.708228499936354e-10
the O 0 1.5688117471768237e-09
others O 0 1.1905402219625216e-09
shared O 0 4.222037164325343e-10
smaller O 0 4.0788838973071506e-10
regions O 0 6.730755397477139e-10
consistent O 0 6.438689137411302e-09
with O 0 1.4290808814099165e-10
cross O 0 5.754905441079927e-09
- O 0 3.84051679347408e-09
over O 0 1.2266908600011561e-09
events O 0 1.2432427309860827e-09
during O 0 7.028576609613424e-10
passage O 0 3.4728488973456706e-09
of O 0 6.219590953371323e-10
this O 0 1.2775695779065899e-10
mutation O 0 7.00614399828936e-10
through O 0 4.376136952810583e-10
several O 0 2.6656883367337514e-09
generations O 0 1.7171252864045528e-07
. O 0 4.3267669980195933e-07

These O 0 3.382129776241527e-08
results O 0 4.828901722930823e-08
indicate O 0 4.132111897092727e-08
that O 0 3.723121810850216e-10
4003delTC O 0 7.3559487390184586e-09
occurs O 0 6.321970169587132e-10
on O 0 6.313030098681338e-10
a O 0 6.443685585111325e-10
single O 0 1.1179099868030562e-09
ancestral O 0 4.760306282491911e-08
allele O 0 4.93925007560847e-08
. O 0 1.5145333875921096e-08
. O 0 1.0087008917025742e-07

The O 0 3.73054376723303e-06
haptoglobin O 0 0.00010009109246311709
- O 0 9.472359465689806e-07
gene O 0 6.62250698724165e-08
deletion O 0 7.158547532526427e-08
responsible O 0 2.2501067675761988e-08
for O 0 6.2047593729630535e-09
anhaptoglobinemia B-Disease 0 2.1122976249898784e-05
. O 0 7.801350534464291e-07

We O 0 7.452803885144021e-08
have O 0 1.0448346632330185e-09
found O 0 3.913909751851463e-10
an O 0 1.2077618072314777e-10
allelic O 0 2.6923267171241605e-08
deletion O 0 6.766723625872828e-09
of O 0 2.0835662084550677e-08
the O 0 8.26191026703782e-08
haptoglobin O 0 1.359341240458889e-05
( O 0 1.1073084671409106e-08
Hp O 0 1.7409478303420656e-08
) O 0 5.736641717213331e-11
gene O 0 1.3994926051363876e-10
from O 0 1.6350378828633438e-09
an O 0 2.3221990996802333e-10
individual O 0 1.517950209972696e-10
with O 0 8.603547319019356e-10
anhaptoglobinemia B-Disease 0 1.414550297340611e-05
. O 0 6.872833751003782e-07

The O 0 3.1077280482350034e-07
Hp O 0 5.295828842122319e-08
gene O 0 1.8015562375239824e-09
cluster O 0 3.21623727650433e-09
consists O 0 9.619718910336417e-11
of O 0 4.916252474562732e-11
coding O 0 9.659216759771994e-10
regions O 0 3.347318866531168e-09
of O 0 5.5142738375479894e-08
the O 0 1.156458750983802e-08
alpha O 0 2.2319990300445625e-09
chain O 0 7.906270638180501e-10
and O 0 6.239048860878782e-11
beta O 0 8.915697069511452e-10
chain O 0 1.847570874069504e-09
of O 0 2.1731538790703553e-09
the O 0 1.2542566985018766e-08
haptoglobin O 0 2.2639088115283812e-07
gene O 0 3.769561995881077e-09
( O 0 5.812852421627213e-10
Hp O 0 1.476108568709833e-09
) O 0 3.584108704268729e-12
and O 0 6.404897012063371e-12
of O 0 2.834195655943006e-10
the O 0 6.749744096978816e-10
alpha O 0 1.1047552872511801e-09
chain O 0 7.504576404748775e-10
and O 0 3.792225700127716e-10
beta O 0 2.920413022522439e-09
chain O 0 2.335780235895868e-09
of O 0 6.465628032970017e-09
the O 0 1.7967494159165653e-08
haptoglobin O 0 8.267488738056272e-07
- O 0 3.210244869933376e-08
related O 0 3.048572239094938e-08
gene O 0 2.2810725752719918e-08
( O 0 7.442388927358934e-09
Hpr O 0 9.306955206511702e-08
) O 0 7.371629695551718e-11
, O 0 5.478349371368374e-11
in O 0 5.183325990643084e-11
tandem O 0 6.231087645858224e-09
from O 0 3.091674471988881e-09
the O 0 2.0089620633712002e-08
5 O 0 9.740944761915671e-08
side O 0 5.332398700375052e-07
. O 0 8.210539022002195e-07

Southern O 0 3.1166548524197424e-06
blot O 0 3.6591004572983366e-06
and O 0 7.412920943750123e-09
PCR O 0 2.6219852955478018e-08
analyses O 0 6.72824285175011e-09
have O 0 1.0093924307508217e-10
indicated O 0 6.728367862862683e-10
that O 0 1.9932833161817598e-11
the O 0 4.584234727933456e-11
individual O 0 4.9734640017451426e-11
with O 0 8.36616192989581e-11
anhaptoglobinemia B-Disease 0 5.367746211959457e-07
was O 0 2.202808380147303e-09
homozygous O 0 8.543659529847147e-11
for O 0 4.146063353749341e-11
the O 0 2.685656419476601e-10
gene O 0 1.499455976050612e-10
deletion O 0 5.83804171672142e-10
and O 0 7.058989504038493e-11
that O 0 3.256095393311398e-11
the O 0 2.703479939913933e-10
gene O 0 3.8090725018591343e-10
deletion O 0 1.0918116410962853e-09
was O 0 2.9242257504336067e-09
included O 0 2.5659580016323957e-10
at O 0 5.970459127091488e-10
least O 0 2.427903988966307e-10
from O 0 2.5997726194049164e-10
the O 0 1.033428564944927e-09
promoter O 0 5.1475602447226265e-08
region O 0 1.8153649250507442e-08
of O 0 1.938281890545568e-08
Hp O 0 1.458544751642421e-08
to O 0 6.1046732113823055e-09
Hpr O 0 3.8902729215806175e-07
alpha O 0 4.339029135991268e-09
but O 0 7.516007816121828e-10
not O 0 3.003848281224464e-10
to O 0 9.922347388169328e-09
Hpr O 0 2.6847992558032274e-06
beta O 0 9.153527003036288e-07
( O 0 4.714054213650343e-08
Hpdel O 0 2.6860875550482888e-06
) O 0 1.5914917383952343e-08
. O 0 1.9266059325673268e-07

In O 0 1.5134707709307804e-08
addition O 0 1.0821446849718086e-08
, O 0 6.871916924389154e-10
we O 0 1.295813595314499e-10
found O 0 1.8645911203929444e-10
seven O 0 8.443269000624198e-11
individuals O 0 2.2484557618551726e-11
with O 0 5.2813753370628547e-11
hypohaptoglobinemia B-Disease 0 8.034920995214634e-08
in O 0 1.1614954831262736e-10
three O 0 9.374393622474386e-11
families O 0 1.795552040384507e-10
, O 0 2.7734132698742364e-11
and O 0 2.683617043863773e-11
the O 0 4.6102971440475926e-10
genotypes O 0 1.2471526922297471e-08
of O 0 5.10181275004129e-09
six O 0 2.745149219052223e-09
of O 0 6.403380048425333e-09
the O 0 5.553090876020406e-09
seven O 0 1.0400905692264928e-09
individuals O 0 2.566271362081096e-10
were O 0 3.498331624385287e-09
found O 0 1.6020041959663445e-09
to O 0 1.4063569198086157e-09
be O 0 2.6263847985319444e-08
Hp2 O 0 2.7155063435202464e-05
/ O 0 3.160814458169625e-06
Hpdel O 0 1.9274935766588897e-05
. O 0 1.2970236866749474e-06

The O 0 1.3485120575751353e-07
phenotypes O 0 3.566665611742792e-07
and O 0 2.5258695135477183e-09
genotypes O 0 5.3833517199564085e-08
in O 0 5.320242579820444e-10
one O 0 4.123730246163859e-10
of O 0 2.3896701284442656e-10
these O 0 7.756303932460185e-11
three O 0 8.718550881248177e-11
families O 0 2.698910261944576e-10
showed O 0 2.0709580716982146e-09
the O 0 6.192353851908194e-10
father O 0 4.242268314413877e-09
to O 0 1.1361948049071202e-09
be O 0 1.2250009895353742e-08
hypohaptoglobinemic B-Disease 0 3.3880810406117234e-06
( O 0 4.357241234487219e-09
Hp2 O 0 4.0726808947511017e-07
) O 0 6.930954699058134e-10
and O 0 1.6329466667741599e-09
Hp2 O 0 2.843680988462438e-07
/ O 0 2.3131789816943638e-08
Hpdel O 0 2.7922263257096347e-07
, O 0 7.738545360069793e-10
the O 0 2.5452333574094155e-09
mother O 0 2.0018886548456294e-09
to O 0 6.293157106540548e-10
be O 0 2.1684296580559703e-09
Hp2 O 0 4.860991111854673e-07
- O 0 2.5147089743882134e-08
1 O 0 4.990937441107235e-08
and O 0 8.296346720726433e-09
Hp1 O 0 9.641771612223238e-07
/ O 0 1.4754139243677855e-08
Hp2 O 0 1.999295449195415e-07
, O 0 1.8128855361343454e-10
one O 0 1.2458865883413495e-10
of O 0 3.412562177285139e-10
the O 0 1.1431289248520216e-09
two O 0 5.74529479546726e-10
children O 0 7.415221769946356e-10
to O 0 7.312077054955068e-10
be O 0 1.1635387764385996e-08
hypohaptoglobinemic B-Disease 0 1.850849002948962e-05
( O 0 2.1361278967901853e-08
Hp2 O 0 2.473327640473144e-06
) O 0 2.2665511689723417e-09
and O 0 6.608875668945302e-09
Hp2 O 0 2.1442242541525047e-06
/ O 0 5.341570030736875e-08
Hpdel O 0 1.0519418083276832e-06
, O 0 1.0489661361745561e-09
and O 0 3.173785401155982e-10
the O 0 1.0747308598624272e-09
other O 0 1.2338007282508556e-09
child O 0 3.4992724273763542e-09
to O 0 1.5824285215515488e-09
be O 0 7.4255579463056165e-09
Hp1 O 0 2.0338916328910273e-06
and O 0 2.0091537322741715e-08
Hp1 O 0 5.882326149730943e-06
/ O 0 2.6003561970355804e-07
Hpdel O 0 1.2130451523262309e-06
, O 0 1.4631275080390083e-09
showing O 0 3.349988286771577e-09
an O 0 1.6155538018480797e-10
anomalous O 0 1.4988233942858642e-07
inheritance O 0 3.037336000488722e-07
of O 0 1.9588874522469268e-07
Hp O 0 8.872108026025671e-08
phenotypes O 0 9.70211715412006e-08
in O 0 6.855122025584137e-10
the O 0 4.637905171023249e-09
child O 0 1.4380234780730916e-08
with O 0 4.641746098599242e-09
Hp1 O 0 2.176823909394443e-05
. O 0 6.02920010805974e-07

The O 0 2.3861873614805518e-06
Hp2 O 0 4.6367622417164966e-05
/ O 0 5.384701466937258e-07
Hpdel O 0 2.9492719022528036e-07
individuals O 0 9.234432107874113e-10
had O 0 1.4827395977690117e-09
an O 0 1.0339918504742585e-10
extremely O 0 5.29725763254163e-10
low O 0 1.0827888807796171e-08
level O 0 5.2091220226202495e-08
of O 0 1.4968978234719543e-07
Hp O 0 1.1786814724246142e-07
( O 0 1.993650355913701e-09
mean O 0 2.1094258784160047e-08
+ O 0 1.0843140607619262e-08
/ O 0 5.076178144491905e-09
- O 0 6.243948469375482e-09
SD O 0 4.287702992655795e-08
= O 0 1.6031727056997624e-08
0 O 0 1.0568993680237782e-08
. O 0 1.5748587989250495e-09
049 O 0 2.8493428061437953e-08
+ O 0 6.626054815939142e-09
/ O 0 6.741615710126325e-09
- O 0 6.103904937049265e-09
0 O 0 5.85168979938544e-09
. O 0 1.6302019734126816e-09
043 O 0 8.483201696662945e-08
mg O 0 3.733130427008291e-08
/ O 0 1.5707130041064943e-09
ml O 0 8.398573503320961e-10
; O 0 1.6548185044484853e-10
n O 0 2.266900278602435e-10
= O 0 5.202553388095055e-10
6 O 0 1.0300181818578835e-09
) O 0 2.8387155907166894e-12
, O 0 3.2751908823902554e-12
compared O 0 1.0149499296563391e-11
with O 0 1.577565226888733e-12
the O 0 1.5567687416950804e-10
level O 0 1.4968878359056248e-09
( O 0 2.2578073091694684e-11
1 O 0 1.0986216381070335e-09
. O 0 2.4066262871436095e-10
64 O 0 1.2655358982982534e-09
+ O 0 2.871419213512638e-10
/ O 0 3.6931055436006943e-10
- O 0 6.690309972690045e-10
1 O 0 7.244747579626676e-10
. O 0 3.6328473562718955e-10
07 O 0 3.7127840801787215e-09
mg O 0 1.1045324654901378e-08
/ O 0 7.266626744772964e-10
ml O 0 2.3092795731205484e-10
) O 0 5.922962641180529e-12
obtained O 0 2.712653712766411e-10
from O 0 4.762626404364312e-10
52 O 0 6.8167267386343156e-09
healthy O 0 1.1432205182515531e-09
volunteers O 0 5.00131935865511e-10
having O 0 4.716027568463232e-10
phenotype O 0 3.193493114395096e-08
Hp2 O 0 2.853547869108297e-07
, O 0 3.202908493982193e-10
whereas O 0 1.960104079046232e-09
the O 0 1.6516596978988218e-09
serum O 0 8.553303842973037e-09
Hp O 0 2.6045734458080005e-09
level O 0 6.1684977126219565e-09
of O 0 8.712470744853817e-10
an O 0 2.032350260305904e-10
individual O 0 1.2691901696282315e-10
with O 0 1.7470476176839611e-09
Hp1 O 0 4.2568622120597865e-06
/ O 0 2.149923545857746e-07
Hpdel O 0 9.771339364306186e-07
was O 0 7.313101946238021e-08
0 O 0 9.64484669907506e-08
. O 0 1.1363431440258864e-07

50 O 0 9.356344321531651e-07
mg O 0 9.20837180728995e-07
/ O 0 1.0946228812258596e-08
ml O 0 3.5703795475683364e-09
, O 0 5.248798271018096e-11
which O 0 4.9933078505315365e-12
was O 0 5.0339517276842827e-11
approximately O 0 2.040700594618805e-11
half O 0 4.357984806357962e-11
the O 0 1.0025463098584098e-10
level O 0 2.329098025555254e-09
of O 0 2.5479729437449805e-09
Hp O 0 2.826051392901263e-09
in O 0 1.9368462389479646e-10
control O 0 2.7316267026122887e-09
sera O 0 4.305519141212244e-08
from O 0 4.019455046577747e-10
the O 0 4.954088694830716e-09
Hp1 O 0 5.36235404524632e-07
phenotype O 0 2.9341661544890485e-08
( O 0 4.1066663958311267e-10
1 O 0 1.1836982949375852e-08
. O 0 2.7075270914167504e-09
26 O 0 1.6685659076642878e-08
+ O 0 4.274481213428771e-09
/ O 0 3.339786891487506e-09
- O 0 4.7552037862885754e-09
0 O 0 1.6172565509009473e-09
. O 0 6.428193533025706e-10
33 O 0 6.88086565503454e-09
mg O 0 1.1330659965835821e-08
/ O 0 8.98944640947974e-10
ml O 0 7.550939318257122e-10
; O 0 2.9550223379359863e-10
n O 0 5.875441244640456e-10
= O 0 1.8761434628089546e-09
9 O 0 7.441721461276529e-09
) O 0 7.483346581294015e-11
, O 0 1.1915664288597583e-10
showing O 0 1.099378366120618e-09
a O 0 1.6371692890260192e-09
gene O 0 4.006521336918922e-09
- O 0 9.631445152535889e-08
dosage O 0 3.1453868132302887e-07
effect O 0 3.0886235435900744e-07
. O 0 2.6941972919303225e-07

The O 0 1.005824827871038e-07
other O 0 1.8851658012408734e-08
allele O 0 1.321310065804937e-07
( O 0 2.6853608225962944e-09
Hp2 O 0 1.1721104442585784e-07
) O 0 8.138868745621863e-11
of O 0 4.073293924378163e-10
individuals O 0 2.3427482176430203e-10
with O 0 1.3906353846238062e-09
Hp2 O 0 3.8017897168174386e-06
/ O 0 4.4964576062511696e-08
Hpdel O 0 5.937237119724159e-07
was O 0 6.086338544264436e-09
found O 0 4.4828696310617033e-11
to O 0 3.394092645825353e-11
have O 0 8.463923312218569e-11
, O 0 9.699679948127482e-11
in O 0 1.7071884184094444e-10
all O 0 1.0801376459923517e-09
exons O 0 1.7956359954496293e-08
, O 0 1.909213676043464e-09
no O 0 1.755354639421114e-09
mutation O 0 1.276052929988225e-09
, O 0 1.0231742536559452e-10
by O 0 1.0495319197056929e-10
DNA O 0 1.784488290468289e-08
sequencing O 0 1.1862685056485134e-07
. O 0 3.888459048084769e-07

On O 0 6.455464074406336e-08
the O 0 1.5724845869868886e-09
basis O 0 8.342539103978197e-09
of O 0 6.825075504757194e-10
the O 0 7.190562589798333e-10
present O 0 4.87362539214331e-10
study O 0 4.6195924863212667e-10
, O 0 3.377573221108321e-11
the O 0 1.1497670870941334e-10
mechanism O 0 5.052984253239856e-09
of O 0 4.9407358204689444e-09
anhaptoglobinemia B-Disease 0 5.71296595808235e-07
and O 0 1.6184014128839408e-09
the O 0 1.7408208208280485e-09
mechanism O 0 2.3527991999117148e-08
of O 0 3.121168878905678e-09
anomalous O 0 1.1311936987112858e-06
inheritance O 0 4.6460175440188323e-07
of O 0 2.2536723065513797e-07
Hp O 0 1.8352061204041092e-07
phenotypes O 0 2.5781866952456767e-07
were O 0 1.1689129664205211e-08
well O 0 1.4274913695544456e-08
explained O 0 5.568652454712719e-07
. O 0 3.8415302583416633e-07

However O 0 3.0698558362018957e-07
, O 0 5.784983159173862e-09
the O 0 2.4594406511369016e-09
mechanism O 0 5.2657728843996665e-08
of O 0 3.938356485377881e-08
hypohaptoglobinemia B-Disease 0 0.0001135235870606266
remains O 0 9.232517186319456e-06
unknown O 0 0.00028016287251375616

ATM O 0 6.943339394638315e-05
mutations O 0 1.4944985196052585e-06
and O 0 2.3812418703528238e-08
phenotypes O 0 1.3340709301701281e-06
in O 0 2.6730772262339997e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.6179576789454586e-08
in O 0 4.738422501593398e-11
the O 0 1.1932949073312216e-10
British O 0 6.072753411245913e-11
Isles O 0 7.472938379216032e-10
: O 0 2.523454535607872e-11
expression O 0 2.5914206891464175e-10
of O 0 5.03706631960199e-10
mutant O 0 2.0396013766799115e-09
ATM O 0 1.0789979398850846e-07
and O 0 8.169153131731832e-10
the O 0 1.3398707698897283e-09
risk O 0 8.81446915457218e-09
of O 0 1.1247931475111272e-08
leukemia B-Disease 1 0.992508590221405
, O 0 4.851732455790625e-07
lymphoma B-Disease 1 1.0
, O 0 0.00011023211118299514
and O 0 0.0053273942321538925
breast B-Disease 1 0.8549203276634216
cancer I-Disease 1 0.9066842198371887
. O 0 9.521021979708166e-07

We O 0 4.1628524627412844e-08
report O 0 6.215028491851626e-09
the O 0 1.1375348440978428e-09
spectrum O 0 2.2803765986623148e-08
of O 0 5.277554393501305e-09
59 O 0 3.352636568365597e-08
ATM O 0 7.151886620704317e-07
mutations O 0 7.131849599772977e-08
observed O 0 1.0441180364750835e-08
in O 0 4.021343258386878e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999940395355225
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.8696366383715883e-11
patients O 0 8.62050708594353e-12
in O 0 2.957359400770909e-12
the O 0 1.7538243080039706e-10
British O 0 2.531811871264722e-09
Isles O 0 6.537192120958935e-08
. O 0 1.7699844079288596e-07

Of O 0 1.8157859358325368e-06
51 O 0 1.5479386092920322e-06
ATM O 0 3.1788888463779585e-06
mutations O 0 7.51399440446221e-08
identified O 0 2.859609660177398e-09
in O 0 4.453203777954329e-11
families O 0 2.2197358534592482e-11
native O 0 1.893909855332776e-11
to O 0 1.523710498052555e-11
the O 0 4.953453203171421e-10
British O 0 1.3610614857384462e-09
Isles O 0 9.666187850143615e-09
, O 0 1.2145634498139657e-09
11 O 0 1.4534736969551432e-08
were O 0 5.494690480389863e-09
founder O 0 8.536520823554383e-08
mutations O 0 5.913625145126389e-09
, O 0 6.896892501551122e-10
and O 0 2.57745574883117e-10
2 O 0 3.1356268692661615e-09
of O 0 8.527968886617998e-10
these O 0 4.670375197690646e-10
11 O 0 3.968448680780057e-09
conferred O 0 5.613867593012856e-09
a O 0 4.4720174785517486e-10
milder O 0 4.6170249845545186e-08
clinical O 0 1.6619871034961875e-09
phenotype O 0 3.0878026802128034e-09
with O 0 1.3919527856731673e-11
respect O 0 1.0720121457197251e-09
to O 0 2.151189448795776e-09
both O 0 3.0921949445428254e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 2.9219243913303217e-08
cellular O 0 2.6715946432886994e-07
features O 0 1.448570259299231e-07
. O 0 2.4346917371076415e-07

We O 0 5.678864312130827e-08
report O 0 2.9432243309202022e-08
, O 0 3.0652796967345353e-10
in O 0 2.5683963289502287e-10
two O 0 6.506675642725668e-09
A B-Disease 1 1.0
- I-Disease 1 0.6331933736801147
T I-Disease 1 1.0
families O 0 8.732938816535807e-09
, O 0 2.47870085567925e-10
an O 0 2.322779468766356e-10
ATM O 0 2.796081588485322e-08
mutation O 0 5.469637187616172e-09
( O 0 6.337279034873688e-10
7271T O 0 3.322994501786525e-08
- O 0 6.600070268092395e-09
- O 0 1.0322410481933275e-08
> O 0 2.8920599248749568e-09
G O 0 1.1664229582208918e-08
) O 0 4.355516988741037e-11
that O 0 1.541739132193687e-11
may O 0 5.174257897144763e-11
be O 0 5.630279228951984e-11
associated O 0 7.802334334172656e-10
with O 0 1.8262008225078397e-11
an O 0 1.2144701910798972e-10
increased O 0 1.522689307975611e-09
risk O 0 1.4681630133850376e-08
of O 0 4.2852910553392576e-08
breast B-Disease 0 1.6287284552163328e-06
cancer I-Disease 0 1.4392190905709867e-06
in O 0 6.687260745152912e-10
both O 0 1.5929062513464487e-09
homozygotes O 0 1.8688512071207697e-08
and O 0 7.652883327047277e-10
heterozygotes O 0 9.935205547151327e-09
( O 0 2.526841791361534e-10
relative O 0 3.2052035692231584e-08
risk O 0 5.516048506848392e-09
12 O 0 5.804468461434453e-09
. O 0 1.138633298758407e-09
7 O 0 1.4474813347931104e-08
; O 0 7.824588976745872e-09
P O 0 6.736470368196024e-07
= O 0 3.464217002147052e-08
. O 0 7.678210955930354e-09
0025 O 0 2.121045667990984e-07
) O 0 2.4475343973762165e-10
, O 0 7.06051120347162e-11
although O 0 2.1391959037497799e-10
there O 0 1.6201330554910243e-10
is O 0 3.363661085775682e-11
a O 0 2.949564203991173e-11
less O 0 5.376327716355433e-10
severe O 0 7.958345122460742e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
phenotype O 0 5.49090817258957e-09
in O 0 8.26933573699895e-12
terms O 0 1.0088553603626593e-10
of O 0 3.530603934209786e-11
the O 0 1.1084082263135286e-10
degree O 0 1.1528624277445942e-08
of O 0 1.3934345233224121e-08
cerebellar B-Disease 1 0.9999997615814209
degeneration I-Disease 1 1.0
. O 0 6.354112429107772e-06

This O 0 1.1620910100873516e-07
mutation O 0 1.3173793433907122e-07
( O 0 1.0141019579634758e-08
7271T O 0 2.3387242720218637e-07
- O 0 1.3860258718523255e-08
- O 0 6.985638734136046e-09
> O 0 2.547953625864352e-09
G O 0 8.240393256642164e-09
) O 0 2.3472465290885758e-11
also O 0 2.093073978026716e-12
allows O 0 1.515385690195603e-12
expression O 0 6.140119662711996e-11
of O 0 3.1061422878231326e-10
full O 0 1.0669736205670688e-09
- O 0 6.739130919974912e-10
length O 0 3.962365435761228e-10
ATM O 0 3.654639257888448e-08
protein O 0 1.8082529251728374e-08
at O 0 2.4905544293574167e-09
a O 0 2.1826779272871022e-10
level O 0 7.734354823263345e-10
comparable O 0 9.471052830889448e-10
with O 0 5.422914287761538e-12
that O 0 1.042777062615352e-11
in O 0 7.162566373342116e-11
unaffected O 0 3.125543202031622e-08
individuals O 0 9.903189379656396e-10
. O 0 1.2289260098441446e-07

In O 0 1.3788090669208941e-08
addition O 0 2.1566874508494038e-08
, O 0 8.165820242211907e-10
we O 0 6.326675294765494e-10
have O 0 1.9125037664657896e-10
studied O 0 8.97505980645974e-09
18 O 0 2.1019600637828262e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
patients O 0 1.8071771634708966e-08
, O 0 2.3153660932972997e-10
in O 0 1.268672389365122e-10
15 O 0 2.0601356176541685e-09
families O 0 1.5788590435050764e-09
, O 0 1.182158815282719e-09
who O 0 2.3087258771425923e-09
developed O 0 3.4313366370497533e-08
leukemia B-Disease 1 0.9999912977218628
, O 0 5.283076234263717e-07
lymphoma B-Disease 1 1.0
, O 0 1.462453838030342e-07
preleukemic O 0 0.022564809769392014
T O 0 0.00019931363931391388
- O 0 4.633266598830232e-06
cell O 0 2.5377235942869447e-05
proliferation O 0 0.00010944678069790825
, O 0 8.035606846590326e-09
or O 0 3.851419450029425e-08
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.634486856971762e-08
mostly O 0 1.5061785152425955e-09
in O 0 8.201282986064484e-10
childhood O 0 1.4436318451771513e-06
. O 0 9.99866301754082e-07

A O 0 9.127566045208368e-06
wide O 0 6.741733500348346e-07
variety O 0 8.915960592048577e-08
of O 0 6.433289456708735e-08
ATM O 0 4.554315182758728e-06
mutation O 0 2.7066612062753848e-08
types O 0 6.43241637732217e-09
, O 0 3.1042526882352206e-10
including O 0 1.2724092612881321e-10
missense O 0 1.2391481618578837e-07
mutations O 0 3.619343758032301e-08
and O 0 3.805022963376814e-09
in O 0 2.2350321593478384e-09
- O 0 7.4351662604499325e-09
frame O 0 8.334829004752464e-08
deletions O 0 3.0776554638123343e-08
, O 0 1.030275642577294e-09
were O 0 8.568828424593278e-10
seen O 0 2.687497557829488e-09
in O 0 1.5755489968238834e-10
these O 0 1.7609985691890984e-09
patients O 0 1.3909437157622051e-08
. O 0 2.4888231564546004e-07

We O 0 4.6368196393586913e-08
also O 0 2.25469376502474e-09
show O 0 3.484710853207673e-10
that O 0 9.661546736261517e-12
25 O 0 3.729646314010182e-10
% O 0 7.095706661131018e-11
of O 0 1.925321430062965e-10
all O 0 3.2097411395426434e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.1086524587256008e-08
carried O 0 2.0540227296805824e-09
in O 0 3.132433201713525e-10
- O 0 9.545668255839246e-09
frame O 0 1.8199418150288693e-07
deletions O 0 1.1884789330451895e-07
or O 0 1.5663697894297002e-08
missense O 0 9.81137233679874e-08
mutations O 0 5.967604632672874e-09
, O 0 7.822700820447892e-11
many O 0 1.218681145581657e-11
of O 0 1.1221949064443848e-10
which O 0 1.613012848289408e-11
were O 0 5.304362851732414e-11
also O 0 1.4685837615435737e-11
associated O 0 2.215752165080076e-10
with O 0 2.877860103001062e-11
expression O 0 6.0730260820207604e-09
of O 0 9.448144488999333e-09
mutant O 0 1.9296288655823446e-07
ATM O 0 1.0583462426438928e-05
protein O 0 8.569458259444218e-06
. O 0 4.881305812887149e-07

The O 0 6.303494046733249e-07
DMPK O 0 0.0008442802354693413
gene O 0 1.7099756632887875e-07
of O 0 4.6454064772660786e-07
severely O 1 0.525577187538147
affected O 0 0.001570014632306993
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.079860319616273e-06
is O 0 1.2037425500821541e-09
hypermethylated O 0 7.163464488257887e-08
proximal O 0 4.8007539277250544e-08
to O 0 1.557384221584357e-09
the O 0 2.305664281720965e-08
largely O 0 9.856069738134465e-08
expanded O 0 6.873916191807439e-08
CTG O 0 2.1517302229767665e-05
repeat O 0 7.783195314914337e-07
. O 0 8.897364409676811e-07

Using O 0 1.789456689493818e-07
methylation O 0 1.6926925354709965e-06
- O 0 1.3284909528010758e-06
sensitive O 0 3.452081500654458e-07
restriction O 0 6.282201781004915e-08
enzymes O 0 2.7188411522161005e-08
, O 0 1.8086280251239373e-09
we O 0 2.5191324026785367e-10
characterized O 0 5.555482185393146e-10
the O 0 3.7672026609314457e-10
methylation O 0 7.962996484423002e-09
pattern O 0 4.6531212660738674e-08
on O 0 3.951198035423431e-09
the O 0 7.682073865922234e-10
5 O 0 1.5449581614035424e-09
side O 0 2.7321478413000477e-09
of O 0 5.235974764872253e-09
the O 0 2.8651141903424104e-08
CTG O 0 1.3679247103937087e-06
repeat O 0 2.941477283968652e-09
in O 0 7.288920023107437e-10
the O 0 7.102158861016505e-09
DMPK O 0 3.6191722756484523e-06
gene O 0 1.8634827014807342e-09
of O 0 6.511691630350924e-09
normal O 0 3.0500362235841294e-09
individuals O 0 2.632534641666684e-11
and O 0 9.871614636836057e-11
of O 0 1.557080436809244e-10
patients O 0 1.627628587463903e-10
affected O 0 1.1617907746952483e-09
with O 0 2.0101109665660033e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.586972940894384e-09
showing O 0 1.942644711760977e-09
expansions O 0 1.4068889164775555e-08
of O 0 9.219513152913805e-09
the O 0 1.6671217295538554e-08
repetitive O 0 2.2934760579573776e-07
sequence O 0 3.389482685633993e-07
. O 0 7.477621579710103e-07

The O 0 4.3523058934624714e-07
gene O 0 1.1391773568902863e-07
segment O 0 3.6280843573877064e-07
analyzed O 0 1.9932940631406382e-08
corresponds O 0 8.898491721254231e-09
to O 0 5.728914009850428e-10
the O 0 8.604076562335194e-09
genomic O 0 5.319720912666526e-07
SacI O 0 1.2675192010647152e-05
- O 0 9.086697616567108e-08
HindIII O 0 2.59186407447487e-07
fragment O 0 4.64778153741463e-08
carrying O 0 2.7460721696570545e-08
exons O 0 5.027089500231341e-08
11 O 0 1.2654598435801745e-07
- O 0 5.001792047210074e-08
15 O 0 1.0315348930589607e-07
. O 0 1.3897800954509876e-07

There O 0 2.4267629683549785e-08
is O 0 1.4943718484872193e-09
constitutive O 0 1.4385011581907747e-07
methylation O 0 3.364366136793251e-07
in O 0 6.790023832081715e-08
intron O 0 4.260151854396099e-06
12 O 0 3.6959528415536624e-07
at O 0 3.0497337988322215e-09
restriction O 0 5.390746959932358e-09
sites O 0 3.7929077656428944e-09
of O 0 1.2963834450374634e-08
SacII O 0 4.527663008957461e-07
and O 0 9.62266444304305e-09
HhaI O 0 6.411510184989311e-07
, O 0 1.9079868796012533e-09
localized O 0 2.0014200075024746e-08
1 O 0 8.625273828499758e-09
, O 0 3.7743516645427633e-10
159 O 0 2.109247665416092e-09
- O 0 7.884103925270836e-10
1 O 0 4.112617801865781e-09
, O 0 3.619063937421174e-10
232 O 0 2.8693782905264698e-09
bp O 0 8.601221956894278e-09
upstream O 0 5.976571770816008e-08
of O 0 2.538665277995733e-08
the O 0 3.2131308103089395e-07
CTG O 0 1.0649098840076476e-05
repeat O 0 4.815638376953757e-08
, O 0 3.189838837514003e-09
whereas O 0 4.137306941487395e-09
most O 0 1.0477383405316232e-09
, O 0 7.796201878518261e-11
if O 0 9.006088930174627e-11
not O 0 8.002240536875149e-11
all O 0 3.364304113073757e-10
, O 0 1.563663781789515e-10
of O 0 5.10720354895966e-10
the O 0 6.291596688079437e-10
other O 0 4.4128406484489346e-10
sites O 0 1.444541375406061e-08
of O 0 4.743511539118117e-08
SacII O 0 6.845406232969253e-07
, O 0 6.211342551409871e-09
HhaI O 0 5.876545401406474e-07
, O 0 2.2510284747312426e-09
and O 0 1.5468806235929833e-09
HpaII O 0 9.8956071781231e-08
in O 0 2.5829871574956087e-10
this O 0 4.665318131813478e-10
region O 0 9.79080549967648e-09
are O 0 5.527262536553224e-10
unmethylated O 0 1.2252316139438335e-07
, O 0 8.330577894177793e-10
in O 0 2.870176041280814e-10
normal O 0 3.5293017397464155e-09
individuals O 0 4.222284674670895e-11
and O 0 8.734096779150491e-11
most O 0 1.8843406002222451e-10
of O 0 9.263080857913053e-10
the O 0 3.873939835585816e-09
patients O 0 4.97498664486784e-09
. O 0 7.291513526297422e-08

In O 0 9.495784603075208e-09
a O 0 2.0421511148782656e-09
number O 0 2.764827922163704e-09
of O 0 2.4916388952078705e-08
young O 0 3.279416915802358e-08
and O 0 1.4829468319987882e-08
severely O 0 3.196301577190752e-06
affected O 0 1.557186024570001e-08
patients O 0 2.8146258657102408e-09
, O 0 6.941124758297335e-11
however O 0 7.24947490926553e-10
, O 0 5.455826068700986e-11
complete O 0 2.4278254406873145e-10
methylation O 0 2.089328710042082e-08
of O 0 6.996613066689861e-09
these O 0 4.3587849996029604e-10
restriction O 0 7.062741058661004e-09
sites O 0 1.0420428964152961e-08
was O 0 7.286505177006575e-09
found O 0 4.5123130232305186e-10
in O 0 2.2910813524124052e-10
the O 0 4.956895782726178e-09
mutated O 0 3.411394970953552e-07
allele O 0 4.45284598526996e-07
. O 0 3.1248404752659553e-07

In O 0 2.5026603012179294e-08
most O 0 5.34957145248427e-09
of O 0 1.0056552257609042e-09
these O 0 1.7798772178334588e-10
patients O 0 2.732771786639887e-10
, O 0 1.857703574303926e-11
the O 0 5.3751558759529416e-11
onset O 0 6.416385076590814e-07
of O 0 1.2152239214913152e-09
the O 0 2.9216498109718714e-09
disease O 0 7.480654312530532e-05
was O 0 5.626208121611853e-07
congenital O 1 0.9999978542327881
. O 0 9.8015868843504e-07

Preliminary O 0 9.398035558660922e-07
in O 0 1.0759317348174591e-07
vivo O 0 1.775989858288085e-06
footprinting O 0 1.0745544386736583e-05
data O 0 3.635200940266259e-08
gave O 0 1.4436929873795634e-08
evidence O 0 1.8301159698808078e-08
for O 0 1.5816469245422127e-09
protein O 0 1.6481392250966564e-08
- O 0 1.3936942711012534e-09
DNA O 0 4.661984576159739e-09
contact O 0 1.3040415858256438e-08
in O 0 6.66356581024985e-10
normal O 0 1.6966426130693435e-07
genes O 0 1.8679745750205257e-08
at O 0 3.69630637209184e-09
an O 0 3.1105532038999684e-10
Sp1 O 0 1.3813255428374305e-08
consensus O 0 2.0349035789735126e-09
binding O 0 2.4624167149767118e-09
site O 0 2.5591178953732197e-08
upstream O 0 1.4371354950526438e-07
of O 0 1.777765312738211e-08
the O 0 1.827695683687125e-07
CTG O 0 1.2654150850721635e-05
repeat O 0 1.0958784102399477e-08
and O 0 3.911089230257403e-10
for O 0 4.0752502067364915e-11
a O 0 3.193086073327578e-11
significant O 0 1.511562403022637e-10
reduction O 0 8.876162582716063e-10
of O 0 2.4923971220225383e-10
this O 0 8.450148220040532e-11
interaction O 0 6.077209402377548e-09
in O 0 5.49632284130297e-10
cells O 0 2.851755276367385e-09
with O 0 6.602597912852559e-10
a O 0 1.077354383482998e-08
hypermethylated O 0 1.7255332522836397e-06
DMPK O 0 1.0572991413937416e-05
gene O 0 4.327988278873818e-08
. O 0 8.721058719629582e-08
. O 0 2.886983452299319e-07

The O 0 3.1278207188734086e-06
hemochromatosis B-Disease 1 1.0
gene O 0 2.204324346166686e-06
product O 0 2.189001122587797e-07
complexes O 0 1.075828670593637e-08
with O 0 1.5233740657816242e-10
the O 0 1.5504546535538566e-09
transferrin O 0 9.730861449952499e-08
receptor O 0 2.9861087114113616e-07
and O 0 5.1959712088489596e-09
lowers O 0 1.1014462231173638e-08
its O 0 1.0649865711531703e-10
affinity O 0 2.5867144537450315e-10
for O 0 9.301352743573688e-11
ligand O 0 1.030475047514301e-07
binding O 0 1.081991854334774e-06
. O 0 1.438088588656683e-06

We O 0 2.2553278711257008e-07
recently O 0 2.052214398418073e-08
reported O 0 1.3221590933198968e-08
the O 0 3.0861169175722125e-10
positional O 0 7.365274257153942e-08
cloning O 0 9.780278809046195e-09
of O 0 5.722812002062483e-09
a O 0 1.764552282068621e-09
candidate O 0 4.323316815657563e-09
gene O 0 1.2518094116842349e-08
for O 0 9.947591195214045e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999922513961792
HFE O 1 0.9999988079071045
. O 0 1.0921766033789027e-06

The O 0 1.1320338444420486e-07
gene O 0 7.603912166587179e-09
product O 0 3.1667141797697695e-08
, O 0 3.202077492048261e-10
a O 0 2.569778279060131e-10
member O 0 2.7340385511109844e-10
of O 0 9.002765644083865e-09
the O 0 5.134126723760346e-08
major O 0 1.1539012234607071e-07
histocompatibility O 0 9.589505367557649e-08
complex O 0 8.78088002309596e-08
class O 0 6.385281192677894e-09
I O 0 5.633156163753483e-08
- O 0 3.5520602015282066e-09
like O 0 2.956183631219744e-10
family O 0 1.3696580536404213e-09
, O 0 6.205155139715757e-11
was O 0 1.101367400058173e-10
found O 0 9.82959807299677e-12
to O 0 3.8016676612295797e-11
have O 0 2.1280492645825433e-10
a O 0 1.7707255661747467e-09
mutation O 0 5.448489215353902e-09
, O 0 2.9088775832519786e-09
Cys O 0 1.4042889517895674e-07
- O 0 4.290173549748033e-08
282 O 0 5.8903371069618515e-08
- O 0 4.302572165215679e-08
- O 0 3.8607012697866594e-08
> O 0 3.3356570838805055e-08
Tyr O 0 1.7057931245290092e-07
( O 0 4.820246424230845e-10
C282Y O 0 1.9763641390113662e-08
) O 0 1.7743480296150693e-11
, O 0 1.0610566245072839e-11
in O 0 1.4239458570597385e-11
85 O 0 4.170543466130994e-09
% O 0 3.590735764280595e-10
of O 0 4.498572070410489e-10
patient O 0 1.3664412712444118e-08
chromosomes O 0 3.539567785537656e-07
. O 0 9.110677865464822e-07

This O 0 1.4839825368540005e-08
mutation O 0 1.7939282770385034e-07
eliminates O 0 1.196300672745565e-06
the O 0 1.4546275295401756e-08
ability O 0 1.0395852179101439e-08
of O 0 1.6347992470855388e-07
HFE O 0 0.0005761101492680609
to O 0 6.769049321064813e-08
associate O 0 7.551146268269804e-07
with O 0 7.42841965717389e-09
beta2 O 0 3.7500089092645794e-05
- O 0 1.0364788067818154e-06
microglobulin O 0 8.28582142275991e-06
( O 0 8.65213056755465e-09
beta2m O 0 9.192236234412121e-07
) O 0 1.2924374903633407e-09
and O 0 1.6960149951117387e-09
prevents O 0 1.8583689254114688e-08
cell O 0 4.322857307670347e-07
- O 0 1.9003594786681788e-07
surface O 0 1.2983824717593961e-06
expression O 0 9.386194506078027e-07
. O 0 4.670665134653973e-07

A O 0 3.6938320135959657e-06
second O 0 5.2440832121192216e-08
mutation O 0 1.1505404629019722e-08
that O 0 4.88225959660582e-10
has O 0 1.6130967395167062e-10
no O 0 3.132779868852964e-10
effect O 0 8.490838254715527e-09
on O 0 2.0022026703259144e-08
beta2m O 0 7.76564604620944e-07
association O 0 2.0617287432855846e-08
, O 0 5.766992217104416e-09
H63D O 0 2.68138410319807e-05
, O 0 7.233784127258502e-10
was O 0 1.8666952428247896e-09
found O 0 7.7971233636287e-11
in O 0 4.30432182951801e-11
eight O 0 3.1158081670312754e-10
out O 0 3.3359720541525917e-10
of O 0 1.3555638833651074e-09
nine O 0 3.1496949493003967e-09
patients O 0 2.792454323330418e-10
heterozygous O 0 3.5913796936348774e-10
for O 0 4.701397604556234e-10
the O 0 1.8497367193504033e-08
C282Y O 0 1.3365682889343589e-06
mutant O 0 4.771446242557431e-07
. O 0 6.607038471884152e-07

In O 0 1.8913965504907537e-08
this O 0 3.209031262940698e-09
report O 0 1.0506727043946285e-08
, O 0 2.6887420068177903e-10
we O 0 1.6774831523846956e-10
demonstrate O 0 1.7625004788968113e-09
in O 0 2.5881123910664883e-09
cultured O 0 4.802805619874562e-07
293 O 0 8.520124339383983e-08
cells O 0 6.210622416347178e-08
overexpressing O 0 1.033939611261303e-06
wild O 0 4.471603887168385e-08
- O 0 1.1144488887282478e-08
type O 0 8.276022533948435e-09
or O 0 5.733606478486308e-09
mutant O 0 3.104883816718029e-08
HFE O 0 5.139486347616185e-07
proteins O 0 1.4877652443345823e-09
that O 0 3.0306429588122796e-10
both O 0 7.429322157470608e-10
the O 0 7.872987595192171e-09
wild O 0 2.4114857666290845e-08
- O 0 1.348954015156778e-08
type O 0 4.4225689777022126e-08
and O 0 1.0646976278394504e-07
H63D O 1 0.9923534989356995
HFE O 0 2.4569962988607585e-05
proteins O 0 3.3397441256965976e-08
form O 0 1.1963180668317364e-08
stable O 0 8.122751893324676e-08
complexes O 0 3.770259660029751e-09
with O 0 2.3000397419981056e-10
the O 0 3.6837575212445017e-09
transferrin O 0 4.646487639092811e-07
receptor O 0 1.772133941813081e-06
( O 0 3.2177116082721113e-08
TfR O 0 1.119849230235559e-06
) O 0 6.277587338843205e-09
. O 0 7.235419019480105e-08

The O 0 4.123979238102038e-07
C282Y O 0 7.0070582296466455e-06
mutation O 0 9.060166661356561e-08
nearly O 0 7.003755797541089e-09
completely O 0 3.850976870722889e-09
prevents O 0 2.198744963877175e-09
the O 0 3.123626912682198e-10
association O 0 7.485078112878796e-10
of O 0 2.276703048309514e-09
the O 0 7.546147706705142e-09
mutant O 0 9.887419594178937e-08
HFE O 0 3.7193040043348446e-06
protein O 0 3.799295456019536e-08
with O 0 7.944332969245238e-10
the O 0 5.515136436429202e-08
TfR O 0 1.2733891708194278e-05
. O 0 3.710033240622579e-07

Studies O 0 2.773616643025889e-07
on O 0 5.416795190171797e-08
cell O 0 3.6835416494795936e-08
- O 0 1.5944054965189025e-08
associated O 0 2.0438548631318554e-08
transferrin O 0 2.1281292106323235e-07
at O 0 4.756383287229937e-09
37 O 0 3.234520873363067e-09
degrees O 0 1.0795285554365819e-08
C O 0 5.259968016702032e-09
suggest O 0 2.7856716933172265e-10
that O 0 4.8690333015466436e-11
the O 0 3.275021143167578e-09
overexpressed O 0 9.395938604939147e-07
wild O 0 1.3456369174491556e-07
- O 0 5.280708492705344e-08
type O 0 1.0410659712078996e-07
HFE O 0 3.4222498470626306e-06
protein O 0 6.022010978767867e-08
decreases O 0 8.887263369672382e-09
the O 0 1.9363363690239055e-10
affinity O 0 2.7211741748800478e-09
of O 0 1.5675316600294309e-09
the O 0 5.841864769706717e-09
TfR O 0 1.8181236782766064e-07
for O 0 3.296630302074277e-09
transferrin O 0 8.917386367102154e-06
. O 0 1.5530889641013346e-06

The O 0 3.304003257653676e-05
overexpressed O 0 0.0007951243314892054
H63D O 0 0.33106529712677
protein O 0 7.468855187653389e-07
does O 0 1.9175709908836325e-09
not O 0 3.0054586597216826e-10
have O 0 3.1812261158670196e-11
this O 0 1.5922090035314085e-11
effect O 0 2.1434487518234846e-09
, O 0 4.451369481350831e-11
providing O 0 3.3571509461260973e-10
the O 0 1.4036763418268094e-10
first O 0 1.0446887105386438e-10
direct O 0 5.157972937652744e-10
evidence O 0 1.2106039504189425e-09
for O 0 1.1923621812126584e-10
a O 0 7.548016101033284e-10
functional O 0 3.78798610256581e-08
consequence O 0 1.578649602151927e-07
of O 0 1.3663266962282705e-08
the O 0 6.92985082650921e-08
H63D O 0 0.00021632385323755443
mutation O 0 5.359705710361595e-07
. O 0 4.821134211852041e-07

Addition O 0 5.614539304588106e-07
of O 0 1.1907587804671493e-06
soluble O 0 4.314365651225671e-05
wild O 0 1.7455150782552664e-06
- O 0 9.543766736896941e-07
type O 0 2.7953994958807016e-06
HFE O 1 0.6093709468841553
/ O 0 1.4745350199518725e-05
beta2m O 0 3.7151210108277155e-06
heterodimers O 0 2.0394280397795228e-07
to O 0 1.9537551576576107e-09
cultured O 0 9.053909622025458e-09
cells O 0 1.3855441238774802e-09
also O 0 8.687243979732528e-11
decreased O 0 3.91357418694227e-10
the O 0 9.260810000799591e-12
apparent O 0 7.745278862714144e-10
affinity O 0 2.0972410474939807e-09
of O 0 2.2805755062194066e-09
the O 0 4.793898167321231e-09
TfR O 0 3.0252575555778094e-08
for O 0 1.4096192268997498e-10
its O 0 2.912762531170898e-10
ligand O 0 4.102098571934221e-08
under O 0 8.898355829956017e-09
steady O 0 8.559558750675933e-08
- O 0 3.782516799777369e-10
state O 0 2.2146114109222736e-10
conditions O 0 9.371881937170201e-09
, O 0 2.205691462808801e-10
both O 0 1.0875876588212208e-10
in O 0 1.9509464876943383e-10
293 O 0 9.653580157475972e-10
cells O 0 5.444912853924677e-10
and O 0 8.781960159076618e-10
in O 0 5.50722889514077e-09
HeLa O 0 8.794151540314488e-07
cells O 0 2.5397579861419217e-07
. O 0 4.4210514715814497e-07

Furthermore O 0 4.979669938620646e-07
, O 0 1.0607850597921242e-08
at O 0 9.604749884317698e-09
4 O 0 1.0335630129532092e-08
degrees O 0 5.368688604789895e-08
C O 0 8.537725904034232e-08
, O 0 3.9005926266710844e-10
the O 0 3.392031766580317e-09
added O 0 1.0497275582110888e-07
soluble O 0 5.203090154282108e-07
complex O 0 1.3094505391109124e-07
of O 0 2.872030790967983e-07
HFE O 0 0.09713346511125565
/ O 0 1.1525232366693672e-05
beta2m O 0 1.8937339518743102e-06
inhibited O 0 1.5193624136600192e-08
binding O 0 1.2167157947828855e-08
of O 0 1.1193229454420361e-08
transferrin O 0 3.440564739776164e-07
to O 0 2.3056115239228347e-08
HeLa O 0 1.4435491948461276e-06
cell O 0 2.216169292523773e-07
TfR O 0 6.58585690871405e-07
in O 0 1.1286522827447243e-09
a O 0 1.9280417262734773e-09
concentration O 0 9.830667124788306e-08
- O 0 6.091079285397427e-08
dependent O 0 1.1757243356669278e-07
manner O 0 1.4060444186725363e-07
. O 0 1.828898774647314e-07

Scatchard O 0 0.0006090720999054611
plots O 0 1.2258105925866403e-06
of O 0 3.440925411268836e-08
these O 0 4.140675857744469e-10
data O 0 7.482683805903889e-09
indicate O 0 8.655266725554611e-09
that O 0 6.795926044134148e-10
the O 0 1.083505729582157e-08
added O 0 5.9118463013874134e-08
heterodimer O 0 1.2280531791475369e-07
substantially O 0 1.234938551419873e-08
reduced O 0 1.9188333144626313e-09
the O 0 1.6937060087762745e-10
affinity O 0 6.570202604194719e-09
of O 0 9.999844508001843e-09
TfR O 0 3.6081920029573666e-07
for O 0 6.673070540585968e-09
transferrin O 0 1.756519850459881e-05
. O 0 2.662412725840113e-06

These O 0 8.588209965409987e-08
results O 0 7.208777930145516e-08
establish O 0 4.054361824046282e-08
a O 0 4.118701824040727e-09
molecular O 0 6.375802996672064e-08
link O 0 4.828883248819693e-08
between O 0 4.5669878545595566e-08
HFE O 0 0.002220994094386697
and O 0 1.291302265116201e-08
a O 0 1.161609652911011e-08
key O 0 5.2069566436330206e-08
protein O 0 4.743059278666806e-08
involved O 0 3.763642286713775e-09
in O 0 1.536650029443365e-09
iron O 0 2.340035933912077e-07
transport O 0 3.204036431725399e-07
, O 0 7.280611113991142e-10
the O 0 1.0345512002629675e-08
TfR O 0 7.271028152899817e-07
, O 0 7.143878266724357e-10
and O 0 4.067657599637897e-10
raise O 0 2.4485209415558984e-09
the O 0 1.262690840775349e-09
possibility O 0 7.956817427157148e-09
that O 0 2.3322088704702537e-10
alterations O 0 1.497608437261988e-08
in O 0 1.9961760022724206e-10
this O 0 2.0946094858587117e-10
regulatory O 0 7.877298813241396e-09
mechanism O 0 4.012748888726492e-08
may O 0 4.850341905893174e-09
play O 0 6.335554303404933e-09
a O 0 4.5352579469692955e-09
role O 0 1.7924426387594394e-09
in O 0 2.441515045692455e-10
the O 0 2.9585089933448216e-09
pathogenesis O 0 0.0009164743823930621
of O 0 3.30027518202769e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 4.7580597311025485e-06
. O 0 1.8672520241125312e-07

Genomic O 0 1.2603595678228885e-06
organization O 0 1.18526322978596e-07
of O 0 8.588094857486794e-08
the O 0 1.9832694420074404e-07
UBE3A O 0 6.204847886692733e-05
/ O 0 9.316348155152809e-07
E6 O 0 1.0131323506357148e-05
- O 0 1.6729769924950233e-07
AP O 0 2.7506964670465095e-06
gene O 0 2.794357856217289e-09
and O 0 1.930411386297237e-09
related O 0 5.86230548549338e-08
pseudogenes O 0 4.258559329173295e-06
. O 0 6.28915529432561e-07

The O 0 2.4587441203038907e-06
UBE3A O 0 6.671989831374958e-05
gene O 0 3.780710926548636e-07
encodes O 0 7.239773935907579e-07
the O 0 2.439381887597847e-07
E6 O 0 8.098793841782026e-06
- O 0 3.45268716728242e-07
AP O 0 4.9028640205506235e-06
ubiquitin O 0 7.128680579171487e-08
- O 0 1.32898554383587e-08
protein O 0 4.872549475010146e-09
ligase O 0 4.253789764874227e-09
and O 0 1.718339026623994e-09
has O 0 4.817746757090902e-10
recently O 0 1.4049619800893254e-10
been O 0 1.511380083585312e-11
shown O 0 1.2637352969635529e-11
to O 0 7.86596655866223e-12
be O 0 2.927292089283107e-11
mutated O 0 8.529766404308248e-08
in O 0 1.3854866587337256e-08
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 7.908781185506086e-08
who O 0 2.211847593969196e-09
lack O 0 3.473950371812862e-08
15q11 O 0 7.439687124133343e-07
- O 0 1.1698190149900256e-07
q13 O 0 9.548290336169885e-07
deletions O 0 2.8941755658706825e-07
or O 0 2.0090272556672062e-08
chromosome O 0 3.0243523951867246e-07
15 O 0 7.043344680823793e-07
paternal O 0 0.0008804561221040785
uniparental B-Disease 0 0.0032453311141580343
disomy I-Disease 0 0.0003104154020547867
. O 0 3.965934411098715e-06

Previous O 0 6.065925390430493e-06
UBE3A O 0 1.574577618157491e-05
cDNA O 0 1.2604157006990135e-07
analysis O 0 1.0076044887341595e-08
has O 0 2.614850835858107e-10
shown O 0 8.209981305906666e-11
a O 0 9.481278262502002e-11
coding O 0 1.8367076748404543e-08
region O 0 2.3627379164281592e-08
of O 0 1.0026850461031245e-08
approximately O 0 2.52226008967682e-08
2 O 0 2.6151982979172317e-07
. O 0 3.3114577036030823e-07

6 O 0 6.243913503567455e-06
kb O 0 5.190350748307537e-06
and O 0 2.0623264873620428e-08
a O 0 2.348459382517376e-08
3 O 0 1.1643496833357858e-07
- O 0 5.217325593775968e-08
untranslated O 0 5.135457467986271e-05
region O 0 1.9719837496268156e-07
( O 0 4.543700082848545e-09
UTR O 0 1.0081783329951577e-05
) O 0 1.33251298883863e-09
of O 0 2.2823563483598264e-08
< O 0 4.7957477988802566e-08
50 O 0 4.1796877070510163e-08
bp O 0 1.390179882321263e-08
, O 0 1.158999285433282e-10
whereas O 0 4.105546458355036e-10
Northern O 0 8.016940999944211e-10
analysis O 0 1.0723106846910468e-09
has O 0 2.0095310138135147e-10
indicated O 0 3.0422783736661074e-10
mRNA O 0 4.3278705064153655e-09
sizes O 0 1.514828085191766e-08
of O 0 2.8949475705530858e-08
5 O 0 2.076457548128019e-07
- O 0 1.7376842720295826e-07
8 O 0 2.752402394889941e-07
kb O 0 6.068476977816317e-06
. O 0 9.239334985977621e-07

We O 0 2.6024846988548234e-07
have O 0 5.6619890997922084e-09
analyzed O 0 1.1036901170768942e-08
additional O 0 3.6107370426918806e-09
cDNA O 0 3.9121154316035245e-08
clones O 0 5.442613471018376e-08
and O 0 8.615140822954004e-10
provide O 0 1.0818882456575807e-09
evidence O 0 4.6863499747473725e-09
for O 0 1.7660428675014828e-10
an O 0 8.450539157323078e-10
additional O 0 4.827969135590138e-09
0 O 0 2.1084207446619985e-07
. O 0 1.9496580705435917e-07

5 O 0 3.3730959785316372e-06
kb O 0 9.54469942371361e-06
of O 0 7.730349125267821e-07
5 O 0 6.729118240400567e-07
- O 0 9.37285165036883e-08
UTR O 0 7.79121182858944e-06
and O 0 8.723466393689705e-09
> O 0 1.6909769584572132e-08
2 O 0 1.2533097226707923e-08
kb O 0 2.4004637566577003e-07
of O 0 5.866007768418058e-08
3 O 0 4.3132004634571786e-07
- O 0 5.696682592315483e-07
UTR O 0 0.0003142713394481689
. O 0 1.662941372160276e-06

We O 0 6.96192472560142e-08
have O 0 5.872539676765598e-10
established O 0 2.2206190219975497e-09
the O 0 2.218534800313421e-10
genomic O 0 2.304168411626506e-09
organization O 0 1.118545589484654e-09
of O 0 5.594658958330001e-09
UBE3A O 0 1.123234505939763e-05
and O 0 4.3274086536371215e-09
the O 0 4.726773639163184e-09
sequence O 0 8.672088824823732e-09
of O 0 2.2731331483782924e-08
intron O 0 5.520539616554743e-07
- O 0 3.9962782238944783e-07
exon O 0 1.5689808208207978e-07
borders O 0 9.618793228582945e-07
. O 0 1.8641094357008114e-06

We O 0 1.952387833625835e-07
have O 0 1.0899748659198849e-08
also O 0 7.858795392223783e-09
mapped O 0 4.5756721078760165e-08
two O 0 3.7745118142140655e-09
highly O 0 1.520687398226528e-08
homologous O 0 1.4573546813778648e-08
processed O 0 1.608782014272947e-07
pseudogenes O 0 2.375508984187036e-06
, O 0 1.6933039859168275e-08
UBE3AP1 O 0 3.1018269510241225e-05
and O 0 1.8163346382493728e-08
UBE3AP2 O 0 2.7279858841211535e-05
, O 0 8.021606157093686e-10
to O 0 3.606323295546332e-10
chromosomes O 0 2.7947735237177085e-09
2 O 0 4.746405046773816e-09
and O 0 4.40470937501658e-10
21 O 0 1.0634470193338075e-08
, O 0 4.2240347331023997e-10
respectively O 0 1.2451126796264589e-09
, O 0 1.4961763772358694e-10
and O 0 1.5074595738351348e-10
determined O 0 2.1879349443310048e-09
their O 0 1.430745300012859e-09
genomic O 0 2.2881148709075205e-07
organization O 0 2.0076181783679203e-07
. O 0 4.392276480302826e-07

These O 0 5.3665285548731845e-08
results O 0 3.506035284317477e-08
will O 0 2.806117282982967e-10
form O 0 1.575816560572818e-10
the O 0 4.5119946667782074e-10
basis O 0 8.386280003769286e-10
for O 0 8.000191654977673e-12
studies O 0 9.962577984801158e-11
of O 0 1.031348548230504e-10
mutation O 0 8.426782049930637e-10
and O 0 8.211096247379146e-10
imprinting O 0 1.64834250426793e-06
of O 0 4.646416584819235e-07
UBE3A O 0 0.006648056209087372
. O 0 5.770967618445866e-06

Mutation O 0 3.083755473198835e-07
spectrum O 0 1.429589957524513e-07
and O 0 4.235266803931381e-09
genotype O 0 1.182218554163228e-07
- O 0 6.553996456659661e-08
phenotype O 0 3.3777716623717424e-08
analyses O 0 1.2044275798928084e-08
in O 0 9.69613389578683e-10
Cowden B-Disease 0 1.4541466953232884e-05
disease I-Disease 0 1.0011611266236287e-05
and O 0 6.858685708266421e-08
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.648527867663233e-09
two O 0 5.991967366725248e-09
hamartoma B-Disease 1 0.8535014390945435
syndromes I-Disease 0 0.0002856467035599053
with O 0 1.3485635008692043e-07
germline O 1 1.0
PTEN O 1 1.0
mutation O 0 1.5971387256286107e-05
. O 0 5.843238568559173e-07

The O 0 5.725910341425333e-06
tumour B-Disease 1 1.0
suppressor O 0 0.008006639778614044
gene O 0 1.2051547855662648e-05
PTEN O 1 0.9721152186393738
, O 0 1.9836377873616584e-08
which O 0 5.587831308773161e-10
maps O 0 2.7045865991226492e-08
to O 0 9.285975544059966e-09
10q23 O 0 1.94880849448964e-05
. O 0 1.8604242768560653e-06

3 O 0 1.4342208487505559e-06
and O 0 8.092160719286312e-09
encodes O 0 2.2623929396559106e-08
a O 0 6.682610020902757e-09
403 O 0 8.540930629408194e-09
amino O 0 1.6734327701328766e-08
acid O 0 9.280203272510335e-09
dual O 0 3.8532640189714584e-08
specificity O 0 1.4322893093776656e-07
phosphatase O 0 2.4735263650654815e-05
( O 0 3.2268201266560936e-07
protein O 0 3.475293851806782e-06
tyrosine O 0 7.440374929501559e-07
phosphatase O 0 5.746018132413155e-07
; O 0 1.135053828704713e-08
PTPase O 0 1.0573857167628375e-07
) O 0 9.680828361169347e-11
, O 0 8.466555928565711e-11
was O 0 4.327992131347713e-10
shown O 0 9.535177508679382e-11
recently O 0 9.856600952096173e-11
to O 0 4.772872375102821e-11
play O 0 1.0746571410535921e-09
a O 0 5.554923188100247e-09
broad O 0 3.214717736454986e-08
role O 0 2.95669289052114e-09
in O 0 2.2382657949293616e-09
human O 0 1.8113603061920003e-07
malignancy B-Disease 0 0.0006418407429009676
. O 0 3.1450147730538447e-07

Somatic O 0 0.000642386032268405
PTEN O 0 0.0010002804920077324
deletions O 0 2.1496214230865007e-06
and O 0 1.7506543770196004e-08
mutations O 0 2.237776186575502e-08
were O 0 2.1362775992628258e-09
observed O 0 2.0386679011608067e-09
in O 0 5.836126582003942e-10
sporadic B-Disease 0 2.6324667032895377e-06
breast I-Disease 0 8.188946594600566e-06
, I-Disease 0 2.995246717318878e-08
brain I-Disease 1 1.0
, I-Disease 0 2.0434124508028617e-06
prostate I-Disease 1 1.0
and I-Disease 0 2.2040860130800866e-05
kidney I-Disease 1 0.9814867377281189
cancer I-Disease 0 6.53986091947445e-07
cell O 0 1.0013551587917391e-07
lines O 0 3.872299814133839e-09
and O 0 8.079659857829213e-11
in O 0 6.718823414297859e-11
several O 0 1.9267623052598992e-09
primary O 0 1.820917390205068e-07
tumours B-Disease 1 1.0
such O 0 7.436514071201827e-09
as O 0 3.9014267372294853e-07
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.847070234362036e-05
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 0 0.01930953748524189
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 4.440295469976263e-06

In O 0 3.0189340805009124e-08
addition O 0 3.94403940617849e-08
, O 0 9.67256941208916e-09
PTEN O 0 0.39638325572013855
was O 0 4.72866972245356e-08
identified O 0 4.378769347113121e-09
as O 0 1.519639136748907e-10
the O 0 1.427440943224667e-10
susceptibility O 0 2.9135693857540446e-09
gene O 0 1.6793278989624127e-09
for O 0 1.5418640808562145e-09
two O 0 3.36198553441136e-08
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 0.9999995231628418
disease I-Disease 1 0.9999964237213135
( O 0 1.4526395197833608e-08
CD B-Disease 0 1.0386713256593794e-05
; O 0 1.380759755420513e-07
MIM O 0 5.425715244200546e-06
158350 O 0 9.47930004713271e-07
) O 0 1.334774402117489e-09
and O 0 1.0164994179717723e-08
Bannayan B-Disease 0 2.7475467504700646e-05
- I-Disease 0 2.1622106942231767e-05
Zonana I-Disease 0 0.38449758291244507
( I-Disease 0 2.1749094969436555e-07
BZS I-Disease 0 9.522611799184233e-05
) I-Disease 0 5.61409274624225e-09
or I-Disease 0 7.622964481868166e-09
Ruvalcaba I-Disease 0 1.961607040357194e-06
- I-Disease 0 2.937325405127922e-07
Riley I-Disease 0 6.958884569030488e-06
- I-Disease 1 0.971838653087616
Smith I-Disease 0 0.000491832266561687
syndrome I-Disease 1 1.0
( O 0 1.2081605746061541e-05
MIM O 0 0.22317707538604736
153480 O 0 4.1233703086618334e-05
) O 0 3.8929705681312043e-08
. O 0 3.9368288184959965e-07

Constitutive O 0 6.594926276193291e-07
DNA O 0 1.3498295459157816e-07
from O 0 5.7854052215589036e-08
37 O 0 6.233764793250884e-08
CD B-Disease 0 2.505143648079411e-08
families O 0 1.500008894872451e-09
and O 0 3.7483879888888794e-10
seven O 0 2.2825816792249043e-09
BZS B-Disease 0 2.800944685077411e-06
families O 0 4.0527264877354696e-10
was O 0 4.445969370436842e-09
screened O 0 9.836960135345407e-10
for O 0 1.7567010068830768e-09
germline O 0 2.8321419449639507e-05
PTEN O 0 0.001494161318987608
mutations O 0 7.330555035878206e-06
. O 0 2.1660016500391066e-06

PTEN O 0 0.0004691888752859086
mutations O 0 8.233497510445886e-07
were O 0 1.660384540969062e-08
identified O 0 2.9399742640379145e-09
in O 0 1.2498803381166823e-10
30 O 0 2.1338708577900434e-09
of O 0 2.3303909912897325e-09
37 O 0 3.311352969603831e-08
( O 0 6.037416122595118e-10
81 O 0 4.0700673054061554e-08
% O 0 3.0264088457521154e-10
) O 0 3.5697068131307352e-12
CD B-Disease 0 6.763068993720367e-10
families O 0 8.639259446718839e-11
, O 0 3.5221159322418316e-11
including O 0 2.7776059230433248e-11
missense O 0 1.1388254250732643e-07
and O 0 8.597154099732052e-09
nonsense O 0 2.4554350375183276e-07
point O 0 2.98329354109228e-07
mutations O 0 5.748754006162926e-08
, O 0 4.076373461003868e-09
deletions O 0 6.532754781574113e-08
, O 0 4.306872192216815e-09
insertions O 0 7.176018357313296e-08
, O 0 4.605412939895359e-09
a O 0 9.23854237555588e-09
deletion O 0 8.863719358487288e-08
/ O 0 3.0802223704995413e-07
insertion O 0 2.2905011576312972e-07
and O 0 3.459271624706162e-08
splice O 0 8.981191967905033e-06
site O 0 1.3113279919707566e-06
mutations O 0 2.5842743980319938e-06
. O 0 1.9743049506359966e-06

These O 0 2.765831652595807e-08
mutations O 0 7.415921743358922e-08
were O 0 9.3207330742473e-10
scattered O 0 5.418487436514852e-09
over O 0 2.27140584119212e-10
the O 0 3.8233757826411363e-10
entire O 0 1.3480093707940455e-09
length O 0 9.321302618658933e-10
of O 0 7.105044996791321e-09
PTEN O 0 6.188171937537845e-06
, O 0 4.497370809097845e-10
with O 0 1.371473507677523e-11
the O 0 2.190940762147875e-10
exception O 0 5.483004050788054e-10
of O 0 3.304314877272674e-10
the O 0 7.956585945656514e-10
first O 0 1.8463801598755936e-09
, O 0 9.534417699796904e-10
fourth O 0 6.021494414198969e-08
and O 0 1.5897018812438546e-08
last O 0 1.752429312773529e-07
exons O 0 5.262838840280892e-06
. O 0 3.581253849915811e-06

A O 0 2.4964421754702926e-05
hot O 0 5.306694674800383e-06
spot O 0 4.345715183262655e-07
for O 0 7.322408013266113e-09
PTEN O 0 1.2607919416041113e-05
mutation O 0 7.778222510523847e-09
in O 0 8.356517700036648e-10
CD B-Disease 0 9.705689052452726e-08
was O 0 2.5971385042566908e-08
identified O 0 3.591765329602481e-09
in O 0 3.822595573410581e-10
exon O 0 8.462140321796596e-09
5 O 0 1.231600599282956e-08
that O 0 6.938451202476159e-11
contains O 0 5.705327876803779e-10
the O 0 8.228017378542063e-09
PTPase O 0 5.309619268700771e-07
core O 0 1.1098038754653317e-07
motif O 0 2.693379741458557e-08
, O 0 1.7996217016591487e-10
with O 0 2.367746450293584e-11
13 O 0 1.6031534988414364e-09
of O 0 4.218706717296072e-09
30 O 0 1.252611880886434e-08
( O 0 5.841806482997924e-10
43 O 0 4.5164590289914486e-08
% O 0 5.615213849452516e-10
) O 0 2.1136313185787792e-11
CD B-Disease 0 6.5480594280131754e-09
mutations O 0 4.090837446568685e-09
identified O 0 3.2593423515692166e-09
in O 0 2.7903193644540636e-10
this O 0 8.444819288300209e-10
exon O 0 7.249412448118164e-08
. O 0 4.51317816896335e-07

Seven O 0 4.592993718688376e-07
of O 0 1.3180228108922165e-07
30 O 0 8.024200326417485e-08
( O 0 1.3786872754550927e-09
23 O 0 3.227164668828664e-08
% O 0 2.44567255336392e-10
) O 0 3.345239016350199e-12
were O 0 8.825845436433166e-12
within O 0 1.3588093150662672e-10
the O 0 7.586697936545761e-10
core O 0 1.0082831458646524e-08
motif O 0 4.910222450860147e-09
, O 0 6.033602784061287e-11
the O 0 2.3050815423086846e-10
majority O 0 8.175368715335196e-11
( O 0 4.388095442564577e-11
five O 0 9.155965430274193e-10
of O 0 3.1980205150716756e-09
seven O 0 1.1245180342456251e-09
) O 0 2.6772572006561468e-11
of O 0 7.670009627425145e-10
which O 0 1.0079076462332637e-09
were O 0 4.368875039517661e-09
missense O 0 5.238784410721564e-07
mutations O 0 1.0615667633828707e-07
, O 0 2.627200235139071e-09
possibly O 0 1.444263020289327e-08
pointing O 0 3.930312075794973e-08
to O 0 5.916780954073886e-10
the O 0 3.5069431802980944e-09
functional O 0 4.4350034755780143e-08
significance O 0 4.621729843279354e-08
of O 0 5.227323018885954e-09
this O 0 2.462374304457171e-09
region O 0 1.2409682881298068e-07
. O 0 4.857788553636055e-07

Germline O 0 0.001287834718823433
PTEN O 0 0.0004694787785410881
mutations O 0 4.088648495326197e-07
were O 0 4.86140105948607e-09
identified O 0 9.79976877424349e-10
in O 0 6.820451842193265e-11
four O 0 1.944378547058534e-10
of O 0 1.9705026499394762e-09
seven O 0 2.4889730276811406e-09
( O 0 1.4610972431938762e-09
57 O 0 2.301872825682949e-07
% O 0 9.309881754404614e-09
) O 0 1.3353804728666319e-09
BZS B-Disease 0 2.976621181005612e-05
families O 0 1.6665461899378897e-08
studied O 0 1.4351358856856677e-07
. O 0 2.0530646338556835e-07

Interestingly O 0 1.0769177833935828e-06
, O 0 8.666136253054901e-09
none O 0 1.7581868405613932e-08
of O 0 2.4972754975038924e-09
these O 0 6.022143339556862e-10
mutations O 0 1.8734981566126407e-08
was O 0 1.1248467934876771e-08
observed O 0 1.3582218683083624e-09
in O 0 2.894077755222213e-10
the O 0 1.7315592515387834e-08
PTPase O 0 1.1388517123123165e-05
core O 0 1.2974862784176366e-06
motif O 0 1.3184014733269578e-06
. O 0 2.078185019627199e-07

It O 0 3.5487165206404825e-08
is O 0 1.3678644883441393e-09
also O 0 1.8828065495579693e-10
worthy O 0 1.65780242866731e-08
of O 0 2.1875929956394202e-09
note O 0 2.072783722439908e-09
that O 0 1.1585218895326932e-10
a O 0 1.3497279960361652e-09
single O 0 1.4745411558436672e-09
nonsense O 0 2.3147503469544972e-08
point O 0 2.3430992257544858e-08
mutation O 0 8.717424559989695e-10
, O 0 2.5322646757253153e-10
R233X O 0 2.1796305205157296e-08
, O 0 4.949770038287227e-10
was O 0 2.1148554019134735e-09
observed O 0 6.344838543448361e-10
in O 0 1.1630762325465227e-10
the O 0 3.786170932329469e-09
germline O 0 8.762743419765684e-08
DNA O 0 3.309850171717699e-08
from O 0 9.575135351269637e-09
two O 0 9.59853641013808e-10
unrelated O 0 5.2875188671919204e-09
CD B-Disease 0 3.825210370678178e-08
families O 0 1.1636869245990056e-09
and O 0 1.7550700892599025e-09
one O 0 3.547024718386638e-08
BZS B-Disease 0 0.00042847709846682847
family O 0 9.540663086227141e-07
. O 0 1.4774240071346867e-06

Genotype O 0 5.188892941987433e-07
- O 0 3.018560619238997e-07
phenotype O 0 7.252053535466985e-08
studies O 0 5.152871906943801e-09
were O 0 1.7039972211030374e-10
not O 0 4.4027833462356725e-11
performed O 0 9.251616833738652e-11
on O 0 5.759437926577959e-10
this O 0 9.899255720702271e-11
small O 0 1.111563285860484e-09
group O 0 7.292619286225488e-10
of O 0 3.6958009985710305e-08
BZS B-Disease 0 0.001965939300134778
families O 0 3.0396716965697124e-07
. O 0 7.041208505143004e-07

However O 0 1.6137637715019082e-07
, O 0 7.759774156568255e-09
genotype O 0 2.2849826919468796e-08
- O 0 3.7726426427298065e-08
phenotype O 0 1.6778656686256e-08
analysis O 0 3.1809805900451238e-09
inthe O 0 5.5213462246683775e-08
group O 0 7.593964901353445e-10
of O 0 1.6633697752510557e-09
CD B-Disease 0 1.49946529859335e-07
families O 0 6.762543414140509e-09
revealed O 0 6.724869106022879e-09
two O 0 1.0139152711863275e-10
possible O 0 7.796086554101578e-10
associations O 0 8.01041399878244e-10
worthy O 0 6.152167486561666e-08
of O 0 1.5417619181334885e-08
follow O 0 7.552915626263257e-09
- O 0 5.39935962606819e-09
up O 0 1.6227658106160447e-09
in O 0 5.503141276008705e-10
independent O 0 7.546033131689e-09
analyses O 0 9.127116840090821e-08
. O 0 2.359234940740862e-07

The O 0 1.6238044509009342e-07
first O 0 1.736023946818932e-08
was O 0 2.0742163542308845e-08
an O 0 2.7435825833421745e-10
association O 0 8.516509164557817e-10
noted O 0 6.691129872393731e-09
in O 0 2.6660429419678167e-10
the O 0 4.035350720243969e-09
group O 0 9.408589185522231e-11
of O 0 1.4832459704905432e-09
CD B-Disease 0 8.260314643848687e-06
families O 0 1.8442979410338012e-07
with O 0 1.06177736824975e-07
breast B-Disease 0 0.0002415865455986932
disease I-Disease 0 0.003870199667289853
. O 0 3.0023909403098514e-07

A O 0 9.423443430023326e-07
correlation O 0 1.5261682051459502e-07
was O 0 9.613822626874935e-09
observed O 0 5.096441602070456e-10
between O 0 6.640069050156683e-10
the O 0 6.202602320648509e-10
presence O 0 8.522672345634419e-09
/ O 0 4.227706540405052e-08
absence O 0 5.182631923617009e-08
of O 0 6.436687183253298e-09
a O 0 1.0510134096364254e-08
PTEN O 0 3.963257313444046e-06
mutation O 0 3.3372336005754732e-09
and O 0 2.1643294101370003e-10
the O 0 2.856293812580901e-10
type O 0 3.541135162876685e-09
of O 0 6.2626144270439e-09
breast O 0 1.8119580147413217e-07
involvement O 0 1.5594308422350878e-07
( O 0 6.062034429987762e-08
unaffected O 0 6.229072459973395e-05
versus O 0 1.4220436241885182e-05
benign O 0 0.0023245092015713453
versus O 0 7.250875114550581e-06
malignant O 0 2.2800973056291696e-06
) O 0 1.5269886688429324e-08
. O 0 1.0358468216509209e-07

Specifically O 0 4.9326406070804296e-08
and O 0 2.9789275490799128e-09
more O 0 3.1942146150321094e-10
directly O 0 8.246729521488305e-09
, O 0 8.637578152725922e-11
an O 0 1.0612049433644799e-10
association O 0 5.042930517618061e-10
was O 0 1.3184395797338766e-08
also O 0 1.7736417889935296e-10
observed O 0 3.9291686571019113e-10
between O 0 1.6966805738150015e-10
the O 0 7.222589193389695e-10
presence O 0 3.735315168285069e-09
of O 0 6.450969092242076e-09
a O 0 4.3397594851057875e-08
PTEN O 1 0.9996206760406494
mutation O 0 2.1440286218421534e-05
and O 0 6.880808996356791e-06
malignant B-Disease 1 0.9999984502792358
breast I-Disease 1 0.9045665264129639
disease I-Disease 0 0.008975732140243053
. O 0 2.0475683015774848e-07

Secondly O 0 6.346039754134836e-06
, O 0 4.254376406720439e-08
there O 0 6.595615609228389e-09
appeared O 0 1.0663963045942637e-08
to O 0 2.335324711388864e-10
be O 0 3.3632394091931417e-10
an O 0 2.051959047122409e-09
interdependent O 0 1.942731415738308e-07
association O 0 3.028288375617194e-08
between O 0 9.672498890722636e-08
mutations O 0 3.0206620067474432e-06
upstream O 0 2.1860148535779445e-06
and O 0 1.2906022917036353e-09
within O 0 8.082597702241401e-09
the O 0 3.6010135318065295e-08
PTPase O 0 3.4562851851660525e-06
core O 0 1.5604646819156187e-07
motif O 0 8.59922479889974e-08
, O 0 5.91781901260191e-10
the O 0 2.0037298487096677e-09
core O 0 3.600134590442394e-08
motif O 0 8.429262621234557e-09
containing O 0 3.1853444881768667e-10
the O 0 5.063846009178974e-10
majority O 0 3.178268204173662e-10
of O 0 7.609236796213281e-09
missense O 0 2.489020118900953e-07
mutations O 0 1.7964103093959238e-08
, O 0 4.6083631355386956e-10
and O 0 9.705158204864617e-11
the O 0 4.3956618900331534e-10
involvement O 0 2.302130042153294e-09
of O 0 5.893177057458843e-09
all O 0 4.855097435196853e-10
major O 0 1.1698096713530504e-08
organ O 0 4.738813856874913e-07
systems O 0 1.2131539506299305e-06
( O 0 2.66817696825683e-08
central O 0 5.760790372733027e-06
nervous O 0 3.3334933959849877e-06
system O 0 1.4139055565465242e-05
, O 0 6.723639955907856e-08
thyroid O 0 0.00017291383119300008
, O 0 2.206203220112002e-07
breast O 0 0.0006263508112169802
, O 0 2.2715430247899349e-07
skin O 1 0.9999955892562866
and O 0 1.5706376871094108e-05
gastrointestinal O 1 1.0
tract O 0 0.021476326510310173
) O 0 2.3618996536356462e-08
. O 0 3.833844743894588e-07

However O 0 6.530549967465049e-07
, O 0 4.805873032864838e-09
these O 0 1.1210680161966025e-09
observations O 0 1.7867090917889072e-08
would O 0 1.7065210355937666e-10
need O 0 3.1486305229755374e-10
to O 0 6.60054566559154e-10
be O 0 7.044735905736843e-10
confirmed O 0 3.247365931713375e-09
by O 0 3.0984792509514136e-10
studying O 0 6.076371628083166e-10
a O 0 6.17905449029621e-11
larger O 0 2.460410764015819e-10
number O 0 4.956874355421803e-10
of O 0 2.649968022794269e-09
CD B-Disease 0 4.770181476487778e-07
families O 0 5.03899322268353e-08
. O 0 3.990942332166014e-07

Molecular O 0 0.0004746164777316153
defects O 1 0.9996813535690308
leading O 0 8.409800784647814e-07
to O 0 1.0607238420945464e-09
human O 0 9.32319110802382e-09
complement B-Disease 0 5.90456636473391e-07
component I-Disease 1 0.9995421171188354
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.000632461564351e-10
an O 0 4.4589518188864474e-10
African O 0 3.70196318044691e-10
- O 0 7.738840679394343e-10
American O 0 3.2278646422412294e-09
family O 0 9.265364475652405e-09
. O 0 7.996911932650619e-08

Complement B-Disease 0 5.533303010452073e-06
component I-Disease 1 0.72647625207901
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.505807555370666e-08
C6D B-Disease 0 0.0014963854337111115
) O 0 3.6819783333363887e-10
was O 0 5.303123717936842e-09
diagnosed O 0 1.0729203081538685e-09
in O 0 8.30984794863987e-11
a O 0 2.900322204624217e-10
16 O 0 1.4952727944717026e-09
- O 0 2.7050378603732383e-10
year O 0 5.402210900840032e-10
- O 0 4.313850110460038e-10
old O 0 9.743561513175791e-09
African O 0 9.77339320584747e-10
- O 0 7.640558741250913e-10
American O 0 1.6078317843781775e-10
male O 0 1.403853006065603e-10
with O 0 4.3740067123820836e-11
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 7.005468205534271e-08

The O 0 1.0050175092146674e-07
patients O 0 1.201845822862424e-08
father O 0 8.552753882895558e-08
and O 0 3.137828441523993e-09
two O 0 3.67705377257721e-09
brothers O 0 9.376087461987481e-08
also O 0 9.923028621017238e-09
had O 0 9.193787064987191e-09
C6D B-Disease 0 0.000803699076641351
, O 0 7.386636857731332e-10
but O 0 5.819108528370975e-10
gave O 0 2.8793014639205694e-09
no O 0 9.346725615699825e-10
history O 0 6.154430742810746e-09
of O 0 2.0814571399796478e-08
meningitis B-Disease 1 1.0
or O 0 5.93317039943031e-09
other O 0 5.6097038125813015e-09
neisserial B-Disease 0 1.439123025193112e-05
infection I-Disease 0 5.154236077942187e-07
. O 0 8.208599666659211e-08

By O 0 2.4954532662491147e-08
using O 0 7.354236775114487e-09
exon O 0 3.051416896937553e-08
- O 0 8.161183728816468e-09
specific O 0 7.724064721159607e-10
polymerase O 0 5.708181927133182e-09
chain O 0 1.2467031851315369e-08
reaction O 0 7.40318562009179e-09
( O 0 3.2708119546143166e-10
PCR O 0 2.266387078009302e-09
) O 0 1.4233247913608693e-10
/ O 0 3.063350684229249e-10
single O 0 2.238469687387834e-10
- O 0 4.87577367369596e-10
strand O 0 5.238669498197623e-10
conformation O 0 1.846474362299233e-10
polymorphism O 0 6.077481573552035e-11
as O 0 2.0237320152993732e-10
a O 0 1.2342614430504995e-10
screening O 0 6.236348243371381e-11
step O 0 4.737322201187055e-10
and O 0 1.387111397965768e-10
nucleotide O 0 1.421548434521469e-09
sequencing O 0 2.3381068192662724e-09
of O 0 4.986938417772535e-09
target O 0 2.0222097774080794e-08
exons O 0 2.524300590778239e-08
, O 0 1.8875969676201976e-09
we O 0 2.7775862165846377e-10
determined O 0 1.0489420443349218e-09
that O 0 2.3757862344098157e-10
the O 0 4.204423920128875e-09
proband O 0 1.2222420764373965e-06
was O 0 1.2861133491526289e-08
a O 0 9.413045898298833e-10
compound O 0 1.9149295482634443e-08
heterozygote O 0 8.239578050961427e-07
for O 0 4.350000359920614e-09
two O 0 3.9779688876251384e-08
C6 O 0 4.879734478890896e-05
gene O 0 7.633551604158129e-07
mutations O 0 4.233809249853948e-06
. O 0 1.9352160052221734e-06

The O 0 3.5158765854248486e-07
first O 0 3.5850732160724874e-08
, O 0 3.830523898074034e-09
1195delC O 0 1.07327537079982e-07
located O 0 9.02150265602586e-09
in O 0 7.022117887167667e-10
exon O 0 3.361716238714507e-08
7 O 0 1.1398348220836851e-07
, O 0 1.0657755789011958e-09
is O 0 1.2267299676071985e-10
a O 0 1.3920251062948807e-10
novel O 0 4.709412304571003e-10
mutation O 0 1.6112518264055353e-10
, O 0 4.665938815873183e-11
while O 0 2.352909256320146e-10
the O 0 2.856093805903015e-09
second O 0 1.2833419660296386e-08
, O 0 1.801188642680529e-09
1936delG O 0 2.1569343644500805e-08
in O 0 1.3517788000072528e-09
exon O 0 1.0697944752280364e-08
12 O 0 3.158835326644294e-08
, O 0 3.790000313586006e-09
has O 0 7.732319229347695e-10
been O 0 3.2688970974525944e-10
described O 0 4.3400863458664674e-10
before O 0 3.730621089825803e-10
to O 0 5.186354679054261e-10
cause O 0 4.303696528040746e-07
C6D B-Disease 0 0.04028225317597389
in O 0 6.796314622192767e-10
an O 0 3.4767308476624237e-10
unrelated O 0 6.434612842554088e-09
African O 0 1.546234584814954e-09
- O 0 1.8289459946529973e-09
American O 0 8.734184486769436e-10
individual O 0 6.175078226533515e-09
. O 0 1.2593163489782455e-07

Both O 0 2.9250582400663916e-08
mutations O 0 1.0789526072585431e-07
result O 0 2.8580840805148e-08
in O 0 2.0797139566042233e-09
premature O 0 4.653968801449082e-07
termination O 0 5.455427753986442e-07
codons O 0 1.1798528021245147e-06
and O 0 1.211616762475387e-07
C6 O 0 0.0001431381970178336
null O 0 6.036183094693115e-06
alleles O 0 3.7738809055554157e-07
. O 0 7.32153125682089e-07

Allele O 0 2.1704049402160308e-07
- O 0 3.6909614919977685e-08
specific O 0 3.6714753459676785e-09
PCR O 0 2.2802895571771842e-08
indicated O 0 3.771165602017845e-09
that O 0 7.843662525042205e-11
the O 0 5.418163695480871e-10
probands O 0 3.2285504403262166e-07
two O 0 5.111484568942615e-09
brothers O 0 6.52075442530986e-08
also O 0 2.3490538403336814e-09
inherited O 0 3.429851602732015e-08
the O 0 2.4964041944741666e-09
1195delC O 0 1.4135002501802774e-08
mutation O 0 2.8509597460590896e-10
from O 0 1.4672683901206796e-10
their O 0 1.4346193677461372e-10
heterozygous O 0 6.232213634049799e-10
mother O 0 1.6346232145636463e-09
and O 0 1.6989604167960692e-10
the O 0 8.17343970282991e-10
1936delG O 0 1.1219991158384346e-08
mutation O 0 7.127505252668698e-10
from O 0 6.523771522992661e-10
their O 0 1.6941559266570039e-09
homozygous O 0 2.182630076674741e-08
father O 0 5.220989010013e-07
. O 0 3.1474446160473235e-08
. O 0 2.376115730839956e-07

PAX6 O 0 0.005128353368490934
mutations O 0 4.526290649664588e-05
reviewed O 0 1.495306241849903e-05
. O 0 5.465480626298813e-06

Mutations O 0 2.7656526526698144e-06
in O 0 2.404009933343332e-07
PAX6 O 0 0.0010861988412216306
are O 0 3.247719204679811e-09
responsible O 0 3.2363227653320337e-09
for O 0 5.213221521138678e-10
human O 0 5.046380024964492e-08
aniridia B-Disease 1 1.0
and O 0 1.4057301989112148e-08
have O 0 1.7420588582783836e-10
also O 0 8.386404071192288e-11
been O 0 4.381171120337868e-11
found O 0 2.171601960754277e-11
in O 0 1.4984831084308148e-11
patients O 0 3.663112868590446e-11
with O 0 8.953165292480136e-11
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.414167437654214e-08
with O 0 3.633468566022202e-07
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 3.049026133794541e-07
with O 0 1.875721356014992e-09
autosomal B-Disease 0 1.7153186490759254e-05
dominant I-Disease 0 0.11332542449235916
keratitis I-Disease 1 1.0
, O 0 4.547107135266515e-09
and O 0 6.523174223005412e-10
with O 0 2.447675617744949e-09
isolated B-Disease 1 0.9999948740005493
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0013681210111826658

No O 0 2.5407973680557916e-07
locus O 0 6.105490513164114e-08
other O 0 1.9598089817662867e-09
than O 0 1.0505137870708836e-09
chromosome O 0 4.336706282970226e-08
11p13 O 0 2.72196018613613e-07
has O 0 1.8110685173766683e-09
been O 0 6.987607159558706e-10
implicated O 0 1.472309718586473e-09
in O 0 1.040981634226057e-09
aniridia B-Disease 1 1.0
, O 0 2.890190309301488e-09
and O 0 2.227320994308002e-09
PAX6 O 0 3.401171125005931e-05
is O 0 9.32638855033474e-10
clearly O 0 3.0128122219252873e-09
the O 0 4.0384997568310155e-09
major O 0 9.737767925344087e-08
, O 0 1.3615444327541582e-09
if O 0 1.9832284703369396e-09
not O 0 9.094752173588461e-10
only O 0 4.600917868913257e-09
, O 0 1.8374671784116003e-09
gene O 0 1.3468638648816977e-08
responsible O 0 2.0829710933867318e-07
. O 0 1.4711589528815239e-06

Twenty O 0 9.222335393133108e-06
- O 0 1.2696278872681432e-07
eight O 0 3.1095300556671646e-08
percent O 0 4.516232721130109e-09
of O 0 7.784451971915018e-10
identified O 0 4.16113588030953e-09
PAX6 O 0 1.8641467249835841e-06
mutations O 0 9.364112685261716e-08
are O 0 4.3277550432208045e-09
C O 0 1.710511241981294e-05
- O 0 8.794361292530084e-07
T O 0 5.553093274102139e-07
changes O 0 4.137859388464449e-09
at O 0 7.250930522673116e-09
CpG O 0 1.6682889736330253e-08
dinucleotides O 0 2.391323903339071e-07
, O 0 6.123129780988279e-10
20 O 0 2.013491373631382e-09
% O 0 1.789790676776093e-10
are O 0 8.099839375608209e-12
splicing O 0 2.023389455985125e-09
errors O 0 4.427320732247608e-08
, O 0 6.516794326394404e-10
and O 0 1.0196130745265819e-10
more O 0 7.304490345916292e-11
than O 0 4.811903306367604e-11
30 O 0 1.4580627816229708e-09
% O 0 1.5600294667184045e-10
are O 0 6.6722326448609426e-12
deletion O 0 1.5211731874131829e-10
or O 0 3.5634994954847343e-10
insertion O 0 5.957040194459751e-09
events O 0 4.677047726886485e-08
. O 0 1.373226155010343e-06

There O 0 8.406482976397456e-08
is O 0 4.001717623935974e-09
a O 0 3.9726137934792405e-09
noticeably O 0 3.1124500310397707e-07
elevated O 0 1.1391360033030651e-07
level O 0 3.787977043145929e-09
of O 0 4.98111774049903e-10
mutation O 0 4.476608805870086e-10
in O 0 1.807651112128994e-10
the O 0 2.9502482679077957e-09
paired O 0 2.595473169719753e-09
domain O 0 1.1756066120582886e-09
compared O 0 3.2349137257803307e-10
with O 0 9.181664109569887e-12
the O 0 2.7850660666572935e-10
rest O 0 2.091464779141461e-09
of O 0 1.2944332272724068e-09
the O 0 8.685033137112441e-09
gene O 0 8.487846514526609e-08
. O 0 9.299233738602197e-07

Increased O 0 1.878927520237994e-07
mutation O 0 1.9110764526431012e-08
in O 0 1.253674941636973e-09
the O 0 4.891993476974221e-09
homeodomain O 0 8.560224955544982e-07
is O 0 5.298227967465152e-10
accounted O 0 1.1719842873958441e-09
for O 0 2.832464991719963e-11
by O 0 2.9394287004436137e-10
the O 0 1.496968593528436e-08
hypermutable O 0 2.0908371425321093e-06
CpG O 0 2.3315178054872376e-07
dinucleotide O 0 2.4179109914257424e-07
in O 0 1.447467568027605e-08
codon O 0 8.979392873698089e-07
240 O 0 1.2018990958040376e-07
. O 0 1.8673178203698626e-07

Very O 0 1.5115472251636675e-07
nearly O 0 5.4106720881463843e-08
all O 0 6.881833436445106e-10
mutations O 0 3.546150262323522e-09
appear O 0 3.36572936188162e-10
to O 0 2.9547277818897655e-11
cause O 0 4.453539759197156e-09
loss O 0 2.5405482162454973e-09
of O 0 1.3574682489192469e-09
function O 0 9.928040611839606e-10
of O 0 3.4498410794725487e-09
the O 0 1.4124268421511488e-09
mutant O 0 3.413833438159486e-09
allele O 0 1.0479062062529465e-09
, O 0 8.453114597184452e-11
and O 0 1.7456367948365248e-11
more O 0 6.0632597033427604e-12
than O 0 1.4934926559351247e-11
80 O 0 8.738033629995812e-10
% O 0 1.0642414033368297e-10
of O 0 2.2914092845383038e-10
exonic O 0 5.044253370556362e-08
substitutions O 0 3.622532718239313e-09
result O 0 8.567459630626217e-09
in O 0 5.070613706692484e-09
nonsense O 0 7.200724780886958e-07
codons O 0 2.3306981802306836e-06
. O 0 1.5531170447502518e-06

In O 0 6.289226917033375e-08
a O 0 1.6563959093218728e-08
gene O 0 7.414971303632001e-09
with O 0 4.305917011837579e-10
such O 0 7.063424289910358e-10
extraordinarily O 0 1.0501641156679398e-07
high O 0 2.6300190469896734e-08
sequence O 0 1.5791180585367215e-09
conservation O 0 9.416910806692158e-09
throughout O 0 4.0330938588795107e-10
evolution O 0 9.450594973259285e-09
, O 0 2.741406546213909e-10
there O 0 5.439141914642676e-10
are O 0 5.488937082631651e-10
presumed O 0 6.265687488848926e-07
undiscovered O 0 2.0324800971138757e-06
missense O 0 2.2469230032129417e-07
mutations O 0 4.592686764226528e-08
, O 0 1.1631743346285361e-09
these O 0 7.362752629802571e-10
are O 0 2.245140184875538e-10
hypothesized O 0 6.6510748020220944e-09
to O 0 3.6885999810110093e-10
exist O 0 7.599794571433449e-09
in O 0 3.6418892346290477e-09
as O 0 2.9266040257880377e-08
- O 0 2.030314405487843e-08
yet O 0 3.4410565064035836e-08
unidentified O 0 9.868217603070661e-07
phenotypes O 0 3.025471642104094e-07
. O 0 1.9752636859493578e-08
. O 0 1.305572538967681e-07

Genetic O 0 1.5170479628068279e-06
heterogeneity O 0 2.9356638151512016e-06
and O 0 1.655483039542105e-08
penetrance O 0 8.428604587606969e-07
analysis O 0 3.4187921382766717e-09
of O 0 4.127297170697375e-09
the O 0 1.2300065854731201e-08
BRCA1 O 0 4.650286768992373e-07
and O 0 6.25754239536036e-08
BRCA2 O 0 1.0920828117377823e-06
genes O 0 1.2838444263252313e-07
in O 0 2.7149081205379844e-08
breast B-Disease 0 3.1533177207165863e-06
cancer I-Disease 0 2.0944794414390344e-06
families O 0 2.3372653146225275e-08
. O 0 1.1077334249876003e-07

The O 0 0.00010413514246465638
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 8.948823051468935e-06
Consortium O 0 2.443456139644695e-07
. O 0 3.102616474848219e-08

The O 0 3.977354268158706e-08
contribution O 0 7.00930442576464e-08
of O 0 9.88560913128822e-08
BRCA1 O 0 2.039129640252213e-06
and O 0 1.8277688695889083e-07
BRCA2 O 0 0.00024358210794162005
to O 0 8.365469739146647e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 1.8167851223438447e-08
assessed O 0 7.855988637395228e-10
by O 0 2.4779667900931557e-11
linkage O 0 1.6571764405171052e-08
and O 0 8.705423187871375e-11
mutation O 0 9.046943749702052e-11
analysis O 0 8.613196961215763e-11
in O 0 2.6410139700172586e-11
237 O 0 4.6517767415821254e-10
families O 0 8.142253538068189e-11
, O 0 3.6880071913047985e-11
each O 0 3.729630146387386e-11
with O 0 4.399719477632402e-11
at O 0 1.2466383481068988e-09
least O 0 1.002875782418755e-09
four O 0 3.029423378819729e-10
cases O 0 5.7238271899962e-09
of O 0 8.896543590708461e-08
breast B-Disease 0 3.159917696393677e-07
cancer I-Disease 0 6.586931533547613e-08
, O 0 1.9464489742215818e-10
collected O 0 9.73477076726681e-10
by O 0 9.201361339528091e-10
the O 0 4.4709389612762607e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 6.892624355714361e-07
Consortium O 0 2.741236748704523e-08
. O 0 5.0407329865720385e-08

Families O 0 2.987339087212604e-08
were O 0 1.375456637475736e-09
included O 0 7.172779037389887e-11
without O 0 2.800417953086054e-10
regard O 0 1.2659124859482063e-09
to O 0 5.96722324330834e-11
the O 0 7.376302901818121e-10
occurrence O 0 2.935754253030609e-07
of O 0 3.710259477429645e-07
ovarian B-Disease 1 0.9999575614929199
or I-Disease 0 2.452388343954226e-06
other I-Disease 0 2.8847651378782757e-07
cancers I-Disease 0 0.010117944329977036
. O 0 3.074065659802727e-07

Overall O 0 2.0480678358580917e-05
, O 0 3.808168713703708e-08
disease O 0 8.23157279228326e-06
was O 0 3.467475906404616e-08
linked O 0 5.199500829888848e-09
to O 0 3.8462477647271953e-10
BRCA1 O 0 4.530675390412853e-09
in O 0 8.681248081510162e-11
an O 0 4.99152039146189e-11
estimated O 0 9.418320984222461e-11
52 O 0 4.17354956150362e-10
% O 0 2.452589520363091e-11
of O 0 8.491898156881561e-11
families O 0 3.5184113955644136e-10
, O 0 1.727289145048161e-10
to O 0 1.3491077144323071e-09
BRCA2 O 0 7.912671406984373e-09
in O 0 1.9092090408623363e-10
32 O 0 5.020130977584358e-09
% O 0 2.258088299678107e-10
of O 0 1.1480731643143116e-10
families O 0 2.6734620073298743e-10
, O 0 1.0767349511997537e-10
and O 0 5.863460411648092e-11
to O 0 3.12759762532977e-10
neither O 0 4.3894559098589525e-09
gene O 0 7.14168502113921e-10
in O 0 1.0832571506469435e-09
16 O 0 7.859589423730995e-09
% O 0 6.154802778546298e-10
( O 0 2.5303804190857093e-11
95 O 0 3.50503048807127e-09
% O 0 8.688342822971151e-10
confidence O 0 5.217889675890319e-09
interval O 0 3.781366331168101e-08
[ O 0 1.417328974184784e-07
CI O 0 3.248946541134501e-06
] O 0 6.47812257170699e-08
6 O 0 7.265857959737332e-08
% O 0 8.294084530291457e-09
- O 0 2.4567541334619136e-09
28 O 0 2.6169638900341852e-08
% O 0 1.309284569650515e-09
) O 0 4.694352198630902e-11
, O 0 5.8788911239116e-11
suggesting O 0 2.0776760312202214e-09
other O 0 1.938417870661624e-09
predisposition O 0 1.4489569366560318e-05
genes O 0 9.27310850329377e-07
. O 0 1.4990193903940963e-06

The O 0 4.894432095170487e-07
majority O 0 2.5028942474136784e-08
( O 0 3.6121143853762305e-09
81 O 0 8.174959731377385e-08
% O 0 7.692777526102645e-10
) O 0 1.3239286403288197e-11
of O 0 1.0128565763878328e-09
the O 0 3.327066622205166e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.6471793646010155e-09
were O 0 2.550907401976943e-11
due O 0 1.8849877214677235e-10
to O 0 1.0564106533994533e-10
BRCA1 O 0 1.98469285450642e-09
, O 0 6.603388669201848e-11
with O 0 4.626932951362628e-12
most O 0 1.4229908917862133e-10
others O 0 2.1516562143109041e-10
( O 0 8.99059021675086e-11
14 O 0 5.924599033590994e-09
% O 0 1.3299079615336495e-09
) O 0 3.4455435032887394e-11
due O 0 3.4438911722389776e-09
to O 0 2.7651193335032076e-08
BRCA2 O 0 9.548924936098047e-06
. O 0 7.445187293342315e-07

Conversely O 0 3.794390011080395e-07
, O 0 1.2646141911432096e-09
the O 0 5.986092177501234e-10
majority O 0 1.1201035238217472e-10
of O 0 5.477056586045137e-10
families O 0 2.1425849983103262e-10
with O 0 1.7818814479486633e-10
male B-Disease 0 7.16250880827829e-08
and I-Disease 0 5.98545852881216e-08
female I-Disease 0 9.448387459087826e-07
breast I-Disease 0 4.986516614735592e-06
cancer I-Disease 1 0.65290766954422
were O 0 5.859105645100726e-09
due O 0 1.4037903284247477e-08
to O 0 7.3520070031918294e-09
BRCA2 O 0 1.621471028556698e-07
( O 0 2.4425828026863883e-09
76 O 0 8.050752597910105e-08
% O 0 3.3367242302517752e-09
) O 0 6.011722231136218e-10
. O 0 1.790892056874327e-08

The O 0 1.0865960575756617e-07
largest O 0 9.938222689243048e-08
proportion O 0 4.341887205328021e-08
( O 0 3.451774421847631e-10
67 O 0 4.1399514927320524e-09
% O 0 1.0943274758590249e-10
) O 0 8.744755679128413e-13
of O 0 3.418534205712476e-11
families O 0 5.016086157549893e-11
due O 0 6.959688381158458e-10
to O 0 1.6558225623963807e-10
other O 0 9.562592939715842e-10
genes O 0 2.0345773954488777e-09
was O 0 1.781685132762334e-09
found O 0 2.2066161398104356e-11
in O 0 2.550727511152484e-11
families O 0 9.143291679336585e-11
with O 0 4.105223452843809e-11
four O 0 2.469032478469302e-10
or O 0 1.123569917660383e-10
five O 0 8.2267533063618e-11
cases O 0 4.839056932937069e-10
of O 0 5.645202350024192e-08
female O 0 7.236795681819785e-06
breast B-Disease 0 5.61028082302073e-06
cancer I-Disease 0 1.7907608480527415e-06
only O 0 3.661672565158369e-08
. O 0 2.362058069138584e-07

These O 0 8.165033449358816e-08
estimates O 0 4.3315563402757107e-07
were O 0 3.1377567211166024e-09
not O 0 1.8790359546105861e-10
substantially O 0 7.166837789895908e-09
affected O 0 5.932216939896762e-10
either O 0 1.924715525847276e-10
by O 0 1.2858275555416299e-10
changing O 0 4.044643731049291e-09
the O 0 1.9002657225541952e-09
assumed O 0 5.10732345304632e-09
penetrance O 0 2.8539007601580124e-08
model O 0 3.825610050967043e-09
for O 0 1.4108678669799701e-09
BRCA1 O 0 6.248058959101854e-09
or O 0 4.722994773054268e-10
by O 0 1.7209161873310563e-10
including O 0 1.9649430693657877e-10
or O 0 6.936976326699096e-09
excluding O 0 1.0131105909749749e-07
BRCA1 O 0 8.655023009396245e-08
mutation O 0 1.6010396564070106e-08
data O 0 1.1151765022532345e-07
. O 0 3.6817158388657845e-07

Among O 0 2.203166538095047e-08
those O 0 2.548220745524077e-09
families O 0 1.5460547286849646e-09
with O 0 8.830396136527696e-11
disease O 0 4.974647893618567e-08
due O 0 4.254893326560705e-09
to O 0 5.968410210499542e-10
BRCA1 O 0 1.4887652000084017e-08
that O 0 2.539190524508683e-10
were O 0 1.0294578384195674e-10
tested O 0 3.2070637812076086e-11
by O 0 1.5042878401261284e-11
one O 0 2.1547774675667597e-10
of O 0 5.099173860934059e-10
the O 0 5.649085088599293e-10
standard O 0 2.2825759338207519e-10
screening O 0 7.053457817818298e-11
methods O 0 1.7204707658535767e-09
, O 0 3.384146018969858e-10
mutations O 0 3.0660178840236085e-09
were O 0 7.127151646635355e-10
detected O 0 1.7676715646786079e-09
in O 0 1.6169934835552624e-10
the O 0 2.4995534531058183e-09
coding O 0 1.8089600928306027e-08
sequence O 0 9.733531314282118e-09
or O 0 5.152449134016024e-09
splice O 0 6.943001551462658e-08
sites O 0 5.151859383545343e-09
in O 0 1.89883359036358e-10
an O 0 3.202651754907748e-10
estimated O 0 8.952418806273954e-10
63 O 0 4.708911482964595e-09
% O 0 1.9058872535726579e-10
( O 0 3.855750094206023e-11
95 O 0 8.786890326462071e-09
% O 0 1.3483746341691472e-09
CI O 0 6.41435988768535e-08
51 O 0 8.908545012786817e-09
% O 0 1.186740483660742e-09
- O 0 1.0472348543899557e-09
77 O 0 7.254430389735944e-09
% O 0 9.364248265697483e-10
) O 0 1.647486869149617e-10
. O 0 1.197719878831549e-08

The O 0 5.507620315370332e-08
estimated O 0 1.9133741702148654e-08
sensitivity O 0 2.473739435515654e-08
was O 0 3.7024594501389174e-09
identical O 0 2.0860176086490156e-10
for O 0 2.2717166689445456e-11
direct O 0 6.770179972193091e-10
sequencing O 0 6.205418401350471e-10
and O 0 3.7560887733434356e-10
other O 0 5.087244514534461e-10
techniques O 0 1.0928125959708268e-07
. O 0 5.043301030127623e-07

The O 0 5.356818633117655e-07
penetrance O 0 9.093687549466267e-05
of O 0 2.4071673578873742e-06
BRCA2 O 0 1.5766306660225382e-06
was O 0 2.604251747584385e-08
estimated O 0 4.0195469175330345e-10
by O 0 6.218733167306922e-11
maximizing O 0 7.296522142041795e-08
the O 0 2.1020637674951104e-08
LOD O 0 9.544019849272445e-05
score O 0 1.0075164880163356e-07
in O 0 1.5323454505278278e-08
BRCA2 O 0 1.8480851338154025e-07
- O 0 2.0983904391869146e-08
mutation O 0 3.510583823640445e-09
families O 0 9.902093589531091e-10
, O 0 1.2390614922974663e-10
over O 0 1.0043205156406998e-10
all O 0 1.6076508180251636e-10
possible O 0 1.5274897791073272e-08
penetrance O 0 3.1282115742214955e-06
functions O 0 1.074465387773671e-07
. O 0 3.5488187677401584e-07

The O 0 3.4080382960155475e-08
estimated O 0 2.7712600214613303e-08
cumulative O 0 2.2339811778238072e-07
risk O 0 1.1574302050121332e-07
of O 0 1.1604298322254181e-07
breast B-Disease 0 2.0922891508234898e-06
cancer I-Disease 0 1.2408717111611622e-06
reached O 0 1.0373039316391441e-07
28 O 0 2.0970540859366338e-08
% O 0 2.355127204367591e-10
( O 0 1.5543852663335578e-11
95 O 0 3.1007394429849455e-09
% O 0 9.742238127330438e-10
CI O 0 4.2161506286220174e-08
9 O 0 4.296927702540643e-09
% O 0 4.4103079521740085e-10
- O 0 1.6924432688636415e-10
44 O 0 1.6279462222712482e-09
% O 0 3.3394970816447156e-11
) O 0 1.7873247641023854e-13
by O 0 2.6811753772032487e-12
age O 0 2.3185391107016784e-10
50 O 0 1.3546222477067715e-10
years O 0 4.574539358426222e-11
and O 0 7.198696500010371e-11
84 O 0 2.8700462006980842e-09
% O 0 6.280012621040498e-11
( O 0 3.019187330699502e-12
95 O 0 7.477629626606586e-10
% O 0 1.998915200029927e-10
CI O 0 2.724988057423161e-08
43 O 0 4.411984555474646e-09
% O 0 2.7713206729451656e-10
- O 0 7.754173692031685e-11
95 O 0 9.35293176240748e-10
% O 0 5.514801809658465e-11
) O 0 6.310203011158921e-13
by O 0 1.474438279802648e-11
age O 0 3.3291467360641036e-09
70 O 0 6.653498196840246e-09
years O 0 5.707333272653159e-09
. O 0 1.1561130008885812e-07

The O 0 1.0591544423732557e-06
corresponding O 1 0.9999988079071045
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 2.4880284854589263e-06
were O 0 2.939312571115238e-09
0 O 0 3.860480646267206e-08
. O 0 3.973524798084327e-08

4 O 0 2.315005531272618e-06
% O 0 2.0427675551104585e-08
( O 0 3.988966379431247e-10
95 O 0 1.6638432853710583e-08
% O 0 1.2607319632707004e-09
CI O 0 1.5690130084067277e-08
0 O 0 1.3340464288802423e-09
% O 0 2.7260560475639295e-10
- O 0 7.462295364968341e-11
1 O 0 2.570641199906021e-10
% O 0 2.6722268495205093e-11
) O 0 1.8170404417205965e-13
by O 0 1.3041434251959139e-12
age O 0 7.685382191757739e-11
50 O 0 5.293084026636308e-11
years O 0 1.537953271679715e-11
and O 0 8.579225524441014e-11
27 O 0 4.106762485633908e-09
% O 0 1.9319280897267532e-10
( O 0 1.119163355739472e-11
95 O 0 1.2339442800879397e-09
% O 0 4.2101036545894033e-10
CI O 0 9.528533517766391e-09
0 O 0 7.536967161492214e-10
% O 0 4.900414518616003e-10
- O 0 1.0820733892247247e-10
47 O 0 1.5766621341839482e-09
% O 0 5.477127085207201e-11
) O 0 5.705732652842854e-13
by O 0 1.0381214984866993e-11
age O 0 1.2816558925266008e-09
70 O 0 4.959278765426234e-09
years O 0 3.0036948484024606e-09
. O 0 8.709422871788775e-08

The O 0 1.5643222184280603e-07
lifetime O 0 7.312801244552247e-07
risk O 0 0.17371195554733276
of O 0 0.0013954078312963247
breast B-Disease 1 0.9994502663612366
cancer I-Disease 1 0.9942227005958557
appears O 0 4.3807153460306836e-09
similar O 0 2.2848703831734873e-11
to O 0 4.366587993964721e-11
the O 0 5.357676524653243e-10
risk O 0 2.433046430994068e-09
in O 0 6.195436941247578e-10
BRCA1 O 0 6.832399090939134e-09
carriers O 0 6.651515449540568e-10
, O 0 1.016498343830996e-10
but O 0 1.798146492815178e-10
there O 0 3.719217989139878e-10
was O 0 1.833318719057786e-09
some O 0 9.815907114907318e-11
suggestion O 0 1.2069249599733212e-08
of O 0 2.6607862579908215e-09
a O 0 7.036655702563621e-09
lower O 0 4.323764102309724e-08
risk O 0 9.297938419194907e-09
in O 0 2.251359099147976e-09
BRCA2 O 0 3.438878337647111e-08
carriers O 0 9.565639391695413e-10
< O 0 6.920443773594798e-09
50 O 0 5.833235672270121e-09
years O 0 2.4014279453865583e-09
of O 0 1.0796686211733686e-08
age O 0 3.777917640945816e-07
. O 0 6.5755205014284e-07

Eye B-Disease 0 0.010090910829603672
movement I-Disease 0 1.8328431906411424e-05
abnormalities I-Disease 0 2.4659468181198463e-05
correlate O 0 1.1476172545599184e-07
with O 0 2.722356229334366e-10
genotype O 0 6.94146606861068e-08
in O 0 2.557067224628895e-09
autosomal O 0 0.16418033838272095
dominant O 1 0.9999966621398926
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 1.6530493667232804e-06

We O 0 1.445060036076029e-07
compared O 0 3.42924408869294e-07
horizontal O 0 4.7213070502039045e-06
eye O 0 0.0001255682873306796
movements O 0 1.440044343326008e-06
( O 0 1.845022268298635e-08
visually O 0 6.045429756795784e-08
guided O 0 1.363507777796258e-07
saccades O 0 9.764473816176178e-07
, O 0 5.8407620961986595e-09
antisaccades O 0 4.2981838532796246e-07
, O 0 1.814799643895526e-09
and O 0 1.0659159110915084e-09
smooth O 0 3.4967770901062067e-09
pursuit O 0 7.183602157567748e-09
) O 0 1.1335490185393482e-10
in O 0 2.7244029254802626e-10
control O 0 8.188860256552744e-09
subjects O 0 9.009228563172655e-08
( O 0 1.5647326767620484e-09
n O 0 5.319190421460007e-09
= O 0 1.2936317794753904e-08
14 O 0 1.9580911114758237e-08
) O 0 1.419900169663535e-10
and O 0 1.1028263025014695e-10
patients O 0 7.48003603501246e-11
with O 0 4.906573411456172e-12
three O 0 1.9487066474366266e-11
forms O 0 1.3881337190824183e-09
of O 0 1.1577300007559188e-08
autosomal O 1 0.8342270851135254
dominant O 1 0.9999992847442627
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 0.9991187453269958
type I-Disease 0 0.0021454717498272657
I I-Disease 0 0.0003920881717931479
spinocerebellar B-Disease 0 2.722185672610067e-05
ataxias I-Disease 0 1.9695207811309956e-06
1 I-Disease 0 1.2412488104018848e-07
and I-Disease 0 4.6862966840421905e-09
2 I-Disease 0 7.112654287766418e-08
( O 0 4.3168646435276514e-09
SCA1 B-Disease 0 2.0822009901166894e-05
, O 0 1.0222505508750146e-08
n O 0 7.084651976185796e-09
= O 0 2.0014086388187025e-08
11 O 0 2.5657845625914888e-08
; O 0 4.1520027416197536e-09
SCA2 B-Disease 0 4.3569630179263186e-06
, O 0 2.7063395968696113e-09
n O 0 3.1941311817718088e-09
= O 0 8.83419559727372e-09
10 O 0 5.166747918394776e-09
) O 0 4.335022896206908e-10
and O 0 5.6335935916251856e-09
SCA3 B-Disease 1 1.0
/ O 0 5.135140668244276e-07
Machado B-Disease 0 3.6848456375082606e-07
- I-Disease 0 1.7442424393721012e-07
Joseph I-Disease 0 7.750338681944413e-07
disease I-Disease 1 0.9984936714172363
( O 0 6.491802650998579e-08
MJD B-Disease 1 1.0
) O 0 3.776290391499515e-09
( O 0 6.064758140134074e-10
n O 0 3.990246799645547e-09
= O 0 1.3085313277372279e-08
16 O 0 4.7864268992725556e-08
) O 0 1.8227542808446628e-09
. O 0 3.299015816082829e-08

In O 0 4.969536462340329e-07
SCA1 B-Disease 0 0.0006239336798898876
, O 0 1.882273359399278e-08
saccade O 0 2.1016714413235604e-07
amplitude O 0 6.508040772956747e-09
was O 0 2.139617372165503e-09
significantly O 0 1.1823618750739229e-09
increased O 0 1.592881826439907e-09
, O 0 1.070573005246267e-10
resulting O 0 2.3998254494728144e-09
in O 0 3.2652160975032984e-09
hypermetria B-Disease 0 1.581254218763206e-05
. O 0 9.09333493837039e-07

The O 0 3.692095447149768e-07
smooth O 0 2.957242202228372e-07
pursuit O 0 2.3597840481670573e-07
gain O 0 9.090907155950845e-07
was O 0 3.151731675643532e-07
decreased O 0 7.679164468754607e-07
. O 0 2.0620636576040852e-07

In O 0 6.862989607725467e-07
SCA2 B-Disease 0 0.0007449249387718737
, O 0 3.693658712222714e-08
saccade O 0 7.511385433645046e-07
velocity O 0 4.276220124665997e-07
was O 0 7.880668562165738e-08
markedly O 0 6.032950068401988e-07
decreased O 0 1.2028741593894665e-06
. O 0 2.2370214480815775e-07

The O 0 1.9823902164262108e-07
percentage O 0 1.2534409279396641e-06
of O 0 3.291329164767376e-08
errors O 0 4.0467296003043884e-07
in O 0 1.257027637535657e-08
antisaccades O 0 4.259355591784697e-06
was O 0 1.3111645102981129e-08
greatly O 0 5.944770009591593e-09
increased O 0 1.214392142401266e-09
and O 0 1.8800111467598413e-10
was O 0 1.120232351325967e-09
significantly O 0 1.4267502734810478e-09
correlated O 0 5.941823033595028e-09
with O 0 9.147878982096458e-11
age O 0 3.1653129894948506e-08
at O 0 7.120986467157309e-09
disease O 0 1.9522964578300162e-07
onset O 0 1.0927287803497165e-06
. O 0 1.2483788225381431e-07

In O 0 1.69775713487752e-08
addition O 0 1.0525178950615555e-08
, O 0 2.2839521940376528e-10
a O 0 1.1523357268394818e-10
correlation O 0 1.8624700670599736e-09
between O 0 9.009615276056593e-10
smooth O 0 5.7080513649054865e-09
pursuit O 0 6.0596740958374085e-09
gain O 0 3.877762111414995e-09
and O 0 9.561913066891137e-11
the O 0 3.6101013844991314e-10
number O 0 2.106288921055466e-09
of O 0 2.6714868539556846e-08
trinucleotide O 0 6.382394531101454e-06
repeats O 0 4.772270472130913e-07
was O 0 7.757838460520361e-08
found O 0 2.3605487342592824e-08
. O 0 1.6106857003705954e-07

In O 0 1.0548088766881847e-06
SCA3 B-Disease 1 1.0
, O 0 6.165136596791854e-07
gaze B-Disease 0 2.205450800829567e-05
- I-Disease 0 2.178434215238667e-07
evoked I-Disease 0 1.5091014802237623e-06
nystagmus I-Disease 0 5.428406893770443e-06
was O 0 1.2461919496331575e-08
often O 0 3.149759619791581e-10
present O 0 1.668083865480341e-10
as O 0 6.250451267675317e-10
was O 0 4.572450418294238e-09
saccade O 0 6.252877682300095e-08
hypometria O 0 3.825477392638277e-07
and O 0 3.8960887849270875e-09
smooth O 0 1.8228037745871006e-08
pursuit O 0 5.272505987363729e-08
gain O 0 2.238096925566424e-07
was O 0 5.506716505010445e-08
markedly O 0 5.950814170319063e-07
decreased O 0 5.344821261132893e-07
. O 0 2.1624504142891965e-07

Three O 0 4.2340897010717526e-08
major O 0 8.796838102398397e-08
criteria O 0 4.2105817499304976e-08
, O 0 5.408161918296628e-09
saccade O 0 1.76201467638748e-07
amplitude O 0 2.2901314622458813e-08
, O 0 9.126064903774989e-10
saccade O 0 5.644642442348413e-08
velocity O 0 9.991973826117828e-08
, O 0 1.3183887315193488e-09
and O 0 6.316739353806611e-10
presence O 0 1.1949770950536731e-08
of O 0 4.038752763335651e-07
gaze B-Disease 0 0.00018259139324072748
- I-Disease 0 7.616731068083027e-07
evoked I-Disease 0 2.0186585061310325e-06
nystagmus I-Disease 0 5.808247465211025e-07
, O 0 2.817965583101767e-10
permitted O 0 1.4954182336879285e-09
the O 0 7.867234086411656e-10
correct O 0 4.932243058419772e-09
assignment O 0 2.0826871338641695e-09
of O 0 8.79189832048155e-10
90 O 0 4.2504484376593155e-09
% O 0 4.329957503657056e-10
of O 0 3.927782543655667e-10
the O 0 2.88243895418816e-09
SCA1 B-Disease 0 1.93233904610679e-06
, O 0 2.683935851344188e-10
90 O 0 1.493488444026525e-09
% O 0 1.1757092521769152e-10
of O 0 2.5906252143492736e-10
the O 0 2.168851542805328e-09
SCA2 B-Disease 0 1.1979320788668701e-06
, O 0 2.972183887894886e-10
and O 0 1.0427914781674374e-10
93 O 0 1.908867730548991e-09
% O 0 6.491582271728191e-11
of O 0 1.2263509652221671e-10
the O 0 3.675214577114616e-10
patients O 0 5.241597711425072e-10
with O 0 1.342208677534984e-09
SCA3 B-Disease 1 1.0
to O 0 1.871433008560075e-09
their O 0 1.214966571794207e-09
genetically O 0 7.4370674063573006e-09
confirmed O 0 9.823896363059248e-09
patient O 0 2.562496659308522e-09
group O 0 4.6256409813594246e-10
and O 0 5.222955401507079e-10
, O 0 4.095910277612802e-10
therefore O 0 4.522421992447789e-09
, O 0 5.601158981072274e-10
may O 0 1.4346530630149346e-09
help O 0 3.0811737161684505e-08
orient O 0 1.922317096614279e-05
diagnoses O 0 8.933423487178516e-06
of O 0 3.1100941555450845e-07
SCA1 B-Disease 1 0.9767906665802002
, O 0 4.885236037921459e-08
SCA2 B-Disease 0 0.002572007942944765
, O 0 6.7411143334084045e-09
and O 0 2.568017087867247e-08
SCA3 B-Disease 1 1.0
at O 0 1.4187510721797025e-08
early O 0 9.552680424462778e-09
clinical O 0 4.094522054742811e-09
stages O 0 2.962880163437376e-09
of O 0 4.995487135062149e-09
the O 0 2.1504028779872897e-08
diseases O 0 5.355745997803751e-07
. O 0 2.210642513489347e-08
. O 0 1.3157182365830522e-07

Genetic O 0 1.6998883722862956e-07
basis O 0 6.291458731766397e-08
and O 0 1.166829133314451e-10
molecular O 0 5.190661678255992e-09
mechanism O 0 3.452838015505222e-08
for O 0 7.121136125221028e-09
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.40272337198257446

Ventricular B-Disease 1 0.9999998807907104
fibrillation I-Disease 1 0.7714273929595947
causes O 0 9.74207796389237e-06
more O 0 2.5019752936117357e-10
than O 0 5.765237592880723e-11
300 O 0 1.5098391981105408e-10
, O 0 9.687952697012836e-12
000 O 0 4.3204126387585973e-10
sudden O 0 1.1080515394112922e-09
deaths O 0 1.3102239293516504e-09
each O 0 6.579714550980498e-11
year O 0 1.0587505178127898e-10
in O 0 2.2409218924934748e-10
the O 0 1.3214733307620463e-08
USA O 0 1.0468464495261287e-07
alone O 0 7.788737121927625e-08
. O 0 1.4353769017816376e-07

In O 0 4.4461156534225665e-08
approximately O 0 5.857667062514338e-08
5 O 0 2.7489072351727373e-08
- O 0 2.3272597182710797e-09
12 O 0 3.486966715371409e-09
% O 0 1.3035826584850696e-10
of O 0 3.397590195297617e-11
these O 0 9.53797370945031e-12
cases O 0 1.704250629508408e-10
, O 0 3.265212752956437e-11
there O 0 6.330293234046991e-11
are O 0 2.1384482726261034e-11
no O 0 3.3432094870278206e-09
demonstrable O 0 4.956840257364092e-06
cardiac O 0 4.010769407614134e-05
or O 0 1.409111860084522e-06
non O 1 0.9999997615814209
- O 0 3.510805981932208e-05
cardiac O 0 5.540776328416541e-05
causes O 0 3.959098293648822e-08
to O 0 5.397140720453386e-11
account O 0 1.0868141803177522e-10
for O 0 7.254450512528265e-11
the O 0 4.1157175445505345e-09
episode O 0 9.16662923344802e-09
, O 0 8.49138051539633e-11
which O 0 1.5922362386899813e-11
is O 0 6.936172122773421e-12
therefore O 0 2.0404526679396184e-10
classified O 0 1.989764131238303e-09
as O 0 1.4211885890347276e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.00014053935592528433
IVF B-Disease 1 1.0
) O 0 2.664312148681347e-08
. O 0 1.188313447642031e-07

A O 0 1.0136262744708802e-06
distinct O 0 8.657598726813376e-08
group O 0 3.3462332904576897e-09
of O 0 2.7501082300318558e-08
IVF B-Disease 1 1.0
patients O 0 6.607302793781855e-08
has O 0 2.994066661266004e-10
been O 0 4.6849777529667236e-11
found O 0 2.5778821785560346e-11
to O 0 4.4431163609415236e-11
present O 0 4.0075437413022996e-10
with O 0 1.3955503419538218e-10
a O 0 3.757710143048598e-09
characteristic O 0 2.3466867560273386e-07
electrocardiographic O 0 2.1588950858131284e-06
pattern O 0 1.7724702274790616e-06
. O 0 6.304492217168445e-07

Because O 0 6.163207189047171e-08
of O 0 3.3098125129527034e-08
the O 0 5.32993471580312e-09
small O 0 3.887876409702784e-10
size O 0 8.133875795124368e-10
of O 0 5.85394177576859e-10
most O 0 1.4867772291093928e-10
pedigrees O 0 3.5075315985011457e-09
and O 0 7.695253462225438e-11
the O 0 5.139569325685045e-10
high O 0 5.1780641996401755e-09
incidence O 0 4.865503200335297e-08
of O 0 1.3110713625863468e-09
sudden B-Disease 0 3.419152605488307e-08
death I-Disease 0 1.1575471603464393e-07
, O 0 2.009282962234238e-09
however O 0 3.776693624502059e-09
, O 0 1.9036965059893163e-10
molecular O 0 3.7100658101252293e-09
genetic O 0 2.1087609436420962e-09
studies O 0 2.3745190258495086e-09
of O 0 7.982248639848422e-09
IVF B-Disease 1 1.0
have O 0 1.6710715033951828e-09
not O 0 9.57721346672713e-10
yet O 0 1.3060803105702234e-08
been O 0 6.108015870864847e-09
done O 0 4.693338695460625e-08
. O 0 2.519606709938671e-07

Because O 0 3.4093557133019203e-07
IVF B-Disease 1 1.0
causes O 0 8.755691669648513e-05
cardiac O 0 0.002447884064167738
rhythm O 0 2.119987129844958e-06
disturbance O 0 3.707138239406049e-05
, O 0 4.0950745572310154e-10
we O 0 1.500139734655903e-10
investigated O 0 6.158067389350208e-10
whether O 0 7.557293124627051e-10
malfunction O 0 8.425189435001812e-07
of O 0 3.200015585846927e-09
ion O 0 5.386679546859341e-08
channels O 0 1.075307665132641e-08
could O 0 1.0691370011528534e-09
cause O 0 1.0382520798657424e-07
the O 0 1.5462316982350899e-09
disorder O 0 4.396670583162177e-09
by O 0 4.3556415418866123e-11
studying O 0 1.915928526941002e-10
mutations O 0 2.980307389766068e-10
in O 0 6.131658375485571e-11
the O 0 1.7219512482569144e-09
cardiac O 0 2.1388272841704747e-07
sodium O 0 1.2948559060532716e-06
channel O 0 1.4303590489816997e-07
gene O 0 1.5727606239579472e-07
SCN5A O 0 0.0005034575005993247
. O 0 9.524563324703195e-07

We O 0 1.2886049205462768e-07
have O 0 4.92487339798231e-09
now O 0 1.148115380544823e-09
identified O 0 2.865429671317088e-09
a O 0 1.6550908421564259e-09
missense O 0 1.7195996804275637e-07
mutation O 0 1.2109278912930677e-08
, O 0 7.016093261924539e-10
a O 0 9.15402753598471e-10
splice O 0 4.6103370010541767e-08
- O 0 5.587514007032723e-09
donor O 0 1.053292564279218e-09
mutation O 0 1.695704465731751e-09
, O 0 5.076850745355799e-11
and O 0 2.0402023820365045e-11
a O 0 1.391425308305827e-10
frameshift O 0 6.676354580292809e-09
mutation O 0 2.016780631386439e-10
in O 0 2.6436800665274873e-11
the O 0 6.630168636334588e-11
coding O 0 8.596662937065958e-09
region O 0 7.068980512059397e-09
of O 0 1.5315652746039632e-08
SCN5A O 0 4.65326702396851e-05
in O 0 2.952240896192393e-09
three O 0 1.913115177387681e-08
IVF B-Disease 1 1.0
families O 0 1.200941284196233e-07
. O 0 2.021296694465491e-07

We O 0 5.382325340974603e-08
show O 0 3.6245093593123556e-09
that O 0 8.887253433176312e-11
sodium O 0 2.382390063004891e-09
channels O 0 3.1084593232755253e-10
with O 0 3.8926657036642e-12
the O 0 1.512436148543017e-10
missense O 0 3.7419344067757265e-08
mutation O 0 3.30233818068848e-09
recover O 0 1.4646277080032633e-08
from O 0 4.056696312204622e-09
inactivation O 0 4.554886956498194e-08
more O 0 1.0377596698640801e-10
rapidly O 0 7.009191560491956e-10
than O 0 2.0603928285733986e-11
normal O 0 6.870239932510458e-10
and O 0 2.0396500460817535e-11
that O 0 4.636405842584068e-11
the O 0 8.147353347531805e-10
frameshift O 0 2.3208471588986868e-07
mutation O 0 1.1644890385298368e-08
causes O 0 3.2933826332737226e-08
the O 0 7.593447648446272e-09
sodium O 0 4.801779951435492e-08
channel O 0 5.0565223119747316e-09
to O 0 5.149420334582544e-10
be O 0 3.5681397836384576e-09
non O 0 3.7480492665054044e-07
- O 0 1.8558969827608962e-07
functional O 0 1.6282594970107311e-06
. O 0 3.93761354189337e-07

Our O 0 4.309426060444821e-07
results O 0 4.471100467640099e-08
indicate O 0 3.922800217992517e-08
that O 0 3.3085656436782074e-10
mutations O 0 3.1045090942427578e-09
in O 0 7.52346629440126e-10
cardiac O 0 4.6566459133146054e-08
ion O 0 7.028455115687393e-07
- O 0 3.5756906413553224e-07
channel O 0 4.823155208555363e-09
genes O 0 3.1296323865781517e-10
contribute O 0 3.6756965526851815e-11
to O 0 1.3300562040630126e-11
the O 0 1.2964612716714896e-10
risk O 0 1.2999928911128222e-09
of O 0 7.635606036338061e-10
developing O 0 1.9072894374971838e-08
IVF B-Disease 1 1.0
. O 0 3.619675226218533e-08
. O 0 1.2589021025632974e-07

Molecular O 0 2.478893520674319e-06
heterogeneity O 0 2.8339040909486357e-06
in O 0 1.8495851961120024e-08
mucopolysaccharidosis B-Disease 0 2.0043855329276994e-05
IVA I-Disease 1 0.9564610123634338
in O 0 2.94004709466833e-09
Australia O 0 1.6736545482842757e-10
and O 0 2.688813893758635e-10
Northern O 0 5.7216222870692945e-09
Ireland O 0 1.5408674336470085e-09
: O 0 1.010968975201365e-09
nine O 0 5.382343015725155e-09
novel O 0 3.1570268621550213e-09
mutations O 0 4.2566061786430964e-09
including O 0 9.907232811912081e-10
T312S O 0 1.5401652717628167e-06
, O 0 1.1605416627702425e-09
a O 0 4.871710812537344e-10
common O 0 1.0911849201988844e-09
allele O 0 5.241940215228169e-09
that O 0 2.152920619558074e-10
confers O 0 8.372894200192604e-08
a O 0 1.1049708703581018e-08
mild O 0 8.865720246831188e-07
phenotype O 0 1.7935467440111097e-06
. O 0 3.928730905045086e-07

Mucopolysaccharidosis B-Disease 0 0.0014897477813065052
IVA I-Disease 1 1.0
( O 0 8.75848054420203e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.2426258183827485e-08
is O 0 5.352814302916897e-10
an O 0 3.759387912083412e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9891653656959534
by O 0 1.2846899932750233e-10
a O 0 1.894525869516883e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.6287390042512015e-09
N O 0 4.614480531017762e-08
- O 0 6.779603989315319e-09
acetylgalactosamine O 0 9.51901739654204e-08
- O 0 2.0153713364834402e-08
6 O 0 6.664359375463391e-08
- O 0 5.873867436889668e-08
sulfate O 0 2.935379370683222e-07
sulfatase O 0 2.294080559295253e-06
( O 0 5.4643425784206556e-08
GALNS O 0 6.128799577709287e-05
) O 0 2.2868139382126174e-08
. O 0 1.8957112501993834e-07

Previous O 0 1.5450552837137366e-07
studies O 0 1.32893234194853e-08
of O 0 1.2143248628859737e-09
patients O 0 9.912783788257329e-11
from O 0 1.2763615164779196e-10
a O 0 1.6726652007914566e-10
British O 0 4.967000699629409e-10
- O 0 6.143894837329356e-10
Irish O 0 2.378429675431448e-10
population O 0 1.733464344289004e-10
showed O 0 2.2725109294352563e-10
that O 0 1.5308941614389227e-11
the O 0 2.7373830979726677e-10
I113F O 0 2.1624293466970812e-08
mutation O 0 8.356963454581035e-10
is O 0 3.090097622227006e-11
the O 0 4.757022206702821e-11
most O 0 3.094467737607687e-11
common O 0 5.873432989966787e-11
single O 0 6.269684077464532e-11
mutation O 0 1.369065083522969e-09
among O 0 5.344859221878551e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 3.8887407072252245e-08
and O 0 6.552540732229772e-10
produces O 0 1.037779973067643e-09
a O 0 2.507555552089258e-10
severe O 0 4.3768679347522266e-08
clinical O 0 2.2830487722558246e-08
phenotype O 0 9.574049499860848e-07
. O 0 2.6956931264976447e-07

We O 0 1.0643464065651642e-07
studied O 0 9.39065571969877e-08
mutations O 0 1.0385150517322472e-08
in O 0 3.4986297192673987e-10
the O 0 3.604530229850411e-09
GALNS O 0 2.0769814454979496e-06
gene O 0 1.2043809283213136e-09
from O 0 2.2340775895912657e-09
23 O 0 6.828672738379282e-09
additional O 0 1.2444556496404857e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.110663117032118e-08
( O 0 8.713763044454481e-11
15 O 0 9.568704717466403e-10
from O 0 6.564387367014035e-10
Australia O 0 5.383959944538219e-11
, O 0 4.6657785274240027e-11
8 O 0 3.0224803215794793e-10
from O 0 3.4419719852074593e-10
Northern O 0 2.657986275522717e-09
Ireland O 0 4.415720289419056e-10
) O 0 6.9600825103322e-11
, O 0 5.116005188932071e-11
with O 0 1.1653939098466015e-11
various O 0 6.605167524043054e-10
clinical O 0 5.196687524744448e-08
phenotypes O 0 6.086484972911421e-06
( O 0 1.7729703927216178e-08
severe O 0 1.0687687790778e-05
, O 0 3.6839120642895296e-09
16 O 0 8.522655470244445e-09
cases O 0 9.473221096456541e-10
; O 0 6.186840484367906e-10
intermediate O 0 3.28740199506683e-08
, O 0 8.874317392049136e-10
4 O 0 4.542123122064368e-09
cases O 0 1.6138484992822555e-09
; O 0 8.978038756879414e-09
mild O 0 1.3422456390799198e-07
, O 0 9.487597374402412e-10
3 O 0 3.4253648806270576e-09
cases O 0 2.3693071948827082e-09
) O 0 4.274399501014159e-09
. O 0 8.23452026565974e-08

We O 0 6.772601324200878e-08
found O 0 7.54233475674937e-09
two O 0 6.670203833714083e-10
common O 0 5.793305835055662e-10
mutations O 0 1.55009682867302e-09
that O 0 6.980556410685068e-11
together O 0 2.6206812761553344e-11
accounted O 0 8.692221387107679e-10
for O 0 1.4324148638056311e-11
32 O 0 1.6739872821247559e-09
% O 0 1.6164784788497144e-10
of O 0 1.16645082481881e-10
the O 0 1.5703116584830923e-09
44 O 0 8.746274815507604e-09
unrelated O 0 3.976601270494484e-09
alleles O 0 3.466665843276928e-10
in O 0 2.3618612621234547e-10
these O 0 2.140233767988775e-09
patients O 0 6.627242310486281e-09
. O 0 7.385911260371358e-08

One O 0 2.1769972136098659e-07
is O 0 8.960794772860936e-09
the O 0 1.1119136722470557e-08
T312S O 0 7.891616178312688e-07
mutation O 0 2.12980584279876e-08
, O 0 6.154016740644863e-10
a O 0 3.770682099890621e-10
novel O 0 1.085898926334039e-09
mutation O 0 7.8190492969199e-10
found O 0 3.0090779867819606e-10
exclusively O 0 9.293129599186045e-10
in O 0 4.874490255879493e-10
milder O 0 1.0388210966993938e-06
patients O 0 1.987326214702989e-08
. O 0 1.3276331856104662e-07

The O 0 1.0688055596119739e-07
other O 0 6.657103313045809e-09
is O 0 1.5834973332573554e-09
the O 0 2.632602580376897e-09
previously O 0 4.344428372604625e-09
described O 0 5.335468511447061e-09
I113F O 0 2.455397805078974e-07
that O 0 1.3717932345613804e-10
produces O 0 1.541061500631713e-09
a O 0 6.3195837451957e-10
severe O 0 1.6733424956782983e-07
phenotype O 0 1.4067729807720752e-06
. O 0 3.1753450002725003e-07

The O 0 7.284187404366094e-07
I113F O 0 4.5808164941263385e-06
and O 0 1.3501895601564229e-08
T312S O 0 2.4593629177616094e-07
mutations O 0 2.1382476234066417e-08
accounted O 0 1.5663548680322492e-08
for O 0 4.19942108864646e-10
8 O 0 7.330624995915969e-09
( O 0 1.6698091520606084e-10
18 O 0 6.021617870999307e-09
% O 0 2.9844313131910383e-10
) O 0 4.28718735859257e-12
and O 0 6.962352916417558e-11
6 O 0 2.1518788972940683e-09
( O 0 9.141006701574028e-11
14 O 0 5.33760591281407e-09
% O 0 3.323054886816834e-10
) O 0 5.198461452970982e-12
of O 0 1.4158949013243216e-10
44 O 0 4.5928509884163304e-09
unrelated O 0 5.435338401582612e-09
alleles O 0 3.313954666239738e-09
, O 0 5.4571636098899035e-09
respectively O 0 3.171150453340488e-08
. O 0 1.7435506549645652e-07

The O 0 1.6321106954819697e-07
relatively O 0 4.0611425333736406e-07
high O 0 2.2497297891277412e-07
residual O 0 7.463953079422936e-05
GALNS O 0 0.06418078392744064
activity O 0 4.209224613305196e-08
seen O 0 3.0978486442734265e-09
when O 0 7.600177431843491e-11
the O 0 1.3318110503313108e-10
T312S O 0 4.7389874247016905e-09
mutant O 0 1.1901112317858065e-09
cDNA O 0 7.576289817734505e-09
is O 0 1.965873908105209e-09
overexpressed O 0 1.7118651385317207e-07
in O 0 6.332566693245667e-10
mutant O 0 5.306381556380302e-09
cells O 0 4.5063866527250696e-10
provides O 0 4.149942056663747e-10
an O 0 1.0288056864760087e-11
explanation O 0 3.527058645147463e-10
for O 0 2.3386665867763945e-11
the O 0 1.6525105728248946e-09
mild O 0 3.815984683797069e-08
phenotype O 0 3.3885072525663418e-09
in O 0 5.6416739335762855e-11
patients O 0 3.550566438081937e-11
with O 0 2.1271271202771835e-11
this O 0 5.510336076319788e-10
mutation O 0 7.259942691462129e-08
. O 0 1.266207192429647e-07

The O 0 8.730757450337023e-09
distribution O 0 5.319515050672408e-09
and O 0 1.5882455073334967e-10
relative O 0 4.225543914770924e-09
frequencies O 0 2.285378331023935e-09
of O 0 9.86446702100352e-10
the O 0 2.339141769169828e-09
I113F O 0 8.64293099311908e-08
and O 0 1.3820521393981267e-09
T312S O 0 9.196719474857673e-08
mutations O 0 4.436905065574592e-09
in O 0 5.818753812114608e-10
Australia O 0 1.239801317165501e-10
corresponded O 0 1.178925512768103e-09
to O 0 1.3296788670125181e-10
those O 0 4.94652319105171e-10
observed O 0 6.568244836913095e-10
in O 0 7.192080958562386e-11
Northern O 0 5.320205165304515e-09
Ireland O 0 6.315679645929606e-10
and O 0 1.6827138571429145e-09
are O 0 1.1302825342340839e-10
unique O 0 2.775721874570536e-10
to O 0 1.583907310864774e-10
these O 0 4.779971973789543e-10
two O 0 6.141059882835975e-10
populations O 0 1.1323525450634975e-09
, O 0 1.2473796995315922e-10
suggesting O 0 2.071530946778921e-09
that O 0 2.1906899905221877e-10
both O 0 9.297508873906679e-10
mutations O 0 6.14961948031123e-09
were O 0 2.580024416332094e-09
probably O 0 1.1951041267721507e-09
introduced O 0 8.389348243875716e-11
to O 0 1.8560539216672112e-10
Australia O 0 3.983262331086479e-11
by O 0 1.6933732194246431e-10
Irish O 0 3.0470184153585933e-09
migrants O 0 1.2058848142260103e-08
during O 0 1.9165069531368317e-09
the O 0 5.987876861013319e-09
19th O 0 5.086230885353871e-07
century O 0 6.168430104480649e-07
. O 0 8.297535600831907e-07

Haplotype O 0 3.5487075820128666e-06
analysis O 0 2.637985403453058e-07
using O 0 1.0873175426695525e-07
6 O 0 8.967702456175175e-07
RFLPs O 0 1.548315253785404e-06
provides O 0 3.2978817454676346e-09
additional O 0 6.911641814433267e-10
data O 0 4.565739786244194e-09
that O 0 1.691026901839976e-10
the O 0 1.5456183000139845e-09
I113F O 0 1.0794095572919105e-07
mutation O 0 2.8840336785407317e-09
originated O 0 2.360579065552315e-09
from O 0 7.021622727698684e-10
a O 0 9.734992811871734e-10
common O 0 2.500173401642769e-09
ancestor O 0 3.153791112708859e-07
. O 0 2.7230041155235085e-07

The O 0 3.14589669869747e-07
other O 0 3.725128294718161e-08
9 O 0 1.235238187291543e-07
novel O 0 1.0552154705578687e-08
mutations O 0 5.638538080887656e-09
identified O 0 3.1316103044076726e-09
in O 0 1.3415502042590788e-10
these O 0 3.521177238674511e-10
23 O 0 3.429614148231508e-09
patients O 0 2.0798836264379617e-10
were O 0 1.0473542172428907e-10
each O 0 3.358526304286791e-11
limited O 0 1.0663666477617184e-10
to O 0 1.1295239743525087e-10
a O 0 2.153053069164912e-09
single O 0 4.636958816917058e-09
family O 0 5.498949917637219e-08
. O 0 5.140230996403261e-07

These O 0 5.005991354778416e-08
data O 0 3.0386569704887734e-08
provide O 0 1.7725536594070945e-09
further O 0 2.283574440653524e-09
evidence O 0 4.658998076223497e-09
for O 0 1.8982432292702356e-10
extensive O 0 1.2273021710029752e-08
allelic O 0 2.098387028581783e-07
heterogeneity O 0 3.526911598328297e-07
in O 0 7.89120857547232e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
in O 0 4.538511344520657e-09
British O 0 1.2581718777937567e-08
- O 0 6.3912271031085766e-09
Irish O 0 3.462211906057888e-10
patients O 0 1.2540736504806915e-10
and O 0 9.75029518929249e-12
provide O 0 2.949013255815203e-11
evidence O 0 8.83830286735332e-10
for O 0 7.372909227587598e-11
their O 0 3.2956101736481003e-10
transmission O 0 2.860204295629387e-09
to O 0 1.3731807357864056e-10
Australia O 0 2.0603142455999368e-11
by O 0 8.326728889729296e-11
British O 0 3.8074619013173105e-09
- O 0 8.48342374126787e-09
Irish O 0 3.945429760676689e-09
migrants O 0 1.1943710021000697e-08
. O 0 5.354491960929408e-09
. O 0 7.875755159147957e-08

Identification O 0 1.4512775692310242e-07
of O 0 1.8119389721960033e-07
constitutional O 0 4.046936737722717e-06
WT1 O 0 0.012720323167741299
mutations O 0 1.3321232472662814e-06
, O 0 2.4232464923557018e-09
in O 0 7.738896329323453e-11
patients O 0 1.188617815284232e-10
with O 0 3.425387751221365e-11
isolated O 0 1.5372994255358208e-07
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.9901747744531804e-10
and O 0 4.2542540670820195e-12
analysis O 0 9.21089107763784e-11
of O 0 2.645330898776166e-10
genotype O 0 2.8966654852524698e-08
/ O 0 6.919667328020296e-08
phenotype O 0 1.491607548587126e-08
correlations O 0 5.2810587014562316e-09
by O 0 6.5843719365688e-11
use O 0 6.606289404409438e-10
of O 0 4.244833817779181e-09
a O 0 3.927469904851932e-09
computerized O 0 8.802712869737661e-08
mutation O 0 4.5224929579035233e-08
database O 0 2.7244456646258186e-07
. O 0 9.223559231941181e-07

Constitutional O 0 7.19582317287859e-07
mutations O 0 9.420621722711076e-07
of O 0 2.296108903010463e-07
the O 0 9.156166669299637e-08
WT1 O 0 8.456014256807975e-06
gene O 0 2.60398866913647e-08
, O 0 2.5212245624572915e-09
encoding O 0 1.1152505585698691e-08
a O 0 6.368959759583959e-08
zinc O 0 3.9655151340411976e-07
- O 0 3.579634366701612e-08
finger O 0 5.2617565415857825e-08
transcription O 0 9.556310942571145e-08
factor O 0 3.825589800499074e-08
involved O 0 3.5111329399484248e-09
in O 0 3.851108765218214e-09
renal O 1 1.0
and O 0 1.5297589925467037e-05
gonadal O 0 0.12141702324151993
development O 0 2.172601489291992e-05
, O 0 2.2304190439026428e-10
are O 0 1.2589668890727879e-11
found O 0 6.619933767826325e-11
in O 0 2.995322045951099e-11
most O 0 1.183121517422947e-10
patients O 0 2.0748791573765857e-10
with O 0 1.5660761576441473e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 6.338472758216085e-06
DDS B-Disease 1 1.0
) O 0 6.9984413819668134e-09
, O 0 1.2501527590913497e-09
or O 0 8.451720212576674e-09
diffuse B-Disease 1 0.9999997615814209
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 6.140556365608063e-07
DMS B-Disease 0 9.924903679348063e-06
) O 0 2.3853580222166215e-10
associated O 0 3.0546123408470294e-09
with O 0 9.241850618124658e-10
pseudohermaphroditism B-Disease 1 1.0
and O 0 5.572307486545469e-07
/ O 0 6.814552307332633e-06
or O 0 2.481840510881739e-07
Wilms B-Disease 0 0.0001652682840358466
tumor I-Disease 0 0.00038479268550872803
( O 0 3.1719554272058303e-07
WT B-Disease 1 1.0
) O 0 4.209369208751923e-08
. O 0 1.7265028873225674e-07

Most O 0 9.508057985385676e-08
mutations O 0 6.131012355581333e-07
in O 0 4.32083702150976e-08
DDS B-Disease 1 1.0
patients O 0 2.502947609173134e-07
lie O 0 6.990959633412785e-08
in O 0 1.7938757146396256e-09
exon O 0 3.311738439037981e-08
8 O 0 5.359910204560947e-08
or O 0 2.61723731576069e-09
exon O 0 1.2116187164679104e-08
9 O 0 3.1384466581130255e-08
, O 0 9.085805441344519e-10
encoding O 0 2.9696256120814724e-08
zinc O 0 1.809383206818893e-06
finger O 0 1.1479252179924515e-06
2 O 0 6.214378913682594e-07
or O 0 1.4083285293509107e-07
zinc O 0 7.949249152261473e-07
finger O 0 1.9416201268995792e-07
3 O 0 2.8465290569101853e-08
, O 0 4.395888653085933e-10
respectively O 0 9.49114453696609e-10
, O 0 8.485567803973026e-11
with O 0 2.86501690427432e-11
a O 0 4.11981737613587e-09
hot O 0 5.995227638777578e-07
spot O 0 8.259024752987898e-07
( O 0 2.5180768581378743e-09
R394W O 0 1.981804302886303e-07
) O 0 7.189753237213381e-10
in O 0 4.141893938935937e-09
exon O 0 1.7015833009281778e-07
9 O 0 2.0479444629017962e-06
. O 0 9.317023454968876e-07

We O 0 4.212348869714333e-08
analyzed O 0 4.549373500140064e-08
a O 0 2.2493760187813905e-09
series O 0 1.308760322338287e-09
of O 0 1.5539066700043236e-09
24 O 0 5.782170298118672e-09
patients O 0 6.911641814433267e-10
, O 0 5.81080183970073e-10
10 O 0 3.045896868059117e-09
with O 0 6.938057905969686e-10
isolated B-Disease 0 1.0695040145947132e-05
DMS I-Disease 1 0.9999970197677612
( O 0 9.776067599887028e-08
IDMS B-Disease 0 0.010133921168744564
) O 0 1.5075752868298764e-09
, O 0 3.8380984501706905e-10
10 O 0 1.2228642543021806e-09
with O 0 5.543479564273923e-10
DDS B-Disease 1 1.0
, O 0 1.9557759856070334e-09
and O 0 7.691295378364771e-10
4 O 0 2.0758072594162513e-08
with O 0 1.7298683596678188e-09
urogenital B-Disease 0 5.9972797316731885e-05
abnormalities I-Disease 0 0.0043829879723489285
and O 0 1.6837183238749276e-06
/ O 0 0.003442077897489071
or O 0 1.2043735296174418e-05
WT B-Disease 1 1.0
. O 0 1.6357084859919269e-06

We O 0 9.124207736022072e-07
report O 0 1.0604147746562376e-06
WT1 O 0 0.00015837639512028545
heterozygous O 0 1.378528224904585e-07
mutations O 0 6.644166461455825e-08
in O 0 3.95469657021863e-09
16 O 0 2.0676317546985956e-08
patients O 0 6.384717754492897e-10
, O 0 1.0777808506778896e-10
4 O 0 2.398836906891688e-09
of O 0 2.3386954595139287e-09
whom O 0 1.7304829569297908e-08
presented O 0 1.033874994504913e-07
with O 0 4.21533066230495e-08
IDMS B-Disease 1 0.9999979734420776
. O 0 3.583652187444386e-06

One O 0 1.453507678661481e-07
male O 0 2.8657154871325474e-08
and O 0 1.4054398755902753e-09
two O 0 1.8031445225830112e-09
female O 0 1.4101557255230546e-08
IDMS B-Disease 0 0.00020188692724332213
patients O 0 9.5850207770809e-09
with O 0 9.698580605288498e-09
WT1 O 1 0.9999997615814209
mutations O 1 0.9761451482772827
underwent O 0 5.780976607638877e-06
normal O 0 8.906880793801975e-06
puberty O 0 7.20724983693799e-06
. O 0 1.669279612315222e-07

Two O 0 2.9353313379942847e-07
mutations O 0 5.573056682806055e-07
associated O 0 1.1739758747353335e-06
with O 0 1.03209734092502e-08
IDMS B-Disease 1 0.9999676942825317
are O 0 1.517145575835599e-10
different O 0 6.472024305370638e-11
from O 0 2.349460626049904e-10
those O 0 1.112676409342761e-10
described O 0 5.850214201963411e-10
in O 0 1.7935266605206834e-09
DDS B-Disease 1 1.0
patients O 0 4.714225099178293e-08
. O 0 1.955007320475488e-07

No O 0 3.9948704397829715e-06
WT1 O 0 0.00012878306733909994
mutations O 0 9.42010956350714e-07
were O 0 1.0711644016225819e-08
detected O 0 9.603925654744216e-09
in O 0 1.1091293855569617e-10
the O 0 6.469509927775619e-10
six O 0 1.6579185802001462e-09
other O 0 5.619888554520003e-09
IDMS B-Disease 1 0.9999998807907104
patients O 0 1.7595489509858453e-08
, O 0 3.843622087273957e-10
suggesting O 0 3.3082832029407427e-09
genetic O 0 5.219614962470587e-08
heterogeneity O 0 5.546658485400258e-06
of O 0 1.6512604616991666e-08
this O 0 3.306819706949682e-09
disease O 0 6.654312301179743e-07
. O 0 9.834811010023259e-08

We O 0 7.282687874976546e-08
analyzed O 0 8.687820951536196e-08
genotype O 0 5.905388320570637e-07
/ O 0 1.1844981884223671e-07
phenotype O 0 3.654151115028981e-08
correlations O 0 4.887453997071134e-08
, O 0 2.6658700247317313e-10
on O 0 2.7332094920673455e-10
the O 0 6.000974023256944e-11
basis O 0 1.655255044141768e-09
of O 0 2.4057772440855274e-10
the O 0 5.593311924734223e-10
constitution O 0 4.317597390723904e-09
of O 0 1.7799672846763315e-08
a O 0 2.6116733664593994e-08
WT1 O 0 5.023714493290754e-06
mutation O 0 8.620010483184615e-09
database O 0 1.1601704485997288e-08
of O 0 2.4568116430145892e-08
84 O 0 1.5645161965949228e-07
germ O 0 1.0382298114564037e-06
- O 0 5.284528015181422e-07
line O 0 4.1672862494124274e-07
mutations O 0 4.956035581926699e-09
, O 0 1.2216397338171703e-10
to O 0 3.906986886792474e-11
compare O 0 1.136903571286041e-09
the O 0 8.414575702886395e-10
distribution O 0 2.1690129692331084e-09
and O 0 3.079337618228095e-10
type O 0 1.2678246008590577e-08
of O 0 1.2495956269731323e-08
mutations O 0 1.8261445688949607e-08
, O 0 4.853569768314969e-10
according O 0 5.696433325041994e-10
to O 0 3.276856286316132e-10
the O 0 2.3423338824102302e-09
different O 0 1.1045872660986333e-08
symptoms O 0 4.131614332436584e-06
. O 0 2.4297253276017727e-07

This O 0 1.8637750898164995e-08
demonstrated O 0 4.638394202061136e-08
( O 0 8.181675337226579e-10
1 O 0 6.302614430353515e-09
) O 0 3.74259234714458e-11
the O 0 1.3863020453808161e-10
association O 0 2.8669372431622264e-10
between O 0 2.963512990561412e-09
mutations O 0 4.89143392456981e-09
in O 0 1.9837465004002297e-09
exons O 0 1.9142648355341407e-08
8 O 0 2.098158269348005e-08
and O 0 9.551273105756763e-10
9 O 0 1.7026668075459384e-08
and O 0 5.003821801352615e-09
DMS B-Disease 0 1.2405428151396336e-06
; O 0 1.4969456785252078e-08
( O 0 8.520262273492563e-10
2 O 0 1.3549287025682588e-08
) O 0 8.758987285473196e-11
among O 0 1.3348017136038948e-10
patients O 0 1.8699654324993986e-10
with O 0 2.0168190728586666e-10
DMS B-Disease 0 1.3048697837803047e-06
, O 0 1.8758847253330657e-10
a O 0 5.399952013318554e-11
higher O 0 3.451188224090629e-10
frequency O 0 8.073903212668654e-10
of O 0 1.125432080861799e-09
exon O 0 2.705111246115166e-09
8 O 0 1.0792959415084624e-08
mutations O 0 5.23773291405405e-09
among O 0 2.2028419088826467e-09
46 O 0 3.691700811714327e-08
, O 0 1.8049716166146368e-09
XY O 0 4.760987621921231e-07
patients O 0 9.367816244942873e-11
with O 0 3.243796897756113e-11
female O 0 1.7227388959817347e-10
phenotype O 0 3.968151085498306e-10
than O 0 2.2586514256128787e-11
among O 0 2.1223704738115856e-10
46 O 0 1.4722655095056325e-08
, O 0 1.3627448058883829e-09
XY O 0 3.204487256880384e-06
patients O 0 1.6428929050515961e-10
with O 0 2.4470895795825065e-11
sexual O 0 2.6509422434983776e-10
ambiguity O 0 3.331154241337231e-09
or O 0 4.844210588217379e-10
male O 0 4.5165232664956534e-10
phenotype O 0 1.0489220603204785e-09
; O 0 2.227625722772686e-10
and O 0 5.291077576075054e-10
( O 0 2.0004943535045783e-10
3 O 0 5.4256021897458595e-09
) O 0 9.118682892106378e-11
statistically O 0 3.9437666465858e-09
significant O 0 3.110096347125335e-10
evidence O 0 2.6847359890780353e-09
that O 0 5.286860949027528e-10
mutations O 0 4.151012866770998e-09
in O 0 2.105915219985377e-09
exons O 0 7.671567914258048e-08
8 O 0 5.2569316011386036e-08
and O 0 4.247693308201406e-09
9 O 0 4.06205593606046e-08
preferentially O 0 2.964475598332683e-08
affect O 0 3.7310943667989704e-08
amino O 0 1.4886032850824904e-08
acids O 0 5.3005653199988956e-09
with O 0 4.465852340707066e-11
different O 0 2.594467418681745e-10
functions O 0 2.0496473407405347e-09
. O 0 3.740947551733598e-09
. O 0 4.70757584025705e-08

The O 0 6.756382617822965e-07
185delAG O 0 9.165614756057039e-06
BRCA1 O 0 2.9966241754664225e-07
mutation O 0 6.653181117144413e-09
originated O 0 2.5658810631767892e-09
before O 0 1.0631012042905397e-10
the O 0 4.6423434540976416e-11
dispersion O 0 4.14546663662918e-09
of O 0 6.044409972538745e-10
Jews O 0 1.389455550615537e-09
in O 0 1.5909498718436055e-10
the O 0 1.1638978669736844e-09
diaspora O 0 5.619298804049322e-09
and O 0 6.455691536899621e-10
is O 0 9.290306718368058e-11
not O 0 1.8009403690566472e-10
limited O 0 1.5627402705220561e-09
to O 0 1.5757850135855733e-08
Ashkenazim O 0 2.1914835087954998e-05
. O 0 1.1847055247926619e-06

The O 0 4.520595950907591e-07
185delAG O 0 2.4918062990764156e-06
mutation O 0 6.951044895231462e-08
in O 0 6.656620588074702e-09
BRCA1 O 0 3.051841801493538e-08
is O 0 4.0070391449376075e-10
detected O 0 7.130768753249583e-10
in O 0 1.2732297161033301e-10
Ashkenazi O 0 8.801298356786447e-09
Jews O 0 7.81505793412407e-09
both O 0 5.817566428589771e-10
in O 0 1.3471663784514476e-09
familial B-Disease 0 0.065109021961689
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.5799443137408673e-10
in O 0 3.2191062315778396e-11
the O 0 1.9671443640678632e-10
general O 0 1.6255849999424754e-09
population O 0 6.088564652451112e-10
. O 0 2.4758257666235295e-08

All O 0 3.064873510538746e-08
tested O 0 1.8967252657375866e-08
Ashkenazi O 0 7.402691348801227e-09
mutation O 0 5.81481529593475e-10
carriers O 0 1.0903480895940731e-10
share O 0 8.806529117055817e-11
the O 0 2.4677319215848925e-11
same O 0 7.240171656652805e-11
allelic O 0 3.054235264698946e-08
pattern O 0 9.15108486765348e-08
at O 0 1.0862660992927431e-08
the O 0 2.0401587974561153e-08
BRCA1 O 0 3.72525306602256e-07
locus O 0 3.6074141007702565e-07
. O 0 5.936478828516556e-07

Our O 0 5.322182232703199e-07
previous O 0 6.036719213398101e-08
study O 0 1.3895854467094182e-09
showed O 0 1.7119010653487976e-09
that O 0 2.7135266256195223e-11
this O 0 2.321791786608074e-10
Ashkenazi O 0 2.3064691490048972e-08
mutation O 0 1.4816229354508437e-09
also O 0 5.770760605483538e-11
occurs O 0 6.771519456272301e-11
in O 0 5.688579815532613e-11
Iraqi O 0 1.1744580064032561e-07
Jews O 0 1.9545650431496142e-08
with O 0 4.984898258064696e-11
a O 0 3.7739558700344844e-10
similar O 0 6.992580403597515e-10
allelic O 0 5.103104854242702e-07
pattern O 0 8.210013788811921e-07
. O 0 3.779182407015469e-07

We O 0 1.4760703948013543e-07
extended O 0 9.06637254161069e-08
our O 0 5.607243558358732e-09
analysis O 0 6.46712905449931e-10
to O 0 1.074451638771734e-10
other O 0 9.482150620243601e-10
non O 0 5.618573339916111e-08
- O 0 8.176515464697331e-09
Ashkenazi O 0 4.713485157736841e-09
subsets O 0 1.9446837473680034e-09
354 O 0 1.897248802507079e-09
of O 0 1.7987157596710546e-10
Moroccan O 0 3.736462250714112e-09
origin O 0 2.117442443605455e-09
, O 0 4.665638431156083e-10
200 O 0 1.1405221211902017e-09
Yemenites O 0 5.374918288225672e-08
and O 0 1.7525010331809199e-09
150 O 0 8.719590383066134e-09
Iranian O 0 2.6105186634595157e-07
Jews O 0 5.335522246241453e-07
. O 0 7.24671565421886e-07

Heteroduplex O 0 1.0208933417743538e-05
analysis O 0 3.852932906056594e-08
complemented O 0 2.995795256310885e-08
by O 0 2.6798080421386317e-10
direct O 0 4.299862688128542e-09
DNA O 0 4.914176177095442e-09
sequencing O 0 1.4275349791148528e-08
of O 0 2.3622602540740445e-08
abnormally O 0 3.425013872515592e-08
migrating O 0 5.005664327484283e-09
bands O 0 1.0425041274686464e-08
were O 0 3.3225178164286717e-09
employed O 0 7.590815442881649e-08
. O 0 8.572155252295488e-08

Four O 0 3.2718947551302335e-08
of O 0 2.754749139910473e-08
Moroccan O 0 2.8806192631236627e-07
origin O 0 1.0269975980747859e-08
( O 0 1.5508858086654698e-10
1 O 0 7.741970953212274e-10
. O 0 9.340322265627421e-11
1 O 0 5.741066511077975e-10
% O 0 5.3540775979410427e-11
) O 0 6.814606387864353e-13
and O 0 6.3346866814584235e-12
none O 0 3.1661789856585187e-10
of O 0 6.969624877228853e-10
the O 0 4.056355695780667e-09
Yemenites O 0 1.6675961944656592e-07
or O 0 1.6347978526454199e-09
Iranians O 0 4.244145923593123e-09
was O 0 1.2989815889596912e-09
a O 0 5.869613822762076e-11
carrier O 0 2.6993271506903227e-10
of O 0 5.764811961128657e-10
the O 0 6.896606841166886e-09
185delAG O 0 7.040369496280618e-07
mutation O 0 3.8363461385415576e-07
. O 0 6.225180300134525e-07

BRCA1 O 0 8.067573617154267e-06
allelic O 0 1.3415128705673851e-06
patterns O 0 1.8303539661701507e-07
were O 0 1.5904926264909136e-09
determined O 0 7.464790452438308e-10
for O 0 1.1879423833516256e-10
four O 0 3.169562945437576e-10
of O 0 3.1155705793040056e-10
these O 0 1.229207985398162e-10
individuals O 0 7.006982494228708e-11
and O 0 6.172484190436478e-10
for O 0 4.850330692640625e-10
12 O 0 6.824844689390375e-09
additional O 0 1.513176250966808e-08
non O 0 4.029911053748947e-07
- O 0 1.5230362748752668e-07
Ashkenazi O 0 5.153621529530028e-08
185delAG O 0 4.783771245797652e-08
mutation O 0 2.5628681399325615e-09
carriers O 0 5.531947788739444e-09
who O 0 1.9546581242479988e-08
had O 0 2.438749561406439e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9556819097488187e-06

Six O 0 1.5845124607949401e-06
non O 0 8.282931048597675e-06
- O 0 3.309964426989609e-07
Ashkenazi O 0 1.9649752047712354e-08
individuals O 0 1.9869679512840577e-10
shared O 0 6.286331455385152e-10
the O 0 2.9801536238771575e-10
common O 0 1.7467734203524543e-10
Ashkenazi O 0 1.5775254436078967e-09
haplotype O 0 6.6874044080122985e-09
, O 0 7.638679133670223e-10
four O 0 6.704822252956433e-10
had O 0 5.189234042468627e-10
a O 0 3.776576829039868e-10
closely O 0 1.895649193173199e-10
related O 0 1.9488275437851144e-09
pattern O 0 3.3195423299048343e-08
, O 0 1.8908788423921408e-10
and O 0 1.2390141690410417e-10
the O 0 5.995293594907025e-09
rest O 0 4.9912230792870105e-08
( O 0 1.8121397715731291e-09
n O 0 1.4817198135119725e-08
= O 0 7.166416082782234e-08
6 O 0 8.865020362236464e-08
) O 0 2.80049261558446e-10
displayed O 0 6.990317213961816e-09
a O 0 3.0558942043512616e-09
distinct O 0 5.2910223757862695e-08
BRCA1 O 0 1.1967605360041489e-06
allelic O 0 3.1909291919873795e-06
pattern O 0 2.30347450269619e-06
. O 0 9.257945521312649e-07

We O 0 6.815637476620395e-08
conclude O 0 9.488835672755158e-08
that O 0 1.2160238371805576e-09
the O 0 7.166454540907807e-09
185delAG O 0 9.128245892497944e-07
BRCA1 O 0 1.0040270126410178e-07
mutation O 0 1.7499858229186316e-09
occurs O 0 7.599137985536686e-10
in O 0 1.4779953649846078e-10
some O 0 8.734034606661112e-10
non O 0 2.538806427310192e-07
- O 0 6.671888996834241e-08
Ashkenazi O 0 4.5181561603158116e-08
populations O 0 4.581887758092762e-09
at O 0 7.837385740394609e-10
rates O 0 3.2772440317074825e-10
comparable O 0 8.997388944997908e-10
with O 0 2.7006803043905236e-11
that O 0 2.5477966958398213e-10
of O 0 1.7813597708027373e-08
Ashkenazim O 0 3.602989863793482e-06
. O 0 6.357454935823625e-07

The O 0 1.54880993363804e-07
majority O 0 1.3276352461843999e-08
of O 0 6.11230674962826e-08
Jewish O 0 9.281000075134216e-07
185delAG O 0 1.8787804378916917e-07
mutation O 0 3.1980083026184047e-09
carriers O 0 5.415229931138299e-10
have O 0 5.726617097190356e-11
a O 0 2.9291868930414466e-10
common O 0 7.399991175383036e-10
allelic O 0 1.913371079353965e-07
pattern O 0 2.485967058873939e-07
, O 0 1.079723643826469e-09
supporting O 0 2.9301494564037966e-09
the O 0 9.353703589454199e-09
founder O 0 6.47542961473846e-08
effect O 0 4.7738723196744104e-08
notion O 0 7.185455075386926e-08
, O 0 4.354289706576253e-10
but O 0 2.9585300875822895e-10
dating O 0 2.7843558569884408e-09
the O 0 1.4800695113947882e-09
mutations O 0 1.0169837194595743e-09
origin O 0 1.0597733801631648e-09
to O 0 2.6169263978026436e-10
an O 0 6.412861353055632e-10
earlier O 0 1.1035506952694618e-09
date O 0 1.322264964187525e-08
than O 0 1.2698688767187605e-09
currently O 0 3.0331659406357403e-09
estimated O 0 4.8336474378629646e-08
. O 0 3.5513343732418434e-07

However O 0 2.229078006621421e-07
, O 0 2.3797650516854674e-09
the O 0 6.164906918293411e-10
different O 0 4.95831153912718e-10
allelic O 0 2.4934746534199803e-07
pattern O 0 2.721342582390207e-07
at O 0 1.4295566508337743e-08
the O 0 2.1061090649254766e-08
BRCA1 O 0 5.712857742423694e-08
locus O 0 3.753398036820954e-09
even O 0 1.241882263691707e-09
in O 0 4.030633049545429e-10
some O 0 8.803308637617135e-10
Jewish O 0 2.0632667130371374e-08
mutation O 0 3.122788694298606e-09
carriers O 0 7.60112417452774e-10
, O 0 1.7733271795439265e-10
might O 0 6.150648879099663e-10
suggest O 0 3.6147060900049155e-09
that O 0 4.2420475465654306e-10
the O 0 2.426752354622863e-09
mutation O 0 4.352871840751504e-09
arose O 0 5.229197963529941e-09
independently O 0 2.984000158079425e-09
. O 0 1.2769545421065231e-08
. O 0 1.77752198737835e-07

Crystal O 0 7.278379598574247e-06
structure O 0 1.907100340758916e-06
of O 0 1.8670558574740426e-06
the O 0 1.3840057135894313e-06
hemochromatosis B-Disease 1 1.0
protein O 1 0.9997852444648743
HFE O 1 0.9926364421844482
and O 0 4.0754248864516285e-09
characterization O 0 5.6038039986106014e-08
of O 0 3.1229494545925718e-09
its O 0 7.848679484112608e-10
interaction O 0 8.035192955446746e-09
with O 0 8.071809332044211e-10
transferrin O 0 1.963926251846715e-06
receptor O 0 7.24035817256663e-06
. O 0 6.811023354202916e-07

HFE O 1 0.9978535771369934
is O 0 8.341538659806247e-07
an O 0 9.677739853941603e-08
MHC O 0 2.2076881123211933e-06
- O 0 1.1549926739462535e-06
related O 0 7.310172804864123e-07
protein O 0 1.0869914603972575e-06
that O 0 3.816330307326865e-10
is O 0 3.4691773759254474e-11
mutated O 0 2.279123112458592e-09
in O 0 6.215594150482673e-10
the O 0 7.593943252004465e-08
iron B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999991655349731
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9999521970748901

HFE O 0 0.00046987191308289766
binds O 0 8.02628733254096e-07
to O 0 5.2683645890283515e-08
transferrin O 0 3.627164460340282e-06
receptor O 0 4.438571977516403e-06
( O 0 6.064404800554257e-08
TfR O 0 5.627903760796471e-07
) O 0 2.347874672459227e-10
and O 0 1.5220961990802806e-10
reduces O 0 3.67665387024374e-09
its O 0 5.045855400176436e-10
affinity O 0 9.441550652411479e-09
for O 0 6.171357203044181e-09
iron O 0 6.382385322467599e-07
- O 0 1.2357730838630232e-07
loaded O 0 3.385634954611305e-07
transferrin O 0 1.6574693972870591e-06
, O 0 3.618377419911667e-08
implicating O 0 1.5773188351886347e-05
HFE O 1 0.92605060338974
in O 0 2.956234538942226e-06
iron O 1 0.9909961223602295
metabolism O 1 0.9999538660049438
. O 0 8.648512448417023e-06

The O 0 3.134886355837807e-06
2 O 0 5.44601607543882e-06
. O 0 9.941423968484742e-07

6 O 0 0.00011138193076476455
A O 0 1.0123838364961557e-05
crystal O 0 1.2758847333316226e-05
structure O 0 7.40630548534682e-06
of O 0 1.142016571975546e-05
HFE O 1 0.9999990463256836
reveals O 0 3.0752150337320927e-07
the O 0 2.639233942502983e-09
locations O 0 1.061224264020666e-08
of O 0 5.449375706234605e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00772740226238966
and O 0 5.0056382150387435e-08
a O 0 6.76316247449904e-09
patch O 0 4.7439456807296665e-07
of O 0 3.3556310086169105e-07
histidines O 0 2.7301102818455547e-06
that O 0 6.309045508245958e-10
could O 0 5.734467345419603e-10
be O 0 1.1664046395409855e-09
involved O 0 3.0295639330546464e-09
in O 0 1.1951230227680298e-08
pH O 0 1.2888314131487277e-06
- O 0 1.0319840839656536e-06
dependent O 0 1.8233586160931736e-06
interactions O 0 1.0585869176793494e-06
. O 0 6.745083851456002e-07

We O 0 3.755720854314859e-07
also O 0 1.4027036421282446e-08
demonstrate O 0 3.505627077515783e-08
that O 0 7.806506552299197e-09
soluble O 0 8.483057172270492e-06
TfR O 0 8.18714306660695e-06
and O 0 3.24202673596119e-08
HFE O 0 1.3830748684995342e-05
bind O 0 6.800573970622281e-08
tightly O 0 5.756555410130204e-08
at O 0 1.5462884306316482e-08
the O 0 2.701785684067204e-09
basic O 0 3.157841632628333e-08
pH O 0 4.1847609821843434e-08
of O 0 1.1110869557739989e-08
the O 0 1.0959996465942368e-08
cell O 0 2.8203450241903738e-08
surface O 0 4.0743703522139185e-08
, O 0 1.8606760576744819e-10
but O 0 1.5805183550821056e-10
not O 0 6.99124702574494e-10
at O 0 6.928341900191981e-09
the O 0 2.9051973271521092e-08
acidic O 0 2.78372044704156e-06
pH O 0 2.284387164763757e-06
of O 0 6.398230425475049e-07
intracellular O 0 1.3979560208099429e-05
vesicles O 0 7.1518930781167e-05
. O 0 4.953593816026114e-06

TfR O 0 0.003178725251927972
HFE O 0 0.0007200305699370801
stoichiometry O 0 1.9402705220272765e-05
( O 0 9.324012495426359e-08
2 O 0 1.6185325080186885e-07
1 O 0 4.2770604835595805e-08
) O 0 2.781339603075139e-10
differs O 0 5.634302802093316e-09
from O 0 3.812330895414107e-09
TfR O 0 2.936434668754373e-07
transferrin O 0 1.2772497370860947e-07
stoichiometry O 0 2.1632138214044971e-07
( O 0 2.124627584976224e-09
2 O 0 7.073161611970136e-09
2 O 0 6.504392580097829e-09
) O 0 7.866435280945439e-11
, O 0 7.003228552626695e-11
implying O 0 4.3424874807129754e-10
a O 0 5.0820535280049484e-11
different O 0 4.396791958294344e-11
mode O 0 4.494920435860195e-09
of O 0 8.325875544556993e-10
binding O 0 7.403058610577773e-09
for O 0 3.428504058433646e-08
HFE O 0 7.500420178985223e-05
and O 0 3.772131762502795e-08
transferrin O 0 6.351624506351072e-07
to O 0 2.0008359413736798e-08
TfR O 0 2.5550855298206443e-06
, O 0 3.000711679135293e-09
consistent O 0 2.913487762157274e-08
with O 0 7.915066935204607e-10
our O 0 1.6939790015157996e-08
demonstration O 0 2.6784054085737807e-08
that O 0 2.707537527513182e-09
HFE O 0 6.916519851074554e-06
, O 0 3.3382521191782644e-09
transferrin O 0 2.5205727638422104e-07
, O 0 5.326703078623041e-09
and O 0 2.8092623782782766e-09
TfR O 0 2.496577735655592e-07
form O 0 1.628763013350465e-09
a O 0 6.7165371042676725e-09
ternary O 0 1.955055779490067e-07
complex O 0 2.0558109099511057e-06
. O 0 2.2516110220749397e-06

Identification O 0 1.8555925862528966e-07
of O 0 1.986497011330357e-07
three O 0 4.03271105398062e-09
novel O 0 4.457100466481734e-09
mutations O 0 2.081984140644977e-09
and O 0 1.1532482607767847e-10
a O 0 1.2901069101900475e-10
high O 0 3.305191120794859e-10
frequency O 0 8.225376491033387e-10
of O 0 4.933501940307394e-10
the O 0 1.1980550995716044e-09
Arg778Leu O 0 8.085838487659203e-08
mutation O 0 1.7791994544325007e-09
in O 0 3.1847491310799114e-10
Korean O 0 1.0610845535552471e-08
patients O 0 9.062146033578244e-10
with O 0 7.59109775039235e-10
Wilson B-Disease 0 1.0214791501539366e-07
disease I-Disease 0 1.296444793297269e-06
. O 0 1.4383557811470382e-07

Four O 0 1.4838743709333357e-06
mutations O 0 4.081884981133044e-07
- O 0 2.747120788626489e-07
- O 0 1.5247280771291116e-07
R778L O 0 7.245865845106891e-07
, O 0 2.607575710911192e-09
A874V O 0 7.582625016766542e-08
, O 0 4.0292186254120566e-10
L1083F O 0 1.2132628235406173e-08
, O 0 1.318717496312516e-10
and O 0 7.794952877615557e-11
2304delC O 0 6.467403501630997e-09
- O 0 1.5610928105758148e-09
- O 0 4.454839608314387e-09
in O 0 3.834588202522582e-09
the O 0 9.881989626592258e-08
copper O 0 1.204659980658107e-07
- O 0 6.629176763084388e-09
transporting O 0 1.2281311967399233e-08
enzyme O 0 9.307414394754687e-09
, O 0 4.727702229700981e-09
P O 0 2.9827216962985403e-07
- O 0 1.4142984561260619e-08
type O 0 3.927157266048198e-08
ATPase O 0 9.029389502757112e-08
( O 0 2.5670412462375225e-09
ATP7B O 0 1.9163692286383593e-06
) O 0 6.585790940372149e-11
, O 0 3.6793020019576517e-11
were O 0 2.787243526258809e-11
identified O 0 1.6221213261502498e-10
in O 0 6.645982375541593e-11
Korean O 0 6.417061548802394e-09
Patients O 0 1.1171810143650873e-09
with O 0 1.2314567143789645e-09
Wilson B-Disease 0 7.745833130456958e-08
disease I-Disease 0 0.16517099738121033
. O 0 3.8691277381985856e-07

Arg778Leu O 0 0.0001687143521849066
, O 0 2.611932714557952e-08
the O 0 4.211631488004741e-09
most O 0 7.166738313912902e-10
frequently O 0 4.662578101388704e-10
reported O 0 3.415062677092351e-10
mutation O 0 5.819963955211449e-10
of O 0 4.777429007951639e-10
this O 0 7.889394693094687e-11
enzyme O 0 5.492186261335519e-09
, O 0 3.9392317185971137e-10
was O 0 8.99946561716547e-10
found O 0 5.520000428971272e-11
in O 0 4.8505869459924966e-11
six O 0 6.339431202206924e-10
of O 0 1.4297359962611722e-09
eight O 0 1.6349100961932095e-09
unrelated O 0 1.431103502369524e-08
patients O 0 4.419941634914437e-10
studied O 0 2.4347686089498666e-09
, O 0 3.2488185752743703e-11
an O 0 2.990190386964464e-11
allele O 0 7.522720224528712e-10
frequency O 0 1.4590503250033748e-09
of O 0 5.303245398380341e-09
37 O 0 5.156748557055835e-07
. O 0 4.96476616262953e-07

5 O 0 1.9711142158485018e-06
% O 0 2.9374925603065094e-08
, O 0 4.072299442103855e-10
which O 0 9.54099924066476e-11
is O 0 2.3235049301240096e-11
considerably O 0 7.833051429706472e-10
higher O 0 9.991888427762774e-10
than O 0 2.0347850140933765e-11
those O 0 3.4347694827241426e-11
in O 0 4.48003995012769e-11
other O 0 3.538885018361526e-10
Asian O 0 2.4974946555289534e-09
populations O 0 7.858105277591676e-09
. O 0 3.7951672027247696e-08

The O 0 2.1951096584871266e-07
novel O 0 8.071123858144347e-08
single O 0 5.252408730171965e-09
nucleotide O 0 3.019948024984842e-08
deletion O 0 3.61436995888198e-08
, O 0 6.4794423160208225e-09
2304delC O 0 9.906975861895262e-08
, O 0 1.6788731516115263e-09
was O 0 6.550782583047976e-09
found O 0 2.5738694509058746e-10
in O 0 2.498632134528833e-10
one O 0 3.069505316588561e-09
patient O 0 3.62140184506643e-08
. O 0 2.388629809502163e-07

Since O 0 6.536307495252913e-08
a O 0 1.3373666618576863e-08
mutation O 0 1.0792094329303836e-08
at O 0 9.537115097657534e-09
cDNA O 0 5.181317419555853e-08
nucleotide O 0 2.766349496141629e-07
2302 O 0 2.298646677445504e-06
( O 0 5.554467996660151e-09
2302insC O 0 6.662936158363664e-08
) O 0 3.714545893096499e-10
had O 0 1.9509176496512737e-09
been O 0 2.107091445768816e-10
previously O 0 4.893297433916644e-10
described O 0 3.7183808809793106e-10
, O 0 9.223385943890605e-12
this O 0 1.3351371223879749e-11
region O 0 9.32507293605056e-10
of O 0 2.919855912608682e-09
the O 0 6.505759841957115e-08
ATP7B O 1 0.999972939491272
gene O 0 2.4572990753313206e-08
may O 0 1.5053464252900994e-08
be O 0 1.2752962019746406e-09
susceptible O 0 4.6761112315607534e-08
to O 0 2.6763919969141625e-09
gene O 0 3.9454849343201204e-07
rearrangements O 0 0.00010835062130354345
causing O 0 0.012480110861361027
Wilson B-Disease 0 2.4224195840361062e-06
disease I-Disease 0 4.725554390461184e-06
. O 0 2.630694666549971e-07

Disruption O 0 5.113417864777148e-05
of O 0 8.056348974605498e-07
splicing O 0 6.134638965704653e-07
regulated O 0 2.0037695946939493e-07
by O 0 6.923255746471568e-09
a O 0 4.4722689551690564e-08
CUG O 0 1.1422768693591934e-05
- O 0 2.0916292697847894e-08
binding O 0 5.001963998552128e-08
protein O 0 5.35162598680472e-07
in O 0 2.2538694466334164e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.1915493056876585e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9571062922477722
DM B-Disease 1 1.0
) O 0 8.02040123204506e-09
is O 0 2.3467108811736637e-10
caused O 0 1.9847192778144063e-09
by O 0 1.0426940560970266e-10
a O 0 4.142289622421913e-09
CTG O 0 1.5838915032873047e-06
expansion O 0 2.7496623644651663e-08
in O 0 3.9356418124469883e-10
the O 0 1.9476980028798607e-09
3 O 0 4.479446591432179e-09
untranslated O 0 4.5338260861171875e-06
region O 0 1.6997107721294924e-08
of O 0 1.190804255202238e-08
the O 0 2.5277850568272697e-07
DM B-Disease 1 1.0
gene O 0 1.2523584018708789e-06
. O 0 2.5009219370986102e-06

One O 0 3.707605955582949e-08
model O 0 1.1816504752459878e-07
of O 0 1.988684346088121e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.0010472808498889208
suggests O 0 2.3084144373797244e-08
that O 0 2.5188923169494615e-10
RNAs O 0 1.4698517958322554e-09
from O 0 5.306591277509654e-10
the O 0 6.422948284345864e-10
expanded O 0 5.030652561188731e-10
allele O 0 8.528261430384987e-10
create O 0 1.9079640645180973e-10
a O 0 7.132537338527811e-10
gain O 0 1.5789863638815405e-08
- O 0 3.746524424030895e-09
of O 0 2.143956834288474e-08
- O 0 9.269341738615822e-09
function O 0 6.253730311378547e-10
mutation O 0 3.5454386648758884e-10
by O 0 8.234461723599651e-11
the O 0 6.031661281546974e-10
inappropriate O 0 3.7945571129682776e-09
binding O 0 1.8320298167395777e-08
of O 0 2.7274476011029947e-08
proteins O 0 4.037513878785148e-09
to O 0 8.736771306416813e-09
the O 0 2.3796101800144243e-07
CUG O 0 0.0018772296607494354
repeats O 0 3.5804650906356983e-06
. O 0 6.944987944734748e-07

Data O 0 3.233258212276269e-07
presented O 0 1.5609840886554593e-07
here O 0 7.74193065211648e-09
indicate O 0 3.460109709862991e-08
that O 0 1.566673790698303e-09
the O 0 1.2276862193516536e-08
conserved O 0 3.4168584761573584e-07
heterogeneous O 0 9.230651585312444e-07
nuclear O 0 5.399277142714709e-06
ribonucleoprotein O 0 1.2733916264551226e-05
, O 0 1.3883096983136056e-07
CUG O 0 2.204710472142324e-05
- O 0 1.1188708981535456e-07
binding O 0 3.8093386933724105e-07
protein O 0 2.0181830677756807e-06
( O 0 3.70747841316188e-08
CUG O 0 0.0001069900463335216
- O 0 4.643337945253734e-07
BP O 0 7.080648174451198e-07
) O 0 3.1716734794073886e-10
, O 0 2.032327084400265e-10
may O 0 4.702752076646277e-10
mediate O 0 2.5855138474639716e-08
the O 0 1.56240727022805e-08
trans O 0 2.0069972350711396e-08
- O 0 6.285003628647701e-09
dominant O 0 1.718051478860616e-08
effect O 0 3.0656803318152015e-08
of O 0 7.663345513719833e-09
the O 0 1.7623332126959212e-08
RNA O 0 5.156045403964526e-07
. O 0 3.4885624700109474e-07

CUG O 1 0.9942644238471985
- O 0 0.00013548227434512228
BP O 0 7.678683323320001e-05
was O 0 4.071294057439445e-08
found O 0 2.7901864152468647e-10
to O 0 4.5618269578495685e-11
bind O 0 4.4096687412675806e-10
to O 0 2.1502449820687275e-10
the O 0 1.9741479562185305e-09
human O 0 6.110045802643072e-08
cardiac O 0 0.006073459517210722
troponin O 0 9.840946404438e-06
T O 0 2.773191408778075e-05
( O 0 6.954489872867953e-09
cTNT O 0 7.816372971092278e-08
) O 0 1.287383394332764e-10
pre O 0 4.286008437048849e-09
- O 0 1.562823759293508e-09
messenger O 0 2.210966076887644e-09
RNA O 0 4.816040011235145e-09
and O 0 5.048647055971855e-10
regulate O 0 1.3185017522232556e-09
its O 0 1.5927906771295852e-09
alternative O 0 2.897284190339633e-08
splicing O 0 1.1139896969325491e-06
. O 0 8.805892548480188e-07

Splicing O 0 2.345917664570152e-06
of O 0 2.284615902681253e-06
cTNT O 0 2.353223317186348e-05
was O 0 6.212529797267052e-07
disrupted O 0 1.3788743444820284e-06
in O 0 1.879109667868306e-08
DM B-Disease 1 1.0
striated O 0 4.916457214676484e-07
muscle O 0 3.0589866639729735e-08
and O 0 3.368428203032181e-09
in O 0 6.705026533992964e-10
normal O 0 4.7905917455182134e-08
cells O 0 9.952312751693171e-09
expressing O 0 7.781765232195426e-10
transcripts O 0 3.094311473716971e-09
that O 0 2.808152044231349e-10
contain O 0 1.392887138962351e-08
CUG O 0 3.878007919411175e-05
repeats O 0 4.913429165753769e-07
. O 0 2.683965192318283e-07

Altered O 0 8.075703021859226e-07
expression O 0 6.213074925653927e-07
of O 0 1.6091779286853125e-07
genes O 0 1.4812090398663713e-07
regulated O 0 1.693802147428869e-07
posttranscriptionally O 0 8.725415341359621e-07
by O 0 1.5631107075364525e-08
CUG O 0 0.15670029819011688
- O 0 2.8421347906260053e-06
BP O 0 8.541567240172299e-07
therefore O 0 8.682018659555979e-09
may O 0 6.893525195117434e-10
contribute O 0 8.978723542441003e-09
to O 0 3.167414419635861e-08
DM B-Disease 1 1.0
pathogenesis O 0 0.00011529967741807923
. O 0 6.177565836651411e-08
. O 0 1.9582299159992544e-07

Identification O 0 7.587312467194351e-08
of O 0 6.673492691788852e-08
a O 0 7.493324183371897e-09
novel O 0 1.8499203946475973e-08
nonsense O 0 2.264983578470492e-08
mutation O 0 1.72371927842363e-09
and O 0 1.4923230706731516e-10
a O 0 2.8113888994596437e-10
missense O 0 2.5115452828572415e-08
substitution O 0 1.2806936844356187e-08
in O 0 2.0012393964208286e-09
the O 0 1.6706007244238208e-08
vasopressin O 0 2.5651246460256516e-07
- O 0 4.640084583229509e-08
neurophysin O 0 2.8795207640541776e-07
II O 0 2.7915794476029987e-07
gene O 0 1.1408461952910898e-09
in O 0 5.170797678921701e-10
two O 0 2.9475977214588056e-10
Spanish O 0 3.7663369312213035e-08
kindreds O 0 5.409355594565568e-07
with O 0 1.8893835385114244e-09
familial B-Disease 0 0.0003910824889317155
neurohypophyseal I-Disease 1 0.999997615814209
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999998807907104
. O 0 2.3937113837746438e-06

Familial B-Disease 1 0.9999979734420776
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 2.2327842088998295e-05
FNDI B-Disease 1 1.0
) O 0 3.342820464879992e-09
is O 0 1.655134224121113e-10
an O 0 3.1706148817534086e-10
autosomal B-Disease 1 0.8701440691947937
dominant I-Disease 1 0.9999563694000244
disease I-Disease 1 0.9999997615814209
caused O 0 2.7388439320930047e-06
by O 0 8.343839508206941e-10
deficiency O 1 0.9991132616996765
in O 0 1.1423709977975705e-08
the O 0 5.815786039420345e-07
antidiuretic O 0 6.448788099078229e-07
hormone O 0 1.6406218605879985e-07
arginine O 0 3.908990890977293e-07
vasopressin O 0 3.863736992570921e-07
( O 0 1.0844216191685518e-08
AVP O 0 1.4364997014126857e-07
) O 0 3.0277641505094266e-11
encoded O 0 1.4299096628977992e-10
by O 0 7.739563989694886e-10
the O 0 5.235668254499615e-08
AVP O 0 4.077040102856699e-06
- O 0 2.350444958665321e-07
neurophysin O 0 4.26744691139902e-06
II O 0 0.2472826987504959
( O 0 7.494813303310366e-07
AVP O 0 0.00010568241123110056
- O 0 5.244271051196847e-06
NPII O 0 0.0004139905795454979
) O 0 2.859260384013851e-09
gene O 0 8.522509808983614e-09
on O 0 3.302673690086522e-08
chromosome O 0 6.902214977344556e-08
20p13 O 0 2.198569518441218e-06
. O 0 1.9894052627478231e-07

In O 0 2.6895449423136597e-08
this O 0 2.8136810659162848e-09
study O 0 2.1135204697486643e-09
, O 0 2.5153298888191955e-10
we O 0 1.8806316226527287e-10
analyzed O 0 1.6941591463037753e-09
two O 0 4.138544229537189e-10
families O 0 1.0695796470727714e-09
with O 0 8.085122016332491e-10
FNDI B-Disease 1 1.0
using O 0 1.5965014865670923e-09
direct O 0 8.134003692816805e-09
automated O 0 3.357333611120339e-08
fluorescent O 0 5.078378606526712e-08
, O 0 7.934565782186098e-10
solid O 0 1.2814902916602477e-08
phase O 0 1.0170036368606361e-08
, O 0 6.571553301526478e-10
single O 0 4.862112379377947e-10
- O 0 2.2700556989718734e-09
stranded O 0 1.0979915643360982e-08
DNA O 0 9.728051697521778e-10
sequencing O 0 1.373312352725975e-09
of O 0 1.0207114264915162e-08
PCR O 0 1.831817257880175e-07
- O 0 6.58945054965443e-07
amplified O 0 6.727116783622478e-07
AVP O 0 1.2439912097761407e-05
- O 0 1.0924620710284216e-06
NPII O 0 1.7605443645152263e-05
DNA O 0 9.724041092340485e-07
. O 0 6.077223702050105e-07

In O 0 1.206252964180976e-08
one O 0 6.543052766261326e-09
of O 0 4.328943870035573e-09
the O 0 2.715812907894133e-09
families O 0 9.145336710147944e-10
, O 0 4.723713434295895e-11
affected O 0 1.077772593394144e-10
individuals O 0 1.7725045389771488e-11
presented O 0 1.0261258509558502e-09
a O 0 4.988781610038018e-10
novel O 0 1.7639061322682892e-09
nonsense O 0 7.499629361973348e-09
mutation O 0 5.26564680747299e-10
in O 0 1.7960109788273115e-10
exon O 0 1.0848679732333721e-09
3 O 0 1.0724400922867972e-08
of O 0 4.768837325030972e-09
the O 0 2.465400994466904e-09
gene O 0 9.399823142075547e-10
, O 0 4.1202710687748834e-10
consisting O 0 5.5193686426813215e-11
in O 0 1.2403099380886573e-10
a O 0 2.1713970621561884e-09
G O 0 3.9771041571157184e-08
to O 0 2.735867354886068e-08
T O 0 8.914971658668946e-07
transition O 0 7.443512828331222e-08
at O 0 1.952880523958811e-08
nucleotide O 0 3.322075770029187e-08
2101 O 0 1.8558506553745246e-06
, O 0 9.964615799162857e-10
which O 0 2.5791362101568183e-11
produces O 0 1.6192834573214299e-10
a O 0 3.978964380202399e-11
stop O 0 2.7758068066319197e-10
signal O 0 1.4625032740411825e-08
in O 0 3.632413037024662e-09
codon O 0 1.215218503602955e-06
82 O 0 3.1052238682605093e-06
( O 0 4.60225386689217e-08
Glu O 0 4.119240657018963e-06
) O 0 1.3374891416617629e-08
of O 0 1.884192215584335e-07
NPII O 0 0.01903635449707508
. O 0 2.9010225262027234e-06

The O 0 3.0180282806213654e-07
premature O 0 2.8065112473996123e-06
termination O 0 1.2637729014386423e-06
eliminates O 0 3.5545568266570626e-07
part O 0 4.499054462314689e-09
of O 0 1.3438307355784218e-08
the O 0 2.433887758002129e-08
C O 0 5.653013772644044e-07
- O 0 9.749956397797632e-09
terminal O 0 1.001389282606624e-08
domain O 0 2.547506428030033e-09
of O 0 3.883091181933196e-09
NPII O 0 7.804270353517495e-06
, O 0 3.6228489652678775e-10
including O 0 6.701686428023379e-11
a O 0 1.3720844460607395e-09
cysteine O 0 2.165714052537737e-09
residue O 0 3.615548749280606e-08
in O 0 1.331646681812515e-09
position O 0 4.4658506226369354e-08
85 O 0 3.5001217923991135e-08
, O 0 1.635557939083654e-10
which O 0 4.523426772040651e-11
could O 0 1.2362806611765365e-10
be O 0 1.1176792130696e-10
involved O 0 1.2314560482451498e-10
in O 0 3.06094455337913e-10
the O 0 1.1994207405052748e-08
correct O 0 4.364171957149665e-07
folding O 0 9.323609901912278e-07
of O 0 5.645471645721045e-08
the O 0 2.905043174905586e-07
prohormone O 0 0.0004936449113301933
. O 0 2.419415977783501e-06

In O 0 1.6900289168120253e-08
the O 0 2.87395351961095e-08
second O 0 2.6850290879565364e-08
family O 0 5.367058353300536e-09
, O 0 2.609086557914253e-10
a O 0 6.487959058887327e-10
G279A O 0 2.7086029419365332e-08
substitution O 0 1.1837299140893265e-08
at O 0 4.4048542591212936e-09
position O 0 7.49325312909832e-09
- O 0 2.869486315226766e-10
1 O 0 1.6245309542028963e-09
of O 0 3.7797473484424415e-10
the O 0 6.323719325962429e-10
signal O 0 5.707049943737275e-09
peptide O 0 9.0704982413925e-10
was O 0 4.013795518176266e-09
observed O 0 3.522205027639558e-10
in O 0 6.350368148000385e-11
all O 0 1.7993609380262399e-10
affected O 0 3.4592699815760852e-09
individuals O 0 3.813668936203385e-09
. O 0 4.310950885155762e-07

This O 0 5.739255470871285e-08
missense O 0 5.689538284059381e-06
mutation O 0 3.214586570265965e-07
, O 0 1.4157477856713285e-08
which O 0 6.463161561498509e-09
replaces O 0 1.7261404536839109e-06
Ala O 0 6.914627306287002e-07
with O 0 1.3325339942582559e-08
Thr O 0 2.7321652851242106e-06
, O 0 2.470116999830907e-09
is O 0 1.357451928640785e-10
frequent O 0 1.6921505308076235e-09
among O 0 3.0606133183397333e-09
FNDI B-Disease 1 1.0
patients O 0 3.041446348106547e-07
and O 0 2.86816370653753e-09
is O 0 1.5470243142079454e-10
thought O 0 1.4799925174280304e-10
to O 0 7.212632574526978e-11
reduce O 0 3.0088784797044354e-09
the O 0 2.536461707336457e-09
efficiency O 0 3.5238752360555736e-08
of O 0 1.1454168280522481e-08
cleavage O 0 4.421253407826953e-08
by O 0 2.2205510763484426e-09
signal O 0 1.1299850939394673e-06
peptidases O 0 4.045833065902116e-06
. O 0 8.074603385921364e-08
. O 0 4.902163368569745e-07

Genetic O 0 2.2171509499457898e-06
heterogeneity O 0 3.4698619856499135e-05
of O 0 6.697006938338745e-06
Saethre B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999986886978149
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.265969410002015e-10
due O 0 3.1286311319433935e-09
to O 0 4.776508633064225e-10
TWIST O 0 4.0389069908997044e-05
and O 0 9.185675509115754e-08
FGFR O 0 0.01690196804702282
mutations O 0 2.283964477101108e-06
. O 0 1.0189820613959455e-06

Thirty O 0 3.4007396607194096e-05
- O 0 1.1690187875501579e-06
two O 0 1.3682983635021628e-08
unrelated O 0 3.722727726085395e-08
patients O 0 7.851809202819027e-10
with O 0 2.9610463386786634e-11
features O 0 9.190731509178818e-10
of O 0 1.0902930114298215e-08
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.1455953963235288e-09
a O 0 6.83777978682798e-10
common O 0 5.416782133949027e-09
autosomal B-Disease 0 3.8938200304983184e-05
dominant I-Disease 1 0.7024393677711487
condition I-Disease 1 0.9981241822242737
of O 0 2.2609354743963195e-07
craniosynostosis B-Disease 1 0.8287168741226196
and O 0 6.865124646537879e-08
limb B-Disease 0 0.13816075026988983
anomalies I-Disease 0 3.0389370294869877e-05
, O 0 4.610106074665055e-09
were O 0 1.048454101315599e-09
screened O 0 2.697393419737182e-09
for O 0 2.835974788339968e-10
mutations O 0 6.716857292587974e-09
in O 0 4.169947054322165e-09
TWIST O 0 1.6991400116239674e-05
, O 0 5.61541284582745e-08
FGFR2 O 0 0.00025876323343254626
, O 0 2.9700334636117987e-08
and O 0 6.966521226559053e-08
FGFR3 O 0 0.10225718468427658
. O 0 2.9202642508607823e-06

Nine O 0 6.214627319423016e-07
novel O 0 7.002636692732267e-08
and O 0 4.71114836031461e-09
three O 0 4.564930211614637e-09
recurrent O 0 3.6195928032611846e-07
TWIST O 0 1.33982507577457e-06
mutations O 0 5.964318461337825e-08
were O 0 3.5637324202753007e-09
found O 0 6.444570432861951e-10
in O 0 5.691046522926513e-10
12 O 0 1.0755517365623746e-08
families O 0 7.861328477076768e-09
. O 0 9.755801499977679e-08

Seven O 0 1.0952665974173215e-07
families O 0 2.786757269390705e-09
were O 0 4.3815243100375767e-10
found O 0 7.996686646194462e-11
to O 0 6.65874716476722e-11
have O 0 8.579389282337146e-11
the O 0 3.644891277687634e-09
FGFR3 O 0 6.022916750225704e-06
P250R O 0 1.392598107941012e-07
mutation O 0 1.7996673040698852e-09
, O 0 1.2410955596564577e-10
and O 0 4.9021696424400574e-11
one O 0 1.4887779897776454e-10
individual O 0 2.4110646812403047e-10
was O 0 8.56499315915471e-09
found O 0 3.295980988138325e-10
to O 0 3.897283329390433e-10
have O 0 6.228411120190458e-10
an O 0 7.030699133991902e-09
FGFR2 O 0 1.7991547792917117e-05
VV269 O 0 7.205450742731045e-07
- O 0 7.014801894911216e-08
270 O 0 4.407234754921774e-08
deletion O 0 8.790532035618526e-08
. O 0 3.0739013823222194e-07

To O 0 4.082522764292662e-08
date O 0 6.364442697304185e-07
, O 0 3.471709808522405e-09
our O 0 9.649879784134896e-10
detection O 0 5.367416733292885e-09
rate O 0 2.809980470530604e-09
for O 0 1.6595534668706335e-10
TWIST O 0 9.086174372896494e-07
or O 0 3.687154759290934e-08
FGFR O 0 1.4453495168709196e-05
mutations O 0 1.4593601882495477e-08
is O 0 1.4953411842100195e-09
68 O 0 1.0076160350536156e-08
% O 0 5.404117153773313e-10
in O 0 2.7297605842413475e-10
our O 0 9.161476555163972e-08
Saethre B-Disease 1 0.507591724395752
- I-Disease 0 0.2970891296863556
Chotzen I-Disease 0 0.0007616069633513689
syndrome I-Disease 0 1.3150852282706182e-05
patients O 0 8.049899635764746e-10
, O 0 9.377577186997499e-11
including O 0 3.4923210157078444e-11
our O 0 6.7599641440097e-09
five O 0 4.534684849843984e-10
patients O 0 1.1034258923237061e-10
elsewhere O 0 9.251797661313788e-10
reported O 0 2.5801623060317525e-09
with O 0 2.5016125282384394e-10
TWIST O 0 1.7060677919289446e-06
mutations O 0 6.499112146229891e-07
. O 0 4.23859887632716e-07

More O 0 1.0261341998329954e-08
than O 0 1.870333887765696e-09
35 O 0 1.011038897047456e-08
different O 0 4.1032918729477785e-10
TWIST O 0 1.178891650965852e-07
mutations O 0 8.281690888622961e-09
are O 0 1.4770991374479792e-10
now O 0 1.8167763127241443e-10
known O 0 1.4443553297827094e-10
in O 0 7.839982829604963e-11
the O 0 2.427543943639421e-09
literature O 0 3.6826914850962567e-08
. O 0 7.182919858905734e-08

The O 0 3.606086096397121e-08
most O 0 1.311716624208259e-09
common O 0 4.3515252512449365e-10
phenotypic O 0 8.833588971413064e-09
features O 0 4.656510288469917e-09
, O 0 1.884620931535963e-10
present O 0 1.4813170134964082e-10
in O 0 2.8384464917374785e-11
more O 0 1.5422654472962982e-11
than O 0 4.22108493991491e-11
a O 0 3.581194507606966e-10
third O 0 2.497366091702702e-09
of O 0 3.6343394960169917e-09
our O 0 1.0300422736975179e-08
patients O 0 1.662456283746394e-09
with O 0 1.7709247401853645e-09
TWIST O 0 3.6023852771904785e-06
mutations O 0 9.553139790341447e-08
, O 0 7.577214411469413e-09
are O 0 3.777500534596356e-09
coronal B-Disease 0 0.00023516204964835197
synostosis I-Disease 0 7.77843379182741e-05
, O 0 1.0296518127006493e-07
brachycephaly B-Disease 0 4.22309385612607e-05
, O 0 3.6710994777422457e-07
low B-Disease 0 0.006819925736635923
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 1.1155407264595851e-06
facial B-Disease 1 1.0
asymmetry I-Disease 1 1.0
, O 0 1.985399649129249e-06
ptosis B-Disease 0 0.006943890359252691
, O 0 1.1033748137379007e-07
hypertelorism B-Disease 0 9.526608482701704e-05
, O 0 1.8709523885718227e-07
broad B-Disease 0 6.460853182943538e-05
great I-Disease 1 0.999661922454834
toes I-Disease 1 0.9369527101516724
, O 0 1.5806200792667369e-07
and O 0 2.083626498006197e-07
clinodactyly B-Disease 0 0.00047386379446834326
. O 0 2.3234879336087033e-06

Significant O 0 3.6013891531183617e-06
intra O 0 3.216397817595862e-05
- O 0 1.5515182383296633e-07
and O 0 2.2337280913831137e-09
interfamilial O 0 2.991478709191142e-07
phenotypic O 0 7.85846836492965e-08
variability O 0 1.1251868272665888e-06
is O 0 3.290892836016468e-10
present O 0 1.3375081597821747e-10
for O 0 1.5182224921694853e-10
either O 0 1.1415172807005547e-08
TWIST O 0 6.867690899525769e-06
mutations O 0 7.622363114023756e-07
or O 0 1.8924507116935274e-07
FGFR O 0 0.00016901610069908202
mutations O 0 1.1456022548372857e-06
. O 0 3.727670048192522e-07

The O 0 1.3232924800377077e-07
overlap O 0 1.1333171556771049e-07
in O 0 8.923761174450817e-10
clinical O 0 3.6109570888953613e-09
features O 0 7.599152418436006e-10
and O 0 9.680163615133353e-11
the O 0 3.9336528478983723e-10
presence O 0 1.0117366944228934e-09
, O 0 7.664945761431952e-11
in O 0 4.9363790832757104e-11
the O 0 4.709169165728611e-10
same O 0 8.151270214362683e-10
genes O 0 2.2248585196393833e-09
, O 0 4.314360257939853e-10
of O 0 7.53009876675037e-10
mutations O 0 4.814164067390436e-10
for O 0 1.2153483774923757e-10
more O 0 2.1282685336299068e-10
than O 0 1.005858507596713e-09
one O 0 5.1831525738066375e-09
craniosynostotic B-Disease 0 3.5620698213278956e-07
condition I-Disease 0 9.659353850111074e-08
- O 0 1.1332000227071148e-08
such O 0 2.790006892183783e-09
as O 0 2.158259526652273e-08
Saethre B-Disease 0 9.123007203015732e-07
- I-Disease 0 9.41465216897086e-08
Chotzen I-Disease 0 1.4764520983590046e-06
, I-Disease 0 3.9499319370861485e-09
Crouzon I-Disease 0 9.346302363155701e-07
, I-Disease 0 6.075030256624814e-09
and I-Disease 0 2.1914779324561096e-08
Pfeiffer I-Disease 0 3.71232999896165e-06
syndromes I-Disease 0 1.4081880181038287e-05
- O 0 4.566430220620532e-07
support O 0 1.5416382836974662e-08
the O 0 2.096082418745482e-08
hypothesis O 0 2.585947811439837e-08
that O 0 1.1719769599238816e-10
TWIST O 0 1.1022894597090271e-07
and O 0 6.947976638471687e-10
FGFRs O 0 9.648802290485037e-08
are O 0 2.981704466664681e-11
components O 0 3.890771704817553e-09
of O 0 1.5882432036207206e-09
the O 0 7.814845437437157e-10
same O 0 4.1062589439810893e-10
molecular O 0 6.538773522635211e-09
pathway O 0 5.930319346703072e-09
involved O 0 4.8879410935454004e-11
in O 0 1.5890415719366224e-11
the O 0 2.1150357853993995e-10
modulation O 0 2.3052157516190164e-08
of O 0 1.0620646584413862e-08
craniofacial O 1 0.9999668598175049
and O 0 1.6824664044179372e-06
limb O 1 0.9997897744178772
development O 0 1.8856231065456086e-07
in O 0 7.951306280062909e-10
humans O 0 1.3234610740653352e-08
. O 0 6.6460277281521485e-09
. O 0 6.017762643750757e-08

Mutation O 0 5.0833502740488257e-08
analysis O 0 1.6504198896427624e-08
of O 0 5.200009312034126e-08
UBE3A O 1 0.9999984502792358
in O 0 4.159966465522302e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 2.6546242679614807e-06
. O 0 1.1595093951655144e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.1791909784078598
AS B-Disease 1 1.0
) O 0 1.7394302664897054e-09
is O 0 2.1818247208926778e-10
caused O 0 4.587230595376468e-09
by O 0 1.101586488694295e-09
chromosome O 0 3.704312518948427e-07
15q11 O 0 1.7390251514370902e-06
- O 0 9.337751549765017e-08
q13 O 0 2.6856187673729437e-07
deletions O 0 2.8444395283599988e-08
of O 0 2.8020648024096317e-09
maternal O 0 1.185860920571713e-08
origin O 0 3.019756222855108e-09
, O 0 2.4123342212689636e-10
by O 0 4.828150657054664e-10
paternal O 1 0.9885421991348267
uniparental B-Disease 1 0.9999575614929199
disomy I-Disease 1 0.9989815354347229
( O 0 9.291256333199271e-07
UPD B-Disease 1 1.0
) O 0 3.336126486175317e-09
15 O 0 1.8662474232655768e-08
, O 0 1.065419349965957e-10
by O 0 3.7391054141799884e-10
imprinting O 0 7.168731372075854e-06
defects O 0 0.05663082003593445
, O 0 2.239017415917033e-09
and O 0 1.777265140612272e-10
by O 0 1.9955591346043633e-10
mutations O 0 7.885009978281232e-09
in O 0 2.355411421461895e-09
the O 0 6.903426452709027e-08
UBE3A O 0 3.634021049947478e-05
gene O 0 6.584041898349824e-07
. O 0 2.0907452835672302e-06

UBE3A O 0 0.0036548872012645006
encodes O 0 5.434829745354364e-06
a O 0 5.331041279532656e-07
ubiquitin O 0 6.890612667120877e-07
- O 0 2.2322136317143304e-07
protein O 0 7.647039268476874e-08
ligase O 0 1.3176757818200713e-07
and O 0 2.337826998655146e-08
shows O 0 5.2571120789934866e-08
brain O 0 1.3039168607065221e-06
- O 0 3.4748513400018055e-08
specific O 0 2.8952953812222404e-08
imprinting O 0 1.0624195965647232e-05
. O 0 3.2027534757617104e-07

Here O 0 3.479574672837771e-07
we O 0 4.773663064838729e-08
describe O 0 1.2622032841136388e-07
UBE3A O 0 2.1532287064474076e-05
coding O 0 9.792935315999785e-07
- O 0 7.62376600960124e-07
region O 0 3.0202070178120266e-08
mutations O 0 9.025976410725889e-09
detected O 0 3.8732088647464025e-09
by O 0 1.6499775157274854e-10
SSCP O 0 1.2639729902730323e-06
analysis O 0 6.147692910296598e-10
in O 0 4.427172795029577e-10
13 O 0 4.068608205898272e-08
AS B-Disease 1 1.0
individuals O 0 3.459070252453955e-10
or O 0 2.5331401420913835e-09
families O 0 2.958599587543631e-09
. O 0 1.9865343148239845e-08

Two O 0 1.8516836917115143e-06
identical O 0 4.675015134125715e-06
de O 0 9.513437362329569e-06
novo O 0 4.1464918467681855e-06
5 O 0 1.6127189610415371e-06
- O 0 3.213602610685484e-07
bp O 0 2.058102808177864e-07
duplications O 0 2.1996778798438754e-07
in O 0 4.722844337834431e-09
exon O 0 2.7075389041897324e-08
16 O 0 9.764998054606622e-08
were O 0 8.438269638588736e-09
found O 0 8.461769951395581e-09
. O 0 7.374664079407012e-08

Among O 0 1.4072946896703797e-07
the O 0 2.2230949525692267e-08
other O 0 8.665987039080392e-09
11 O 0 1.9492485847649732e-08
unique O 0 5.945427705711381e-09
mutations O 0 1.1459063031793448e-08
, O 0 2.1539403594061923e-09
8 O 0 1.8064396201111776e-08
were O 0 2.8268978269352374e-09
small O 0 3.9413681207634e-09
deletions O 0 7.850079697391266e-08
or O 0 1.813786631998937e-08
insertions O 0 1.8932450984721072e-07
predicted O 0 7.718873007434013e-08
to O 0 1.548456918243346e-09
cause O 0 4.078204085544712e-07
frameshifts O 0 4.1174694160872605e-06
, O 0 1.8752168706726025e-09
1 O 0 1.5883864890042787e-08
was O 0 5.031135064115233e-09
a O 0 2.3735127752111396e-10
mutation O 0 2.423725942168886e-10
to O 0 1.7221048198567956e-10
a O 0 1.9829258235404268e-09
stop O 0 5.394017676962903e-09
codon O 0 2.842552149218136e-08
, O 0 2.56399745879321e-09
1 O 0 2.547245436801404e-08
was O 0 1.093037305111011e-08
a O 0 1.5863147462269467e-09
missense O 0 4.8408068664684833e-08
mutation O 0 3.3710505498163457e-09
, O 0 2.0882509610409272e-10
and O 0 1.1524896315062705e-10
1 O 0 8.571677589941373e-09
was O 0 8.178902000111066e-09
predicted O 0 1.8053504247106389e-09
to O 0 1.173858510394865e-10
cause O 0 4.850508883436078e-09
insertion O 0 1.0360973412559815e-08
of O 0 1.6869178054434997e-08
an O 0 1.1564191382262834e-08
isoleucine O 0 6.888089387757645e-07
in O 0 1.4743780640813497e-09
the O 0 1.8354155528754745e-08
hect O 0 1.2662436574828462e-06
domain O 0 9.071302287111394e-08
of O 0 3.044040042254892e-08
the O 0 1.1342751804477302e-07
UBE3A O 0 7.178439773269929e-06
protein O 0 1.9751851709770563e-07
, O 0 1.3006252741476487e-09
which O 0 2.336612292541673e-10
functions O 0 5.837240135697641e-10
in O 0 1.0000373862339984e-09
E2 O 0 1.731774830204813e-07
binding O 0 1.7386879491709806e-08
and O 0 6.0046549954506645e-09
ubiquitin O 0 2.3690243722285231e-07
transfer O 0 3.482131432974711e-06
. O 0 1.8849231082640472e-06

Eight O 0 1.7396440910033562e-07
of O 0 1.1592945270422206e-08
the O 0 8.907079518394312e-10
cases O 0 6.391906448577345e-10
were O 0 3.363611333906391e-10
familial O 0 2.1600539135135932e-09
, O 0 2.057978371050595e-10
and O 0 9.773966358483932e-11
five O 0 7.198535101338166e-10
were O 0 1.3972848433851937e-09
sporadic O 0 6.326426955638453e-07
. O 0 2.6592991275720124e-07

In O 0 8.075358692849477e-08
two O 0 9.380197951713853e-09
familial O 0 2.5680808590777815e-08
cases O 0 1.0574029429832876e-09
and O 0 1.2167007679142472e-10
one O 0 1.170143287820835e-10
sporadic O 0 2.9425208936117997e-09
case O 0 6.417070763653498e-10
, O 0 2.2684357170454916e-10
mosaicism O 0 5.252020969237492e-07
for O 0 5.750253162517538e-09
UBE3A O 0 1.5332216207752936e-05
mutations O 0 2.7983167782963392e-08
was O 0 3.2284004358729135e-09
detected O 0 3.092504308188637e-10
in O 0 9.944291050334453e-12
the O 0 1.9362143832690748e-10
mother O 0 8.469693280055424e-10
of O 0 1.6076302511436324e-09
three O 0 3.1158515767515382e-09
AS B-Disease 1 1.0
sons O 0 7.827159009821116e-08
, O 0 2.0279515566823392e-10
in O 0 4.291034541581418e-11
the O 0 7.457148232248301e-10
maternal O 0 4.403528919283417e-08
grandfather O 0 2.306672115537367e-07
of O 0 7.751035013825458e-08
two O 0 1.1202756056150065e-08
AS B-Disease 1 1.0
first O 0 6.2850276094650326e-09
cousins O 0 1.436855434633344e-08
, O 0 5.143981907096418e-10
and O 0 1.6379837763924598e-10
in O 0 2.6682911435926826e-10
the O 0 7.70511654479833e-09
mother O 0 1.71460445841376e-08
of O 0 1.4012169202715086e-08
an O 0 3.701684647694492e-08
AS B-Disease 1 1.0
daughter O 0 1.9772518498939462e-05
. O 0 1.7201341506734025e-06

The O 0 1.2667470628002775e-07
frequencies O 0 2.1669421812475775e-08
with O 0 2.2838127222701843e-10
which O 0 2.3251599257090305e-10
we O 0 1.8557035075250639e-10
detected O 0 1.0035379194306415e-09
mutations O 0 2.548293798199097e-09
were O 0 8.800186135360377e-10
5 O 0 1.989775455513154e-09
( O 0 8.159074804670041e-11
14 O 0 2.9393292244606073e-09
% O 0 1.3085624250841477e-10
) O 0 1.1953621686239257e-12
of O 0 9.689214014452219e-11
35 O 0 4.83435236287022e-10
in O 0 2.2152864612157153e-11
sporadic O 0 1.8634045417798006e-09
cases O 0 1.3680227783918752e-10
and O 0 2.90789975432304e-10
8 O 0 4.184758761738294e-09
( O 0 8.81551984188711e-11
80 O 0 1.482567069110985e-09
% O 0 1.5084834770195954e-10
) O 0 2.655392832701109e-12
of O 0 1.5349589654878315e-10
10 O 0 1.2508588609350113e-09
in O 0 4.2486145157560884e-10
familial O 0 1.811083194525054e-08
cases O 0 3.5526019903642236e-09
. O 0 8.699457154648371e-09
. O 0 9.700877967588895e-08

The O 0 1.162428998213727e-05
hemochromatosis B-Disease 1 1.0
845 O 0 7.576735242764698e-06
G O 0 6.481694185822562e-07
- O 0 5.073954056911134e-08
- O 0 1.6297489580097135e-08
> O 0 5.930014257415905e-09
A O 0 1.848333219811593e-08
and O 0 1.4440026951945129e-10
187 O 0 2.307668223178183e-10
C O 0 4.072286063916408e-09
- O 0 7.746357444382568e-10
- O 0 1.6431224159063618e-09
> O 0 2.1464763300116374e-09
G O 0 2.202011373242385e-08
mutations O 0 4.2218459839205025e-09
: O 0 5.074374809233007e-10
prevalence O 0 2.792743591939484e-09
in O 0 1.7794496431911e-10
non O 0 1.9347766055943794e-08
- O 0 9.949504331530079e-09
Caucasian O 0 8.443711507766238e-09
populations O 0 3.934067738242675e-09
. O 0 2.514828878474873e-08

Hemochromatosis B-Disease 1 0.9926553964614868
, O 0 4.397821840029792e-07
the O 0 1.1675162568280939e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 1.7151775466572872e-07
leads O 0 4.89113008370623e-05
, O 0 3.857210550961554e-09
if O 0 3.943550552776287e-08
untreated O 1 0.9999998807907104
, O 0 5.561641702733766e-10
to O 0 2.0470569683794793e-09
progressive O 1 0.9901112914085388
iron B-Disease 1 0.970011293888092
overload I-Disease 1 0.9999940395355225
and O 0 6.127914389253419e-07
premature B-Disease 0 2.075898191833403e-05
death I-Disease 0 1.1335889212205075e-05
. O 0 1.1713366347976262e-06

The O 0 1.8619137335917912e-05
hemochromatosis B-Disease 1 1.0
gene O 0 0.07149864733219147
, O 0 4.011802957393229e-06
HFE O 1 0.999900221824646
, O 0 2.8470935831137467e-08
recently O 0 3.1799796129661217e-09
has O 0 1.6295668980870204e-10
been O 0 7.965449827507243e-11
identified O 0 9.81673742295186e-10
, O 0 3.8015805781110856e-11
and O 0 2.2105295024998917e-11
characterization O 0 7.309738148109091e-09
of O 0 4.138924758478879e-09
this O 0 2.9522170819085147e-10
gene O 0 3.5428173728035972e-09
has O 0 1.7580250588622448e-09
shown O 0 1.5873853620451683e-10
that O 0 3.806935322536731e-11
it O 0 1.8386153710636677e-11
contains O 0 6.665126089933082e-11
two O 0 8.320854422150248e-11
mutations O 0 1.3628590478376168e-09
that O 0 2.753559047441456e-10
result O 0 1.0027252805855369e-08
in O 0 7.475208896323693e-09
amino O 0 1.0737647215819379e-07
acid O 0 1.9171588760968916e-08
substitutions O 0 5.907695665996471e-09
- O 0 8.443132415436594e-09
cDNA O 0 2.0542158196690252e-08
nucleotides O 0 5.631638266834216e-09
845 O 0 2.3062669995965734e-08
G O 0 2.1258770743770583e-08
- O 0 9.79925030009099e-09
- O 0 6.953853493030238e-09
> O 0 7.268225132861517e-09
A O 0 9.349086127485862e-08
( O 0 5.795239288453047e-10
C282Y O 0 1.461622112230998e-08
) O 0 2.942372040459773e-11
and O 0 6.299927246544712e-11
187 O 0 2.887929617667595e-10
C O 0 3.1602922501150488e-09
- O 0 7.853860894968534e-10
- O 0 1.8229453502272008e-09
> O 0 5.604142927495559e-09
G O 0 2.2646688080385502e-07
( O 0 1.2317345365886467e-08
H63D O 0 2.9236916816444136e-05
) O 0 9.710389825556831e-09
. O 0 5.871044805871861e-08

Although O 0 1.0708906756917713e-06
hemochromatosis B-Disease 1 1.0
is O 0 9.6824628315062e-09
common O 0 1.555448769785528e-09
in O 0 4.2626163709869047e-10
Caucasians O 0 1.135424110287886e-08
, O 0 4.935967745645087e-10
affecting O 0 4.68769112416112e-09
> O 0 5.219054521887756e-09
= O 0 6.411886577240011e-09
1 O 0 7.342968011414541e-09
/ O 0 4.5483020127967677e-10
300 O 0 7.433003518242387e-11
individuals O 0 7.427458821596122e-12
of O 0 2.1389061355403527e-10
northern O 0 3.0521704608155176e-10
European O 0 2.1666549110399558e-10
origin O 0 2.9329227935193103e-09
, O 0 2.527916764805127e-10
it O 0 8.670757167816845e-11
has O 0 2.444514729527114e-11
not O 0 3.593145572744483e-11
been O 0 2.653800512675275e-10
recognized O 0 1.1847095526817952e-09
in O 0 3.45455386518978e-10
other O 0 2.6818647302917498e-09
populations O 0 5.5338393423198795e-08
. O 0 1.9233674208862794e-07

The O 0 1.7582010514161084e-07
present O 0 8.935995055026069e-09
study O 0 5.66550806269106e-10
used O 0 1.0219473878247953e-10
PCR O 0 5.3004947098145294e-09
and O 0 8.016512453856706e-10
restriction O 0 1.4195929765037363e-08
- O 0 8.840667753418074e-09
enzyme O 0 4.007775000758329e-09
digestion O 0 3.3674518729043257e-09
to O 0 1.1980522129917404e-10
analyze O 0 1.0787603033080018e-09
the O 0 3.2113686709855926e-10
frequency O 0 2.3772741553074184e-09
of O 0 1.4271285264655376e-09
the O 0 7.193090123536194e-09
845 O 0 1.4466423614578616e-08
G O 0 7.902506204970905e-09
- O 0 4.8793573625971476e-09
- O 0 4.287692867421811e-09
> O 0 2.1511239456373232e-09
A O 0 1.0104817427247781e-08
and O 0 1.771592872401584e-10
187 O 0 1.1764854368490063e-10
C O 0 1.0746509238046542e-09
- O 0 1.3437499724044955e-10
- O 0 2.9266403189787127e-10
> O 0 4.851468671240866e-10
G O 0 6.2960539004564e-09
mutations O 0 1.940570815150977e-09
in O 0 7.185078088056684e-10
HLA O 0 1.1130936172776273e-08
- O 0 2.5571551542924453e-09
typed O 0 4.0182668303856417e-10
samples O 0 7.521765328644126e-12
from O 0 4.4796128612079045e-11
non O 0 1.2126654125310665e-09
- O 0 2.858010494932728e-10
Caucasian O 0 3.4853755992436675e-10
populations O 0 8.347576796463585e-11
, O 0 1.192723263904183e-11
comprising O 0 1.654442034759729e-11
Australian O 0 4.605744396979361e-10
Aboriginal O 0 9.185071037087766e-10
, O 0 1.1499996094288534e-10
Chinese O 0 1.3496661566136936e-09
, O 0 3.1459293503566244e-10
and O 0 1.3960248512745466e-09
Pacific O 0 1.9507139015217945e-08
Islanders O 0 3.363756491125969e-07
. O 0 1.5809472131422808e-07

Results O 0 4.976811851520324e-07
showed O 0 1.2813356420338096e-07
that O 0 8.411944474318034e-10
the O 0 7.579339822427755e-09
845 O 0 1.9122612826549812e-08
G O 0 1.868316701347794e-08
- O 0 8.803548112723547e-09
- O 0 5.913737943785691e-09
> O 0 2.5643251966300795e-09
A O 0 4.713269330380854e-09
mutation O 0 3.3096259066667244e-10
was O 0 1.6772400135423027e-10
present O 0 7.237861785608368e-12
in O 0 4.534801353872631e-12
these O 0 5.1679847901109355e-11
populations O 0 6.150003284410843e-10
( O 0 6.239191802093202e-11
allele O 0 3.718054752965827e-10
frequency O 0 5.201203912008623e-10
0 O 0 1.242014407987213e-10
. O 0 4.7163134508920734e-11
32 O 0 1.2151010198024892e-09
% O 0 1.574978203411348e-10
) O 0 5.386545376406815e-12
, O 0 2.4472016427190546e-11
and O 0 5.5553946859410175e-11
, O 0 7.834780740845204e-11
furthermore O 0 1.0988290277680335e-09
, O 0 2.080212807564763e-10
it O 0 1.5404787168105116e-10
was O 0 8.369968718113796e-09
always O 0 5.30736388171249e-09
seen O 0 8.0576612049299e-09
in O 0 5.318234186368898e-10
conjunction O 0 6.775700001071527e-09
with O 0 1.609974598082431e-09
HLA O 0 3.899659077433171e-06
haplotypes O 0 6.09961219311117e-08
common O 0 9.846646831235262e-10
in O 0 1.851464537239167e-10
Caucasians O 0 2.9877191831673144e-09
, O 0 2.0749424400889893e-10
suggesting O 0 1.953129213916327e-09
that O 0 4.2589023974137774e-10
845 O 0 5.769698496749243e-09
G O 0 1.573934760301654e-08
- O 0 1.2356311529515551e-08
- O 0 1.74368963712368e-08
> O 0 1.5326669711157592e-08
A O 0 1.7904211802033387e-07
may O 0 1.3759263728374549e-09
have O 0 1.2605630428375036e-10
been O 0 7.702287418975828e-11
introduced O 0 3.131081852125739e-11
into O 0 7.415883185313277e-11
these O 0 3.639649692743774e-11
populations O 0 1.4493611866228662e-10
by O 0 7.841198246261172e-10
Caucasian O 0 2.1879596090457198e-07
admixture O 0 1.7098647049351712e-06
. O 0 4.859335831497447e-07

187 O 0 1.4593899777537445e-07
C O 0 8.357911696066367e-08
- O 0 1.7728714052367422e-09
- O 0 1.1312709657929076e-09
> O 0 5.004440195577331e-10
G O 0 4.581424573046888e-09
was O 0 8.708517240663127e-10
present O 0 3.703586048953156e-11
at O 0 2.4121950964461902e-11
an O 0 5.042540170141496e-12
allele O 0 5.5392697373424227e-11
frequency O 0 2.2046484082771656e-10
of O 0 5.111959744397154e-10
2 O 0 5.650955259284274e-08
. O 0 1.8073035334964516e-07

68 O 0 1.7641480098973261e-06
% O 0 3.0315812082903904e-09
in O 0 6.702606525355037e-11
the O 0 2.6034147060371993e-10
two O 0 4.430338040872783e-11
populations O 0 1.178722536243626e-10
analyzed O 0 7.684067271362949e-10
( O 0 8.324251704605601e-11
Australian O 0 1.9529950989749523e-09
Aboriginal O 0 6.8058656488290126e-09
and O 0 1.261020621257103e-09
Chinese O 0 1.4247684809731709e-08
) O 0 1.8880614849337007e-09
. O 0 8.684490637733688e-08

In O 0 7.345825725479926e-09
the O 0 2.9878403751126825e-08
Australian O 0 1.7452933320782904e-08
Aboriginal O 0 4.95194418803635e-09
samples O 0 4.6155587685170474e-10
, O 0 3.181434282684137e-10
187 O 0 5.877245912166984e-10
C O 0 2.739688476083302e-09
- O 0 4.78084738464446e-10
- O 0 1.1814916822672217e-09
> O 0 1.5990887503036788e-09
G O 0 1.8087911612951757e-08
was O 0 5.604549269122572e-09
found O 0 3.837847400989247e-11
to O 0 2.1462201807431747e-11
be O 0 5.552258999785842e-11
associated O 0 5.427309712757733e-09
with O 0 9.323524174931208e-10
HLA O 0 9.356717782793567e-06
haplotypes O 0 1.7360611082040123e-07
common O 0 3.837280271312693e-09
in O 0 3.565878980982262e-10
Caucasians O 0 4.8242498884576435e-09
, O 0 8.436620846374865e-11
suggesting O 0 3.6520431123676644e-10
that O 0 2.6919322673735202e-11
it O 0 8.539390722317464e-11
was O 0 3.8409839198116913e-10
introduced O 0 5.3528927818069505e-11
by O 0 1.3942785814791137e-10
recent O 0 1.4429167194407455e-08
admixture O 0 2.698514435905963e-06
. O 0 5.112906364956871e-07

In O 0 1.7231647220228297e-08
the O 0 1.3097398721129139e-08
Chinese O 0 2.0089112595655934e-09
samples O 0 2.6590954438354686e-10
analyzed O 0 1.4306715812040238e-09
, O 0 8.145888130695056e-11
187 O 0 1.0376072917539503e-10
C O 0 9.112549603784714e-10
- O 0 7.670986762464693e-11
- O 0 2.1273106887154114e-10
> O 0 2.709892310548412e-10
G O 0 2.9309206173167013e-09
was O 0 1.0498067970488023e-09
present O 0 6.307526723148271e-11
in O 0 4.812160392386744e-11
association O 0 3.5362129890970095e-10
with O 0 8.146323893232221e-11
a O 0 7.018342018660917e-10
wide O 0 2.040648094947528e-09
variety O 0 2.6988138390748873e-09
of O 0 1.1214771333811768e-08
HLA O 0 2.1226474018476438e-06
haplotypes O 0 1.8471989449153625e-07
, O 0 1.3738834514498421e-09
showing O 0 2.011169453197681e-09
this O 0 7.470326440772723e-11
mutation O 0 2.1635659930296924e-10
to O 0 6.091453730316942e-11
be O 0 1.4526933822534005e-10
widespread O 0 4.7070618514055695e-09
and O 0 5.552833748367902e-10
likely O 0 3.099521306282327e-09
to O 0 1.4674651493962187e-09
predate O 0 4.737959500289435e-07
the O 0 1.24202035323151e-08
more O 0 9.840001036209856e-10
genetically O 0 9.450631388574493e-09
restricted O 0 1.1577697911491214e-08
845 O 0 3.957580574365238e-08
G O 0 8.720459732103336e-08
- O 0 5.486451470915199e-08
- O 0 4.505806927568301e-08
> O 0 2.0516470300435685e-08
A O 0 7.542266189375368e-08
mutation O 0 3.2935520977162014e-08
. O 0 6.960862464211459e-08

Genotype O 0 4.0093013922160026e-06
- O 0 1.1552217529242625e-06
phenotype O 0 2.6137172426388133e-07
correlations O 0 3.550017027009744e-07
in O 0 2.614793537247806e-08
attenuated B-Disease 1 0.9999343156814575
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
. O 0 2.765019871731056e-06

Germ O 0 0.00012952889665029943
- O 0 1.477224850532366e-05
line O 0 8.174879440048244e-07
mutations O 0 9.167804648768652e-08
of O 0 1.643173597187797e-08
the O 0 6.6239058682526775e-09
tumor B-Disease 0 3.9512985949841095e-07
suppressor O 0 1.0500341886654496e-05
APC O 0 4.8369120264624144e-08
are O 0 9.127470307346286e-11
implicated O 0 1.8409120894347097e-09
in O 0 1.1193075355464543e-09
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00024053300148807466
AAPC B-Disease 1 1.0
) O 0 4.3740258637292584e-10
, O 0 1.6334995855959988e-11
a O 0 1.6557805473937925e-11
variant O 0 3.1094594987735036e-07
of O 0 6.314724942058092e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.0555480912444182e-05
FAP B-Disease 0 1.4118214494374115e-05
) O 0 9.143701795721881e-09
. O 0 4.566787481508072e-08

AAPC B-Disease 1 1.0
is O 0 1.8612103858117734e-08
recognized O 0 3.3854841152702875e-09
by O 0 1.9476893708958443e-10
the O 0 8.147943986180906e-10
occurrence O 0 1.856501974373259e-08
of O 0 5.936317215571307e-09
< O 0 7.495857090589197e-08
100 O 0 2.9667438283809133e-08
colonic B-Disease 0 9.319467153545702e-07
adenomas I-Disease 0 4.529308341716387e-07
and O 0 3.1761471230851157e-10
a O 0 1.4630376077295892e-10
later O 0 1.3469941828603282e-09
onset O 0 1.0116319572262e-05
of O 0 1.5616883501934353e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.9854228250923995e-10
age O 0 1.1352848661161374e-09
> O 0 1.1681345890579564e-09
40 O 0 3.0350986168770078e-09
years O 0 1.1114827946911987e-09
) O 0 4.492158589552986e-10
. O 0 2.5289512706194728e-08

The O 0 1.3126889086834126e-07
aim O 0 7.990401940105585e-08
of O 0 9.261512445846165e-09
this O 0 2.686578737254308e-10
study O 0 1.649678588178105e-10
was O 0 3.8302880311924525e-10
to O 0 5.62920578206505e-11
assess O 0 2.9177643412481302e-08
genotype O 0 7.866302098591405e-07
- O 0 9.821715138969012e-07
phenotype O 0 4.4401838295016205e-07
correlations O 0 1.41433429234894e-06
in O 0 1.284329300688114e-07
AAPC B-Disease 1 1.0
families O 0 4.767357495438773e-07
. O 0 4.478906419080886e-07

By O 0 4.1372377523885007e-08
protein O 0 6.81880976571847e-07
- O 0 1.03497988845902e-07
truncation O 0 1.3029891476890043e-07
test O 0 7.427597648046458e-09
( O 0 1.286501039032828e-08
PTT O 0 3.195327735738829e-07
) O 0 4.698141181647131e-11
assay O 0 2.3549351357843307e-09
, O 0 4.621502486257256e-11
the O 0 8.031200704472496e-11
entire O 0 7.310710370411755e-10
coding O 0 3.941698523135528e-09
region O 0 5.402522429420742e-09
of O 0 4.187745261674536e-09
the O 0 1.1764462293228917e-08
APC B-Disease 0 1.780554725883121e-08
gene O 0 4.119919516654136e-09
was O 0 2.1389615412203966e-08
screened O 0 7.920790690008062e-10
in O 0 3.279755980689636e-11
affected O 0 2.0183468785184289e-10
individuals O 0 7.79419445651186e-11
from O 0 1.5954915610905118e-08
11 O 0 3.909289034709218e-07
AAPC B-Disease 1 1.0
kindreds O 0 1.6848621271492448e-06
, O 0 9.127700817401774e-10
and O 0 1.7846807365273776e-10
their O 0 5.230482158502525e-10
phenotypic O 0 9.380791965440949e-08
differences O 0 6.139122206150205e-07
were O 0 5.5056037950862446e-08
examined O 0 8.069912951214064e-07
. O 0 9.575794592819875e-07

Five O 0 4.4122353415332327e-07
novel O 0 2.4645893859087664e-07
germ O 0 7.458842446794733e-06
- O 0 1.607449235052627e-06
line O 0 9.86510258371709e-07
APC B-Disease 0 2.5544999004978308e-08
mutations O 0 4.708974099543184e-09
were O 0 1.0867027278038677e-09
identified O 0 1.8753170127894236e-09
in O 0 9.457875593810172e-10
seven O 0 3.832593975516829e-08
kindreds O 0 1.2145142136432696e-05
. O 0 7.808392297192768e-07

Mutations O 0 8.061090284172678e-07
were O 0 3.208518606356847e-08
located O 0 2.94524449273581e-09
in O 0 2.7595094612142823e-11
three O 0 6.297917916342488e-12
different O 0 1.391822681412469e-11
regions O 0 5.123096946668682e-10
of O 0 2.1544703798781484e-09
the O 0 9.740532824764614e-09
APC B-Disease 0 1.1932074883702626e-08
gene O 0 1.866210963541448e-09
( O 0 6.62660704087159e-10
1 O 0 7.816861824494481e-09
) O 0 7.625210185491227e-11
at O 0 1.1039106295740453e-09
the O 0 1.218454559470672e-09
5 O 0 4.2837364766512565e-09
end O 0 6.234083471667873e-09
spanning O 0 1.501778790213848e-08
exons O 0 2.3290814610277266e-08
4 O 0 1.569480012619806e-08
and O 0 1.0466437716516452e-09
5 O 0 7.035676041766692e-09
, O 0 1.0217199308826252e-09
( O 0 1.53385859569255e-10
2 O 0 4.591869995351772e-09
) O 0 5.277307410511689e-11
within O 0 2.4734256309777436e-10
exon O 0 2.8192947976179994e-09
9 O 0 1.199553434361178e-08
, O 0 4.527926089625822e-10
and O 0 7.946651670032168e-10
( O 0 2.0498026886972553e-10
3 O 0 7.113167388439479e-09
) O 0 5.6801882641899226e-11
at O 0 1.7859653755891713e-09
the O 0 1.963880169597587e-09
3 O 0 1.3098997442284599e-08
distal O 0 4.311386447852783e-08
end O 0 3.30540892434783e-08
of O 0 2.5676937909224762e-08
the O 0 6.22337026356945e-08
gene O 0 2.775101108909439e-07
. O 0 2.958849108836148e-06

Variability O 0 3.0790379241807386e-06
in O 0 3.9698413445421465e-09
the O 0 2.93502688819558e-09
number O 0 9.026424940827837e-09
of O 0 4.4964579615225375e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 7.646977273623179e-09
most O 0 2.8832334089679e-11
apparent O 0 1.411942007756295e-09
in O 0 1.6402745481314263e-11
individuals O 0 2.373348392814556e-11
with O 0 2.4775131599041877e-11
mutations O 0 9.763313491006897e-10
in O 0 1.5714614332029697e-10
region O 0 5.318338214266305e-09
1 O 0 1.7506744498518856e-08
, O 0 2.5133648495767602e-09
and O 0 2.2124604370787893e-08
upper O 0 3.7705387512687594e-05
- O 0 3.802192168222973e-06
gastrointestinal O 0 2.913626985900919e-06
manifestations O 0 3.2435286811960395e-06
were O 0 1.1073036931819047e-09
more O 0 2.3245877445177143e-10
severe O 0 3.2898732627018035e-08
in O 0 6.180012057654949e-10
them O 0 7.470733365266824e-09
. O 0 2.966167755857896e-07

In O 0 6.6172387569451985e-09
individuals O 0 4.5830830797122246e-10
with O 0 2.265763410225219e-10
mutations O 0 3.1464464367303435e-09
in O 0 1.1425572293832786e-10
either O 0 4.1236281056455937e-10
region O 0 1.099529356451967e-09
2 O 0 7.997178474994371e-10
or O 0 1.933136983822692e-10
region O 0 1.2902207080500716e-09
3 O 0 1.4851143648186849e-09
, O 0 5.449876661067776e-11
the O 0 2.490306016955657e-10
average O 0 1.981640185277911e-09
number O 0 1.810170680016654e-09
of O 0 2.255907993742312e-08
adenomas B-Disease 0 5.946326382400002e-07
tended O 0 6.672945573882316e-08
to O 0 1.921580228270159e-09
be O 0 2.4035267109923097e-09
lower O 0 1.4179043716922024e-08
than O 0 1.1041564190739095e-10
those O 0 1.3645179430810117e-10
in O 0 6.225438220486268e-11
individuals O 0 1.7380322875348853e-11
with O 0 2.6035030034621265e-11
mutations O 0 5.6457671870902e-10
in O 0 7.088591519321952e-11
region O 0 1.5275530840241913e-09
1 O 0 4.0537799783635364e-09
, O 0 1.2448318764679556e-10
although O 0 9.043204518555115e-10
age O 0 1.0874622091705533e-08
at O 0 2.933459697374019e-09
diagnosis O 0 1.4770583867118603e-08
was O 0 2.609954252719149e-09
similar O 0 1.300982543916973e-09
. O 0 2.0045418125391734e-07

In O 0 1.0722318677380827e-07
all O 0 9.156512987829046e-07
AAPC B-Disease 1 1.0
kindreds O 0 6.379774276865646e-05
, O 0 7.275104074722094e-09
a O 0 4.8909858385570715e-09
predominance O 0 5.3279327403288335e-06
of O 0 2.4985760319395922e-05
right O 1 1.0
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 5.774518285761587e-06
rectal B-Disease 0 0.24581341445446014
polyp I-Disease 0 3.636838243892271e-07
sparing O 0 1.622990168925753e-07
was O 0 9.641241405233814e-08
observed O 0 5.162456062635101e-08
. O 0 1.0320879795244764e-07

No O 0 3.4369622881058604e-05
desmoid B-Disease 1 0.9656764268875122
tumors I-Disease 1 1.0
were O 0 2.1144085593505224e-08
found O 0 6.315269973633519e-10
in O 0 1.3099259177362654e-10
these O 0 2.6847051248779508e-09
kindreds O 0 8.220315066864714e-06
. O 0 3.371425805198669e-07

Our O 0 6.773796030756785e-07
data O 0 1.4423613947656122e-07
suggest O 0 4.792903851580377e-08
that O 0 1.6206687103448303e-09
, O 0 8.474460022611652e-10
in O 0 3.2803475491505196e-09
AAPC B-Disease 1 1.0
families O 0 9.052666172237878e-09
, O 0 1.9538361206716814e-10
the O 0 1.2280597372349433e-10
location O 0 1.5681603571238156e-08
of O 0 6.193738855131414e-09
the O 0 4.085326921199339e-08
APC B-Disease 0 4.511917381933017e-07
mutation O 0 2.0709787662553936e-08
may O 0 6.651556638814782e-09
partially O 0 3.852595398257108e-08
predict O 0 6.8469581115948586e-09
specific O 0 9.83386971853406e-09
phenotypic O 0 5.603749855254136e-07
expression O 0 3.3328224162687548e-06
. O 0 3.6391456887940876e-06

This O 0 1.071448441081202e-08
should O 0 2.2707573599234365e-09
help O 0 1.5135652731146365e-09
in O 0 3.9632877535389355e-10
the O 0 1.0924344762131e-09
design O 0 4.319461055501961e-08
of O 0 1.4994347097285754e-08
tailored O 0 1.2487907952163368e-07
clinical O 0 8.535364770523302e-08
- O 0 4.762967265037332e-08
management O 0 2.673937737895926e-09
protocols O 0 3.411295024235983e-09
in O 0 1.3947146215720352e-10
this O 0 1.4250960134187807e-10
subset O 0 1.754947120957695e-08
of O 0 9.455895622068056e-09
FAP B-Disease 0 3.8522208001268154e-07
patients O 0 3.1402114242240486e-09
. O 0 4.439554501800558e-09
. O 0 1.3964628919893585e-07

Wilms B-Disease 0 0.0016632525948807597
' I-Disease 0 7.343093329836847e-06
tumor I-Disease 0 6.391302918018482e-07
1 O 0 1.9560162911602674e-07
and O 0 1.45094203318763e-08
Dax O 0 1.3652666893904097e-05
- O 0 1.255271531164226e-08
1 O 0 1.212721567611652e-08
modulate O 0 1.1644135433641623e-08
the O 0 4.4417736155821785e-09
orphan O 0 4.379606721727214e-08
nuclear O 0 3.7815109266148283e-08
receptor O 0 1.853689610697984e-07
SF O 0 6.696828222629847e-06
- O 0 4.473685066841426e-08
1 O 0 2.189029935095732e-08
in O 0 3.269601811517475e-10
sex O 0 1.8135219714832118e-10
- O 0 2.1160849461576703e-10
specific O 0 1.8298244863768076e-10
gene O 0 3.955066052441225e-09
expression O 0 3.648356994290225e-08
. O 0 9.734296213537164e-08

Products O 0 3.052255692637118e-07
of O 0 3.1475292416871525e-07
steroidogenic O 0 6.933433724043425e-06
factor O 0 3.81947700134333e-07
1 O 0 3.272684807598125e-07
( O 0 8.914426530282071e-09
SF O 0 6.659811788267689e-06
- O 0 6.359722704019077e-08
1 O 0 6.1924659178203e-08
) O 0 1.6466991104024942e-09
and O 0 7.431806725577417e-09
Wilms B-Disease 0 1.213607447425602e-06
tumor I-Disease 0 1.6164420912900823e-06
1 O 0 1.2954166095369146e-06
( O 0 1.8215040142877115e-08
WT1 O 0 4.587925559462747e-06
) O 0 7.826301273716751e-10
genes O 0 1.0051853793768828e-09
are O 0 1.7394814755267163e-11
essential O 0 4.982647627826964e-10
for O 0 1.8416662639353376e-10
mammalian O 0 3.152251508709014e-07
gonadogenesis O 0 6.761294457646727e-07
prior O 0 9.51983114561017e-09
to O 0 2.216361982831927e-09
sexual O 0 3.74159192517709e-08
differentiation O 0 1.5387176972581074e-06
. O 0 6.83079178998014e-07

In O 0 3.6983536233492487e-08
males O 0 5.567322602928471e-09
, O 0 4.0090442077200805e-09
SF O 0 6.923984983586706e-06
- O 0 1.423287443458321e-07
1 O 0 1.7421942288819992e-07
participates O 0 1.8361044906711754e-09
in O 0 1.5624623816989924e-10
sexual O 0 1.3466466830536206e-10
development O 0 2.4606547355254804e-10
by O 0 1.1953217929350224e-11
regulating O 0 1.5589415314209987e-09
expression O 0 9.00974050921377e-09
of O 0 6.282438569371607e-09
the O 0 3.383045665827922e-08
polypeptide O 0 2.492771500328672e-06
hormone O 0 2.0797413924356078e-07
Mullerian O 0 1.7624025758777861e-06
inhibiting O 0 1.954446275931332e-07
substance O 0 3.647498090231238e-07
( O 0 1.8566441895018215e-07
MIS O 0 0.00010728980123531073
) O 0 3.274304205547196e-08
. O 0 1.7969726684441412e-07

Here O 0 5.805163141303638e-07
, O 0 2.9195458495223647e-08
we O 0 5.644671841054105e-09
show O 0 9.034192949286535e-09
that O 0 5.851109374788166e-09
WT1 O 0 1.8687658666749485e-05
- O 0 2.0740681065944955e-06
KTS O 0 6.633336306549609e-05
isoforms O 0 7.672620654375351e-07
associate O 0 1.0858807399927173e-06
and O 0 7.967706494582671e-09
synergize O 0 2.6642237571650185e-07
with O 0 5.250545775936644e-09
SF O 0 2.220963688159827e-05
- O 0 1.1404686972582567e-07
1 O 0 5.060037366888537e-08
to O 0 4.630189121002104e-09
promote O 0 1.8516682587232935e-07
MIS O 0 3.680068766698241e-05
expression O 0 2.643145364800148e-07
. O 0 5.854176379216369e-07

In O 0 8.98736303156511e-08
contrast O 0 4.946108447256847e-07
, O 0 9.15202846840657e-08
WT1 O 0 5.6944067182485014e-05
missense O 0 1.8468551843398018e-06
mutations O 0 1.2577956454151717e-07
, O 0 1.6362390331536858e-09
associated O 0 2.8658779793744316e-09
with O 0 3.101914836101116e-10
male B-Disease 0 8.36405149584607e-08
pseudohermaphroditism I-Disease 1 1.0
in O 0 4.908277517756687e-08
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.0091097613649254e-08
fail O 0 1.3025699630020426e-08
to O 0 3.991632357980279e-09
synergize O 0 3.587727803733287e-07
with O 0 1.3241730378865668e-08
SF O 0 0.0004043691442348063
- O 0 3.632294465205632e-06
1 O 0 4.6108125388855115e-06
. O 0 5.331717147782911e-07

Additionally O 0 1.5716809684818145e-06
, O 0 6.854445011583721e-09
the O 0 1.1126330079491709e-08
X O 0 1.5350094599853037e-06
- O 0 1.862798342244787e-07
linked O 0 7.084971684889751e-07
, O 0 2.3928596881717112e-09
candidate O 0 7.103229560101454e-09
dosage O 0 9.632768183109874e-08
- O 0 1.1210109285286762e-08
sensitive O 0 1.2804983740011266e-08
sex O 0 7.566928195146261e-10
- O 0 2.792189590650196e-09
reversal O 0 1.2309031127699654e-08
gene O 0 1.3740198978595686e-09
, O 0 3.892924205217696e-09
Dax O 0 6.49699302357476e-07
- O 0 2.25713780999115e-09
1 O 0 5.542212910825128e-09
, O 0 3.7066971714239116e-10
antagonizes O 0 8.463124423485624e-09
synergy O 0 8.78040662399826e-09
between O 0 1.866015963969403e-08
SF O 0 4.610513769875979e-06
- O 0 9.741557960296632e-08
1 O 0 1.6085826359812927e-07
and O 0 2.379271535346561e-08
WT1 O 0 3.8575840335397515e-06
, O 0 1.2273391192252348e-09
most O 0 2.3969512485955136e-10
likely O 0 4.594934155388586e-10
through O 0 7.247590722014863e-11
a O 0 2.8941993246434095e-10
direct O 0 4.359701932798998e-09
interaction O 0 1.2457903153517691e-08
with O 0 3.4487819267070563e-09
SF O 0 0.00039681553607806563
- O 0 4.485169029067038e-06
1 O 0 4.044278284709435e-06
. O 0 3.7773159533571743e-07

We O 0 1.1632641161440915e-07
propose O 0 9.195473893441886e-08
that O 0 1.8391476785950545e-08
WT1 O 0 2.067328205157537e-05
and O 0 1.0464910360497015e-07
Dax O 0 0.00020091985061299056
- O 0 5.82836783280527e-08
1 O 0 3.003433235448938e-08
functionally O 0 7.473754948250644e-09
oppose O 0 3.336270981701972e-10
each O 0 2.8524922007777676e-11
other O 0 1.2826113782171689e-10
in O 0 1.9450721588931685e-10
testis O 0 3.19370023760257e-08
development O 0 3.605815868112927e-09
by O 0 1.5941584718959234e-09
modulating O 0 6.218837143023848e-07
SF O 0 3.0110040825093165e-05
- O 0 3.350869519636035e-07
1 O 0 3.659051230897603e-07
- O 0 1.4045032514786726e-07
mediated O 0 6.625708692808985e-07
transactivation O 0 2.157997641916154e-06
. O 0 2.5859872465616718e-08
. O 0 7.27707814007772e-08

A O 0 2.0444535948627163e-06
mouse O 0 1.2470674448650243e-07
model O 0 8.782554772324147e-08
for O 0 4.9105342014854614e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9919310212135315
centre O 0 0.00015549614909105003
mutations O 0 1.6104058886412531e-06
. O 0 3.599640763241041e-07

Imprinting O 0 1.0625603863445576e-05
in O 0 5.93478084454091e-08
the O 0 1.1759317430914962e-07
15q11 O 0 1.5574822782582487e-06
- O 0 6.052664502931293e-08
q13 O 0 3.5307752455082664e-07
region O 0 4.94231944259127e-09
involves O 0 1.1894644158516599e-09
an O 0 1.142732242165323e-09
imprinting O 0 5.891769205845776e-07
centre O 0 1.1356014510965906e-06
( O 0 3.299738038364808e-09
IC O 0 2.1733059838879853e-05
) O 0 9.942973111520814e-10
, O 0 2.3594881604083184e-10
mapping O 0 1.1542413691500997e-09
in O 0 1.86763077225649e-10
part O 0 3.5429240097251125e-10
to O 0 9.109543674945542e-10
the O 0 1.641215874315094e-08
promoter O 0 3.8678254554724845e-07
and O 0 8.923544569938713e-09
first O 0 2.1029221031199086e-08
exon O 0 8.183648958492995e-08
of O 0 6.079930585656257e-07
SNRPN O 1 0.7702417969703674
. O 0 5.998733286105562e-06

Deletion O 0 3.6020821880811127e-07
of O 0 8.50046717459918e-08
this O 0 6.018356923931378e-09
IC O 0 1.2030866855639033e-05
abolishes O 0 3.0510846045217477e-06
local O 0 8.783592875261093e-08
paternally O 0 2.544332460274745e-07
derived O 0 2.0040202830529097e-09
gene O 0 7.690811876237547e-10
expression O 0 9.305936021775096e-10
and O 0 1.135163074650336e-10
results O 0 1.5452173984797923e-09
in O 0 1.3637490248186168e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999988079071045
PWS B-Disease 1 1.0
) O 0 2.0306170256390033e-07
. O 0 1.4852942342713504e-07

We O 0 4.655544927345545e-08
have O 0 7.721324690734832e-10
created O 0 2.6024478128050532e-09
two O 0 4.2470427175089753e-10
deletion O 0 1.3950745003654674e-09
mutations O 0 6.380764361324509e-09
in O 0 7.660287404398503e-10
mice O 0 1.0830506491643632e-09
to O 0 3.9520250960656256e-10
understand O 0 4.702765821207322e-08
PWS B-Disease 1 1.0
and O 0 3.649204272093698e-09
the O 0 1.4508584333938757e-09
mechanism O 0 5.623459475856407e-09
of O 0 6.724981127526064e-10
this O 0 2.37001240854795e-09
IC O 0 6.46740008960478e-05
. O 0 1.2791626886610175e-06

Mice O 0 9.915944247040898e-06
harbouring O 0 1.2155755030107684e-05
an O 0 1.851342723568905e-08
intragenic O 0 5.174394459572795e-07
deletion O 0 6.386048578832515e-09
in O 0 3.536687165350827e-09
Snrpn O 0 7.416688731609611e-06
are O 0 5.186109319765819e-09
phenotypically O 0 2.309513911313843e-05
normal O 0 7.997885518307157e-07
, O 0 6.400275309736969e-10
suggesting O 0 2.5304649486912467e-09
that O 0 1.8381708655201834e-10
mutations O 0 1.189968745762826e-08
of O 0 4.985904311638478e-08
SNRPN O 0 0.0012922356836497784
are O 0 1.0909518843860155e-09
not O 0 1.0022791485653215e-09
sufficient O 0 5.395543567487948e-08
to O 0 2.189806558305918e-08
induce O 0 0.0002575176185928285
PWS B-Disease 1 1.0
. O 0 3.0582967156078666e-05

Mice O 0 1.6301008542995987e-07
with O 0 4.3343204025880766e-10
a O 0 5.378594791771718e-10
larger O 0 1.423420492585592e-09
deletion O 0 1.0807972294912815e-09
involving O 0 1.1915693987063491e-09
both O 0 2.0936878897259703e-09
Snrpn O 0 1.0898958180405316e-06
and O 0 9.966574232578296e-10
the O 0 6.16277073817173e-09
putative O 0 2.4121311525959754e-06
PWS O 1 1.0
- O 0 1.2931833737184206e-07
IC O 0 2.2681970222038217e-06
lack O 0 9.591257565944034e-09
expression O 0 5.7266338338024525e-09
of O 0 7.670891477573605e-09
the O 0 1.3300201828769787e-08
imprinted O 0 2.5984621743191383e-07
genes O 0 1.7988244849220791e-07
Zfp127 O 0 7.078399903548416e-06
( O 0 5.2689448359899416e-09
mouse O 0 3.520656832733948e-08
homologue O 0 8.341952479895554e-07
of O 0 4.777069406713963e-08
ZNF127 O 0 4.118049764656462e-05
) O 0 7.1192749473425465e-09
, O 0 2.2613187766751253e-08
Ndn O 0 1.4158903240968357e-06
and O 0 5.066186137270279e-09
Ipw O 0 7.442525316037063e-07
, O 0 6.008698871795559e-09
and O 0 1.102934077401585e-09
manifest O 0 1.1543387579138198e-08
several O 0 2.7988811268642166e-09
phenotypes O 0 4.643838451556803e-07
common O 0 1.017480943943383e-08
to O 0 1.0442419551282e-07
PWS B-Disease 1 1.0
infants O 1 0.9990602135658264
. O 0 1.8732678199739894e-06

These O 0 5.661157764791369e-09
data O 0 6.512300032568419e-09
demonstrate O 0 2.390902364979297e-09
that O 0 7.889575104336188e-11
both O 0 2.2137583433057273e-10
the O 0 7.983766980856899e-10
position O 0 6.278018549465969e-09
of O 0 1.6552581527662369e-09
the O 0 2.2794881537890888e-09
IC O 0 2.181399850087473e-06
and O 0 5.998413432628524e-10
its O 0 4.4574977042799446e-10
role O 0 7.135027013660533e-10
in O 0 7.668133489291407e-11
the O 0 2.7289170922983885e-10
coordinate O 0 1.2334595567153883e-09
expression O 0 1.4519913271726637e-08
of O 0 1.9487467639578426e-08
genes O 0 7.421140146846028e-09
is O 0 9.565767067343245e-10
conserved O 0 1.5986383772315094e-08
between O 0 3.199613018978198e-09
mouse O 0 4.141072817986924e-09
and O 0 5.981983242087097e-10
human O 0 1.8474369811727342e-09
, O 0 1.6575320282985473e-10
and O 0 4.066072825659184e-11
indicate O 0 8.579916221940209e-10
that O 0 8.763866715666424e-11
the O 0 1.496676671486341e-09
mouse O 0 1.429250606754806e-09
is O 0 5.252513701758943e-11
a O 0 5.230509775300263e-11
suitable O 0 1.5315352319689168e-09
model O 0 8.498660108990919e-10
system O 0 1.1099336033604246e-10
in O 0 5.896386851000912e-11
which O 0 2.8963735923537293e-11
to O 0 7.742911867225644e-11
investigate O 0 1.0077827461429933e-09
the O 0 1.1585246095791035e-09
molecular O 0 4.119291130422198e-09
mechanisms O 0 1.0900579994199688e-08
of O 0 2.3283919237115924e-09
imprinting O 0 4.64454714688145e-08
in O 0 8.341576041015486e-11
this O 0 5.7757819360571006e-11
region O 0 1.3825847133830393e-09
of O 0 2.50742759888567e-09
the O 0 5.331175501055441e-09
genome O 0 5.743599817975564e-09
. O 0 1.2718039066328402e-08
. O 0 2.2125286136542854e-07

Mutations O 0 5.122330435369804e-07
of O 0 7.077159125401522e-08
the O 0 1.78043926268856e-08
ATM O 0 6.288183840297279e-07
gene O 0 1.7318072309535637e-08
detected O 0 1.7688192244236234e-08
in O 0 4.221119287439734e-10
Japanese O 0 1.8965311028296128e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 6.081414085201686e-06
: O 0 9.088712421556622e-11
possible O 0 5.792432644646794e-10
preponderance O 0 5.484714051817718e-07
of O 0 1.0709580777756855e-08
the O 0 1.2900098766976953e-08
two O 0 3.0116173999061857e-09
founder O 0 9.921915733457354e-08
mutations O 0 2.7740204799897583e-08
4612del165 O 0 2.3359689294011332e-07
and O 0 1.069123278796269e-08
7883del5 O 0 1.785406311682891e-06
. O 0 3.6499861266747757e-07

The O 0 7.174218126237975e-07
ATM O 0 0.00023853511083871126
( O 0 1.1643217476375867e-05
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 2.4648461049991965e-09
mutated O 0 3.813043658595916e-09
) O 0 2.391333311924093e-11
gene O 0 8.831440440060234e-11
on O 0 1.0368322866938229e-09
human O 0 7.364789333941246e-10
chromosome O 0 6.276332698007536e-08
11q22 O 0 1.5109346804820234e-06
. O 0 2.2850356629078306e-07

3 O 0 8.882596375769936e-06
has O 0 9.508852372164256e-09
recently O 0 2.9763720377218306e-09
been O 0 1.2462668397272836e-10
identified O 0 3.7556591170329057e-10
as O 0 5.138693984219067e-11
the O 0 3.626137584644695e-11
gene O 0 1.348746808682577e-10
responsible O 0 1.6372997402314127e-10
for O 0 3.563361758440742e-11
the O 0 1.544722350033112e-09
human O 0 5.122199127072236e-07
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9916821122169495
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.2347568179602604e-08
. O 0 9.537536982406891e-08

In O 0 4.959562538431328e-09
order O 0 4.268256414974303e-09
to O 0 1.2024184981029862e-09
define O 0 1.4809852899588805e-08
the O 0 2.2959296686053676e-09
types O 0 2.511161945051299e-08
of O 0 9.497360231591756e-09
disease O 0 2.1125508453678776e-07
- O 0 1.7906733873473968e-08
causing O 0 5.592922747155171e-08
ATM O 0 2.8887211556138936e-07
mutations O 0 8.064303891330837e-09
in O 0 6.880573333312157e-10
Japanese O 0 8.697998623574676e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
patients O 0 1.0792341242904513e-08
as O 0 5.25890164748688e-10
well O 0 7.940708507403471e-11
as O 0 1.3779401231150956e-10
to O 0 1.0965004598739725e-10
look O 0 1.169059626882074e-09
for O 0 1.3652025343535712e-10
possible O 0 2.252519948342524e-08
mutational O 0 5.059225259174127e-06
hotspots O 0 6.165018930914812e-07
, O 0 6.163240584555751e-09
reverse O 0 4.428570932191178e-08
- O 0 2.0388906563084674e-08
transcribed O 0 7.319043149323079e-09
RNA O 0 4.384142826552306e-09
derived O 0 1.0878059564234377e-09
from O 0 9.83812475929824e-10
ten O 0 1.2716746544683133e-09
patients O 0 1.183920600444921e-10
belonging O 0 1.8258848599739252e-10
to O 0 8.048713084907178e-11
eight O 0 4.680701937154197e-10
unrelated O 0 4.765909000781221e-09
Japanese O 0 1.37468433081267e-07
A B-Disease 1 1.0
- I-Disease 0 2.459251663822215e-05
T I-Disease 1 1.0
families O 0 8.443744370367767e-09
was O 0 2.4798605391396222e-09
analyzed O 0 3.544153859280641e-10
for O 0 2.5574745446399483e-11
mutations O 0 3.5726596681051603e-10
by O 0 1.3556356037724981e-10
the O 0 8.044481747404575e-10
restriction O 0 2.5534558911743943e-09
endonuclease O 0 1.037952745974735e-08
fingerprinting O 0 2.0308053017004113e-09
method O 0 7.547562574927724e-08
. O 0 3.542691615621152e-07

As O 0 3.9928877981765254e-07
has O 0 4.010283216615562e-09
been O 0 4.993617741533285e-10
reported O 0 2.420953715276397e-10
by O 0 4.0972291531771177e-11
others O 0 9.196834405145182e-10
, O 0 3.426709471732181e-10
mutations O 0 2.055217995788894e-09
that O 0 2.7992963502754264e-10
lead O 0 3.674880177939599e-09
to O 0 1.849739361681202e-09
exon O 0 2.7956707171483686e-08
skipping O 0 8.511272397981884e-08
or O 0 1.5640292616581064e-08
premature O 0 8.830257058889401e-08
protein O 0 5.7048438861784234e-08
truncation O 0 2.0937135047915945e-07
were O 0 5.63319613178237e-09
also O 0 8.122558181611339e-10
predominant O 0 2.7890132869856643e-08
in O 0 1.3814223098762568e-09
our O 0 9.623916241707775e-08
mutants O 0 1.274430928788206e-06
. O 0 7.233003884721256e-07

Six O 0 3.849304519576435e-08
different O 0 2.877154958724759e-09
mutations O 0 1.348033151771233e-08
were O 0 9.857056282314147e-10
identified O 0 1.3151562061608502e-09
on O 0 3.433186235302088e-10
12 O 0 6.476139624567168e-10
of O 0 1.190626486291535e-09
the O 0 6.154430742810746e-09
16 O 0 7.281992964180972e-08
alleles O 0 4.125024588574888e-08
examined O 0 7.442582727890112e-07
. O 0 9.253778898710152e-07

Four O 0 1.2448597885850177e-07
were O 0 5.110578182865311e-09
deletions O 0 5.644071876531598e-08
involving O 0 3.641035029033901e-09
a O 0 2.4784136964939307e-09
loss O 0 2.695944267827599e-08
of O 0 1.707092600611304e-08
a O 0 7.70946773087644e-09
single O 0 7.3058910032841595e-09
exon O 0 2.2857587822500136e-08
exon O 0 6.873470681512117e-08
7 O 0 2.2987006786934217e-07
, O 0 8.535573137180563e-09
exon O 0 2.2027590418360887e-08
16 O 0 1.9840905451928847e-07
, O 0 1.4006984905279296e-08
exon O 0 6.610227387682244e-08
33 O 0 3.516302342632116e-07
or O 0 1.9956829078182636e-08
exon O 0 1.903608222164621e-07
35 O 0 2.3176455670181895e-06
. O 0 4.398736166422168e-07

The O 0 3.998355850853841e-07
others O 0 6.02831988771868e-08
were O 0 6.9039112204904995e-09
minute O 0 1.1366098107146172e-07
deletions O 0 1.0891336188478817e-07
, O 0 4.208090320645397e-09
4649delA O 0 5.738609587524479e-08
in O 0 1.6521259915691644e-09
exon O 0 3.150008964780682e-08
33 O 0 1.2774934532444604e-07
and O 0 2.3242430202685682e-09
7883del5 O 0 1.958708111260421e-07
in O 0 3.154101646529739e-09
exon O 0 1.4811158166594396e-07
55 O 0 7.782476245665748e-07
. O 0 4.130457682549604e-07

The O 0 4.927572376800526e-07
mutations O 0 7.818331937414769e-07
4612del165 O 0 5.045485522714444e-07
and O 0 9.983945892244606e-10
7883del5 O 0 4.595858982270329e-08
were O 0 5.434413474780797e-10
found O 0 6.212615838441238e-11
in O 0 1.2166652234302244e-11
more O 0 1.649086249499998e-11
than O 0 2.2146019393320948e-11
two O 0 3.785452160065539e-11
unrelated O 0 9.908253106871712e-10
families O 0 1.5533785369115094e-10
; O 0 7.090836251499866e-11
44 O 0 1.7405253904811957e-09
% O 0 1.390539211554298e-10
( O 0 4.675762815126161e-12
7 O 0 3.875925969065719e-10
of O 0 5.074132780613638e-10
16 O 0 1.6027040805610682e-09
) O 0 1.9540737083989512e-11
of O 0 4.536847564295954e-10
the O 0 5.128151236988288e-10
mutant O 0 3.1208535755666844e-09
alleles O 0 9.181725935114571e-10
had O 0 9.606448969634585e-10
one O 0 2.527270615004795e-10
of O 0 8.341596302585685e-10
the O 0 7.095199983098155e-09
two O 0 9.888659668888522e-09
mutations O 0 7.126124614842411e-07
. O 0 7.879177701397566e-07

The O 0 3.970256727825472e-07
4612del165 O 0 7.168828801695781e-07
mutations O 0 9.638590370286693e-09
in O 0 1.7269828622712424e-10
three O 0 2.4490229288964827e-11
different O 0 1.425380646846719e-11
families O 0 8.322854905262744e-11
were O 0 2.8497187248843758e-11
all O 0 1.1213576942004089e-11
ascribed O 0 1.7713639444139062e-09
to O 0 1.216450135066438e-10
the O 0 3.1709492809284257e-09
same O 0 4.206477832724431e-09
T O 0 2.6025437804833018e-08
- O 0 5.193117491586463e-09
- O 0 6.6111578433947216e-09
> O 0 1.690666495690607e-09
A O 0 3.0254234673066094e-09
substitution O 0 3.188482589067121e-09
at O 0 2.2421371426162295e-09
the O 0 6.329451407438569e-10
splice O 0 3.2191294963013206e-08
donor O 0 1.2813973881975471e-08
site O 0 1.006097321010202e-07
in O 0 1.1018033596599253e-08
intron O 0 1.2489480468502734e-05
33 O 0 6.330909400276141e-06
. O 0 1.0038907021225896e-06

Microsatellite O 0 1.3666201994055882e-05
genotyping O 0 2.578801513664075e-06
around O 0 3.200353049237492e-08
the O 0 1.690954221089669e-08
ATM O 0 2.2107240056357114e-06
locus O 0 4.2839673142225365e-08
also O 0 8.827891195828386e-10
indicated O 0 4.715865475901637e-10
that O 0 1.2316527138456212e-11
a O 0 5.037323336232191e-11
common O 0 1.9145404706044644e-10
haplotype O 0 2.735058579617089e-08
was O 0 4.625422711512783e-09
shared O 0 1.8649894129030287e-10
by O 0 2.4693233569017536e-11
the O 0 1.9439928833353548e-10
mutant O 0 1.4028955774847418e-09
alleles O 0 4.730207336933745e-10
in O 0 4.254550600713003e-10
both O 0 8.628563641366327e-09
mutations O 0 5.913204859098187e-07
. O 0 6.988652785366867e-07

This O 0 2.2399840204911925e-08
suggests O 0 3.514417556971239e-08
that O 0 2.8653351913376923e-10
these O 0 1.160054718951642e-09
two O 0 3.3210667549354866e-09
founder O 0 1.26122372989812e-07
mutations O 0 1.3723965963663431e-08
may O 0 1.4092246258812224e-09
be O 0 2.3390780978793657e-10
predominant O 0 2.261301546013783e-08
among O 0 3.8512612543506464e-10
Japanese O 0 1.4475006970826598e-08
ATM O 0 7.258031473611481e-07
mutant O 0 4.3805258087559196e-07
alleles O 0 3.003794404321525e-07
. O 0 5.916945156059228e-07

W474C O 0 4.326375710661523e-05
amino O 0 7.227914693430648e-07
acid O 0 2.6822856824537666e-08
substitution O 0 8.061550538229767e-09
affects O 0 2.06675143665791e-09
early O 0 2.8623964309915095e-10
processing O 0 1.5985398560403041e-09
of O 0 2.570279766800354e-09
the O 0 1.4614568444315523e-09
alpha O 0 8.239524618147698e-10
- O 0 1.0641114378540095e-10
subunit O 0 8.18185796891413e-11
of O 0 7.325883233377795e-10
beta O 0 1.8580312843852198e-09
- O 0 2.1044779252576973e-09
hexosaminidase O 0 3.797542191819048e-08
A O 0 2.3179666186479153e-08
and O 0 1.0984681220183035e-10
is O 0 4.925600899374771e-11
associated O 0 1.7330189505671e-09
with O 0 1.5167412881211817e-09
subacute O 0 8.635097037767991e-05
G B-Disease 0 0.1549125462770462
( I-Disease 0 1.4872290421408252e-06
M2 I-Disease 1 0.8197320103645325
) I-Disease 0 7.024187453907871e-08
gangliosidosis I-Disease 0 2.543977643654216e-05
. O 0 5.571356496147928e-07

Mutations O 0 4.093537313565321e-07
in O 0 3.542035642567498e-08
the O 0 5.631125787886049e-08
HEXA O 0 3.6957771953893825e-06
gene O 0 8.012084329322988e-09
, O 0 3.499404099827075e-10
encoding O 0 4.652930263304711e-10
the O 0 3.1001834432942132e-09
alpha O 0 1.5053648605434233e-10
- O 0 6.525136680979315e-11
subunit O 0 1.0234085107141411e-10
of O 0 3.781463753238512e-10
beta O 0 2.6889177551225885e-09
- O 0 3.6708029949039656e-09
hexosaminidase O 0 1.2762038181790558e-07
A O 0 2.1159262075798324e-07
( O 0 1.8654315869781612e-09
Hex O 0 1.8895003961461043e-07
A O 0 6.676510366787625e-08
) O 0 2.0685686497046163e-10
, O 0 1.0263093153106695e-10
that O 0 8.658923578153122e-11
abolish O 0 1.4053334496111347e-08
Hex O 0 4.042999250941648e-07
A O 0 5.2912650261305316e-08
enzyme O 0 1.6028920413191372e-07
activity O 0 1.7871647628453502e-07
cause O 1 0.7734478116035461
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.180636299835669e-08
TSD B-Disease 0 4.6671768359374255e-05
) O 0 3.4541122739817354e-10
, O 0 1.0737386674231075e-10
the O 0 6.139665997828558e-10
fatal O 0 9.536663725384642e-08
infantile B-Disease 0 5.053671543464588e-07
form I-Disease 0 7.212983543780638e-09
of I-Disease 0 1.3408515542323585e-06
G I-Disease 0 0.0033234034199267626
( I-Disease 0 6.141850690255524e-07
M2 I-Disease 0 0.00028503622161224484
) I-Disease 0 8.869465162320012e-09
gangliosidosis I-Disease 0 4.660427066482953e-07
, I-Disease 0 2.304133106534323e-09
Type I-Disease 0 2.2248764608434612e-08
1 I-Disease 0 3.9252594774552563e-07
. O 0 4.197951852802362e-07

Less O 0 4.1934745809157903e-07
severe O 0 0.00024394842330366373
, O 0 4.94381175997205e-08
subacute O 0 1.453105596738169e-05
( O 0 3.526939407194618e-09
juvenile O 0 2.41070983975078e-06
- O 0 6.79054153351899e-07
onset O 1 0.9999861717224121
) O 0 1.3212911875726263e-09
and O 0 1.720261622040198e-08
chronic O 1 0.9999995231628418
( O 0 5.465577435082025e-10
adult O 0 4.356254805770732e-07
- O 0 2.394276243933291e-08
onset O 0 3.30967395711923e-07
) O 0 4.139402362546285e-11
variants O 0 5.203367181572105e-10
are O 0 2.1413870676667557e-11
characterized O 0 7.702669752029934e-11
by O 0 1.358715310401104e-11
a O 0 3.623263633567575e-10
broad O 0 2.072775728834131e-09
spectrum O 0 6.106932293192813e-09
of O 0 6.137664265715159e-10
clinical O 0 2.415254440890635e-09
manifestations O 0 1.755770639988441e-08
and O 0 3.055548869479452e-10
are O 0 3.4681455624019364e-11
associated O 0 1.72944281118248e-09
with O 0 1.1146646106130476e-10
residual O 0 2.4054274035734124e-05
levels O 0 7.714428562621833e-08
of O 0 7.35626031200809e-08
Hex O 0 1.3488403283190564e-06
A O 0 1.9505732495872508e-07
enzyme O 0 2.104326739527096e-07
activity O 0 5.812614176647912e-07
. O 0 3.5558588251660694e-07

We O 0 1.6597552132679994e-07
identified O 0 1.1784588593855005e-07
a O 0 2.3208688304521274e-08
1422 O 0 1.9969925233453978e-06
G O 0 3.7919841133771115e-07
- O 0 1.2457410036859073e-07
- O 0 8.000588280765442e-08
> O 0 3.83532885450677e-08
C O 0 2.1306269104570674e-07
( O 0 6.831561982778567e-10
amino O 0 2.3985988750752085e-09
acid O 0 8.336394907715317e-10
W474C O 0 9.7555319378273e-10
) O 0 2.9291822331405093e-13
substitution O 0 2.607408906840636e-11
in O 0 7.537404728141794e-12
the O 0 1.2798474779973645e-10
first O 0 2.400359633281113e-10
position O 0 3.2009801476107214e-09
of O 0 2.675090593484697e-09
exon O 0 5.5749524996429045e-09
13 O 0 4.2316351311910694e-08
of O 0 9.745442497433032e-08
HEXA O 0 7.010671106399968e-05
of O 0 3.058806044009543e-07
a O 0 4.050327362392636e-08
non O 0 1.480414084653603e-06
- O 0 2.57916553891846e-07
Jewish O 0 9.925831363943871e-06
proband O 0 0.00016007423982955515
who O 0 6.526027718223304e-09
manifested O 0 8.426577657871803e-09
a O 0 1.3602309278937241e-09
subacute O 0 1.6874786012976983e-07
variant O 0 1.0931545801895481e-07
of O 0 1.2912993270219886e-06
G B-Disease 1 0.8172914385795593
( I-Disease 0 4.277245807315921e-06
M2 I-Disease 1 0.9880401492118835
) I-Disease 0 7.879450691916645e-08
gangliosidosis I-Disease 0 1.6541247532586567e-05
. O 0 8.560780315747252e-07

On O 0 2.570830872627994e-07
the O 0 5.743624598153474e-08
second O 0 1.7687221998130553e-07
maternally O 0 2.972311449411791e-06
inherited O 0 7.916423214737733e-07
allele O 0 1.4695308436785126e-07
, O 0 2.063742066127361e-09
we O 0 1.9453579025441314e-10
identified O 0 1.8174912685964273e-09
the O 0 1.0627489999137651e-09
common O 0 3.378274016085925e-08
infantile O 1 0.999718964099884
disease O 0 0.0004532159073278308
- O 0 3.364276324191451e-07
causing O 0 2.826581294357311e-05
4 O 0 2.7215344289288623e-06
- O 0 1.1075243122604661e-07
bp O 0 4.361500671734575e-08
insertion O 0 1.78899366432006e-08
, O 0 4.482232807134778e-09
+ O 0 5.5854282976497416e-08
TATC O 0 1.5776964573888108e-05
1278 O 0 9.76666228780232e-07
, O 0 3.4485319044819107e-09
in O 0 2.2330466364905988e-09
exon O 0 8.759501923805146e-08
11 O 0 5.639111009259068e-07
. O 0 6.675471695416491e-07

Pulse O 0 1.3225926522864029e-05
- O 0 4.636678454517096e-07
chase O 0 1.6857727658248223e-08
analysis O 0 1.0597471788997836e-09
using O 0 1.3252841046806907e-09
proband O 0 5.080258915768354e-07
fibroblasts O 0 5.825533833103691e-08
revealed O 0 1.8180676519818917e-08
that O 0 3.6474137599107337e-10
the O 0 2.67767363837379e-09
W474C O 0 2.6384601170548194e-08
- O 0 5.70447855618994e-10
containing O 0 3.9168973620107295e-10
alpha O 0 4.560254673879882e-10
- O 0 1.6441405181755187e-10
subunit O 0 7.822745229368877e-11
precursor O 0 5.300545335984452e-09
was O 0 1.3199593418278255e-08
normally O 0 7.273199820190257e-10
synthesized O 0 3.5155018895949297e-09
, O 0 2.777480190285786e-10
but O 0 3.065835085802604e-10
not O 0 1.7697961152141062e-10
phosphorylated O 0 1.8596276518678678e-08
or O 0 1.8816084246253695e-09
secreted O 0 7.712467997578187e-09
, O 0 3.3714153691022375e-10
and O 0 4.3332867849521506e-10
the O 0 6.522008266784951e-09
mature O 0 1.569497953823884e-08
lysosomal O 0 1.558630771114622e-07
alpha O 0 7.2843375775732966e-09
- O 0 2.0752046747674058e-09
subunit O 0 8.527903383459545e-10
was O 0 2.777969188016982e-09
not O 0 8.846195997946893e-10
detected O 0 6.291770660027396e-08
. O 0 7.871084761745806e-08

When O 0 3.899250486938399e-07
the O 0 1.0500919955802601e-07
W474C O 0 3.4560343920020387e-07
- O 0 2.296779211263811e-09
containing O 0 6.682517872391713e-10
alpha O 0 3.0219268754017037e-10
- O 0 2.0332653616339513e-10
subunit O 0 1.8855379757543034e-10
was O 0 2.548629085552534e-09
transiently O 0 2.544817334637628e-08
co O 0 3.071789489439425e-09
- O 0 7.283569858351768e-10
expressed O 0 2.2289178835954715e-10
with O 0 1.0531067337615774e-11
the O 0 6.629713444894492e-11
beta O 0 1.167830970816297e-10
- O 0 2.093306430972497e-11
subunit O 0 1.3303403517683776e-11
to O 0 2.4473137058556027e-11
produce O 0 7.529151191398853e-10
Hex O 0 1.4542452220212e-07
A O 0 1.5046724399780942e-07
( O 0 1.2428397200281438e-09
alphabeta O 0 1.42185342610901e-07
) O 0 2.2462366688902335e-10
in O 0 9.511496035230493e-10
COS O 0 1.8330193825022434e-06
- O 0 2.3229590695450497e-08
7 O 0 1.2773565316592794e-08
cells O 0 1.3776516594177224e-09
, O 0 3.4599942355661994e-10
the O 0 4.4999967641068395e-10
mature O 0 2.7371485633587156e-10
alpha O 0 1.2727101317278056e-10
- O 0 7.849379479729635e-11
subunit O 0 8.121655431514441e-11
was O 0 6.867083013339936e-10
present O 0 9.942777851046358e-11
, O 0 2.0173644005305746e-11
but O 0 1.5430158886720058e-11
its O 0 4.4290116713030514e-11
level O 0 5.631173860543015e-10
was O 0 9.294583436236792e-10
much O 0 1.046268002791173e-10
lower O 0 5.151591930818711e-10
than O 0 2.476209168267296e-11
that O 0 1.0716435377977618e-10
from O 0 1.413979489051087e-09
normal O 0 6.6585887914527575e-09
alpha O 0 9.752518792538467e-10
- O 0 1.0759758639622419e-09
subunit O 0 2.282651179186246e-09
transfections O 0 3.99534378914268e-08
, O 0 9.003512518868106e-11
although O 0 6.510070260645762e-11
higher O 0 7.978180338596985e-10
than O 0 2.2693824250352712e-11
in O 0 1.3699995304872203e-10
those O 0 6.152901521616627e-10
cells O 0 4.497398897740368e-09
transfected O 0 3.341776988463607e-08
with O 0 1.7198792390260564e-10
an O 0 1.1992394854942745e-09
alpha O 0 9.8241736967708e-10
- O 0 6.510321726160839e-10
subunit O 0 1.402290950025531e-09
associated O 0 4.8761503279592944e-08
with O 0 2.9042389826372528e-08
infantile O 1 0.9997907280921936
TSD B-Disease 0 0.25136080384254456
. O 0 2.990243046951946e-06

Furthermore O 0 7.023342618595052e-07
, O 0 3.647951718477316e-09
the O 0 1.6886489984102582e-09
precursor O 0 6.325389989569885e-08
level O 0 3.286912786393259e-08
of O 0 6.412999020710686e-09
the O 0 4.280224175090552e-09
W474C O 0 2.5762000532836282e-08
alpha O 0 3.713292173745941e-10
- O 0 8.078396979138702e-11
subunit O 0 1.348435668679926e-10
was O 0 9.29573529262484e-10
found O 0 2.7530481366833115e-11
to O 0 2.043871495660543e-11
accumulate O 0 2.2479081096538067e-10
in O 0 6.13131906357367e-11
comparison O 0 3.024944517093786e-09
to O 0 4.719536983444073e-10
the O 0 7.391150802504853e-09
normal O 0 3.1796780319837126e-08
alpha O 0 6.330975743651379e-09
- O 0 7.731084217255102e-09
subunit O 0 6.492790749490496e-09
precursor O 0 1.1076426176259702e-07
levels O 0 1.1299781021989475e-07
. O 0 1.4719320517997403e-07

We O 0 1.8644404065071285e-07
conclude O 0 3.61520449132513e-07
that O 0 6.3660308136093136e-09
the O 0 2.9282398728014414e-08
1422 O 0 1.798349217096984e-06
G O 0 6.0173613292136e-07
- O 0 1.4420092497857695e-07
- O 0 1.0241558356938185e-07
> O 0 2.6123309737613454e-08
C O 0 2.6267805708357628e-08
mutation O 0 1.881589467567224e-10
is O 0 4.820783962994346e-12
the O 0 1.3476173302273686e-11
cause O 0 3.6151057702937806e-09
of O 0 6.039043487504614e-09
Hex B-Disease 0 7.5219618338451255e-06
A I-Disease 0 1.4815221220487729e-05
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.2176165853361454e-08
the O 0 5.6903900258475915e-08
proband O 0 9.212516488332767e-06
. O 0 2.222610078206344e-07

The O 0 1.5827953347979928e-07
resulting O 0 2.966843624108151e-07
W474C O 0 5.966560365777696e-07
substitution O 0 2.700618040307745e-07
clearly O 0 6.595328727598826e-08
interferes O 0 1.2856180120479621e-08
with O 0 7.000570262372108e-11
alpha O 0 2.4433785550392884e-10
- O 0 6.707594202293166e-11
subunit O 0 4.5680001448111796e-11
processing O 0 1.4271993586945086e-09
, O 0 3.3753062844699144e-11
but O 0 2.3933958981370296e-11
because O 0 3.87493370723746e-11
the O 0 3.624802888402279e-11
base O 0 8.728934242085984e-11
substitution O 0 2.067902959979051e-09
falls O 0 8.540510521015676e-08
at O 0 4.5492390410295513e-10
the O 0 8.917499516591931e-10
first O 0 1.3025145406686534e-09
position O 0 2.5341321929772676e-08
of O 0 1.934706617134907e-08
exon O 0 3.0498284786517615e-08
13 O 0 2.286339224610856e-07
, O 0 1.648264813525202e-08
aberrant O 0 2.984115710091828e-08
splicing O 0 2.783964170305353e-08
may O 0 8.779971416572607e-09
also O 0 7.224076892242692e-10
contribute O 0 1.3414228616781543e-09
to O 0 5.161006289000625e-09
Hex B-Disease 0 5.370907092583366e-05
A I-Disease 0 3.6100925626669778e-06
deficiency I-Disease 0 1.9760868781304453e-06
in O 0 5.402522429420742e-09
this O 0 6.729603541089091e-09
proband O 0 3.483034788587247e-06
. O 0 2.6889447113376264e-08
. O 0 1.0486188983804823e-07

Two O 0 1.1426917723156294e-07
frequent O 0 2.0718604787361983e-07
missense O 0 9.915850569086615e-06
mutations O 0 3.917046797141666e-06
in O 0 3.524091027884424e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.143289515923243e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.4952051919390215e-08
an O 0 5.47638251191529e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 5.731747660320252e-05
by O 0 1.4884400656445251e-10
early O 0 1.15591944904736e-06
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999964237213135
goiter B-Disease 1 1.0
. O 0 2.722068711591419e-05

A O 0 2.2345680008584168e-06
century O 0 1.7472659408213076e-07
after O 0 2.658919306952612e-09
its O 0 4.961601615671718e-11
recognition O 0 1.5067647129995976e-09
as O 0 3.3893994277889306e-09
a O 0 6.390666218436536e-09
syndrome O 0 1.0480870571427658e-07
by O 0 1.2783745173550187e-09
Vaughan O 0 3.417226537294482e-07
Pendred O 0 3.0235729354899377e-05
, O 0 1.5856370660927155e-09
the O 0 2.247686481382516e-09
disease O 0 2.9686571423326313e-08
gene O 0 1.775952007676551e-08
( O 0 2.752138961170658e-08
PDS O 0 0.00019366653577890247
) O 0 5.038805483970066e-10
was O 0 6.065420610212868e-09
mapped O 0 5.94125637576326e-09
to O 0 4.591957925015322e-09
chromosome O 0 8.436679195256147e-07
7q22 O 0 1.599861388967838e-05
- O 0 5.781241270597093e-06
q31 O 0 3.421509973122738e-05
. O 0 9.50718458625488e-07

1 O 0 2.3246514047059463e-06
and O 0 6.062404622753093e-08
, O 0 8.16621259502881e-09
recently O 0 3.925110902969209e-09
, O 0 2.166419266202979e-10
found O 0 7.867545503970064e-11
to O 0 1.475246591553514e-10
encode O 0 2.57195313935199e-08
a O 0 5.4914345071210846e-08
putative O 0 3.867652139888378e-06
sulfate O 0 4.13709085478331e-06
transporter O 0 3.6849083699053153e-05
. O 0 1.2694296174231567e-06

We O 0 3.384368696401907e-08
performed O 0 1.873118549156061e-09
mutation O 0 1.5954786380945052e-09
analysis O 0 2.4440602874875594e-09
of O 0 3.4180294150587542e-09
the O 0 1.6320942819447737e-08
PDS B-Disease 0 2.157345625164453e-05
gene O 0 2.666618925672992e-09
in O 0 5.736491281993494e-10
patients O 0 2.5081053900422035e-10
from O 0 1.156875151231418e-09
14 O 0 8.230261805408645e-09
Pendred B-Disease 0 1.9554411423428064e-08
families O 0 1.6678038117223792e-10
originating O 0 6.771381233505736e-10
from O 0 2.1039270325928783e-10
seven O 0 9.582781790307138e-11
countries O 0 2.885092685589452e-11
and O 0 2.3072280197489192e-10
identified O 0 6.520167961099332e-09
all O 0 3.817933968974785e-09
mutations O 0 2.0533525457722135e-07
. O 0 3.0004102313796466e-07

The O 0 1.570999188515998e-07
mutations O 0 5.090064192359023e-08
include O 0 7.821827630039024e-09
three O 0 1.5838417244395941e-09
single O 0 1.770961821634387e-09
base O 0 1.0867799993263816e-08
deletions O 0 5.742474229464278e-08
, O 0 3.012490479292751e-09
one O 0 2.501714169156344e-09
splice O 0 3.5857368629876873e-07
site O 0 5.4609042621223125e-08
mutation O 0 1.1789171416864974e-08
and O 0 6.832685972568697e-09
10 O 0 1.1335625060837629e-07
missense O 0 5.1533647820178885e-06
mutations O 0 3.2980206015054137e-06
. O 0 2.1400485366029898e-06

One O 0 4.512024815994664e-07
missense O 0 4.965602784068324e-06
mutation O 0 2.0669799027928093e-07
( O 0 5.455831342260353e-09
L236P O 0 7.360414855384079e-08
) O 0 5.406918662798077e-11
was O 0 4.70355920878518e-10
found O 0 2.972664128741975e-11
in O 0 8.926237353434896e-12
a O 0 6.338412433803953e-11
homozygous O 0 1.0342345035940781e-10
state O 0 2.360114048638451e-10
in O 0 1.219142148345398e-10
two O 0 2.196673398735527e-10
consanguineous O 0 2.6093035287999555e-08
families O 0 2.662104703343715e-10
and O 0 5.5460781800409364e-11
in O 0 2.6886789669666733e-11
a O 0 2.078444083508657e-10
heterozygous O 0 3.155442018787369e-10
state O 0 3.0998448252717026e-10
in O 0 4.257635355386924e-10
five O 0 5.995576257689095e-10
additional O 0 7.593361495139561e-09
non O 0 2.457473442518676e-07
- O 0 5.237995424067776e-07
consanguineous O 0 5.3499538807955105e-06
families O 0 9.168940806603132e-08
. O 0 2.7750849085350637e-07

Another O 0 1.9618899216311547e-07
missense O 0 4.237727353029186e-06
mutation O 0 1.1596355165011119e-07
( O 0 5.521469503833032e-09
T416P O 0 1.573437202750938e-07
) O 0 1.3797916975644142e-10
was O 0 7.849143557336902e-10
found O 0 1.5024584007483632e-11
in O 0 9.281534742167086e-12
a O 0 6.0964754078352e-11
homozygous O 0 9.17979581238626e-11
state O 0 1.1149452888714606e-10
in O 0 8.702469300736482e-11
one O 0 3.1863409133414677e-10
family O 0 1.9551035790321691e-10
and O 0 7.564240206425765e-11
in O 0 5.013484766225318e-11
a O 0 2.2210668026989566e-10
heterozygous O 0 9.035338449647767e-11
state O 0 9.564393721461784e-11
in O 0 3.1721633653170045e-10
four O 0 1.5244153717119957e-09
families O 0 1.5742649850380985e-08
. O 0 1.354546839138493e-07

Pendred B-Disease 0 3.103294511674903e-05
patients O 0 4.0041246762712035e-08
in O 0 3.1261317978703573e-09
three O 0 2.049584724161946e-09
non O 0 2.2602579363706354e-08
- O 0 6.125294049752483e-09
consanguineous O 0 4.719343849046709e-08
families O 0 1.1978082969932302e-09
were O 0 1.9912779758435306e-10
shown O 0 4.491933561223682e-11
to O 0 6.780256911476101e-11
be O 0 2.0594510818927603e-10
compound O 0 1.2306213825752366e-08
heterozygotes O 0 2.949056998602373e-08
for O 0 3.2574405395280337e-09
L236P O 0 7.494955980291707e-07
and O 0 2.635422369223761e-08
T416P O 0 7.074418135744054e-06
. O 0 7.601427114423132e-07

In O 0 8.098384185473151e-09
total O 0 4.790589258618638e-09
, O 0 2.4711810375777077e-10
one O 0 1.164208174309067e-10
or O 0 6.790014384083776e-11
both O 0 4.629292435498478e-11
of O 0 5.851441553517134e-10
these O 0 1.2326734077916512e-10
mutations O 0 2.535087917365786e-09
were O 0 5.470708885901843e-10
found O 0 1.6320086948518053e-10
in O 0 1.3230003204078855e-10
nine O 0 2.7143007841345934e-09
of O 0 3.04254088590028e-09
the O 0 1.0930602201142392e-08
14 O 0 4.600130054654983e-08
families O 0 1.049661157992432e-08
analyzed O 0 1.1229501950538179e-07
. O 0 2.723619445532677e-07

The O 0 5.463380858827804e-09
identification O 0 2.5805032777270753e-08
of O 0 1.8015226643797178e-08
two O 0 3.784748958679529e-09
frequent O 0 1.4778254353586817e-07
PDS B-Disease 0 0.00014778997865505517
mutations O 0 2.566548040761063e-08
will O 0 6.133673569053144e-10
facilitate O 0 7.588047523654495e-09
the O 0 1.063322652150589e-09
molecular O 0 1.3931187936577771e-07
diagnosis O 0 4.879550942860078e-06
of O 0 5.667340019499534e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.2108126813691342e-06

Insertional O 0 4.4588919990928844e-05
mutation O 0 7.922309208652223e-08
by O 0 4.319294255594741e-09
transposable O 0 7.472353331650083e-07
element O 0 1.03042594901126e-07
, O 0 6.32706464998023e-09
L1 O 0 8.576421350880992e-07
, O 0 1.1157244017567791e-09
in O 0 6.611508007736688e-10
the O 0 5.681974002413881e-08
DMD B-Disease 1 1.0
gene O 0 6.837016996996681e-08
results O 0 1.5235826822390663e-07
in O 0 1.9660623351569484e-08
X B-Disease 1 0.9999964237213135
- I-Disease 0 0.03997078537940979
linked I-Disease 0 0.0988047644495964
dilated I-Disease 0 0.004309761803597212
cardiomyopathy I-Disease 1 1.0
. O 0 5.141190740687307e-06

X B-Disease 1 0.9999496936798096
- I-Disease 1 0.9975581169128418
linked I-Disease 1 0.9918563365936279
dilated I-Disease 1 0.9999489784240723
cardiomyopathy I-Disease 1 1.0
( O 0 1.4548861145158298e-05
XLDCM B-Disease 1 1.0
) O 0 2.724257486264037e-10
is O 0 1.6407689443220796e-11
a O 0 4.428741401385494e-11
clinical O 0 1.535308213895803e-09
phenotype O 0 1.1733317251128028e-07
of O 0 3.3731360815636435e-08
dystrophinopathy B-Disease 0 6.89721400704002e-06
which O 0 5.975677175307226e-10
is O 0 6.213801001520025e-11
characterized O 0 7.18784406994466e-11
by O 0 2.3067518381547636e-11
preferential O 0 8.109531535183123e-08
myocardial B-Disease 0 1.0157018550671637e-05
involvement I-Disease 0 2.9443008031648787e-09
without O 0 7.270370416812e-10
any O 0 9.396793343441345e-10
overt O 0 4.182925650297875e-08
clinical O 0 9.855294358374067e-09
signs O 0 8.338724910572637e-08
of O 0 6.30041725457886e-08
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 2.894685894716531e-05

To O 0 1.7526120998923034e-08
date O 0 5.102710929349996e-07
, O 0 3.489940780809775e-09
several O 0 1.6041047379289353e-09
mutations O 0 3.8580587613523676e-08
in O 0 3.379458268781832e-09
the O 0 2.759146013886493e-07
Duchenne B-Disease 1 0.9999547004699707
muscular I-Disease 1 0.9999613761901855
dystrophy I-Disease 1 0.9999927282333374
gene O 0 0.07025931030511856
, O 0 1.207638547384704e-06
DMD O 1 1.0
, O 0 2.198853987778193e-09
have O 0 7.605949203792761e-11
been O 0 1.4409019810646129e-10
identified O 0 3.4392289016693667e-10
in O 0 6.296384247317377e-11
patients O 0 1.985157177530894e-10
with O 0 3.345727583869973e-10
XLDCM B-Disease 1 1.0
, O 0 4.452000157417757e-10
but O 0 9.907340919879104e-11
a O 0 6.001328600735434e-11
pathogenic O 0 1.0776066705631138e-09
correlation O 0 1.4631386102692545e-09
of O 0 6.081299352977965e-10
these O 0 1.0690555107828459e-09
cardiospecific O 0 2.7874662578142306e-07
mutations O 0 1.6947870662420428e-08
in O 0 4.549197907266489e-09
DMD O 1 1.0
with O 0 2.664000797736321e-09
the O 0 3.5981024382181204e-08
XLDCM B-Disease 1 0.9088070392608643
phenotype O 0 2.3391211811940593e-07
has O 0 1.9566901432455097e-09
remained O 0 2.5703791095565975e-08
to O 0 6.296891341683875e-10
be O 0 1.3301115764363658e-08
elucidated O 0 2.2179054212756455e-05
. O 0 1.1652609828161076e-06

We O 0 1.73604775000058e-07
report O 0 2.476146931940093e-08
here O 0 2.2697296819806922e-10
the O 0 3.9158870590583206e-11
identification O 0 3.2436209274067096e-09
of O 0 2.4603745707452163e-09
a O 0 3.880321841620571e-09
unique O 0 4.413788090573689e-08
de O 0 6.18123237927648e-07
novo O 0 1.103506974686752e-06
L1 O 0 6.702225618937518e-07
insertion O 0 8.871224643769438e-09
in O 0 2.733737680671311e-09
the O 0 1.6811139147421272e-08
muscle O 0 1.4359978983691235e-08
exon O 0 1.050985254380521e-08
1 O 0 1.3980134383473342e-08
in O 0 2.4937392151258564e-09
DMD O 1 1.0
in O 0 4.199511405289513e-09
three O 0 3.5420943955699613e-09
XLDCM B-Disease 0 7.689381163800135e-06
patients O 0 2.1069025690767518e-10
from O 0 3.6987873874849697e-10
two O 0 1.026358234512692e-10
unrelated O 0 3.5521550145745096e-09
Japanese O 0 9.989264526666375e-09
families O 0 6.440715072386638e-09
. O 0 6.933407092901689e-08

The O 0 1.9802322981377074e-07
insertion O 0 1.553911062046609e-07
was O 0 1.4840595952136937e-07
a O 0 6.6257892505916516e-09
5 O 0 1.2130870530313587e-08
- O 0 9.950296142591242e-10
truncated O 0 2.1372759118065687e-09
form O 0 2.314041597228922e-10
of O 0 1.1670010513498141e-09
human O 0 4.294264943638382e-09
L1 O 0 6.153118761176302e-07
inversely O 0 1.0457468135882664e-07
integrated O 0 6.972819655004514e-09
in O 0 2.737623461257499e-10
the O 0 1.7943240226969692e-09
5 O 0 6.853804190853907e-09
- O 0 2.205553739642596e-09
untranslated O 0 1.9409328615438426e-06
region O 0 4.236171413651846e-09
in O 0 4.189932012454989e-10
the O 0 7.058687412353493e-09
muscle O 0 7.1663865952587e-09
exon O 0 8.279606333871925e-09
1 O 0 2.0460197092120325e-08
, O 0 1.0205858380629707e-10
which O 0 1.6310026246246778e-11
affected O 0 4.0882536245234746e-10
the O 0 2.550524236255569e-10
transcription O 0 3.478019428015955e-09
or O 0 3.2192551402410174e-10
the O 0 1.4628037670050276e-09
stability O 0 2.1824302365303083e-08
of O 0 8.10875455670157e-09
the O 0 4.8780455230712505e-09
muscle O 0 3.421904093414696e-09
form O 0 2.556296729849805e-09
of O 0 4.498473415992521e-08
dystrophin O 0 1.819147001924648e-07
transcripts O 0 1.2399965498843812e-08
but O 0 4.387788188342512e-10
not O 0 3.283636904050091e-11
that O 0 7.082456149332117e-11
of O 0 2.126269160740435e-09
the O 0 1.5541861131396217e-08
brain O 0 1.54541487518145e-06
or O 0 3.23069961893907e-08
Purkinje O 0 4.752617314807139e-06
cell O 0 8.469798018495567e-08
form O 0 1.4427213201884115e-08
, O 0 1.2371326185700582e-09
probably O 0 3.809307536073447e-09
due O 0 3.6287428617498563e-09
to O 0 4.866380631796119e-10
its O 0 5.453685281153753e-10
unique O 0 1.7128646279118698e-09
site O 0 2.1259337401602352e-08
of O 0 1.309040520425242e-08
integration O 0 2.2399333943212696e-07
. O 0 1.326138999502291e-06

We O 0 9.138230439020845e-08
speculate O 0 1.3930350917235046e-07
that O 0 1.040643612948422e-10
this O 0 1.7340488420169997e-11
insertion O 0 1.988250453166529e-09
of O 0 1.5200833924922108e-09
an O 0 2.4810149490406275e-09
L1 O 0 8.054697104853403e-07
sequence O 0 4.698997191354692e-09
in O 0 7.456341322154003e-09
DMD O 1 1.0
is O 0 1.2364272938825138e-09
responsible O 0 1.5587117707660525e-10
for O 0 2.285245256916646e-11
some O 0 2.1764701152449106e-11
of O 0 1.3922694941381764e-10
the O 0 4.951608567616006e-11
population O 0 4.2326864235775474e-11
of O 0 1.4507883783210218e-10
Japanese O 0 4.168563272344272e-09
patients O 0 3.203048937194808e-10
with O 0 1.7331313051371922e-09
XLDCM B-Disease 0 0.0001627768942853436
. O 0 4.92836207399705e-08
. O 0 2.516407846542279e-07

Severe O 0 0.0012445782776921988
early O 1 0.9987816214561462
- O 1 0.9727728962898254
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 3.241427037892208e-08
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 9.902005331241526e-07
red O 0 0.00016508495900779963
hair O 0 1.540634002594743e-05
pigmentation O 0 2.771478466456756e-05
caused O 0 1.054879362527572e-06
by O 0 2.9261519429724103e-08
POMC O 0 0.0015721694799140096
mutations O 0 2.240916217033373e-07
in O 0 4.84928763810899e-09
humans O 0 5.0478238478035564e-08
. O 0 9.053049865315188e-08

Sequential O 0 6.359386588883353e-06
cleavage O 0 1.5863631688262103e-06
of O 0 2.2217093942344945e-07
the O 0 1.9932064887484557e-08
precursor O 0 2.1012385786889354e-07
protein O 0 3.079629209423729e-07
pre O 0 4.023732174118777e-07
- O 0 7.377772703875962e-08
pro O 0 7.93013782640628e-07
- O 0 1.1082465789513662e-06
opiomelanocortin O 0 4.784601969731739e-06
( O 0 2.2612496763940726e-08
POMC O 0 2.940906369985896e-06
) O 0 7.998582352009009e-10
generates O 0 4.932215080799551e-09
the O 0 4.583041501859952e-09
melanocortin O 0 1.0550755860094796e-06
peptides O 0 2.813259527556511e-07
adrenocorticotrophin O 0 1.522936418041354e-05
( O 0 1.0777000625239452e-07
ACTH O 0 4.271803845767863e-06
) O 0 5.000110991915108e-09
, O 0 5.897855093195403e-09
melanocyte O 0 5.647330453939503e-06
- O 0 4.485990302782739e-06
stimulating O 0 5.737650781156844e-07
hormones O 0 3.5813351928482007e-07
( O 0 1.7763655435487635e-08
MSH O 0 1.402311113452015e-06
) O 0 1.8645519850313264e-10
alpha O 0 2.4863525127649666e-10
, O 0 1.3588630221050835e-11
beta O 0 4.635238720629431e-11
and O 0 1.7063607471445863e-11
gamma O 0 5.955014814595927e-10
as O 0 3.898606715235786e-10
well O 0 2.3779078706098744e-10
as O 0 7.000093282805153e-10
the O 0 8.338573720401143e-10
opioid O 0 2.7321906514998773e-08
- O 0 1.178548370006638e-08
receptor O 0 8.225588743471235e-08
ligand O 0 7.623176543347654e-07
beta O 0 9.886124416880193e-07
- O 0 8.394416113333136e-07
endorphin O 0 2.103591032209806e-05
. O 0 6.282063509388536e-07

While O 0 4.936443431802218e-08
a O 0 2.3950603722511232e-09
few O 0 1.5163825750619253e-09
cases O 0 2.0542854084482087e-09
of O 0 2.7809180735971495e-08
isolated O 0 0.010315953753888607
ACTH B-Disease 1 0.9999938011169434
deficiency I-Disease 1 0.9999881982803345
have O 0 8.516919614010021e-09
been O 0 3.6594502983433586e-09
reported O 0 2.376686047966814e-08
( O 0 4.117444607487641e-09
OMIM O 0 0.000261069304542616
201400 O 0 4.449226253200322e-06
) O 0 2.9214546337641423e-09
, O 0 2.2348958239604144e-09
an O 0 1.8130014822759222e-08
inherited O 1 0.9999983310699463
POMC O 1 1.0
defect O 1 0.999997615814209
has O 0 2.3423128325816833e-08
not O 0 4.0102199339031586e-10
been O 0 6.337919633558897e-10
described O 0 1.1109169140155473e-09
so O 0 8.746336987996983e-10
far O 0 1.4425781458271558e-08
. O 0 1.0537959127532304e-07

Recent O 0 1.7151448616914422e-07
studies O 0 1.3604445570081225e-08
in O 0 1.9171239595827672e-10
animal O 0 4.454041135915077e-09
models O 0 3.378208157656104e-09
elucidated O 0 1.1465932914234145e-07
a O 0 9.20989451369536e-10
central O 0 5.263882218997651e-09
role O 0 1.892044965146056e-09
of O 0 6.810268349255466e-09
alpha O 0 9.126104316692363e-09
- O 0 1.4578466434045367e-08
MSH O 0 1.0681468438633601e-06
in O 0 3.096765899268661e-10
the O 0 4.6534803788134127e-10
regulation O 0 1.784242531499558e-09
of O 0 1.2469807408876932e-09
food O 0 6.4419931611325865e-09
intake O 0 4.027420619223676e-10
by O 0 1.469561625166982e-11
activation O 0 1.2497649137799272e-08
of O 0 2.3905982970973128e-08
the O 0 7.562462656096614e-08
brain O 0 1.6001260974007891e-06
melanocortin O 0 9.412242434336804e-07
- O 0 1.2724352416171314e-07
4 O 0 9.538155865129738e-08
- O 0 1.9290800068461067e-08
receptor O 0 3.980473550768693e-08
( O 0 6.676685870843357e-09
MC4 O 0 4.026122041977942e-06
- O 0 2.93617610225283e-08
R O 0 1.5837157363307597e-08
; O 0 2.3172845864394276e-09
refs O 0 2.5939108638795005e-08
3 O 0 6.2373421982897526e-09
- O 0 6.169800781385959e-10
5 O 0 5.811766068397617e-10
) O 0 2.647559038324032e-12
and O 0 3.2169438553969476e-12
the O 0 2.644501978510405e-11
linkage O 0 1.589889997433147e-08
of O 0 1.7740112712161249e-09
human O 0 9.513717458276005e-08
obesity B-Disease 1 1.0
to O 0 1.1171212843663625e-09
chromosome O 0 3.3628113627059975e-09
2 O 0 2.1576451736393665e-09
in O 0 9.952378504651804e-11
close O 0 2.121444575564624e-09
proximity O 0 4.644101547768287e-09
to O 0 1.5817033793830149e-10
the O 0 7.522336531451401e-09
POMC O 0 3.539737008395605e-06
locus O 0 1.2260996662405432e-08
, O 0 3.230055389824571e-10
led O 0 3.412633786670227e-10
to O 0 6.853274892026917e-11
the O 0 6.569397248412656e-10
proposal O 0 2.317828373676889e-09
of O 0 1.7173430455486027e-09
an O 0 1.6637663469154518e-09
association O 0 1.1084600792798938e-08
of O 0 9.253690791410918e-07
POMC O 1 0.9999997615814209
with O 0 5.5750298599832604e-08
human O 0 0.003439562860876322
obesity B-Disease 1 1.0
. O 0 4.2169634184574534e-07

The O 0 1.2857532283305773e-07
dual O 0 3.0305480436254584e-07
role O 0 9.318500815425068e-08
of O 0 5.401844305197301e-07
alpha O 0 1.056791461451212e-06
- O 0 7.506758947783965e-07
MSH O 0 1.9171122403349727e-05
in O 0 2.6834972022271586e-09
regulating O 0 5.62856996566552e-08
food O 0 1.0599522681786766e-07
intake O 0 2.4134873655157207e-08
and O 0 1.1412640832375587e-09
influencing O 0 1.2229276080688578e-06
hair O 0 9.17277648113668e-05
pigmentation O 0 2.451337240927387e-05
predicts O 0 1.5560607025122408e-08
that O 0 7.024310993974936e-11
the O 0 2.544329469333917e-10
phenotype O 0 3.200723908136638e-09
associated O 0 1.7053799483690568e-09
with O 0 6.711523004021558e-11
a O 0 1.4398011671801214e-09
defect O 0 1.7224621728928469e-07
in O 0 1.9821777996753553e-08
POMC O 0 0.4963160455226898
function O 0 2.0831926406117418e-08
would O 0 1.0295094776680003e-09
include O 0 6.2475105089276894e-09
obesity B-Disease 1 1.0
, O 0 1.5002492581572824e-09
alteration O 0 2.305785926637327e-07
in O 0 1.218399425795269e-08
pigmentation O 1 0.9999998807907104
and O 0 7.656281377421692e-05
ACTH B-Disease 1 0.999998927116394
deficiency I-Disease 1 0.8517594337463379
. O 0 3.0003209303686162e-06

The O 0 1.9981479226771626e-07
observation O 0 5.057816906628432e-06
of O 0 6.294265109119124e-09
these O 0 3.3512539410196496e-09
symptoms O 0 0.00715234549716115
in O 0 7.700455273429441e-10
two O 0 1.5283661003451243e-09
probands O 0 1.8061144828607212e-06
prompted O 0 1.5944207731877214e-08
us O 0 4.0865463790673573e-10
to O 0 6.779054401162554e-11
search O 0 1.3428770317958083e-09
for O 0 1.702087221167048e-10
mutations O 0 1.7721218270594363e-08
within O 0 1.729578791298536e-08
their O 0 2.0153797208877222e-07
POMC O 0 0.002391830086708069
genes O 0 3.472885282462812e-06
. O 0 1.291263629354944e-06

Patient O 0 3.194779196746822e-07
1 O 0 2.1012145623444667e-07
was O 0 7.554874947857115e-09
found O 0 1.6375058253803587e-10
to O 0 3.353488320367859e-11
be O 0 1.560859774762946e-10
a O 0 3.63115731927266e-10
compound O 0 8.65284022211199e-09
heterozygote O 0 1.1482324424605395e-07
for O 0 8.369341886194093e-10
two O 0 5.995576257689095e-10
mutations O 0 3.797192782428738e-09
in O 0 1.8753170127894236e-09
exon O 0 2.5642922452107086e-08
3 O 0 1.1829764900994633e-07
( O 0 6.180050693416206e-09
G7013T O 0 5.830646614413126e-07
, O 0 5.216128862173264e-09
C7133delta O 0 8.828337882960113e-08
) O 0 5.651258974670448e-11
which O 0 1.7421111428439495e-11
interfere O 0 2.0364945840789517e-10
with O 0 8.518531366408233e-12
appropriate O 0 2.4010340382574213e-09
synthesis O 0 1.7508153860035236e-07
of O 0 2.650596684361517e-07
ACTH O 0 1.9720640921150334e-05
and O 0 1.5378682860500703e-07
alpha O 0 2.5181727778544882e-06
- O 0 2.6366576548753073e-06
MSH O 0 0.00028201742679812014
. O 0 1.0331284556741593e-06

Patient O 0 3.2837112939887447e-07
2 O 0 1.9514365590111993e-07
was O 0 9.451641247437692e-09
homozygous O 0 4.0219091945736807e-10
for O 0 8.766374431923296e-11
a O 0 3.716835172973276e-10
mutation O 0 6.479734526720904e-10
in O 0 5.047934292790046e-10
exon O 0 1.7772331162291266e-08
2 O 0 2.131740757249645e-07
( O 0 1.0943724149115042e-08
C3804A O 0 4.262946049493621e-07
) O 0 8.760629444104495e-10
which O 0 1.0014479245867847e-09
abolishes O 0 2.3970785605342826e-06
POMC O 0 0.00010744829342002049
translation O 0 2.6844513740797993e-06
. O 0 1.999655069084838e-06

These O 0 9.654321786456421e-09
findings O 0 7.087517239767749e-09
represent O 0 1.001956184687458e-09
the O 0 3.865302522498837e-10
first O 0 5.177861611693757e-11
examples O 0 4.71824967984702e-10
of O 0 1.914569752736739e-10
a O 0 5.665713453950616e-10
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 6.236795080383217e-09
the O 0 5.112176904020771e-09
POMC O 0 4.032871459003218e-07
gene O 0 3.284459093588765e-10
and O 0 8.983442462140445e-11
define O 0 9.511369469805686e-10
a O 0 3.311962371022048e-10
new O 0 4.737812364652427e-09
monogenic B-Disease 0 0.32330265641212463
endocrine I-Disease 1 0.9972330927848816
disorder I-Disease 0 0.026833755895495415
resulting O 0 7.005028379580835e-08
in O 0 8.148130503649043e-10
early O 0 8.925945621740539e-06
- O 0 8.808196071186103e-06
onset O 1 0.9999974966049194
obesity B-Disease 1 1.0
, O 0 1.7643612792994645e-08
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 4.072329829796217e-06
red O 0 0.00013665792357642204
hair O 0 4.72906640425208e-06
pigmentation O 0 5.348244940250879e-06
. O 0 8.000527884632902e-08
. O 0 4.043091905714391e-07

A O 0 6.235501359697082e-07
European O 0 1.3381455232774897e-07
multicenter O 0 1.778165460564196e-05
study O 0 4.141564602377912e-08
of O 0 5.571436076934333e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.7084769154962487e-08
classification O 0 4.456158819721168e-08
of O 0 1.7035308275126226e-08
105 O 0 2.519336916861903e-08
mutations O 0 1.5988174117964604e-09
and O 0 1.1505063568506557e-10
a O 0 1.714668129704222e-10
general O 0 1.6646638234529831e-10
system O 0 3.995253780586516e-11
for O 0 3.3199047677623383e-11
genotype O 0 2.5786714985542858e-09
- O 0 1.1401914967734683e-09
based O 0 1.0607946743235175e-09
prediction O 0 1.5088166094301414e-07
of O 0 1.2399515192385024e-08
metabolic O 0 0.00038315169513225555
phenotype O 0 1.5919364159344696e-05
. O 0 1.6567219063290395e-06

Phenylketonuria B-Disease 0 0.0003572204732336104
( O 0 7.858564003981883e-07
PKU B-Disease 0 4.6178050979506224e-05
) O 0 1.0894614099754563e-08
and O 0 1.009285544029126e-08
mild B-Disease 1 0.999998927116394
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.00012845572200603783
MHP B-Disease 1 1.0
) O 0 2.8408648766742317e-09
are O 0 2.0288838664672681e-10
allelic B-Disease 0 5.592698357759218e-07
disorders I-Disease 0 1.2144595302743255e-06
caused O 0 2.1826675578040522e-08
by O 0 7.262314360989564e-11
mutations O 0 2.0494166363960176e-09
in O 0 7.024712755931972e-11
the O 0 4.75941175359651e-10
gene O 0 7.806774782181947e-09
encoding O 0 4.519044125572691e-07
phenylalanine O 0 3.0152597901178524e-05
hydroxylase O 0 4.216715387883596e-05
( O 0 2.6536193331594404e-07
PAH O 0 0.0004023452347610146
) O 0 5.208774211951095e-08
. O 0 1.7043994660070894e-07

Previous O 0 5.75306899008865e-07
studies O 0 2.6040730460863415e-08
have O 0 1.057376269875121e-10
suggested O 0 5.705675376610486e-10
that O 0 1.9619611490995226e-11
the O 0 1.4123184566283697e-10
highly O 0 2.0550650070561005e-09
variable O 0 2.7192979814572027e-06
metabolic O 1 0.9061064720153809
phenotypes O 0 0.026315664872527122
of O 0 0.0001947230484802276
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.0005390722071751952
with O 0 7.33208267433838e-08
PAH O 1 1.0
genotypes O 0 5.289751788950525e-05
. O 0 3.2114030545926653e-07

We O 0 1.5326354230182915e-07
identified O 0 6.386136419678223e-08
both O 0 7.723095940548319e-09
causative O 0 1.0788451163534774e-06
mutations O 0 6.540010843991695e-08
in O 0 2.4906967599491736e-09
686 O 0 1.46904596931563e-07
patients O 0 8.0614392938827e-10
from O 0 2.6375026607183827e-09
seven O 0 3.7145619913303562e-09
European O 0 1.2332742826970389e-08
centers O 0 1.2437135410436895e-07
. O 0 2.3845421992518823e-07

On O 0 2.065065984879766e-08
the O 0 3.2783378789424944e-10
basis O 0 3.066556120145947e-09
of O 0 1.6412830816658897e-10
the O 0 1.2818165973094153e-10
phenotypic O 0 1.6121386892109513e-08
characteristics O 0 1.6392267809806071e-07
of O 0 9.443211013149266e-08
297 O 0 3.354172122271848e-07
functionally O 0 4.7132900249380327e-07
hemizygous O 0 7.032538178464165e-07
patients O 0 7.731994489112992e-10
, O 0 7.66305977006887e-11
105 O 0 4.77633799178534e-09
of O 0 1.4958575489387727e-09
the O 0 3.051292996048005e-09
mutations O 0 5.617948772851378e-09
were O 0 2.8123436912608213e-10
assigned O 0 1.209735506213505e-10
to O 0 2.73413635482056e-11
one O 0 1.9880294632734774e-10
of O 0 6.126155138730383e-10
four O 0 4.508037276806931e-10
arbitrary O 0 1.1224833684764235e-07
phenotype O 0 5.501986493072764e-07
categories O 0 5.120338073538733e-07
. O 0 7.588462267449358e-07

We O 0 5.182928575209189e-08
proposed O 0 2.4373486340323325e-08
and O 0 2.1339154887556333e-09
tested O 0 5.005842962368945e-10
a O 0 8.265114287420161e-11
simple O 0 5.2993772564624564e-11
model O 0 9.661256517023986e-11
for O 0 9.85934077435413e-12
correlation O 0 1.115300962695187e-09
between O 0 4.1625627944519294e-10
genotype O 0 9.647179943783613e-09
and O 0 1.7373711358459332e-09
phenotypic O 0 7.123665568542492e-08
outcome O 0 2.2762103526474675e-06
. O 0 1.3541066437028348e-06

The O 0 7.501964915945791e-08
observed O 0 2.7558579418496265e-08
phenotype O 0 3.727999953184735e-08
matched O 0 1.598677989989028e-08
the O 0 2.4032515977268076e-09
predicted O 0 1.7707703747760206e-08
phenotype O 0 2.754185546294252e-09
in O 0 8.369242104899755e-11
79 O 0 3.850176177877529e-09
% O 0 6.419981213312553e-11
of O 0 3.560399544633164e-11
the O 0 3.907098602984327e-11
cases O 0 1.1012245282326916e-10
, O 0 4.9480964464665433e-11
and O 0 4.415616830510949e-11
in O 0 4.678075635200507e-11
only O 0 1.5316396761999584e-10
5 O 0 8.497816894603716e-10
of O 0 3.4346006594354606e-10
184 O 0 6.093548998720166e-10
patients O 0 1.1228157986709064e-10
was O 0 1.0012474183085374e-09
the O 0 8.650641314389418e-10
observed O 0 2.45454345737528e-09
phenotype O 0 1.4576290174872497e-09
more O 0 3.663385220176174e-11
than O 0 4.2841650366165496e-11
one O 0 2.7632346411010644e-10
category O 0 1.8169816762281243e-09
away O 0 5.045376116896705e-09
from O 0 1.7539423247114883e-09
that O 0 1.1907697050617116e-09
expected O 0 8.691797859228245e-08
. O 0 5.923398020968307e-07

Among O 0 3.300394837424392e-07
the O 0 3.3282020694969106e-08
seven O 0 5.495393029519846e-09
contributing O 0 6.518177997349994e-09
centers O 0 3.241833468337063e-09
, O 0 6.376925376638809e-11
the O 0 1.0883866030653166e-10
proportion O 0 8.77487693617951e-10
of O 0 6.488005271920727e-11
patients O 0 1.7431946511270446e-11
for O 0 3.616619503876706e-11
whom O 0 1.8487799069433208e-09
the O 0 1.2291007100984075e-09
observed O 0 2.1304464858928895e-09
phenotype O 0 1.0754301893456386e-09
did O 0 1.6256676560466587e-10
not O 0 1.3365979156798602e-10
match O 0 3.0244426962866555e-09
the O 0 9.864415062565968e-09
predicted O 0 8.292015962751975e-08
phenotype O 0 2.068353666118128e-08
was O 0 1.2812801486461467e-08
4 O 0 9.846275794700432e-09
% O 0 1.372207458771868e-09
- O 0 1.9154473562821295e-09
23 O 0 2.1212677836501825e-08
% O 0 3.464744047221302e-09
( O 0 5.090505794669298e-10
P O 0 9.613935958441289e-08
< O 0 2.8041926558586283e-09
. O 0 8.065638157361832e-10
0001 O 0 9.230967989992678e-09
) O 0 2.681490030020939e-10
, O 0 7.75599307001329e-11
suggesting O 0 4.5195569509104416e-10
that O 0 3.0852681520698866e-11
differences O 0 4.0756956143361833e-10
in O 0 2.1130951155523547e-11
methods O 0 1.3900458561977302e-10
used O 0 3.7149835291350186e-11
for O 0 3.513393395659925e-11
mutation O 0 1.7751892178452522e-09
detection O 0 6.5663812165439595e-09
or O 0 3.0731255318272588e-09
phenotype O 0 3.568263906572611e-08
classification O 0 2.516377106687173e-09
may O 0 1.9658354111218301e-10
account O 0 3.76910724853019e-10
for O 0 2.9215522362457946e-11
a O 0 1.2784324987524798e-10
considerable O 0 2.520527342397827e-09
proportion O 0 7.589783912465009e-09
of O 0 5.675981018526954e-09
genotype O 0 4.030337663607497e-07
- O 0 2.3855982362874784e-06
phenotype O 0 2.9335337785596494e-06
inconsistencies O 0 8.250032806245144e-06
. O 0 2.3351258278125897e-06

Our O 0 5.551504500544979e-07
data O 0 1.3774926799214882e-07
indicate O 0 7.033920468302313e-08
that O 0 2.070515758845204e-09
the O 0 2.2021163559315937e-08
PAH O 0 1.5095423805178143e-05
- O 0 3.0627930414084403e-08
mutation O 0 1.1833251045700877e-09
genotype O 0 3.53145429565771e-10
is O 0 1.263412291452326e-11
the O 0 4.2423935892044184e-11
main O 0 2.9482345453857306e-09
determinant O 0 2.3338179744314402e-07
of O 0 3.1886727924757e-08
metabolic O 1 0.9297330975532532
phenotype O 0 7.866842111070582e-07
in O 0 1.6499468458164301e-09
most O 0 2.894487982629812e-09
patients O 0 8.28619484138926e-09
with O 0 4.025858046929898e-08
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 9.477045750827529e-06

In O 0 1.9907634651872286e-08
the O 0 1.4441143392218692e-08
present O 0 3.577871332538507e-09
study O 0 5.64394753155284e-10
, O 0 2.6119783419487064e-11
the O 0 7.496476356338988e-11
classification O 0 4.059458991179099e-09
of O 0 2.2295493451451875e-08
105 O 0 6.330482733574172e-07
PAH O 0 2.035782381426543e-05
mutations O 0 1.3354091166206672e-08
may O 0 2.6560084687154983e-10
allow O 0 7.925320122392776e-11
the O 0 3.611313748042022e-10
prediction O 0 3.4103990742551105e-08
of O 0 8.62702909110169e-10
the O 0 2.6006763409469613e-09
biochemical O 0 2.7600250973591756e-07
phenotype O 0 6.676994246390677e-08
in O 0 1.907739299866762e-09
> O 0 2.0918449195050925e-08
10 O 0 8.751682045726739e-09
, O 0 3.88482218616204e-10
000 O 0 3.9527963124896814e-09
genotypes O 0 2.7356637843922726e-08
, O 0 6.285971188013662e-10
which O 0 2.426066292304796e-10
may O 0 3.1926128407633314e-10
be O 0 1.2280526595631613e-10
useful O 0 3.755417754547352e-09
for O 0 4.286872523628915e-10
the O 0 5.642626810242746e-09
management O 0 9.021038138712356e-09
of O 0 1.0343858747319246e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 8.506841453481684e-08
newborns O 0 6.310459070846264e-07
. O 0 3.47227512520476e-07

Somatic O 0 1.1021376849384978e-05
instability O 0 5.52684787180624e-06
of O 0 2.873998141694756e-07
the O 0 2.8667523110925686e-07
CTG O 0 7.240899140015244e-05
repeat O 0 5.4276544148024186e-08
in O 0 2.0859629579206285e-09
mice O 0 2.8196498469412745e-09
transgenic O 0 9.068063633321799e-09
for O 0 8.573369097986117e-11
the O 0 3.894141897831105e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 6.6835048073699e-07
is O 0 4.2473019545852253e-10
age O 0 1.3209434657213137e-09
dependent O 0 2.1013493167743036e-09
but O 0 1.20172774509264e-10
not O 0 6.149355330498096e-11
correlated O 0 4.910906348243316e-09
to O 0 1.3075868166012583e-10
the O 0 1.4768576361845476e-09
relative O 0 5.686971462637302e-07
intertissue O 0 2.058636027868488e-06
transcription O 0 2.113092023137142e-06
levels O 0 6.763835358469805e-07
and O 0 2.5365073952343664e-07
proliferative O 1 0.9779853820800781
capacities O 0 9.60661272983998e-05
. O 0 5.545341991819441e-06

A O 0 0.0011754832230508327
( O 0 1.3901648117098375e-06
CTG O 0 0.000112970890768338
) O 0 7.897924092503672e-09
nexpansion O 0 5.096417794447916e-07
in O 0 1.365896062921479e-09
the O 0 9.169479397996838e-09
3 O 0 5.5494510320386325e-08
- O 0 3.481538612959412e-08
untranslated O 0 0.0001398788735968992
region O 0 2.3310174412927154e-07
( O 0 5.446941120368365e-09
UTR O 0 0.00019586118287406862
) O 0 2.534880305660181e-09
of O 0 2.3775429625061406e-08
the O 0 3.3471644655946875e-07
DM O 1 1.0
protein O 0 1.0919007763732225e-05
kinase O 0 3.0640576369478367e-06
gene O 0 3.4415560890010966e-07
( O 0 7.825053103260871e-07
DMPK O 1 1.0
) O 0 4.811263054627091e-10
is O 0 4.0821197117013597e-11
responsible O 0 1.852565670312778e-11
for O 0 5.0971778881026e-11
causing O 0 0.00013767261407338083
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5773779153823853
DM B-Disease 1 1.0
) O 0 3.2565974805720543e-08
. O 0 6.48704983063908e-08

Major O 0 1.089256056729937e-05
instability O 0 6.0630060033872724e-05
, O 0 1.1219798423667271e-08
with O 0 1.810131905477519e-10
very O 0 4.129153408083397e-10
large O 0 4.502709594067511e-10
expansions O 0 2.5505888512356023e-09
between O 0 1.040590613676784e-09
generations O 0 1.2274170124726425e-08
and O 0 2.2407391497836215e-09
high O 0 4.5505084145247565e-09
levels O 0 1.6660622881303766e-09
of O 0 1.32086530602038e-09
somatic O 0 5.447857347462559e-07
mosaicism O 0 3.202562538717757e-06
, O 0 2.230824192039904e-09
is O 0 3.7538544495063775e-10
observed O 0 1.9068226997376314e-09
in O 0 5.399100055925032e-10
patients O 0 1.0600366806556849e-08
. O 0 1.7481960412624176e-07

There O 0 4.6254072572082805e-08
is O 0 1.2952062755644533e-09
a O 0 1.3483488769949759e-09
good O 0 3.2714750908269252e-09
correlation O 0 6.763536397613734e-09
between O 0 3.0284084129306166e-09
repeat O 0 7.104313581862698e-09
size O 0 4.154214749974017e-08
( O 0 1.0652125848054084e-09
at O 0 2.2089892137699962e-09
least O 0 4.2064277061548694e-10
in O 0 1.75453707118578e-10
leucocytes O 0 3.1585223325691913e-08
) O 0 3.7053096701988864e-11
, O 0 1.9798888223343525e-11
clinical O 0 3.1217151086337935e-10
severity O 0 3.231451728424872e-08
and O 0 6.738051228083464e-10
age O 0 2.4724281288968086e-08
of O 0 2.5814090420794855e-08
onset O 0 8.358974810107611e-06
. O 0 3.843157401206554e-07

The O 0 1.2730242815450765e-06
trinucleotide O 0 0.0008521346026100218
repeat O 0 1.4406211903406074e-06
instability O 0 2.356161758143571e-06
mechanisms O 0 3.94692250438311e-07
involved O 0 2.1300698094250947e-08
in O 0 9.028714664793824e-09
DM B-Disease 1 1.0
and O 0 2.633029350107563e-09
other O 0 3.4794905845458857e-10
human O 0 5.525159707531202e-08
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.8902875098536498e-10
unknown O 0 1.620480105657407e-07
. O 0 3.298650952388016e-08

We O 0 9.527772704132076e-08
studied O 0 1.1435203361997992e-07
somatic O 0 8.312346722050279e-07
instability O 0 6.368789939870112e-08
by O 0 5.223782517660425e-10
measuring O 0 4.3136239469276916e-08
the O 0 9.340705986460307e-09
CTG O 0 9.86979898698337e-07
repeat O 0 4.855127411218518e-09
length O 0 2.5292246075281355e-09
at O 0 1.259059523306405e-09
several O 0 1.698118035076135e-10
ages O 0 3.1437892289432057e-09
in O 0 6.333022994908788e-11
various O 0 3.8478764619043204e-10
tissues O 0 1.73775962508671e-08
of O 0 8.236197501787501e-09
transgenic O 0 4.700855527062231e-08
mice O 0 1.0671934447259446e-09
carrying O 0 3.2951088524413308e-09
a O 0 1.3778048035817392e-08
( O 0 1.5304292944051667e-08
CTG O 0 4.380569407658186e-06
) O 0 3.2500242497235377e-09
55expansion O 0 4.0564822256783373e-07
surrounded O 0 1.9119369198961067e-08
by O 0 5.450066509204987e-10
45 O 0 1.3314517488538513e-08
kb O 0 1.2147731354161806e-07
of O 0 1.2918664360483945e-08
the O 0 2.0698058378343376e-08
human O 0 1.9923785998798849e-07
DM B-Disease 1 1.0
region O 0 1.3520094910290936e-07
, O 0 9.82233738788807e-10
using O 0 1.1408636257925764e-09
small O 0 1.2019604866964073e-08
- O 0 5.4412847561025046e-08
pool O 0 1.1308297587220295e-07
PCR O 0 6.240224479370227e-07
. O 0 9.676675745140528e-07

These O 0 1.6097735056064266e-07
mice O 0 3.947584303887197e-08
have O 0 2.911218488499401e-10
been O 0 5.5556913236554095e-11
shown O 0 1.0978390939386795e-11
to O 0 4.913456794208848e-12
reproduce O 0 4.4278311572831797e-10
the O 0 2.4301927137315715e-10
intergenerational O 0 6.4333978144759385e-09
and O 0 9.247506232989977e-11
somatic O 0 1.7643823468915798e-07
instability O 0 9.531190414691082e-08
of O 0 1.7140779462465616e-08
the O 0 4.636457262563454e-08
55 O 0 2.3065358334406483e-07
CTG O 0 2.2126391741039697e-06
repeat O 0 1.0098015756909717e-08
suggesting O 0 1.1042796899118912e-08
that O 0 2.4427912470592617e-10
surrounding O 0 1.394896309570015e-09
sequences O 0 3.1352068163847946e-10
and O 0 9.30801324905417e-10
the O 0 9.692066038624603e-10
chromatin O 0 3.1904491493151e-08
environment O 0 1.4055773434051844e-08
are O 0 1.1464779126058033e-10
involved O 0 4.076558257626317e-10
in O 0 9.830958269674284e-10
instability O 0 7.426438628499454e-07
mechanisms O 0 2.3860213786974782e-06
. O 0 1.0387190059191198e-06

As O 0 4.138808762377266e-08
observed O 0 7.725409645331638e-09
in O 0 9.94922755293004e-11
some O 0 1.904404689501149e-10
of O 0 9.106363996203015e-10
the O 0 7.620852282563817e-10
tissues O 0 1.5194466129742068e-08
of O 0 9.52234060491719e-08
DM B-Disease 1 1.0
patients O 0 1.5031421662925482e-09
, O 0 3.675773574407515e-11
there O 0 2.737611699832332e-11
is O 0 1.0596874072676954e-11
a O 0 4.3428000778833464e-11
tendency O 0 8.913316751346656e-10
for O 0 7.548415364988514e-11
repeat O 0 2.086894212993684e-09
length O 0 1.5074258508107619e-09
and O 0 1.1786759346321674e-09
somatic O 0 3.031224480309902e-07
mosaicism O 0 9.302589631943192e-08
to O 0 1.0883678680517761e-10
increase O 0 1.9340147539015362e-10
with O 0 1.0636969603738944e-11
the O 0 1.8069065688131047e-10
age O 0 3.059603681521139e-09
of O 0 1.902467072767422e-09
the O 0 4.901520522793135e-09
mouse O 0 7.148477720875235e-08
. O 0 2.207167142387334e-07

Furthermore O 0 1.2790882237823098e-06
, O 0 1.1425017376609503e-08
we O 0 6.210770786552189e-10
observed O 0 8.953341401607418e-10
no O 0 1.8944526503084091e-10
correlation O 0 5.882965781189853e-10
between O 0 1.1344488543008069e-10
the O 0 2.538110832617235e-10
somatic O 0 3.291549717232556e-07
mutation O 0 2.5053969565647094e-08
rate O 0 8.660980377328542e-09
and O 0 5.946162451309078e-10
tissue O 0 1.27281154504999e-07
proliferation O 0 1.7445334378862754e-05
capacity O 0 3.5286777233523026e-07
. O 0 3.0450684107563575e-07

The O 0 3.525825320593867e-07
somatic O 0 2.3320990294450894e-06
mutation O 0 3.715570073836716e-08
rates O 0 2.4957089728161463e-09
in O 0 1.860110850071539e-11
different O 0 7.84390191688189e-11
tissues O 0 7.411492752851245e-09
were O 0 7.283347258635331e-10
also O 0 3.103789447678196e-11
not O 0 6.6569783539749405e-12
correlated O 0 5.700084848569986e-10
to O 0 3.735247181002599e-11
the O 0 1.218740441899513e-09
relative O 0 2.954319313630549e-07
inter O 0 9.486209364695242e-07
- O 0 5.500691457882567e-08
tissue O 0 1.1156185308891509e-08
difference O 0 8.015324404198054e-09
in O 0 4.1358905883415176e-11
transcriptional O 0 6.521348794308324e-09
levels O 0 2.588522063362575e-09
of O 0 1.0460929900091287e-09
the O 0 3.7920395712376376e-09
three O 0 1.0860128352163656e-09
genes O 0 1.3890030459151603e-08
( O 0 7.757642528360975e-09
DMAHP O 0 3.9683975046500564e-05
, O 0 1.5565714051035684e-08
DMPK O 0 1.602024531166535e-05
and O 0 8.854135202795987e-09
59 O 0 5.203739661396867e-08
) O 0 2.9520086375356414e-10
surrounding O 0 1.1562955926081031e-08
the O 0 1.2460493969967956e-08
repeat O 0 3.498233169807463e-08
. O 0 4.496903471817859e-08
. O 0 3.9133027485149796e-07

A O 0 9.365887763124192e-07
novel O 0 1.0960879137655866e-07
missense O 0 8.93690014436288e-07
mutation O 0 1.471271815489672e-08
in O 0 4.46428727318704e-10
patients O 0 3.6013123039246864e-10
from O 0 5.736294772518136e-10
a O 0 2.1845656394958723e-09
retinoblastoma B-Disease 0 3.499853164612432e-06
pedigree O 0 5.033191285974681e-08
showing O 0 2.4284840804966734e-09
only O 0 3.4008337812529987e-10
mild O 0 7.156455872348033e-09
expression O 0 2.6328887958726455e-09
of O 0 4.0300198733689285e-09
the O 0 1.0330466260199955e-08
tumor B-Disease 0 9.861012131295865e-07
phenotype O 0 7.121192311387858e-07
. O 0 2.020895664145428e-07

We O 0 5.4907747681909314e-08
have O 0 2.629836071132985e-10
used O 0 3.354795330423599e-10
single O 0 8.42164116221511e-10
strand O 0 3.0802498329762784e-09
conformation O 0 8.902341086525212e-10
polymorphism O 0 6.357157578129602e-10
analysis O 0 3.211184651519261e-10
to O 0 1.9056946298778854e-10
study O 0 4.817066745488319e-10
the O 0 2.823007605456951e-09
27 O 0 3.1932373190102226e-08
exons O 0 6.41788417965472e-08
of O 0 2.6519412443803958e-08
the O 0 6.832141252743895e-08
RB1 O 0 1.763495447448804e-06
gene O 0 5.07870356880602e-10
in O 0 7.547407143704277e-11
individuals O 0 2.025823953033523e-11
from O 0 3.1108321474349054e-10
a O 0 1.7760960757673416e-10
family O 0 3.009388016561587e-10
showing O 0 9.587887150885877e-10
mild O 0 4.143553500313146e-09
expression O 0 1.1878479311278056e-09
of O 0 1.4709707896187751e-09
the O 0 1.646772140873054e-08
retinoblastoma B-Disease 0 1.4248087609303184e-05
phenotype O 0 2.134268243025872e-06
. O 0 4.455955320281646e-07

In O 0 1.4716590612806613e-08
this O 0 1.1643906949743155e-09
family O 0 3.4058791342772565e-09
affected O 0 1.9886070568020386e-09
individuals O 0 8.1667970996957e-11
developed O 0 1.5742738668222955e-08
unilateral B-Disease 0 1.666788449483647e-07
tumors I-Disease 1 1.0
and O 0 1.8335146734216323e-09
, O 0 6.656652312697631e-11
as O 0 5.135176311954481e-11
a O 0 2.4570002282731096e-11
result O 0 7.25749960128752e-10
of O 0 2.3572810370353636e-09
linkage O 0 1.5146713394642575e-07
analysis O 0 4.4279452993123414e-08
, O 0 3.894959466066439e-09
unaffected O 0 3.23148228176251e-08
mutation O 0 7.261639067834835e-10
carriers O 0 4.851875567979391e-10
were O 0 1.0620275769923637e-09
also O 0 3.3676170185792387e-10
identified O 0 1.9364261305554464e-09
within O 0 3.871088782858578e-09
the O 0 2.4833406442326122e-08
pedigree O 0 3.43256579071749e-06
. O 0 1.0125096423507784e-06

A O 0 3.4907129702332895e-06
single O 0 3.3084109674064166e-08
band O 0 1.4454371033423286e-08
shift O 0 1.8117674471795908e-08
using O 0 4.175956025420646e-09
SSCP O 0 5.206673085922375e-05
was O 0 4.344910919940048e-08
identified O 0 6.281396291996089e-09
in O 0 3.388324620878791e-10
exon O 0 4.325229951973597e-09
21 O 0 1.2745868360752866e-08
which O 0 6.620123199629901e-11
resulted O 0 2.3518915703846233e-09
in O 0 5.020348026185673e-10
a O 0 1.0531605809660505e-08
missense O 0 7.904466201580362e-07
mutation O 0 1.7573990263031192e-08
converting O 0 8.174709620334397e-08
a O 0 1.8634374043813295e-08
cys O 0 4.495111340929725e-07
- O 0 1.2602522758697887e-07
- O 0 1.1047183079426759e-07
> O 0 2.716902436361579e-08
arg O 0 2.6767507321778794e-08
at O 0 2.6856681323295106e-09
nucleotide O 0 3.962654648859143e-09
position O 0 4.434436462474878e-08
28 O 0 4.240830620005909e-08
in O 0 8.205711110598202e-10
the O 0 2.7569830862717026e-08
exon O 0 4.6280462129288935e-07
. O 0 1.132098191192199e-06

The O 0 6.720960641359852e-07
mutation O 0 1.4035593949301983e-06
destroyed O 0 6.080242656025803e-06
an O 0 2.8716028666053717e-08
NdeI O 0 1.8578073195385514e-06
restriction O 0 5.191753871258697e-07
enzyme O 0 1.1489120197438751e-06
site O 0 1.7586114609002834e-06
. O 0 4.374172419829847e-07

Analysis O 0 4.95879888262607e-08
of O 0 3.4507181112530816e-08
all O 0 1.9170407483670715e-09
family O 0 4.9367607779515765e-09
members O 0 6.157183790600484e-11
demonstrated O 0 1.5212950343901355e-10
that O 0 2.6203914038624987e-11
the O 0 4.922635632453876e-10
missense O 0 1.6827283388920478e-07
mutation O 0 8.480079571882015e-08
co O 0 4.0216414731730765e-07
- O 0 1.5514767710556043e-06
segregated O 0 4.8113601991417454e-08
with O 0 7.912183686009655e-10
patients O 0 5.266171942963638e-09
with O 0 3.877525411866145e-09
tumors B-Disease 1 1.0
or O 0 6.714803362228849e-07
who O 0 7.78013742319672e-09
, O 0 2.5499930292327555e-11
as O 0 3.3255578846258516e-11
a O 0 2.6490103513521213e-11
result O 0 8.418813979282902e-10
of O 0 2.652643216194406e-09
linkage O 0 5.674100478358923e-08
analysis O 0 3.391198788449401e-08
had O 0 2.3428979645245818e-08
been O 0 2.6446005385594162e-09
predicted O 0 6.459599966035512e-09
to O 0 2.713057001280106e-10
carry O 0 4.3264756222072265e-09
the O 0 1.5312117795929225e-08
predisposing O 0 2.76926439255476e-05
mutation O 0 1.1523324019435677e-06
. O 0 9.914742804539856e-07

These O 0 2.950975641624609e-08
observations O 0 3.134839516860666e-07
point O 0 1.9457827349356194e-08
to O 0 1.5839435318909523e-10
another O 0 1.140291527867987e-09
region O 0 8.352314395665417e-09
of O 0 6.698868570964578e-09
the O 0 8.17714251866164e-08
RB1 O 0 0.00010480309720151126
gene O 0 1.6899580401741332e-08
where O 0 2.2473788163779318e-08
mutations O 0 2.9706550552788258e-09
only O 0 1.6492411603064028e-10
modify O 0 1.0682075224366372e-09
the O 0 3.4999045328554246e-10
function O 0 8.021682207370873e-10
of O 0 1.9576120724451584e-09
the O 0 2.459300096901984e-09
gene O 0 2.1152224416454146e-09
and O 0 4.844101564316361e-09
raise O 0 5.355410781504588e-09
important O 0 3.7643674843934605e-09
questions O 0 3.378388457875303e-09
for O 0 1.6846270212145242e-10
genetic O 0 1.0844670939036405e-08
counseling O 0 1.7652120876121558e-09
in O 0 2.583588343263443e-10
families O 0 5.687725845859859e-10
with O 0 5.504125280553218e-11
these O 0 5.52491163929858e-10
distinctive O 0 1.2572842322811084e-08
phenotypes O 0 1.8955937264308886e-07
. O 0 3.705011408783321e-08
. O 0 2.19396682155093e-07

Maternal B-Disease 0 0.0001255777315236628
disomy I-Disease 0 0.00048268568934872746
and O 0 4.734202320832992e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 3.1532003959000576e-06
with O 0 8.707549264963532e-11
gamete O 0 4.9098879628672876e-08
complementation O 0 3.969987361074345e-08
in O 0 6.494480647711853e-11
a O 0 6.788770934296195e-11
case O 0 5.941468428360963e-10
of O 0 2.531174603248587e-09
familial O 0 1.7647618477667493e-08
translocation O 0 8.2031213821665e-08
( O 0 2.5520778823562296e-09
3 O 0 2.1988467935329936e-08
; O 0 2.0987616089485073e-09
15 O 0 1.3397589704311486e-08
) O 0 2.5749546939124457e-10
( O 0 1.870925220304187e-10
p25 O 0 1.0417687157371347e-08
; O 0 6.501312821427518e-10
q11 O 0 1.9929784045302767e-08
. O 0 1.03788488914347e-09
2 O 0 7.348039954280239e-09
) O 0 1.5953477427999019e-09
. O 0 3.6804234326837104e-08

Maternal B-Disease 1 0.9992324113845825
uniparental I-Disease 1 0.9999998807907104
disomy I-Disease 1 0.9999998807907104
( I-Disease 0 2.839728222170379e-05
UPD I-Disease 1 1.0
) I-Disease 0 2.3136630389331003e-09
for I-Disease 0 1.8528281686691628e-10
chromosome I-Disease 0 7.483083486192754e-09
15 I-Disease 0 1.0667177363643532e-08
is O 0 9.08169373037282e-11
responsible O 0 5.2097205022194615e-11
for O 0 2.5433967432153537e-11
an O 0 6.737495977793273e-11
estimated O 0 2.3141738525467304e-10
30 O 0 6.52492837538432e-10
% O 0 5.675347344857862e-11
of O 0 2.4034553861018715e-11
cases O 0 2.792023001685351e-10
of O 0 1.2144302274919028e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9998130202293396
PWS B-Disease 1 1.0
) O 0 5.954657211759695e-08
. O 0 1.5708883438492194e-07

We O 0 1.0669968730780965e-07
report O 0 2.3100573898204857e-08
on O 0 2.7554307724386717e-09
an O 0 7.733377827001675e-11
unusual O 0 7.339645557991048e-10
case O 0 2.3953299344015022e-09
of O 0 1.760686885177165e-08
maternal B-Disease 0 0.03913678601384163
disomy I-Disease 0 0.27774325013160706
15 I-Disease 0 1.7012004605021502e-07
in O 0 1.0285109652841129e-08
PWS B-Disease 1 1.0
that O 0 1.1333723959339181e-09
is O 0 1.3440447366175334e-10
most O 0 1.1839160207749444e-10
consistent O 0 3.2837652597095257e-09
with O 0 4.3798029092378954e-10
adjacent O 0 1.0585985421585065e-07
- O 0 1.3346731719821037e-08
1 O 0 2.5034241346588715e-08
segregation O 0 2.1669132266310953e-08
of O 0 5.6669589021396405e-09
a O 0 1.7606568647465792e-08
paternal O 0 3.581475993996719e-06
t O 0 3.467317455374541e-08
( O 0 1.7213767078416709e-09
3 O 0 1.4158125338781247e-08
; O 0 9.525802369125813e-10
15 O 0 4.6831512001688225e-09
) O 0 8.437811560568775e-11
( O 0 5.905097938407877e-11
p25 O 0 1.0198980326947549e-08
; O 0 2.6004867703655066e-10
q11 O 0 8.590548716824742e-09
. O 0 1.0921442916700386e-10
2 O 0 3.2061417409856574e-10
) O 0 4.65997769885651e-12
with O 0 5.639369179966103e-12
simultaneous O 0 4.065456860047334e-09
maternal O 0 2.687489484287653e-07
meiotic O 0 1.2397764521665522e-06
nondisjunction O 0 3.5671525893121725e-06
for O 0 1.0031651953568144e-08
chromosome O 0 4.790925345332653e-07
15 O 0 7.836658255655493e-07
. O 0 2.8730883627758885e-07

The O 0 2.6655072815628955e-07
patient O 0 3.371702348431427e-07
( O 0 6.575430422373074e-09
J O 0 3.016741629835451e-07
. O 0 1.1138320266113055e-09
B O 0 7.908763421937692e-09
. O 0 7.013922082022006e-11
) O 0 9.558224871308862e-12
, O 0 2.7045412784310052e-11
a O 0 2.0979760984030094e-10
17 O 0 2.4722097702323254e-09
- O 0 4.937719122466433e-10
year O 0 1.8329272544193032e-09
- O 0 8.038427701251294e-09
old O 0 3.6285098303778796e-07
white O 0 7.395197343385007e-09
male O 0 4.3132923899236175e-09
with O 0 9.469174333531782e-10
PWS B-Disease 1 1.0
, O 0 1.748471034623833e-09
was O 0 1.9713108923014033e-09
found O 0 3.2009648404107693e-11
to O 0 8.586182459469072e-11
have O 0 4.259348984625433e-10
47 O 0 2.374701324470152e-08
chromosomes O 0 2.129142417928165e-09
with O 0 2.1244075942838947e-10
a O 0 7.824872305661756e-09
supernumerary O 0 4.278841061022831e-06
, O 0 1.526260717810146e-08
paternal O 0 9.447294360143133e-06
der O 0 2.932381448772503e-06
( O 0 1.4793074543106854e-09
15 O 0 5.268040226269477e-09
) O 0 6.324050658146341e-12
consisting O 0 3.8462531770644404e-11
of O 0 1.311734165732048e-09
the O 0 6.895580551002922e-09
short O 0 4.604271186536835e-09
arm O 0 1.3299060519500472e-08
and O 0 1.7867388679704277e-09
the O 0 7.490969267109904e-08
proximal O 0 0.05560797080397606
long O 0 2.9213794050519937e-07
arm O 0 1.41986149060358e-07
of O 0 4.062885139433092e-08
chromosome O 0 8.565258013959465e-08
15 O 0 1.8072121577006328e-07
, O 0 4.7952237736126335e-09
and O 0 8.122066574856035e-09
distal O 0 1.2751536814903375e-05
chromosome O 0 1.4232986359274946e-05
arm O 0 4.6006014599697664e-05
3p O 0 0.00028527440736070275
. O 0 2.0370887341414345e-06

The O 0 6.899056188558461e-06
t O 0 1.1639410502084502e-07
( O 0 4.984275658870274e-09
3 O 0 1.1217573536725922e-08
; O 0 3.1898797492324604e-10
15 O 0 6.147927722466306e-10
) O 0 5.516398102201059e-12
was O 0 1.899394946880406e-10
present O 0 1.7194847976020888e-11
in O 0 8.007213815608427e-12
the O 0 1.6394559321231128e-10
balanced O 0 4.72200389900479e-10
state O 0 8.37946448339899e-11
in O 0 1.6819204362583662e-10
the O 0 1.1853514836346335e-09
patients O 0 4.286055121927035e-10
father O 0 1.9998363853801493e-08
and O 0 7.580973182541584e-09
a O 0 4.406612674756616e-08
sister O 0 1.4970634083510959e-06
. O 0 9.851668210103526e-07

Fluorescent O 0 1.4125131428954774e-06
in O 0 2.0351142993035864e-08
situ O 0 1.1475274419581183e-07
hybridization O 0 2.1645825132310392e-09
analysis O 0 4.984739288005358e-10
demonstrated O 0 5.920788859192783e-10
that O 0 1.0908056402580968e-10
the O 0 3.86782650352302e-09
PWS B-Disease 1 1.0
critical O 0 1.0987692178332509e-07
region O 0 2.1765147906194215e-08
resided O 0 1.6920198220304883e-07
on O 0 3.926219349636995e-09
the O 0 1.227727808306156e-09
derivative O 0 3.836504891552295e-09
chromosome O 0 1.962038087555129e-09
3 O 0 3.7676786135421025e-09
and O 0 2.0248053234084296e-10
that O 0 6.279593511848702e-11
there O 0 2.055726561200899e-10
was O 0 9.592386884804682e-10
no O 0 1.0845218473276574e-10
deletion O 0 3.866519326933826e-10
of O 0 2.467442472564585e-09
the O 0 2.74045799386613e-08
PWS B-Disease 1 1.0
region O 0 1.248652523599958e-07
on O 0 2.208699534378411e-08
the O 0 4.809430631524947e-09
normal O 0 1.7103941374330134e-08
pair O 0 4.024796496082672e-09
of O 0 3.5560596689521162e-09
15s O 0 1.5653429841222533e-07
present O 0 1.1979072844781058e-08
in O 0 1.4262394820718782e-08
J O 0 4.914807141176425e-05
. O 0 1.0827928917933605e-06

B O 0 0.001466175657697022
. O 0 1.0990183909598272e-05

Methylation O 0 1.1322471209496143e-06
analysis O 0 1.4102531054049905e-07
at O 0 3.772081313968556e-08
exon O 0 1.0786251003480629e-08
alpha O 0 4.412455734126297e-09
of O 0 2.580679003827413e-09
the O 0 1.582144859568757e-09
small O 0 2.007271904247432e-09
nuclear O 0 3.88014598229347e-08
ribonucleoprotein O 0 3.167073714394064e-07
- O 0 4.146116694414559e-08
associated O 0 5.041107797865152e-08
polypeptide O 0 9.002595220408693e-07
N O 0 2.3660756198751187e-07
( O 0 1.7040046040861512e-09
SNRPN O 0 2.992924919453799e-06
) O 0 9.127696515287553e-11
gene O 0 2.1765708679843954e-10
showed O 0 1.1939876864985877e-09
a O 0 7.077338021188595e-11
pattern O 0 1.1048396642010516e-09
characteristic O 0 1.0887359902511662e-09
of O 0 2.476371052662074e-10
only O 0 2.476635563297691e-10
the O 0 1.1714389458461483e-09
maternal O 0 1.03606616619345e-07
chromosome O 0 3.2509994696283684e-08
15 O 0 7.116684486163649e-08
in O 0 2.7936133406569752e-08
J O 0 4.0252107282867655e-05
. O 0 9.975938155548647e-07

B O 0 0.0013790519442409277
. O 0 9.67959567788057e-06

Maternal B-Disease 0 0.0005194586119614542
disomy I-Disease 0 0.0001997291255975142
was O 0 1.7458334866660152e-07
confirmed O 0 4.569224554273887e-09
by O 0 5.5030334455974383e-11
polymerase O 0 4.386894847385747e-09
chain O 0 2.5226292166280473e-09
reaction O 0 9.539001810665582e-10
analysis O 0 7.864848772243249e-10
of O 0 1.9374604143251872e-09
microsatellite O 0 1.0620791357496273e-07
repeats O 0 4.7280025228246814e-08
at O 0 4.986900226100488e-09
the O 0 4.992020130600849e-09
gamma O 0 1.2514219349668565e-07
- O 0 6.982017453083245e-08
aminobutyric O 0 6.514178494398948e-07
acid O 0 9.096928721419317e-08
receptor O 0 2.9013662583565747e-07
beta3 O 0 8.090572691799025e-07
subunit O 0 3.5567399692126855e-08
( O 0 1.7640854110823057e-08
GABRB3 O 0 7.634186658833642e-06
) O 0 4.917701801332441e-09
locus O 0 7.116616274061016e-08
. O 0 1.2125241255489527e-07

A O 0 2.5952625946956687e-05
niece O 0 9.159499313682318e-06
( O 0 1.7360965998136635e-08
B O 0 1.2999791465517774e-07
. O 0 7.200801066531426e-10
B O 0 6.1033107456864855e-09
. O 0 3.075468005264703e-11
) O 0 2.9444871020578578e-12
with O 0 6.9571327865336485e-12
45 O 0 1.2603328380933476e-09
chromosomes O 0 2.1918100667761564e-10
and O 0 6.838311167323141e-11
the O 0 2.801865683910165e-10
derivative O 0 5.232327904280965e-10
3 O 0 5.214593756797115e-10
but O 0 1.019677189906254e-10
without O 0 6.638435356975947e-10
the O 0 1.1640182151495537e-08
der O 0 5.458581426864839e-07
( O 0 8.874012635828876e-10
15 O 0 8.434601461715374e-09
) O 0 1.0507717612684431e-10
demonstrated O 0 7.89843301873816e-10
a O 0 8.616718449871996e-10
phenotype O 0 1.3046113522818814e-08
consistent O 0 7.783699906838137e-09
with O 0 4.6890994559456445e-11
that O 0 1.0275687245542287e-10
reported O 0 1.73147929327655e-09
for O 0 3.021488892418489e-10
haploinsufficiency O 0 3.3369667562510585e-06
of O 0 1.1410735822892093e-07
distal O 0 1.6554615285713226e-05
3 O 0 1.774890552042052e-05
p O 0 1.0854504580493085e-05
. O 0 6.565945795955486e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 6.718398253724445e-06
with O 0 8.356234815209973e-09
unbalanced O 0 3.2318082958227023e-05
segregation O 0 6.490118948931922e-07
of O 0 3.117631024451839e-07
non O 0 2.440997377561871e-06
- O 0 1.873570028010363e-07
Robertsonian O 0 1.477688897466578e-06
translocations O 0 2.4630807615722006e-07
has O 0 2.5585797924776443e-09
been O 0 3.0918673177282585e-10
reported O 0 1.5182752832743063e-09
previously O 0 8.028157583161999e-10
but O 0 5.472879371914985e-10
has O 0 1.0557801161104052e-10
not O 0 8.481280261429802e-11
, O 0 7.271351576410012e-11
to O 0 2.9996743977633855e-10
our O 0 6.13486994538448e-09
knowledge O 0 7.030352833226061e-08
, O 0 1.376889935400527e-09
been O 0 5.969514327297532e-10
observed O 0 8.954519903348057e-10
in O 0 7.768221482740145e-11
a O 0 6.861701762339578e-10
case O 0 1.0907027281348292e-08
of O 0 3.4806961934918945e-07
PWS B-Disease 1 1.0
. O 0 8.106984751066193e-06

Furthermore O 0 8.129786692734342e-06
, O 0 8.38038758388393e-08
our O 0 3.71082506944731e-08
findings O 0 3.597958553314129e-08
are O 0 3.7198491509293774e-10
best O 0 1.380832115316366e-09
interpreted O 0 3.4825666794802146e-09
as O 0 6.944624320048831e-10
true O 0 1.6314345430146204e-08
gamete O 0 7.820039513717347e-07
complementation O 0 1.277326759918651e-06
resulting O 0 7.103015065013096e-08
in O 0 2.0614809415064883e-08
maternal B-Disease 1 0.9999463558197021
UPD I-Disease 1 1.0
15 I-Disease 0 0.00012763874838128686
and O 0 8.927938324632123e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999986886978149
- I-Disease 1 1.0
Jampel I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999901056289673
type I-Disease 0 3.62397258868441e-07
2 I-Disease 0 3.10216108800887e-07
and O 0 9.705575010343637e-09
Stuve B-Disease 1 0.9886903762817383
- I-Disease 0 0.38336384296417236
Wiedemann I-Disease 1 0.999940037727356
syndrome I-Disease 1 1.0
: O 0 1.2640546387387985e-09
a O 0 5.554507409577525e-10
case O 0 8.324541611592906e-10
for O 0 1.9777575410717674e-10
" O 0 1.2053208431339613e-09
lumping O 0 2.323145054106135e-08
" O 0 5.297121674630034e-08
. O 0 2.3253180359006365e-07

Recent O 0 5.0349868274679466e-08
studies O 0 5.53897949728821e-09
demonstrated O 0 1.8402941392992034e-09
the O 0 4.0853462279777375e-10
existence O 0 5.303558481273285e-09
of O 0 1.514365188803879e-09
a O 0 7.358386677758233e-10
genetically O 0 7.567292570342943e-09
distinct O 0 2.057462467064397e-08
, O 0 2.4299473544431294e-10
usually O 0 5.524455545802276e-11
lethal O 0 3.475232601690692e-10
form O 0 2.12654824305325e-10
of O 0 2.545039290424711e-09
the O 0 3.7969773103441185e-08
Schwartz B-Disease 1 0.9996448755264282
- I-Disease 1 0.9999994039535522
Jampel I-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
( O 0 1.5248529905420583e-07
SJS B-Disease 0 0.0009568908135406673
) O 0 3.880647359011391e-09
of O 0 1.0082486596729723e-06
myotonia B-Disease 1 1.0
and O 0 0.036192383617162704
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 7.826694741197571e-07
which O 0 1.5553279553159882e-08
we O 0 5.877798248121735e-09
called O 0 1.8058885942195957e-08
SJS B-Disease 0 5.132186743139755e-06
type I-Disease 0 2.309398041688837e-06
2 I-Disease 0 7.3079258982033934e-06
. O 0 5.463622869683604e-07

This O 0 6.148754039259074e-08
disorder O 1 0.957748293876648
is O 0 3.521931635219744e-09
reminiscent O 0 1.288733955107091e-07
of O 0 6.349320624821075e-09
another O 0 1.2568760476838747e-09
rare O 0 2.987827318889913e-09
condition O 0 2.0565647673720377e-07
, O 0 4.526631014467597e-10
the O 0 4.194860014905544e-09
Stuve B-Disease 1 0.7711616158485413
- I-Disease 1 0.9994516968727112
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.337065886124037e-06
SWS B-Disease 1 0.9566515684127808
) O 0 3.8500644339301004e-10
, O 0 1.244271630174154e-10
which O 0 1.4549812743513968e-10
comprises O 0 1.6193121288310408e-09
campomelia B-Disease 0 9.101629075303208e-06
at O 0 8.698316378286108e-08
birth O 0 2.2137830910651246e-06
with O 0 3.9065824353201606e-08
skeletal B-Disease 1 0.9999998807907104
dysplasia I-Disease 1 0.9999986886978149
, O 0 1.1556180368188507e-07
contractures B-Disease 0 9.88181127468124e-05
, O 0 7.1906760545914494e-09
and O 0 1.0792357008071463e-09
early B-Disease 0 1.0427512364685754e-07
death I-Disease 0 1.0675256589820492e-06
. O 0 5.117506702845276e-07

To O 0 6.368010563306825e-09
test O 0 4.757224614237998e-10
for O 0 1.0872745065393374e-10
possible O 0 1.68933933508697e-08
nosologic O 0 3.136997747787973e-06
identity O 0 3.908073153979785e-08
between O 0 3.683815563704229e-08
these O 0 1.6442331940424992e-08
disorders O 0 5.220351226853381e-07
, O 0 7.31333271719592e-10
we O 0 1.387997911050931e-10
reviewed O 0 1.5376028228430982e-09
the O 0 5.74504277484067e-10
literature O 0 9.248798393812763e-10
and O 0 7.635441584552538e-11
obtained O 0 2.224459505484333e-09
a O 0 2.56454885105839e-10
follow O 0 9.631454522818217e-10
- O 0 7.529107892700893e-10
up O 0 1.1297680568844726e-09
of O 0 9.29070154143119e-10
the O 0 8.695338893360827e-10
only O 0 7.362556120327213e-10
two O 0 4.694766797541661e-10
surviving O 0 1.667092952573057e-08
patients O 0 5.100438404959107e-10
, O 0 3.4344568855537716e-10
one O 0 1.062179566524435e-09
with O 0 1.2949765704206584e-09
SJS B-Disease 0 3.96951833181447e-07
type I-Disease 0 2.758803141489352e-08
2 I-Disease 0 2.1400754945943845e-08
at O 0 1.9999575329165964e-09
age O 0 7.366615650816755e-10
10 O 0 1.7769702376213559e-10
years O 0 9.46765305043229e-11
and O 0 1.003493330098415e-10
another O 0 1.4227744538075626e-09
with O 0 1.5834490385557842e-09
SWS B-Disease 0 1.1848200301756151e-05
at O 0 1.2255618742074148e-08
age O 0 4.2507508624112234e-08
7 O 0 7.03459122064487e-08
years O 0 2.4238486773242585e-08
. O 0 2.569913988281769e-07

Patients O 0 1.4318439411908912e-07
reported O 0 3.590616159954152e-08
as O 0 8.114072747034129e-10
having O 0 6.511042260903821e-10
either O 0 3.6413215553920963e-08
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 3.896272028214298e-05
SWS B-Disease 0 0.00045603804755955935
presented O 0 1.1732277371834243e-09
a O 0 6.027621457516119e-11
combination O 0 3.7200409419568814e-10
of O 0 2.625355488561354e-10
a O 0 5.100350697340161e-10
severe O 0 1.0340781386730669e-07
, O 0 4.244073092962708e-09
prenatal O 0 2.4007961201277794e-06
- O 0 5.572840564127546e-06
onset O 1 0.9999918937683105
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 3.143743043665381e-08
with O 0 5.2677187056815455e-09
congenital B-Disease 1 1.0
joint I-Disease 0 9.934088893714943e-07
contractures I-Disease 1 1.0
, O 0 1.5240789963399948e-08
respiratory O 1 1.0
and O 0 4.5596156184046777e-08
feeding O 0 8.012819307623431e-06
difficulties O 0 0.0011954966466873884
, O 0 4.486800264658086e-09
tendency O 0 6.175363154170554e-08
to O 0 2.0968771163865085e-09
hyperthermia B-Disease 0 0.00039876962546259165
, O 0 8.886140157038369e-10
and O 0 1.6811763092761112e-10
frequent O 0 1.2085090705937773e-09
death O 0 2.1173750752723208e-08
in O 0 3.439230455981601e-09
infancy O 0 1.1954020919802133e-06
) O 0 1.8530153800266902e-10
with O 0 6.598892959841507e-11
a O 0 2.4083495198112814e-09
distinct O 0 7.51552775568598e-08
campomelic B-Disease 0 0.00010589041630737484
- I-Disease 0 5.782200241810642e-05
metaphyseal I-Disease 0 0.00040492397965863347
skeletal I-Disease 0 0.013940469361841679
dysplasia I-Disease 1 0.9930148124694824
. O 0 1.7210717487614602e-05

The O 0 5.326675633909872e-08
similarity O 0 4.951125447405502e-07
of O 0 1.0973953123993851e-07
the O 0 3.5268673315158594e-08
clinical O 0 7.287996339755409e-08
and O 0 4.067442382904574e-09
radiographic O 0 1.4471838767349254e-05
findings O 0 2.2395529697405436e-07
is O 0 1.9770645121042207e-09
so O 0 9.073145568194718e-10
extensive O 0 9.816085722036405e-09
that O 0 1.312339792391981e-09
these O 0 1.531100934926144e-08
disorders O 0 6.47754177407478e-07
appear O 0 4.634456374219553e-09
to O 0 5.000213021411071e-10
be O 0 4.975250211813886e-10
a O 0 1.3974047474718532e-09
single O 0 3.436535500611626e-09
entity O 0 5.005533125768125e-07
. O 0 7.658591130166315e-07

The O 0 4.740531380775792e-07
follow O 0 8.022058040069169e-08
- O 0 1.114066350282883e-08
up O 0 8.443820642689559e-10
observation O 0 4.2924408916178436e-08
of O 0 1.6360290899797292e-10
an O 0 4.1109355503055056e-11
identical O 0 1.7864618118146325e-10
and O 0 1.4956249780317954e-11
unique O 0 4.195626346348291e-10
pattern O 0 5.341254905033566e-07
of O 0 3.1841332770454756e-07
progressive O 1 1.0
bone B-Disease 1 0.9999929666519165
dysplasia I-Disease 1 0.9999234676361084
in O 0 1.6640177236126874e-08
the O 0 5.777851441735038e-08
two O 0 4.5986253693897083e-10
patients O 0 1.9354612357247447e-10
( O 0 7.906824500691911e-11
one O 0 7.301164672846028e-10
with O 0 7.608303986827991e-10
SJS B-Disease 0 9.132045164506053e-08
type I-Disease 0 5.062226193786046e-09
2 I-Disease 0 1.0959453788927931e-08
, O 0 3.0036420572976397e-10
one O 0 7.650635680533924e-10
with O 0 1.2224001810778873e-09
SWS B-Disease 0 4.699551936937496e-06
) O 0 4.167941269894726e-10
surviving O 0 3.40489435757263e-07
beyond O 0 5.830891609548416e-07
infancy O 0 1.0568055586190894e-06
adds O 0 8.875134405172957e-09
to O 0 3.444178553468902e-10
the O 0 6.602056679128054e-10
evidence O 0 4.598969649549645e-09
in O 0 2.389930198187784e-10
favor O 0 5.018292892344789e-09
of O 0 2.2700816781906497e-09
identity O 0 5.8180273043717534e-08
. O 0 3.3320935699521215e-07

The O 0 5.699644134438131e-07
hypothesis O 0 2.3283321297640214e-06
that O 0 4.2453542903331254e-08
SWS B-Disease 0 3.6653589631896466e-05
and O 0 5.635079958210554e-08
SJS B-Disease 0 2.2483836801256984e-06
type I-Disease 0 2.5733376673997554e-07
2 I-Disease 0 2.388666189290234e-07
are O 0 2.4998050851543496e-10
the O 0 1.619546941000749e-09
same O 0 1.7766152993203832e-09
disorder O 0 1.3642933538449142e-07
should O 0 6.5303196183919e-10
be O 0 7.691398629106061e-10
testable O 0 9.621548713312222e-08
by O 0 2.868205950523617e-10
molecular O 0 2.5614667720219586e-08
methods O 0 3.095534850672266e-08
. O 0 3.06963556795381e-08
. O 0 1.8669315693387034e-07

A O 0 5.256802069197875e-07
mouse O 0 2.4009070287434042e-08
model O 0 2.7286025883199727e-08
of O 0 9.059420769119697e-09
severe O 1 0.9772188663482666
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.8177834153175354
defects O 1 0.9999995231628418
in O 0 2.351193195693213e-08
hemostasis O 0 3.469776129350066e-05
and O 0 3.1621027574146865e-08
thrombosis B-Disease 0 5.366587174648885e-06
. O 0 3.8428493098763283e-07

von B-Disease 1 0.9998466968536377
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.9999771118164062
( I-Disease 1 0.959226667881012
vWf I-Disease 1 1.0
) I-Disease 0 0.0001037221954902634
deficiency I-Disease 1 1.0
causes O 1 1.0
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 9.440272492611257e-07
humans O 0 9.071178510566824e-07
. O 0 3.510250579097374e-08

We O 0 3.305314422163974e-08
generated O 0 3.076951315961196e-08
a O 0 4.692324750976695e-09
mouse O 0 3.5317393454192825e-09
model O 0 1.4105127066343925e-09
for O 0 4.009185344822086e-11
this O 0 1.0267890010462466e-10
disease O 0 5.494897314939351e-10
by O 0 2.685040384475812e-11
using O 0 1.1327536131311433e-10
gene O 0 3.857078212377019e-09
targeting O 0 1.3254496877834754e-07
. O 0 1.575401142872579e-07

vWf B-Disease 0 0.002530659781768918
- I-Disease 0 0.0012093615951016545
deficient I-Disease 0 7.576425559818745e-05
mice O 0 6.678598651888024e-07
appeared O 0 1.4489377520021662e-07
normal O 0 3.4229305612143435e-08
at O 0 8.192074241186731e-10
birth O 0 5.005575953731523e-10
; O 0 1.597228460603617e-10
they O 0 1.0962870888864273e-10
were O 0 3.587614094691105e-10
viable O 0 8.483331015440854e-08
and O 0 1.4531162051412139e-08
fertile O 0 4.768548933498096e-06
. O 0 1.0580490652500885e-06

Neither O 0 0.00015093266847543418
vWf O 0 0.006119563709944487
nor O 0 0.0005968917394056916
vWf O 0 0.0032320725731551647
propolypeptide O 0 0.002465854398906231
( O 0 6.471576625699527e-07
von B-Disease 0 0.0004857023013755679
Willebrand I-Disease 0 4.443860598257743e-05
antigen O 0 1.844808110718077e-07
II O 0 0.0012506976490840316
) O 0 2.1038757402891406e-09
were O 0 6.80483669412979e-10
detectable O 0 1.905849345007482e-08
in O 0 1.2137964244818278e-10
plasma O 0 9.423900770855198e-09
, O 0 1.2059779563866613e-10
platelets O 0 2.5460589192505267e-09
, O 0 5.3519640108579125e-11
or O 0 1.025550061539704e-10
endothelial O 0 7.395616896666013e-10
cells O 0 3.067742171403154e-10
of O 0 7.143156066646839e-10
the O 0 1.6069742203583814e-09
homozygous O 0 9.34993948931151e-09
mutant O 0 1.986428657119177e-07
mice O 0 1.4821246452356718e-07
. O 0 2.2266219446009927e-07

The O 0 1.8267407142502634e-07
mutant O 0 6.508732326437894e-07
mice O 0 1.3535498055716744e-07
exhibited O 0 1.608085540283355e-07
defects O 0 7.847509664316021e-07
in O 0 1.6053597340359715e-09
hemostasis O 0 4.925317398374318e-07
with O 0 2.3353646794177507e-10
a O 0 1.4482124388592865e-09
highly O 0 6.063072710560391e-09
prolonged O 0 2.13649627767154e-06
bleeding O 0 3.400225750738173e-06
time O 0 8.519958072383815e-09
and O 0 4.213519755325024e-09
spontaneous O 0 3.440197531290323e-07
bleeding O 0 2.997109902480588e-07
events O 0 7.527370393667354e-10
in O 0 1.427767626349663e-10
approximately O 0 5.226941657276996e-10
10 O 0 1.3898716622051666e-09
% O 0 8.249431138196428e-10
of O 0 1.8890520259162713e-09
neonates O 0 5.695373488379118e-07
. O 0 7.449569920936483e-07

As O 0 4.902224048919379e-08
in O 0 3.3913070129898415e-09
the O 0 5.1530784084263814e-09
human O 0 4.99341057391689e-09
disease O 0 1.8273156854320405e-07
, O 0 8.098761244967889e-11
the O 0 1.6619544629392635e-10
factor O 0 1.4332307562980873e-09
VIII O 0 6.160088332762825e-07
level O 0 9.49122522797552e-08
in O 0 2.570446300254048e-09
these O 0 8.489866587524375e-09
mice O 0 7.399599599722251e-09
was O 0 2.027198409138009e-09
reduced O 0 1.9347905499955687e-09
strongly O 0 1.910462205101382e-10
as O 0 9.932050321070918e-11
a O 0 8.300976572783725e-11
result O 0 1.4806399439848406e-09
of O 0 2.149795008676847e-09
the O 0 2.4404873677497108e-09
lack O 0 1.8467156692736353e-08
of O 0 2.098217377621836e-09
protection O 0 2.8492232573285037e-08
provided O 0 3.3225003193138036e-08
by O 0 2.957314748641693e-08
vWf O 0 0.0001924075768329203
. O 0 2.4722828584344825e-06

Defective O 0 3.773794014705345e-05
thrombosis B-Disease 0 7.063429620757233e-06
in O 0 1.6960999715820435e-08
mutant O 0 2.0631139818760857e-07
mice O 0 1.7661154316783723e-08
was O 0 4.8710258049311506e-09
also O 0 5.233503214130408e-11
evident O 0 5.610525377619524e-10
in O 0 3.9269115736928484e-11
an O 0 9.789936916693165e-11
in O 0 4.4728765830059913e-11
vivo O 0 3.3649800723623002e-09
model O 0 6.777961747417294e-09
of O 0 1.5707287914779045e-08
vascular B-Disease 0 0.2532840371131897
injury I-Disease 1 1.0
. O 0 5.036373477196321e-05

In O 0 7.14787518063531e-09
this O 0 1.331870169707372e-09
model O 0 1.4173527240757267e-08
, O 0 7.634863297134586e-10
the O 0 5.081418841257346e-09
exteriorized O 0 1.916654355227365e-06
mesentery O 0 9.190051969198976e-06
was O 0 1.2773618607297976e-07
superfused O 0 4.542835938536882e-07
with O 0 1.4740069165242176e-09
ferric O 0 2.029877350651077e-07
chloride O 0 1.3882329596981435e-07
and O 0 6.162359067474199e-09
the O 0 7.570136517642823e-09
accumulation O 0 3.879512860294199e-06
of O 0 1.0295786978531396e-06
fluorescently O 0 3.3692288070596987e-06
labeled O 0 8.768310522100364e-08
platelets O 0 1.0413241824380748e-07
was O 0 9.668529088457944e-09
observed O 0 1.1070122596379406e-09
by O 0 1.1576544167724023e-09
intravital O 0 2.137453975592507e-06
microscopy O 0 6.466579520747473e-07
. O 0 6.043372877684305e-07

We O 0 1.4182214158608986e-07
conclude O 0 2.753431544988416e-07
that O 0 2.4270347953603277e-09
these O 0 6.068649138768478e-09
mice O 0 2.0802266575969952e-08
very O 0 1.7687779019226468e-09
closely O 0 4.740162484750954e-09
mimic O 0 2.647355756835168e-07
severe O 0 0.007152572274208069
human O 0 0.0243918988853693
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 4.1471224676570273e-07
will O 0 2.8716434785636125e-10
be O 0 1.586017428500952e-10
very O 0 6.229097099241798e-11
useful O 0 5.151679638437656e-10
for O 0 4.269848016824618e-11
investigating O 0 9.545444434877481e-10
the O 0 2.398873322206896e-09
role O 0 5.824164261980513e-09
of O 0 1.539364191671666e-08
vWf O 0 1.1165871001139749e-06
in O 0 4.463319047687264e-09
normal O 0 6.63702280689904e-07
physiology O 0 7.565736837022996e-08
and O 0 1.1134433375303843e-09
in O 0 6.546806985419096e-10
disease O 0 1.341694755296885e-08
models O 0 1.6923708656690906e-08
. O 0 6.606494018512876e-09
. O 0 7.494542586528041e-08

Oral O 0 9.508344760433829e-07
contraceptives O 0 1.1318136472482365e-07
and O 0 5.924019608194442e-10
the O 0 8.441598531305772e-10
risk O 0 1.756763055027477e-07
of O 0 4.171468026470393e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.162936314358376e-06

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 0 2.727073479036335e-06
Study O 0 3.6171816653052247e-09
Group O 0 1.0605539779717787e-09
. O 0 8.601370282690368e-09

BACKGROUND O 0 0.0013686591992154717
Women O 0 1.2866924414822734e-08
with O 0 4.58004190129202e-10
mutations O 0 2.1538746342031345e-09
in O 0 1.222719148152862e-10
either O 0 1.2516749858804133e-09
the O 0 5.177313244786319e-09
BRCA1 O 0 1.5964840116566847e-08
or O 0 8.218006275484413e-10
the O 0 2.9348925512096002e-09
BRCA2 O 0 1.6820280279716826e-08
gene O 0 1.2583633024476626e-09
have O 0 3.6885436371925096e-10
a O 0 8.429997810921463e-10
high O 0 4.19262047302027e-09
lifetime O 0 9.852889171213519e-09
risk O 0 5.510496066563064e-06
of O 1 0.979206919670105
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.628247426007874e-07

Oral O 0 2.3775673980708234e-05
contraceptives O 0 0.00010365000343881547
protect O 0 3.999825639766641e-05
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.291817263217922e-09
general O 0 1.569255481115306e-08
, O 0 4.176318665893852e-11
but O 0 4.516521184827482e-11
it O 0 2.6849021270147766e-11
is O 0 1.5020774554730387e-11
not O 0 2.5376738904681062e-11
known O 0 3.939832626809192e-10
whether O 0 1.649248293489336e-09
they O 0 2.454534131501873e-09
also O 0 8.34256719262072e-10
protect O 0 1.260549220560847e-09
against O 0 7.525049028345165e-09
hereditary B-Disease 1 0.9999997615814209
forms I-Disease 1 1.0
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6859634399679635e-07

METHODS O 0 9.910451126415865e-07
We O 0 1.0809235284625629e-08
enrolled O 0 2.673704280198308e-08
207 O 0 9.937366485246457e-09
women O 0 7.117900158171153e-10
with O 0 5.1577195847585244e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.828378322163651e-11
161 O 0 7.060632634114938e-11
of O 0 5.2296215968805626e-11
their O 0 1.5136712716579126e-10
sisters O 0 3.946663884590862e-09
as O 0 1.7404588881220207e-09
controls O 0 3.344523324955162e-09
in O 0 7.75476904912864e-10
a O 0 3.046652263805072e-09
case O 0 1.60218522893274e-08
- O 0 3.068148757279232e-08
control O 0 2.5383746660168072e-08
study O 0 1.3774578810910043e-08
. O 0 7.552645797659352e-08

All O 0 5.440288575186969e-08
the O 0 1.7521577078127848e-08
patients O 0 2.1427497554071806e-09
carried O 0 5.342451481205046e-10
a O 0 2.991668024421301e-11
pathogenic O 0 5.742062936242576e-10
mutation O 0 9.629874675454175e-10
in O 0 2.8168853360988066e-10
either O 0 2.3813052862919903e-08
BRCA1 O 0 4.562034305877205e-08
( O 0 2.1451869169908377e-09
179 O 0 8.433572062926942e-09
women O 0 8.353394087556865e-10
) O 0 2.5932750391532977e-10
or O 0 4.712756851432687e-09
BRCA2 O 0 8.716801147556907e-08
( O 0 1.8655668121425606e-09
28 O 0 2.4876555926311994e-07
women O 0 1.7050261647000298e-08
) O 0 1.7555564113536093e-08
. O 0 2.8208032176735287e-07

The O 0 1.3746868887665187e-07
control O 0 1.214402374216661e-07
women O 0 2.651990627100531e-09
were O 0 2.325679870907038e-09
enrolled O 0 1.6121133317170688e-09
regardless O 0 2.094562745469375e-09
of O 0 6.352685044674899e-10
whether O 0 4.862010238859682e-10
or O 0 6.464945800921384e-10
not O 0 3.1283731161124706e-10
they O 0 4.306492107364335e-10
had O 0 1.7794300477547154e-09
either O 0 5.264574998165017e-09
mutation O 0 6.507708860681305e-08
. O 0 1.8037064819509396e-07

Lifetime O 0 1.3124251836416079e-06
histories O 0 1.725798142615531e-06
of O 0 7.77964146436716e-07
oral O 0 1.8144274349651823e-07
- O 0 1.0734530597744651e-08
contraceptive O 0 7.493234921440717e-10
use O 0 1.0010445250507871e-10
were O 0 7.051574602012778e-11
obtained O 0 4.824118327029225e-10
by O 0 1.063805085688152e-10
interview O 0 6.770076721451801e-10
or O 0 3.536845469276351e-11
by O 0 1.2848461877768003e-11
written O 0 1.1435290214745208e-11
questionnaire O 0 1.3718501161441576e-11
and O 0 2.053648570643496e-11
were O 0 7.296260817746258e-11
compared O 0 2.9796989875485735e-10
between O 0 2.0315053805841643e-10
patients O 0 6.307238065161869e-11
and O 0 2.4150320632188027e-10
control O 0 2.9922415656358226e-09
women O 0 6.756119552697726e-10
, O 0 2.3844254348759364e-10
after O 0 1.8471400797803739e-10
adjustment O 0 2.8323705603128246e-09
for O 0 5.3830353369255235e-11
year O 0 3.93872073845003e-10
of O 0 2.060092541000813e-09
birth O 0 3.364423051266385e-08
and O 0 2.0680813506146478e-08
parity O 0 3.306712869743933e-06
. O 0 1.3779698520011152e-06

RESULTS O 0 9.274911462853197e-06
The O 0 8.195489442641701e-08
adjusted O 0 1.4990907857281854e-06
odds O 0 7.972815865286975e-07
ratio O 0 9.332570272135854e-08
for O 0 1.0481970491582615e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.759443766351069e-08
with O 0 2.0505602424392144e-11
any O 0 2.7524249546218016e-10
past O 0 6.529348173245353e-10
use O 0 2.2952979794599315e-10
of O 0 1.408488325971291e-09
oral O 0 9.650271692862589e-09
contraceptives O 0 4.1050729038261125e-08
was O 0 4.651772655961395e-08
0 O 0 1.3601673742869025e-07
. O 0 2.4228694428529707e-07

5 O 0 7.574435585411265e-07
( O 0 4.091399219419145e-09
95 O 0 5.588497842268225e-08
percent O 0 5.457808871511816e-09
confidence O 0 2.826374911890639e-09
interval O 0 8.788415328808696e-09
, O 0 7.654810119106514e-10
0 O 0 1.7510342065207851e-09
. O 0 4.309853030015631e-10
3 O 0 2.151275602102487e-09
to O 0 8.078154256629944e-10
0 O 0 1.131144244936877e-08
. O 0 2.271978827295129e-09
8 O 0 4.968863009935376e-08
) O 0 4.431095046442124e-09
. O 0 1.0124653471166312e-07

The O 0 8.638563997465099e-08
risk O 0 7.168207361019086e-08
decreased O 0 1.118520565057679e-08
with O 0 8.182197107353684e-12
increasing O 0 1.5402348840787283e-10
duration O 0 1.6605802288793825e-09
of O 0 5.466129771036776e-10
use O 0 5.916205303435618e-10
( O 0 1.1548315637099904e-09
P O 0 9.12903246330643e-08
for O 0 6.046647071933364e-10
trend O 0 4.366986061654643e-08
, O 0 2.3113243263761518e-10
< O 0 7.203204699379739e-10
0 O 0 1.7475976221703604e-09
. O 0 5.801930602622463e-10
001 O 0 7.204761676149474e-09
) O 0 1.0811610287597695e-11
; O 0 1.0065906441703021e-11
use O 0 1.8395588871622515e-11
for O 0 1.0084302143331669e-10
six O 0 2.0230218888972473e-10
or O 0 7.607821317368035e-11
more O 0 3.9435218979200215e-11
years O 0 1.5823069243747767e-10
was O 0 6.992286749607501e-10
associated O 0 2.443564794951669e-10
with O 0 1.4861924191311715e-11
a O 0 3.76994130357744e-10
60 O 0 1.5578061063337145e-09
percent O 0 3.320013985952386e-10
reduction O 0 5.866214736194308e-10
in O 0 7.497223397656683e-10
risk O 0 2.2048530468055105e-07
. O 0 5.17701039370877e-07

Oral O 0 1.5026639630377758e-05
- O 0 9.256400517188013e-07
contraceptive O 0 3.283453864355579e-08
use O 0 4.141198939322521e-09
protected O 0 6.805935845477507e-05
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.009030498044794e-10
for O 0 1.2459803154507565e-12
carriers O 0 1.0285309930135877e-11
of O 0 7.555472913978178e-11
the O 0 2.8974982413387806e-09
BRCA1 O 0 4.372495254756359e-08
mutation O 0 1.9679308849163135e-08
( O 0 3.88633614178957e-09
odds O 0 1.0603384481555622e-07
ratio O 0 1.0057267019192295e-08
, O 0 8.98346452782306e-10
0 O 0 1.401702642844782e-09
. O 0 3.2643052150227447e-10
5 O 0 9.322457250604543e-10
; O 0 1.6469904606797314e-10
95 O 0 7.039286487042773e-09
percent O 0 2.066806725764536e-09
confidence O 0 4.912864337569545e-09
interval O 0 4.126297525886002e-09
, O 0 4.3629855284166297e-10
0 O 0 1.8437337212517946e-09
. O 0 4.215921500794195e-10
3 O 0 1.0343907952403697e-09
to O 0 4.208016435303108e-10
0 O 0 3.2145446304809866e-09
. O 0 6.263758400848474e-10
9 O 0 2.5060600261639365e-09
) O 0 1.4351495686293347e-11
and O 0 1.0876866247955252e-11
for O 0 9.789801781734386e-12
carriers O 0 1.8374662902331806e-10
of O 0 8.133193007964223e-10
the O 0 3.051073704796181e-08
BRCA2 O 0 2.079254727505031e-06
mutation O 0 8.087720004823495e-08
( O 0 7.2298016462468695e-09
odds O 0 2.156973835099052e-07
ratio O 0 1.509953051481716e-08
, O 0 9.423698488220111e-10
0 O 0 1.5083663207349218e-09
. O 0 2.2700198665237536e-10
4 O 0 1.7365627824617036e-09
; O 0 1.6476124631292777e-10
95 O 0 3.841527984604909e-09
percent O 0 9.457875593810172e-10
confidence O 0 1.0498708569173232e-09
interval O 0 1.1288395773689786e-09
, O 0 2.545474941939574e-10
0 O 0 9.969635117457187e-10
. O 0 1.7054993528553553e-10
2 O 0 8.677047969030127e-10
to O 0 5.230791355614883e-10
1 O 0 1.0965182539734997e-08
. O 0 3.85559228988086e-09
1 O 0 6.068778901635596e-08
) O 0 7.643405020019145e-09
. O 0 1.6011412640182243e-07

CONCLUSIONS O 0 0.000632809882517904
Oral O 0 5.429214525065618e-06
- O 0 3.4193945452898333e-07
contraceptive O 0 1.263819182639736e-08
use O 0 3.689338556878141e-10
may O 0 1.8584697669687955e-10
reduce O 0 6.214266323745221e-10
the O 0 4.222367178119413e-10
risk O 0 2.3195615028726024e-07
of O 0 0.0007861343328841031
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.040467489943353e-09
women O 0 4.0039044996165174e-11
with O 0 5.34876743590873e-12
pathogenic O 0 4.3431586105313613e-10
mutations O 0 1.1206511274508557e-09
in O 0 2.086849304472338e-10
the O 0 1.2831289808445945e-08
BRCA1 O 0 2.8850397484347923e-06
or O 0 7.978687790455297e-07
BRCA2 O 0 2.986687104566954e-05
gene O 0 3.101524998783134e-05

A O 0 8.99663007203344e-07
Japanese O 0 4.4415983779799717e-07
family O 0 2.4011452381955678e-08
with O 0 1.676837779740481e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 6.38905373051557e-10
a O 0 1.4098752165736528e-09
codon O 0 3.094690725902183e-08
291 O 0 8.283207897363809e-09
deletion O 0 1.319017450818194e-09
: O 0 8.382506355708585e-10
a O 0 2.0376222931162147e-09
clinical O 0 3.133751036443755e-08
, O 0 1.3074629157117101e-09
biochemical O 0 7.982211513990478e-07
, O 0 3.0291071873023157e-09
pathological O 0 6.74352213536622e-06
, O 0 4.176960111124117e-09
and O 0 2.064316717564907e-09
genetic O 0 2.2188551440649462e-07
report O 0 1.436971075463589e-07
. O 0 2.6353299631409755e-07

We O 0 4.0361300079894136e-08
report O 0 5.690463211749375e-09
a O 0 5.81120040976657e-10
Japanese O 0 4.839880940465946e-09
family O 0 2.005840604724085e-09
with O 0 2.1540882411130724e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 2.9584160188278474e-07
ALD B-Disease 1 1.0
) O 0 1.0923630056058897e-10
with O 0 1.1060614230062882e-11
a O 0 1.6052333073890424e-10
three O 0 8.818395319520889e-11
base O 0 3.946769133733596e-09
pair O 0 4.652559670859091e-09
deletion O 0 1.1745225236836632e-08
( O 0 9.998966987723179e-09
delGAG O 0 6.617329404434713e-07
291 O 0 2.5361147848457222e-08
) O 0 1.3954572219976313e-10
in O 0 5.745689479752514e-10
the O 0 7.542151791994911e-08
ALD B-Disease 1 1.0
gene O 0 5.091315415484132e-06
. O 0 4.999440079700435e-06

A O 0 6.183236678225512e-07
variety O 0 3.920967373005624e-08
of O 0 1.953167405588374e-08
phenotypes O 0 2.3008765026588662e-07
were O 0 2.402577914395465e-09
observed O 0 1.4176845253288661e-09
within O 0 5.51827694650342e-10
this O 0 8.787623406725231e-10
family O 0 3.885759980448711e-08
. O 0 2.028662038355833e-07

While O 0 1.0423813279203387e-07
the O 0 1.1242167374803103e-07
proband O 0 8.963436812337022e-06
( O 0 4.617304760756724e-09
patient O 0 2.696196155227426e-08
1 O 0 5.353524201723303e-08
) O 0 2.3921281622207857e-10
was O 0 2.2829038659466505e-09
classified O 0 6.265156171636477e-10
as O 0 4.919575302686496e-10
having O 0 1.4697726369305997e-10
a O 0 7.942359964152601e-11
rare O 0 3.824513761241377e-10
intermediate O 0 7.232076715268931e-09
type O 0 3.765380007791919e-09
of O 0 5.813376446894836e-09
adult O 0 1.1311532688296211e-07
cerebral O 0 3.6085950796405086e-06
and O 0 4.2234990615952483e-08
cerebello O 0 0.0001788817171473056
- O 0 2.3450566004612483e-06
brain O 0 1.0333166073905886e-06
stem O 0 1.2341756061573506e-08
forms O 0 3.959194749825201e-09
, O 0 3.693753636291319e-10
his O 0 5.3087103601967556e-09
younger O 0 1.3785599151105998e-07
brother O 0 4.0838628478923056e-07
( O 0 8.425625197538977e-10
patient O 0 4.508116990820099e-09
2 O 0 5.1682071955383435e-09
) O 0 9.159541874970145e-11
and O 0 1.1656530185533143e-09
nephew O 0 3.865808650971303e-07
( O 0 1.1213695527700906e-09
patient O 0 6.428285104220777e-08
3 O 0 2.053898953136013e-07
) O 0 1.3943589616260965e-09
had O 0 1.0389728188897607e-08
a O 0 1.056784437736269e-08
childhood O 0 8.757178875384852e-06
ALD B-Disease 1 1.0
type O 0 3.479590668575838e-05
. O 0 1.4145704199108877e-06

Another O 0 1.491867124059354e-06
nephew O 0 4.4976433855481446e-05
( O 0 1.7280555653087504e-08
patient O 0 6.635479365968422e-08
4 O 0 3.260792524883982e-08
) O 0 6.054826778845168e-11
of O 0 4.718618829002708e-10
patient O 0 9.8703631934427e-09
1 O 0 9.183047211536177e-08
was O 0 6.159562193630563e-09
classified O 0 3.0906543990738555e-09
as O 0 2.195178927522079e-09
having O 0 2.192898307384894e-09
an O 0 4.123150709745005e-09
adolescent O 0 2.4423327360523217e-08
form O 0 1.5244626894173052e-08
. O 0 3.1263007826964895e-07

The O 0 1.266744646954976e-07
tau O 0 5.843260808546802e-08
level O 0 1.931937276822282e-08
in O 0 4.6108422635526836e-10
the O 0 4.9425925574553276e-09
cerebrospinal O 0 1.064370167114248e-06
fluid O 0 5.453903213492595e-07
( O 0 2.4718811886259573e-08
CSF O 1 0.8798664212226868
) O 0 3.2617597511830354e-10
in O 0 1.3797442355301115e-10
patient O 0 5.194038976696902e-09
1 O 0 4.3240113711817685e-08
was O 0 1.2225361167850224e-08
as O 0 3.32485539100702e-10
high O 0 2.3302222373899895e-09
as O 0 1.1676305755603522e-10
that O 0 5.263053881598978e-11
of O 0 8.680143270822782e-10
patients O 0 3.387531588572301e-09
with O 0 1.2941376859032516e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9922385811805725
( O 0 2.1506645353497333e-09
AD B-Disease 0 4.051690666528884e-06
) O 0 1.4593259933803893e-09
. O 0 2.317887215497194e-08

His O 0 7.66910886795813e-07
brain O 0 2.088832161462051e-06
magnetic O 0 2.2166258872857725e-07
resonance O 0 3.891500455210917e-08
image O 0 4.486827975824781e-08
( O 0 1.5234503658589915e-09
MRI O 0 2.6207433734271035e-07
) O 0 3.0029259634467564e-10
showed O 0 2.0339683270975684e-09
abnormalities B-Disease 0 1.0897067248549774e-08
in I-Disease 0 3.063105602496563e-10
the I-Disease 0 6.459649259937805e-09
bilateral I-Disease 0 5.387644819165871e-07
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9998258948326111
and O 0 2.459149470723787e-07
brain O 0 1.6894357031560503e-05
stem O 0 8.583869970379965e-08
, O 0 2.41846154214187e-10
but O 0 6.467865826254027e-11
not O 0 1.6005760952730874e-11
in O 0 7.308252614190991e-11
the O 0 5.454801499382711e-09
cerebral O 0 1.9355611584614962e-06
white O 0 3.147671012726505e-09
matter O 0 7.4367978442069216e-09
, O 0 1.2825257522663946e-10
where O 0 8.130086881497078e-11
marked O 0 2.471138571547016e-10
reductions O 0 3.101342516131922e-09
of O 0 2.4615198768174196e-09
the O 0 1.9602211409619485e-08
cerebral O 0 6.20302785137028e-07
blood O 0 1.3123779396551072e-08
flow O 0 2.1170439623574566e-08
and O 0 1.3104963780818935e-09
oxygen O 0 4.321675906027167e-09
metabolism O 0 5.6194092934447326e-08
were O 0 1.0088423429976956e-09
clearly O 0 2.2613866335063904e-09
demonstrated O 0 4.373959250347781e-10
by O 0 1.7191446877173888e-10
positron O 0 8.619323921266187e-08
emission O 0 1.2512704472555924e-07
tomography O 0 3.310734655315173e-07
( O 0 3.7120141627156045e-08
PET O 0 4.887621798843611e-06
) O 0 3.966369632735223e-08
. O 0 4.190384004232328e-07

In O 0 3.434027817661445e-08
patients O 0 8.60207460817719e-09
2 O 0 2.4445791169114273e-08
and O 0 1.2005371141654564e-09
3 O 0 1.0774940939484168e-08
, O 0 1.0507057029984779e-10
the O 0 1.9844456633499874e-10
autopsy O 0 1.697167917313891e-08
findings O 0 1.1934145227598947e-08
showed O 0 9.130143752145159e-09
massive O 0 5.104657319066064e-08
demyelination B-Disease 1 1.0
of I-Disease 0 1.534599732622155e-06
the I-Disease 0 4.269203373041819e-07
cerebral I-Disease 0 0.00012782997509930283
white I-Disease 0 1.3752311511794346e-09
matter I-Disease 0 9.9126573616104e-10
with O 0 2.4844586023892168e-12
sparing O 0 1.5815293519239049e-09
of O 0 1.9437862430748964e-09
the O 0 1.6199804164784837e-08
U O 0 9.902099691316835e-07
- O 0 1.6877683606253413e-07
fibers O 0 3.666953034553444e-07
, O 0 1.1725230786296947e-09
compatible O 0 7.474723950906537e-09
with O 0 7.393822359924584e-11
the O 0 5.293419591545501e-10
findings O 0 1.5926366003782277e-08
of O 0 2.4122353892153114e-08
childhood O 0 0.0005053701461292803
ALD B-Disease 1 1.0
. O 0 8.847056051308755e-06

Oleic O 0 0.00038052027230151
and O 0 1.933494786499068e-06
erucic O 0 0.00023189348576124758
acids O 0 6.02385352976853e-06
( O 0 3.731627984393526e-08
Lorenzos O 0 2.55630425272102e-06
Oil O 0 3.671505623970006e-07
) O 0 9.969344794136248e-11
were O 0 4.58976433248548e-11
administered O 0 1.1229972680937284e-11
to O 0 1.66477092528039e-11
patients O 0 5.097245889262858e-11
1 O 0 8.446897070690795e-10
and O 0 3.8438860427980615e-10
4 O 0 3.859079722445813e-09
, O 0 5.937047381499028e-11
but O 0 4.4603192667080904e-11
sufficient O 0 1.6456472851089643e-09
effectiveness O 0 4.711139478530413e-09
was O 0 5.9279674502477064e-09
not O 0 6.028337828922758e-10
obtained O 0 1.454425699876083e-07
. O 0 4.6245162366176373e-07

The O 0 3.627402520578471e-07
findings O 0 1.348689551150528e-07
in O 0 7.280124836306356e-10
this O 0 5.370752176325766e-10
family O 0 1.6007396519412964e-09
suggest O 0 1.0144844964088406e-09
that O 0 5.835144173405027e-11
delGAG291 O 0 9.249332855176817e-09
is O 0 2.3612474822631846e-11
part O 0 2.8272400046103208e-11
of O 0 2.77040113072502e-10
the O 0 5.638255973217099e-10
cause O 0 3.9193299272710647e-08
of O 0 2.3471159238397377e-08
Japanese O 0 7.749673613943742e-07
ALD B-Disease 1 1.0
with O 0 1.0122674920509667e-09
phenotypic O 0 1.7018916764754977e-07
variations O 0 7.385164053630433e-07
. O 0 4.44077215888683e-07

Moreover O 0 6.798732101742644e-07
, O 0 1.5118427620919306e-09
although O 0 5.280088588577314e-10
the O 0 2.8254948380990186e-10
scale O 0 3.003299609005694e-09
of O 0 2.0880128737132964e-09
the O 0 2.271840271461656e-09
study O 0 3.089456190874529e-10
is O 0 4.4787926839484626e-11
limited O 0 7.016655589886511e-10
, O 0 4.385754814872911e-10
there O 0 1.6566257254879702e-09
is O 0 3.8882694286535013e-10
a O 0 1.384062309206513e-09
possibility O 0 4.503736050764928e-08
that O 0 1.234823088225312e-08
PET O 0 3.4054082789225504e-06
can O 0 8.731789513660715e-09
detect O 0 2.0091196972771286e-07
an O 0 2.1407245753835014e-08
insidious B-Disease 0 3.444255753493053e-06
lesion I-Disease 0 3.856154216919094e-05
which O 0 7.366826593191433e-10
is O 0 2.842142632353273e-10
undetectable O 0 2.8904880711166925e-09
by O 0 2.0058242566900475e-10
computed O 0 5.3192337645668886e-08
tomogram O 0 1.726438540572417e-06
( O 0 6.0301919013738825e-09
CT O 0 4.4565504708771186e-07
) O 0 2.888420058688723e-10
or O 0 6.787195250268496e-10
MRI O 0 7.789450506834328e-08
analysis O 0 4.957803501071112e-09
, O 0 1.3640753804278205e-10
and O 0 5.264760502554644e-11
that O 0 2.6731342833707927e-11
the O 0 1.9399629125338436e-10
higher O 0 5.332436714411415e-09
level O 0 2.981827007531024e-09
of O 0 1.1972670632687255e-09
tau O 0 5.933691316073464e-09
reflects O 0 3.570781226258646e-09
the O 0 1.2774428737039045e-10
process O 0 6.324648027522528e-10
of O 0 2.7288511450507258e-09
neuronal B-Disease 0 0.00039519942947663367
degeneration I-Disease 1 0.9999998807907104
in O 0 4.961088961863425e-07
ALD B-Disease 1 1.0
. O 0 2.8811298307118705e-06

Lorenzos O 0 3.087698860326782e-05
Oil O 0 1.232147951668594e-06
should O 0 5.196583163780133e-10
be O 0 8.01907776293298e-11
given O 0 1.6474679953581983e-10
in O 0 5.795966137589481e-11
the O 0 6.068657243396558e-10
early O 0 1.709115871051381e-08
stage O 0 5.5326547787615254e-09
. O 0 1.0269309846933083e-08
. O 0 1.186470015568375e-07

Nonsense O 0 4.062849711772287e-06
mutation O 0 8.929336559049261e-08
in O 0 3.1864821892213513e-09
exon O 0 4.2700499136572034e-08
4 O 0 8.50392112283771e-08
of O 0 4.266693665044841e-09
human O 0 3.257049074889551e-09
complement O 0 5.810585790300138e-08
C9 O 0 0.00014478380035143346
gene O 0 5.19579312907581e-09
is O 0 3.450201235821737e-10
the O 0 2.1456154908339187e-10
major O 0 1.5853770518603483e-09
cause O 0 4.0272713164313245e-08
of O 0 1.4298075612373395e-08
Japanese O 0 5.860919145561638e-07
complement B-Disease 0 9.017004231282044e-06
C9 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.6028580069541931
. O 0 2.3740935830574017e-06

Deficiency B-Disease 0 0.00018763294792734087
of I-Disease 0 1.6977406630758196e-05
the I-Disease 0 4.5747034960186284e-07
ninth I-Disease 0 1.070756866283773e-06
component I-Disease 0 2.896649675676599e-07
of I-Disease 0 4.306478285087678e-09
human I-Disease 0 4.647229268073261e-09
complement I-Disease 0 1.4489017985397368e-07
( O 0 1.0321406840319014e-08
C9 O 1 0.9141943454742432
) O 0 5.343796516399379e-10
is O 0 4.3574692465409015e-11
the O 0 7.160763648705881e-11
most O 0 2.0672906442253947e-10
common O 0 9.390222821537009e-09
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.544051522894279e-09
Japan O 0 5.371707967327666e-09
but O 0 3.273426807393065e-10
is O 0 2.9046388558273684e-11
rare O 0 1.1287917128788294e-10
in O 0 3.797188952159303e-11
other O 0 3.129853320960052e-10
countries O 0 2.2383084274935072e-09
. O 0 1.62670772851925e-07

We O 0 7.834508153337083e-08
studied O 0 3.272275250765233e-08
the O 0 5.330969554684373e-10
molecular O 0 1.9829228037337998e-08
basis O 0 3.132340609113271e-08
of O 0 3.102598356008457e-08
C9 B-Disease 1 0.9999998807907104
deficiency I-Disease 0 0.0014556775568053126
in O 0 7.762145770584539e-08
four O 0 5.040607931050545e-08
Japanese O 0 1.154308847617358e-06
C9 B-Disease 1 0.5917105078697205
- I-Disease 0 3.179852910761838e-06
deficient I-Disease 0 1.2844444086113072e-07
patients O 0 2.8771070859079373e-08
who O 0 5.6176059359813735e-09
had O 0 2.902991402820021e-09
suffered O 0 3.4335364773596666e-08
from O 0 5.161527649732989e-09
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.7795828455291485e-07

Direct O 0 4.5911721713309817e-07
sequencing O 0 8.171966214831627e-08
of O 0 1.6696586158104765e-07
amplified O 0 3.791152494159178e-07
C9 O 0 1.0489851774764247e-05
cDNA O 0 5.464113073117005e-08
and O 0 2.2714330416562234e-09
DNA O 0 2.1896145341315787e-08
revealed O 0 2.0689611801572028e-08
a O 0 3.623382704986966e-09
nonsense O 0 1.9171734422229747e-08
substitution O 0 3.4940317306109137e-08
( O 0 3.1087812324415154e-09
CGA O 0 4.5479160348804726e-07
- O 0 4.70644465622172e-08
- O 0 4.6874252035422614e-08
> O 0 2.6126301122531004e-08
TGA O 0 2.0592652560935676e-07
) O 0 3.055764252746229e-10
at O 0 6.502181015832775e-10
codon O 0 4.4279180322348566e-09
95 O 0 3.6570220185438984e-09
in O 0 1.5287969501454057e-10
exon O 0 2.558892209236774e-09
4 O 0 1.764001211768118e-08
in O 0 1.121076564913892e-09
the O 0 3.314170982093856e-08
four O 0 6.644216909990064e-08
C9 B-Disease 0 0.0013635980430990458
- I-Disease 0 3.7562217585218605e-06
deficient I-Disease 0 4.99272800880135e-07
individuals O 0 1.3302637213996604e-08
. O 0 2.6751919790513057e-07

An O 0 1.038852275314639e-07
allele O 0 2.0864818850441225e-07
- O 0 1.7719054667963974e-08
specific O 0 2.3197610499181565e-09
polymerase O 0 2.5533452685522207e-08
chain O 0 1.7190119550036798e-08
reaction O 0 6.93945079177638e-09
system O 0 6.702060573182678e-10
designed O 0 4.0359565689485066e-10
to O 0 7.34737340413183e-11
detect O 0 4.302608824779952e-10
exclusively O 0 1.6729682916771793e-10
only O 0 2.3481241256950725e-11
one O 0 2.7893388987454415e-11
of O 0 7.712077504384851e-11
the O 0 2.8854740818928803e-10
normal O 0 2.7102138311363433e-09
and O 0 1.5993380231282828e-10
mutant O 0 1.8441629334731147e-09
alleles O 0 4.370006301268603e-10
indicated O 0 9.492556740653413e-10
that O 0 1.4946240425861568e-11
all O 0 3.8289274528757744e-11
the O 0 3.909530477130829e-10
four O 0 1.3123241382473338e-10
patients O 0 5.261267116418722e-11
were O 0 9.794569322263413e-11
homozygous O 0 4.721544821784107e-10
for O 0 1.8042478622248836e-10
the O 0 1.1356054985256492e-09
mutation O 0 9.866650829692958e-10
in O 0 3.622185607010664e-10
exon O 0 1.871140131726179e-09
4 O 0 8.39447888978384e-09
and O 0 1.9351660551780725e-10
that O 0 6.885795406086359e-11
the O 0 6.145078890185118e-10
parents O 0 7.626450582165489e-10
of O 0 1.7355527015538996e-09
patient O 0 6.56558007960939e-09
2 O 0 5.7785456419878756e-08
were O 0 1.630973933686164e-08
heterozygous O 0 1.7438134136682493e-07
. O 0 5.281766561893164e-07

The O 0 5.442655037768418e-08
common O 0 1.915747915859356e-08
mutation O 0 2.2908915653374606e-08
at O 0 5.33363708754564e-09
codon O 0 4.3664449833613617e-08
95 O 0 2.7289825510479204e-08
in O 0 1.1632298457797674e-09
exon O 0 1.8005437141255243e-08
4 O 0 5.1701029235573515e-08
might O 0 5.514807277506861e-09
be O 0 8.15929657171921e-10
responsible O 0 9.568869030474048e-10
for O 0 3.971596385099474e-10
most O 0 7.902174026241937e-09
Japanese O 0 1.3658545867656358e-06
C9 B-Disease 1 0.5885300040245056
deficiency I-Disease 0 1.6903237337828614e-05
. O 0 1.1082639161941188e-07
. O 0 4.2927112531288003e-07

BRCA1 O 0 1.6597599596934742e-06
required O 0 4.796516250848981e-08
for O 0 2.542139299066548e-08
transcription O 0 7.4977538133680355e-06
- O 0 6.628055416513234e-06
coupled O 0 3.3166265893669333e-06
repair O 0 7.244995003929944e-07
of O 0 2.504379281731417e-08
oxidative O 0 1.2587571518452023e-06
DNA O 0 4.36976279161172e-06
damage O 1 0.9936829805374146
. O 0 7.409346949316387e-07

The O 0 8.327173418365419e-06
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 1.7362709741064464e-06
gene O 0 7.27216615814541e-08
BRCA1 O 0 1.9740741663554218e-07
encodes O 0 3.4356460787421383e-08
a O 0 1.365730017965916e-08
zinc O 0 8.100967363589007e-08
finger O 0 3.403614456942705e-08
protein O 0 4.6094314143374504e-08
of O 0 8.654276406616646e-09
unknown O 0 2.296172283422493e-07
function O 0 3.7769407157384194e-08
. O 0 1.177829673792985e-07

Association O 0 7.279923011083156e-07
of O 0 8.573747436457779e-07
the O 0 4.023156350285717e-07
BRCA1 O 0 8.554074781841337e-08
protein O 0 4.200819248012522e-08
with O 0 2.9228858222651866e-10
the O 0 1.7806999208502816e-09
DNA O 0 2.076690464036801e-08
repair O 0 2.9586274763460096e-07
protein O 0 4.19670300288999e-07
Rad51 O 0 2.1985329112794716e-07
and O 0 1.971031532432832e-10
changes O 0 1.2783007985461836e-10
in O 0 4.855613133791792e-11
the O 0 2.1034332609026762e-10
phosphorylation O 0 1.5653833784767812e-09
and O 0 2.944832988571733e-10
cellular O 0 2.9609761309501437e-09
localization O 0 1.4984489382641186e-07
of O 0 2.0403767564403097e-08
the O 0 1.9897385072908946e-08
protein O 0 7.288969072760665e-08
after O 0 4.824121102586787e-09
exposure O 0 2.3047322272873316e-08
to O 0 1.8691428405048782e-09
DNA O 0 1.3008522614654794e-07
- O 0 7.28889943957256e-08
damaging O 0 2.483777450379421e-07
agents O 0 8.064395373708066e-09
are O 0 2.9484353847308853e-10
consistent O 0 7.513059507857633e-09
with O 0 1.4152299124270407e-11
a O 0 2.68521094248797e-10
role O 0 4.428490352204051e-10
for O 0 1.926718118383519e-09
BRCA1 O 0 7.480860375608245e-08
in O 0 6.348133574363146e-09
DNA O 0 9.517335683995043e-07
repair O 0 2.3779710318194702e-05
. O 0 2.2748042738385266e-06

Here O 0 3.615583921146026e-07
, O 0 4.856627988658602e-09
it O 0 2.0602720918194706e-10
is O 0 6.58651952423206e-11
shown O 0 1.8095830389697198e-10
that O 0 1.2815280781008909e-10
mouse O 0 2.5367810074783392e-09
embryonic O 0 6.322712664541541e-08
stem O 0 1.691990689778322e-07
cells O 0 5.877341635596167e-08
deficient B-Disease 0 3.06964729190895e-08
in I-Disease 0 1.1618904727228596e-09
BRCA1 I-Disease 0 1.5712892320607352e-08
are O 0 1.4262108161133824e-10
defective O 0 1.0487705814909987e-08
in O 0 5.733450381129046e-10
the O 0 1.5373623485359644e-09
ability O 0 6.826364473688784e-10
to O 0 1.320323739228968e-09
carry O 0 4.726981028824184e-09
out O 0 3.4169409524054117e-09
transcription O 0 3.21231595989957e-07
- O 0 2.9974674475852225e-07
coupled O 0 1.0856788321689237e-06
repair O 0 6.752840135959559e-07
of O 0 4.4373134500119704e-08
oxidative O 0 3.5746336379816057e-07
DNA O 0 5.059342811364331e-07
damage O 0 0.008271445520222187
, O 0 8.505377735446018e-09
and O 0 1.9995074485024134e-09
are O 0 2.551745759138413e-10
hypersensitive O 0 3.0752326551919396e-07
to O 0 1.9663886519083462e-08
ionizing O 0 1.8483546227798797e-05
radiation O 0 2.591980592114851e-05
and O 0 3.106933377239329e-08
hydrogen O 0 1.5578224576984212e-07
peroxide O 0 2.1638049929606495e-06
. O 0 2.4143764676409774e-07

These O 0 5.885193843369052e-08
results O 0 8.143740615196293e-08
suggest O 0 2.817861570747482e-07
that O 0 2.5318568575016798e-08
BRCA1 O 0 2.1731223398546717e-07
participates O 0 1.6582546891186212e-08
, O 0 1.1545320255379465e-09
directly O 0 1.7827492815314372e-09
or O 0 1.1783545250665384e-09
indirectly O 0 1.3892627492850806e-08
, O 0 1.5624593285856747e-10
in O 0 1.9662178829538135e-10
transcription O 0 4.285691659333679e-07
- O 0 5.192957814870169e-07
coupled O 0 1.1078629995608935e-06
repair O 0 3.9940417195794e-07
of O 0 1.8392668721389782e-08
oxidative O 0 5.958315227871935e-07
DNA O 0 1.2717731578959501e-06
damage O 0 0.0002938198740594089
. O 0 9.027804992456367e-08
. O 0 1.6253228807272535e-07

Truncation O 0 3.620639290602412e-06
mutations O 0 1.8984556504619832e-07
in O 0 2.7676929637010517e-09
the O 0 5.969665206606578e-09
transactivation O 0 3.0228234209062066e-06
region O 0 6.726487811192783e-08
of O 0 5.34388355788451e-08
PAX6 O 0 4.320183506933972e-05
result O 0 3.8036935734453436e-07
in O 0 3.1361071961555353e-08
dominant O 0 1.933637395268306e-05
- O 0 7.337104079851997e-07
negative O 0 1.44735778917493e-07
mutants O 0 1.8135415302822366e-07
. O 0 1.2452682085495326e-07

PAX6 O 0 0.003955846652388573
is O 0 8.131789286380808e-08
a O 0 5.540818026616989e-09
transcription O 0 6.997843371436829e-08
factor O 0 5.7279692100564716e-08
with O 0 8.772534920709063e-10
two O 0 1.1337313310377795e-09
DNA O 0 1.202435129243895e-08
- O 0 8.679701402058981e-09
binding O 0 3.78453393068412e-08
domains O 0 2.413731863271096e-07
( O 0 8.910567395048474e-09
paired O 0 1.5710135414792603e-08
box O 0 1.1068312488760057e-08
and O 0 9.613249085660414e-10
homeobox O 0 1.288839683866172e-07
) O 0 4.091779692849684e-10
and O 0 8.154831254714168e-10
a O 0 8.204384727150682e-09
proline O 0 9.147856872004922e-08
- O 0 2.2689795287078596e-07
serine O 0 1.58109045855781e-07
- O 0 6.171972586344054e-07
threonine O 0 2.2654074882666464e-07
( O 0 8.490611769218503e-09
PST O 0 8.042899025895167e-06
) O 0 6.227060200814094e-09
- O 0 1.6894293963787277e-08
rich O 0 2.9065166273767318e-08
transactivation O 0 3.3346664167765994e-06
domain O 0 6.616963332817249e-07
. O 0 3.7139056985324714e-07

PAX6 O 1 0.9951966404914856
regulates O 0 8.981182327261195e-05
eye O 0 0.0018697627820074558
development O 0 1.2982670227756898e-07
in O 0 7.2103939485757e-10
animals O 0 8.642493942723206e-10
ranging O 0 4.598557534762904e-09
from O 0 2.4448154611889095e-09
jellyfish O 0 5.493472343687245e-10
to O 0 2.904690377114605e-10
Drosophila O 0 3.3211684513645423e-09
to O 0 1.2595446907681662e-09
humans O 0 3.425209982310662e-08
. O 0 2.8145043984295626e-07

Heterozygous O 0 5.7726520452661134e-08
mutations O 0 4.444979495588086e-08
in O 0 1.0078539114388718e-09
the O 0 1.6022119186942518e-09
human O 0 3.185576913367072e-09
PAX6 O 0 4.976682703272672e-06
gene O 0 5.285966331314285e-09
result O 0 9.18789666570774e-09
in O 0 2.430030621169976e-10
various O 0 1.1126090049273785e-09
phenotypes O 0 3.731308240162434e-08
, O 0 3.0746602486253494e-10
including O 0 2.1592455601293636e-10
aniridia B-Disease 1 1.0
, O 0 2.638757123918367e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.0155042907153984e-08
autosomal B-Disease 0 2.9795710361213423e-06
dominant I-Disease 0 4.7689376515336335e-05
keratitis I-Disease 1 1.0
, O 0 1.0819015727747683e-07
and O 0 1.831380700423324e-07
familial B-Disease 1 0.999990701675415
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.011088084429502487

It O 0 1.2159548923307284e-08
is O 0 8.765025372170498e-10
believed O 0 6.766191495977125e-10
that O 0 1.0620143653383707e-11
the O 0 2.425881440171196e-10
mutated O 0 2.8105663574251594e-08
allele O 0 6.664016183322019e-08
of O 0 3.6524372859503274e-08
PAX6 O 0 3.531154288793914e-05
produces O 0 2.658281772482951e-08
an O 0 1.6341338282543916e-09
inactive O 0 4.869214809133382e-09
protein O 0 2.378980923367635e-08
and O 0 1.7397155938070341e-09
aniridia B-Disease 1 1.0
is O 0 1.462251542072579e-09
caused O 0 1.974902019696856e-08
due O 0 7.438159421724322e-09
to O 0 2.1573365316385207e-09
genetic O 0 1.4787419786443934e-06
haploinsufficiency O 0 5.211576717556454e-05
. O 0 7.574724349979078e-07

However O 0 7.221210580610204e-07
, O 0 9.013762181098173e-09
several O 0 5.879592368529529e-09
truncation O 0 2.058943096017174e-07
mutations O 0 2.717565728005411e-08
have O 0 4.408979015213532e-10
been O 0 1.1498547947130788e-10
found O 0 2.8657765396844503e-11
to O 0 1.702566906902625e-11
occur O 0 2.545144650589748e-10
in O 0 1.468561938722246e-10
the O 0 3.4067564325113153e-09
C O 0 1.2616507660823117e-07
- O 0 4.643641027257672e-09
terminal O 0 1.6110444533978807e-08
half O 0 1.62920732460492e-09
of O 0 1.4240668644305288e-09
PAX6 O 0 4.7161856286948023e-07
in O 0 2.885947592012883e-10
patients O 0 3.218493804801881e-10
with O 0 2.882531158210355e-10
Aniridia B-Disease 1 1.0
resulting O 0 8.108990101618474e-08
in O 0 3.1081631712837066e-10
mutant O 0 4.4524779418964044e-09
proteins O 0 1.1868536153869513e-09
that O 0 1.1357825097091379e-10
retain O 0 4.803563768973618e-09
the O 0 1.3366857842811442e-08
DNA O 0 1.7868247326191522e-08
- O 0 7.536309354350124e-09
binding O 0 1.3257879238892656e-08
domains O 0 2.0192304717170373e-08
but O 0 2.3558335282558573e-09
have O 0 7.395828394152204e-10
lost O 0 1.664913185095429e-08
most O 0 5.336890929186211e-10
of O 0 1.4422912864020532e-09
the O 0 1.0194195709800624e-08
transactivation O 0 3.182361979270354e-06
domain O 0 1.4967422430345323e-06
. O 0 9.572515864419984e-07

It O 0 2.9454032102194105e-08
is O 0 9.16108466864074e-10
not O 0 1.5579271206433987e-10
clear O 0 3.40006378607427e-09
whether O 0 2.4926535835412267e-10
such O 0 1.116590930827499e-09
mutants O 0 1.1047941939068551e-07
really O 0 2.2080634209942218e-08
behave O 0 3.5723481950356017e-09
as O 0 6.7454357655094555e-09
loss O 0 3.146490357153198e-08
- O 0 1.2173565266948572e-08
of O 0 1.7310020439254004e-07
- O 0 4.8896083626459586e-08
function O 0 2.3433930351757226e-09
mutants O 0 4.2695105229029195e-09
as O 0 9.825334990054557e-10
predicted O 0 8.760583369848973e-09
by O 0 2.946817678761704e-09
haploinsufficiency O 0 6.45063573756488e-06
. O 0 8.583949124840728e-07

Contrary O 0 1.156694565906946e-06
to O 0 2.067784610204626e-09
this O 0 6.863350998642659e-10
theory O 0 9.92473516703285e-08
, O 0 5.835670280340821e-10
our O 0 1.6412589065595284e-09
data O 0 1.1885964212865474e-08
showed O 0 4.809632692115429e-09
that O 0 2.3509802438148597e-10
these O 0 8.701377951503275e-10
mutants O 0 1.9465399958562557e-08
are O 0 1.0445099229983157e-09
dominant O 0 9.778081278000172e-08
- O 0 1.2562391127346473e-08
negative O 0 6.6016947464220266e-09
in O 0 2.4629087658212256e-10
transient O 0 6.67107471485906e-08
transfection O 0 2.5724684604711e-08
assays O 0 2.9509121812765216e-09
when O 0 5.5666329323855734e-09
they O 0 7.943151691947037e-10
are O 0 7.167312299216633e-10
coexpressed O 0 7.873815093262237e-07
with O 0 5.117171575363955e-09
wild O 0 2.282722562085837e-07
- O 0 4.838776135329681e-07
type O 0 1.4635255638495437e-06
PAX6 O 0 0.0003443780879024416
. O 0 2.7929529551329324e-06

We O 0 3.423080841002957e-08
found O 0 3.730096675980121e-09
that O 0 3.0724439659124414e-10
the O 0 4.555927191063347e-09
dominant O 0 1.1010160960722715e-07
- O 0 1.2670122728764e-08
negative O 0 6.059870383268162e-09
effects O 0 3.968304795876065e-09
result O 0 1.4732423059271582e-09
from O 0 1.3369223506032313e-09
the O 0 6.154979304007213e-10
enhanced O 0 7.414091007795776e-10
DNA O 0 1.9456818378671414e-09
binding O 0 4.344254289634364e-09
ability O 0 5.1552015989386746e-09
of O 0 2.1995262500240642e-08
these O 0 1.0713320008903793e-08
mutants O 0 3.4281453054063604e-07
. O 0 2.5524207103444496e-07

Kinetic O 0 1.6404495681854314e-06
studies O 0 2.1684016360268288e-08
of O 0 4.6758144023328896e-09
binding O 0 2.0363101427278707e-08
and O 0 4.994820113068954e-09
dissociation O 0 1.1303466607159862e-07
revealed O 0 4.22137924616095e-09
that O 0 5.2578264658764695e-11
various O 0 6.16252049390198e-10
truncation O 0 1.4974318673921516e-07
mutants O 0 1.9393285199953425e-08
have O 0 1.2938631277492618e-09
3 O 0 1.3684914534906056e-08
- O 0 4.740361436716967e-09
5 O 0 2.3182186836834262e-08
- O 0 4.471473413758531e-09
fold O 0 1.0526323812598548e-08
higher O 0 6.361114746056273e-09
affinity O 0 5.932839775013576e-10
to O 0 1.7188758749675515e-10
various O 0 9.151653324046549e-10
DNA O 0 3.566302586577308e-09
- O 0 6.666897034435237e-10
binding O 0 4.708531897712476e-10
sites O 0 2.00182737053467e-09
when O 0 4.2280812184714023e-10
compared O 0 4.973400025143349e-10
with O 0 3.7644425771032886e-11
the O 0 1.1833003465966385e-09
wild O 0 2.051701741834222e-08
- O 0 9.204230622117393e-08
type O 0 5.070172051091504e-07
PAX6 O 0 0.00016250736371148378
. O 0 2.357397988816956e-06

These O 0 2.249111297203399e-08
results O 0 1.185135101167134e-08
provide O 0 3.463997311214939e-09
a O 0 7.795432632740074e-10
new O 0 2.2070001381990778e-10
insight O 0 5.233249389391403e-09
into O 0 2.589533310004555e-10
the O 0 4.0638420406580167e-10
role O 0 1.1774939912001514e-09
of O 0 3.2534541727358146e-09
mutant O 0 4.681858456478949e-07
PAX6 O 0 4.240499038132839e-05
in O 0 3.3986907510552555e-08
causing O 0 7.394942258542869e-06
aniridia B-Disease 1 1.0
. O 0 1.538246579002589e-07
. O 0 2.807031194151932e-07

Reversal O 0 6.596243565581972e-06
of O 0 1.8669634016532655e-07
severe O 1 0.9997155070304871
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 4.682966334712546e-07
excellent O 0 1.1879191674779577e-07
neuropsychologic O 0 2.381068270551623e-06
outcome O 0 9.301007821704843e-07
in O 0 1.1444122982595673e-08
very B-Disease 0 6.07495209692388e-08
- I-Disease 0 1.0694112262399358e-07
long I-Disease 0 4.000307995966068e-08
- I-Disease 0 7.161675341649243e-08
chain I-Disease 0 1.57417858304143e-07
acyl I-Disease 0 1.2646434015550767e-06
- I-Disease 0 2.691018323730532e-07
coenzyme I-Disease 0 9.307914439204978e-08
A I-Disease 0 1.9707758838194422e-06
dehydrogenase I-Disease 0 2.2004925995133817e-05
deficiency I-Disease 0 0.0007133978069759905
. O 0 9.254908945877105e-07

Very B-Disease 0 4.034635821881238e-06
- I-Disease 0 1.922682940858067e-06
long I-Disease 0 1.921090699852357e-07
- I-Disease 0 5.659260438051206e-08
chain I-Disease 0 4.5888345567846045e-08
acyl I-Disease 0 1.486295957420225e-07
- I-Disease 0 1.985166875329014e-08
coenzyme I-Disease 0 3.970189954571879e-09
A I-Disease 0 3.624331412765969e-08
dehydrogenase I-Disease 0 8.117547878327969e-08
( I-Disease 0 8.74042083154336e-09
VLCAD I-Disease 0 0.000336722529027611
) I-Disease 0 5.815447567947274e-10
deficiency I-Disease 0 3.667389592010295e-08
is O 0 1.6602595687142951e-10
a O 0 3.727818609355893e-10
disorder O 0 0.0009884150931611657
of O 0 7.084110984578729e-05
fatty O 0 6.521309842355549e-06
acid O 0 9.189144378751735e-08
beta O 0 9.919636223543193e-10
oxidation O 0 4.440722900511673e-09
that O 0 4.2055289806164353e-10
reportedly O 0 4.403854614309921e-09
has O 0 5.4363697571391256e-11
high O 0 8.280849894681808e-10
rates O 0 1.4824709237970524e-09
of O 0 7.922029698903543e-10
morbidity O 0 1.6859518154888065e-06
and O 0 3.009689208965938e-08
mortality O 0 5.927850907028187e-06
. O 0 7.883672878961079e-07

We O 0 8.844041055056096e-09
describe O 0 9.654045562967895e-09
the O 0 2.644020558051352e-09
outcome O 0 4.924142871232107e-08
of O 0 1.2756959044679661e-08
a O 0 2.8203166468898644e-09
5 O 0 8.171229914921696e-09
- O 0 1.223510515124815e-09
year O 0 2.7757232068381654e-09
- O 0 9.093090724832109e-09
old O 0 1.6462044527543185e-07
girl O 0 2.5009423865185454e-08
with O 0 1.5492633842484338e-09
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.0084734824999941e-08
was O 0 9.859050242866374e-10
first O 0 9.038923776127916e-11
seen O 0 5.546694215041725e-10
at O 0 1.5820866838822667e-10
5 O 0 5.814571046869332e-10
months O 0 3.2246999515095354e-10
of O 0 5.554031123899961e-10
age O 0 9.237695941521906e-09
with O 0 2.8269936391822625e-10
severe O 0 0.00026588604669086635
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 0 1.8828925021807663e-05
hepatomegaly B-Disease 1 1.0
, O 0 4.2850786030612653e-07
encephalopathy B-Disease 0 7.851141162973363e-06
, O 0 4.3678607397623637e-08
and O 0 6.192099277768648e-08
hypotonia B-Disease 0 0.024669179692864418
. O 0 4.58193062513601e-06

Biochemical O 0 5.275314106256701e-05
studies O 0 1.4935909575797268e-06
indicated O 0 1.7533498976263218e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 3.1775339266459923e-06
by O 0 9.069772155534395e-10
a O 0 8.15276646193297e-09
stable O 0 2.3736696164178284e-07
yet O 0 2.3601300469522357e-08
inactive O 0 8.693688613448103e-08
enzyme O 0 7.782646207488142e-07
. O 0 3.757963611406012e-07

Molecular O 0 6.974516963964561e-07
genetic O 0 1.448570259299231e-07
analysis O 0 6.244724914949984e-08
of O 0 7.945886437710215e-08
her O 0 5.7522090202155596e-08
VLCAD O 1 0.9997705817222595
gene O 0 1.2641523028378288e-07
revealed O 0 2.2068788041451626e-07
a O 0 2.059716130986544e-08
T1372C O 0 4.1899644998011354e-07
( O 0 3.365910661301541e-09
F458L O 0 2.4799334141789586e-07
) O 0 1.1181274794935803e-09
missense O 0 9.055553817916007e-08
mutation O 0 1.0345215351037496e-08
and O 0 6.573687372224413e-09
a O 0 5.5965831080584394e-08
1668 O 0 0.00015130486281123012
ACAG O 1 0.9815077185630798
1669 O 0 0.00014736712910234928
splice O 0 4.4223968870937824e-05
site O 0 3.318046992717427e-06
mutation O 0 1.5357181837316602e-06
. O 0 8.303188110403426e-07

After O 0 3.722252017723804e-08
initial O 0 4.7407436198909636e-08
treatment O 0 9.912756837593406e-09
with O 0 4.808061726535584e-10
intravenous O 0 2.3571384843990018e-08
glucose O 0 1.565629617061859e-07
and O 0 1.517649894644535e-09
carnitine O 0 3.706672657699528e-08
, O 0 1.8392720679827335e-10
the O 0 6.029510224436763e-10
patient O 0 1.6673943337153219e-09
has O 0 3.5775418738559495e-10
thrived O 0 1.7146403408219157e-08
on O 0 9.925621213824343e-09
a O 0 3.191648190181695e-08
low O 0 7.051510237943148e-07
- O 0 1.319154421253188e-07
fat O 0 2.7724502160708653e-07
diet O 0 2.7028640658954828e-08
supplemented O 0 9.973424752729443e-09
with O 0 4.3856546172449384e-10
medium O 0 8.14973901697158e-08
- O 0 4.467077374670225e-08
chain O 0 1.0494633073676596e-07
triglyceride O 0 8.698363558323763e-07
oil O 0 5.248490992926236e-07
and O 0 2.2527937293403966e-09
carnitine O 0 4.221719152042169e-08
and O 0 8.111132876464922e-10
avoidance O 0 1.0571579167617529e-07
of O 0 4.5267306347795966e-08
fasting O 0 3.027772095265391e-07
. O 0 5.11541827563633e-07

Her O 0 3.443848527240334e-06
ventricular O 1 0.9699875116348267
hypertrophy O 1 0.9993749260902405
resolved O 0 2.1646058030455606e-06
significantly O 0 3.7626463722517656e-08
over O 0 1.2705182461658637e-09
1 O 0 2.9897715414506365e-09
year O 0 3.2469432698079004e-10
, O 0 9.548700025119317e-11
and O 0 2.2217701289850567e-10
cognitively O 0 2.7947910652414976e-08
, O 0 6.726494361508628e-10
she O 0 4.111321838529136e-10
is O 0 5.299478217368758e-11
in O 0 1.1738629512869636e-10
the O 0 2.6093118776771007e-09
superior O 0 2.839133799170668e-07
range O 0 4.9385057820927614e-08
for O 0 3.4907330359601474e-09
age O 0 5.843729127263941e-07
. O 0 5.230173769632529e-07

Clinical O 0 2.8532863893815374e-07
recognition O 0 1.4697295227961149e-05
of O 1 1.0
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.1930123494939835e-08
important O 0 3.461870567988967e-09
because O 0 1.9062616762877127e-10
it O 0 2.236940493949291e-11
is O 0 9.8284731048226e-12
one O 0 3.9014982217144833e-11
of O 0 3.3796435094934907e-10
the O 0 1.4881370580255293e-09
few O 0 8.130436768283289e-09
directly O 0 4.889020388532117e-08
treatable O 0 1.4711375115439296e-05
causes O 0 1.6547829773116973e-07
of O 0 1.6212105435897683e-08
cardiomyopathy B-Disease 1 1.0
in O 0 1.8371808963024705e-08
children O 0 1.1422969237173675e-08
. O 0 6.511728933844552e-09
. O 0 5.920433210349074e-08

Cloning O 0 8.238558280027064e-08
of O 0 3.8671572610837757e-08
a O 0 2.2188575421466794e-09
novel O 0 5.547649450932113e-09
member O 0 1.6750860698522274e-09
of O 0 6.350325598702966e-09
the O 0 2.672516430379801e-08
low O 0 2.5064085207304743e-07
- O 0 2.5477895349013124e-08
density O 0 1.6907769406770967e-08
lipoprotein O 0 3.49648615838305e-07
receptor O 0 3.829303750535473e-05
family O 0 7.463656856998568e-07
. O 0 4.0820248159434414e-07

A O 0 1.0007162245528889e-06
gene O 0 2.9363498299517232e-08
encoding O 0 5.347819254097885e-08
a O 0 3.467542342150409e-08
novel O 0 3.248408475542419e-08
transmembrane O 0 3.7063330182718346e-08
protein O 0 3.0314208032677925e-08
was O 0 3.392271130664426e-09
identified O 0 1.5203437120359098e-10
by O 0 1.3368316870154828e-11
DNA O 0 4.5190395869809663e-10
sequence O 0 1.3904728757285767e-10
analysis O 0 2.888949079959957e-10
within O 0 5.226862276330735e-10
the O 0 6.587280498848713e-09
insulin B-Disease 1 0.9550449848175049
- I-Disease 0 0.009845703840255737
dependent I-Disease 1 0.9995334148406982
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.8142835617472883e-08
IDDM B-Disease 0 0.00013545644469559193
) O 0 9.197606565258809e-10
locus O 0 2.1135740269073722e-08
IDDM4 O 0 3.674633944683592e-06
on O 0 3.729422459741727e-08
chromosome O 0 2.733197561610723e-07
11q13 O 0 4.420799541549059e-06
. O 0 6.60708849409275e-07

Based O 0 1.5336881631355936e-07
on O 0 3.5409886578463556e-08
its O 0 2.4645403495782148e-09
chromosomal O 0 6.545326982632105e-07
position O 0 9.112902716879034e-07
, O 0 1.3061617343268495e-09
this O 0 1.3113107821816072e-10
gene O 0 9.565001013456254e-10
is O 0 3.557970862377857e-10
a O 0 2.3438834206856995e-10
candidate O 0 7.221611642016512e-10
for O 0 5.5981549257344554e-11
conferring O 0 3.0871149192535086e-08
susceptibility O 0 6.875371241221728e-07
to O 0 5.692930571399302e-08
diabetes B-Disease 1 0.9999692440032959
. O 0 1.480916807850008e-06

The O 0 8.436051643911924e-07
gene O 0 3.6167460848446353e-07
, O 0 1.3702342016586044e-07
termed O 0 3.732749860319018e-07
low O 0 4.6112077711768507e-07
- O 0 2.3247407554549682e-08
density O 0 6.315176825921753e-09
lipoprotein O 0 2.711011504175076e-08
receptor O 0 1.6439265948520188e-07
related O 0 4.739975167922239e-08
protein O 0 4.794161441168399e-07
5 O 0 3.231192735597688e-08
( O 0 6.105240202280982e-10
LRP5 O 0 8.19848935407208e-07
) O 0 6.76627850970668e-11
, O 0 2.575336298382691e-11
encodes O 0 9.093845121377342e-11
a O 0 2.2978603742007664e-10
protein O 0 2.5701192285509933e-08
of O 0 5.51644063762069e-08
1615 O 0 4.303985406295396e-06
amino O 0 6.177790510264458e-07
acids O 0 1.2938285465224908e-07
that O 0 5.377014944407676e-10
contains O 0 3.8957301273789824e-10
conserved O 0 2.208091931521494e-09
modules O 0 2.498022344532558e-10
which O 0 5.297042665608487e-11
are O 0 8.50080682929244e-12
characteristic O 0 3.159930539453626e-09
of O 0 3.4564933137914977e-09
the O 0 3.935705805702128e-08
low O 0 1.8169534996559378e-06
- O 0 1.9531718464804726e-07
density O 0 7.489169462360223e-08
lipoprotein O 0 1.0704026180974324e-06
( O 0 1.1225176166362871e-07
LDL O 0 1.0376209502283018e-05
) O 0 8.761484870944969e-09
receptor O 0 1.3407351389105315e-06
family O 0 1.247105529955661e-07
. O 0 6.399451280003632e-08

These O 0 1.6065275332266538e-08
modules O 0 1.491815204701652e-08
include O 0 1.0903984382082399e-09
a O 0 3.5567719880447157e-09
putative O 0 3.5506707263266435e-07
signal O 0 2.45561242451231e-08
peptide O 0 2.5067821152191527e-09
for O 0 2.6634253136315067e-10
protein O 0 2.7707949712407753e-08
export O 0 6.926719464672715e-08
, O 0 1.2669947313526109e-09
four O 0 1.850032238515098e-09
epidermal O 0 1.2990967945825105e-07
growth O 0 4.08163494114433e-08
factor O 0 3.6127779878825095e-08
( O 0 2.3591082864982127e-08
EGF O 0 9.91309843811905e-06
) O 0 3.101875201139137e-09
repeats O 0 3.6431744288023538e-09
with O 0 1.0092422036978022e-10
associated O 0 9.724865357441104e-09
spacer O 0 1.2533485005405964e-07
domains O 0 6.351370274160217e-08
, O 0 5.202645425583796e-09
three O 0 2.3025561457501453e-09
LDL O 0 3.728853812390298e-07
- O 0 1.9623914226940542e-07
receptor O 0 5.931181021878729e-06
( O 0 2.2765652474276976e-08
LDLR O 1 0.8536697626113892
) O 0 4.238432660397251e-10
repeats O 0 1.9338164403137625e-09
, O 0 5.410684053575032e-11
a O 0 1.804227323098928e-10
single O 0 8.740601020740257e-10
transmembrane O 0 5.440784267563004e-09
spanning O 0 1.76508514471152e-08
domain O 0 3.563292239050497e-08
, O 0 2.660461406733816e-09
and O 0 1.7245972427915035e-09
a O 0 2.2802851162850857e-08
cytoplasmic O 0 1.4203087630448863e-06
domain O 0 1.4650155435447232e-06
. O 0 8.802475690572464e-07

The O 0 2.9461457984325534e-07
encoded O 0 8.635154102876186e-08
protein O 0 6.268072070270136e-07
has O 0 9.942706657994904e-10
a O 0 2.0363624675390213e-10
unique O 0 6.405404540110737e-10
organization O 0 6.19316020689098e-09
of O 0 3.7655901508060197e-08
EGF O 0 0.008451187051832676
and O 0 8.08170455002255e-07
LDLR O 1 0.9999123811721802
repeats O 0 6.837264265868725e-08
; O 0 2.1467874145031374e-09
therefore O 0 4.72447547750221e-09
, O 0 1.3248140362520644e-09
LRP5 O 0 3.0394559871638194e-05
likely O 0 1.79754131579557e-08
represents O 0 1.744167588135781e-09
a O 0 3.577910745455881e-10
new O 0 3.3325250892168867e-10
category O 0 2.62874388923251e-09
of O 0 5.2903441627449865e-09
the O 0 3.694757921834935e-08
LDLR O 0 0.0013432634295895696
family O 0 9.168518886326638e-07
. O 0 1.068332267095684e-06

Both O 0 3.0648271831523743e-07
human O 0 4.840843530473649e-07
and O 0 4.437423584136013e-08
mouse O 0 1.0089260626955365e-07
LRP5 O 0 3.9260692574316636e-05
cDNAs O 0 3.5956057331532065e-07
have O 0 5.152289705989688e-10
been O 0 4.4157119627463715e-10
isolated O 0 1.7157222309549525e-09
and O 0 2.098916734860623e-10
the O 0 1.0451296494906614e-09
encoded O 0 5.232268507349147e-10
mature O 0 2.1732158295151294e-09
proteins O 0 6.18199269553088e-10
are O 0 8.948453783519383e-11
95 O 0 4.299255618178677e-09
% O 0 2.4836460665866866e-10
identical O 0 4.2274844735956663e-10
, O 0 3.5151895283469514e-11
indicating O 0 1.770465440920077e-09
a O 0 3.4169195251010365e-10
high O 0 2.4645920859711623e-09
degree O 0 1.168866070599961e-08
of O 0 1.9640449266944415e-09
evolutionary O 0 4.965177780036356e-08
conservation O 0 9.991612159865326e-08
. O 0 2.0900621677810705e-08
. O 0 2.897417914482503e-07

The O 0 1.9949882243963657e-06
APC B-Disease 0 1.0415977840239066e-06
variants O 0 8.753021063512278e-08
I1307K O 0 4.4488729145086836e-07
and O 0 3.9857286360245325e-09
E1317Q O 0 1.9822805086278095e-07
are O 0 3.2725966381264016e-10
associated O 0 2.962936207495659e-07
with O 0 4.1516093915561214e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.914014916148403e-10
but O 0 5.7235698819324554e-11
not O 0 4.649485657592933e-11
always O 0 2.4257887365486397e-10
with O 0 5.161778643403281e-11
a O 0 1.950634764824599e-09
family O 0 8.691496411472599e-09
history O 0 5.1412609280987454e-08
. O 0 4.270905549219606e-07

Classical O 1 0.9996901750564575
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.2679956802894594e-06
FAP B-Disease 0 7.370167168119224e-06
) O 0 1.0809476647111183e-09
is O 0 4.113973051111941e-10
a O 0 6.581741818223463e-09
high O 1 0.9969479441642761
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
that O 0 2.6463906066531706e-10
predisposes O 0 1.6669943647684704e-08
to O 0 6.331633828349226e-11
hundreds O 0 2.4896981698496745e-10
or O 0 5.9990852563363e-11
thousands O 0 8.40104097399319e-10
of O 0 1.8298088377832755e-08
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 2.670988408226549e-07
carcinoma I-Disease 1 1.0
and O 0 5.151051252205718e-10
that O 0 3.814050464345797e-11
results O 0 5.963334825942468e-10
from O 0 1.9143659990561446e-09
truncating O 0 2.46557618766019e-08
mutations O 0 6.607426605853561e-09
in O 0 2.1045580833600752e-09
the O 0 5.198908681336434e-08
APC B-Disease 0 5.018371780352027e-07
gene O 0 2.954062949811487e-07
. O 0 1.8958246528200107e-06

A O 0 5.75282797399268e-07
variant O 0 8.415978527409607e-07
of O 0 1.0524119886667904e-07
FAP B-Disease 0 4.091989831067622e-05
is O 0 2.680009991706811e-08
attenuated B-Disease 1 0.9149768352508545
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9953411817550659
coli I-Disease 1 1.0
, O 0 1.8395079903754663e-09
which O 0 3.5799977565753593e-11
results O 0 1.7341225677647287e-10
from O 0 5.489355636711934e-10
germ O 0 2.4512846152902057e-07
- O 0 2.8325880307988882e-08
line O 0 2.9428145253973526e-08
mutations O 0 6.539543351280486e-10
in O 0 2.2107118913261559e-10
the O 0 1.662056825502134e-09
5 O 0 2.1059554100588684e-09
and O 0 1.1939643718150705e-10
3 O 0 2.0732384697907946e-09
regions O 0 3.927859371088971e-09
of O 0 2.3412853877857742e-08
the O 0 1.9564006947803136e-07
APC B-Disease 0 1.0837475201697089e-06
gene O 0 4.023517305995483e-07
. O 0 3.003507572429953e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999984502792358
coli I-Disease 1 1.0
patients O 0 4.6839127776365785e-07
have O 0 3.3623542838867593e-10
" O 0 3.44835243692998e-10
multiple O 0 8.82311557148796e-09
" O 0 4.870136308454676e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.581845486877455e-09
typically O 0 3.1728167315669964e-10
fewer O 0 4.4631978668441263e-10
than O 0 3.462897329997716e-11
100 O 0 3.6676520154266257e-10
) O 0 3.0493452814889244e-12
without O 0 4.8111511302684207e-11
the O 0 5.47910494752557e-10
florid O 0 1.3713531643588794e-07
phenotype O 0 7.073110452893161e-08
of O 0 1.1453949788631235e-08
classical O 0 4.149733285885304e-07
FAP B-Disease 0 1.1176822226843797e-05
. O 0 5.138016376804444e-07

Another O 0 3.643552304311015e-07
group O 0 8.764895476076617e-09
of O 0 6.539696784102489e-09
patients O 0 2.4324431358024867e-09
with O 0 2.0107503162503093e-10
multiple O 0 2.0144496204466122e-07
adenomas B-Disease 1 0.9999622106552124
has O 0 1.1096271679278402e-09
no O 0 4.626682093000767e-10
mutations O 0 1.1809847544341778e-09
in O 0 1.9211614243896946e-10
the O 0 4.800889019662691e-09
APC B-Disease 0 5.489934284952369e-09
gene O 0 5.646575429452128e-10
, O 0 2.615110350490113e-10
and O 0 1.1091948887154146e-10
their O 0 2.2411054956261722e-10
phenotype O 0 7.721357775380966e-09
probably O 0 5.652167622827164e-10
results O 0 2.403773013970323e-10
from O 0 9.841201187299475e-10
variation O 0 5.774545996928282e-08
at O 0 6.00037308728929e-09
a O 0 4.855285062888015e-09
locus O 0 1.3834585921301823e-08
, O 0 7.84742215653722e-10
or O 0 4.913499052072723e-10
loci O 0 3.106611634606793e-09
, O 0 3.3526845188980303e-10
elsewhere O 0 1.6627164090010638e-09
in O 0 2.906447027495318e-10
the O 0 8.463415746007286e-09
genome O 0 8.043906518651056e-08
. O 0 1.3935041920376534e-07

Recently O 0 1.1984589036728721e-06
, O 0 6.0912972443816216e-09
however O 0 3.173423968050315e-09
, O 0 8.837472420530901e-11
a O 0 1.9196304268387365e-10
missense O 0 2.4004949139566634e-08
variant O 0 7.704120719154162e-08
of O 0 9.350834062615831e-08
APC B-Disease 0 1.8387028433153318e-07
( O 0 4.448946544499677e-09
I1307K O 0 1.7114994932398986e-07
) O 0 2.1757488866125385e-10
was O 0 7.451290695570378e-10
described O 0 9.03463207024835e-11
that O 0 1.3788017602656133e-11
confers O 0 2.2975765734400966e-09
an O 0 6.251735934492686e-11
increased O 0 8.222725833562095e-10
risk O 0 6.887170656000308e-08
of O 0 8.779855124885216e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.953558730922623e-09
including O 0 2.1879924261281047e-10
multiple O 0 8.759095670995976e-09
adenomas B-Disease 0 7.040953278192319e-07
, O 0 1.7684066433432122e-09
in O 0 3.852592911357533e-09
Ashkenazim O 0 1.4826981896476354e-05
. O 0 7.184960963968479e-07

We O 0 1.0213428680572179e-07
have O 0 5.173877770658919e-09
studied O 0 1.4057408570522512e-08
a O 0 1.2936902660243277e-09
set O 0 2.1555266460637768e-09
of O 0 1.5927299479301382e-09
164 O 0 4.892581451088063e-09
patients O 0 2.3034728291460027e-10
with O 0 1.4606899023661413e-10
multiple O 0 2.699909600778483e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 1.5291111310489214e-07
/ I-Disease 0 3.5859532090398716e-06
or I-Disease 0 1.6069604669155524e-07
carcinoma I-Disease 1 1.0
and O 0 1.7119533568532574e-09
analyzed O 0 1.5926577390246166e-08
codons O 0 1.6442244543668494e-07
1263 O 0 1.8101909518009052e-06
- O 0 1.1669442301354138e-07
1377 O 0 5.867641448276117e-07
( O 0 6.182314216118812e-09
exon O 0 3.1233323483093045e-08
15G O 0 9.339798339169647e-07
) O 0 2.599395698688056e-10
of O 0 3.4834166662278676e-09
the O 0 8.339038792826159e-09
APC B-Disease 0 1.6497651245117595e-08
gene O 0 2.2496249307835114e-09
for O 0 6.027432331023874e-09
germ O 0 5.9628277995216195e-06
- O 0 9.59235649133916e-07
line O 0 4.1813822804215306e-07
variants O 0 1.1623104256841543e-07
. O 0 2.5729059416335076e-07

Three O 0 4.202518155693724e-08
patients O 0 2.5616950782847425e-09
with O 0 8.251567484851563e-11
the O 0 2.0850361437396714e-09
I1307K O 0 2.497777096266418e-08
allele O 0 6.47684350596478e-10
were O 0 5.633125563231367e-11
detected O 0 1.853418390984629e-10
, O 0 5.7378208087599525e-12
each O 0 9.888418209258454e-12
of O 0 2.0283315027569415e-09
Ashkenazi O 0 2.021797911311296e-07
descent O 0 1.041587779582187e-06
. O 0 2.6833097876988177e-07

Four O 0 4.2012680978587014e-07
patients O 0 4.268877518143199e-08
had O 0 1.3705209411796204e-08
a O 0 1.975179797497617e-09
germ O 0 7.612780450472201e-07
- O 0 9.294715397345499e-08
line O 0 5.250678469792547e-08
E1317Q O 0 5.636100652850473e-08
missense O 0 1.6627044630013188e-08
variant O 0 5.615377496326346e-09
of O 0 2.6616389092737336e-09
APC O 0 2.682995603464633e-09
that O 0 1.0329352650995105e-10
was O 0 9.52649292784713e-10
not O 0 2.1356277857265127e-11
present O 0 3.3491565076815277e-10
in O 0 1.4855101870825393e-10
controls O 0 3.7566283417334034e-09
; O 0 3.064478670822268e-10
one O 0 5.654582913017236e-10
of O 0 4.4443559943374567e-10
these O 0 1.868150911743527e-10
individuals O 0 7.263592505246663e-10
had O 0 5.360827337597129e-09
an O 0 2.896596018597819e-10
unusually O 0 9.2443186439084e-10
large O 0 2.054174469412473e-10
number O 0 8.476189750084018e-10
of O 0 2.2286819501005084e-08
metaplastic B-Disease 0 1.7716267393552698e-05
polyps I-Disease 0 2.667948706402967e-07
of I-Disease 0 3.314588425951115e-08
the I-Disease 0 1.346233773347194e-07
colorectum I-Disease 0 2.959759694931563e-05
. O 0 1.7661208175923093e-06

There O 0 1.1424324242170769e-07
is O 0 1.565246043888635e-09
increasing O 0 1.1571156255385517e-09
evidence O 0 5.911708012007466e-09
that O 0 2.0812525314273245e-10
there O 0 3.373718249211066e-10
exist O 0 3.9962104736446236e-09
germ O 0 1.832953131497561e-07
- O 0 4.737676917443423e-09
line O 0 2.836344048517958e-09
variants O 0 9.88643056309968e-10
of O 0 1.1669120114632392e-09
the O 0 2.6183257784140324e-09
APC B-Disease 0 1.0315621246093087e-08
gene O 0 8.104869553271499e-10
that O 0 2.249593844538822e-10
predispose O 0 7.279007263605308e-08
to O 0 5.79930881094981e-10
the O 0 1.3675357513065478e-09
development O 0 6.4254512821548815e-09
of O 0 7.027293857930772e-09
multiple O 0 0.23923614621162415
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 4.523443749349099e-06
carcinoma I-Disease 1 1.0
, O 0 1.4234660672407529e-10
but O 0 3.577853985303747e-11
without O 0 8.253361882815113e-11
the O 0 1.0760128343889619e-09
florid O 0 7.542208635413772e-08
phenotype O 0 1.980046704375127e-08
of O 0 3.5952059107557943e-09
classical O 0 6.89560977207293e-08
FAP B-Disease 0 4.484064959342504e-07
, O 0 6.123597184881646e-10
and O 0 9.516062937642289e-11
possibly O 0 3.545107263303038e-10
with O 0 4.488062352314692e-11
importance O 0 5.161156479971396e-08
for O 0 1.5955438925630006e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.0875617739714016e-08
in O 0 4.06276227937763e-11
the O 0 1.5153352184160696e-10
general O 0 7.222231146464253e-10
population O 0 3.043700291804896e-10
. O 0 1.1027784241335326e-09
. O 0 5.916888667911735e-08

Genomic O 0 2.849104419055948e-07
structure O 0 9.543505541387276e-08
of O 0 1.880611932847387e-08
the O 0 5.594587193513689e-08
human O 1 0.9999837875366211
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.0003524484927766025
CLD B-Disease 1 1.0
) O 0 1.6339569697265688e-08
gene O 0 3.114849107532791e-07
. O 0 9.408599908056203e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999997615814209
CLD B-Disease 1 1.0
) O 0 6.658563478367796e-09
is O 0 2.251057396041034e-10
caused O 0 1.4286455352063854e-09
by O 0 4.7639503453211773e-11
mutations O 0 3.793645397820455e-09
in O 0 2.6549801246389393e-10
a O 0 4.290741650869734e-10
gene O 0 7.221777065247181e-10
which O 0 2.807070409449608e-10
encodes O 0 5.360193622294673e-09
an O 0 3.389063474301679e-09
intestinal O 0 3.6021819482812134e-07
anion O 0 1.597209461579041e-06
transporter O 0 1.121108107327018e-05
. O 0 8.75675937095366e-07

We O 0 8.865257683510208e-08
report O 0 4.507302620027076e-08
here O 0 2.051450342932526e-09
the O 0 7.546000491132077e-10
complete O 0 9.360177077866183e-10
genomic O 0 5.101717803768224e-08
organization O 0 8.313010724236847e-09
of O 0 1.3374560126067081e-08
the O 0 1.5034240519185005e-08
human O 0 1.249867835895202e-07
CLD B-Disease 1 0.9999890327453613
gene O 0 2.502297569151324e-08
which O 0 2.532478227124102e-09
spans O 0 7.831726378526582e-09
approximately O 0 9.102144593597927e-10
39kb O 0 1.4438174389397318e-07
, O 0 1.463576815297074e-09
and O 0 2.2221355866491876e-09
comprises O 0 1.8604222162821316e-08
21 O 0 3.881183090470586e-07
exons O 0 2.8831859708589036e-06
. O 0 2.4271278107335092e-06

All O 0 9.790051080926787e-07
exon O 0 3.115873369097244e-06
/ O 0 2.7060939373768633e-06
intron O 0 9.566977041686187e-07
boundaries O 0 6.72270417112486e-08
conform O 0 5.626477062037338e-08
to O 0 7.689613390482464e-09
the O 0 1.0745124967570518e-07
GT O 0 2.7023697839467786e-06
/ O 0 1.7385889350407524e-06
AG O 0 3.7238587538013235e-05
rule O 0 6.905427767378569e-07
. O 0 1.0567622439339175e-06

An O 0 3.908890988668645e-09
analysis O 0 2.9896687347985562e-09
of O 0 2.340534210887313e-09
the O 0 3.3170597379950095e-09
putative O 0 4.523476775375457e-07
promoter O 0 4.917207547805447e-07
region O 0 2.760403283730284e-08
sequence O 0 4.523552199486858e-09
shows O 0 9.63892166083724e-09
a O 0 8.896573255867679e-09
putative O 0 3.719743745023152e-06
TATA O 0 5.956922905170359e-06
box O 0 3.9589554035046604e-07
and O 0 1.3280024191431039e-08
predicts O 0 6.618629555532607e-08
multiple O 0 7.504294075033613e-09
transcription O 0 7.20492209893564e-07
factor O 0 3.517791640206269e-07
binding O 0 5.071395321465388e-07
sites O 0 1.6462970506836427e-06
. O 0 1.0122054163730354e-06

The O 0 1.9453565869298473e-07
genomic O 0 3.757859587949497e-07
structure O 0 8.33926563359455e-08
was O 0 2.3826409289995354e-08
determined O 0 1.0554604967794035e-09
using O 0 9.719848537148579e-11
DNA O 0 3.1214248963351565e-09
from O 0 7.51440243362822e-10
several O 0 2.9878144403028273e-10
sources O 0 4.037236767118202e-09
including O 0 8.723508027053128e-11
multiple O 0 1.751468414745716e-09
large O 0 1.6424998250386125e-08
- O 0 2.00007672646052e-08
insert O 0 6.28751166686925e-08
libaries O 0 2.883455749724817e-07
and O 0 3.7448577572263275e-10
genomic O 0 1.8010855029615414e-09
DNA O 0 1.1632814711504125e-08
from O 0 1.9155869779297063e-08
Finnish O 0 2.5027233277796768e-05
CLD B-Disease 0 0.25778019428253174
patients O 0 2.561569445447276e-08
and O 0 7.413557323587838e-09
controls O 0 8.866320513334358e-07
. O 0 4.245577258643607e-07

Exon O 0 4.818275556317531e-07
- O 0 9.200386585916931e-08
specific O 0 9.800203315535327e-09
primers O 0 3.313273566618591e-08
developed O 0 4.866818947846241e-09
in O 0 1.0862380439569108e-10
this O 0 5.3092818336208936e-11
study O 0 5.478098877298443e-11
will O 0 9.885231522233084e-12
facilitate O 0 9.473908324508784e-10
mutation O 0 2.2598689586317278e-09
screening O 0 7.158841297538743e-10
studies O 0 1.079344835730467e-09
of O 0 4.956269283873382e-10
patients O 0 5.435781824658648e-10
with O 0 1.8088133768578984e-10
the O 0 1.4683533500203794e-08
disease O 0 2.632825442105968e-07
. O 0 9.02549857073609e-08

Genomic O 0 1.658018078387613e-07
sequencing O 0 8.417762131784912e-08
of O 0 5.825789273217197e-08
a O 0 6.664740936912494e-08
BAC O 0 9.223531378665939e-06
clone O 0 6.53201993827679e-07
H O 1 0.9999994039535522
_ O 0 5.052271490058047e-09
RG364P16 O 0 5.145322035104982e-08
revealed O 0 9.252732469100522e-10
the O 0 1.296911328330097e-10
presence O 0 3.4724365050031736e-10
of O 0 1.550206296663248e-09
another O 0 2.6837070343788128e-09
, O 0 3.4767838608118495e-10
highly O 0 8.925991612507289e-10
homologous O 0 3.7616884607238887e-10
gene O 0 1.4481019716683363e-09
3 O 0 3.555233973884242e-08
of O 0 1.6455791396197128e-08
the O 0 6.253139872569591e-08
CLD B-Disease 0 7.406641816487536e-05
gene O 0 1.8522150924127345e-08
, O 0 2.657585929100037e-09
with O 0 5.709657052710426e-11
a O 0 2.0249367460589696e-10
similar O 0 9.55739098973396e-11
genomic O 0 8.59659632368448e-09
structure O 0 9.12723585599906e-09
, O 0 7.393685108603165e-10
recently O 0 3.924779390374056e-10
identified O 0 1.1346290573754914e-09
as O 0 4.2368158981176407e-10
the O 0 8.336622059346155e-09
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 3.888933974849351e-07
( O 0 5.928546897848719e-08
PDS B-Disease 0 9.723310540721286e-06
) O 0 5.341146969151112e-10
. O 0 1.9543364704333044e-09
. O 0 5.105923506221188e-08

The O 0 8.844819490150257e-07
APCI1307K O 0 0.26829802989959717
allele O 0 8.696804343344411e-07
and O 0 1.58531445748622e-08
cancer B-Disease 0 1.3348901006793312e-07
risk O 0 7.64818874898765e-09
in O 0 1.5199261294007727e-10
a O 0 4.5305179052768096e-10
community O 0 3.5568173406552717e-10
- O 0 4.88225959660582e-10
based O 0 3.8281336434131674e-10
study O 0 1.7839048294110427e-10
of O 0 1.108043101716305e-09
Ashkenazi O 0 2.4844920787359115e-08
Jews O 0 1.4587013197342458e-07
. O 0 2.54582516845403e-07

Mutations O 0 3.5832073308483814e-07
in O 0 3.296399242458392e-08
APC O 0 3.393244014660013e-07
are O 0 6.117071849054412e-10
classically O 0 3.754459498850338e-08
associated O 0 4.648703821885647e-08
with O 0 3.9660676520725247e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.1025825844844803e-06
FAP B-Disease 0 6.195122296048794e-06
) O 0 1.829894291649481e-10
, O 0 3.194950554119558e-11
a O 0 1.563347784561131e-10
highly O 0 2.0588174720614916e-07
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.43742433190345764
by O 0 7.456341322154003e-09
multiple O 0 1.5041588596886868e-07
intestinal O 0 0.14688503742218018
polyps B-Disease 0 9.382116417100406e-08
and O 0 1.5555695620506071e-10
, O 0 7.633574328202997e-12
without O 0 2.9050876287906036e-11
surgical O 0 5.032008587591008e-09
intervention O 0 3.741375653731893e-09
, O 0 7.237754839906074e-11
the O 0 1.6067557007115596e-10
development O 0 1.489756584760471e-08
of O 0 1.036585558722436e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.213128062564465e-08
CRC B-Disease 0 6.061773092369549e-06
) O 0 3.4807667859126923e-09
. O 0 4.0888270547156935e-08

APC B-Disease 0 1.875403722806368e-05
is O 0 1.0325526034193899e-07
a O 0 6.842378041937991e-08
tumour O 1 0.999982476234436
- O 0 6.765641842321202e-07
suppressor O 0 6.377676413649169e-07
gene O 0 8.286873409701911e-09
, O 0 8.733751499789832e-10
and O 0 2.0975840508974386e-10
somatic O 0 2.2212475414562505e-07
loss O 0 6.005768682371126e-08
occurs O 0 3.9946197460949406e-08
in O 0 2.1982010878218716e-08
tumours B-Disease 1 1.0
. O 0 5.504823093360756e-06

The O 0 5.56857457922888e-06
germline O 0 3.3940072171390057e-05
T O 0 1.2548342738227802e-06
- O 0 3.429301997925904e-08
to O 0 5.4626934087309564e-09
- O 0 5.720400597652997e-09
A O 0 1.697203444450679e-08
transversion O 0 3.5576761092670495e-08
responsible O 0 1.6918043355129697e-10
for O 0 9.10307731971649e-11
the O 0 3.0081268587167642e-09
APC O 0 3.2489410273228714e-08
I1307K O 0 3.147582816609429e-08
allele O 0 8.987560695672414e-10
converts O 0 1.4434031747612153e-09
the O 0 7.418022862637486e-10
wild O 0 3.1405946732121492e-09
- O 0 9.737258777064994e-10
type O 0 5.501472610802693e-10
sequence O 0 3.0974275921913375e-10
to O 0 7.644961330655065e-10
a O 0 2.021064737789402e-08
homopolymer O 0 1.516449628979899e-05
tract O 0 6.881484750920208e-06
( O 0 3.170400830754261e-08
A8 O 0 6.4545124587311875e-06
) O 0 2.8412699970559174e-10
that O 0 1.5095513727914067e-10
is O 0 2.5519014679176166e-10
genetically O 0 5.693744853374483e-08
unstable O 0 1.0938070772681385e-05
and O 0 1.5481623094615315e-08
prone O 0 1.2215225808631658e-07
to O 0 8.176094468126394e-09
somatic O 0 5.616621638182551e-05
mutation O 0 2.0492886960710166e-06
. O 0 3.082996613557043e-07

The O 0 6.933029794709e-07
I1307K O 0 1.9137521576340077e-06
allele O 0 6.747986702748676e-08
was O 0 1.615986988667828e-08
found O 0 9.639155029717017e-10
in O 0 1.6892385268363341e-09
6 O 0 3.4330886933275906e-07
. O 0 1.7340852309644106e-07

1 O 0 1.9219130535930162e-06
% O 0 3.9877992463743794e-08
of O 0 2.6866532110148e-08
unselected O 0 4.888686817139387e-05
Ashkenazi O 0 1.3065366033515602e-07
Jews O 0 2.301911550262048e-08
and O 0 5.238698919107776e-10
higher O 0 6.238960459370446e-09
proportions O 0 6.2252194510392656e-09
of O 0 8.245660154670986e-09
Ashkenazim O 0 2.824536977641401e-07
with O 0 5.489397270075358e-10
family O 0 2.4873973991645926e-09
or O 0 1.8376626609306612e-10
personal O 0 4.7444137507568485e-09
histories O 0 1.7148268582900528e-08
of O 0 1.9979897558641824e-07
CRC B-Disease 0 0.0077471123076975346
( O 0 3.273223825317473e-08
ref O 0 8.214000217776629e-07
. O 0 3.234417533803935e-08
2 O 0 2.0324614524724893e-07
) O 0 1.1003249866803344e-08
. O 0 1.242738960627321e-07

To O 0 1.8097090048740938e-08
evaluate O 0 8.456190414563025e-08
the O 0 2.18174367461188e-08
role O 0 1.8096883991347568e-08
of O 0 3.983055663070445e-08
I1307K O 0 2.3526345103164203e-06
in O 0 1.0152167106980414e-08
cancer B-Disease 0 4.080787050497747e-07
, O 0 4.414063781155164e-09
we O 0 4.645155815552471e-09
genotyped O 0 9.903440059133573e-07
5 O 0 9.267524347933431e-08
, O 0 1.2828940576525838e-08
081 O 0 1.604323529136309e-06
Ashkenazi O 0 6.044231071200556e-08
volunteers O 0 6.761498472229732e-09
in O 0 4.847851564626637e-10
a O 0 2.001323551326095e-09
community O 0 5.217720477901366e-09
survey O 0 8.09139280022464e-08
. O 0 1.4053820507342607e-07

Risk O 0 3.338453097967431e-06
of O 0 1.2412219803081825e-06
developing O 0 0.0040541221387684345
colorectal B-Disease 1 1.0
, I-Disease 0 2.0385384686960606e-06
breast I-Disease 0 2.064109139610082e-06
and I-Disease 0 6.994798518178413e-09
other I-Disease 0 3.6839893358120435e-09
cancers I-Disease 0 3.311743284939439e-06
were O 0 8.032201015417684e-10
compared O 0 8.313085775313311e-10
between O 0 1.836258478604691e-09
genotyped O 0 7.212849340021421e-08
I1307K O 0 8.238790094594606e-09
carriers O 0 1.4611301057954051e-10
and O 0 1.662008447533836e-10
non O 0 1.674555716313364e-09
- O 0 2.5248808599442896e-10
carriers O 0 1.4052997654445676e-10
and O 0 9.655435478927998e-11
their O 0 6.622510179132846e-11
first O 0 1.7374605087994155e-09
- O 0 5.691982440936272e-09
degree O 0 7.800451840012101e-08
relatives O 0 3.049916017516807e-07
. O 0 6.701170605083462e-07

Sperm O 0 8.84392719058269e-08
DNA O 0 6.889943193755244e-08
analysis O 0 1.415550698879997e-08
in O 0 1.949794325994958e-09
a O 0 5.153798454671232e-08
Friedreich B-Disease 1 0.955187976360321
ataxia I-Disease 1 1.0
premutation O 1 0.999313235282898
carrier O 0 1.645444882569791e-07
suggests O 0 5.5334279380758744e-08
both O 0 3.774346168938791e-09
meiotic O 0 3.2434437002848426e-07
and O 0 7.02907643201911e-09
mitotic O 0 1.3413038857379433e-07
expansion O 0 1.415267831816891e-07
in O 0 8.577565324685565e-09
the O 0 1.4658075997431297e-07
FRDA B-Disease 0 0.00019053118012379855
gene O 0 6.579842306564387e-07
. O 0 2.5173444555548485e-06

Friedreich B-Disease 1 0.9999998807907104
ataxia I-Disease 1 1.0
is O 0 2.414041318843374e-06
usually O 0 2.8452262768041692e-08
caused O 0 2.173652369208412e-08
by O 0 4.5992987196541435e-11
an O 0 2.644209677604703e-11
expansion O 0 1.673055249895583e-09
of O 0 2.7946138736467674e-09
a O 0 5.248936219004463e-08
GAA O 1 0.999984622001648
trinucleotide O 1 0.5029886364936829
repeat O 0 1.456132707744473e-07
in O 0 3.5953500177043907e-09
intron O 0 1.3281473343340622e-07
1 O 0 4.5377781532351946e-08
of O 0 7.146293778959034e-09
the O 0 3.305812157350374e-08
FRDA B-Disease 0 4.642979183699936e-05
gene O 0 4.459577667148551e-07
. O 0 1.4214942893886473e-06

Occasionally O 0 7.129713708309282e-07
, O 0 6.446688960437541e-09
a O 0 3.152718308641056e-09
fully O 0 5.5691709022198665e-09
expanded O 0 3.7151359766340875e-09
allele O 0 4.5797121650537065e-09
has O 0 2.1968744878808621e-10
been O 0 1.3512677088378666e-10
found O 0 5.53544640680137e-11
to O 0 6.913378897133171e-11
arise O 0 7.18848180980558e-09
from O 0 2.0449302251535073e-09
a O 0 1.140876726424267e-09
premutation O 0 1.7532047991153377e-07
of O 0 5.536349156898268e-09
100 O 0 8.522802019683695e-09
or O 0 2.33306396424382e-09
less O 0 2.2309444958068525e-08
triplet O 0 2.0559816675813636e-06
repeats O 0 1.173528062281548e-06
. O 0 6.225542392712669e-07

We O 0 1.2957981709860178e-07
have O 0 3.806837511888261e-09
examined O 0 4.272428810736528e-08
the O 0 2.3097743717670483e-09
sperm O 0 8.860605582583503e-09
DNA O 0 2.224919093407607e-08
of O 0 1.8223831332875307e-08
a O 0 3.781994450946513e-08
premutation O 0 8.67095968715148e-06
carrier O 0 3.048118912829523e-07
. O 0 3.72932674963522e-07

This O 0 3.6517821655479565e-08
mans O 0 1.0837105946848169e-05
leucocyte O 0 6.415693860617466e-07
DNA O 0 3.745626031559368e-08
showed O 0 1.56868082967776e-08
one O 0 3.554674332661989e-10
normal O 0 5.48468825911641e-10
allele O 0 1.1125978610637688e-10
and O 0 2.5716206941694963e-11
one O 0 4.232742975562864e-11
allele O 0 6.672710717303687e-10
of O 0 5.399367619673967e-10
approximately O 0 6.649016337512137e-10
100 O 0 5.27413313022862e-09
repeats O 0 5.253233226198972e-08
. O 0 1.100153284028238e-07

His O 0 9.054005545294785e-07
sperm O 0 3.794697533976432e-07
showed O 0 2.4899476258610775e-08
an O 0 2.023415462959477e-10
expanded O 0 2.6298260791257633e-10
allele O 0 2.902991402820021e-09
in O 0 8.760896452741918e-10
a O 0 7.547126479323651e-09
tight O 0 4.72262158268677e-08
range O 0 1.594567464735519e-07
centering O 0 6.289214837806867e-08
on O 0 1.9244446036736917e-09
a O 0 4.915748363920613e-10
size O 0 2.6503370609276544e-09
of O 0 1.2168248630928247e-08
approximately O 0 1.828305329354407e-08
320 O 0 1.3148790856121195e-07
trinucleotide O 0 2.283369940414559e-05
repeats O 0 1.7039653812389588e-06
. O 0 8.519260177308752e-07

His O 0 1.1622964848356787e-06
affected O 0 2.6929310479317792e-05
son O 0 0.00036773132160305977
has O 0 3.7105754024935322e-09
repeat O 0 4.620952065437223e-09
sizes O 0 3.560785089007368e-08
of O 0 1.6108200995290645e-08
1040 O 0 7.371359345142992e-08
and O 0 6.978301048121693e-09
540 O 0 1.4620103172546806e-07
. O 0 1.3029331569214264e-07

These O 0 2.997292725126499e-08
data O 0 2.1657811544173455e-08
suggest O 0 5.924045254346311e-09
that O 0 1.6669356173171224e-10
expansion O 0 3.191409136960033e-09
occurs O 0 5.385071832897381e-10
in O 0 5.375360920267802e-11
two O 0 1.1794105969631374e-10
stages O 0 1.0586419518787693e-09
, O 0 1.3064202497581334e-10
the O 0 4.566260425331592e-10
first O 0 1.3840305568280087e-09
during O 0 1.3126277842445688e-09
meiosis O 0 3.1277183065725467e-09
followed O 0 1.0675271777671469e-09
by O 0 1.4432922912366308e-10
a O 0 1.2999333831587023e-09
second O 0 5.7439279999016435e-09
mitotic O 0 2.522994577702775e-07
expansion O 0 1.3652426105181803e-06
. O 0 1.40224699407554e-06

We O 0 2.8569505872155787e-08
also O 0 1.8588146577513953e-09
show O 0 4.4026682299858066e-10
that O 0 5.1592882743811685e-11
in O 0 1.415824679718014e-10
all O 0 2.976813517907573e-10
informative O 0 6.292092180615327e-09
carrier O 0 5.396320057471371e-10
father O 0 1.499717017239277e-09
to O 0 1.94571039835445e-10
affected O 0 4.872010794798598e-09
child O 0 3.1145559464818007e-09
transmissions O 0 2.2982659331205468e-08
, O 0 8.829402486920657e-11
with O 0 2.4807842412266634e-12
the O 0 1.3986467539695013e-10
notable O 0 5.61906021712133e-10
exception O 0 6.151707587775945e-09
of O 0 7.129561829799513e-09
the O 0 1.3277744237427669e-08
premutation O 0 2.6571976263767283e-07
carrier O 0 4.079430127035266e-09
, O 0 7.047396555215357e-10
the O 0 9.457298277837367e-10
expansion O 0 2.1210006195815367e-08
size O 0 1.467057320070353e-08
decreases O 0 1.420308421984373e-07
. O 0 3.1094828045752365e-08
. O 0 3.9607456869816815e-07

The O 0 3.402138588626258e-07
R496H O 0 4.538575922197197e-06
mutation O 0 2.2788030662468373e-07
of O 0 5.941803138398427e-08
arylsulfatase O 0 3.608479892136529e-05
A O 0 4.995261519979977e-07
does O 0 5.390541346628197e-09
not O 0 4.529898234295615e-09
cause O 0 0.00018528684449847788
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 1.9620561033661943e-06

Deficiency B-Disease 0 0.35562118887901306
of I-Disease 0 0.004192613530904055
arylsulfatase I-Disease 1 1.0
A I-Disease 1 0.9999923706054688
( O 0 2.25504049922165e-06
ARSA O 0 0.16681034862995148
) O 0 5.931292346161854e-09
enzyme O 0 4.813182385987602e-07
activity O 0 3.9859440903455834e-07
causes O 0 0.0013483589282259345
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.086817175950273e-06
MLD B-Disease 1 1.0
) O 0 2.5676252235484753e-08
. O 0 8.66858655967917e-08

A O 0 5.90609772643802e-07
number O 0 7.636749188577596e-08
of O 0 2.591102941096324e-07
ARSA O 0 8.078416431089863e-05
gene O 0 1.5383537288471416e-07
mutations O 0 2.9438032811412995e-07
responsible O 0 2.259684706018561e-08
for O 0 1.0660098581638522e-08
MLD B-Disease 1 1.0
have O 0 2.50667198109511e-09
been O 0 3.192821562691961e-09
identified O 0 1.9873491297062174e-08
. O 0 5.98515015326484e-08

Recently O 0 4.925307734993112e-07
, O 0 3.1083069451653955e-09
the O 0 1.4801965209088053e-09
R496H O 0 8.497630687998026e-08
mutation O 0 1.0486385093599893e-08
of O 0 2.581807834189931e-08
ARSA O 0 3.36373777827248e-05
was O 0 2.8089155890143047e-08
proposed O 0 9.002675271929661e-10
to O 0 1.4668906367365508e-10
be O 0 2.4183186009274493e-10
a O 0 8.982350974129361e-10
cause O 0 3.0231902314881154e-07
of O 0 1.4237872392186546e-06
MLD B-Disease 1 1.0
( O 0 3.2883963285712525e-07
Draghia O 0 9.464924914937e-06
et O 0 8.74467502853804e-07
al O 0 4.721167101706669e-07
. O 0 6.350010739453182e-09
, O 0 1.1927359100383228e-09
1997 O 0 4.434975942047004e-09
) O 0 2.954607003502474e-09
. O 0 8.542808416223124e-08

We O 0 1.4238534618016274e-07
have O 0 4.546890419732108e-09
investigated O 0 1.4166364969980805e-08
the O 0 5.2006510209423595e-09
R496H O 0 5.789168966430225e-08
mutation O 0 5.783534762215936e-10
and O 0 3.3009935063166296e-11
found O 0 2.68929444685595e-11
this O 0 9.3448261281881e-12
mutation O 0 2.922389552573179e-10
at O 0 2.576207303039979e-10
a O 0 6.70090649634858e-11
relatively O 0 2.3620863598416975e-10
high O 0 1.7749750280682264e-10
frequency O 0 6.823600712246858e-11
in O 0 7.303845896144967e-12
an O 0 4.195688241281914e-11
African O 0 4.358799779446976e-11
American O 0 1.4581288954040872e-10
population O 0 6.358148729734836e-11
( O 0 3.3952517880520006e-11
f O 0 2.5347062226899197e-09
= O 0 2.1444628295341772e-09
0 O 0 2.991351388814678e-09
. O 0 1.547432404436222e-09
09 O 0 2.3794802572751905e-08
, O 0 1.5897191341096573e-09
n O 0 5.384365397986812e-09
= O 0 6.340597735743358e-08
61 O 0 1.1456970128165267e-07
subjects O 0 1.1490365636745992e-07
) O 0 1.0670635930409844e-08
. O 0 1.3744718785346777e-07

The O 0 1.6600146409473382e-05
ARSA O 0 7.583053229609504e-05
enzyme O 0 2.571580921539862e-07
activity O 0 7.476239005654861e-08
in O 0 5.262534297223453e-10
subjects O 0 4.868759173604076e-09
with O 0 2.008939889441841e-11
and O 0 2.928302739180211e-11
without O 0 2.8673691199188056e-10
the O 0 7.38377747833141e-10
R496H O 0 1.0524034976810981e-08
mutation O 0 6.088970994078124e-10
was O 0 1.3530840892173046e-09
determined O 0 6.440490918357966e-10
and O 0 5.711533468399921e-10
found O 0 7.614561203794779e-10
to O 0 9.85574177825299e-10
be O 0 6.885788828014938e-09
normal O 0 4.142694933761959e-07
. O 0 3.8974101812527806e-07

It O 0 3.164311124237429e-08
is O 0 2.5932860303612415e-09
therefore O 0 8.007241092400363e-09
concluded O 0 4.794885821723938e-09
that O 0 1.787450326640183e-10
the O 0 2.6622788418251275e-09
R496H O 0 4.70748602765525e-07
mutation O 0 6.492694382131958e-08
of O 0 9.775843778925264e-08
ARSA O 0 2.924162799899932e-05
does O 0 6.550994857690284e-09
not O 0 1.1857403947601597e-09
negatively O 0 9.017924185172888e-09
influence O 0 6.952964426432118e-09
the O 0 2.2034387647806852e-09
activity O 0 2.2029102098031217e-08
of O 0 3.7723186352423e-08
ARSA O 0 5.3066574764670804e-05
and O 0 4.757553462297892e-09
is O 0 2.494451312173851e-10
not O 0 3.3009700528552344e-10
a O 0 2.8562407994314754e-09
cause O 0 1.3942845953351934e-06
of O 0 7.201162588899024e-06
MLD B-Disease 1 1.0

Down O 0 3.183148010066361e-06
- O 0 5.2207298040229944e-08
regulation O 0 3.841999074438718e-08
of O 0 4.635219141846392e-08
transmembrane O 0 2.4242870040325215e-06
carbonic O 0 7.466757961083204e-05
anhydrases O 0 1.8243992599309422e-05
in O 0 8.083047475793137e-08
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.7764843106269836
lines O 0 2.9109326504794808e-08
by O 0 4.745597248501099e-10
wild O 0 2.0018818602807187e-08
- O 0 1.3716586977352563e-08
type O 0 1.2614113131803606e-07
von B-Disease 0 0.00103117641992867
Hippel I-Disease 0 0.01920761726796627
- I-Disease 0 0.0026521789841353893
Lindau I-Disease 0 0.003521883627399802
transgenes O 0 0.0007030951092019677
. O 0 6.4702776398917194e-06

To O 0 1.4157957650695607e-07
discover O 0 1.205211503929604e-07
genes O 0 5.884756149043824e-08
involved O 0 1.1658068288511458e-08
in O 0 1.455618381385193e-08
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Lindau I-Disease 1 0.999998927116394
( O 0 4.352265932539012e-06
VHL B-Disease 1 0.9999997615814209
) O 0 8.019196684472263e-08
- O 0 5.497963115885796e-07
mediated O 0 3.471179661573842e-05
carcinogenesis O 0 0.0012054030084982514
, O 0 3.379413193727032e-09
we O 0 9.980460902170307e-10
used O 0 8.94801832629355e-09
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 3.850160737783881e-06
stably O 0 3.879251266880601e-07
transfected O 0 7.504039700734211e-08
with O 0 6.667888463596228e-10
wild O 0 1.5102813222256373e-08
- O 0 1.8785362598805477e-08
type O 0 1.309330599497116e-07
VHL O 0 0.0005168872885406017
- O 0 1.932810846483335e-06
expressing O 0 1.4509869572520984e-07
transgenes O 0 1.9781855371547863e-05
. O 0 7.508119210797304e-07

Large O 0 1.058476868820435e-06
- O 0 2.0985351056879153e-07
scale O 0 1.6237642341820901e-07
RNA O 0 4.029115814319084e-07
differential O 0 2.9883679530939844e-07
display O 0 2.695574075062268e-08
technology O 0 2.7509319266982857e-08
applied O 0 1.515758718539928e-08
to O 0 3.490951139273335e-10
these O 0 4.765915440074764e-10
cell O 0 1.494948342894986e-08
lines O 0 2.761012751761882e-09
identified O 0 8.535356310623854e-10
several O 0 4.3094663948473055e-10
differentially O 0 9.078330265310797e-08
expressed O 0 1.4284221583338308e-09
genes O 0 2.496237438975868e-09
, O 0 2.5360635813598265e-10
including O 0 7.624890302482257e-11
an O 0 4.252086682754452e-09
alpha O 0 2.637619900269783e-08
carbonic O 0 1.0929361451417208e-06
anhydrase O 0 8.709918688509788e-07
gene O 0 7.21862960517683e-08
, O 0 1.0609372225189873e-07
termed O 0 5.334399247658439e-06
CA12 O 0 0.018269233405590057
. O 0 3.90354716728325e-06

The O 0 1.1430769291109755e-06
deduced O 0 1.9432109183981083e-06
protein O 0 1.4869978315346088e-07
sequence O 0 7.401830259823328e-09
was O 0 1.2789167058713247e-08
classified O 0 2.069828530792961e-09
as O 0 6.266040464275591e-10
a O 0 1.316617037616652e-09
one O 0 3.0949844909144986e-09
- O 0 1.073015098995711e-08
pass O 0 1.5039924505799718e-07
transmembrane O 0 9.63707407208858e-07
CA O 0 1.2062871519447071e-06
possessing O 0 7.259042433815921e-08
an O 0 3.0643299453458894e-08
apparently O 0 4.400489572731203e-08
intact O 0 7.816145952688203e-09
catalytic O 0 1.5487079396692138e-09
domain O 0 6.898343674066609e-09
in O 0 1.103373836741639e-09
the O 0 5.4991385667335635e-08
extracellular O 0 3.207753616152331e-05
CA O 0 7.65325894462876e-05
module O 0 1.0044002465292579e-06
. O 0 3.859700825614709e-07

Reintroduced O 0 8.288398930744734e-06
wild O 0 5.355727353162365e-06
- O 0 1.2282738452995545e-06
type O 0 8.5489421053353e-07
VHL B-Disease 0 0.002626521047204733
strongly O 0 2.6310727818668056e-08
inhibited O 0 1.929076276496744e-08
the O 0 5.47803913342193e-10
overexpression O 0 9.094586772562252e-08
of O 0 3.0086317881483637e-09
the O 0 4.530589237106142e-09
CA12 O 0 3.1690574360254686e-06
gene O 0 1.3286198807804794e-09
in O 0 6.476362224283605e-10
the O 0 1.9208409085536005e-08
parental O 0 0.0001771061506588012
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999655485153198
lines O 0 1.0249818842567038e-06
. O 0 7.27131990174712e-08

Similar O 0 3.108557677933277e-08
results O 0 5.918615642031e-08
were O 0 4.774006523433627e-09
obtained O 0 1.54431063492666e-08
with O 0 1.3987887514943509e-09
CA9 O 0 7.107478722900851e-06
, O 0 8.227165615437571e-10
encoding O 0 4.819881382900348e-09
another O 0 1.0161063102032131e-07
transmembrane O 0 1.1264849035796942e-06
CA O 0 1.6399005744460737e-06
with O 0 2.4884365679156417e-09
an O 0 1.7842024746528296e-08
intact O 0 1.0231092772983175e-07
catalytic O 0 1.0955319851291279e-07
domain O 0 1.023514869302744e-06
. O 0 5.250228127806622e-07

Although O 0 3.347211929849436e-08
both O 0 6.659935269937023e-09
domains O 0 7.605713392422331e-08
of O 0 1.576407981929151e-07
the O 0 2.3100403723219642e-07
VHL B-Disease 0 0.0009248965070582926
protein O 0 2.494935245067609e-07
contribute O 0 3.032251782997264e-09
to O 0 3.1555802415539347e-10
regulation O 0 3.731016207098037e-08
of O 0 1.933552624677759e-07
CA12 O 1 0.9097701907157898
expression O 0 2.1414437867406377e-07
, O 0 4.127234110029576e-09
the O 0 1.0596769683957064e-08
elongin O 0 2.3252160019637813e-07
binding O 0 5.974554539989185e-08
domain O 0 2.6838984013011213e-07
alone O 0 2.6630571525743107e-08
could O 0 1.0932271088393009e-08
effectively O 0 9.853775395640696e-08
regulate O 0 2.685019580894732e-06
CA9 O 0 0.007168912794440985
expression O 0 1.1157334483868908e-05
. O 0 2.53726716437086e-06

We O 0 1.457201278753928e-06
mapped O 0 8.104781954898499e-06
CA12 O 0 0.004537052940577269
and O 0 1.196484390675323e-06
CA9 O 0 0.0011421736562624574
loci O 0 3.2717736075937864e-07
to O 0 1.138501293240779e-08
chromosome O 0 9.898779040895533e-08
bands O 0 7.71386936548879e-08
15q22 O 0 5.130779072715086e-07
and O 0 1.189240439458672e-08
17q21 O 0 3.1832394142838893e-06
. O 0 2.8182003575238923e-07

2 O 0 1.909735601657303e-06
respectively O 0 2.411693174053653e-07
, O 0 6.5010312688684735e-09
regions O 0 2.1553757889591907e-08
prone O 0 4.471612058409846e-08
to O 0 1.8723755879079818e-09
amplification O 0 8.103315707330694e-08
in O 0 2.6657747120850672e-09
some O 0 6.613806835531477e-09
human O 0 7.229845095935161e-07
cancers B-Disease 0 0.006384883541613817
. O 0 4.260548109868978e-07

Additional O 0 2.0154219271262264e-07
experiments O 0 4.807543874107978e-08
are O 0 1.219007256247906e-10
needed O 0 1.4784443669313418e-09
to O 0 2.3610685628838723e-10
define O 0 9.35604038687643e-09
the O 0 1.4163393124988488e-08
role O 0 1.5339331582708837e-08
of O 0 4.0961771219372167e-07
CA O 0 5.038868039264344e-06
IX O 1 0.991858184337616
and O 0 1.1641003538898076e-06
CA O 0 6.267292519623879e-06
XII O 0 4.32426077168202e-06
enzymes O 0 1.1977946412500273e-09
in O 0 1.6090588583761445e-10
the O 0 5.814138615001241e-10
regulation O 0 6.513604766666958e-09
of O 0 2.0501136788197982e-08
pH O 0 5.2505583880702034e-08
in O 0 1.1616577699768982e-09
the O 0 1.841755903342346e-08
extracellular O 0 8.144049274960707e-07
microenvironment O 0 1.309492176915228e-06
and O 0 1.6045423878452425e-09
its O 0 9.201185924290201e-10
potential O 0 1.8301614446158965e-08
impact O 0 5.597287326963851e-07
on O 0 2.274291546200402e-07
cancer B-Disease 0 7.126015475478198e-07
cell O 0 3.856848707073368e-06
growth O 0 3.8594504303546273e-07
. O 0 1.475729760613831e-07

A O 0 1.7959447973225906e-07
gene O 0 5.829543070490217e-09
encoding O 0 4.825945865150061e-08
a O 0 5.9337846636253744e-08
transmembrane O 0 2.5025369154718646e-07
protein O 0 5.5649479691055603e-08
is O 0 2.1406693084813355e-10
mutated O 0 1.5789552998413114e-09
in O 0 7.981965782777323e-11
patients O 0 4.539444375950552e-10
with O 0 1.697419538260192e-09
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 6.202837084856583e-06
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 0 1.0983141010001418e-06
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 5.183775630968057e-09
. O 0 1.938219185149137e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.010527893900871277
WFS B-Disease 1 0.9991633892059326
; O 0 4.966167921338638e-07
OMIM O 1 0.9983178377151489
222300 O 0 4.812718543689698e-06
) O 0 1.2961107742626155e-09
is O 0 1.85663456830909e-10
an O 0 2.8624309589275754e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 1.3261778519790823e-07
by O 0 1.4722001395739426e-09
young O 0 1.173854400349228e-07
- O 0 5.320978857525915e-07
onset O 1 1.0
non O 1 1.0
- O 0 0.015701454132795334
immune O 1 0.9999979734420776
insulin B-Disease 1 1.0
- I-Disease 1 0.9190504550933838
dependent I-Disease 0 0.001609221682883799
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.654902170855621e-08
progressive O 0 9.787634553504176e-06
optic B-Disease 0 0.00019093399168923497
atrophy I-Disease 0 8.982563485915307e-06
. O 0 4.254619909715984e-07

Linkage O 0 5.997920652589528e-06
to O 0 2.270507337698291e-08
markers O 0 2.721264706906368e-07
on O 0 9.755168406400117e-08
chromosome O 0 3.7674800523745944e-07
4p O 0 8.938757673604414e-06
was O 0 2.501686680034254e-08
confirmed O 0 1.2501480961546463e-09
in O 0 2.0214095675097354e-10
five O 0 1.0034191255670066e-09
families O 0 8.742539137074345e-09
. O 0 8.736208911841459e-08

On O 0 6.836547328248344e-08
the O 0 7.358811782154362e-09
basis O 0 7.439695082211983e-08
of O 0 1.6593368457051838e-08
meiotic O 0 3.965533323935233e-05
recombinants O 1 0.9964315891265869
and O 0 1.0669948125041628e-07
disease O 0 7.192241469056171e-07
- O 0 2.020474987318721e-08
associated O 0 3.851955909794924e-08
haplotypes O 0 6.602937219213345e-07
, O 0 9.549524504492979e-10
the O 0 4.493651672987653e-09
WFS B-Disease 0 2.506387318135239e-06
gene O 0 6.388692241898752e-09
was O 0 2.3758701672704774e-08
localized O 0 1.6626282572929085e-08
to O 0 1.2011462935390682e-09
a O 0 3.2542128991508434e-08
BAC O 0 6.1593805185111705e-06
/ O 0 1.2928849457694014e-07
P1 O 0 5.02871046137443e-07
contig O 0 6.560680958500598e-07
of O 0 4.794529218088428e-09
less O 0 2.5085755694931322e-09
than O 0 8.518036276328189e-10
250 O 0 2.153526423853691e-08
kb O 0 2.039687842625426e-06
. O 0 5.912827418796951e-07

Mutations O 0 3.5690749200512073e-07
in O 0 5.269316538658586e-09
a O 0 2.8857671807713814e-09
novel O 0 8.600335554831418e-09
gene O 0 5.354205523389055e-09
( O 0 1.527122606148623e-08
WFS1 O 0 4.131182504352182e-05
) O 0 1.7845240563030274e-10
encoding O 0 1.8859884765021206e-09
a O 0 9.494353747641071e-09
putative O 0 1.3049651670371532e-07
transmembrane O 0 1.0866079591664857e-08
protein O 0 1.3434463319583756e-08
were O 0 7.018074454911982e-10
found O 0 7.389381467826084e-11
in O 0 2.2036213132015092e-11
all O 0 3.312965179969041e-11
affected O 0 1.804671134753022e-10
individuals O 0 3.718322524881579e-11
in O 0 5.561005544940656e-10
six O 0 1.1005852229573065e-08
WFS B-Disease 0 4.1050448089663405e-06
families O 0 1.4745101806212801e-09
, O 0 1.7958567966047667e-10
and O 0 1.657449004432987e-11
these O 0 4.930460553720373e-11
mutations O 0 1.874036925642031e-09
were O 0 1.9526477657016983e-10
associated O 0 1.758437506715893e-09
with O 0 8.59022852850444e-11
the O 0 5.206606257246449e-09
disease O 0 1.6925717716276267e-07
phenotype O 0 3.5130310038766766e-07
. O 0 6.911832173273069e-08

WFS1 O 0 0.1667080521583557
appears O 0 3.191271105151827e-07
to O 0 1.1478044070756255e-09
function O 0 2.6438289335573018e-09
in O 0 4.5653197888739783e-10
survival O 0 4.2741976358229294e-07
of O 0 5.915173773018978e-08
islet O 0 8.519100447301753e-08
beta O 0 8.407941720633971e-08
- O 0 4.826332755669682e-08
cells O 0 9.85664794228569e-09
and O 0 5.560032434459572e-09
neurons O 0 1.117806505135377e-07
. O 0 1.0863054455967358e-08
. O 0 4.2735535998872365e-08

Stable O 0 4.050461939186789e-06
interaction O 0 8.220789027291175e-08
between O 0 1.1349001738381048e-08
the O 0 9.837185510619406e-10
products O 0 3.6956440130353485e-09
of O 0 2.158579537336891e-09
the O 0 1.3407533749898448e-08
BRCA1 O 0 2.221268715629776e-07
and O 0 2.6348645931761894e-08
BRCA2 O 0 2.1998667421030405e-07
tumor B-Disease 0 1.3794409881029424e-07
suppressor O 0 2.6594639734867087e-07
genes O 0 4.459413283086633e-09
in O 0 1.0679589435014236e-09
mitotic O 0 1.2281034855732287e-07
and O 0 3.185177277487128e-08
meiotic O 0 2.066916295007104e-06
cells O 0 1.942777316799038e-06
. O 0 1.3064136510365643e-06

BRCA1 O 0 2.9226657716208138e-05
and O 0 4.0341294038626074e-07
BRCA2 O 0 4.2276624867554347e-07
account O 0 7.867759777013816e-10
for O 0 3.8802586144193185e-11
most O 0 5.605313435630421e-11
cases O 0 1.8306517413080314e-10
of O 0 1.8001926616051378e-09
familial O 0 4.16879579745455e-08
, O 0 1.3917975660859838e-09
early O 0 1.610448308042578e-08
onset O 0 7.203676432254724e-06
breast B-Disease 0 5.026409439778945e-07
and I-Disease 0 4.998034910386195e-07
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.3374776286489976e-10
encode O 0 9.275717693935093e-11
products O 0 1.0395173610788788e-09
that O 0 1.2478271194105162e-10
each O 0 1.641264346652349e-10
interact O 0 2.731506798525629e-09
with O 0 1.5428378574711132e-09
hRAD51 O 0 1.979666876650299e-06
. O 0 5.532667728402885e-07

Results O 0 1.4503783063446463e-07
presented O 0 1.2976579455425963e-07
here O 0 3.986785568343976e-09
show O 0 7.231217846737081e-10
that O 0 1.851097192195894e-10
BRCA1 O 0 7.679265223714538e-09
and O 0 2.686754374536804e-09
BRCA2 O 0 3.9491354186793615e-08
coexist O 0 6.9262404700509705e-09
in O 0 2.868424664459468e-10
a O 0 1.1624247120423092e-09
biochemical O 0 1.0557191387761122e-07
complex O 0 2.0541373046967237e-08
and O 0 2.8529412166022894e-09
colocalize O 0 8.555214208172401e-07
in O 0 1.8177893634785391e-09
subnuclear O 0 2.015959353229846e-06
foci O 0 2.6206311076748534e-07
in O 0 8.387239791574075e-10
somatic O 0 8.154978559105075e-08
cells O 0 3.796142955536652e-09
and O 0 6.123258566859135e-10
on O 0 8.575008481059854e-10
the O 0 2.9790397926277024e-10
axial O 0 9.71705915731036e-09
elements O 0 2.5665318759138245e-09
of O 0 7.776309374207813e-09
developing O 0 7.251500733218563e-08
synaptonemal O 0 3.950789050577441e-06
complexes O 0 1.1348826092216768e-06
. O 0 1.854619199548324e-06

Like O 0 1.6736055385990767e-06
BRCA1 O 0 1.601752774149645e-05
and O 0 1.446520400349982e-06
RAD51 O 0 0.004485532641410828
, O 0 8.546774097339949e-07
BRCA2 O 0 9.71566350926878e-06
relocates O 0 1.7922848201123998e-06
to O 0 3.100492662611032e-08
PCNA O 0 5.75173771721893e-06
+ O 0 1.0988883580864695e-08
replication O 0 9.49829770391375e-10
sites O 0 9.793863497975508e-10
following O 0 5.712121886602972e-10
exposure O 0 2.9835518944310024e-08
of O 0 4.8746716885261776e-08
S O 0 8.062105507633532e-07
phase O 0 8.692859410075471e-08
cells O 0 2.64515165326884e-08
to O 0 4.792767072103743e-08
hydroxyurea O 0 5.389697889768286e-06
or O 0 3.0816445928394387e-07
UV O 0 0.0001153339835582301
irradiation O 0 3.7888351016590605e-06
. O 0 4.306324399294681e-07

Thus O 0 7.291707788681379e-07
, O 0 1.0690401097690483e-07
BRCA1 O 0 1.3305965751442272e-07
and O 0 2.2956724521350225e-08
BRCA2 O 0 3.191891551068693e-08
participate O 0 1.2558336592860542e-09
, O 0 3.383545665869292e-10
together O 0 9.759937996678403e-11
, O 0 5.106402800603149e-11
in O 0 7.595714335284498e-11
a O 0 2.1797377236509874e-09
pathway O 0 1.2652427017201262e-07
( O 0 1.5823741206233422e-09
s O 0 8.111337379546057e-09
) O 0 4.294743380373056e-11
associated O 0 1.0106373515839095e-09
with O 0 3.7438774302955835e-11
the O 0 6.799115159772384e-10
activation O 0 1.1485451700821159e-08
of O 0 7.576694827093888e-09
double O 0 4.393794661439188e-09
- O 0 2.952101674225105e-08
strand O 0 1.4669621073437611e-08
break O 0 2.3675061910921613e-08
repair O 0 1.7882983627259819e-07
and O 0 3.6368515310414296e-08
/ O 0 1.7786310024803242e-07
or O 0 9.431866843101488e-09
homologous O 0 9.427209235468581e-09
recombination O 0 1.5778303108504588e-08
. O 0 1.1573506952800017e-07

Dysfunction O 0 0.0002795366744976491
of O 0 1.4974360738051473e-06
this O 0 4.363595262901754e-09
pathway O 0 1.120038888302588e-07
may O 0 1.0091195656869445e-09
be O 0 1.2709441832292612e-10
a O 0 4.265942876724438e-10
general O 0 2.539065846463018e-09
phenomenon O 0 9.094947017729282e-09
in O 0 6.434446725434029e-11
the O 0 4.676748432963507e-10
majority O 0 3.113127464149379e-11
of O 0 1.482509948136368e-10
cases O 0 5.309881978554643e-10
of O 0 1.7826684128863235e-08
hereditary B-Disease 1 0.999981164932251
breast I-Disease 1 0.9999961853027344
and I-Disease 1 0.999929666519165
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.033993056789086e-09
. O 0 7.180533945216894e-09

A O 0 3.15917804982746e-06
novel O 0 4.7061664076863963e-07
Arg362Ser O 0 1.5955758954078192e-06
mutation O 0 5.503049127497661e-09
in O 0 5.919659762376739e-10
the O 0 3.9569902909875054e-09
sterol O 0 5.66301253002166e-07
27 O 0 6.356702328957908e-07
- O 0 1.1412999612048225e-07
hydroxylase O 0 4.494451388836751e-07
gene O 0 6.07708372513116e-08
( O 0 3.089347444529267e-08
CYP27 O 0 0.028997186571359634
) O 0 4.061463110272001e-10
: O 0 3.486703634147936e-11
its O 0 8.184074251627038e-11
effects O 0 3.893785738284805e-09
on O 0 3.695855399499237e-09
pre O 0 1.2034767848945194e-08
- O 0 4.366325967453122e-09
mRNA O 0 1.4386351665507391e-08
splicing O 0 3.3781450525793844e-08
and O 0 7.0136620955452145e-09
enzyme O 0 7.038470073439385e-08
activity O 0 2.3075567412433884e-07
. O 0 3.372412891167187e-07

A O 0 1.3769609950031736e-06
novel O 0 1.452559814651977e-07
C O 0 1.360356662871709e-07
to O 0 4.564170430487735e-10
A O 0 8.00656962951507e-09
mutation O 0 5.660971691412442e-10
in O 0 2.1010235218277273e-10
the O 0 4.902642292137216e-09
sterol O 0 7.048114980534592e-07
27 O 0 6.321398018371838e-07
- O 0 1.0862748212048245e-07
hydroxylase O 0 3.489034838821681e-07
gene O 0 3.230490364103389e-08
( O 0 2.3136511373422763e-08
CYP27 O 0 4.363014522823505e-05
) O 0 3.692492700491101e-10
was O 0 1.4315696406086431e-09
identified O 0 1.6813911374313761e-10
by O 0 3.8549267944443244e-11
sequencing O 0 9.386820210011138e-09
amplified O 0 1.153863706804259e-07
CYP27 O 0 1.5902862742223078e-06
gene O 0 3.2076115097368074e-09
products O 0 1.857755727030508e-08
from O 0 2.1712314168809144e-09
a O 0 6.339551661405096e-10
patient O 0 2.4456925373783633e-09
with O 0 1.7175428856930353e-09
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 9.152708457804692e-08
CTX B-Disease 0 9.638562914915383e-05
) O 0 2.99985494223165e-08
. O 0 2.180404692353477e-07

The O 0 1.8077051322507032e-07
mutation O 0 2.905267706410086e-07
changed O 0 1.3495721873368893e-07
the O 0 1.5897018812438546e-08
adrenodoxin O 0 5.519492560779327e-07
cofactor O 0 5.958668225503061e-08
binding O 0 1.242380989197045e-07
residue O 0 2.2678532332065515e-06
362Arg O 0 6.514470101137704e-07
to O 0 1.428520945978562e-08
362Ser O 0 3.7570855511148693e-06
( O 0 1.2279863881303754e-07
CGT O 0 0.0001285403996007517
362Arg O 0 1.1686609013850102e-06
to O 0 3.6841317552216424e-08
AGT O 0 1.820934994611889e-05
362Ser O 0 1.6040726791288762e-07
) O 0 1.801744309304354e-10
, O 0 1.43083461745519e-10
and O 0 8.490699809904356e-11
was O 0 1.789579817668141e-09
responsible O 0 6.737062019368523e-10
for O 0 1.2902897639222033e-09
deficiency O 0 6.047882925486192e-05
in O 0 2.9121212108407235e-08
the O 0 7.946937330416404e-07
sterol O 0 2.6314853585063247e-06
27 O 0 4.3918115011365444e-07
- O 0 2.0237841624748398e-08
hydroxylase O 0 6.227383408941023e-08
activity O 0 6.062413238083764e-09
, O 0 4.8820152781514636e-11
as O 0 2.0654884053117328e-11
confirmed O 0 1.769275351226618e-11
by O 0 1.1936859486971763e-11
expression O 0 6.357982473836898e-10
of O 0 1.6272568847952584e-09
mutant O 0 2.3713415675530314e-09
cDNA O 0 1.995264398146901e-08
into O 0 7.866896822861236e-08
COS O 0 4.504652679315768e-05
- O 0 3.753647490611911e-07
1 O 0 2.5468185071986227e-07
cells O 0 1.732868497583695e-07
. O 0 2.710960700369469e-07

Quantitative O 0 9.820453072961755e-08
analysis O 0 1.6239710021181963e-08
showed O 0 3.86596088475244e-09
that O 0 2.384183128700812e-11
the O 0 2.6784843787375223e-10
expression O 0 3.1611964157463035e-09
of O 0 1.2439193675106708e-08
CYP27 O 0 1.5593354873999488e-06
gene O 0 2.0560686486703617e-09
mRNA O 0 1.0518155235672566e-08
in O 0 3.463255793256792e-10
the O 0 7.270855584273761e-10
patient O 0 4.735743353023736e-09
represented O 0 1.016227990646712e-08
52 O 0 5.985185111967439e-07
. O 0 2.8087291070733045e-07

5 O 0 4.165367499808781e-07
% O 0 3.834785378131755e-09
of O 0 1.9099239967346193e-09
the O 0 4.573043721478598e-09
normal O 0 2.714320999075426e-07
level O 0 9.130057492257038e-07
. O 0 2.1980423525747028e-07

As O 0 1.3744136495574821e-08
the O 0 2.0902524155985702e-09
mutation O 0 3.4091940381841823e-09
occurred O 0 2.676485344466073e-08
at O 0 4.0484929297868177e-10
the O 0 2.77722067565378e-10
penultimate O 0 8.926319239321856e-09
nucleotide O 0 4.852128032695191e-09
of O 0 7.406772972728959e-09
exon O 0 1.0340993839008661e-08
6 O 0 9.936402989296766e-08
( O 0 1.0196329336409349e-09
- O 0 3.0829652164499066e-09
2 O 0 8.767587544866728e-09
position O 0 2.0672768386020834e-08
of O 0 7.680466040937972e-09
exon O 0 2.4460296899064815e-08
6 O 0 7.552226293228159e-07
- O 0 3.262622385591385e-07
intron O 0 7.966203270370897e-07
6 O 0 3.317371692901361e-07
splice O 0 2.619786414470582e-07
site O 0 3.876536425195809e-08
) O 0 3.3965552592718495e-10
of O 0 3.938557480154259e-09
the O 0 6.1739475754052364e-09
gene O 0 9.991475202753008e-09
, O 0 9.086849495076876e-09
we O 0 1.445406017097639e-09
hypothesized O 0 7.979005900438096e-09
that O 0 6.449645678641147e-11
the O 0 5.070059927447801e-10
mutation O 0 4.2573287117875225e-09
may O 0 3.932207004453403e-09
partially O 0 2.6686045373480738e-08
affect O 0 9.213062313051523e-09
the O 0 6.787884920811393e-09
normal O 0 8.379696936344772e-09
splicing O 0 1.288168238744447e-08
efficiency O 0 1.7274427221991573e-08
in O 0 1.998066156971845e-09
exon O 0 1.7599516510813373e-08
6 O 0 2.6606914005355975e-08
and O 0 6.318908729596728e-10
cause O 0 2.8187354672581932e-09
alternative O 0 1.0591914012536563e-09
splicing O 0 4.921830942805627e-09
elsewhere O 0 6.798263285645589e-09
, O 0 7.57423013197922e-11
which O 0 1.1267433167039265e-11
resulted O 0 6.282411812996713e-10
in O 0 1.694306916988353e-10
decreased O 0 1.69975304942227e-08
transcript O 0 3.085360944510285e-08
in O 0 1.0360335922499075e-09
the O 0 8.128250073013987e-09
patient O 0 6.959162845987521e-08
. O 0 1.8940360746455553e-07

Transfection O 0 2.1464058590936475e-05
of O 0 1.9212202460039407e-06
constructed O 0 5.144409556123719e-07
minigenes O 0 8.765367056184914e-06
, O 0 1.4942292958508574e-09
with O 0 1.878927569087807e-11
or O 0 6.700944660265051e-11
without O 0 1.4314788243652288e-10
the O 0 4.5743236976036883e-10
mutation O 0 3.9276026875256775e-10
, O 0 7.331037166213861e-11
into O 0 1.0700509367467248e-09
COS O 0 7.136487511161249e-06
- O 0 4.4386844422206195e-08
1 O 0 1.7593844603425168e-08
cells O 0 1.687290307472722e-09
confirmed O 0 1.4818406501859727e-09
that O 0 1.761053629312226e-11
the O 0 1.4365306166830294e-10
mutant O 0 2.6052937585063773e-09
minigene O 0 7.391012957214116e-08
was O 0 4.622195071135593e-09
responsible O 0 1.2712642050161094e-10
for O 0 1.1319869347437006e-10
a O 0 1.1078487016646932e-09
mRNA O 0 2.0102845610381337e-08
species O 0 4.803378250706203e-10
alternatively O 0 4.4930281717370235e-08
spliced O 0 1.4201963267623796e-06
at O 0 5.700699290400735e-08
an O 0 8.216396452098707e-09
activated O 0 6.944353003746073e-08
cryptic O 0 3.417640641600883e-07
5 O 0 1.9450332899850764e-08
splice O 0 1.7606642188638943e-07
site O 0 1.0654127180487194e-07
88 O 0 1.5440051015502831e-07
bp O 0 3.240073453980585e-08
upstream O 0 2.2203320071412236e-08
from O 0 4.24581347857611e-09
the O 0 5.59522428389414e-09
3 O 0 1.560158935376421e-08
end O 0 1.0469317857086935e-08
of O 0 2.014084010681927e-08
exon O 0 9.580474369386138e-08
6 O 0 1.12639679628046e-06
. O 0 6.525638127641287e-07

Our O 0 1.4298080941443914e-07
data O 0 3.9724184830447484e-08
suggest O 0 9.942655587735771e-09
that O 0 1.4210786714041745e-10
the O 0 1.0884452228410169e-09
C O 0 5.16004172723683e-09
to O 0 3.9384780159412713e-11
A O 0 4.033757328159027e-09
mutation O 0 1.182528741594524e-09
at O 0 4.1808795314679514e-10
the O 0 5.719545947968641e-10
penultimate O 0 1.5010400034043414e-08
nucleotide O 0 7.1581074401194655e-09
of O 0 5.561294535993966e-09
exon O 0 8.359965164572714e-09
6 O 0 5.913503997589942e-08
of O 0 1.0481946866036651e-08
the O 0 3.861960706785794e-08
CYP27 O 0 7.698692570556886e-06
gene O 0 1.6564045690614648e-09
not O 0 5.283272708211939e-10
only O 0 8.647506599679389e-10
causes O 0 3.0710587850535376e-08
the O 0 2.831031187255917e-09
deficiency B-Disease 0 8.601652012885097e-08
in I-Disease 0 1.1769394347993511e-09
the I-Disease 0 2.3950068595013363e-08
sterol I-Disease 0 5.427922928902262e-07
27 I-Disease 0 2.3844376073611784e-07
- I-Disease 0 4.3522845771803986e-08
hydroxylase I-Disease 0 9.036608616952435e-08
activity I-Disease 0 2.4959483369002555e-08
, O 0 3.838244999609941e-10
but O 0 1.2292250550771655e-09
also O 0 2.382621655527828e-09
partially O 0 1.506161950715068e-08
leads O 0 2.1698984831175494e-09
to O 0 2.1685897522161213e-10
alternative O 0 1.359661094824105e-08
pre O 0 2.27876775227287e-08
- O 0 2.4795578923431094e-09
mRNA O 0 7.398767376542992e-09
splicing O 0 2.640096319339591e-08
of O 0 1.3174869195609062e-08
the O 0 1.5802063657588405e-08
gene O 0 1.1789084908286895e-07
. O 0 1.0957425047308789e-06

To O 0 2.5848478912848805e-08
our O 0 2.8347987068855218e-08
knowledge O 0 6.14301001178319e-08
, O 0 3.2609945299633125e-10
this O 0 6.457129969605901e-11
is O 0 3.476828547288591e-11
the O 0 1.0040677317357805e-10
first O 0 3.604666010126323e-10
report O 0 7.736788987244836e-10
regarding O 0 5.8720388551591896e-09
effects O 0 7.051329475871171e-08
on O 0 2.9462123407597574e-08
pre O 0 1.4739569564881094e-08
- O 0 1.200527899314352e-09
mRNA O 0 3.5550695720587555e-09
splicing O 0 1.5937722253056563e-09
of O 0 1.176876485153855e-09
a O 0 2.905488072357798e-10
mutation O 0 5.312728590389781e-10
at O 0 1.4992708186056802e-09
the O 0 1.389606540946886e-09
- O 0 2.0010411105886305e-09
2 O 0 4.510103845944968e-09
position O 0 1.5518045515250378e-08
of O 0 1.2479902444795243e-08
a O 0 3.2161651120077295e-08
5 O 0 2.3944502913764154e-07
splice O 0 3.2461900900671026e-06
site O 0 1.38864629661839e-06
. O 0 1.1542505262696068e-06

ATM O 0 0.00021682234364561737
germline O 0 3.0764451366849244e-05
mutations O 0 7.078940029714431e-07
in O 0 2.3511393720809792e-08
classical O 0 0.19103319942951202
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 2.948331257357495e-06
in O 0 1.3742182392029179e-10
the O 0 3.1961222557441715e-10
Dutch O 0 6.644367278596519e-09
population O 0 6.324093471121728e-10
. O 0 6.080142611608608e-09

Germline O 0 3.2312378607457504e-05
mutations O 0 6.630266398133244e-07
in O 0 7.887191344480016e-09
the O 0 4.885336135629359e-09
ATM O 0 1.702635188394197e-07
gene O 0 1.1941858613084833e-09
are O 0 1.4020916372370351e-11
responsible O 0 2.315042428591152e-11
for O 0 5.242044992526118e-11
the O 0 1.9550036256532621e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.999998927116394
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.53594700186477e-08
. O 0 8.605016432738921e-08

In O 0 5.078059217566988e-08
our O 0 8.374843218916794e-08
study O 0 6.970239496695285e-09
, O 0 3.75352499082382e-10
we O 0 1.7145536379548076e-10
have O 0 2.1537573807739463e-11
determined O 0 6.911865524372729e-10
the O 0 6.621578285681551e-10
ATM O 0 1.4942648363103217e-07
mutation O 0 3.735072695576491e-09
spectrum O 0 5.566537009116246e-09
in O 0 3.3714281366670207e-10
19 O 0 2.383145591977609e-08
classical O 0 7.304135124286404e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.5632767847459945e-09
, O 0 1.940739062511465e-11
including O 0 1.5546395551110925e-12
some O 0 9.42239515577814e-12
immigrant O 0 8.035510035142579e-10
populations O 0 1.0442544051691982e-10
, O 0 4.093932137738676e-11
as O 0 1.0014913204292597e-10
well O 0 2.055083603291763e-10
as O 0 2.776849861163555e-10
12 O 0 1.2473065913454207e-09
of O 0 7.451830263960346e-10
Dutch O 0 3.0801572847849457e-08
ethnic O 0 8.576681587157964e-09
origin O 0 1.607302237971453e-07
. O 0 4.128146429138724e-07

Both O 0 3.7712684530788465e-08
the O 0 2.900114992598901e-08
protein O 0 1.6672495917191554e-07
truncation O 0 4.877954893345304e-07
test O 0 1.1566176461030864e-08
( O 0 4.687139210091118e-08
PTT O 0 3.116322204732569e-06
) O 0 5.345162645831181e-10
and O 0 2.556427292077501e-10
the O 0 3.6564620775614287e-10
restriction O 0 2.9729847472736992e-09
endonuclease O 0 3.4026538031639575e-08
fingerprinting O 0 1.4127563119359365e-08
( O 0 1.714915143224971e-08
REF O 0 4.977927687832562e-07
) O 0 1.018380796358187e-10
method O 0 6.165895016785328e-10
were O 0 1.5301182543225877e-10
used O 0 1.0259589705574612e-10
and O 0 1.0222028085093982e-10
compared O 0 3.0616043034115137e-10
for O 0 2.3568830914699745e-11
their O 0 1.128290100238516e-10
detection O 0 3.426488648372583e-09
efficiency O 0 4.34595293086204e-09
, O 0 9.915545468031084e-11
identifying O 0 2.386628672468305e-09
76 O 0 1.474660038525144e-08
% O 0 2.5368379619195025e-10
and O 0 3.6129446656651965e-11
60 O 0 2.8040628152758984e-10
% O 0 1.0942189515583678e-10
of O 0 9.86952533588159e-11
the O 0 4.26887303284218e-10
mutations O 0 8.634919446137701e-09
, O 0 5.491997967510542e-09
respectively O 0 6.172253819158868e-08
. O 0 4.216665843159717e-07

Most O 0 4.7481098164325886e-08
patients O 0 1.1195536053776323e-08
were O 0 8.517630489812689e-10
found O 0 1.3791312536426403e-10
to O 0 7.562725445886542e-11
be O 0 7.116854883193469e-10
compound O 0 1.4182673169216287e-07
heterozygote O 0 3.35915683535859e-05
. O 0 5.423659104053513e-07

Seventeen O 0 3.993605787400156e-06
mutations O 0 1.671964326988018e-07
were O 0 5.569999572685447e-09
distinct O 0 3.806191806177139e-09
, O 0 9.950822110749158e-11
of O 0 1.384161951722973e-10
which O 0 1.0875684901268112e-11
10 O 0 2.6182844781175163e-10
were O 0 1.503680513437189e-10
not O 0 2.2804524935082782e-10
reported O 0 1.8962186487669896e-08
previously O 0 3.471195242354952e-08
. O 0 1.0510558468013187e-07

Mutations O 0 3.032684389836504e-06
are O 0 1.4225012279212024e-08
small O 0 2.5537397974062515e-08
deletions O 0 3.627222895374871e-07
or O 0 2.017922184904819e-07
point O 0 1.4081741710469942e-06
mutations O 0 3.311261878025107e-07
frequently O 0 6.693940690638556e-08
affecting O 0 2.1316797926829167e-07
splice O 0 4.262647053110413e-06
sites O 0 1.0290916634403402e-06
. O 0 1.849936325015733e-06

Moreover O 0 5.393369519879343e-06
, O 0 6.728091506147393e-08
a O 0 1.1634283225703257e-07
16 O 0 1.3289597973198397e-06
. O 0 5.419977355813899e-07

7 O 0 7.910191015980672e-06
- O 0 2.6654970497475006e-07
kb O 0 6.890408599247166e-07
genomic O 0 4.245006479663971e-08
deletion O 0 1.0717795539960662e-08
of O 0 1.6423555848632532e-08
the O 0 3.836190032302511e-09
3 O 0 5.053427898360496e-09
end O 0 2.198895954208524e-09
of O 0 4.052921998010106e-09
the O 0 2.753560490731388e-09
gene O 0 8.268176698855711e-10
, O 0 2.0020135549358997e-10
most O 0 6.900507942830814e-11
likely O 0 3.587764807466698e-10
a O 0 1.0449617560137625e-10
result O 0 4.6133052933328145e-10
of O 0 4.732950698027594e-10
recombination O 0 1.1229421559288966e-10
between O 0 1.6410584002812811e-09
two O 0 1.3960781419797286e-09
LINE O 0 4.5593156983159133e-07
elements O 0 3.670949988432426e-09
, O 0 1.2612176858439739e-09
was O 0 6.761201820637552e-09
identified O 0 3.0670488371242755e-08
. O 0 1.831181606348764e-07

The O 0 5.482005462909001e-07
most O 0 1.3892416106386918e-08
frequently O 0 1.7900578797025446e-09
found O 0 1.748323430472709e-10
mutation O 0 3.174203122568997e-10
, O 0 3.360217659675868e-11
identified O 0 1.6329833318895481e-10
in O 0 7.387464251440434e-11
three O 0 1.5439144407380923e-10
unrelated O 0 1.5327605851211956e-08
Turkish O 0 9.680920811661053e-07
A B-Disease 1 1.0
- I-Disease 0 5.061168849351816e-05
T I-Disease 1 0.9999996423721313
individuals O 0 8.141853857779324e-10
, O 0 9.045774684857122e-10
was O 0 3.0299278641621186e-09
previously O 0 3.836685691371855e-10
described O 0 7.399803686469753e-11
to O 0 3.922375618747864e-11
be O 0 1.9613859147948887e-10
a O 0 1.542490690731313e-09
Turkish O 0 1.1190943496330874e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
founder O 0 2.6840752980206162e-05
mutation O 0 1.0164683317270828e-06
. O 0 2.9698981052206364e-07

The O 0 1.325042688904432e-07
presence O 0 1.239346687498255e-07
of O 0 1.50285686117968e-07
a O 0 2.1475869971254724e-08
founder O 0 1.0064274391652361e-07
mutation O 0 3.767398393250687e-09
among O 0 2.3842341989599447e-10
relatively O 0 5.849254414158622e-10
small O 0 6.601902358127631e-11
ethnic O 0 9.698125635893007e-11
population O 0 1.1099563108907251e-11
groups O 0 1.7491889013621087e-12
in O 0 6.841255860423612e-12
Western O 0 9.3921881383352e-10
Europe O 0 3.412699012272924e-10
could O 0 1.0053751164917912e-09
indicate O 0 7.275576141552165e-09
a O 0 1.1423008094979537e-09
high O 0 1.2918508485171287e-09
carrier O 0 7.542427793438833e-11
frequency O 0 3.528007608277761e-10
in O 0 6.815731312670437e-11
such O 0 8.681401708621195e-10
communities O 0 4.5973145290645334e-08
. O 0 7.781956128383172e-07

In O 0 3.856048369499376e-09
patients O 0 3.289921668425677e-09
of O 0 5.217910103993972e-09
Dutch O 0 9.999237704505504e-08
ethnic O 0 1.7592796108800712e-09
origin O 0 5.994665208675087e-09
, O 0 2.0630402941534953e-10
however O 0 1.0158225371981189e-09
, O 0 2.891760442214064e-10
no O 0 1.3082310790224483e-09
significant O 0 2.1372446923351163e-08
founder O 0 1.7040873956375435e-07
effect O 0 9.237805898010265e-08
could O 0 1.404918048564241e-08
be O 0 5.88835735726434e-09
identified O 0 2.227662605491787e-07
. O 0 3.5067614589934237e-07

The O 0 7.632264242829478e-08
observed O 0 3.064458198309694e-08
genetic O 0 3.040547014165895e-08
heterogeneity O 0 2.2925750897684338e-07
including O 0 3.738477860615319e-10
the O 0 2.060744686005478e-09
relative O 0 6.796787488383416e-07
high O 0 8.949797347668209e-08
percentage O 0 4.6584670343463586e-08
of O 0 9.61167678781294e-09
splice O 0 2.558128073815169e-07
- O 0 4.745628956470682e-08
site O 0 3.903260648030482e-08
mutations O 0 1.3201431059428614e-08
had O 0 3.797555159223975e-09
no O 0 1.5228751593099332e-09
reflection O 0 8.191672229429514e-09
on O 0 2.830124135044798e-09
the O 0 8.401622508813489e-09
phenotype O 0 1.1624506441876292e-06
. O 0 3.218405595362128e-07

All O 0 2.7935973534454206e-08
patients O 0 1.107760461138696e-08
manifested O 0 5.9012901232335935e-08
classical O 0 4.1038993003894575e-07
A B-Disease 1 1.0
- I-Disease 0 0.00039781321538612247
T I-Disease 1 1.0
and O 0 3.83776388446222e-09
increased O 0 7.209242980366071e-09
cellular O 0 1.687168982300591e-08
radioresistant O 0 1.3346736693620187e-07
DNA O 0 4.821676924393614e-08
synthesis O 0 7.936009183140413e-07
. O 0 3.1843941883380467e-07

Determination O 0 1.8060785578200012e-07
of O 0 1.1446310566043394e-07
the O 0 6.716651679283814e-09
genomic O 0 7.599333429197941e-08
structure O 0 2.317665881435005e-08
of O 0 8.758060054958605e-09
the O 0 1.2054479192613599e-08
COL4A4 O 0 3.094808926107362e-05
gene O 0 2.258636389029789e-09
and O 0 3.8967554183422237e-10
of O 0 4.674564069162557e-10
novel O 0 4.656394825275356e-09
mutations O 0 6.769416813767748e-07
causing O 0 3.4574425171740586e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.102538009145064e-06

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.555511808248866e-08
a O 0 3.530870262835606e-09
progressive O 0 0.14481590688228607
hematuric B-Disease 1 0.9999994039535522
glomerulonephritis I-Disease 1 1.0
characterized O 0 3.234257519579842e-07
by O 0 7.462900519783489e-09
glomerular B-Disease 1 0.9995658993721008
basement I-Disease 0 0.00020929037418682128
membrane I-Disease 0 5.620732395072991e-07
abnormalities I-Disease 0 1.8277968649726972e-07
and O 0 2.2958934753347648e-10
associated O 0 2.4065358594782538e-09
with O 0 1.0281667184308674e-10
mutations O 0 3.3526283971241355e-09
in O 0 3.247153657071067e-10
either O 0 2.6362505511912104e-09
the O 0 1.8656743705491863e-08
COL4A3 O 0 6.356855010380968e-05
or O 0 2.3805140081378795e-09
the O 0 1.3470899062895114e-08
COL4A4 O 0 2.1325124635040993e-06
gene O 0 4.694025612650421e-09
, O 0 7.696887016628295e-10
which O 0 1.3626738626371093e-10
encode O 0 3.889109478905084e-09
the O 0 3.1274691281169e-08
alpha3 O 0 1.93903088074876e-06
and O 0 3.7441473921262514e-08
alpha4 O 0 1.1273500604147557e-06
type O 0 1.5730290670035174e-07
IV O 0 6.604842928936705e-05
collagen O 0 2.0428824427654035e-06
chains O 0 1.3171372756914934e-06
, O 0 5.38770699165525e-08
respectively O 0 1.0815178086431843e-07
. O 0 2.689401981115225e-07

To O 0 2.282369493400438e-08
date O 0 2.7349105380380934e-07
, O 0 1.2162998386244794e-09
mutation O 0 9.60111296022248e-11
screening O 0 6.816772146756023e-11
in O 0 8.124831363254259e-11
the O 0 2.3612138910777958e-09
two O 0 7.738221174946602e-10
genes O 0 6.2240084197640044e-09
has O 0 3.178153018534857e-10
been O 0 1.0750788453917082e-10
hampered O 0 3.975114903909116e-09
by O 0 5.545929687711393e-11
the O 0 1.6177378325821223e-09
lack O 0 6.361675985999682e-08
of O 0 8.04006816679248e-09
genomic O 0 5.971501337853624e-08
structure O 0 3.653788738233743e-08
information O 0 1.7460699552884762e-07
. O 0 4.3892492840313935e-07

We O 0 4.725072244582407e-08
report O 0 9.916727883307885e-09
here O 0 3.3268218735393873e-10
the O 0 2.0550758317305906e-10
complete O 0 4.1865610977964707e-10
characterization O 0 4.5406959969795935e-08
of O 0 2.568432133642773e-09
the O 0 2.75297762364346e-09
48 O 0 5.3564964019869876e-08
exons O 0 5.8874729091940026e-08
of O 0 1.8932155398942996e-08
the O 0 4.620275362299253e-08
COL4A4 O 0 4.908886330667883e-05
gene O 0 4.758016203254556e-09
, O 0 1.0900865765606227e-09
a O 0 3.062234910089501e-10
comprehensive O 0 1.0322740440216194e-09
gene O 0 5.890679610764948e-10
screen O 0 1.0696658669928638e-08
, O 0 3.532599768263367e-10
and O 0 3.3723142334185496e-11
the O 0 4.6599533259916726e-11
subsequent O 0 7.683095826216402e-11
detection O 0 1.8434033188796661e-09
of O 0 1.300637819667827e-09
10 O 0 1.701146890020766e-09
novel O 0 1.0714275022749575e-09
mutations O 0 7.943454227721247e-10
in O 0 2.1793872262421132e-10
eight O 0 3.2459852583599513e-09
patients O 0 1.0148837326084958e-08
diagnosed O 0 2.2009369615716423e-07
with O 0 5.876587660935684e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.3302760635269806e-06

Furthermore O 0 1.920482191053452e-06
, O 0 3.7137493080763306e-08
we O 0 6.672955965569827e-09
identified O 0 1.6802195190734892e-08
a O 0 2.3088404521587336e-09
glycine O 0 4.529241426354247e-09
to O 0 1.2391045967063974e-09
alanine O 0 3.1745333473054416e-08
substitution O 0 1.3439999335673747e-08
in O 0 1.576815455983649e-09
the O 0 6.009753583668953e-09
collagenous O 0 6.896536319800362e-07
domain O 0 1.1401702693092375e-08
that O 0 2.1333812494361837e-10
is O 0 2.490201655991342e-10
apparently O 0 6.8669683273014925e-09
silent O 0 3.823136918157388e-09
in O 0 9.310956172736695e-11
the O 0 1.5371043327050415e-09
heterozygous O 0 4.900031491672507e-10
carriers O 0 4.059356739638531e-10
, O 0 7.336538598856635e-10
in O 0 1.987560338534422e-09
11 O 0 1.9711582410764095e-07
. O 0 6.933472604941926e-07

5 O 0 2.490969848167879e-07
% O 0 2.6721380663730088e-09
of O 0 1.0810590200804882e-09
all O 0 6.235789662412117e-11
control O 0 1.0160448177254366e-10
individuals O 0 3.6624977356458643e-11
, O 0 2.7368078289735642e-11
and O 0 1.865831794622963e-11
in O 0 2.6302108060982654e-11
one O 0 9.936900607909749e-11
control O 0 2.379178520861558e-10
individual O 0 2.0960402857816973e-10
homozygous O 0 1.39612599259209e-09
for O 0 4.893110916448506e-10
this O 0 1.0783695048033337e-09
glycine O 0 5.3747744033216804e-08
substitution O 0 5.393824267230229e-07
. O 0 1.0475130238774e-06

There O 0 7.821980574362897e-08
has O 0 3.9273126972716454e-09
been O 0 3.570847506573216e-10
no O 0 2.3553381467422696e-10
previous O 0 5.342410958064647e-10
finding O 0 2.75502087809798e-09
of O 0 1.224145451672598e-09
a O 0 5.576055728262475e-10
glycine O 0 6.590883949719739e-10
substitution O 0 2.8727462630939726e-09
that O 0 1.1276102968027502e-10
is O 0 2.1685389595127447e-11
not O 0 8.900294563851663e-12
associated O 0 4.950355125821204e-10
with O 0 1.8351500874480564e-11
any O 0 1.3849178470692891e-09
obvious O 0 1.0569058161991052e-07
phenotype O 0 1.5540823739002008e-08
in O 0 4.320346580488632e-10
homozygous O 0 5.299928051982761e-09
individuals O 0 1.2175283004012272e-08
. O 0 5.977929049549857e-07

Founder O 0 0.0001888635306386277
BRCA1 O 0 3.92652418668149e-06
and O 0 8.812826024495735e-08
BRCA2 O 0 1.1007746536506602e-07
mutations O 0 4.6891219795952566e-09
in O 0 3.658959801811079e-10
French O 0 3.6243594081497577e-07
Canadian O 0 2.5646266294643283e-05
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.858616702880681e-08
. O 0 3.015389182792205e-08

We O 0 4.004781573030414e-08
have O 0 1.3182402947009564e-09
identified O 0 4.561596878005503e-09
four O 0 2.1175303177578542e-10
mutations O 0 7.233108001436506e-10
in O 0 7.882761110522551e-11
each O 0 3.315274443860261e-10
of O 0 1.508202984723539e-08
the O 0 2.4124256015056744e-06
breast B-Disease 0 0.000422835408244282
cancer I-Disease 0 0.0028449837118387222
- O 0 3.0821530572211486e-07
susceptibility O 0 5.386797283790656e-07
genes O 0 4.804170572469957e-08
, O 0 2.6048960766189566e-09
BRCA1 O 0 7.633920162675167e-09
and O 0 1.9468957557222666e-09
BRCA2 O 0 5.2124686789056796e-09
, O 0 5.3194487009688984e-11
in O 0 1.3319431668712411e-10
French O 0 1.956616983989079e-07
Canadian O 0 7.557046615147556e-07
breast B-Disease 0 2.7788992156274617e-05
cancer I-Disease 0 0.04291044920682907
and O 0 0.010991254821419716
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.2926819604206514e-10
from O 0 5.276816761323744e-10
Quebec O 0 3.6214292009617566e-08
. O 0 4.4768182050347605e-08

To O 0 3.883618759914498e-08
identify O 0 3.455978401234461e-07
founder O 0 3.6111941881245002e-06
effects O 0 3.605047459132038e-05
, O 0 7.65858221285498e-09
we O 0 6.279572417611234e-10
examined O 0 1.7748675862350183e-09
independently O 0 2.888223216146457e-09
ascertained O 0 3.2114181180986634e-07
French O 0 5.186587159755618e-08
Canadian O 0 1.258668635983895e-08
cancer B-Disease 0 3.3691607281838287e-09
families O 0 3.247430796493589e-11
for O 0 3.099711676571304e-12
the O 0 2.117537395429636e-11
distribution O 0 6.12200901084492e-10
of O 0 3.480745136563712e-10
these O 0 1.253141812540548e-09
eight O 0 3.731955544594712e-08
mutations O 0 9.454291785004898e-07
. O 0 6.763144710930646e-07

Mutations O 0 5.41029407941096e-07
were O 0 1.6860527196627118e-08
found O 0 9.670959588703454e-10
in O 0 2.5803775782762273e-10
41 O 0 1.889370082608366e-08
of O 0 2.7366122701266704e-09
97 O 0 5.633156163753483e-08
families O 0 4.450279256218437e-09
. O 0 7.474741892110615e-08

Six O 0 2.911805552230362e-07
of O 0 6.671634622534839e-08
eight O 0 2.050152581034581e-08
mutations O 0 9.249583143855489e-08
were O 0 9.416893043123764e-09
observed O 0 9.764510089382838e-09
at O 0 2.1111112857852277e-09
least O 0 3.3737843629921827e-09
twice O 0 3.1390033683464935e-08
. O 0 8.300370524239042e-08

The O 0 2.0997931642341428e-06
BRCA1 O 0 1.8566861399449408e-06
C4446T O 0 1.4389364650924108e-06
mutation O 0 4.183156931958365e-08
was O 0 1.8506154830788546e-08
the O 0 4.159102784395685e-10
most O 0 9.937981687579978e-11
common O 0 1.0975299141735562e-10
mutation O 0 4.17093914961697e-10
found O 0 1.4554668581467922e-10
, O 0 5.676819778144271e-11
followed O 0 1.4500525780114515e-10
by O 0 1.9583394628153172e-10
the O 0 4.019489807660648e-08
BRCA2 O 0 2.4973019208118785e-06
8765delAG O 0 5.219943659540149e-07
mutation O 0 1.886108691451227e-07
. O 0 3.4541000104582054e-07

Together O 0 4.531334596435954e-08
, O 0 3.651028146478552e-09
these O 0 6.735764168652736e-10
mutations O 0 1.1154441814653637e-08
were O 0 9.204819129138286e-10
found O 0 1.8006586499641486e-10
in O 0 8.306868387597532e-11
28 O 0 7.413839764325303e-09
of O 0 1.3448814284444666e-09
41 O 0 1.2092983503464438e-08
families O 0 4.0823397440270526e-10
identified O 0 8.39966318721963e-10
to O 0 3.578470297860292e-10
have O 0 6.458980572610074e-10
a O 0 4.267328712614926e-09
mutation O 0 1.266691498358341e-07
. O 0 1.3953047073300695e-07

The O 0 1.9147475427416794e-07
odds O 0 4.2402157873766555e-07
of O 0 1.0473747424910584e-09
detection O 0 5.640345523971746e-09
of O 0 5.151218340770924e-10
any O 0 1.2324200548974318e-09
of O 0 1.4033164852378377e-08
the O 0 1.4101341427874559e-08
four O 0 6.89037404910664e-09
BRCA1 O 0 5.0608289114961735e-08
mutations O 0 3.502653100895259e-08
was O 0 1.0929502280987435e-07
18 O 0 1.7327991486126848e-07
. O 0 3.3084148753914633e-07

7x O 0 0.0006940726307220757
greater O 0 1.4596240589526133e-06
if O 0 9.337858841718116e-08
one O 0 4.551081289605463e-09
or O 0 1.3347711824707176e-10
more O 0 1.6563618532305924e-11
cases O 0 6.198710988947198e-10
of O 0 7.911904020829752e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.2666250270854107e-09
also O 0 2.293222556293273e-11
present O 0 2.020737743801959e-11
in O 0 3.1483166768042636e-11
the O 0 1.8376073995796105e-09
family O 0 4.567188227611041e-08
. O 0 2.2228687157621607e-07

The O 0 2.0895883778848656e-07
odds O 0 5.347941964828351e-07
of O 0 1.638912672241588e-09
detection O 0 3.824653926898236e-09
of O 0 7.990408890101719e-10
any O 0 3.3494709228421016e-09
of O 0 1.8035134274896336e-08
the O 0 6.49636078264848e-08
four O 0 3.6744754794426626e-08
BRCA2 O 0 3.0262248174039996e-07
mutations O 0 4.320746427310951e-08
was O 0 1.1345888850655683e-07
5 O 0 1.9745336032883642e-07
. O 0 2.640456955305126e-07

3x O 0 6.091479008318856e-06
greater O 0 3.578269058834849e-08
if O 0 8.06334998770808e-09
there O 0 4.232052930319696e-09
were O 0 1.1612146799677703e-09
at O 0 7.091813802873048e-10
least O 0 1.8776638577300275e-10
five O 0 4.8045938755292283e-11
cases O 0 5.229285338081979e-10
of O 0 5.411463721571863e-09
breast B-Disease 0 2.470726769843168e-07
cancer I-Disease 0 4.091558309937682e-07
in O 0 1.7215473491205557e-09
the O 0 3.547133076153841e-08
family O 0 1.3615638749797654e-07
. O 0 1.9170717280303506e-07

Interestingly O 0 2.9779007491015363e-06
, O 0 7.085219078106775e-09
the O 0 2.4176325386093822e-09
presence O 0 1.6474571040703267e-08
of O 0 1.2358437118109578e-07
a O 0 6.208928482465126e-08
breast B-Disease 0 1.5556756238765956e-07
cancer I-Disease 0 2.7839694993758712e-08
case O 0 1.3964189804482885e-09
< O 0 1.5920678109182518e-09
36 O 0 2.135344567832931e-09
years O 0 1.6625727183861017e-10
of O 0 5.099815569842292e-10
age O 0 2.3239550284159805e-09
was O 0 8.537017204268693e-10
strongly O 0 2.565438139701115e-11
predictive O 0 5.240268219353084e-10
of O 0 1.6804999058983583e-10
the O 0 1.825989359716118e-10
presence O 0 3.0871591394365794e-10
of O 0 5.944880698827149e-10
any O 0 2.060155157579402e-09
of O 0 1.2205602750725575e-08
the O 0 1.0679066519969638e-08
eight O 0 6.848655864644115e-09
mutations O 0 6.738725488730779e-08
screened O 0 3.7251643902891374e-07
. O 0 3.127547358872107e-07

Carriers O 0 4.470767933639763e-08
of O 0 4.153177002308439e-08
the O 0 7.933676826610281e-09
same O 0 1.8574750626498826e-09
mutation O 0 1.767948121234042e-09
, O 0 4.7985313639253846e-11
from O 0 5.4575739760753805e-11
different O 0 1.2208617450326642e-10
families O 0 6.545233799393202e-10
, O 0 1.3125243947254006e-10
shared O 0 2.7161947691034527e-10
similar O 0 2.433991896921839e-10
haplotypes O 0 2.097474194329152e-08
, O 0 1.2401822624408254e-10
indicating O 0 8.87611151245693e-10
that O 0 1.0974873787539252e-11
the O 0 2.621322603424403e-10
mutant O 0 1.3225796013927038e-09
alleles O 0 4.467924918927224e-10
were O 0 5.214693676869331e-10
likely O 0 4.211846704738065e-10
to O 0 9.643122411695515e-11
be O 0 1.4836469552914622e-10
identical O 0 9.138222956117659e-10
by O 0 1.9614870838680076e-10
descent O 0 4.181136770142757e-09
for O 0 1.304087532405518e-10
a O 0 5.626503707389929e-10
mutation O 0 1.6664564173041185e-09
in O 0 5.366267430417793e-10
the O 0 8.18155410087229e-09
founder O 0 2.438693229578348e-07
population O 0 6.282941722446367e-09
. O 0 7.62757821348714e-08

The O 0 3.148325822266429e-09
identification O 0 1.5108605921909657e-08
of O 0 9.798409195127533e-09
common O 0 9.267206735330547e-08
BRCA1 O 0 3.117499090876663e-06
and O 0 4.757070541927533e-07
BRCA2 O 0 7.277826625795569e-07
mutations O 0 7.717176231381018e-09
will O 0 2.268777526959198e-10
facilitate O 0 7.144845826090318e-10
carrier O 0 6.921875572718506e-11
detection O 0 6.715726863504301e-10
in O 0 3.173628027042241e-10
French O 0 7.272179232131748e-07
Canadian O 0 4.634053311747266e-06
breast B-Disease 0 0.0014649593504145741
cancer I-Disease 1 0.8873839378356934
and O 0 0.01352353859692812
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.9880153079299134e-09
. O 0 7.710952765194179e-09

Are O 0 8.916946825365812e-08
Dp71 O 0 1.731733573251404e-05
and O 0 4.850215162832683e-08
Dp140 O 0 5.0201037993247155e-06
brain O 0 4.0594645724922884e-06
dystrophin O 0 2.8970966923225205e-06
isoforms O 0 4.398333430799539e-08
related O 0 4.533346587010101e-09
to O 0 3.3996858106455363e-10
cognitive B-Disease 0 3.908978669642238e-06
impairment I-Disease 1 0.7230388522148132
in O 0 1.1578607228557303e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9996392726898193

Molecular O 0 1.4333853641801397e-06
study O 0 1.5898109495537938e-08
and O 0 3.0011451657152577e-10
neuropsychological O 0 4.404871134511268e-09
analysis O 0 5.61761659412241e-09
were O 0 1.4340182374894539e-09
performed O 0 7.457660045062653e-10
concurrently O 0 4.0951859681115366e-09
on O 0 3.630452605207779e-09
49 O 0 8.976086540712913e-09
patients O 0 2.8817451203089206e-10
with O 0 1.486398115702059e-09
Duchenne B-Disease 1 0.9999984502792358
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6335717439651489
DMD B-Disease 1 1.0
) O 0 2.336331683672199e-10
in O 0 1.202371362196697e-11
order O 0 6.515212674917947e-11
to O 0 4.691818808466586e-11
find O 0 5.653374990366444e-10
a O 0 1.324565873650485e-10
molecular O 0 5.425902394051718e-09
explanation O 0 3.6498097877313285e-09
for O 0 8.838298842794856e-11
the O 0 2.7160562687811307e-09
cognitive B-Disease 0 3.894229394063586e-06
impairment I-Disease 0 3.1934619073581416e-06
observed O 0 1.6055595963848646e-08
in O 0 8.646269811229956e-10
most O 0 1.808363414568248e-08
DMD B-Disease 1 1.0
patients O 0 9.277464130263979e-08
. O 0 1.5556074117739627e-07

Complete O 0 2.505119844897763e-08
analysis O 0 1.5234279615583546e-08
of O 0 1.2881609556814055e-08
the O 0 7.797934742370671e-09
dystrophin O 0 5.047800186730456e-07
gene O 0 6.049905465488337e-08
was O 0 3.0347274559971993e-07
performed O 0 8.115863536772849e-11
to O 0 4.019069799188202e-11
define O 0 1.2103452684542049e-09
the O 0 1.3212911875726263e-09
localization O 0 7.390251965944117e-08
of O 0 1.0969031016827557e-08
deletions O 0 9.138056356050583e-08
and O 0 5.2409707684830664e-09
duplications O 0 1.0135029526736616e-07
in O 0 1.0227221292069544e-09
relation O 0 1.0930602201142392e-08
to O 0 3.373126222783185e-10
the O 0 2.573816715312205e-09
different O 0 2.8655460226900686e-08
DMD B-Disease 1 1.0
promoters O 0 9.370199222757947e-06
. O 0 2.1477442260220414e-06

Qualitative O 0 3.9901200921121927e-07
analysis O 0 4.5178634167086784e-08
of O 0 7.29175013702843e-08
the O 0 1.0460220778440998e-07
Dp71 O 0 2.241994252472068e-06
transcript O 0 4.1898406522022924e-08
and O 0 8.767879478011054e-11
testing O 0 1.6364808813618126e-11
for O 0 2.776313554053722e-11
the O 0 1.750028177927021e-10
specific O 0 1.1792807841359831e-09
first O 0 1.3238188323327904e-09
exon O 0 4.010864085302046e-09
of O 0 1.5072826542450457e-08
Dp140 O 0 4.337761083661462e-07
were O 0 1.4215952859331082e-08
also O 0 1.6987798945322652e-09
carried O 0 1.393947535177631e-08
out O 0 1.51934216319205e-08
. O 0 2.1916497416896163e-07

Neuropsychological O 0 3.649867892363545e-07
analysis O 0 3.067885501195633e-08
assessed O 0 1.365251307561266e-07
verbal O 0 4.334812331308058e-08
and O 0 4.451441881769824e-09
visuospatial O 0 1.266862000193214e-06
intelligence O 0 3.653077840226615e-08
, O 0 3.5611773530064283e-09
verbal O 0 1.9323501021517586e-08
memory O 0 1.1589648920562468e-06
, O 0 7.0976091670615915e-09
and O 0 3.863211084365048e-09
reading O 0 2.1458882315528172e-07
skills O 0 9.507085110271873e-07
. O 0 2.0448901523195673e-06

Comparison O 0 2.2100853129813913e-06
of O 0 1.409134569030357e-07
molecular O 0 6.464285888796439e-07
and O 0 1.9251176652801405e-08
psychometric O 0 5.44663180335192e-07
findings O 0 7.731352980044903e-08
demonstrated O 0 1.3371346696544606e-08
that O 0 5.526334945216149e-10
deletions O 0 2.6698723232243537e-08
and O 0 1.2852398034723933e-09
duplications O 0 2.750895333747394e-08
that O 0 5.355183518851447e-10
were O 0 4.402567477246322e-10
localized O 0 1.9909533577333605e-08
in O 0 3.1473215700295043e-10
the O 0 1.78146764007181e-09
distal O 0 1.7592208223504713e-07
part O 0 4.114712570668644e-09
of O 0 3.906373891027215e-08
the O 0 5.1506440001958254e-08
gene O 0 1.5088533089624434e-08
seemed O 0 6.240890826347822e-08
to O 0 3.5360511740911704e-10
be O 0 1.424723533594019e-10
preferentially O 0 2.068415660971823e-09
associated O 0 3.969856887664491e-09
with O 0 2.7021822557316e-09
cognitive B-Disease 0 0.0001305626065004617
impairment I-Disease 1 0.7871236801147461
. O 0 1.785379026841838e-06

Two O 0 4.5673709792026784e-07
altered O 0 1.0505323189136107e-06
Dp71 O 0 4.5683000280405395e-06
transcripts O 0 7.495057019468732e-08
and O 0 2.7961066795256784e-09
two O 0 6.100409621900837e-10
deleted O 0 5.583827622501758e-09
Dp140 O 0 9.913947884854224e-09
DNA O 0 8.09441125237953e-10
sequences O 0 3.0489297198066367e-10
were O 0 2.831024303873164e-10
found O 0 7.304350874148824e-11
in O 0 4.351290161519472e-11
four O 0 1.0932071914382391e-10
patients O 0 1.9245796623046374e-10
with O 0 1.5555012833345927e-10
severe O 1 0.9966012239456177
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 0.9999970197677612
. O 0 1.7077802567655453e-06

These O 0 1.029217813197647e-07
findings O 0 8.998803480153583e-08
suggest O 0 1.1123655774269992e-08
that O 0 1.0035067915525886e-10
some O 0 8.564559478285716e-11
sequences O 0 7.34856481221513e-11
located O 0 5.452977513975554e-10
in O 0 4.198425981871701e-11
the O 0 8.336618062543266e-10
distal O 0 3.715208762855582e-08
part O 0 4.815908782873635e-10
of O 0 4.000763720313216e-09
the O 0 4.290285904318125e-09
gene O 0 1.450996767182744e-09
and O 0 5.4560183038177e-09
, O 0 2.2703836033421965e-10
in O 0 4.5961588701626255e-11
particular O 0 2.2076791506009386e-09
, O 0 2.0234927622375665e-10
some O 0 6.927862727934553e-10
DMD B-Disease 1 0.9999958276748657
isoforms O 0 2.6771182604079513e-08
expressed O 0 3.531436032488955e-09
in O 0 7.871046592278219e-10
the O 0 9.516617716087694e-09
brain O 0 2.691290319489781e-07
may O 0 9.127213429493963e-10
be O 0 3.5683400678721e-11
related O 0 3.886045096823665e-10
to O 0 1.7000074958861688e-10
the O 0 1.782973657604714e-09
cognitive B-Disease 0 8.433686389253126e-07
impairment I-Disease 0 1.0821012210726622e-06
associated O 0 1.1650115538941463e-07
with O 0 3.2743855626904406e-08
DMD B-Disease 1 1.0
. O 0 6.181526401860538e-08
. O 0 1.4004518789079157e-07

I1307K O 0 6.489598308689892e-05
APC O 0 2.494533646313357e-06
and O 0 5.000237379704231e-08
hMLH1 O 0 3.810937698744965e-07
mutations O 0 4.140126819152101e-08
in O 0 2.4254751540553343e-09
a O 0 1.0190463584081044e-08
non O 0 1.5447974988092028e-07
- O 0 1.6580111505959394e-08
Jewish O 0 3.4073210031237977e-07
family O 0 9.388681831978829e-09
with O 0 1.0974634534477445e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.987946006920538e-06

We O 0 1.9662198980086032e-08
describe O 0 7.0830843412750255e-09
a O 0 2.6424171739591884e-09
French O 0 7.829070369780311e-08
Canadian O 0 1.7650286565640272e-07
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.685469091076811e-07
HNPCC B-Disease 1 0.8668361902236938
) O 0 2.7290630866261267e-10
kindred O 0 2.767161433325782e-08
which O 0 2.285825174974665e-11
carries O 0 4.861185343152385e-10
a O 0 7.482305053319038e-11
novel O 0 2.2231319007914863e-09
truncating O 0 3.913428514579209e-08
mutation O 0 1.0731665334162699e-08
in O 0 5.953144199821736e-09
hMLH1 O 0 7.1580948315386195e-06
. O 0 9.939546998793958e-07

Interestingly O 0 1.568291168041469e-06
, O 0 1.963764972856552e-08
the O 0 1.6015528458979134e-08
I1307K O 0 3.404683468488656e-07
APC O 0 1.9333748824124086e-08
polymorphism O 0 8.452365030109377e-09
, O 0 8.500524173449264e-10
associated O 0 2.6253568208289835e-09
with O 0 3.4043622088031356e-11
an O 0 8.685190067136972e-11
increased O 0 5.688767235056957e-10
risk O 0 3.4798063097696286e-08
of O 0 0.00016390389646403491
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.902713873240373e-10
is O 0 1.4341371840087547e-11
also O 0 2.5964052956239936e-12
present O 0 1.9653959015819567e-11
in O 0 5.39602910964998e-11
this O 0 1.3296720391409167e-09
family O 0 5.999311269988539e-08
. O 0 2.329624209096437e-07

The O 0 1.458708140944509e-07
I1307K O 0 3.2991297871376446e-07
polymorphism O 0 2.1889130508156995e-08
has O 0 1.741966682011764e-09
previously O 0 1.5813181875046212e-09
only O 0 1.5122197938310933e-10
been O 0 7.702860571612291e-11
identified O 0 1.884779138316972e-10
in O 0 1.5146236695406934e-11
individuals O 0 7.468517471131975e-11
of O 0 1.6935654656435872e-08
self O 0 5.606744224451177e-08
- O 0 1.0301940278623078e-07
reported O 0 7.614408303879827e-08
Ashkenazi O 0 4.062187741737944e-08
Jewish O 0 3.85324199214665e-08
origins O 0 1.684809376456542e-07
. O 0 1.3592921277449932e-07

In O 0 2.8796380391327148e-08
addition O 0 1.572101560043393e-08
, O 0 4.181198443031775e-10
in O 0 6.153814263720747e-11
this O 0 2.1174131892287562e-10
family O 0 2.9084226138564873e-09
, O 0 1.7511669891945303e-10
there O 0 7.021364045733947e-11
appears O 0 4.0122549727072965e-10
to O 0 3.705012685539799e-11
be O 0 2.174334323701288e-10
no O 0 1.3005186927372847e-09
relationship O 0 9.950903434585712e-10
between O 0 2.0103563258544455e-09
the O 0 3.1456726112821798e-09
I1307K O 0 1.2227809875753337e-08
polymorphism O 0 5.319390483649045e-10
and O 0 1.2862298726101784e-10
the O 0 2.756906647416457e-10
presence O 0 3.352813804369248e-09
or O 0 8.71669758595317e-09
absence O 0 8.450480777355551e-07
of O 0 4.34245883695894e-08
cancer B-Disease 0 1.3652058328261774e-07
. O 0 2.7108356448479753e-08
. O 0 1.629233707944877e-07

Identification O 0 6.120344409055178e-08
of O 0 2.1965163909953844e-08
a O 0 9.563212444163582e-10
novel O 0 1.2953544903382408e-09
mutation O 0 2.5623938526564416e-09
of O 0 3.5110658824777374e-09
the O 0 2.090181716596362e-08
CPO O 0 2.867637476811069e-06
gene O 0 4.046148305292263e-09
in O 0 3.7347520631669795e-09
a O 0 1.5076278003789412e-08
Japanese O 0 3.367781857832597e-07
hereditary B-Disease 0 0.01658022776246071
coproporphyria I-Disease 0 0.012858493253588676
family O 0 9.873075441646506e-07
. O 0 5.150604920345359e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.0018748636357486248
HCP B-Disease 1 1.0
) O 0 1.0265436856116139e-07
is O 0 2.578706137512654e-09
an O 0 3.4676859161919538e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 8.679402974109962e-09
by O 0 8.254054384426723e-11
a O 0 2.4081336924552943e-09
deficiency B-Disease 1 0.6407052874565125
of I-Disease 1 0.7292483448982239
coproporphyrinogen I-Disease 0 0.17035271227359772
oxidase I-Disease 0 1.0270744610352267e-07
( O 0 2.7279247749589786e-09
CPO O 0 3.0506782877637306e-07
) O 0 1.8749394398165364e-11
caused O 0 3.6351138765766677e-10
by O 0 2.485559327802811e-11
a O 0 5.801772950952966e-11
mutation O 0 1.3591618108765857e-10
in O 0 1.4260720382353043e-10
the O 0 1.135779381655766e-08
CPO O 0 5.010633230995154e-06
gene O 0 1.3298659951033187e-07
. O 0 9.059559147317486e-07

Only O 0 1.4467396169948188e-07
11 O 0 6.886435954811532e-08
mutations O 0 2.377325358793314e-08
of O 0 1.7375477057157696e-08
the O 0 3.145150806460606e-09
gene O 0 4.336182968245339e-09
have O 0 2.108101471165469e-09
been O 0 9.73935820880456e-10
reported O 0 3.5103493445376444e-09
in O 0 1.0194171062849477e-09
HCP B-Disease 1 0.9952583909034729
patients O 0 1.2155031470229005e-07
. O 0 3.2078798994916724e-07

We O 0 1.1215139039677524e-07
report O 0 3.66080605829211e-08
another O 0 1.895856138744989e-09
mutation O 0 1.067993582459792e-09
in O 0 3.344304833063916e-10
a O 0 1.909406632805144e-09
Japanese O 0 6.239355343495845e-08
family O 0 7.364459264636025e-08
. O 0 2.454391108130949e-07

Polymerase O 0 5.859499196958495e-07
chain O 0 7.054651973703585e-07
reaction O 0 1.1892442586258767e-07
- O 0 2.4235760065494105e-08
single O 0 1.3582398539213614e-09
strand O 0 1.0933849381444816e-09
conformational O 0 8.385096506025036e-10
polymorphism O 0 3.74691555560247e-10
and O 0 2.0997215077755982e-10
direct O 0 2.3396906634332026e-09
sequence O 0 6.405355690297654e-10
analyses O 0 2.7029452009941224e-09
demonstrated O 0 2.6851765255742066e-09
a O 0 3.748590327035117e-09
C O 0 2.3591892883700893e-08
to O 0 5.845250394820312e-10
T O 0 5.5435451784546785e-09
substitution O 0 1.4284493587979341e-09
in O 0 1.324990256401648e-10
exon O 0 4.000929587633095e-10
1 O 0 2.3031445639531967e-09
of O 0 1.7052042000642587e-09
the O 0 8.090247582970278e-09
CPO O 0 2.600643824735016e-07
gene O 0 2.0930650546091556e-09
at O 0 6.279587516644369e-09
nucleotide O 0 4.756537386185755e-09
position O 0 1.5186179425086266e-08
85 O 0 1.0641856285076301e-08
, O 0 6.349714504194637e-11
which O 0 6.591861778648678e-11
lies O 0 1.31237987144317e-09
in O 0 6.356160736631367e-11
the O 0 4.631637740004635e-09
putative O 0 6.533440455314121e-07
presequence O 0 2.910514638188033e-07
for O 0 8.402242790417347e-10
targeting O 0 2.231463902546693e-08
to O 0 1.7837976429291302e-08
mitochondria O 0 2.903909489759826e-06
. O 0 1.6327253433701117e-06

This O 0 4.577965562191366e-09
mutation O 0 6.020767884251654e-09
changes O 0 1.5730935443158955e-09
the O 0 2.1640953473678337e-09
codon O 0 1.3121101538615676e-08
for O 0 4.233197126168875e-10
glutamine O 0 5.78033976239567e-09
to O 0 2.73772809977757e-10
a O 0 3.6479932408184368e-09
termination O 0 2.9351244279496314e-07
codon O 0 7.069481853250181e-07
at O 0 2.7043603267884464e-07
amino O 0 4.684056023052108e-07
acid O 0 1.6097182253815845e-07
position O 0 2.2353985684731015e-07
29 O 0 1.1367847037035972e-06
. O 0 4.015114996036573e-07

MaeI O 0 4.268498014425859e-05
restriction O 0 6.260514737732592e-07
analysis O 0 1.0897237956442041e-07
showed O 0 2.1107499748040937e-08
two O 0 2.7750549080884923e-10
other O 0 7.675772517590218e-11
carriers O 0 2.2835949797794797e-10
in O 0 2.573653512527585e-10
the O 0 5.0954231944899675e-09
family O 0 1.0794774851774491e-07
. O 0 2.440687012494891e-07

The O 0 6.539308287756285e-06
C O 0 0.011592547409236431
- O 0 1.7631775335757993e-05
T O 0 1.2187525726403692e-06
mutation O 0 9.689446578420302e-09
is O 0 2.933463749688059e-10
located O 0 4.2881076467438106e-10
within O 0 2.6278804132751077e-10
a O 0 4.957905197500168e-10
recently O 0 2.006750321470463e-10
proposed O 0 3.0087796143440926e-10
putative O 0 9.219987440189925e-09
alternative O 0 1.7604913082891471e-09
translation O 0 3.956982741470938e-09
initiation O 0 2.7526887436124525e-09
codon O 0 6.744203062680754e-08
( O 0 7.69818253587573e-09
TIC O 0 3.216030108887935e-08
- O 0 9.54654222340423e-09
1 O 0 8.619961633371531e-09
) O 0 4.9901589804779434e-11
, O 0 4.929539068609934e-11
supporting O 0 1.0397667449257852e-10
that O 0 2.0394097521858612e-10
TIC O 0 4.978764955865245e-09
- O 0 1.7914446592826039e-09
1 O 0 4.665169139883574e-09
is O 0 1.8226906095542006e-10
the O 0 2.63605937078637e-09
real O 0 2.389342910191772e-07
TIC O 0 4.7205144682038735e-08
rather O 0 3.346386501235088e-09
than O 0 1.4445212803693153e-09
TIC O 0 1.3029724854618507e-08
- O 0 7.399232782034915e-09
2 O 0 5.907255573589509e-09
. O 0 2.443640623184251e-09
. O 0 2.9488207431427327e-08

Human B-Disease 0 1.0199022426604643e-07
complement I-Disease 0 9.887529586194432e-07
factor I-Disease 0 2.7072012017015368e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999901056289673
associated O 1 0.9996098875999451
with O 1 0.7565941214561462
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999966621398926

This O 0 1.0637716485462079e-08
study O 0 2.392348541491174e-09
reports O 0 1.9246906290959487e-09
on O 0 3.278669558071101e-10
six O 0 7.499049992087947e-11
cases O 0 2.760326689443815e-10
of O 0 1.3756717986979083e-09
deficiency B-Disease 0 1.908880307155414e-07
in I-Disease 0 6.199846191989877e-10
the I-Disease 0 1.9078887358858765e-09
human I-Disease 0 5.830641525150781e-10
complement I-Disease 0 1.984817643574388e-09
regulatory I-Disease 0 2.415627697871514e-09
protein I-Disease 0 4.123372931985614e-08
Factor I-Disease 0 2.6439815670187272e-08
H I-Disease 1 0.9996660947799683
( O 0 4.5043524465882e-09
FH O 0 1.209148763336998e-07
) O 0 2.1062266514215722e-11
in O 0 1.3547042827799505e-11
the O 0 4.92732972479093e-11
context O 0 2.1194992427808756e-09
of O 0 3.8240832722635787e-10
an O 0 5.099302757827218e-09
acute B-Disease 1 0.9999998807907104
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.1747341634181794e-06

Five O 0 1.753519285330185e-07
of O 0 1.348758527086602e-08
the O 0 1.1457286230864838e-09
cases O 0 5.560464866327663e-10
were O 0 1.803900362418176e-10
observed O 0 4.430323607973463e-10
in O 0 3.920311297811452e-11
children O 0 1.6665827051731696e-10
presenting O 0 8.603108447857721e-09
with O 0 1.5690488908148836e-08
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999984502792358
HUS B-Disease 1 1.0
) O 0 9.97310280581587e-07
. O 0 1.583812945682439e-06

Two O 0 9.436438297427685e-09
of O 0 8.851264610143517e-09
the O 0 1.316624476110917e-09
children O 0 5.688051696317586e-10
exhibited O 0 8.59935145314239e-09
a O 0 1.6944436964649867e-09
homozygous O 0 1.9944652152048548e-08
deficiency O 0 3.041762397515413e-07
characterized O 0 9.368178455204657e-10
by O 0 7.18532178201059e-11
the O 0 3.3072362626285212e-09
absence O 0 8.354389535725204e-08
of O 0 9.897868302743973e-09
the O 0 3.276233062621259e-09
150 O 0 1.5596791635985596e-09
- O 0 5.515941037259608e-10
kD O 0 5.254670587540033e-10
form O 0 3.972958073639177e-11
of O 0 3.247512814219533e-10
Factor O 0 3.967827844064686e-09
H O 1 0.999998927116394
and O 0 1.3943642906966147e-09
the O 0 3.732701259195892e-09
presence O 0 1.5021677235438347e-09
, O 0 2.4169122259110054e-10
upon O 0 1.4307043327832503e-09
immunoblotting O 0 7.883900821070711e-08
, O 0 3.3341907013095806e-10
of O 0 2.066806725764536e-09
the O 0 1.9077695867508737e-08
42 O 0 7.077496633201008e-08
- O 0 2.3464087561819724e-08
kD O 0 4.172248324607608e-08
Factor O 0 1.8683488534065873e-08
H O 0 0.00013187539298087358
- O 0 8.200727563689725e-08
like O 0 4.107561846211638e-09
protein O 0 1.6205990505113732e-07
1 O 0 1.1895789242544197e-07
( O 0 3.909204515650799e-09
FHL O 0 1.1462689144536853e-06
- O 0 9.983607718311305e-09
1 O 0 7.958183445566647e-09
) O 0 5.2519429777353466e-11
and O 0 1.5283653509445827e-10
other O 0 6.793645090930056e-10
FH O 0 1.6682882630902895e-07
- O 0 7.731644657837933e-09
related O 0 1.257051618352989e-08
protein O 0 3.04681719853761e-07
( O 0 1.1975851421652806e-08
FHR O 0 6.230141298146918e-05
) O 0 2.9846036753156113e-09
bands O 0 4.686522458996478e-08
. O 0 1.2671023341681575e-07

Southern O 0 1.9581266315071844e-06
blot O 0 1.8201237708126428e-06
and O 0 1.4169356798987565e-09
PCR O 0 4.9619659492350365e-09
analysis O 0 1.0763063773566728e-09
of O 0 6.220729487083076e-10
DNA O 0 4.0684895452614e-09
of O 0 3.687293359533328e-09
one O 0 6.359619497686708e-10
patient O 0 3.7196667967975827e-09
with O 0 4.303256917470577e-10
homozygous O 0 1.906696489584192e-08
deficiency O 0 5.834507419422152e-07
ruled O 0 5.277707870732229e-08
out O 0 5.254891521921934e-10
the O 0 6.64418312035231e-11
presence O 0 1.4745515919400987e-10
of O 0 2.333147286481818e-10
a O 0 6.493539733698483e-11
large O 0 8.560444714200699e-11
deletion O 0 2.95620056212087e-10
of O 0 1.4847235663140168e-09
the O 0 7.91303378377961e-09
FH O 0 2.2965357970861078e-07
gene O 0 7.185146921884211e-10
as O 0 1.1609423422598297e-09
the O 0 1.873379229522243e-09
underlying O 0 1.6496808541432983e-07
defect O 0 3.78680127255393e-08
for O 0 4.306494272299233e-09
the O 0 4.3461878362904827e-07
deficiency O 1 0.9372645616531372
. O 0 8.102718311420176e-06

The O 0 4.9989210992862354e-08
other O 0 3.979150786648233e-09
four O 0 1.5770230676892538e-09
children O 0 2.7060698126746274e-10
presented O 0 2.13365924928155e-09
with O 0 2.5519064639212274e-10
heterozygous O 0 1.0047756404674146e-08
deficiency O 0 2.6280542897438863e-07
and O 0 7.713759075933524e-10
exhibited O 0 1.4844354190302056e-08
a O 0 6.0335830776026e-10
normal O 0 1.2117781444942466e-08
immunoblotting O 0 2.888197059291997e-08
pattern O 0 4.960045263402435e-09
of O 0 4.821441579316854e-10
proteins O 0 2.866729076345109e-10
of O 0 3.616457577848564e-09
the O 0 3.181995822387762e-08
FH O 0 1.2191280802653637e-05
family O 0 1.782698006991268e-07
. O 0 4.6207867399061797e-07

Factor B-Disease 0 0.00575675442814827
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
is O 0 1.709024388674152e-08
the O 0 5.056512986101325e-09
only O 0 2.763669471050889e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 6.974004463700112e-06
with O 0 2.735277604415387e-08
HUS B-Disease 1 1.0
. O 0 2.633755002534599e-06

These O 0 6.594687107508435e-08
observations O 0 1.6793134705039847e-07
suggest O 0 8.135804030473537e-09
a O 0 1.5436031342019874e-09
role O 0 1.6645028688699881e-09
for O 0 6.551191256143341e-10
FH O 0 7.85352142429474e-07
and O 0 5.56237722548758e-09
/ O 0 2.4895440375871658e-08
or O 0 2.778488328303297e-09
FH O 0 9.273819756572266e-08
receptors O 0 2.930903963971332e-09
in O 0 1.3045302338365872e-10
the O 0 7.414811542538757e-10
pathogenesis O 0 3.268756245233817e-06
of O 0 1.8060882567283443e-08
idiopathic O 0 0.008302210830152035
HUS B-Disease 1 1.0
. O 0 2.7947172043241153e-07
. O 0 8.457317335341941e-07

Further O 0 8.642238213951714e-08
evidence O 0 2.7703244143140182e-08
for O 0 5.307027040046819e-10
a O 0 5.563095539784513e-10
major O 0 3.1215321438793353e-09
ancient O 0 2.2387579790006384e-08
mutation O 0 5.16204295308853e-07
underlying O 0 6.671990604445455e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.8240483729291554e-08
linkage O 0 4.793059815710876e-07
disequilibrium O 0 2.8936761964359903e-07
studies O 0 4.185235491505068e-10
in O 0 3.74379173495587e-11
the O 0 4.32537616834594e-10
Japanese O 0 5.11520026336143e-09
population O 0 1.1625177487317728e-09
. O 0 3.800215964133713e-08

The O 0 3.624699047577451e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.009815989062190056
DM B-Disease 1 1.0
) O 0 1.524927184526348e-09
mutation O 0 2.0047734583528154e-09
is O 0 1.7763501780621027e-10
an O 0 7.982716154764091e-10
unstable O 0 4.3193830379095743e-07
( O 0 3.2371023195310045e-08
CTG O 0 3.0051896828808822e-05
) O 0 1.4319410102103802e-09
n O 0 2.96363733554017e-09
repeat O 0 1.8685581970601106e-09
, O 0 3.232569767419591e-10
present O 0 2.7474003627681043e-10
at O 0 2.9703986492712886e-10
a O 0 1.63120177087972e-11
copy O 0 2.7865326712728233e-10
number O 0 3.937901948969369e-10
of O 0 2.277775745795907e-09
5 O 0 8.637818460499602e-09
- O 0 8.285735653146276e-09
37 O 0 6.046352751809536e-08
repeats O 0 8.442778032247134e-09
on O 0 6.563902310574576e-09
normal O 0 1.0473711675729191e-08
chromosomes O 0 1.6455908857793133e-09
but O 0 8.790388972279572e-10
amplified O 0 2.630203388420682e-09
to O 0 6.507416272505395e-10
50 O 0 7.895228470999882e-09
- O 0 9.538274614584452e-10
3000 O 0 8.839601828292132e-10
copies O 0 9.24725096496104e-09
on O 0 9.82069678912012e-08
DM B-Disease 1 0.9999911785125732
chromosomes O 0 3.7255301776895067e-07
. O 0 4.7507370481980615e-07

Previous O 0 2.3641177904210053e-07
findings O 0 1.7785080075327642e-08
in O 0 9.147639867812529e-10
Caucasian O 0 1.7884206116036694e-08
populations O 0 2.1032418029420796e-09
of O 0 2.1257258175921834e-09
a O 0 3.2234240165962547e-08
DM B-Disease 1 1.0
founder O 0 1.0628005838952959e-05
chromosome O 0 5.910402833819717e-08
raise O 0 5.6652083024744115e-09
a O 0 5.218335208390101e-10
question O 0 7.337784269090264e-10
about O 0 6.459704299244251e-11
the O 0 1.5661441588044056e-10
molecular O 0 1.6046556305937543e-09
events O 0 2.442614166486834e-10
involved O 0 2.2249251052652852e-10
in O 0 2.2206261829360585e-10
the O 0 2.3464967746633647e-09
expansion O 0 8.362903258785082e-08
mutation O 0 9.394454281164144e-08
. O 0 2.3810970617432758e-07

To O 0 2.388228459437869e-08
investigate O 0 2.2027842661032082e-08
whether O 0 4.227277194956969e-09
a O 0 8.485366187471755e-09
founder O 0 3.4584402897053224e-08
chromosome O 0 3.1032834080235716e-09
for O 0 3.816898186403961e-10
the O 0 8.403064910567082e-09
DM B-Disease 1 1.0
mutation O 0 9.947601631310476e-10
exists O 0 2.0028881331235482e-10
in O 0 1.4615503252102258e-11
the O 0 1.7646893668565866e-10
Japanese O 0 3.772057333151224e-09
population O 0 2.3993665387855856e-10
, O 0 1.5020121257869334e-10
we O 0 5.368170907793512e-10
genotyped O 0 9.051081661937133e-08
families O 0 5.611370257341264e-10
using O 0 2.338756965869493e-10
polymorphic O 0 6.379316186411188e-09
markers O 0 2.4583867386240854e-08
near O 0 3.1854727922109305e-07
the O 0 3.746098116153007e-07
( O 0 7.767032883521097e-08
CTG O 0 1.0513889719732106e-05
) O 0 3.820891603112386e-09
n O 0 8.29535018453953e-09
repeat O 0 1.2402496807339958e-08
region O 0 4.0779156051939935e-08
and O 0 1.4618674271105192e-08
constructed O 0 5.528501105800387e-07
haplotypes O 0 4.539199380815262e-06
. O 0 1.0217213457508478e-06

Six O 0 1.0910215308967963e-07
different O 0 1.3424729772282262e-08
haplotypes O 0 2.7588697548708296e-07
were O 0 1.7198801272044761e-09
found O 0 5.650162560044691e-10
and O 0 3.1075184647733067e-09
DM B-Disease 1 1.0
alleles O 0 2.1525368154584612e-08
were O 0 8.200004231184721e-09
always O 0 7.28740889854862e-09
haplotype O 0 4.2845312009376357e-07
A O 0 7.670213335586595e-07
. O 0 5.750200671172934e-07

To O 0 4.8602419866483615e-09
find O 0 2.435000867606618e-09
an O 0 9.822369306800027e-11
origin O 0 1.6657127899222246e-09
of O 0 2.861235470774659e-09
the O 0 1.3632289963538824e-08
( O 0 1.9718381594202583e-08
CTG O 0 9.005617357615847e-06
) O 0 1.37950273426668e-09
n O 0 3.024500427883936e-09
repeat O 0 1.6704533312150716e-09
mutation O 0 9.653727817138247e-10
and O 0 3.874874379694582e-11
to O 0 2.3440879445835172e-11
investigate O 0 4.705210110422797e-10
the O 0 3.203037002297293e-10
mechanism O 0 2.2366526408745813e-09
of O 0 5.328082419708835e-10
the O 0 1.9248218297018838e-10
expansion O 0 1.5697995126018327e-09
mutation O 0 1.3236313434195068e-10
in O 0 5.228235552823257e-11
the O 0 4.851311019571369e-10
Japanese O 0 2.419644040685398e-09
population O 0 1.4412400439756112e-10
we O 0 2.3520790870534825e-10
have O 0 2.2073917693710143e-10
studied O 0 2.8111974970101983e-09
90 O 0 6.527322238270017e-09
Japanese O 0 8.683546326437863e-08
DM B-Disease 1 0.9990807771682739
families O 0 2.1497457147745536e-09
comprising O 0 9.237215436996848e-10
190 O 0 1.3537397869356482e-09
affected O 0 6.832108767618195e-10
and O 0 6.279021191879508e-10
130 O 0 2.913597363374265e-09
unaffected O 0 1.081569465100074e-07
members O 0 2.0567003655713734e-09
. O 0 1.1583687609117987e-07

The O 0 2.6689053811423946e-07
results O 0 1.3219666072927794e-07
suggest O 0 2.574814850220264e-08
that O 0 3.294535477760263e-10
a O 0 4.3849518460703507e-10
few O 0 8.851141486410086e-10
common O 0 7.209404184749246e-10
ancestral O 0 9.002147471903754e-09
mutations O 0 2.540519128402252e-09
in O 0 3.354635458308053e-10
both O 0 1.1172001102011109e-09
Caucasian O 0 2.7676667624376705e-09
and O 0 1.9725059086095342e-10
Japanese O 0 1.5196021108110358e-09
populations O 0 9.835172953831517e-11
have O 0 6.581781994419167e-12
originated O 0 6.672860181078377e-11
by O 0 5.665848432784282e-12
expansion O 0 2.1504387159865246e-09
of O 0 9.70782898512823e-10
an O 0 1.458758225325596e-09
ancestral O 0 2.4928796804601916e-08
n O 0 3.9086973657731505e-09
= O 0 6.998348123232745e-09
5 O 0 3.22263571383985e-09
repeat O 0 1.318708031661231e-09
to O 0 4.89312279583487e-09
n O 0 1.3937374809813718e-08
= O 0 3.775716450604705e-08
19 O 0 2.1837423958004365e-07
- O 0 2.588977920936486e-08
37 O 0 3.7827515342314655e-08
copies O 0 3.290889694085308e-08
. O 0 1.382789065473844e-07

These O 0 7.294709725158555e-09
data O 0 8.318942867902024e-09
support O 0 1.8597616779914006e-09
multistep O 0 1.723865494795973e-07
models O 0 1.737230235221432e-07
of O 0 1.4416724525290192e-07
triplet O 0 1.3624980965687428e-06
repeat O 0 7.61596297138567e-08
expansion O 0 1.3411478505531704e-07
that O 0 2.6095310357021617e-09
have O 0 4.984843648969672e-10
been O 0 1.5956359844526702e-10
proposed O 0 1.2962733664245718e-10
for O 0 4.686991905700211e-10
both O 0 4.8900467675139225e-08
DM B-Disease 1 1.0
and O 0 2.1681168504983361e-07
Friedreichs B-Disease 0 2.5769928470253944e-05
ataxia I-Disease 0 0.0016408179653808475
. O 0 2.800613856379641e-07
. O 0 5.247175067779608e-07

The O 0 3.637406464918058e-08
molecular O 0 2.2239755992359278e-07
basis O 0 2.6422580390317307e-07
of O 0 4.970882514498953e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.8101844467821593e-09
the O 0 8.514625116085028e-10
western O 0 2.6850945911149893e-09
Cape O 0 3.811356563687696e-09
, O 0 2.332404269722588e-10
South O 0 1.643724267808011e-09
Africa O 0 5.519690038369163e-09
. O 0 1.0308622933052902e-07

Deficiency B-Disease 0 0.00010855704749701545
of I-Disease 0 1.6733401935198344e-05
the I-Disease 0 2.92216498110065e-07
sixth I-Disease 0 4.198712701963814e-07
component I-Disease 0 9.503416720235691e-08
of I-Disease 0 1.095376855886343e-08
human I-Disease 0 1.0133517136523551e-08
complement I-Disease 0 1.584802475917968e-07
( O 0 6.245747474764585e-09
C6 O 0 3.4228767162858276e-06
) O 0 1.171071989380934e-10
has O 0 8.022413289232588e-11
been O 0 2.0283566493084493e-11
reported O 0 4.501281639091026e-11
in O 0 2.413767753381424e-12
a O 0 2.0924045482373366e-11
number O 0 3.514814481131445e-11
of O 0 8.386660116377342e-11
families O 0 2.314556879490226e-11
from O 0 1.298847140951409e-10
the O 0 5.795195434643574e-10
western O 0 4.900753580727724e-09
Cape O 0 4.406568443471315e-09
, O 0 3.188742603299488e-10
South O 0 2.884160243965539e-09
Africa O 0 6.703840149668849e-09
. O 0 1.107401814692821e-07

Meningococcal B-Disease 0 0.0009594218572601676
disease I-Disease 0 0.0001385191862937063
is O 0 3.1732466654332825e-10
endemic O 0 8.642670606962e-11
in O 0 1.1703323206380123e-11
the O 0 2.103629909155913e-10
Cape O 0 6.28435303795527e-10
and O 0 9.358738610465434e-12
almost O 0 6.27042515133347e-11
all O 0 1.4143341012240462e-11
pedigrees O 0 4.9745980668092216e-09
of O 0 4.163263511713922e-09
total O 0 4.57612600257562e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.1277710143531294e-07
C6Q0 O 0 0.41597771644592285
) O 0 5.19424447897876e-10
have O 0 6.915805428331367e-11
been O 0 9.464836553396694e-11
ascertained O 0 4.133309872145219e-08
because O 0 9.754675955875314e-10
of O 0 6.6438983203909174e-09
recurrent O 0 1.4286280020314734e-05
disease O 0 9.581124686519615e-06
. O 0 2.6717449941315863e-07

We O 0 1.733773480339096e-08
have O 0 6.122393703122953e-10
sequenced O 0 2.5164446082470704e-09
the O 0 6.176146261083204e-10
expressed O 0 2.639264140569253e-09
exons O 0 7.412541691564911e-08
of O 0 2.94471789175077e-08
the O 0 5.486001342092095e-08
C6 O 0 1.3665660389960976e-06
gene O 0 1.6112249312527638e-09
from O 0 2.1069115341276756e-09
selected O 0 5.179553452805408e-10
cases O 0 1.484499051462862e-10
and O 0 9.767667230597965e-11
have O 0 2.6613317452572893e-11
found O 0 2.3100857338143044e-10
three O 0 3.1292859969944686e-10
molecular O 0 5.499536541719863e-07
defects O 0 0.0003558100142981857
leading O 0 1.37142649236921e-07
to O 0 3.1972275937874883e-09
total O 0 6.952503639467977e-08
deficiency O 0 2.555036644480424e-06
879delG O 0 2.277417706864071e-06
, O 0 5.285781812247592e-10
which O 0 6.328168544733614e-11
is O 0 2.4832847583811102e-11
the O 0 5.627144583630894e-11
common O 0 4.155708832609406e-10
defect O 0 8.411610963321436e-09
in O 0 1.096425616964325e-09
the O 0 2.502240370461095e-08
Cape O 0 3.940535364677089e-08
and O 0 2.1272306138797603e-09
hitherto O 0 4.688837975663773e-07
unreported O 0 4.2773621089509106e-07
, O 0 1.0582705822770322e-09
and O 0 1.4288035199427895e-09
1195delC O 0 5.6381434632157834e-08
and O 0 5.654370305308021e-09
1936delG O 0 1.2790061987288937e-07
, O 0 5.753058585078463e-10
which O 0 3.078221844088347e-10
have O 0 2.0808794964910504e-10
been O 0 7.111589650499184e-10
previously O 0 1.9631385406171376e-09
reported O 0 1.903624813337501e-09
in O 0 3.221269917474956e-10
African O 0 3.179160934507763e-09
- O 0 2.7998119378480624e-08
Americans O 0 2.5130640679549288e-08
. O 0 1.9866901368459366e-07

We O 0 2.3794171966073918e-07
also O 0 1.7751698777601632e-08
show O 0 2.9389817246538996e-09
that O 0 2.1077065093244585e-10
the O 0 2.064651560829134e-09
879delG O 0 3.073760694860539e-07
and O 0 1.3870280923811151e-08
1195delC O 0 7.063779776217416e-06
defects O 0 7.702026778133586e-05
are O 0 1.8932542200644775e-09
associated O 0 1.3787465036330104e-07
with O 0 9.891979679821361e-09
characteristic O 1 0.9856542944908142
C6 O 1 0.999996542930603
/ O 0 1.1709819773386698e-05
C7 O 0 1.727903145365417e-05
region O 0 2.301784363112347e-08
DNA O 0 8.844332199942073e-08
marker O 0 2.853849707662448e-07
haplotypes O 0 1.115789274308554e-07
, O 0 6.332929181063207e-10
although O 0 5.179187634318794e-10
small O 0 1.1749162753815767e-09
variations O 0 2.2873374305731886e-08
were O 0 4.1627394864462985e-09
observed O 0 7.219565389959826e-08
. O 0 1.8906631282789021e-07

The O 0 3.4296431294933427e-07
1936delG O 0 1.8001699118030956e-06
defect O 0 7.510217869821645e-07
was O 0 1.4858665053907316e-07
observed O 0 2.462872350506018e-09
only O 0 1.9073019552617865e-10
once O 0 6.114924677724787e-10
in O 0 6.909713773373127e-11
the O 0 3.337208287490512e-09
Cape O 0 9.588477567490372e-09
, O 0 2.345502403411359e-10
but O 0 2.442530622204231e-10
its O 0 2.5095123201701597e-10
associated O 0 8.06491851079727e-09
haplotype O 0 7.055204065409271e-08
could O 0 1.5160420474558123e-08
be O 0 2.6899963145865513e-08
deduced O 0 5.372245595935965e-06
. O 0 1.0418342526463675e-06

The O 0 4.60598599261175e-08
data O 0 1.2360860779381255e-08
from O 0 2.2055410831001154e-09
the O 0 2.3412261018762592e-09
haplotypes O 0 3.0308079601581994e-08
indicate O 0 2.642346785819427e-09
that O 0 2.544949320726353e-11
these O 0 1.0347771250973636e-10
three O 0 9.265302414185328e-11
molecular O 0 3.123588498965546e-08
defects O 0 2.491328245923796e-07
account O 0 1.2931229420587442e-09
for O 0 5.287345006266264e-10
the O 0 3.9496327985943935e-08
defects O 0 0.00950082391500473
in O 0 2.6326576474389185e-09
all O 0 3.1676183898099453e-09
the O 0 1.335516142120241e-08
38 O 0 4.035791079104456e-08
unrelated O 0 3.249375168934421e-08
C6Q0 O 0 2.272551455462235e-06
individuals O 0 6.674556463082126e-10
we O 0 1.4774521606142343e-09
have O 0 3.1534505562369475e-10
studied O 0 4.7279726800297794e-09
from O 0 1.09118292179744e-09
the O 0 7.797250844987502e-09
Cape O 0 9.939473955000722e-08
. O 0 9.827985536503547e-08

We O 0 1.3566980783252802e-07
have O 0 3.7738421276856116e-09
also O 0 1.4753485100271746e-09
observed O 0 2.878005611606227e-09
the O 0 1.5390581031837769e-09
879delG O 0 1.2573711671848287e-07
defect O 0 4.198496128537954e-08
in O 0 4.531591546452773e-09
two O 0 2.7948711789349545e-08
Dutch O 1 0.9996410608291626
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 3.4886163575720275e-06
, O 0 5.244897849365771e-10
but O 0 1.5496172400819574e-10
the O 0 7.146385705425473e-10
879delG O 0 2.6541982833805378e-08
defect O 0 9.908823983550974e-09
in O 0 1.548445149879285e-09
the O 0 9.64955759741315e-08
Cape O 0 6.941929342474396e-08
probably O 0 6.39625152842882e-09
did O 0 9.309238380161844e-10
not O 0 2.3667584558850763e-10
come O 0 1.3277814403522825e-09
from O 0 2.1135930783344747e-09
The O 0 2.6502713357245966e-09
Netherlands O 0 1.0624455093477536e-08
. O 0 1.6468320040985418e-08
. O 0 2.3437701202055905e-07

Complement B-Disease 1 0.9999097585678101
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 8.61667714957548e-08
seven O 0 1.3868429071806077e-08
further O 0 1.8728263384559796e-08
molecular O 0 6.744949587300653e-06
defects O 0 0.02552163228392601
and O 0 4.125046082492645e-09
their O 0 1.964097329221204e-09
associated O 0 2.3190504805370438e-07
marker O 0 2.8944041332579218e-06
haplotypes O 0 4.394574261823436e-06
. O 0 6.329643724711786e-07

Seven O 0 9.32860260149937e-08
further O 0 1.7038656707768496e-08
molecular O 0 1.2996321174796321e-07
bases O 0 1.5924307206205413e-07
of O 0 1.803148552426137e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 6.657131024212504e-08
described O 0 1.2519220149442845e-07
. O 0 1.3176105539969285e-07

All O 0 1.516395009559801e-08
these O 0 3.5245117935289727e-09
new O 0 5.176928219441379e-09
molecular O 0 1.3141695376361895e-07
defects O 0 2.2801444288234052e-07
involve O 0 4.7324655305658325e-09
single O 0 2.9161548731337916e-09
- O 0 5.11200148878288e-09
nucleotide O 0 5.942537129044467e-09
events O 0 5.8449409756633486e-09
, O 0 7.696887016628295e-10
deletions O 0 4.487501925609649e-09
and O 0 4.658702312809737e-10
substitutions O 0 2.686149747077593e-09
, O 0 2.191994086242488e-10
some O 0 9.764170583181908e-10
of O 0 1.0415242890360332e-08
which O 0 2.876068716517466e-09
alter O 0 1.5830336508315668e-07
splice O 0 6.706465001116158e-07
sites O 0 1.481805185221674e-07
, O 0 4.889120219786491e-09
and O 0 3.433449746736983e-09
others O 0 1.8330855056092332e-08
codons O 0 2.8163110528112156e-06
. O 0 1.3135246490492136e-06

They O 0 2.299432289021297e-08
are O 0 6.099641902679309e-10
distributed O 0 6.544163877464371e-09
along O 0 8.470522061543306e-09
the O 0 2.096594187150913e-08
C7 O 0 1.7928848592418944e-06
gene O 0 4.370933837094526e-09
, O 0 9.788430066492992e-10
but O 0 2.818008326688215e-10
predominantly O 0 2.447753943979336e-10
towards O 0 5.619020360114746e-09
the O 0 4.235201966906743e-09
3 O 0 5.086580046054223e-08
end O 0 9.545635748509085e-08
. O 0 3.882101111685188e-07

All O 0 4.686745924686875e-08
were O 0 5.092576582654829e-09
found O 0 1.0479022094500579e-09
in O 0 2.487325068134538e-10
compound O 0 1.1141088052113446e-08
heterozygous O 0 1.0410555972839575e-08
individuals O 0 2.7595330465146617e-09
. O 0 2.0399765787715296e-07

The O 0 4.5077682443661615e-05
C6 O 1 0.9962772727012634
/ O 0 9.252651216229424e-05
C7 O 0 5.847911597811617e-05
marker O 0 1.957882602710015e-07
haplotypes O 0 1.821101562882177e-07
associated O 0 6.864731716405004e-08
with O 0 3.665541647990267e-09
most O 0 1.6869540786501602e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999997615814209
are O 0 1.834211538209729e-08
tabulated O 0 1.6473038044750865e-07
. O 0 2.961265721523887e-08
. O 0 1.4410304061129864e-07

A O 0 7.755878868920263e-06
genome O 0 1.729942624706382e-07
- O 0 3.649366320246372e-08
wide O 0 5.9453144629628696e-09
search O 0 3.786104485481445e-10
for O 0 4.7914065076648527e-11
chromosomal O 0 1.8729787143456633e-07
loci O 0 3.2251898574031657e-07
linked O 0 1.1127145853606635e-06
to O 0 3.723812591616138e-09
mental O 0 9.020066499942914e-06
health O 0 1.2284034767162666e-07
wellness O 0 7.651532740737821e-08
in O 0 2.741343818613018e-10
relatives O 0 1.7504873994766967e-08
at O 0 3.409473592341783e-09
high O 0 2.948302046945628e-09
risk O 0 1.6402136315818439e-09
for O 0 4.6398229702759863e-10
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 2.336150373594137e-06
the O 0 1.1823324541637703e-07
Old O 0 2.5458852803694754e-08
Order O 0 1.0613922185598312e-08
Amish O 0 4.1567164998923545e-07
. O 0 2.7583041628531646e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999794960021973
BPAD B-Disease 1 1.0
; O 1 0.9261028170585632
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 5.367068567352362e-09
is O 0 9.612510787349038e-11
characterized O 0 5.026755747761236e-11
by O 0 1.793360598911775e-11
episodes O 0 1.3613625782227246e-09
of O 0 2.512348995509228e-09
mania B-Disease 0 4.6128967312597524e-08
and O 0 7.169065785461726e-09
/ O 0 6.937614216440124e-08
or O 0 1.331213006494636e-08
hypomania B-Disease 0 1.0663493412721436e-06
interspersed O 0 8.243506322003213e-09
with O 0 5.359778940117188e-11
periods O 0 2.8417279196446543e-08
of O 0 8.581132249219081e-09
depression B-Disease 0 7.100887842170778e-07
. O 0 2.492732846803847e-07

Compelling O 0 2.6898173928202596e-06
evidence O 0 2.2122837606275425e-07
supports O 0 1.511987690605565e-08
a O 0 2.041620483783646e-10
significant O 0 1.1238190378293211e-09
genetic O 0 1.5706360656508878e-08
component O 0 6.288627218964393e-08
in O 0 3.867441089600021e-10
the O 0 1.4586302166108567e-09
susceptibility O 0 5.6824074334826946e-08
to O 0 5.100042166361618e-09
develop O 0 9.073055480257608e-07
BPAD B-Disease 1 1.0
. O 0 5.098681867821142e-06

To O 0 8.77039774138666e-09
date O 0 2.408861519143102e-07
, O 0 2.200910120819799e-09
however O 0 4.82793183209651e-09
, O 0 4.4825382294888527e-10
linkage O 0 4.712202184009584e-08
studies O 0 2.0604264960866203e-09
have O 0 3.8497392773617634e-11
attempted O 0 8.12398426308647e-10
only O 0 4.4058076631436904e-11
to O 0 1.1398277460772377e-10
identify O 0 5.656203949655492e-09
chromosomal O 0 6.854381808807375e-07
loci O 0 8.670471629557142e-08
that O 0 7.289114867248259e-10
cause O 0 3.2382015291432253e-08
or O 0 2.4426188849346886e-10
increase O 0 4.426725097594897e-10
the O 0 2.0915993936831967e-10
risk O 0 7.28293469975938e-09
of O 0 1.5003873699015458e-08
developing O 0 2.3676743694522884e-06
BPAD B-Disease 1 1.0
. O 0 4.375242042442551e-06

To O 0 1.1931414078958369e-08
determine O 0 3.8973688276655594e-08
whether O 0 7.530548629119949e-09
there O 0 2.7738922270259536e-09
could O 0 1.4263176195683513e-09
be O 0 8.486818470210267e-10
protective O 0 3.611014065540985e-08
alleles O 0 9.052563143541192e-09
that O 0 7.676024815772564e-10
prevent O 0 7.421819603337099e-09
or O 0 1.714953512532702e-09
reduce O 0 2.3342170418771957e-09
the O 0 1.078392153353036e-09
risk O 0 8.14835221518706e-09
of O 0 3.3424953915783817e-09
developing O 0 1.9155693564698595e-07
BPAD B-Disease 1 1.0
, O 0 4.258950969671105e-10
similar O 0 5.950777370866689e-11
to O 0 1.201333615918898e-10
what O 0 2.474289106935146e-10
is O 0 5.777566966513881e-11
observed O 0 2.5280130766525133e-10
in O 0 3.9297887860501035e-11
other O 0 5.328582908248336e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 3.4838885110133333e-09
we O 0 2.2374198327401729e-10
used O 0 3.6618710841374025e-10
mental O 0 2.9299448556230345e-07
health O 0 6.322784429357853e-08
wellness O 0 5.725522100874514e-07
( O 0 1.016731587810682e-09
absence O 0 1.6948266079452878e-07
of O 0 9.637892262048808e-09
any O 0 3.0377297122186064e-08
psychiatric B-Disease 0 1.936051012307871e-05
disorder I-Disease 0 6.561983241226699e-07
) O 0 1.0571805930670308e-10
as O 0 1.4008492976724796e-10
the O 0 1.581803021899475e-10
phenotype O 0 9.284647717322514e-09
in O 0 4.5405529336406403e-10
our O 0 1.449774700290618e-08
genome O 0 1.9091892511369224e-08
- O 0 3.9765502890531934e-08
wide O 0 1.1734413618569306e-07
linkage O 0 1.5743978565296857e-07
scan O 0 5.0599698653286396e-08
of O 0 1.2996142828569646e-08
several O 0 7.191883089063822e-09
large O 0 5.837356908955371e-08
multigeneration O 0 2.798242803692119e-06
Old O 0 1.0387095983332983e-07
Order O 0 8.182600375050697e-09
Amish O 0 1.55494589648697e-07
pedigrees O 0 2.713283322464122e-07
exhibiting O 0 1.241999569856489e-07
an O 0 3.19777049284653e-09
extremely O 0 8.743556101364902e-09
high O 0 3.3297517632036033e-08
incidence O 0 2.1116375137353316e-06
of O 0 6.26161408945336e-07
BPAD B-Disease 1 1.0
. O 0 1.4280230971053243e-05

We O 0 1.739969377467787e-07
have O 0 4.386543572820756e-09
found O 0 2.0029808922572556e-09
strong O 0 2.171181678889411e-09
evidence O 0 4.948582432717785e-09
for O 0 3.638263024186017e-10
a O 0 2.2574091484983683e-09
locus O 0 4.6776541751114564e-08
on O 0 2.2293068724366094e-08
chromosome O 0 3.543962350249785e-07
4p O 0 4.616079240804538e-05
at O 0 1.8924292533029075e-07
D4S2949 O 0 5.023418907512678e-07
( O 0 1.2144059091667714e-09
maximum O 0 5.765950561453792e-08
GENEHUNTER O 0 5.285462975734845e-06
- O 0 7.692183601193392e-08
PLUS O 0 8.277383045651732e-08
nonparametric O 0 1.1487340856319861e-07
linkage O 0 1.683395112195285e-08
score O 0 1.3744241300628346e-08
= O 0 5.476735953635625e-09
4 O 0 1.6363147281595047e-08
. O 0 1.437457819442045e-09
05 O 0 1.0978726550092688e-07
, O 0 5.146703507818984e-09
P O 0 1.7454371459280082e-07
= O 0 5.889109644385826e-09
5 O 0 7.746228547489409e-09
. O 0 3.8405295610388634e-10
22 O 0 2.1380588410835344e-09
x O 0 3.766306377883666e-09
10 O 0 1.0747765344376603e-08
( O 0 6.86755430301389e-10
- O 0 4.3458783238747856e-09
4 O 0 8.12676237416099e-09
) O 0 9.671342199313315e-11
; O 0 9.78725323008689e-10
SIBPAL O 0 8.641576982881816e-07
Pempirical O 0 4.7840721606462466e-08
value O 0 3.0867897127251354e-09
< O 0 5.357349563972491e-10
3 O 0 8.0705464533537e-10
x O 0 1.6337878827599184e-09
10 O 0 4.324726798898837e-09
( O 0 3.1594829530412483e-10
- O 0 2.239384677693579e-09
5 O 0 4.4112105079818775e-09
) O 0 5.621448445625177e-11
) O 0 2.2630584906035978e-11
and O 0 2.4015719968240035e-11
suggestive O 0 9.667953104752769e-10
evidence O 0 1.0226400837254346e-09
for O 0 1.4181274210489647e-10
a O 0 1.951475869788055e-09
locus O 0 3.165228434909295e-08
on O 0 5.8593542462404e-08
chromosome O 0 4.632370291801635e-06
4q O 0 6.451494846260175e-05
at O 0 1.2900497381451714e-07
D4S397 O 0 5.847570037076366e-07
( O 0 1.7789686390656811e-09
maximum O 0 6.386014206327673e-08
GENEHUNTER O 0 6.322118679236155e-06
- O 0 7.918335853673852e-08
PLUS O 0 1.0622736823506784e-07
nonparametric O 0 1.9224616210067325e-07
linkage O 0 2.3907714918891543e-08
score O 0 2.4471400905667906e-08
= O 0 3.021790373480826e-09
3 O 0 6.188283663277616e-09
. O 0 7.15646653048907e-10
29 O 0 4.095594263731073e-08
, O 0 2.8355380266020802e-09
P O 0 7.67483214758613e-08
= O 0 2.5151201121786926e-09
2 O 0 3.6597500585600073e-09
. O 0 3.3377159369685216e-10
57 O 0 1.667476934308354e-09
x O 0 2.0795949406959835e-09
10 O 0 7.188002193458942e-09
( O 0 4.366448869141948e-10
- O 0 2.279922917125532e-09
3 O 0 3.24036220078483e-09
) O 0 1.047725864400384e-10
; O 0 9.096625674942516e-10
SIBPAL O 0 1.0590433703328017e-06
Pempirical O 0 6.642583372240551e-08
value O 0 8.553091568330728e-09
< O 0 9.652162402673525e-10
1 O 0 8.280676144778454e-10
x O 0 4.49055015394606e-09
10 O 0 8.493089787009467e-09
( O 0 6.306362654306952e-10
- O 0 2.6012272336117803e-09
3 O 0 4.01022948182117e-09
) O 0 5.349484397121351e-11
) O 0 9.759393813923989e-12
that O 0 2.2917839501146453e-11
are O 0 3.516343119458476e-11
linked O 0 1.2691431017231025e-08
to O 0 3.4964369177714616e-09
mental O 1 0.9709739685058594
health O 0 0.0023180535063147545
wellness O 0 0.00037712164339609444
. O 0 1.1362005807313835e-06

These O 0 8.79452315416529e-08
findings O 0 1.4090875311012496e-07
are O 0 6.508334982058273e-10
consistent O 0 1.2138924532223427e-08
with O 0 3.491428673951802e-11
the O 0 3.057915864967953e-10
hypothesis O 0 2.6870925484701047e-09
that O 0 7.558741826896309e-12
certain O 0 5.718815421218437e-10
alleles O 0 5.79665782041161e-09
could O 0 4.382512575062947e-09
prevent O 0 1.5684086918099638e-08
or O 0 5.97863314411029e-09
modify O 0 2.2949674161054645e-08
the O 0 1.7284107478587885e-09
clinical O 0 1.0674667372256863e-08
manifestations O 0 2.2390661058580008e-07
of O 0 1.2255412684680778e-07
BPAD B-Disease 1 1.0
and O 0 1.8597757778238133e-09
perhaps O 0 2.286320022193422e-09
other O 0 1.2546484962072668e-09
related O 0 1.6541928289370844e-06
affective B-Disease 1 0.9999953508377075
disorders I-Disease 1 0.9956904053688049
. O 0 4.422199708642438e-06

Segregation O 0 7.053177796478849e-06
distortion O 0 2.6438678105478175e-05
in O 0 3.8807425539744145e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00011043455015169457

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999992847442627
DM B-Disease 1 1.0
) O 0 1.0836095043487148e-07
is O 0 2.0518418075710088e-09
an O 0 9.128153788395821e-10
autosomal B-Disease 0 0.012969586998224258
dominant I-Disease 1 0.9999991655349731
disease I-Disease 1 0.9999998807907104
which O 0 2.442637758726107e-10
, O 0 1.4741628057146627e-11
in O 0 1.2427625768751671e-11
the O 0 4.5226697387157344e-10
typical O 0 4.608532666594556e-09
pedigree O 0 1.4312263374449685e-08
, O 0 2.2375135078078756e-10
shows O 0 6.920031214718847e-10
a O 0 7.15908776705021e-10
three O 0 5.813928227738074e-10
generation O 0 3.1570465353070176e-08
anticipation O 0 6.680191404484503e-07
cascade O 0 3.023968019988388e-06
. O 0 9.592594096829998e-07

This O 0 1.6272568847952584e-09
results O 0 1.034004704081326e-08
in O 0 1.9195764977553154e-09
infertility B-Disease 1 0.9901294112205505
and O 0 3.1790057164471364e-07
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 7.369179115812585e-07
CDM B-Disease 0 4.119584673389909e-07
) O 0 1.2036035362816833e-11
with O 0 1.9381117804390113e-12
the O 0 1.665279858453772e-10
disappearance O 0 4.42999841254732e-08
of O 0 4.3787046877241664e-08
DM B-Disease 1 1.0
in O 0 1.0304941788774613e-08
that O 0 7.0636430038462095e-09
pedigree O 0 2.7091277843283024e-06
. O 0 8.870972010299738e-07

The O 0 4.108127527047145e-08
concept O 0 4.027509348247804e-08
of O 0 1.2738042620696888e-08
segregation O 0 9.149113111561746e-08
distortion O 0 8.736606105230749e-07
, O 0 7.946151514559574e-10
where O 0 2.371137175494198e-10
there O 0 3.1388190657732906e-11
is O 0 4.9198518523030366e-12
preferential O 0 6.503160787652007e-10
transmission O 0 1.4749067522856762e-09
of O 0 4.0700945391769494e-10
the O 0 4.5900463985226736e-10
larger O 0 3.785145530343925e-09
allele O 0 1.3886481298186482e-08
at O 0 5.501527677864715e-09
the O 0 1.4499489608965632e-08
DM B-Disease 1 1.0
locus O 0 1.9782762095132966e-08
, O 0 9.801787159702258e-10
has O 0 3.1630223440437533e-10
been O 0 2.7374877364927386e-10
put O 0 1.89238780201606e-09
forward O 0 1.3964756462314654e-08
to O 0 2.9462330353169364e-09
explain O 0 3.748477794829341e-08
partially O 0 1.1743057370949828e-07
the O 0 1.7246236660994896e-09
maintenance O 0 3.799578252028368e-08
of O 0 3.021929728674877e-08
DM B-Disease 1 1.0
in O 0 1.1276173328411687e-09
the O 0 2.8449642641703576e-09
population O 0 1.9272325957331304e-09
. O 0 1.977872443603701e-08

In O 0 1.5542692466397057e-08
a O 0 5.722255558282541e-09
survey O 0 8.244668947554601e-09
of O 0 5.753807652553178e-09
DM B-Disease 1 1.0
in O 0 4.230874761645964e-09
Northern O 0 7.102405419345814e-08
Ireland O 0 3.8677381297702595e-09
, O 0 4.752483739878244e-09
59 O 0 5.113320611371819e-08
pedigrees O 0 1.9148497187870817e-07
were O 0 2.5151404514645037e-08
ascertained O 0 4.230879312672187e-06
. O 0 3.2822146067701397e-07

Sibships O 0 1.0178312550124247e-05
where O 0 7.800032619798003e-09
the O 0 7.391089962283104e-10
status O 0 2.116756103731632e-09
of O 0 1.1700812541093342e-09
all O 0 1.2376183411433317e-10
the O 0 8.073533508401454e-10
members O 0 1.124397450147363e-10
had O 0 6.290672982522949e-10
been O 0 1.555246209594685e-10
identified O 0 1.0792665650072308e-09
were O 0 1.5951430454297366e-10
examined O 0 3.931065195583727e-10
to O 0 3.3690997908175646e-11
determine O 0 6.919107509162359e-10
the O 0 7.341899865842549e-10
transmission O 0 1.204209354455088e-08
of O 0 2.6308206724223737e-09
the O 0 2.2061691140606854e-08
DM B-Disease 1 1.0
expansion O 0 3.836279915958585e-08
from O 0 2.323228054379456e-09
affected O 0 5.619663401290609e-09
parents O 0 4.133802744554771e-10
to O 0 1.4751487809050445e-09
their O 0 9.480039864229184e-09
offspring O 0 9.517171974948724e-07
. O 0 5.473135047395772e-07

Where O 0 1.6022349313971063e-07
the O 0 3.9487890290956784e-08
transmitting O 0 2.6365694338892354e-07
parent O 0 1.1790569942604634e-07
was O 0 3.621608613002536e-08
male O 0 3.913322554893739e-09
, O 0 2.0735588801557014e-09
58 O 0 7.979588190210052e-08
. O 0 8.078547608647568e-08

3 O 0 2.3728817666324176e-07
% O 0 3.3603619886690694e-09
of O 0 7.100977028606792e-10
the O 0 4.6500381323255624e-10
offspring O 0 2.8941786744951514e-09
were O 0 4.064570902073683e-10
affected O 0 1.5997660973710026e-09
, O 0 4.8145105957519974e-11
and O 0 1.4057762766361837e-11
in O 0 1.9077156521163374e-11
the O 0 1.060553381226903e-10
case O 0 7.837415161304762e-10
of O 0 1.0857041932155198e-09
a O 0 2.3989008557379066e-09
female O 0 1.6745374864512996e-08
transmitting O 0 6.135820029840033e-08
parent O 0 5.502758426700893e-08
, O 0 1.2396489168509106e-08
68 O 0 5.333100716597983e-07
. O 0 4.65079239120314e-07

7 O 0 3.2387563351221615e-06
% O 0 4.348924065311621e-08
were O 0 2.604394477856431e-09
affected O 0 1.2393255133247294e-07
. O 0 1.8879045171615871e-07

Studies O 0 3.606278937695606e-07
on O 0 5.885788922910251e-08
meiotic O 0 6.368152298819041e-07
drive O 0 1.0946588702154258e-07
in O 0 1.1435743907384222e-08
DM B-Disease 1 1.0
have O 0 3.194604858425265e-10
shown O 0 3.9755736896962546e-11
increased O 0 4.190505928369781e-11
transmission O 0 2.4364119055597655e-10
of O 0 4.160560437838079e-11
the O 0 6.401590368909638e-11
larger O 0 4.512906437437181e-10
allele O 0 6.8246230888746595e-09
at O 0 3.617657950982789e-09
the O 0 1.2141656569042425e-08
DM B-Disease 1 1.0
locus O 0 1.0450145637719288e-08
in O 0 3.2375822023311684e-09
non O 0 5.4875886235095095e-06
- O 0 2.134694659616798e-05
DM O 1 1.0
heterozygotes O 0 1.897114202620287e-06
for O 0 3.7493357751827716e-08
CTGn O 0 2.5247703888453543e-05
. O 0 7.180864827205369e-07

This O 0 4.5968761241965694e-08
study O 0 4.669753916886066e-09
provides O 0 1.8400310164423672e-09
further O 0 1.0065821509641637e-09
evidence O 0 1.8181300021069546e-08
that O 0 3.178251661850595e-09
the O 0 2.2481596317902586e-07
DM B-Disease 1 1.0
expansion O 0 1.408648358847131e-06
tends O 0 1.0727207921945592e-07
to O 0 1.5060606095573803e-09
be O 0 6.176562372672834e-09
transmitted O 0 5.336132602451471e-08
preferentially O 0 1.462802430296506e-07
. O 0 1.6319798135100427e-07

Diagnosis O 0 0.0002799754438456148
of O 0 2.019289240706712e-05
hemochromatosis B-Disease 1 1.0
. O 1 0.99809330701828

If O 0 7.345789526880253e-06
untreated O 1 1.0
, O 0 1.397915241341252e-07
hemochromatosis B-Disease 1 1.0
can O 0 4.3344942923795315e-07
cause O 1 0.9999995231628418
serious O 0 0.22110801935195923
illness O 1 0.9999793767929077
and O 0 3.4918165581210303e-10
early B-Disease 0 7.616191233239533e-09
death I-Disease 0 4.6034745793122056e-08
, O 0 1.0895580271341743e-10
but O 0 2.1951739037628926e-10
the O 0 7.490162379220067e-10
disease O 0 1.7555965570181797e-08
is O 0 1.8384022082429397e-10
still O 0 2.275264837647839e-10
substantially O 0 1.506156266373182e-08
under O 0 2.372958931573521e-07
- O 0 5.8926461861119606e-06
diagnosed O 0 8.1588194689175e-07
. O 0 2.3333240051215398e-07

The O 0 8.619190339231864e-07
cornerstone O 0 3.942614057450555e-06
of O 0 2.6317453105662025e-08
screening O 0 1.5124023144963417e-09
and O 0 1.124697626697646e-10
case O 0 2.1180554532485019e-10
detection O 0 1.1742082861587733e-09
is O 0 4.001995956848248e-11
the O 0 7.030047377565296e-11
measurement O 0 8.93563711912293e-09
of O 0 2.9996929384878968e-09
serum O 0 1.5201248260154898e-08
transferrin O 0 8.802108197869529e-08
saturation O 0 5.575614636654791e-08
and O 0 2.509954022400507e-09
the O 0 1.6286238135876374e-08
serum O 0 4.359608851700614e-07
ferritin O 0 8.083854481810704e-06
level O 0 2.905854216805892e-06
. O 0 1.0255354254695703e-06

Once O 0 7.584388868053793e-07
the O 0 1.8101095733413786e-08
diagnosis O 0 4.3946187133769854e-07
is O 0 1.7326156065422538e-09
suspected O 0 5.1302599501923396e-08
, O 0 1.1755326712048486e-09
physicians O 0 1.449306674672357e-09
must O 0 1.0959553264910937e-09
use O 0 1.1138050481918071e-08
serum O 0 1.5457420659004129e-06
ferritin O 0 1.4484236999123823e-05
levels O 0 9.440362305213057e-07
and O 0 9.202211259662363e-08
hepatic O 1 0.9999376535415649
iron O 0 0.00010489067790331319
stores O 0 1.5367378409791854e-06
on O 0 7.635118492999027e-08
liver O 0 3.12300500127094e-07
biopsy O 0 1.2176676555952781e-08
specimens O 0 6.979255506855964e-10
to O 0 1.9444489074427196e-10
assess O 0 5.99699800929443e-09
patients O 0 4.71664873824551e-10
for O 0 1.5760238947226668e-10
the O 0 3.5326688241354987e-09
presence O 0 5.77477763386014e-08
of O 0 8.498990382577176e-07
iron B-Disease 0 0.0001445261441404
overload I-Disease 0 0.004608399700373411
. O 0 5.382173640100518e-06

Liver O 0 0.0002831300371326506
biopsy O 0 8.597027772339061e-06
is O 0 5.438853811767785e-09
also O 0 9.042579185436495e-11
used O 0 1.631388427125735e-11
to O 0 2.910728602589785e-11
establish O 0 1.305489272240834e-09
the O 0 1.8696488801595024e-09
presence O 0 6.797822305060208e-09
or O 0 6.187351075936931e-09
absence O 0 1.28252918329963e-06
of O 0 4.256235186517188e-08
cirrhosis B-Disease 0 0.00046034608385525644
, O 0 2.933614740019408e-10
which O 0 2.6549790144159147e-11
can O 0 1.7085599601784907e-10
affect O 0 3.8220161258095686e-08
prognosis O 0 6.6166999204142485e-06
and O 0 1.465206089790172e-08
management O 0 1.0390048998942802e-07
. O 0 4.885795306108776e-07

A O 0 1.566195805935422e-06
DNA O 0 1.3000587273381825e-07
- O 0 1.6622129450638568e-08
based O 0 1.7351655667852128e-09
test O 0 1.0704545583273273e-10
for O 0 2.53854159915079e-10
the O 0 2.2462389281940887e-08
HFE O 0 6.366698471538257e-06
gene O 0 2.6767862593146674e-08
is O 0 1.6132484237374456e-09
commercially O 0 4.85506257419388e-09
available O 0 2.0324832927798298e-09
, O 0 6.325598378431607e-11
but O 0 8.222032082949582e-11
its O 0 1.0709345216186605e-10
place O 0 1.0683582907233813e-09
in O 0 6.073981595466904e-11
the O 0 8.753764935143238e-10
diagnosis O 0 1.9304718534840504e-07
of O 0 3.311125595928388e-08
hemochromatosis B-Disease 1 1.0
is O 0 1.1124615184598952e-07
still O 0 1.087335643745746e-08
being O 0 7.855407879731047e-09
evaluated O 0 6.361578641644883e-08
. O 0 2.3211303812331607e-07

Currently O 0 2.4479575699842826e-07
, O 0 2.2561263968157164e-09
the O 0 1.1270260280582534e-09
most O 0 1.9596359257523233e-10
useful O 0 1.5563744737434604e-09
role O 0 1.0531434058158595e-10
for O 0 4.0066856082932034e-11
this O 0 7.08068673138662e-11
test O 0 7.323602141395824e-11
is O 0 3.6928359675725275e-11
in O 0 8.941283477503781e-12
the O 0 3.44967318599565e-11
detection O 0 2.268350396406049e-09
of O 0 4.894915139885825e-09
hemochromatosis B-Disease 1 1.0
in O 0 8.100746740069553e-09
the O 0 1.5763923499889643e-08
family O 0 4.153824839647768e-09
members O 0 1.1309229941414145e-10
of O 0 5.325846985648752e-10
patients O 0 1.3101457418951412e-10
with O 0 1.4577443419039326e-11
a O 0 2.2920430831074867e-10
proven O 0 3.871170051183981e-09
case O 0 3.693966688089745e-09
of O 0 7.721563832774336e-09
the O 0 6.050551348835143e-08
disease O 0 9.92914465314243e-07
. O 0 2.1679969108845398e-07

It O 0 1.3964596590199108e-08
is O 0 1.209943700786198e-09
crucial O 0 1.7421170284137588e-08
to O 0 7.203497354169031e-09
diagnose O 1 0.9799638390541077
hemochromatosis B-Disease 1 1.0
before O 1 0.9999998807907104
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 5.24247809607914e-07
because O 0 1.4999115283131914e-09
phlebotomy O 0 2.112865189474178e-07
therapy O 0 2.130759346741229e-09
can O 0 1.9141095652930318e-10
avert O 0 2.6374144113106013e-07
serious O 0 1.0896113963099197e-05
chronic O 1 1.0
disease O 1 0.9938594698905945
and O 0 5.254510715424487e-10
can O 0 9.864500188916381e-11
even O 0 5.492477028745668e-10
lead O 0 1.0254703752821115e-09
to O 0 4.1077319323790107e-10
normal O 0 2.960006284524752e-08
life O 0 6.0998894824138006e-09
expectancy O 0 4.359554495181328e-08
. O 0 5.196139518659493e-09
. O 0 1.2787781145107147e-07

Prevalence O 0 3.190207735315198e-06
of O 0 3.4190090758556835e-08
the O 0 2.484662786628178e-08
I1307K O 0 5.628118628919765e-07
APC B-Disease 0 1.6422179172081997e-08
gene O 0 3.720821706298949e-10
variant O 0 2.4666284570429298e-09
in O 0 1.2518940051275962e-10
Israeli O 0 7.217277442350678e-09
Jews O 0 1.1910989972108155e-09
of O 0 7.519961736646152e-11
differing O 0 5.994821861143862e-10
ethnic O 0 4.161133937419237e-10
origin O 0 2.5890802834993565e-09
and O 0 3.9383524219616106e-10
risk O 0 1.66242859478416e-08
for O 0 8.571992538008999e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3777320191366016e-06

BACKGROUND O 0 0.00014066013682167977
& O 0 2.6829052330867853e-06
AIMS O 0 2.946054564745282e-06
Israeli O 0 7.664831400688854e-07
Jews O 0 1.3049663039055304e-07
of O 0 3.021716565854149e-08
European O 0 4.505549355826588e-08
birth O 0 6.224889261829958e-07
, O 0 3.209663290704157e-08
i O 0 1.3117548824936875e-08
. O 0 1.4416147164908466e-09
e O 0 1.5151048193828842e-09
. O 0 9.404952372449316e-10
, O 0 5.60704871421791e-10
Ashkenazim O 0 1.9366677861398784e-07
, O 0 5.977638384280226e-10
have O 0 1.1241786668225728e-10
the O 0 1.7371888372252897e-09
highest O 0 4.0052785266198043e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.2846747665662406e-07
of O 0 8.596506145819305e-11
any O 0 1.4809130310933227e-10
Israeli O 0 7.843733129675456e-08
ethnic O 0 9.191016836496146e-09
group O 0 4.994582081252474e-09
. O 0 4.2826112434113384e-08

The O 0 2.8365295747789787e-06
I1307K O 0 6.187476174090989e-06
APC B-Disease 0 2.54839790159167e-07
gene O 0 1.137973804077319e-08
variant O 0 1.2618494338312303e-07
was O 0 2.856242176108026e-08
found O 0 4.87312357133618e-10
in O 0 6.265454821630101e-10
6 O 0 2.1014268725139118e-07
. O 0 1.8874581542149826e-07

1 O 0 4.3222098611295223e-07
% O 0 7.99306487664353e-09
of O 0 1.9718937593893315e-09
American O 0 1.5811342235494408e-09
Jews O 0 5.535409908219435e-09
, O 0 3.9914324623246955e-10
28 O 0 1.4815953797153725e-08
% O 0 1.205394450920494e-09
of O 0 1.0300515995709247e-09
their O 0 8.055175726440211e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 5.045164730432816e-09
, O 0 1.8235244911291026e-11
but O 0 7.024428781698955e-12
not O 0 1.5027536506839745e-11
in O 0 1.63245389428468e-10
non O 0 2.4823322064548847e-08
- O 0 1.869614330018976e-08
Jews O 0 1.0066501232586234e-07
. O 0 1.701865812719916e-07

We O 0 1.0741621281340485e-07
assessed O 0 5.277677814774506e-07
the O 0 8.702212284106281e-09
I1307K O 0 1.2822610528928635e-07
prevalence O 0 7.073039931526637e-09
in O 0 4.2005086908769584e-11
Israeli O 0 5.1388169275412565e-09
Jews O 0 7.338483709595778e-10
of O 0 7.547047709000054e-11
differing O 0 7.036638494106739e-10
ethnic O 0 2.1850814213575376e-10
origin O 0 1.1725588278110877e-09
and O 0 3.194531861261396e-10
risk O 0 1.5268488695596716e-08
for O 0 5.0432241494036134e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.01410580555239e-06

METHODS O 0 8.822637482808204e-07
DNA O 0 4.8222744908343884e-08
samples O 0 4.05524946955893e-09
from O 0 2.3273571958526418e-09
500 O 0 2.881200833471098e-10
unrelated O 0 1.5885431858819743e-09
Jews O 0 1.238561031513541e-09
of O 0 7.645967747826887e-10
European O 0 1.0456002730308e-09
or O 0 8.717391253298956e-10
non O 0 3.974447881915921e-09
- O 0 1.3946747923210268e-10
European O 0 1.6902271249286116e-10
origin O 0 1.225266665905167e-09
, O 0 4.148816359905716e-11
with O 0 1.0572325133406668e-11
or O 0 5.420269788558585e-11
without O 0 1.1814368927609564e-10
a O 0 1.6835027816242132e-10
personal O 0 2.8159949927442085e-09
and O 0 1.2365948265369298e-09
/ O 0 7.533492940581255e-09
or O 0 1.4694676586657351e-09
family O 0 1.2859213693872107e-09
history O 0 2.3131558890554516e-09
of O 0 2.9498317122289563e-09
neoplasia B-Disease 0 4.280553156377209e-08
, O 0 1.686428108271798e-09
were O 0 4.355377725140386e-10
examined O 0 3.213551424963157e-09
for O 0 2.0995212512975314e-10
the O 0 1.750052658344714e-09
I1307K O 0 9.318853244622005e-09
variant O 0 8.960755470965864e-10
by O 0 2.079193345272401e-10
the O 0 1.8159215242619098e-09
allele O 0 1.6763772592298665e-09
- O 0 1.3708053581140689e-09
specific O 0 1.4976361262242222e-09
oligonucleotide O 0 4.4242565877539164e-07
( O 0 4.051640800639689e-08
ASO O 0 1.5228838492475916e-06
) O 0 8.823144992398113e-10
method O 0 6.561101173474526e-08
. O 0 1.699319369663499e-07

RESULTS O 0 2.4947667043306865e-06
In O 0 4.254958607674553e-09
persons O 0 3.987966579188651e-08
at O 0 9.03050612066636e-09
average O 0 1.2279836703044111e-08
risk O 0 5.3669251265375806e-09
for O 0 1.408048611040158e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.657307041076251e-09
I1307K O 0 3.453134311826034e-08
was O 0 2.227728890247249e-09
found O 0 1.4825267402596154e-10
in O 0 4.183663415702199e-10
5 O 0 7.842327676144123e-08
. O 0 1.8248741184834216e-07

0 O 0 3.3350531225551094e-07
% O 0 8.779602822528432e-09
of O 0 1.6370756972250433e-09
120 O 0 4.566349520729318e-09
European O 0 6.848734024345049e-09
and O 0 3.88675136520078e-09
1 O 0 1.5775239603499358e-07
. O 0 2.1079020484648936e-07

6 O 0 4.3570912566792686e-06
% O 0 3.072810628168554e-08
of O 0 6.648715356050161e-09
188 O 0 1.081983658224317e-08
non O 0 1.9951919227878534e-08
- O 0 5.073322650872569e-09
European O 0 1.080618350357554e-08
Jews O 0 8.450337674048569e-08
( O 0 3.988709806890256e-09
P O 0 2.1217699952558178e-07
= O 0 1.1760356244394643e-08
0 O 0 8.543733720500768e-09
. O 0 1.6024381821466704e-09
08 O 0 2.5071706488688505e-08
) O 0 2.0374006926004995e-09
. O 0 3.915205581961345e-08

It O 0 3.0299638353881164e-08
occurred O 0 3.076646351019008e-07
in O 0 5.20938714387853e-09
15 O 0 1.2670226112732053e-07
. O 0 2.544322796893539e-07

4 O 0 3.651953193184454e-07
% O 0 2.8610391833439053e-09
of O 0 1.1759587748016997e-09
52 O 0 1.2334389509760513e-08
Ashkenazi O 0 2.9772024845442502e-08
Israelis O 0 1.9154299479851034e-08
with O 0 5.91964810503498e-10
familial O 0 1.1221515450188235e-07
cancer B-Disease 0 5.84370673095691e-06
( O 0 5.930839819257017e-09
P O 0 6.19228330833721e-07
= O 0 3.636364098724698e-09
0 O 0 3.3323932502327125e-09
. O 0 4.133573761055942e-10
02 O 0 2.013307076609294e-09
) O 0 6.241081436375584e-12
and O 0 3.5824291449992884e-11
was O 0 3.106254697904376e-10
not O 0 2.0497430142096817e-11
detected O 0 3.0968666520081456e-10
in O 0 2.0147121471136842e-10
51 O 0 2.086696149206091e-08
non O 0 3.4313366370497533e-08
- O 0 5.544708692184486e-09
European O 0 9.34747923508894e-09
Jews O 0 8.239940996190853e-08
at O 0 1.4043767926352757e-08
increased O 0 5.079628451198914e-08
cancer B-Disease 0 1.37770015840033e-07
risk O 0 1.239613993675448e-07
. O 0 9.6857910136805e-08

Colorectal B-Disease 0 0.0001301022566622123
neoplasia I-Disease 0 8.561614959035069e-05
occurred O 0 1.5439445633091964e-05
personally O 0 7.699269666261443e-09
or O 0 1.4165270345589676e-10
in O 0 2.0617570151149067e-11
the O 0 6.547827557934482e-11
families O 0 6.129284579881045e-11
of O 0 2.3967042239725345e-10
13 O 0 2.133024423756069e-09
of O 0 1.1705774127790392e-08
20 O 0 5.7269421205319304e-08
Ashkenazi O 0 1.2083092748582658e-08
I1307K O 0 2.0641524045572623e-08
carriers O 0 1.4554392413490547e-10
, O 0 6.15813441906532e-11
8 O 0 3.7326283730543253e-10
of O 0 9.739654638352135e-10
whom O 0 1.7843829525077126e-08
also O 0 1.1915722630817527e-08
had O 0 4.677152887211378e-09
a O 0 1.5343449843996382e-09
personal O 0 2.6955225607139255e-08
or O 0 4.51113635335787e-09
family O 0 3.361669831392078e-09
history O 0 2.0124865329762542e-08
of O 0 6.412268049871273e-08
noncolonic O 0 1.7778127585188486e-05
neoplasia B-Disease 0 6.94867703714408e-05
. O 0 2.9485393042705255e-06

CONCLUSIONS O 0 0.00011008713772753254
The O 0 5.255618589217192e-07
I1307K O 0 8.012123544176575e-06
APC O 0 1.5141787912398286e-07
variant O 0 7.264679879881442e-08
may O 0 2.9477733587413013e-09
represent O 0 1.3843552970627115e-09
a O 0 2.594557679813647e-09
susceptibility O 0 8.655105432353594e-08
gene O 0 1.9412269125496096e-08
for O 0 5.79239411990784e-08
colorectal B-Disease 1 1.0
, I-Disease 0 4.811688381067825e-09
or I-Disease 0 9.44689548809663e-10
other I-Disease 0 2.4360506944987037e-09
, I-Disease 0 1.080708522671614e-09
cancers I-Disease 0 1.1739984095981981e-08
in O 0 6.108140659932815e-10
Ashkenazi O 0 1.4500677991691191e-08
Jews O 0 3.055889763459163e-08
, O 0 2.2316160031010668e-09
and O 0 2.2671911015237356e-09
partially O 0 6.152801290681964e-08
explains O 0 7.384203914995169e-09
the O 0 3.9571540488836376e-10
higher O 0 1.2648657232716687e-08
incidence O 0 1.5018825934021152e-06
of O 0 1.406374252610476e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.670509145045855e-10
European O 0 4.444070000886313e-09
Israelis O 0 1.2749362099384598e-07
. O 0 7.229017739973642e-08

Systematic O 0 1.0616579260158687e-07
analysis O 0 4.243338835863142e-08
of O 0 4.962829791566037e-08
coproporphyrinogen O 0 7.840344551368617e-06
oxidase O 0 5.438150765257888e-07
gene O 0 1.375887222820893e-06
defects O 1 0.9193037152290344
in O 0 2.1376644454562665e-08
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
and O 0 9.386176280656855e-09
mutation O 0 1.1903365404464239e-08
update O 0 1.197455361534594e-07
. O 0 7.131849599772977e-08

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 7.1017329901224e-06
HC B-Disease 1 1.0
) O 0 2.759170225630214e-09
is O 0 1.244418734724917e-10
an O 0 2.582465352674035e-10
acute O 1 0.9999998807907104
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9988188147544861
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 0 6.740461230947403e-06
caused O 0 1.1796215204640248e-07
by O 0 2.105833840637672e-10
deficient B-Disease 0 1.3902488049666317e-08
activity I-Disease 0 7.218378783591106e-09
of I-Disease 0 4.006101228526404e-09
coproporphyrinogen I-Disease 0 3.283078626736824e-07
III I-Disease 0 4.9848290473164525e-06
oxidase I-Disease 0 1.6471311425902968e-07
( O 0 5.2801851779804565e-08
CPO O 0 5.679476998921018e-06
) O 0 9.613144058562284e-09
. O 0 1.1685011003237378e-07

Clinical O 0 9.360520607515355e-07
manifestations O 0 5.2598476031562313e-05
of O 0 9.870009165524607e-08
the O 0 7.086057518534972e-09
disease O 0 8.523375072400086e-08
are O 0 8.542611930340005e-12
characterized O 0 2.313113763030561e-11
by O 0 3.650681753425422e-12
acute O 0 5.2940912098620174e-08
attacks O 0 9.247193011319155e-10
of O 0 1.55582036143187e-08
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.8053787798066878e-08
precipitated O 0 8.084016123177662e-09
by O 0 6.283427250730611e-11
drugs O 0 1.0322879218094272e-09
, O 0 1.0830072394441004e-09
fasting O 0 2.3227020307103885e-08
, O 0 8.812182983319872e-09
cyclical O 0 2.5457198717049323e-05
hormonal O 0 2.403753796897945e-06
changes O 0 2.3293308970551152e-07
, O 0 3.96910166955422e-08
or O 0 1.9129697648168076e-07
infectious B-Disease 0 4.629741852113511e-06
diseases I-Disease 0 4.583779173117364e-06
. O 0 1.780983609478426e-07

Skin O 1 0.9999977350234985
photosensitivity O 1 0.9999998807907104
may O 0 4.214344244246604e-06
also O 0 1.1360977936192285e-08
be O 0 1.8898989040394554e-09
present O 0 3.17365547175541e-08
. O 0 2.007438268947226e-07

The O 0 3.890677362505812e-07
seven O 0 1.256680661754217e-07
exons O 0 3.7175627198848815e-07
, O 0 6.369929916871797e-09
the O 0 4.7207100450918915e-09
exon O 0 9.248556587238e-09
/ O 0 2.092104089967961e-08
intron O 0 3.491647149189703e-08
boundaries O 0 4.838137002138865e-09
and O 0 2.985917346709499e-10
part O 0 4.1248315874042873e-10
of O 0 2.5447479679030494e-09
3 O 0 9.839949299816908e-09
noncoding O 0 1.1109936970399303e-08
sequence O 0 1.9305881338027575e-09
of O 0 1.828465556741321e-08
the O 0 9.238281251100489e-08
CPO O 0 9.072207944882393e-07
gene O 0 5.6387534641544335e-09
were O 0 8.730907552489953e-09
systematically O 0 3.1575448922183114e-09
analyzed O 0 8.601578338485183e-10
by O 0 6.507674260580742e-11
an O 0 3.6939298841964785e-10
exon O 0 2.9830996006730004e-10
- O 0 7.636013488188098e-10
by O 0 1.5631724803455427e-09
- O 0 5.3283621070931986e-08
exon O 0 1.5684028298323938e-08
denaturing O 0 2.932006964329048e-06
gradient O 0 9.125869837589562e-07
gel O 0 3.3728088055795524e-07
electrophoresis O 0 4.516011031796552e-08
( O 0 1.7734066659613745e-08
DGGE O 0 1.2076099665137008e-05
) O 0 3.7607700287267676e-10
strategy O 0 1.1470974170535442e-09
followed O 0 1.3504174167788818e-10
by O 0 8.708043834626533e-12
direct O 0 1.875942040596712e-10
sequencing O 0 2.97495139633952e-10
in O 0 3.1525965171752546e-10
seven O 0 7.310323457687673e-09
unrelated O 0 1.4146309013085556e-07
heterozygous O 0 5.039137107587521e-08
HC B-Disease 0 4.133383754378883e-06
patients O 0 2.9063875750523493e-09
from O 0 3.707116169593405e-09
France O 0 8.81781581085761e-09
, O 0 9.532236111553516e-10
Holland O 0 4.255777952266726e-09
, O 0 6.062456647804026e-10
and O 0 5.712535999791157e-10
Czech O 0 3.761842748417621e-08
Republic O 0 3.546673781329446e-07
. O 0 3.2041023132478585e-06

Seven O 0 3.6823618643211375e-07
novel O 0 3.584669627798576e-08
mutations O 0 1.6417262216350537e-08
and O 0 1.06553366130413e-09
two O 0 1.838100782691754e-10
new O 0 8.979678667309088e-10
polymorphisms O 0 1.3140837751279832e-08
were O 0 8.29161717064153e-09
detected O 0 1.322886049592853e-07
. O 0 5.540197633990829e-08

Among O 0 7.825711634268373e-08
these O 0 7.299427728924002e-09
mutations O 0 5.2183306564757004e-08
two O 0 6.878569269730406e-09
are O 0 9.251268084931041e-10
missense O 0 2.4440996071461996e-07
( O 0 4.887004134701556e-09
G197W O 0 3.6216988519299775e-07
, O 0 4.214589122142343e-09
W427R O 0 8.004572293884848e-08
) O 0 1.6692550119934424e-10
, O 0 1.9744406110078216e-10
two O 0 3.2384758763548405e-10
are O 0 3.1327079819121195e-10
nonsense O 0 6.01081069362408e-08
( O 0 2.6395763352837776e-09
Q306X O 0 2.961153597880184e-07
, O 0 3.19981419139026e-09
Q385X O 0 1.401588889393679e-07
) O 0 5.40483879873932e-10
, O 0 8.322382782921522e-10
two O 0 6.569874089201733e-10
are O 0 2.3658108805335587e-10
small O 0 3.628009226375184e-09
deletions O 0 1.3543761667733634e-07
( O 0 9.623784436030292e-09
662de14bp O 0 4.969081714989443e-07
; O 0 1.3818420185884861e-08
1168del3bp O 0 5.70503914332221e-07
removing O 0 9.919246934941839e-08
a O 0 1.1740745264887664e-08
glycine O 0 1.7937566099135438e-08
at O 0 1.3918381114308431e-08
position O 0 6.90213353138347e-09
390 O 0 2.1349781942348045e-09
) O 0 1.8787233921346846e-11
, O 0 3.434428783033461e-11
and O 0 3.924777863817397e-11
one O 0 2.7872448793431204e-10
is O 0 6.77636557977479e-11
a O 0 7.128891921226455e-10
splicing O 0 6.645333172627943e-08
mutation O 0 1.279727257497143e-07
( O 0 1.884249023476059e-08
IVS1 O 0 5.056427653471474e-06
- O 0 6.412598452243401e-08
15c O 0 2.2613194516907242e-07
- O 0 9.891942376327734e-09
- O 0 4.261545338835049e-09
> O 0 2.385645681002302e-09
g O 0 2.224871176181864e-09
) O 0 1.0912613868097054e-10
which O 0 6.48742379261158e-11
creates O 0 2.9080731156483353e-09
a O 0 8.28310919853692e-10
new O 0 1.1400913546566471e-09
acceptor O 0 1.4852822971533897e-08
splice O 0 2.023484967139666e-06
site O 0 9.286251270168577e-07
. O 0 3.9775142113285256e-07

The O 0 3.9755342129410565e-08
pathological O 0 3.499122158245882e-06
significance O 0 1.7768995803635335e-06
of O 0 2.338853448691225e-07
the O 0 1.1792076293204445e-07
point O 0 7.144237770262407e-07
mutations O 0 5.351063947500734e-08
G197W O 0 3.816283822288824e-07
, O 0 1.6782361056399964e-09
W427R O 0 7.029213122677902e-08
, O 0 6.405941888054656e-10
and O 0 3.258855407750616e-10
the O 0 2.808656862640646e-09
in O 0 2.030270618291752e-09
- O 0 1.1844887737311183e-08
frame O 0 5.907258682213978e-08
deletion O 0 9.144695667373526e-09
390delGly O 0 5.950490944428566e-08
were O 0 4.715865475901637e-10
assessed O 0 3.3367115737092945e-09
by O 0 1.1508729386155991e-10
their O 0 5.114807466455318e-10
respective O 0 4.041075030158936e-08
expression O 0 3.181158092502301e-08
in O 0 2.38862796209105e-09
a O 0 1.9514831972600177e-09
prokaryotic O 0 1.3297455359051469e-09
system O 0 1.346159517190415e-09
using O 0 5.328793517556107e-10
site O 0 3.3825813261501025e-08
- O 0 8.60737614516438e-09
directed O 0 5.22348608811285e-09
mutagenesis O 0 9.72087036643643e-07
. O 0 1.7904552862546552e-07

These O 0 9.30924226594243e-09
mutations O 0 3.7941248365314095e-08
resulted O 0 2.928178410854798e-08
in O 0 4.012216670012947e-10
the O 0 7.290490988687282e-10
absence O 0 7.199047136197123e-09
or O 0 2.9757118991113884e-10
a O 0 1.4736743769727667e-10
dramatic O 0 2.930562903458167e-09
decrease O 0 4.163488043218422e-08
of O 0 3.52630245004093e-08
CPO O 0 1.747672286001034e-05
activity O 0 6.762577413610416e-07
. O 0 6.486282586593006e-07

The O 0 9.186867089283623e-08
two O 0 8.848124011251457e-09
polymorphisms O 0 5.0942208673632194e-08
were O 0 8.649518878911522e-10
localized O 0 2.7228267640566628e-08
in O 0 1.898268625621924e-10
noncoding O 0 1.5325500868357267e-08
part O 0 2.57000998260537e-09
of O 0 1.2456145448425104e-08
the O 0 4.212571624861994e-09
gene O 0 1.1460674631535994e-09
1 O 0 1.1796908339078982e-08
) O 0 4.0805157863754715e-11
a O 0 4.518522500607247e-10
C O 0 9.822642255130631e-09
/ O 0 6.390711848602848e-10
G O 0 1.8773105292524406e-09
polymorphism O 0 2.7857516293749995e-10
in O 0 2.478034444308719e-10
the O 0 4.332727066014286e-09
promotor O 0 1.3224273516243557e-06
region O 0 5.17586471460163e-08
, O 0 5.3734088290013915e-09
142 O 0 3.486974975430712e-08
bp O 0 3.6305372930200974e-08
upstream O 0 8.412273189151165e-08
from O 0 8.453074684666717e-09
the O 0 1.1346706685344543e-08
transcriptional O 0 1.6289695281557215e-07
initiation O 0 2.6767557059770297e-08
site O 0 1.395818429728024e-07
( O 0 1.6336757502344312e-09
- O 0 1.3736118020801769e-08
142C O 0 1.7933946594439476e-07
/ O 0 4.1682692852873515e-09
G O 0 1.2303914331823762e-08
) O 0 1.322409959314541e-10
, O 0 8.668375739429024e-11
and O 0 3.8366618909657646e-11
2 O 0 9.068387707422687e-10
) O 0 2.212769377452073e-11
a O 0 7.38104577457932e-10
6 O 0 1.361737300697996e-08
bp O 0 3.778617418959129e-09
deletion O 0 1.9750358293268988e-10
polymorphism O 0 3.5129327224936446e-10
in O 0 2.60724108969157e-10
the O 0 1.3777041729667872e-09
3 O 0 4.079531379375112e-09
noncoding O 0 9.897188846252902e-09
part O 0 9.263416700378002e-10
of O 0 6.252493633951417e-09
the O 0 5.9331174639964956e-08
CPO O 0 1.5685245671193115e-06
gene O 0 1.5193652558309623e-08
, O 0 6.48877929165792e-09
574 O 0 4.891529670203454e-08
bp O 0 1.275598648931009e-08
downstream O 0 2.53550513917844e-08
of O 0 2.2890471740311114e-09
the O 0 1.5273053932673974e-09
last O 0 4.793109242839932e-10
base O 0 1.0859134702556617e-09
of O 0 4.942373732497174e-10
the O 0 1.7326553525265354e-09
normal O 0 2.021164924315144e-08
termination O 0 1.0990082444095606e-07
codon O 0 4.293054871595814e-07
( O 0 6.616572534312581e-08
+ O 0 8.41488656533329e-07
574 O 0 1.3499882243195316e-06
delATTCTT O 0 3.480342002148973e-06
) O 0 2.9170021065283436e-08
. O 0 2.729298387293966e-07

Five O 0 1.5310504295484861e-06
intragenic O 0 3.47182503901422e-05
dimorphisms O 0 8.729387445782777e-06
are O 0 2.499024320812282e-09
now O 0 7.581895111741233e-10
well O 0 1.5206540193712925e-10
characterized O 0 2.76499545481812e-10
and O 0 2.2942026750571998e-11
the O 0 5.3216507589493034e-11
high O 0 3.9437120236129886e-10
degree O 0 1.4917006518899711e-09
of O 0 5.63596613822881e-10
allelic O 0 4.35042579738365e-08
heterogeneity O 0 1.389838502063867e-07
in O 0 4.561857558371685e-09
HC B-Disease 1 0.9719139933586121
is O 0 4.147428178669088e-09
demonstrated O 0 1.6326914265007986e-09
with O 0 8.142594931648262e-11
seven O 0 1.8693058212448932e-10
new O 0 6.209453090599837e-11
different O 0 1.7333344828895925e-11
mutations O 0 2.2442923908183587e-10
making O 0 7.323881778820152e-11
a O 0 7.686760256087055e-11
total O 0 5.104136002742621e-10
of O 0 1.906139246443672e-09
nineteen O 0 1.0868059234780958e-06
CPO O 0 3.948733501601964e-05
gene B-Disease 0 1.6154989452843438e-06
defects I-Disease 0 0.0013126663397997618
reported O 0 1.0248260196021874e-07
so O 0 1.2677682237338672e-09
far O 0 7.06441127817925e-09
. O 0 4.749284965299694e-09
. O 0 4.7276234482751534e-08

Coincidence O 0 5.456397502712207e-06
of O 0 1.0257784310852003e-07
two O 0 5.762495369765475e-09
novel O 0 3.699842565652034e-08
arylsulfatase O 0 6.510402954518213e-07
A O 0 7.161469994798608e-08
alleles O 0 8.666549256020062e-09
and O 0 6.631706295223694e-09
mutation O 0 3.635825152059624e-08
459 O 0 6.928251394811014e-08
+ O 0 5.748238507408132e-08
1G O 0 8.516628895449685e-07
> O 0 1.1943777522560595e-08
A O 0 1.6339631869755067e-08
within O 0 9.350006324737592e-10
a O 0 9.957491498013837e-10
family O 0 1.9864991873674853e-09
with O 0 5.905551603291315e-10
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 1.0827360535925479e-10
molecular O 0 4.443372891849151e-10
basis O 0 5.440220496311099e-10
of O 0 2.559803480295386e-10
phenotypic O 0 1.5095160676992236e-07
heterogeneity O 0 2.7094898541690782e-05
. O 0 2.5184633614117047e-06

In O 0 1.9702856235426225e-08
a O 0 1.2721337760979168e-08
family O 0 3.6402016956316174e-09
with O 0 1.0606626688058896e-10
three O 0 7.763248932590727e-10
siblings O 0 5.6793600933247035e-09
, O 0 7.925168854505671e-11
one O 0 1.770537882972434e-11
developed O 0 1.0747016471190918e-10
classical O 0 3.243299406818778e-09
late O 0 2.6387656362203415e-06
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.1872102351494505e-08
MLD B-Disease 1 1.0
) O 0 3.4076708121943966e-10
, O 0 1.9628006164840173e-10
fatal O 0 2.4020613054176465e-08
at O 0 3.910681112273551e-09
age O 0 1.1637119712304411e-08
5 O 0 9.393017030845385e-09
years O 0 1.3719300140380142e-09
, O 0 2.7518579082119743e-10
with O 0 3.102465229165574e-10
deficient O 0 9.262259226261449e-08
arylsulfatase O 0 2.212115987276775e-06
A O 0 2.00058207155962e-06
( O 0 2.1403041117196153e-08
ARSA O 0 1.5372596635643276e-06
) O 0 3.3220790007781886e-10
activity O 0 1.3016180355762685e-09
and O 0 9.246888671432529e-11
increased O 0 4.8481130221489366e-09
galactosylsulfatide O 0 4.3535305849218275e-07
( O 0 1.3304363832844501e-08
GS O 1 1.0
) O 0 1.1184693171628624e-08
excretion O 0 6.117450368492428e-08
. O 0 7.488755215945275e-08

The O 0 1.2123311421419203e-07
two O 0 4.012226106908656e-09
other O 0 5.039298311970697e-09
siblings O 0 1.0517637605289565e-07
, O 0 5.2745754430816305e-09
apparently O 0 1.3367348117299116e-07
healthy O 0 2.0715949844429815e-08
at O 0 1.0718470555559634e-08
12 O 0 3.768548584304199e-09
( O 0 1.9443711918309958e-10
1 O 0 5.035762473681871e-09
/ O 0 4.975487244429644e-10
2 O 0 7.997804640780259e-10
) O 0 7.410209598712747e-12
and O 0 2.58520392593109e-11
15 O 0 1.7881254810170333e-10
years O 0 1.543572908380142e-10
, O 0 7.420850045569694e-11
respectively O 0 3.6154487736972385e-10
, O 0 1.08546761856676e-10
and O 0 2.655309583321497e-10
their O 0 2.5142854465087794e-09
father O 0 1.5961329609126551e-06
, O 0 2.380106600696763e-08
apparently O 0 2.3264091453256697e-07
healthy O 0 8.285325314716374e-09
as O 0 1.8605917917469128e-09
well O 0 1.2027235873901532e-09
, O 0 1.0439363817837943e-09
presented O 0 7.193257545168308e-08
ARSA O 0 3.9432281482731923e-05
and O 0 9.120400079609681e-08
GS O 1 1.0
values O 0 9.85978854117775e-09
within O 0 1.4012588867018394e-09
the O 0 1.5111797369016244e-09
range O 0 2.7876145836103206e-08
of O 0 4.000018094529878e-08
MLD B-Disease 1 1.0
patients O 0 2.0244759468823759e-07
. O 0 4.953873826707422e-07

Mutation O 0 1.1862884008451147e-08
screening O 0 2.4255306652065656e-09
and O 0 1.5580310652740792e-10
sequence O 0 1.5482641557706955e-10
analysis O 0 2.506928831191857e-10
disclosed O 0 5.316887818906935e-09
the O 0 6.579705114084788e-10
involvement O 0 3.6586544904793072e-09
of O 0 3.2534788196869613e-09
three O 0 4.835329914243403e-10
different O 0 3.0179023724485887e-09
ARSA O 0 1.183033782581333e-05
mutations O 0 1.09149986826651e-08
being O 0 7.422580328153572e-10
the O 0 1.3111882413152642e-10
molecular O 0 1.9416037666530883e-09
basis O 0 5.157807958511285e-09
of O 0 3.576929863413625e-09
intrafamilial O 0 1.5900133121249382e-06
phenotypic O 0 1.611146331015334e-06
heterogeneity O 0 5.798960046377033e-05
. O 0 3.7914883250778075e-06

The O 0 5.042118118581129e-07
late O 0 2.745163146755658e-05
infantile O 0 0.015023240819573402
patient O 0 1.4383887503299775e-07
inherited O 0 9.274797889702313e-07
from O 0 5.23248324668657e-08
his O 0 1.1890752915633129e-07
mother O 0 3.3278531930136523e-08
the O 0 4.672418008055956e-09
frequent O 0 4.189279145805358e-09
0 O 0 1.3625765404867707e-08
- O 0 1.2792192194410745e-08
type O 0 1.8824350078716634e-08
mutation O 0 3.50371536228522e-08
459 O 0 3.298896444903221e-08
+ O 0 9.439696135871145e-09
1G O 0 1.6019110660181468e-07
> O 0 3.0222455649209223e-09
A O 0 1.8223031972297576e-08
, O 0 9.644299941991008e-11
and O 0 6.545605030217061e-11
from O 0 7.684726188728064e-10
his O 0 8.359008596414697e-09
father O 0 1.4895065625353254e-08
a O 0 9.434524272933231e-10
novel O 0 2.0964412428270407e-09
, O 0 1.0633932623349551e-10
single O 0 4.697623956495534e-10
basepair O 0 1.758164245302396e-07
microdeletion O 0 5.083632004243555e-07
of O 0 1.7166692956038787e-08
guanine O 0 2.6948031361939684e-08
at O 0 1.3406024734763378e-08
nucleotide O 0 1.1537973243491706e-08
7 O 0 1.8084461927969642e-08
in O 0 6.743168246003961e-10
exon O 0 1.035625185608069e-08
1 O 0 7.353693121103788e-08
( O 0 4.129289354892762e-09
7delG O 0 3.8105849853309337e-07
) O 0 9.811444101615052e-09
. O 0 1.7386706474553648e-07

The O 0 3.3076167937906575e-07
two O 0 4.6536893449911076e-08
clinically O 0 0.002086764434352517
unaffected O 0 4.455871930986177e-06
siblings O 0 8.129524786681941e-08
carried O 0 8.423492126041765e-09
the O 0 5.756167542614321e-09
maternal O 0 5.691159685738967e-07
mutation O 0 8.23133277094712e-08
459 O 0 1.0031234864982252e-07
+ O 0 3.4618988564716346e-08
1G O 0 6.431682777474634e-07
> O 0 8.348109759026556e-09
A O 0 4.8388130835519405e-08
and O 0 5.773020950172736e-10
, O 0 1.1323173648714047e-10
on O 0 4.0056330474769197e-10
their O 0 2.407617993860356e-10
paternal O 0 2.483237437900243e-07
allele O 0 8.963529474215193e-09
, O 0 4.107943429865202e-10
a O 0 2.4077467797312124e-10
novel O 0 1.4260428393697566e-09
cytosine O 0 6.788736239826676e-10
to O 0 2.401848164801379e-10
thymidine O 0 9.374388554306279e-08
transition O 0 1.0813032957912583e-07
at O 0 3.551228644482762e-08
nucleotide O 0 1.9218511226881674e-07
2435 O 0 2.8782299068552675e-06
in O 0 2.888774108811276e-09
exon O 0 2.094719597778294e-08
8 O 0 1.8133022194888326e-08
, O 0 1.3341017179868686e-10
resulting O 0 5.344286124753239e-10
in O 0 2.832632219063047e-11
substitution O 0 1.0745490719443751e-08
of O 0 1.670884408611073e-08
alanine O 0 4.85983662201761e-07
464 O 0 2.447103497615899e-07
by O 0 5.626305465966652e-08
valine O 0 4.639327744371258e-05
( O 0 1.8468324469722575e-07
A464V O 0 9.161228263110388e-06
) O 0 5.202489461453297e-08
. O 0 2.4532371867280744e-07

The O 0 1.0710009519243613e-06
fathers O 0 1.1271038147242507e-06
genotype O 0 1.0303158148872171e-07
thus O 0 6.377262451451315e-08
was O 0 9.314112503489014e-08
7delG O 0 2.889784354920266e-06
/ O 0 1.1625559181993594e-06
A464V O 0 1.1947890925512183e-05
. O 0 1.1978213478869293e-06

Mutation O 0 6.659556106569653e-07
A464V O 0 2.0548191059788223e-06
was O 0 1.7119280215638355e-08
not O 0 1.0188586779813491e-10
found O 0 2.3022254935778363e-10
in O 0 2.5745763854168047e-10
18 O 0 2.2498062079989722e-08
unrelated O 0 4.264629751560278e-07
MLD B-Disease 1 1.0
patients O 0 1.0131546268610236e-08
and O 0 1.7234726978898607e-09
50 O 0 1.3122654074493312e-08
controls O 0 1.0302234443315683e-07
. O 0 1.6535808811113384e-07

A464V O 0 8.199521107599139e-05
, O 0 5.706965922058771e-08
although O 0 1.942371419261235e-08
clearly O 0 8.199398138231118e-08
modifying O 0 1.212035613207263e-06
ARSA O 0 0.0019730529747903347
and O 0 2.1822299913765164e-06
GS O 1 1.0
levels O 0 1.4902843759045936e-06
, O 0 3.934442549535788e-09
apparently O 0 3.8685591619014303e-08
bears O 0 7.943522462028341e-08
little O 0 1.980869246409611e-09
significance O 0 8.61475069058315e-09
for O 0 2.4778737395259043e-10
clinical O 0 1.7646339500743125e-08
manifestation O 0 4.6953723540354986e-06
of O 0 3.553512897269684e-07
MLD B-Disease 1 1.0
, O 0 1.498825596968345e-08
mimicking O 0 1.1912863584484512e-07
the O 0 3.469924081400677e-08
frequent O 0 9.53786184254568e-07
ARSA O 0 0.0009011594811454415
pseudodeficiency O 0 5.721721026930027e-05
allele O 0 5.636709374812199e-06
. O 0 1.3786428780804272e-06

Our O 0 4.0863952222025546e-07
results O 0 3.920182223282609e-08
demonstrate O 0 8.532544448769386e-09
that O 0 1.3148045152622245e-10
in O 0 5.863773355763158e-11
certain O 0 3.111604973682347e-09
genetic O 0 2.8750179126291187e-07
conditions O 0 1.3987036027174327e-06
MLD B-Disease 1 1.0
- O 0 2.781451485134312e-06
like O 0 1.237287250432928e-07
ARSA O 0 0.00013650412438437343
and O 0 9.273112056007449e-08
GS O 1 1.0
values O 0 1.3668114640097428e-08
need O 0 5.44418621295506e-10
not O 0 1.373977182028696e-10
be O 0 2.713279600996543e-10
paralleled O 0 2.9438865567499306e-08
by O 0 6.653355089092372e-10
clinical O 0 3.278622529023778e-08
disease O 0 4.388763557017228e-07
, O 0 3.1459293503566244e-10
a O 0 2.909686380725418e-10
finding O 0 2.088363482144473e-09
with O 0 4.90887851201105e-11
serious O 0 8.826414266138727e-09
diagnostic O 0 6.51713634169937e-08
and O 0 8.862532041575832e-09
prognostic O 1 0.9943056702613831
implications O 0 9.267272616853006e-06
. O 0 2.993961288666469e-06

Moreover O 0 2.4830244456097716e-06
, O 0 4.7891663967902787e-08
further O 0 7.421171517307812e-07
ARSA O 0 0.0005690819816663861
alleles O 0 1.7805895424771734e-07
functionally O 0 1.3818082322814007e-07
similar O 0 2.0371160314169856e-10
to O 0 3.8789657597071425e-10
A464V O 0 4.492805416589363e-08
might O 0 4.0423198122141457e-10
exist O 0 1.1588230375281228e-09
which O 0 5.186473472917896e-10
, O 0 1.59182111936218e-10
together O 0 6.472358066167416e-11
with O 0 2.6544486053659e-10
0 O 0 2.0507314957285416e-08
- O 0 7.090058762315721e-09
type O 0 8.722351729772981e-09
mutations O 0 1.2659977066675765e-08
, O 0 6.328461088500603e-10
may O 0 1.1472790495403729e-09
cause O 0 2.3705793239514605e-07
pathological O 0 0.0008475948125123978
ARSA O 1 0.9033476114273071
and O 0 1.3379813026404008e-06
GS O 1 1.0
levels O 0 2.4682350385774043e-07
, O 0 3.6996269936473425e-10
but O 0 6.374857586255445e-11
not O 0 2.8799906903742567e-11
clinical O 0 9.846909954092098e-10
outbreak O 0 9.62909041390958e-09
of O 0 1.4662033809287323e-09
the O 0 6.010189235183816e-09
disease O 0 5.377122391792e-08
. O 0 9.901304665049793e-09
. O 0 8.664073902764358e-08

Human O 0 0.05136255919933319
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.9924089908599854
to O 0 4.914788291898731e-07
hematological B-Disease 1 0.9999998807907104
malignancy I-Disease 1 0.9988994598388672
and O 0 2.6106276251880445e-08
neurofibromatosis B-Disease 0 0.0015148974489420652
type I-Disease 0 4.156456725468161e-06
1 I-Disease 0 9.56956409936538e-06
. O 0 5.793095851913677e-07

Heterozygous O 0 4.4710583324558684e-07
germ O 0 4.6869345169398e-06
- O 0 2.2352769235567393e-07
line O 0 4.798127051230949e-08
mutations O 0 1.2762939594068712e-09
in O 0 9.42710909335176e-11
the O 0 3.8986586181621874e-10
DNA O 0 7.754081110533662e-08
mismatch O 0 2.528655022615567e-05
repair O 0 5.923555818299064e-06
genes O 0 1.6244315474978066e-06
lead O 0 7.529343974965741e-07
to O 0 8.572188647804069e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.2920269177338923e-07

The O 0 4.679831988596561e-08
disease O 0 2.864841803784657e-07
susceptibility O 0 1.2197089915844117e-07
of O 0 1.2482925804135903e-08
individuals O 0 1.0220415624928592e-09
who O 0 5.4990231035390025e-08
constitutionally O 0 1.096961721458456e-08
lack O 0 4.373579898242497e-08
both O 0 1.4234666778634164e-09
wild O 0 2.140794030935922e-08
- O 0 9.354184982157676e-09
type O 0 7.04992819677841e-09
alleles O 0 4.7222590282558485e-09
is O 0 8.850887800448959e-10
unknown O 0 4.6141244069985987e-07
. O 0 2.7618048648037075e-07

We O 0 8.502478010541381e-08
have O 0 3.2796279025859576e-09
identified O 0 2.240287422239362e-08
three O 0 6.208626945891638e-10
offspring O 0 4.556901078700548e-09
in O 0 2.5458149477408654e-10
a O 0 7.841456373114397e-09
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.300350215340586e-08
who O 0 1.2622400347162e-10
developed O 0 7.705538984659199e-10
hematological B-Disease 0 5.264002993499162e-06
malignancy I-Disease 0 5.988198608974926e-06
at O 0 2.7028319582456106e-09
a O 0 2.33048330633423e-10
very O 0 8.321109079556521e-11
early O 0 1.670007465648382e-09
age O 0 2.5288389160493807e-09
, O 0 1.91616986167098e-10
and O 0 2.7668153879112367e-10
at O 0 9.456305738453352e-10
least O 0 6.389090922986895e-10
two O 0 1.3089793138298944e-10
of O 0 3.3820618527968804e-10
them O 0 2.5960808502922816e-10
displayed O 0 4.8704244193231716e-08
signs O 0 2.1808746453189087e-07
of O 0 3.991466712705005e-08
neurofibromatosis B-Disease 0 9.320350363850594e-05
type I-Disease 0 3.724329872056842e-06
1 I-Disease 0 1.9185223209206015e-05
( O 0 2.5640972012297425e-07
NF1 B-Disease 0 0.0003598518669605255
) O 0 1.697725480198642e-07
. O 0 6.014188329572789e-07

DNA O 0 8.386400196513932e-08
sequence O 0 1.172159258544525e-08
analysis O 0 6.430747934160763e-09
and O 0 3.3329380921820473e-10
allele O 0 1.1309020386818247e-09
- O 0 1.309733571597249e-10
specific O 0 4.848746404384485e-11
amplification O 0 7.811655766687409e-10
in O 0 1.744838856732045e-10
two O 0 1.0799420246954128e-09
siblings O 0 4.6990265900603845e-08
revealed O 0 3.098199030659998e-08
a O 0 1.3689300359942536e-08
homozygous O 0 1.6139176750584738e-07
MLH1 O 0 6.778815441066399e-05
mutation O 0 1.4254376878852781e-07
( O 0 1.0853279164280139e-08
C676T O 0 3.5484569593791093e-07
- O 0 9.520142896235484e-08
- O 0 1.1877062178200504e-07
> O 0 9.55521741730081e-08
Arg226Stop O 0 8.98900566426164e-07
) O 0 6.381676964650751e-09
. O 0 5.115105494724048e-08

Thus O 0 5.536768412639503e-07
, O 0 1.3976453772102104e-08
a O 0 1.0729004351617277e-08
homozygous O 0 8.617827518264676e-08
germ O 0 2.062243947875686e-05
- O 0 1.7407010091119446e-06
line O 0 8.631182595308928e-07
MLH1 O 0 3.191599898855202e-05
mutation O 0 2.660239495355654e-08
and O 0 1.4272564241579744e-09
consequent O 0 9.737582331581507e-06
mismatch O 1 0.9457724094390869
repair O 1 0.8626490235328674
deficiency O 1 0.9999995231628418
results O 0 8.300812623929232e-07
in O 0 3.0650999516268485e-09
a O 0 7.988965933236614e-09
mutator O 0 2.6907921437668847e-06
phenotype O 0 2.992340242258251e-08
characterized O 0 9.936698130985633e-10
by O 0 4.868701553029098e-10
leukemia B-Disease 0 0.0025186361744999886
and O 0 2.556742515480437e-07
/ O 0 0.08479814231395721
or O 0 1.412545543644228e-06
lymphoma B-Disease 1 1.0
associated O 0 3.912006832251791e-06
with O 0 3.273072701759361e-09
neurofibromatosis B-Disease 0 0.18131741881370544
type I-Disease 0 1.292018737331091e-06
1 I-Disease 0 1.3762913795289933e-06
. O 0 2.1567533536881456e-08
. O 0 1.634874138289888e-07

Missense O 0 2.6350049665779807e-05
mutations O 0 6.805893804084917e-07
in O 0 5.0651234317911076e-09
the O 0 5.522323043294364e-09
most O 0 7.0016958897412e-10
ancient O 0 8.670070883454173e-09
residues O 0 7.173117211323188e-08
of O 0 4.2968126834352915e-09
the O 0 2.4370882201196764e-08
PAX6 O 0 7.231583003886044e-05
paired O 0 5.097652433505573e-08
domain O 0 2.431168688588059e-08
underlie O 0 7.825443049114256e-08
a O 0 9.442013837457353e-10
spectrum O 0 7.324227624394553e-08
of O 0 4.29021218550929e-09
human O 0 3.714070044225082e-05
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 6.54567702440545e-05

Mutations O 0 3.5322605640430993e-07
of O 0 2.6533985675314398e-08
the O 0 3.408810345106872e-09
human O 0 1.5715558632223292e-08
PAX6 O 0 0.0003918829606845975
gene O 0 1.732000669107947e-06
underlie O 1 0.9999957084655762
aniridia B-Disease 1 1.0
( O 0 0.003985974937677383
congenital B-Disease 1 1.0
absence I-Disease 1 0.9999784231185913
of I-Disease 0 3.548352196958149e-06
the I-Disease 0 6.409040054222714e-08
iris I-Disease 0 3.5890144545192015e-07
) O 0 2.3548710204046586e-10
, O 0 7.704417659404328e-11
a O 0 1.1408021055592243e-10
rare O 0 8.946841489887447e-09
dominant O 1 0.9999998807907104
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 0.18580591678619385
eye I-Disease 1 0.9999346733093262
. O 0 5.820535307066166e-07

The O 0 5.4484196709836397e-08
spectrum O 0 9.133332241617609e-07
of O 0 3.620183122166054e-07
PAX6 O 0 0.00021533666586037725
mutations O 0 1.017668068925559e-06
in O 0 3.574148976781544e-08
aniridia B-Disease 1 1.0
patients O 0 8.285578445565989e-09
is O 0 3.0411703710875315e-10
highly O 0 7.389103218180537e-10
biased O 0 1.7506208038753357e-08
, O 0 3.107764393051049e-11
with O 0 6.468356232580685e-12
92 O 0 2.7645221667427222e-09
% O 0 6.385907774797417e-11
of O 0 2.5823799695845473e-11
all O 0 7.250715305939792e-11
reported O 0 2.3106379032356017e-09
mutations O 0 3.750220578524477e-09
leading O 0 2.2528883203420946e-09
to O 0 3.8717143380218033e-10
premature O 0 1.329682106643304e-07
truncation O 0 8.076041240201448e-07
of O 0 1.7580133260253206e-07
the O 0 1.5150686749620945e-07
protein O 0 1.3786468571197474e-06
( O 0 1.2356594858431436e-08
nonsense O 0 9.690818103536003e-08
, O 0 1.054237142028569e-09
splicing O 0 4.026961875069901e-09
, O 0 7.974695903634199e-10
insertions O 0 5.052569918007066e-09
and O 0 7.481595898362059e-10
deletions O 0 8.92017482101437e-09
) O 0 1.4698454953165907e-10
and O 0 6.009842623555528e-10
just O 0 1.943319283270739e-09
2 O 0 2.643223862008881e-09
% O 0 2.361635886849456e-10
leading O 0 1.4393225500342055e-10
to O 0 5.181138938020746e-12
substitution O 0 2.287798839262223e-09
of O 0 8.150994545985668e-09
one O 0 4.923887075847233e-09
amino O 0 1.1935101795756964e-08
acid O 0 1.0886425094724927e-09
by O 0 1.6617009157560148e-10
another O 0 1.966474805215057e-08
( O 0 1.2273350336045041e-08
missense O 0 7.334725751206861e-07
) O 0 1.59928177367874e-08
. O 0 1.4679731918931793e-07

The O 0 3.922441393910958e-08
extraordinary O 0 9.270030965069509e-09
conservation O 0 3.771915757511124e-08
of O 0 5.830110616500406e-09
the O 0 9.69134994477372e-09
PAX6 O 0 3.7256120322126662e-06
protein O 0 1.0466926170238366e-07
at O 0 1.0515828208212952e-08
the O 0 4.919681551029953e-09
amino O 0 9.005396606198701e-08
acid O 0 4.535113617976094e-08
level O 0 4.366536643374275e-08
amongst O 0 5.599060060035299e-08
vertebrates O 0 1.3319754543772433e-07
predicts O 0 2.1220001755750673e-08
that O 0 6.046681488847128e-10
pathological O 0 5.830469262946281e-07
missense O 0 1.204105615215667e-06
mutations O 0 8.30743474011797e-08
should O 0 1.3509746654705168e-09
in O 0 3.9165315435241155e-10
fact O 0 1.1868718230445552e-09
be O 0 2.1997970112153098e-10
common O 0 4.1480427426243693e-10
even O 0 4.633101957640662e-10
though O 0 6.488466430809581e-10
they O 0 1.7913207028819045e-10
are O 0 3.8861933115974523e-10
hardly O 0 6.318733625221284e-08
ever O 0 2.0524845822933457e-08
seen O 0 5.9459754453428104e-08
in O 0 2.341173654940576e-08
aniridia B-Disease 1 1.0
patients O 0 1.817128634229448e-07
. O 0 3.832777224488382e-07

This O 0 6.339760716400633e-09
indicates O 0 2.9165846626710845e-08
that O 0 2.6852825518730583e-10
there O 0 5.160609717336229e-10
is O 0 1.2128081872120333e-10
a O 0 3.434423856418789e-10
heavy O 0 1.616053850739263e-07
ascertainment O 0 8.027688636502717e-06
bias O 0 7.438608236043365e-07
in O 0 8.921940408690432e-10
the O 0 1.5436031342019874e-09
selection O 0 3.4109564062134723e-09
of O 0 1.1808248823186318e-09
patients O 0 1.8612156260644497e-10
for O 0 4.991475011095758e-10
PAX6 O 0 8.636089887659182e-07
mutation O 0 1.1544527556139883e-09
analysis O 0 6.78803624420965e-10
and O 0 1.307412234030636e-10
that O 0 2.3378202151924654e-10
the O 0 7.45824735304268e-09
missing O 0 1.1704510143317748e-06
PAX6 O 0 8.922646520659328e-05
missense O 0 7.731094228802249e-06
mutations O 0 9.717699640532373e-07
frequently O 0 5.555604687401683e-08
may O 0 2.146071942377148e-08
underlie O 0 7.168971023929771e-06
phenotypes O 0 3.826710326393368e-06
distinct O 0 7.959416592484558e-08
from O 0 3.474560017480144e-08
textbook O 0 9.238206985173747e-06
aniridia B-Disease 1 1.0
. O 0 2.129553422491881e-06

Here O 0 2.3184622932603816e-07
we O 0 8.120873751238378e-09
present O 0 4.832234168361538e-09
four O 0 1.3388667952085598e-09
novel O 0 2.1452903453678118e-08
PAX6 O 0 1.1500968867039774e-05
missense O 0 5.128861175762722e-07
mutations O 0 5.965979710254032e-08
, O 0 2.026730561155432e-09
two O 0 3.5911879026073734e-10
in O 0 1.555281736731473e-10
association O 0 1.1437177871442827e-09
with O 0 1.0210181311531841e-10
atypical O 0 6.671914434264181e-07
phenotypes O 0 6.758367590009584e-07
ectopia B-Disease 0 2.570306378402165e-06
pupillae I-Disease 0 2.4777045837254263e-06
( O 0 1.75381842382194e-09
displaced B-Disease 0 4.161915612144185e-08
pupils I-Disease 0 2.0792032984218167e-08
) O 0 2.0421433433170932e-09
and O 0 3.4846419794121175e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999561309814453
( O 0 1.0481466361511593e-08
searching B-Disease 0 1.2464255405575386e-07
gaze I-Disease 0 3.069041838443809e-07
) O 0 5.204218306298358e-11
, O 0 1.160682799872248e-10
and O 0 2.97868757437314e-10
two O 0 1.0643433911994293e-09
in O 0 1.7351357017858504e-09
association O 0 2.4327459158257625e-08
with O 0 1.2126885051699787e-09
more O 0 1.0722416732278361e-08
recognizable O 0 0.26369571685791016
aniridia B-Disease 1 1.0
phenotypes O 0 8.01960050011985e-06
. O 0 8.18741000330192e-07

Strikingly O 0 1.4723133972438518e-05
, O 0 2.4996596792448145e-08
all O 0 4.6723998003983525e-09
four O 0 3.7037590772115436e-09
mutations O 0 1.0078851531147848e-08
are O 0 1.675631716713255e-10
located O 0 1.2843428542907986e-09
within O 0 1.527494686293096e-09
the O 0 4.4942453314433806e-08
PAX6 O 0 2.8105932869948447e-05
paired O 0 4.6874252035422614e-08
domain O 0 2.6917515327795627e-08
and O 0 3.986762919794273e-09
affect O 0 1.04561515001933e-07
amino O 0 1.0355564938890893e-07
acids O 0 1.9842810061732052e-08
which O 0 3.186735875182478e-10
are O 0 3.4674513260668505e-11
highly O 0 4.944769038672803e-10
conserved O 0 4.3510706149163525e-09
in O 0 5.070021624753451e-10
all O 0 1.8570782689408816e-09
known O 0 2.3098371215724e-08
paired O 0 5.3795336185658016e-08
domain O 0 6.09023089737093e-08
proteins O 0 6.415498177148038e-08
. O 0 2.2952856681968115e-07

Our O 0 1.7263793949950923e-07
results O 0 2.988176461826697e-08
support O 0 2.5303152906275272e-09
the O 0 1.24906351928189e-09
hypothesis O 0 3.987949082073783e-09
that O 0 1.2516689941455272e-11
the O 0 8.654382765982405e-11
under O 0 3.4006911175943344e-10
- O 0 5.203902864181487e-10
representation O 0 6.419460962803214e-09
of O 0 1.4005409276762748e-08
missense O 0 4.683609517996956e-07
mutations O 0 7.57681348773076e-08
is O 0 1.719670295052822e-09
caused O 0 1.2446194297410784e-08
by O 0 2.6344257886279365e-09
ascertainment O 0 0.003237387863919139
bias O 0 9.092076652450487e-06
and O 0 1.4092541578136775e-09
suggest O 0 3.4251754765790565e-09
that O 0 1.49931025927863e-10
a O 0 6.925734985507859e-10
substantial O 0 6.681427322519085e-08
burden O 0 2.9471732432284625e-06
of O 0 6.283924449235201e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.7024267315864563
related I-Disease 0 0.025379858911037445
disease I-Disease 1 0.9999823570251465
remains O 0 6.526789064764671e-08
to O 0 3.583046082056285e-10
be O 0 6.736509128302259e-10
uncovered O 0 5.096281441296924e-08
. O 0 9.740699802307518e-09
. O 0 1.0739326938846716e-07

The O 0 4.3383526104889825e-08
chromosomal O 0 3.736899429895857e-07
order O 0 3.997287478796352e-08
of O 0 8.291668507354188e-08
genes O 0 3.132559527330159e-07
controlling O 0 1.6872691048774868e-06
the O 0 2.223852391125547e-07
major O 0 1.62619727461788e-07
histocompatibility O 0 6.614180847464013e-07
complex O 0 1.817842871787434e-07
, O 0 1.468170696128368e-09
properdin O 0 5.239224165620726e-08
factor O 0 7.145530833696512e-09
B O 0 2.285026390325129e-08
, O 0 1.324570869654096e-10
and O 0 1.6032872252047525e-10
deficiency B-Disease 0 3.302901347979059e-07
of I-Disease 0 7.5212010415270925e-06
the I-Disease 0 3.132920767257019e-07
second I-Disease 0 3.4707845486536826e-08
component I-Disease 0 6.104896499437018e-08
of I-Disease 0 1.8375697408146152e-08
complement I-Disease 0 1.5665855812585505e-07
. O 0 9.357735848425364e-07

The O 0 2.417929145792641e-08
relationship O 0 5.339071851295785e-09
of O 0 1.1706085878415706e-08
the O 0 1.185882836374219e-09
genes O 0 4.331849046135261e-10
coding O 0 1.3248696584255981e-09
for O 0 3.389365454964377e-10
HLA O 0 2.52287595259304e-08
to O 0 1.5958277754801742e-10
those O 0 2.900510387426891e-10
coding O 0 4.322046720517392e-09
for O 0 6.847489797401352e-10
properdin O 0 4.643094371203915e-07
Factor O 0 2.4800840492389398e-08
B O 0 8.93046134819997e-08
allotypes O 0 6.745991498746662e-08
and O 0 1.2006418081966785e-10
for O 0 1.0355293705854862e-10
deficiency B-Disease 0 8.660423134188022e-08
of I-Disease 0 4.342905768339733e-08
the I-Disease 0 6.860042756073881e-09
second I-Disease 0 4.606528936079712e-09
component I-Disease 0 2.116563457832399e-08
of I-Disease 0 1.906060198564319e-08
complement I-Disease 0 4.217920590576796e-08
( O 0 5.850528950190892e-09
C2 O 0 2.5529068636842567e-08
) O 0 3.197762610263055e-10
was O 0 2.7509829969574184e-09
studied O 0 9.116999932778924e-10
in O 0 3.188095967776583e-11
families O 0 3.7344299874675357e-10
of O 0 7.090826259492644e-10
patients O 0 2.681292077255648e-09
with O 0 5.265790026243167e-09
connective O 1 0.9999998807907104
tissue O 1 1.0
disorders O 1 1.0
. O 0 1.7359017192575266e-06

Patients O 0 2.5396241554176413e-08
were O 0 1.4829291128393152e-09
selected O 0 5.16792886262607e-10
because O 0 2.0575310899495491e-10
they O 0 9.745912410430435e-11
were O 0 2.0243652587570438e-10
heterozygous O 0 2.332886106515275e-09
or O 0 3.105355972365942e-09
homozygous O 0 1.098605793004026e-07
for O 0 8.397346391575411e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.442791113338899e-06

12 O 0 1.7525873090562527e-06
families O 0 2.5084286647825138e-08
with O 0 1.129858429038677e-09
15 O 0 4.032743916582149e-08
matings O 0 5.874393878002593e-07
informative O 0 5.161870717529382e-07
for O 0 1.642115279310019e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 6.877509406422178e-08
found O 0 5.821301485298136e-08
. O 0 1.3869730253190937e-07

Of O 0 1.3615598618343938e-05
57 O 0 4.898428869637428e-06
informative O 0 1.0638586900313385e-06
meioses O 0 2.3362995307252277e-06
, O 0 2.0997146243928455e-09
two O 0 4.252481700106614e-10
crossovers O 0 1.6566328753242487e-08
were O 0 3.60994983905627e-10
noted O 0 4.314510526626236e-09
between O 0 1.5566307354220044e-08
the O 0 3.6518945307761896e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.50770258500188e-08
and O 0 8.52512727078647e-09
the O 0 9.764174357940192e-09
HLA O 0 1.4078477761358954e-07
- O 0 8.412754226583274e-08
B O 0 8.208849777702198e-08
gene O 0 3.813623306037073e-10
, O 0 1.1228607627034037e-10
with O 0 1.4908877084274241e-12
a O 0 3.204452675431568e-11
recombinant O 0 8.97268856436817e-11
fraction O 0 3.033998829948814e-09
of O 0 8.069227064311235e-09
0 O 0 2.3492573575367715e-07
. O 0 2.9483436492228066e-07

035 O 0 0.0024177730083465576
. O 0 3.4836881241062656e-05

A O 0 3.5361604204808827e-06
lod O 0 8.173443347914144e-06
score O 0 1.9526055439200718e-07
of O 0 2.2468045202117537e-08
13 O 0 2.5564933281430058e-08
was O 0 2.648078423206357e-09
calculated O 0 1.6141223913024305e-09
for O 0 2.199301851746327e-10
linkage O 0 6.806699730077526e-06
between O 0 1.2489194887166377e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.7390782975089678e-08
HLA O 0 5.618738896373543e-07
- O 0 2.2890969830768881e-07
B O 0 2.1337359612516593e-07
at O 0 1.3381308561211114e-10
a O 0 2.3546171522975667e-12
maximum O 0 1.1276657559122771e-11
likelihood O 0 7.081429193034339e-11
value O 0 2.3991833519865224e-10
of O 0 1.1479658890145572e-10
the O 0 1.2064518828402981e-10
recombinant O 0 8.249458754994166e-11
fraction O 0 4.344097082054077e-09
of O 0 1.1854583981119049e-08
0 O 0 2.3145123861922912e-07
. O 0 3.4024662909359904e-07

04 O 0 0.0012114511337131262
. O 0 2.8129046768299304e-05

18 O 0 1.4410704807232833e-06
families O 0 1.3599878556647127e-08
with O 0 1.0489561441673345e-09
21 O 0 3.3415215483501015e-08
informative O 0 1.72219856153788e-08
matings O 0 4.760106619983162e-08
for O 0 2.9531983525288297e-09
both O 0 3.374822199475602e-08
properdin O 0 5.6256676543853246e-06
Factor O 0 2.7126827717438573e-07
B O 0 9.069984798770747e-07
allotype O 0 4.6090445948721026e-07
and O 0 1.145473582653267e-08
HLA O 0 2.3247415015248407e-07
- O 0 4.113091449653439e-07
B O 0 1.2854030728703947e-06
were O 0 2.4658053376924727e-09
found O 0 3.1144196110943767e-09
. O 0 4.0931421807499646e-08

Of O 0 1.7972597561310977e-05
72 O 0 7.692930921621155e-06
informative O 0 1.0355500990044675e-06
meioses O 0 4.826056738238549e-06
, O 0 5.455862428505043e-09
three O 0 1.892770606914951e-09
recombinants O 0 7.296729904737731e-07
were O 0 5.038250705524661e-09
found O 0 1.6927541590661122e-09
, O 0 1.0538345890376277e-10
giving O 0 2.1835773467149266e-10
a O 0 2.543931454379589e-10
recombinant O 0 9.039876069927288e-10
fraction O 0 1.658627901690579e-08
of O 0 4.607638004472392e-08
0 O 0 5.28056773418939e-07
. O 0 3.8692203929713287e-07

042 O 0 0.004589325748383999
. O 0 4.219072434352711e-05

A O 0 3.337571342854062e-06
lod O 0 8.14748909760965e-06
score O 0 1.4609901199946762e-07
of O 0 4.162503230986658e-08
16 O 0 8.70384297968485e-08
between O 0 2.5798190250725384e-08
HLA O 0 6.778965939702175e-07
- O 0 2.2997795667833998e-07
B O 0 1.0499498870331081e-07
and O 0 1.5344261972138895e-10
Factor O 0 9.34285759868203e-10
B O 0 1.5751600912494723e-08
allotypes O 0 2.3932122061864902e-08
was O 0 1.2558455386724177e-09
calculated O 0 1.8002269674965987e-09
at O 0 1.0826018553844463e-10
a O 0 1.5367479858086064e-11
maximum O 0 1.589584991412707e-10
likelihood O 0 1.5768244487901484e-09
value O 0 2.4413020494051807e-09
of O 0 1.0064860056502312e-09
the O 0 7.723799377856722e-10
recombinant O 0 5.072226527680357e-10
fraction O 0 8.401141116110011e-09
of O 0 9.806766954056911e-09
0 O 0 4.3625493617582833e-07
. O 0 4.095923316072003e-07

04 O 0 0.002106297528371215
. O 0 3.497676152619533e-05

A O 0 6.385106416928465e-07
crossover O 0 1.6098042010526115e-07
was O 0 2.764434015034567e-08
shown O 0 2.725364656175344e-10
to O 0 2.1346593936932834e-10
have O 0 1.4092024769318812e-10
occurred O 0 4.689837407312325e-09
between O 0 4.2229794661174935e-10
genes O 0 2.529763898362347e-10
for O 0 1.5070254766325064e-10
Factor O 0 3.3991622849782743e-09
B O 0 1.8130014822759222e-08
and O 0 8.066376455673208e-10
HLA O 0 3.511790680477134e-08
- O 0 1.2217860501095856e-07
D O 0 1.892154166682758e-08
, O 0 6.206863356617021e-10
in O 0 1.9483879787340896e-10
which O 0 5.747596287797307e-10
HLA O 0 5.3584482628821206e-08
- O 0 9.686289814681004e-08
D O 0 2.100693130557829e-08
segregared O 0 1.5495396610276657e-07
with O 0 8.251556105065561e-10
HLA O 0 6.800289042985241e-08
- O 0 3.6779532308628404e-08
A O 0 4.487401952246728e-07
and O 0 3.352046418214627e-09
B O 0 6.429199288504606e-07
. O 0 3.464355913251893e-08

These O 0 5.3284537671061116e-08
studies O 0 1.1886031714425371e-08
suggest O 0 3.1796034694053787e-09
that O 0 1.0836451874718378e-10
the O 0 2.7983140804543893e-10
genes O 0 3.817298421804338e-10
for O 0 1.9707233067656205e-10
Factor O 0 5.8473080599696914e-08
B O 0 0.4049237370491028
and O 0 1.3850361938239075e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.404737298178361e-09
located O 0 2.85212520267919e-09
outside O 0 2.1853407972116656e-09
those O 0 1.7318615985750796e-10
for O 0 2.9250774025157966e-10
HLA O 0 8.155585362601414e-08
, O 0 2.1554805162971036e-10
that O 0 2.025437630115423e-11
the O 0 9.488695940085279e-11
order O 0 1.087372525354624e-09
of O 0 1.2136470495249796e-08
genese O 0 4.691866593020677e-07
is O 0 4.029881761624665e-09
HLA O 0 5.4113943548372845e-08
- O 0 7.850199068570873e-08
A O 0 1.4895399544911925e-06
, O 0 3.5354055238911997e-09
- O 0 3.934270242922366e-09
B O 0 3.221691002863736e-08
, O 0 7.652402045366102e-10
- O 0 2.4381192620381853e-09
D O 0 1.5340143599829048e-09
, O 0 3.1833946589898687e-10
Factor O 0 9.485864538305577e-09
B O 0 3.413488229853101e-06
allotype O 0 6.406336615327746e-05
, O 0 2.462261818436673e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 9.165418424217364e-10
that O 0 2.700396850574549e-11
the O 0 1.2059779563866613e-10
genes O 0 4.204464332246971e-09
coding O 0 2.548013640080171e-07
for O 0 1.226726880076967e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 3.585023611307747e-09
Factor O 0 1.6991631213159053e-08
B O 0 1.1203144367755158e-07
allotypes O 0 3.182116969924209e-08
are O 0 7.923566663903259e-11
approximately O 0 3.7489814030955415e-10
3 O 0 1.5256865770751915e-09
- O 0 4.672727760279827e-10
- O 0 6.034561184087295e-10
5 O 0 1.0374989756201103e-09
centimorgans O 0 1.0026544927654868e-08
from O 0 1.0807168493442987e-09
the O 0 2.0328243532929946e-09
HLA O 0 6.860841228473191e-09
- O 0 3.37897487767691e-09
A O 0 3.4310751573229936e-08
and O 0 8.330275358403583e-10
HLA O 0 3.588863251025032e-08
- O 0 3.160034722782257e-08
B O 0 2.8026756027088595e-08
loci O 0 8.295061859620034e-10
, O 0 3.940251250278415e-11
and O 0 2.937217743331777e-12
that O 0 7.259205172735483e-13
the O 0 1.0627498880921848e-11
apparent O 0 1.1580385539389226e-09
lack O 0 1.9848782617515326e-09
of O 0 1.2183872799553797e-09
recombinants O 0 1.0301920383426477e-07
between O 0 8.734917789077201e-10
the O 0 2.5386106550229215e-09
Factor O 0 2.0582632487275987e-08
B O 0 7.829785317881033e-07
gene O 0 4.3121517023791966e-07
and O 1 0.9999433755874634
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.506606477936657e-08
suggests O 0 1.8826037617714064e-08
that O 0 2.0638659184446517e-11
these O 0 4.709607356878642e-11
two O 0 1.9749679669445186e-10
genes O 0 7.304622684500828e-09
lie O 0 1.477675493077868e-08
in O 0 7.275572366793881e-10
close O 0 2.8661526485507238e-08
proximity O 0 1.4887402244312398e-07
to O 0 3.000906190209207e-09
one O 0 1.1980946013068206e-08
another O 0 6.332162172384415e-08
. O 0 4.111977602860861e-07

Distribution O 0 3.8736803276151477e-07
of O 0 2.6434551614329393e-07
emerin O 0 3.5791508707916364e-06
and O 0 9.847778592586565e-09
lamins O 0 5.453759968077065e-06
in O 0 3.623196187518829e-09
the O 0 7.0328333379166e-08
heart O 0 1.0828718899347223e-07
and O 0 1.7424153231360151e-09
implications O 0 5.589584972653938e-08
for O 0 1.2404104410279615e-08
Emery B-Disease 0 0.0929655060172081
- I-Disease 1 0.9998084902763367
Dreifuss I-Disease 1 0.9999988079071045
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.003742855740711093

Emerin O 0 0.00015155135770328343
is O 0 5.270927516676238e-08
a O 0 2.0434690384263376e-08
nuclear O 0 1.992515308302245e-07
membrane O 0 6.593719348302329e-08
protein O 0 7.823174286158974e-08
which O 0 7.527973244769726e-10
is O 0 4.4503278839869154e-10
missing O 0 2.319027991859457e-08
or O 0 7.0628489723389976e-09
defective O 0 6.078417982280371e-07
in O 0 3.555369687546772e-08
Emery B-Disease 1 0.9998996257781982
- I-Disease 1 0.9999992847442627
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9601677060127258
EDMD B-Disease 1 1.0
) O 0 9.43151121646224e-08
. O 0 1.8805909007824084e-07

It O 0 8.719673871837585e-09
is O 0 1.1042160519281197e-09
one O 0 1.0119799442875888e-09
member O 0 1.1006203726182662e-09
of O 0 7.775879495852678e-09
a O 0 1.0424246355000832e-08
family O 0 1.140862480042415e-07
of O 0 3.000764934313338e-07
lamina O 1 0.9958174824714661
- O 0 4.860605713474797e-06
associated O 0 1.5498500260946457e-06
proteins O 0 7.958806058638856e-09
which O 0 6.606238334150305e-10
includes O 0 3.724279218353388e-10
LAP1 O 0 5.39157263119705e-05
, O 0 1.0688113505352703e-08
LAP2 O 0 0.00011261906911386177
and O 0 4.2644341391451235e-08
lamin O 0 1.2412053365551401e-05
B O 0 1.0382465006841812e-05
receptor O 0 8.569229976274073e-06
( O 0 1.4579670732928207e-06
LBR O 1 0.9592450857162476
) O 0 8.109206817152881e-08
. O 0 3.6406760273166583e-07

A O 0 1.1087698112532962e-05
panel O 0 6.479005492110446e-07
of O 0 1.5542238429588906e-07
16 O 0 7.995691930773319e-08
monoclonal O 0 2.6293871968618987e-08
antibodies O 0 1.6829520887995386e-08
( O 0 4.409830722806873e-09
mAbs O 0 6.147381981236322e-08
) O 0 3.178826091243536e-10
has O 0 3.1277705425658553e-10
been O 0 1.6302756367103655e-10
mapped O 0 1.3390916153710464e-09
to O 0 1.9761738079271396e-10
six O 0 4.149332821778984e-10
specific O 0 1.7683865483064665e-09
sites O 0 3.9707067855943023e-08
throughout O 0 1.6142585934630915e-08
the O 0 1.5962470456543087e-07
emerin O 0 9.612502935851808e-07
molecule O 0 6.211366088137993e-09
using O 0 1.923853965024591e-09
phage O 0 4.947129372823156e-09
- O 0 2.291222545025562e-09
displayed O 0 3.588779495800054e-09
peptide O 0 5.630947930157504e-10
libraries O 0 1.4521180924376154e-09
and O 0 6.118798245857704e-10
has O 0 1.5715484469325247e-10
been O 0 8.484547786569152e-11
used O 0 3.161766334858207e-11
to O 0 5.149607407162193e-10
localize O 0 3.739922647127969e-07
emerin O 0 8.109328177852149e-07
in O 0 1.2711508512452951e-09
human O 0 1.3638843832097791e-08
and O 0 5.335684605256574e-08
rabbit O 0 6.224437925084203e-07
heart O 0 9.9186775059934e-07
. O 0 6.304757107500336e-07

Several O 0 7.660644314455567e-07
mAbs O 0 1.5110600770640303e-06
against O 0 4.1981600418239395e-08
different O 0 6.080678360831371e-08
emerin O 0 3.0596513624914223e-06
epitopes O 0 2.7328587748343125e-07
did O 0 7.191361728331458e-09
not O 0 6.505120886401983e-10
recognize O 0 5.244630507661441e-09
intercalated O 0 6.398803975571354e-08
discs O 0 1.874631294640494e-08
in O 0 1.3068195414689399e-09
the O 0 2.530229892272473e-08
heart O 0 8.226466974292634e-08
, O 0 1.8288763836693533e-09
though O 0 1.1043718162184746e-09
they O 0 6.761727289195107e-10
recognized O 0 2.1301387320704634e-08
cardiomyocyte O 0 6.831527912254387e-07
nuclei O 0 2.236889145024179e-07
strongly O 0 1.862541942898588e-08
, O 0 9.834446590417656e-10
both O 0 1.980665187417685e-09
at O 0 2.1645256254032574e-08
the O 0 4.124411390193927e-08
rim O 0 3.040379112917435e-07
and O 0 1.9977424159378643e-09
in O 0 4.50974235732815e-09
intranuclear O 0 6.878728981973836e-06
spots O 0 1.4633063756264164e-06
or O 0 1.1490146079040642e-07
channels O 0 5.719649607272004e-07
. O 0 5.264628271106631e-07

A O 0 1.3624404346046504e-05
polyclonal O 0 1.4005340744915884e-05
rabbit O 0 7.662631560378941e-07
antiserum O 0 1.8089673403665074e-06
against O 0 4.259264230199733e-08
emerin O 0 4.685281055571977e-06
did O 0 6.171016142531016e-09
recognize O 0 5.488552279331316e-09
both O 0 8.293040920648309e-09
nuclear O 0 1.6689453730123205e-07
membrane O 0 6.960663512245446e-08
and O 0 1.7795115381247228e-09
intercalated O 0 1.3996409364835927e-08
discs O 0 1.0489866753005117e-08
but O 0 3.438187734516873e-09
, O 0 3.2447824982462237e-10
after O 0 2.058834214224703e-10
affinity O 0 8.556448882757195e-10
purification O 0 7.731184026305016e-10
against O 0 8.432989306861316e-10
a O 0 5.55334489504844e-09
pure O 0 1.6784969147920492e-07
- O 0 4.037084622154907e-08
emerin O 0 5.997669632051839e-07
band O 0 5.424567017797699e-09
on O 0 3.5641809503772492e-09
a O 0 1.3157784861661526e-09
western O 0 3.918298574490109e-08
blot O 0 1.2988977005079505e-06
, O 0 3.2872997657307224e-09
it O 0 1.3157734901625417e-09
stained O 0 3.989165122675331e-07
only O 0 5.9824887266302085e-09
the O 0 1.2953429440187847e-08
nuclear O 0 7.355417892540572e-07
membrane O 0 3.800161721301265e-06
. O 0 5.442431074698106e-07

These O 0 5.6360576650149596e-08
results O 0 3.3946090383096816e-08
would O 0 2.1979735809196654e-09
not O 0 5.353692489329376e-10
be O 0 4.2207165540375513e-10
expected O 0 3.86992971002087e-09
if O 0 9.685048318885947e-09
immunostaining O 0 1.4475057241725153e-06
at O 0 1.7475818125944897e-08
intercalated O 0 3.309111917815244e-08
discs O 0 1.9139070772666855e-08
were O 0 1.2833094586994775e-09
due O 0 2.8697397791432877e-09
to O 0 2.1601681554628271e-10
a O 0 4.0232439602050363e-10
product O 0 4.932026786974575e-09
of O 0 1.0116156801132092e-08
the O 0 3.3160997503500766e-08
emerin O 0 4.0075138940665056e-07
gene O 0 6.728294810187663e-09
and O 0 1.176264419200379e-08
, O 0 4.365033334785551e-10
therefore O 0 2.144466826337066e-09
, O 0 1.8171089632978976e-10
cast O 0 1.0767006175527172e-09
some O 0 1.7120047046681464e-10
doubt O 0 2.6510500461540687e-09
upon O 0 3.4808200766178743e-09
the O 0 4.2665940225283805e-10
hypothesis O 0 9.023206182234844e-09
that O 0 2.786107455854392e-10
cardiac B-Disease 0 2.0092415979888756e-06
defects I-Disease 0 3.727745934156701e-05
in O 0 2.7657366175048992e-08
EDMD B-Disease 1 1.0
are O 0 7.192798023858415e-10
caused O 0 4.683490928414358e-09
by O 0 1.33194830165273e-10
absence O 0 8.876696000470474e-08
of O 0 3.7594038104771244e-08
emerin O 0 5.761735337728169e-06
from O 0 1.0988257770350174e-07
intercalated O 0 2.575282223915565e-06
discs O 0 2.526893467802438e-06
. O 0 9.819494835028308e-07

Although O 0 2.663956877313467e-07
emerin O 0 9.768034033186268e-06
was O 0 3.801542547421377e-08
abundant O 0 1.0189569188412406e-08
in O 0 5.902939248514372e-10
the O 0 1.0829974250725627e-08
membranes O 0 9.802619160836912e-08
of O 0 8.82742838825834e-08
cardiomyocyte O 0 3.067652016852662e-07
nuclei O 0 1.6110851674966398e-07
, O 0 7.006838997902776e-10
it O 0 2.5819479887445596e-10
was O 0 3.5798919384433248e-09
absent O 0 7.1035004545194624e-09
from O 0 1.896268475576335e-09
many O 0 1.8551347125139728e-09
non O 0 1.0971714203833471e-07
- O 0 2.4212656768440866e-08
myocyte O 0 1.484831102516182e-07
cells O 0 4.943733422635432e-09
in O 0 8.54500026292726e-10
the O 0 1.3376728169589569e-08
heart O 0 1.849222286409713e-07
. O 0 2.7915447731174936e-07

This O 0 2.4511657148451604e-09
distribution O 0 4.826866728535606e-08
of O 0 6.847405131793494e-08
emerin O 0 8.000869456736837e-06
was O 0 7.0433689991489246e-09
similar O 0 8.218205976850967e-11
to O 0 1.0750850210072826e-10
that O 0 1.445656233611814e-10
of O 0 4.171800682684079e-09
lamin O 0 1.772035943758965e-06
A O 0 1.0900351981035783e-06
, O 0 1.730515286624268e-09
a O 0 2.1494053203952035e-09
candidate O 0 1.0917017512213079e-08
gene O 0 1.6877924613467599e-09
for O 0 1.9371242387933307e-09
an O 0 1.5845729173236123e-09
autosomal O 0 1.2533336146702823e-08
form O 0 1.1832243629328332e-08
of O 0 1.5914271216388443e-06
EDMD B-Disease 1 1.0
. O 0 8.296346095448826e-06

In O 0 5.166100791598183e-08
contrast O 0 5.142805434843467e-07
, O 0 1.0412228590439554e-07
lamin O 0 8.823297685012221e-05
B1 O 0 0.00029343130881898105
was O 0 2.041624384219176e-06
absent O 0 1.9006093907592003e-06
from O 0 1.0993016985594295e-07
cardiomyocyte O 0 1.6753175486883265e-06
nuclei O 0 4.020947130811692e-07
, O 0 1.1773434449580122e-09
showing O 0 7.929168432951883e-09
that O 0 3.965089145907541e-09
lamin O 0 1.3273918739287183e-05
B1 O 0 4.33110380981816e-06
is O 0 4.167678702149402e-10
not O 0 8.725221239958003e-11
essential O 0 1.4542965720565348e-09
for O 0 3.1366062525073346e-10
localization O 0 5.957525672783959e-07
of O 0 7.72678347971123e-08
emerin O 0 1.6345387621186092e-06
to O 0 5.58924106996983e-09
the O 0 3.152407046513872e-08
nuclear O 0 2.2852327674627304e-06
lamina O 1 0.6174754500389099
. O 0 2.8899660264869453e-06

Lamin O 0 0.3245651423931122
B1 O 0 0.07526814937591553
is O 0 1.8948907154481276e-07
also O 0 1.078592148928692e-08
almost O 0 2.0292148406042543e-08
completely O 0 3.308266798285331e-07
absent O 0 7.918915230220591e-07
from O 0 5.691909876759382e-08
skeletal O 0 3.0634353151981486e-06
muscle O 0 1.6256341268672259e-06
nuclei O 0 0.00017959201068151742
. O 0 6.066794639991713e-07

In O 0 7.242418291752983e-07
EDMD B-Disease 1 1.0
, O 0 9.034692993736826e-09
the O 0 7.370129506689693e-10
additional O 0 2.0307160397692314e-09
absence O 0 1.0281936368983224e-07
of O 0 1.4694579419938236e-07
lamin O 0 0.0003436434781178832
B1 O 0 0.0011995227541774511
from O 0 1.3763255992671475e-06
heart O 1 0.5353162288665771
and O 0 1.7739703253027983e-06
skeletal O 1 0.6112911701202393
muscle O 0 1.6041036360547878e-05
nuclei O 1 0.9999902248382568
which O 0 1.948873062929124e-08
already O 0 3.0546762896932478e-09
lack O 0 6.473984370813923e-08
emerin O 0 1.0884727998927701e-06
may O 0 3.4731004738830507e-09
offer O 0 2.6448123691125147e-09
an O 0 9.66485086406621e-11
alternative O 0 2.9337283713459783e-09
explanation O 0 4.9215515218747896e-08
of O 0 1.4090534072863647e-08
why O 0 1.77869807771458e-08
these O 0 1.0793865357072718e-08
tissues O 0 5.617576803729207e-08
are O 0 9.725770189206173e-10
particularly O 0 6.012172981684216e-09
affected O 0 1.9939708550964497e-08
. O 0 1.0791270987908774e-08
. O 0 1.6791597090559662e-07

Genetic O 0 1.3244185481653403e-07
mapping O 0 1.4672536963189486e-07
of O 0 7.821592618029172e-08
the O 0 1.1602162430790486e-07
copper B-Disease 0 7.739740794932004e-06
toxicosis I-Disease 0 8.560896822018549e-05
locus O 0 1.7014599507092498e-07
in O 0 1.0176827380803388e-08
Bedlington O 0 1.3778102584183216e-05
terriers O 0 1.8803824559654458e-06
to O 0 1.2185227049599234e-08
dog O 0 5.0952511543300716e-08
chromosome O 0 2.8644803862221124e-08
10 O 0 1.6512320399897362e-08
, O 0 2.456682912654884e-10
in O 0 1.2040565766646694e-10
a O 0 6.833008048268141e-10
region O 0 1.2043264163708045e-08
syntenic O 0 2.564816554695426e-07
to O 0 1.7374274241532817e-09
human O 0 2.7637801380819838e-08
chromosome O 0 4.410682947764144e-07
region O 0 2.730725157107372e-07
2p13 O 0 4.415574949234724e-06
- O 0 6.173444262458361e-07
p16 O 0 1.1410293154767714e-06
. O 0 3.528442675815313e-07

Abnormal O 1 0.9999994039535522
hepatic B-Disease 1 1.0
copper I-Disease 0 0.000231284269830212
accumulation I-Disease 0 0.000385002902476117
is O 0 1.1306043878889227e-09
recognized O 0 1.3886474192759124e-09
as O 0 9.369143239013056e-10
an O 0 3.270844706193543e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 6.339279678968524e-08
man O 0 3.112933768534276e-07
, O 0 1.0704838127040261e-09
mouse O 0 8.56987902864148e-09
, O 0 4.091469829603511e-09
rat O 0 4.0314212412795314e-08
and O 0 1.4526174041407103e-08
dog O 0 9.834715228862478e-07
. O 0 1.140284211942344e-06

The O 0 5.769525657228769e-08
major O 0 2.225072393002847e-07
cause O 1 0.5809633731842041
of O 0 0.002685357118025422
hepatic B-Disease 1 1.0
copper I-Disease 0 0.005225684959441423
accumulation I-Disease 1 0.9999514818191528
in O 0 4.543416309843451e-07
man O 0 1.1089285180787556e-05
is O 0 6.038797795149264e-10
a O 0 2.088514916565032e-09
dysfunctional O 0 8.038538368282389e-08
ATP7B O 0 0.0004263407608959824
gene O 0 3.645519086603599e-08
, O 0 8.791902317284439e-09
causing O 0 1.2465947065720684e-06
Wilson B-Disease 0 2.3008325911177963e-07
disease I-Disease 0 6.055870107957162e-05
( O 0 1.3524190656255541e-08
WD B-Disease 0 6.761224540241528e-06
) O 0 1.560852425086523e-08
. O 0 1.3542471322125493e-07

Mutations O 0 1.2702639651251957e-06
in O 0 4.0681893409555414e-08
the O 0 8.798046025049189e-08
ATP7B O 0 0.0004384618659969419
genes O 0 2.7573300087624375e-08
have O 0 6.406993269258976e-10
also O 0 1.9547680141229762e-10
been O 0 8.24115498065936e-11
demonstrated O 0 4.145243315267777e-10
in O 0 3.2005084693587094e-10
mouse O 0 3.044458196654887e-08
and O 0 4.482089366319997e-08
rat O 0 9.202578326039657e-07
. O 0 1.6530353263988218e-07

The O 0 2.84483553514292e-06
ATP7B O 0 0.0007689957274124026
gene O 0 9.514734244930878e-08
has O 0 4.903942141254447e-09
been O 0 2.89305690515107e-10
excluded O 0 2.5796209612849452e-09
in O 0 3.258300920738755e-11
the O 0 2.1846813247350383e-10
much O 0 9.898788455586782e-10
rarer O 0 6.338832463370636e-07
human O 0 6.864038226694902e-08
copper B-Disease 0 8.025789952625928e-07
overload I-Disease 0 3.194958480889909e-05
disease O 0 1.2545898243843112e-05
non B-Disease 0 1.766552304616198e-05
- I-Disease 0 1.6808132841106271e-07
Indian I-Disease 0 6.964671506182185e-09
childhood I-Disease 0 4.2992252247131546e-07
cirrhosis I-Disease 1 0.8080461025238037
, O 0 9.651113241915255e-10
indicating O 0 1.7026311027734664e-08
genetic O 0 1.0612631484718804e-07
heterogeneity O 0 2.918833388321218e-06
. O 0 6.14640953244816e-07

By O 0 1.0765984548299912e-08
investigating O 0 2.4258095976392724e-08
the O 0 3.798648950947836e-09
common O 0 8.650253846553824e-08
autosomal O 1 0.9999086856842041
recessive O 1 0.9999998807907104
copper B-Disease 1 0.9992857575416565
toxicosis I-Disease 1 0.5083948969841003
( O 0 6.026009202741989e-08
CT B-Disease 0 2.6704867650551023e-06
) O 0 2.8644883687256595e-10
in O 0 1.7097343540939391e-09
Bedlington O 0 1.4698080121888779e-05
terriers O 0 6.083548669266747e-06
, O 0 3.2805351768416813e-09
we O 0 9.589570248991208e-10
have O 0 6.779972416826041e-11
identified O 0 8.333946865946018e-10
a O 0 8.250733429804313e-11
new O 0 1.2424408724065472e-10
locus O 0 1.1677780964447493e-09
involved O 0 4.3535089422341855e-10
in O 0 2.7641002819933647e-09
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.9305382181755704e-07

We O 0 1.3648048025061144e-07
examined O 0 1.290930953246061e-07
whether O 0 6.549357944862777e-09
the O 0 3.205539655937173e-08
WD B-Disease 0 4.639032340492122e-06
gene O 0 4.3105893610118073e-07
ATP7B O 1 0.9999992847442627
was O 0 1.2394390580539039e-07
also O 0 6.010129061095881e-10
causative O 0 6.207162339677552e-09
for O 0 4.729864833130648e-10
CT B-Disease 0 1.6999321417188185e-07
by O 0 4.275114429130866e-10
investigating O 0 1.0603198319358853e-08
the O 0 1.887299383440677e-08
chromosomal O 0 1.468036430196662e-06
co O 0 2.893066266551614e-07
- O 0 6.621319670330195e-08
localization O 0 1.9528920347511303e-06
of O 0 3.455052421941218e-07
ATP7B O 0 0.00021201508934609592
and O 0 1.3827726519366479e-08
C04107 O 0 8.887944602520292e-08
, O 0 1.7712718791695892e-10
using O 0 6.634912758096689e-11
fluorescence O 0 4.0456464844851325e-09
in O 0 1.874330024520532e-09
situ O 0 1.4589878105653042e-07
hybridization O 0 2.896377893080171e-08
( O 0 6.936949681346505e-09
FISH O 0 2.103802216879558e-06
) O 0 6.25719343005926e-09
. O 0 1.255659896060024e-07

C04107 O 0 9.866304026218131e-05
is O 0 2.9780316879168822e-08
an O 0 2.885255367957029e-09
anonymous O 0 3.8394201595792765e-08
microsatellite O 0 4.278210496977408e-07
marker O 0 3.396332886040909e-07
closely O 0 2.3187006092939555e-08
linked O 0 2.4626206140965223e-07
to O 0 4.576047274440498e-08
CT B-Disease 0 0.00042731623398140073
. O 0 6.25830637090985e-07

However O 0 3.8131622659420827e-06
, O 0 2.2496890039747086e-07
BAC O 0 1.3993259017297532e-05
clones O 0 2.1778235748115549e-07
containing O 0 4.1243954029823726e-08
ATP7B O 0 0.00013533535820897669
and O 0 6.298864541065541e-09
C04107 O 0 4.613512487594562e-07
mapped O 0 1.1438187286216817e-08
to O 0 1.1096145113853595e-09
the O 0 1.129535842636642e-08
canine O 0 1.0342378686800657e-07
chromosome O 0 1.4833463524155377e-07
regions O 0 1.8665932088879345e-07
CFA22q11 O 0 3.343675416545011e-06
and O 0 1.1142533118402298e-08
CFA10q26 O 0 1.7497300177637953e-06
, O 0 3.229133183069166e-09
respectively O 0 5.0721227218275544e-09
, O 0 4.659093666425917e-10
demonstrating O 0 3.667765646753196e-09
that O 0 1.835929408500192e-09
WD B-Disease 0 1.3915666841057828e-06
cannot O 0 2.150804867540046e-08
be O 0 8.907134585456333e-09
homologous O 0 2.1669627869869146e-08
to O 0 6.872932800661147e-08
CT B-Disease 0 7.973730680532753e-05
. O 0 6.081421020098787e-07

The O 0 7.638519491592888e-06
copper O 0 4.7141534196271095e-06
transport O 0 7.104735573193466e-07
genes O 0 3.0875898460180906e-07
CTR1 O 0 0.026556918397545815
and O 0 2.8634588034037733e-08
CTR2 O 1 0.9839500188827515
were O 0 7.224370435210403e-09
also O 0 4.173947576457948e-10
excluded O 0 6.40347819214071e-09
as O 0 1.6598771246378874e-09
candidate O 0 4.981861589925529e-09
genes O 0 2.8349973479890878e-09
for O 0 1.124816129127737e-09
CT B-Disease 0 1.172068550658878e-06
since O 0 4.70214400749569e-09
they O 0 1.0474066058918652e-09
both O 0 5.154906279614124e-09
mapped O 0 2.941142263068741e-08
to O 0 5.676620062899929e-09
canine O 0 1.1297642004137742e-06
chromosome O 0 1.3149220876584877e-06
region O 0 1.3620719983009622e-06
CFA11q22 O 0 0.00014210546214599162
. O 0 3.7966408399370266e-06

2 O 0 4.579241431201808e-05
- O 0 4.162355253356509e-06
22 O 0 4.709219410869991e-06
. O 0 6.541046104757697e-07

5 O 0 7.368438673438504e-05
. O 0 5.3646731430490036e-06

A O 0 3.0160017558955587e-06
transcribed O 0 8.412096974552696e-08
sequence O 0 1.3303551149590476e-08
identified O 0 1.0406605355228749e-08
from O 0 3.2576392694494416e-09
the O 0 5.918860956910521e-09
C04107 O 0 6.383323380987349e-08
- O 0 1.0588823151636007e-09
containing O 0 9.794237643134807e-10
BAC O 0 3.3264672083532787e-07
was O 0 1.4144380111602572e-09
found O 0 2.593862451216733e-11
to O 0 3.5579286045139824e-11
be O 0 1.0819908163872682e-10
homologous O 0 1.5102828709867566e-10
to O 0 2.0674287282140824e-10
a O 0 1.1629658347445115e-09
gene O 0 4.590731794706926e-09
expressed O 0 7.99857069466725e-09
from O 0 5.181413076371655e-09
human O 0 3.9585152933341305e-09
chromosome O 0 3.295110673207091e-08
2p13 O 0 1.9433799991475098e-07
- O 0 7.51946771515577e-09
p16 O 0 1.2940637006408906e-08
, O 0 1.0972305702905416e-10
a O 0 1.5739812231352346e-10
region O 0 1.6378315370602081e-09
devoid O 0 1.1670109500983017e-07
of O 0 7.047584738018031e-10
any O 0 2.888498551456564e-09
positional O 0 1.5163594753175857e-06
candidate O 0 1.5320377997340984e-06
genes O 0 2.6715003969002282e-06
. O 0 1.766070340636361e-06

Molecular O 0 7.136530655316164e-08
analysis O 0 3.102870849147621e-08
of O 0 3.464382203333116e-08
the O 0 2.7338487029737735e-08
APC B-Disease 0 2.8853394340444538e-08
gene O 0 6.910771399581961e-10
in O 0 3.34240468635727e-10
205 O 0 5.226104549116428e-10
families O 0 8.973202042517059e-11
: O 0 3.924927396981026e-11
extended O 0 3.091674471988881e-09
genotype O 0 1.7871860436002862e-08
- O 0 1.0236480108005708e-07
phenotype O 0 6.281111097905523e-08
correlations O 0 6.750921244247365e-08
in O 0 7.024502646224562e-10
FAP B-Disease 0 2.57135486236848e-08
and O 0 2.0792399052504962e-11
evidence O 0 3.344770849178502e-10
for O 0 3.484616067916946e-11
the O 0 5.423209659127792e-10
role O 0 1.5658790930572764e-09
of O 0 1.7003886298994075e-08
APC B-Disease 0 1.7207891289672261e-07
amino O 0 9.195667161066012e-08
acid O 0 2.167752377602028e-08
changes O 0 1.4887283406039842e-08
in O 0 2.2122078746633633e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999901056289673
. O 0 3.0583424859287334e-07

BACKGROUND O 0 0.00023519548994954675
/ O 0 8.934539437177591e-07
AIMS O 0 3.354453781412303e-07
The O 0 1.850399278247039e-09
development O 0 2.8960688069901153e-08
of O 0 1.1207739447627318e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.2003115435497165e-11
a O 0 7.686873707002384e-12
variable O 0 2.4054241931636966e-10
range O 0 3.074812626735479e-10
of O 0 2.2872304050736147e-10
extracolonic O 0 2.4427711764474225e-07
manifestations O 0 2.137545834557386e-06
in O 0 7.722231032403215e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.644635881983049e-08
FAP B-Disease 0 3.4033752172035747e-07
) O 0 4.651934046306927e-11
is O 0 5.247944873804089e-12
the O 0 1.0291786520233437e-11
result O 0 4.804376896316853e-10
of O 0 2.381921992977709e-09
the O 0 1.0631955760231904e-08
dominant O 0 2.644420055730734e-05
inheritance O 0 0.00045827028225176036
of O 0 6.717424639646197e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.327850895904703e-07
APC B-Disease 0 1.2738217947116937e-07
) O 0 2.297957824026753e-09
gene O 0 2.6346484105488344e-08
mutations O 0 1.5185852362264995e-06
. O 0 9.73605779108766e-07

In O 0 1.6102948308116538e-08
this O 0 6.35941355131564e-10
study O 0 2.439895230299527e-10
, O 0 1.0753613277625362e-11
direct O 0 6.567815041824687e-11
mutation O 0 4.274403400672533e-11
analysis O 0 2.2234954155653242e-10
of O 0 8.137724383239231e-10
the O 0 3.285983263268122e-09
APC B-Disease 0 1.931259419052367e-08
gene O 0 3.6158229743676884e-09
was O 0 2.2083792572402672e-08
performed O 0 4.211289997280154e-11
to O 0 6.41944206125622e-11
determine O 0 2.0732424665936833e-09
genotype O 0 5.7174254664005275e-08
- O 0 1.1262986276960874e-07
phenotype O 0 5.6292787320444404e-08
correlations O 0 3.829342176686623e-08
for O 0 1.5007987075321694e-09
nine O 0 1.6144220182923164e-08
extracolonic O 0 5.060766170572606e-07
manifestations O 0 1.1259999865842474e-07
and O 0 4.1406442163882673e-10
to O 0 1.991289355629533e-10
investigate O 0 2.2526605025774415e-09
the O 0 3.5099543271854827e-09
incidence O 0 1.0381654647062533e-06
of O 0 1.793640436176247e-08
APC B-Disease 0 2.94048703608496e-07
mutations O 0 2.6457175295035995e-07
in O 0 4.891651173011269e-08
non O 1 0.9999997615814209
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.713886821467895e-07

METHODS O 0 3.665760914373095e-06
The O 0 2.874524511753407e-07
APC B-Disease 0 1.37585942638907e-07
gene O 0 2.6484535453619173e-08
was O 0 3.243900792426757e-08
analysed O 0 5.802808455968034e-09
in O 0 3.225967271092145e-10
190 O 0 4.2214756135194875e-09
unrelated O 0 1.4107610191160802e-08
FAP B-Disease 0 3.4951594329868385e-07
and O 0 4.33615010564381e-09
15 O 0 1.6111219736103521e-07
non O 1 0.8573143482208252
- O 1 0.9987494945526123
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.2889417311257034e-09
using O 0 1.3597166448331421e-10
denaturing O 0 5.9094112714319635e-08
gradient O 0 2.6203252900813823e-08
gel O 0 5.4748663380621565e-09
electrophoresis O 0 5.968967542457904e-10
, O 0 2.6343138781470543e-10
the O 0 6.534618401943249e-10
protein O 0 8.711528387550516e-09
truncation O 0 1.2586422570848299e-08
test O 0 5.561164306833177e-10
, O 0 1.0691165730492003e-09
and O 0 6.873202007540158e-10
direct O 0 3.5622523597567124e-08
sequencing O 0 1.460839484934695e-07
. O 0 3.8340130004144157e-07

RESULTS O 0 2.0519879399216734e-05
Chain O 0 4.111569751330535e-07
terminating O 0 1.6171685501831234e-07
signals O 0 5.273683001405516e-08
were O 0 3.123794001247404e-10
only O 0 1.2060584475559466e-10
identified O 0 3.7144964881719034e-10
in O 0 2.0670767181263372e-11
patients O 0 6.414020703449097e-11
belonging O 0 3.081012112104986e-10
to O 0 2.6933100194526105e-10
the O 0 1.4676477810837696e-08
FAP B-Disease 0 3.2478575917593844e-07
group O 0 8.72369565474429e-10
( O 0 2.5808893910905795e-10
105 O 0 1.0445901033051541e-08
patients O 0 7.525719492029737e-10
) O 0 1.5023051691542832e-09
. O 0 6.586328282764953e-08

Amino O 0 3.008306066476507e-06
acid O 0 4.935332142963489e-08
changes O 0 2.6210238424084764e-09
were O 0 5.102296918302329e-10
identified O 0 5.386592283329605e-10
in O 0 5.800489602525438e-11
four O 0 7.267524082532617e-11
patients O 0 3.819386820702597e-11
, O 0 8.175567861590238e-12
three O 0 2.0696054245372686e-11
of O 0 2.5915356527406175e-09
whom O 0 7.491826892191966e-08
belonged O 0 1.3029149386056815e-06
to O 0 7.409047597661811e-09
the O 0 1.467108319275212e-07
non O 0 2.4668308924447047e-06
- O 0 1.49474942645611e-07
FAP O 0 6.193663011799799e-06
group O 0 1.6297549976229675e-08
of O 0 8.351090059477428e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.068535635175067e-07
. O 0 2.8673776242271742e-08

Genotype O 0 5.195139692659723e-06
- O 0 1.70231669471832e-06
phenotype O 0 1.138749397000538e-07
correlations O 0 5.5809028509656855e-08
identified O 0 2.6123396779098584e-09
significant O 0 3.5861451586072235e-09
differences O 0 1.6626758636562045e-08
in O 0 6.336916547056148e-10
the O 0 2.5005073567285763e-09
nature O 0 8.891705149949303e-09
of O 0 2.1350881063142424e-09
certain O 0 3.639349444028994e-08
extracolonic O 0 1.0017742170020938e-05
manifestations O 0 1.6482154308050667e-07
in O 0 7.33937965957665e-10
FAP B-Disease 0 4.1445986198596074e-08
patients O 0 4.101138179057884e-11
belonging O 0 9.656245941735975e-11
to O 0 1.7306958643992232e-10
three O 0 1.0027764174580511e-09
mutation O 0 1.1412836187219e-07
subgroups O 0 4.3563048279793293e-07
. O 0 3.1129903277360427e-07

CONCLUSIONS O 0 3.1623632821720093e-05
Extended O 0 5.481117000272206e-07
genotype O 0 3.510415638174891e-07
- O 0 1.5490786609007046e-07
phenotype O 0 3.599338072035607e-08
correlations O 0 6.988666712004488e-08
made O 0 2.0258610344825456e-09
in O 0 1.5982005996395543e-10
this O 0 7.087321007848146e-11
study O 0 7.70040697872787e-11
may O 0 1.388056197759724e-10
have O 0 1.0390491245182432e-10
the O 0 5.271224012837195e-10
potential O 0 2.7794104795475505e-09
to O 0 2.8620963932191046e-10
determine O 0 5.749288156664534e-09
the O 0 1.9999268907611167e-09
most O 0 2.1435619945719964e-10
appropriate O 0 3.304562401496014e-09
surveillance O 0 9.290174851628308e-09
and O 0 3.3697713508473726e-09
prophylactic O 0 1.6738772501412313e-07
treatment O 0 5.7260001184999965e-09
regimens O 0 2.119252551224804e-09
for O 0 1.3764532569293664e-10
those O 0 5.471856856509305e-10
patients O 0 2.1509832803801032e-10
with O 0 5.738523892184766e-11
mutations O 0 2.309351376794666e-09
associated O 0 5.695675486805385e-09
with O 0 1.5540660425195085e-10
life O 0 3.4161067308247084e-09
threatening O 0 4.9568509297159835e-08
conditions O 0 2.861281132027216e-07
. O 0 2.779309511424799e-07

This O 0 2.2257339082898397e-08
study O 0 4.647132012536304e-09
also O 0 1.5310992751427221e-10
provided O 0 2.0805898670595013e-10
evidence O 0 4.541349518660809e-10
for O 0 5.360821855870945e-11
the O 0 3.9531558582162063e-10
pathological O 0 4.898130328001571e-07
nature O 0 2.2068256555485277e-08
of O 0 2.863234982442009e-08
amino O 0 1.760915324666712e-08
acid O 0 2.866818116231684e-09
changes O 0 3.9121561545840677e-10
in O 0 1.04062425343443e-09
APC O 0 6.462584423161388e-08
associated O 0 3.0216877888733507e-08
with O 0 8.403253093369756e-10
both O 0 5.9800244756047505e-09
FAP B-Disease 0 6.446865882026032e-06
and O 0 3.438825757484665e-08
non O 1 0.9999934434890747
- O 1 0.9999982118606567
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.0135257078047744e-08
. O 0 3.8945188740591163e-10
. O 0 5.354317877959147e-09

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 4.189013509403594e-07
cancer B-Disease 0 0.009829651564359665
risk O 0 6.582334322047245e-08
of O 0 1.4649209845174482e-08
the O 0 1.7041744015955373e-08
APC O 0 1.0832064845089917e-07
I1307K O 0 1.9203542933610152e-07
polymorphism O 0 3.343121690591033e-08
. O 0 1.1900396401642865e-07

Germ O 0 7.387195364572108e-05
- O 0 6.780163403163897e-06
line O 0 8.341379498233437e-07
and O 0 1.6168555383444527e-09
somatic O 0 4.1801743577707384e-07
truncating O 0 2.489520909421117e-07
mutations O 0 3.191854958117801e-08
of O 0 1.1449887260539526e-08
the O 0 1.2110941582932355e-08
APC B-Disease 0 3.5790606034424854e-08
gene O 0 9.042278037441065e-09
are O 0 9.803713396649982e-10
thought O 0 1.8836552317935684e-09
to O 0 6.955308551326311e-10
initiate O 0 1.1280356915222001e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 7.600719072797801e-06
formation O 0 8.213407198809364e-08
in O 0 3.774816192958497e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 9.31146182381326e-09
sporadic O 0 1.9756816982408054e-05
colorectal O 1 1.0
carcinogenesis O 1 0.9999997615814209
, O 0 2.182351366286639e-08
respectively O 0 4.9349182518199086e-08
. O 0 1.3779236951450002e-07

Recently O 0 8.804431672615465e-07
, O 0 1.377147995640371e-08
an O 0 1.178400044210548e-08
isoleucine O 0 5.520619197341148e-07
- O 0 4.7212253662110015e-08
- O 0 1.0285369711482417e-07
> O 0 5.897678079236357e-08
lysine O 0 3.609203815813089e-07
polymorphism O 0 1.6174640293797893e-08
at O 0 1.3191413295032817e-08
codon O 0 3.8308105132500714e-08
1307 O 0 3.451297914125462e-07
( O 0 1.0067184863515877e-09
I1307K O 0 8.594273026574228e-08
) O 0 6.479089487143597e-11
of O 0 8.029596432201913e-10
the O 0 3.3836828894351356e-09
APC B-Disease 0 9.067492534597932e-09
gene O 0 8.547868524111379e-10
has O 0 5.300310190747837e-10
been O 0 8.488821451324569e-11
identified O 0 1.502929308783152e-10
in O 0 6.151514020391602e-11
6 O 0 3.4366733903112845e-09
% O 0 5.752696652372435e-10
- O 0 1.5992221436000875e-10
7 O 0 1.0524190408034428e-09
% O 0 1.366713686667964e-10
of O 0 1.3610347571191284e-10
the O 0 1.33854760608898e-09
Ashkenazi O 0 4.393459818174961e-09
Jewish O 0 1.1672153021891063e-08
population O 0 2.7702438121224304e-09
. O 0 3.104516466123641e-08

To O 0 8.959495367832915e-09
assess O 0 6.702462229668527e-08
the O 0 3.3393476872589645e-09
risk O 0 1.7251970518827875e-08
of O 0 1.068692578876096e-09
this O 0 2.1409551909101765e-10
common O 0 4.598118774623572e-09
APC B-Disease 0 8.90946623144373e-08
allelic O 0 7.650263711411753e-08
variant O 0 6.306596844751766e-08
in O 0 1.2821357309178438e-08
colorectal O 1 1.0
carcinogenesis O 1 0.9996434450149536
, O 0 8.627445424735924e-09
we O 0 2.077398475464065e-09
have O 0 2.981546676217306e-10
analyzed O 0 4.922394047923717e-09
a O 0 6.256355433720273e-10
large O 0 2.7983368955375454e-09
cohort O 0 3.930859193701508e-08
of O 0 1.231260071676843e-08
unselected O 0 0.0001356466964352876
Ashkenazi O 0 3.6257978308640304e-07
Jewish O 0 8.947900482780824e-07
subjects O 0 2.963820691093133e-07
with O 0 1.3519315444909807e-08
adenomatous B-Disease 0 1.2708117083093384e-06
polyps I-Disease 0 2.357701021082903e-07
and O 0 3.952841165499876e-09
. O 0 1.035157115580887e-08
or O 0 0.00024348043370991945
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.091985278924625e-10
for O 0 6.475519426230036e-11
the O 0 2.7505422384166422e-09
APC O 0 6.04434617912375e-08
I1307K O 0 2.1790326343307242e-07
polymorphism O 0 1.448700146511328e-07
. O 0 7.339714898080274e-07

The O 0 1.613954395907058e-06
APC O 0 2.6515879198996117e-06
I1307K O 0 1.4844886209175456e-06
allele O 0 1.6593968865663555e-08
was O 0 1.3565681022953413e-08
identified O 0 1.1653594755856034e-09
in O 0 3.3546670996642547e-10
48 O 0 9.280327617489093e-09
( O 0 1.3172694879326485e-10
10 O 0 4.821423260636948e-10
. O 0 1.4651010959987332e-10
1 O 0 2.3268600379822146e-09
% O 0 2.569557899789743e-10
) O 0 8.81526275586797e-12
of O 0 2.86661999693294e-10
476 O 0 1.294157492282011e-08
patients O 0 5.043961692763332e-09
. O 0 1.3314547686604783e-07

Compared O 0 1.1875879835088199e-08
with O 0 2.1160918503571047e-11
the O 0 8.0770251598139e-11
frequency O 0 1.5806358999448378e-10
in O 0 5.504185215249313e-12
two O 0 5.0968253055561075e-12
separate O 0 1.0512042625254736e-11
population O 0 2.7352838743999186e-11
control O 0 7.32494342958745e-11
groups O 0 3.92972911156253e-11
, O 0 2.5403096293175054e-10
the O 0 2.9018731861896185e-09
APC O 0 3.4824751082851435e-08
I1307K O 0 4.17754364434586e-08
allele O 0 3.049652308462214e-09
is O 0 5.941692277078303e-11
associated O 0 3.5337588411010756e-10
with O 0 1.6479198214347512e-11
an O 0 7.979728683382703e-11
estimated O 0 1.6731981078432767e-10
relative O 0 7.253807776663734e-09
risk O 0 7.267975110636371e-09
of O 0 3.631998879427556e-08
1 O 0 1.5206619536911603e-06
. O 0 1.2361130075078108e-06

5 O 0 1.920902286656201e-05
- O 0 1.8342766452406067e-06
1 O 0 3.219297241230379e-06
. O 0 5.439467827272892e-07

7 O 0 7.5974944593326654e-06
for O 0 2.3470269638892205e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.00014916894724592566
( O 0 7.149528613581424e-08
both O 0 9.14967230869479e-08
P O 0 4.290257493266836e-06
= O 0 8.06276929665728e-08
. O 0 9.019746727290112e-09
01 O 0 4.1351560753355443e-07
) O 0 9.752803009632771e-09
. O 0 1.1517859377363493e-07

Furthermore O 0 1.1286086873951717e-06
, O 0 2.091322137687257e-08
compared O 0 1.8536571388949596e-08
with O 0 2.1329349397802844e-09
noncarriers O 0 2.1595851649180986e-06
, O 0 8.32378344028939e-09
APC O 0 8.310271226719124e-08
I1307K O 0 8.836187248562055e-08
carriers O 0 1.335846655514672e-09
had O 0 6.503495519893931e-10
increased O 0 4.6173725953835287e-10
numbers O 0 6.204400881948402e-10
of O 0 1.1087561979650218e-08
adenomas B-Disease 0 7.30785250198096e-05
and O 0 8.695296855876222e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999984860420227
per O 0 3.612577970102393e-08
patient O 0 1.9802167017246575e-08
( O 0 1.6876829933565318e-09
P O 0 2.979140276693215e-07
= O 0 7.441210758685202e-09
. O 0 1.3119418884599554e-09
03 O 0 8.459574374342083e-09
) O 0 6.22435852859482e-11
, O 0 7.325446499395483e-11
as O 0 2.33677716066083e-10
well O 0 3.92795490578024e-10
as O 0 1.218698697513787e-09
a O 0 2.823481448643861e-09
younger O 0 1.486644691794936e-07
age O 0 9.472702231505536e-07
at O 0 1.2984948227767745e-07
diagnosis O 0 1.4123057781034731e-06
. O 0 2.82970546550132e-07

We O 0 6.776658523222068e-08
conclude O 0 1.1678559985739412e-07
that O 0 1.3552278188555533e-09
the O 0 1.7413896102880244e-08
APC O 0 3.1954741075423954e-07
I1307K O 0 4.131482000957476e-07
variant O 0 9.225796304690448e-08
leads O 0 2.3422501271852525e-08
to O 0 6.762939652737998e-10
increased O 0 6.517098682934375e-08
adenoma B-Disease 1 1.0
formation O 0 7.668100465707539e-08
and O 0 2.1673873806804522e-09
directly O 0 4.316592860931223e-09
contributes O 0 2.640593299574334e-09
to O 0 1.8203212548417724e-10
3 O 0 4.85254458837403e-09
% O 0 7.191111039972498e-10
- O 0 1.5538170750062363e-10
4 O 0 1.1683216616376058e-09
% O 0 1.0304165853902703e-10
of O 0 8.549984331640559e-11
all O 0 5.913904366217082e-10
Ashkenazi O 0 3.1490125707023253e-07
Jewish O 0 0.0010626971488818526
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.480742520878266e-07

The O 0 4.4324494297143247e-08
estimated O 0 3.315384944357902e-08
relative O 0 2.8155784548289375e-07
risk O 0 1.3466454618082935e-08
for O 0 2.6042590306474267e-10
carriers O 0 2.5848860829569276e-09
may O 0 1.1461548377056374e-09
justify O 0 7.553434322460362e-09
specific O 0 1.366993296336716e-09
clinical O 0 6.884616765567841e-10
screening O 0 4.268016148833986e-11
for O 0 4.8808231761787724e-11
the O 0 7.281680813875369e-10
360 O 0 7.252338174446038e-10
, O 0 4.1216051405168486e-11
000 O 0 1.4673308124102391e-09
Americans O 0 6.365016153031533e-11
expected O 0 2.4116578178912107e-10
to O 0 5.625065413461527e-10
harbor O 0 5.35018642722207e-08
this O 0 1.2215838063323048e-10
allele O 0 3.178936447412184e-09
, O 0 1.552489942158175e-10
and O 0 6.87142912014771e-11
genetic O 0 5.060003527290746e-10
testing O 0 9.826585378736041e-11
in O 0 1.5220032179019682e-10
the O 0 8.544413510058746e-10
setting O 0 8.020768937910816e-09
of O 0 1.5434007849535192e-08
long O 0 4.83107331916699e-09
- O 0 1.1032712521341637e-08
term O 0 3.3100967300470074e-08
- O 0 8.762437886389307e-09
outcome O 0 1.5495508876028907e-08
studies O 0 5.190126994847333e-09
may O 0 9.30224508532973e-10
impact O 0 2.2994761650352302e-08
significantly O 0 1.533670683784294e-07
on O 0 1.869698280643206e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 3.3176987823679838e-09
in O 0 3.664389538332591e-12
this O 0 7.197470484193724e-12
population O 0 1.1493352103375543e-10
. O 0 1.082576073230257e-08

Localization O 0 1.2576844028444611e-06
of O 0 2.2385152931292396e-07
human O 0 8.283922170448932e-08
BRCA1 O 0 1.8111529698217055e-07
and O 0 2.3194026699258075e-09
its O 0 7.802066770423721e-10
loss O 0 5.369239275410109e-09
in O 0 1.956440121020364e-09
high O 0 2.7473511181597132e-06
- O 0 1.6299858884849527e-07
grade O 0 3.0812387308287725e-07
, O 0 2.9110548638300315e-08
non B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999998807907104
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.2903409697173629e-05

Although O 0 3.3848142066972287e-08
the O 0 1.1074710926095577e-08
link O 0 8.135388185337433e-08
between O 0 6.497252513781859e-08
the O 0 1.9459169209312677e-07
BRCA1 O 0 7.161235771491192e-06
tumour B-Disease 1 0.9999997615814209
- O 0 5.452894242807815e-07
suppressor O 0 1.7989463003686978e-06
gene O 0 3.8777933752953686e-08
and O 0 6.6016845323702e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.6389709861796007e-10
established O 0 1.5832156419204324e-10
, O 0 1.0653091256362934e-11
the O 0 8.86913459341443e-11
role O 0 1.5747228521156842e-10
, O 0 5.824424970102271e-11
if O 0 8.416851243753243e-11
any O 0 8.12616862688742e-10
, O 0 7.639509580492643e-10
of O 0 4.757553462297892e-09
BRCA1 O 0 1.3560512002186442e-07
in O 0 3.6884912901768985e-08
non B-Disease 1 0.9999997615814209
- I-Disease 1 0.9998639822006226
familial I-Disease 1 0.5514386892318726
cancers I-Disease 1 0.9870097637176514
is O 0 2.699122703120338e-09
unclear O 0 9.007406731598167e-08
. O 0 1.1660564069870816e-07

BRCA1 O 0 1.1338634976709727e-05
mutations O 0 4.704640730324172e-07
are O 0 1.5698414790321635e-09
rare O 0 5.362034372069502e-09
in O 0 2.6470934333389096e-09
sporadic B-Disease 0 1.4134635421214625e-05
cancers I-Disease 0 0.001505839405581355
, O 0 2.3130267146065364e-10
but O 0 1.2943561500389222e-10
loss O 0 1.2999886500608682e-08
of O 0 1.9615450597143536e-08
BRCA1 O 0 2.8708472044058908e-08
resulting O 0 1.7718312150805104e-08
from O 0 1.6801705582381032e-09
reduced O 0 4.718495372202369e-09
expression O 0 2.170809088042347e-09
or O 0 8.013119057181939e-10
incorrect O 0 1.85739423841369e-08
subcellular O 0 4.4130391074759245e-07
localization O 0 1.3604190485239087e-07
is O 0 1.289726325737206e-09
postulated O 0 3.131647829945905e-08
to O 0 8.875484791559529e-10
be O 0 2.5060362673912095e-09
important O 0 2.3462520815087373e-08
in O 0 2.0910508879978806e-08
non B-Disease 0 0.23560836911201477
- I-Disease 0 0.4938635528087616
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 7.101863275238429e-07

Epigenetic O 0 0.00011952629574807361
loss O 0 0.00041621760465204716
, O 0 4.1058871858012935e-08
however O 0 3.034324791428844e-08
, O 0 4.234909367628603e-10
has O 0 2.8975670821052013e-11
not O 0 5.999722853949896e-12
received O 0 7.393187451132377e-11
general O 0 5.017294357756441e-10
acceptance O 0 2.4052326796919488e-09
due O 0 1.5468039071819817e-09
to O 0 1.4627669908673369e-10
controversy O 0 3.1902467334532503e-09
regarding O 0 4.638117445665557e-09
the O 0 3.3442235647385132e-09
subcellular O 0 4.160633125138702e-06
localization O 0 2.6793768483912572e-06
of O 0 3.034686812952714e-07
BRCA1 O 0 6.857639078816646e-08
proteins O 0 2.7222331056009352e-09
, O 0 3.2026092888770563e-10
reports O 0 1.2355362288829497e-09
of O 0 5.375322964518148e-10
which O 0 6.901994947794421e-11
have O 0 8.903813103477987e-11
ranged O 0 2.169692514542021e-08
from O 0 1.0729775956619392e-09
exclusively O 0 3.259945424716193e-09
nuclear O 0 1.7781756511681124e-08
, O 0 2.996466130777975e-10
to O 0 4.698026967453472e-10
conditionally O 0 1.025347629024509e-08
nuclear O 0 5.292978055848607e-09
, O 0 1.1109566044886776e-10
to O 0 3.79994397059491e-10
the O 0 4.487179339207614e-08
ER O 0 8.34233833302278e-06
/ O 0 5.253243173797273e-08
golgi O 0 3.8715489836249617e-07
, O 0 2.1148471862630913e-09
to O 0 2.7482349729268662e-09
cytoplasmic O 0 1.0663188731996343e-06
invaginations O 0 1.507641286480066e-06
into O 0 3.00641929129597e-08
the O 0 8.07696025617588e-08
nucleus O 0 5.528708697966067e-06
. O 0 6.109731884862413e-07

In O 0 1.625390488868561e-08
an O 0 4.521283347713734e-09
attempt O 0 5.9646465544460625e-09
to O 0 1.056540077648549e-09
resolve O 0 7.448225147754783e-09
this O 0 5.222168808494132e-10
issue O 0 4.736628422818967e-09
, O 0 1.1332902394300959e-09
we O 0 1.9521684269108164e-09
have O 0 1.630015344922242e-09
comprehensively O 0 2.736828434990457e-07
characterized O 0 6.321651113694315e-08
19 O 0 2.94008884793584e-07
anti O 0 2.6697557586885523e-07
- O 0 6.933479426152189e-07
BRCA1 O 0 3.954804697059444e-07
antibodies O 0 1.2492326106894325e-07
. O 0 1.600007095703404e-07

These O 0 1.3147135291546874e-07
reagents O 0 1.2956735417901655e-06
detect O 0 1.2574898278217006e-07
a O 0 2.9618304253631322e-08
220 O 0 2.0887588547680025e-08
- O 0 1.2034171881225575e-08
kD O 0 1.5192261670904372e-08
protein O 0 7.1651835575892164e-09
localized O 0 9.144154766715928e-09
in O 0 9.77087161180279e-11
discrete O 0 2.941314525273242e-09
nuclear O 0 2.9347706487214964e-08
foci O 0 1.546081165315627e-07
in O 0 1.0302912967219413e-09
all O 0 1.636083046818726e-09
epithelial O 0 6.700046384366942e-08
cell O 0 1.2796223813893448e-07
lines O 0 5.3999884563893374e-09
, O 0 2.6510876827146035e-11
including O 0 3.0229328155245705e-12
those O 0 9.123379829389933e-11
derived O 0 2.5958508231838096e-08
from O 0 8.452223454469276e-08
breast B-Disease 0 2.6241125397064025e-06
malignancies I-Disease 0 3.583108991733752e-06
. O 0 5.41547251486918e-07

Immunohistochemical O 0 0.00012933093239553273
staining O 0 1.8163254935643636e-05
of O 0 1.0707966566769755e-06
human O 0 3.0255583283178566e-07
breast O 0 7.199619176390115e-07
specimens O 0 5.28343910843887e-08
also O 0 3.3146752009827196e-09
revealed O 0 4.0226801445442106e-08
BRCA1 O 0 3.0888472224432917e-07
nuclear O 0 3.564468897820916e-07
foci O 0 1.0367099093855359e-05
in O 0 8.372894200192604e-08
benign O 1 0.9999998807907104
breast O 1 0.7200362086296082
, O 0 9.45020204312641e-08
invasive B-Disease 0 5.866757874173345e-06
lobular I-Disease 1 0.9750192165374756
cancers I-Disease 1 0.9999996423721313
and O 0 3.40294573106803e-05
low B-Disease 1 1.0
- I-Disease 1 0.9999908208847046
grade I-Disease 1 0.9999549388885498
ductal I-Disease 1 0.9999998807907104
carcinomas I-Disease 1 1.0
. O 0 6.925067737029167e-06

Conversely O 0 2.7547864647203824e-06
, O 0 6.0991816042133e-08
BRCA1 O 0 5.6562928563153037e-08
expression O 0 5.634241162510989e-08
was O 0 2.6595090574232927e-08
reduced O 0 1.0226425928294702e-08
or O 0 6.173614397475546e-10
undetectable O 0 3.913366963814724e-09
in O 0 1.4449056534582283e-11
the O 0 1.4313668306176197e-10
majority O 0 6.568028759756928e-11
of O 0 4.834004307952e-09
high O 0 6.8516760620696e-07
- O 0 4.819552827939333e-07
grade O 0 5.833622935824678e-07
, O 0 7.250933720115427e-08
ductal B-Disease 0 0.0002470526087563485
carcinomas I-Disease 1 1.0
, O 0 1.0467635647160023e-09
suggesting O 0 1.274326089095723e-09
that O 0 6.961756171541822e-11
absence O 0 2.3600355447683796e-08
of O 0 7.05201514961118e-08
BRCA1 O 0 2.7022970527923462e-08
may O 0 5.942012437643029e-10
contribute O 0 3.2910624225834795e-10
to O 0 1.366992491425023e-10
the O 0 1.3416814326205895e-09
pathogenesis O 0 1.0796335345730768e-06
of O 0 1.342001287873984e-09
a O 0 5.637438849070975e-10
significant O 0 1.7430178189670187e-08
percentage O 0 4.0352915675612167e-07
of O 0 1.2330653476055886e-07
sporadic B-Disease 1 0.9939415454864502
breast I-Disease 0 0.0003845227474812418
cancers I-Disease 0 0.42521345615386963
. O 0 8.703510445684515e-08
. O 0 3.2171047337214986e-07

